FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Sherman, JC Colvin, MK Mancuso, SM Batchelor, TT Oh, KS Loeffler, JS Yeap, BY Shih, HA AF Sherman, Janet Cohen Colvin, Mary K. Mancuso, Sarah M. Batchelor, Tracy T. Oh, Kevin S. Loeffler, Jay S. Yeap, Beow Y. Shih, Helen A. TI Neurocognitive effects of proton radiation therapy in adults with low-grade glioma SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Neurocognitive function; Proton radiation therapy; Low-grade glioma; Tumor laterality; Neuropsychology ID COGNITIVE DEFICITS; CLINICAL-OUTCOMES; FOLLOW-UP; RADIOTHERAPY; CHEMOTHERAPY; TUMORS; TRIAL AB To understand neurocognitive effects of proton radiation therapy (PRT) in patients with low-grade glioma, we evaluated 20 patients who received this therapy prospectively and over 5 years with a comprehensive neuropsychological battery. 20 patients were evaluated at baseline and at yearly intervals for up to 5 years with a battery of neuropsychological measures that assessed intellectual, attention, executive, visuospatial and memory functions as well as mood and functional status. We evaluated change in cognitive functioning over time. We analyzed the relationship between cognitive performance and tumor location and also examined whether patients' performance differed from that reported in a study of normative practice effects. Overall, patients exhibited stability in cognitive functioning. Tumor location played a role in performance; those with tumors in the left hemisphere versus in the right hemisphere were more impaired at baseline on verbal measures (p < .05). However, we found greater improvement in verbal memory over time in patients with left than with right hemisphere tumors (p < .05). Results of our study, the first to investigate, in depth, neurocognitive effects of PRT in adults with low-grade gliomas, are promising. We hypothesize that the conformal advantage of PRT may contribute to preservation of cognitive functioning, although larger sample sizes and a longer period of study are required. Our study also highlights the need to consider normative practice effects when studying neurocognitive functioning in response to treatment over time, and the need to utilize comprehensive neuropsychological batteries given our findings that differentiate patients with left and right hemisphere tumors. C1 [Sherman, Janet Cohen] Massachusetts Gen Hosp, Dept Psychiat & Neurol, Psychol Assessment Ctr, Boston, MA 02114 USA. [Colvin, Mary K.; Mancuso, Sarah M.] Massachusetts Gen Hosp, Dept Psychiat, Psychol Assessment Ctr, Boston, MA 02114 USA. [Batchelor, Tracy T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Oh, Kevin S.; Loeffler, Jay S.; Shih, Helen A.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Yeap, Beow Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Sherman, JC (reprint author), Massachusetts Gen Hosp, Dept Psychiat & Neurol, Psychol Assessment Ctr, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM jsherman@mgh.harvard.edu FU Pappas Award in Brain Tumor Research - Massachusetts General Hospital; Massachusetts General Hospital on Proton Therapy Research and Treatment Center [C06CA059267] FX This study was supported by a Pappas Award in Brain Tumor Research sponsored by Massachusetts General Hospital and by the Federal Share of program income earned by Massachusetts General Hospital on Proton Therapy Research and Treatment Center (grant C06CA059267). NR 22 TC 2 Z9 2 U1 0 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2016 VL 126 IS 1 BP 157 EP 164 DI 10.1007/s11060-015-1952-5 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CZ0ZR UT WOS:000366835900019 PM 26498439 ER PT J AU Bandopadhayay, P Silvera, VM Ciarlini, PDSC Malkin, H Bi, WL Bergthold, G Faisal, AM Ullrich, NJ Marcus, K Scott, RM Beroukhim, R Manley, PE Chi, SN Ligon, KL Goumnerova, LC Kieran, MW AF Bandopadhayay, Pratiti Silvera, V. Michelle Ciarlini, Pedro D. S. C. Malkin, Hayley Bi, Wenya Linda Bergthold, Guillaume Faisal, Ahmed M. Ullrich, Nicole J. Marcus, Karen Scott, R. Michael Beroukhim, Rameen Manley, Peter E. Chi, Susan N. Ligon, Keith L. Goumnerova, Liliana C. Kieran, Mark W. TI Myxopapillary ependymomas in children: imaging, treatment and outcomes SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Myxopapillary ependymoma; Pediatrics; Outcomes; Dissemination ID SPINAL-CORD EPENDYMOMAS; ANDERSON-CANCER-CENTER; TERM-FOLLOW-UP; 1ST 2 DECADES; ADJUVANT RADIATION; CLINICAL ARTICLE; RADIOTHERAPY; SURGERY; RESECTION; TUMOR AB Myxopapillary ependymomas (MPEs) are rare spinal tumors in children. The natural history and clinical course of pediatric MPEs are largely unknown and the indication for adjuvant therapy remains to be clarified. We performed an IRB-approved, retrospective review of children with MPEs treated at the Dana-Farber/Boston Children's Cancer and Blood Disorder Center between 1982 and 2013. Eighteen children (age range 8-21 years, median age 14 years) met inclusion criteria. We reviewed the histopathology, magnetic resonance imaging, tumor location and stage, surgical management, adjuvant therapy, and clinical outcomes. The median follow-up duration was 9.4 years (range 1-30 years). Children most commonly presented with pain, scoliosis, and urinary symptoms. All primary tumors were located in the lower thoracic or lumbar spine. Nine children (50 %) had leptomeningeal tumor seeding at presentation, most commonly located within the distal thecal sac. A gross-total resection was achieved in nine children (50 %). Three children were treated with irradiation following initial surgery. No child received adjuvant chemotherapy at diagnosis. The 10-year event-free survival (EFS) was 26 % +/- A 14.8. Children with disseminated disease trended towards inferior EFS compared to those with localized disease (10-year EFS 12.7 % +/- A 12 vs. 57 +/- A 25 %, p value 0.07). The 10-year overall survival was 100 %. The efficacy of adjuvant irradiation could not be assessed due to the small sample size. Although children with MPEs frequently present with disseminated tumor and/or develop recurrent or progressive disease, their overall survival is excellent. Treatment should aim to minimize both tumor- and therapy-related morbidity. C1 [Bandopadhayay, Pratiti; Malkin, Hayley; Bergthold, Guillaume; Faisal, Ahmed M.; Ullrich, Nicole J.; Marcus, Karen; Manley, Peter E.; Chi, Susan N.; Kieran, Mark W.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Bandopadhayay, Pratiti; Malkin, Hayley; Bergthold, Guillaume; Faisal, Ahmed M.; Ullrich, Nicole J.; Marcus, Karen; Manley, Peter E.; Chi, Susan N.; Goumnerova, Liliana C.; Kieran, Mark W.] Boston Childrens Hosp, Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA 02215 USA. [Silvera, V. Michelle] Boston Childrens Hosp, Dept Radiol, Boston, MA 02215 USA. [Ciarlini, Pedro D. S. C.; Ligon, Keith L.] Boston Childrens Hosp, Dept Pathol, Div Neuropathol, Boston, MA 02215 USA. [Bi, Wenya Linda; Scott, R. Michael; Goumnerova, Liliana C.] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02215 USA. [Ullrich, Nicole J.; Goumnerova, Liliana C.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA. [Beroukhim, Rameen; Ligon, Keith L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. RP Ligon, KL (reprint author), Boston Childrens Hosp, Dept Pathol, Div Neuropathol, 300 Longwood Ave, Boston, MA 02215 USA. EM Keith_Ligon@dfci.harvard.edu; liliana.goumnerova@childrens.harvard.edu; mark_kieran@dfci.harvard.edu FU Stop and Shop Pediatric Brain Tumor Program; Pediatric Low-Grade Astrocytoma Foundation; Phillipe Foundation; Team Jack Foundation; St. Baldrick's Foundation; Pediatric Brain Tumor Foundation; Jared Branfman Sunflowers For Life Fund For Pediatric Brain And Spinal Cancer Research FX We gratefully acknowledge the following funding sources for this project: Stop and Shop Pediatric Brain Tumor Program (PB, PEM, SNC, NJU, KM, LCG, MWK); Pediatric Low-Grade Astrocytoma Foundation (PB, HM, GB, RB, KLL, MWK), Phillipe Foundation (GB), Team Jack Foundation (PB, PEM, SNC, LCG, MWK), St. Baldrick's Foundation (PB), Pediatric Brain Tumor Foundation (PB), Jared Branfman Sunflowers For Life Fund For Pediatric Brain And Spinal Cancer Research (PB, RB). NR 25 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2016 VL 126 IS 1 BP 165 EP 174 DI 10.1007/s11060-015-1955-2 PG 10 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CZ0ZR UT WOS:000366835900020 PM 26468139 ER PT J AU Imber, BS Braunstein, SE Wu, FY Nabavizadeh, N Boehling, N Weinberg, VK Tihan, T Barnes, M Mueller, S Butowski, NA Clarke, JL Chang, SM McDermott, MM Prados, MD Berger, MS Haas-Kogan, DA AF Imber, Brandon S. Braunstein, Steve E. Wu, Fred Y. Nabavizadeh, Nima Boehling, Nicholas Weinberg, Vivian K. Tihan, Tarik Barnes, Michael Mueller, Sabine Butowski, Nicholas A. Clarke, Jennifer L. Chang, Susan M. McDermott, Michael M. Prados, Michael D. Berger, Mitchel S. Haas-Kogan, Daphne A. TI Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Central neurocytoma; Intraventricular neurocytoma; Benign central nervous system tumor; Progression free survival; MIB-1 labeling index ID MIB-1 LABELING INDEX; RECURRENT CENTRAL NEUROCYTOMAS; GAMMA-KNIFE RADIOSURGERY; LONG-TERM OUTCOMES; RADIATION-THERAPY; MANAGEMENT; RECOMMENDATIONS; RADIOTHERAPY; FEATURES AB Central neurocytomas are uncommon intraventricular neoplasms whose optimal management remains controversial due to their rarity. We assessed outcomes for a historical cohort of neurocytoma patients and evaluated effects of tumor atypia, size, resection extent, and adjuvant radiotherapy. Progression-free survival (PFS) was measured by Kaplan-Meier and Cox proportional hazards methods. A total of 28 patients (15 males, 13 females) were treated between 1995 and 2014, with a median age at diagnosis of 26 years (range 5-61). Median follow-up was 62.2 months and 3 patients were lost to follow-up postoperatively. Thirteen patients experienced recurrent/progressive disease and 2-year PFS was 75 % (95 % CI 53-88 %). Two-year PFS was 48 % for MIB-1 labeling > 4 % versus 90 % for a parts per thousand currency sign4 % (HR 5.4, CI 2.2-27.8, p = 0.0026). Nine patients (32 %) had gross total resections (GTR) and 19 (68 %) had subtotal resections (STR). PFS for > 80 % resection was 83 versus 67 % for a parts per thousand currency sign80 % resection (HR 0.67, CI 0.23-2.0, p = 0.47). Three STR patients (16 %) received adjuvant radiation which significantly improved overall PFS (p = 0.049). Estimated 5-year PFS was 67 % for STR with radiotherapy versus 53 % for STR without radiotherapy. Salvage therapy regimens were diverse and resulted in stable disease for 54 % of patients and additional progression for 38 %. Two patients with neuropathology-confirmed atypical neurocytomas died at 4.3 and 113.4 months after initial surgery. For central neurocytomas, MIB-1 labeling index > 4 % is predictive of poorer outcome and our data suggest that adjuvant radiotherapy after STR may improve PFS. Most patients requiring salvage therapy will be stabilized and multiple modalities can be effectively utilized. C1 [Imber, Brandon S.; Braunstein, Steve E.; Boehling, Nicholas] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA. [Wu, Fred Y.] Indiana Univ Sch Med, Dept Radiat Oncol, Bloomington, IN USA. [Nabavizadeh, Nima] Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97201 USA. [Weinberg, Vivian K.] Univ Calif San Francisco, Dept Biostat, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Tihan, Tarik; Barnes, Michael] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. [Butowski, Nicholas A.; Clarke, Jennifer L.; Chang, Susan M.; McDermott, Michael M.; Prados, Michael D.; Berger, Mitchel S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Mueller, Sabine] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Mueller, Sabine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Haas-Kogan, Daphne A.] Harvard Univ, Dept Radiat Oncol, Brigham & Womens Hosp, Dana Farber Canc Inst,Boston Childrens Hosp,Med S, Boston, MA 02215 USA. RP Haas-Kogan, DA (reprint author), Harvard Univ, Dept Radiat Oncol, Brigham & Womens Hosp, Dana Farber Canc Inst,Boston Childrens Hosp,Med S, 450 Brookline Ave,D1622, Boston, MA 02215 USA. EM dhaas-kogan@lroc.harvard.edu FU NIH Brain Tumor SPORE grant [P50 CA097257]; Nancy and Stephen Grand Philanthropic Fund; V Foundation; National Center for Advancing Translational Sciences, National Institutes of Health through UCSF-CTSI [TL1 TR000144] FX This research was supported in part by the NIH Brain Tumor SPORE grant P50 CA097257 (DHK), Nancy and Stephen Grand Philanthropic Fund (DHK), and The V Foundation (DHK) as well as by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number TL1 TR000144 (BSI). NR 34 TC 2 Z9 2 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2016 VL 126 IS 1 BP 193 EP 200 DI 10.1007/s11060-015-1959-y PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CZ0ZR UT WOS:000366835900023 PM 26493740 ER PT J AU Ferguson, S Trupin, L Yazdany, J Yelin, E Barton, J Katz, P AF Ferguson, S. Trupin, L. Yazdany, J. Yelin, E. Barton, J. Katz, P. TI Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication SO LUPUS LA English DT Article DE Contraception; family planning; teratogen; systemic lupus erythematosus ID UNITED-STATES; UNINTENDED PREGNANCY; RHEUMATOID-ARTHRITIS; ERYTHEMATOSUS; WOMEN; VALIDATION; HEALTH; CARE; OUTCOMES; IMPACT AB Objective Family planning discussions are an important aspect of medical care for women with systemic lupus erythematosus (SLE) as active disease is a risk factor for poor pregnancy outcomes, and the medications used for treatment can be harmful to the fetus when used during conception and pregnancy. Our objective was to examine the impact of patient perception of quality and type of communication on receiving contraception counseling. Methods Data were derived from patients enrolled in the University of California, San Francisco Lupus Outcomes Study. Individuals participate in a yearly structured telephone interview that includes assessment of contraception counseling when starting new medications, and measures of communication and decision making. Logistic regression was performed to identify predictors of not receiving contraception counseling. Results Of the 68 women included in this analysis, one-third did not receive contraception counseling when starting new medications. Older age, white race, depressive symptoms, and higher SLE disease activity were independently associated with not receiving contraception counseling. Participants who did not receive contraception counseling rated their physicians lower in shared decision-making (SDM) communication. Conclusions This study demonstrates a gap in family planning counseling among women with SLE starting new medications. Future studies to address these potential areas of intervention, including education about the need for contraception through menopause, and mechanisms to engage in SDM surrounding contraception are needed to improve quality of care for women with lupus. C1 [Ferguson, S.; Trupin, L.; Yazdany, J.; Yelin, E.; Katz, P.] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA. [Barton, J.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR USA. RP Ferguson, S (reprint author), Univ Calif San Francisco, Div Rheumatol, Room 270,3333 Calif St,Box 0920, San Francisco, CA 94143 USA. EM sancia.ferguson@ucsf.edu FU National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [P60-AR-053308]; NIH/National Center for Research Resources through a University of California, San Francisco (UCSF), Clinical and Translational Science Institute grant [Ul1-RR-024131] FX This work was supported by the National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant (P60-AR-053308), and the NIH/National Center for Research Resources through a University of California, San Francisco (UCSF), Clinical and Translational Science Institute grant (Ul1-RR-024131). NR 29 TC 0 Z9 0 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 EI 1477-0962 J9 LUPUS JI Lupus PD JAN PY 2016 VL 25 IS 1 BP 12 EP 17 DI 10.1177/0961203315596079 PG 6 WC Rheumatology SC Rheumatology GA CY7PV UT WOS:000366601700002 PM 26190169 ER PT B AU Oral, E Muratoglu, OK AF Oral, Ebru Muratoglu, Orhun K. BA Sonntag, R Kretzer, JP BF Sonntag, R Kretzer, JP TI Crosslinked Polyethylene SO MATERIALS FOR TOTAL JOINT ARTHROPLASTY: BIOTRIBOLOGY OF POTENTIAL BEARINGS LA English DT Article; Book Chapter ID MOLECULAR-WEIGHT POLYETHYLENE; TOTAL KNEE ARTHROPLASTY; TOTAL HIP-ARTHROPLASTY; IN-VIVO OXIDATION; CRACK PROPAGATION RESISTANCE; FEMORAL-HEAD PENETRATION; TOTAL JOINT ARTHROPLASTY; TERM-FOLLOW-UP; VITAMIN-E; TIBIAL INSERTS C1 [Oral, Ebru; Muratoglu, Orhun K.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Harris Orthopaed Biomech & Biomat Lab, Boston, MA 02114 USA. RP Oral, E (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Harris Orthopaed Biomech & Biomat Lab, Boston, MA 02114 USA. NR 173 TC 0 Z9 0 U1 1 U2 1 PU IMPERIAL COLL PRESS PI COVENT GARDEN PA 57 SHELTON STREET, COVENT GARDEN WC2H 9HE, ENGLAND BN 978-1-78326-717-0; 978-1-78326-716-3 PY 2016 BP 133 EP 182 PG 50 WC Engineering, Biomedical; Materials Science, Biomaterials; Orthopedics SC Engineering; Materials Science; Orthopedics GA BE0DK UT WOS:000365859700007 ER PT J AU Verdeguer, F Soustek, MS Hatting, M Blattler, SM McDonald, D Barrow, JJ Puigserver, P AF Verdeguer, Francisco Soustek, Meghan S. Hatting, Maximilian Blaettler, Sharon M. McDonald, Devin Barrow, Joeva J. Puigserver, Pere TI Brown Adipose YY1 Deficiency Activates Expression of Secreted Proteins Linked to Energy Expenditure and Prevents Diet-Induced Obesity SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID YIN YANG 1; TRANSCRIPTION FACTOR; MICE LACKING; ADAPTIVE THERMOGENESIS; BEIGE ADIPOCYTES; SKELETAL-MUSCLE; WHITE FAT; IN-VIVO; TISSUE; ABLATION AB Mitochondrial oxidative and thermogenic functions in brown and beige adipose tissues modulate rates of energy expenditure. It is unclear, however, how beige or white adipose tissue contributes to brown fat thermogenic function or compensates for partial deficiencies in this tissue and protects against obesity. Here, we show that the transcription factor Yin Yang 1 (YY1) in brown adipose tissue activates the canonical thermogenic and uncoupling gene expression program. In contrast, YY1 represses a series of secreted proteins, including fibroblast growth factor 21 (FGF21), bone morphogenetic protein 8b (BMP8b), growth differentiation factor 15 (GDF15), angiopoietin-like 6 (Angptl6), neuromedin B, and nesfatin, linked to energy expenditure. Despite substantial decreases in mitochondrial thermogenic proteins in brown fat, mice lacking YY1 in this tissue are strongly protected against diet-induced obesity and exhibit increased energy expenditure and oxygen consumption in beige and white fat depots. The increased expression of secreted proteins correlates with elevation of energy expenditure and promotion of beige and white fat activation. These results indicate that YY1 in brown adipose tissue controls antagonistic gene expression programs associated with energy balance and maintenance of body weight. C1 [Verdeguer, Francisco; Soustek, Meghan S.; Hatting, Maximilian; Blaettler, Sharon M.; McDonald, Devin; Barrow, Joeva J.; Puigserver, Pere] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Verdeguer, Francisco; Soustek, Meghan S.; Hatting, Maximilian; Blaettler, Sharon M.; McDonald, Devin; Barrow, Joeva J.; Puigserver, Pere] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA. [Hatting, Maximilian] Rhein Westfal TH Aachen, Fac Med, Aachen, Germany. RP Puigserver, P (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA. EM Pere_Puigserver@dfci.harvard.edu FU NIH/NIDDK [RO1DK081418] FX NIH/NIDDK provided funding to Pere Puigserver under grant number RO1DK081418. NR 54 TC 2 Z9 2 U1 2 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 EI 1098-5549 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 2016 VL 36 IS 1 BP 184 EP 196 DI 10.1128/MCB.00722-15 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CZ1ME UT WOS:000366869100015 ER PT J AU Tang, YY Holzel, BK Posner, MI AF Tang, Yi-Yuan Hoelzel, Britta K. Posner, Michael I. TI Traits and states in mindfulness meditation SO NATURE REVIEWS NEUROSCIENCE LA English DT Letter ID NEUROSCIENCE C1 [Tang, Yi-Yuan] Texas Tech Univ, Dept Psychol Sci, Lubbock, TX 79409 USA. [Hoelzel, Britta K.] Tech Univ Munich, Dept Neuroradiol, D-81675 Munich, Germany. [Hoelzel, Britta K.] Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Posner, Michael I.] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA. RP Tang, YY (reprint author), Texas Tech Univ, Dept Psychol Sci, Lubbock, TX 79409 USA. EM yiyuan.tang@ttu.edu NR 16 TC 0 Z9 0 U1 7 U2 31 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-003X EI 1471-0048 J9 NAT REV NEUROSCI JI Nat. Rev. Neurosci. PD JAN PY 2016 VL 17 IS 1 DI 10.1038/nrn.2015.7 PG 1 WC Neurosciences SC Neurosciences & Neurology GA CY8RT UT WOS:000366676700010 ER PT J AU Fox, MD Qian, TY Madsen, JR Wang, DH Li, ML Ge, ML Zuo, HC Groppe, DM Mehta, AD Hong, B Liu, HS AF Fox, Michael D. Qian, Tianyi Madsen, Joseph R. Wang, Danhong Li, Meiling Ge, Manling Zuo, Huan-cong Groppe, David M. Mehta, Ashesh D. Hong, Bo Liu, Hesheng TI Combining task-evoked and spontaneous activity to improve pre-operative brain mapping with fMRI SO NEUROIMAGE LA English DT Article ID INTRINSIC FUNCTIONAL CONNECTIVITY; INDEPENDENT COMPONENT ANALYSIS; MODE NETWORK CONNECTIVITY; TEMPORAL-LOBE EPILEPSY; HUMAN CEREBRAL-CORTEX; SPONTANEOUS FLUCTUATIONS; ELECTROCORTICAL STIMULATION; CLINICAL-APPLICATION; MOTOR CORTEX; LANGUAGE AB Noninvasive localization of brain function is used to understand and treat neurological disease, exemplified by pre-operative fMRI mapping prior to neurosurgical intervention. The principal approach for generating these maps relies on brain responses evoked by a task and, despite known limitations, has dominated clinical practice for over 20 years. Recently, pre-operative fMRI mapping based on correlations in spontaneous brain activity has been demonstrated, however this approach has its own limitations and has not seen widespread clinical use. Here we show that spontaneous and task-based mapping can be performed together using the same pre-operative fMRI data, provide complimentary information relevant for functional localization, and can be combined to improve identification of eloquent motor cortex. Accuracy, sensitivity, and specificity of our approach are quantified through comparison with electrical cortical stimulation mapping in eight patients with intractable epilepsy. Broad applicability and reproducibility of our approach are demonstrated through prospective replication in an independent dataset of six patients from a different center. In both cohorts and every individual patient, we see a significant improvement in signal to noise and mapping accuracy independent of threshold, quantified using receiver operating characteristic curves. Collectively, our results suggest that modifying the processing of fMRI data to incorporate both task-based and spontaneous activity significantly improves functional localization in pre-operative patients. Because this method requires no additional scan time or modification to conventional pre-operative data acquisition protocols it could have widespread utility. (C) 2015 Elsevier Inc. All rights reserved. C1 [Fox, Michael D.] Beth Israel Deaconess Med Ctr, Dept Neurol, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA. [Fox, Michael D.] Harvard Univ, Sch Med, Boston, MA USA. [Fox, Michael D.; Qian, Tianyi; Wang, Danhong; Li, Meiling; Liu, Hesheng] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA. [Fox, Michael D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. [Qian, Tianyi; Hong, Bo] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing 100084, Peoples R China. [Madsen, Joseph R.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Neurosurg, Boston, MA USA. [Ge, Manling] Hebei Univ Technol, Dept Biomed Engn, Key Lab Electromagnet Field & Elect Apparat Relia, Tianjin, Peoples R China. [Zuo, Huan-cong] Tsinghua Univ, Affiliated Hosp 2, Beijing 100084, Peoples R China. [Groppe, David M.; Mehta, Ashesh D.] Hofstra North Shore LIJ Sch Med, Dept Neurosurg, Manhasset, NY 11030 USA. [Groppe, David M.; Mehta, Ashesh D.] Feinstein Inst Med Res, Manhasset, NY 11030 USA. [Groppe, David M.] Univ Toronto, Dept Psychol, Toronto, ON M5S 3G3, Canada. RP Hong, B (reprint author), Tsinghua Univ, Dept Biomed Engn, Beijing 100084, Peoples R China. EM Hongbo@tsinghua.edu.cn; Hesheng@nmr.mgh.harvard.edu FU NIH [R25NS065743, K23NS083741, K25NS069805, R01NS091604, P50 MH106435]; American Brain Foundation; Sidney Baer Foundation; NARSAD Young Investigator Grant [8822] FX We thank Abraham Snyder, Marcus Raichle, and Joshua Shimony for early discussions on this concept. MDF was supported by NIH grants R25NS065743, K23NS083741, the American Brain Foundation, and the Sidney Baer Foundation. HL was supported by NIH grants K25NS069805, R01NS091604, P50 MH106435, and NARSAD Young Investigator Grant (8822). NR 61 TC 1 Z9 1 U1 3 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 BP 714 EP 723 DI 10.1016/j.neuroimage.2015.09.030 PN A PG 10 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY8GL UT WOS:000366646700066 PM 26408860 ER PT J AU Aranovich, GJ McClure, SM Fryer, S Mathalon, DH AF Aranovich, Gabriel J. McClure, Samuel M. Fryer, Susanna Mathalon, Daniel H. TI The effect of cognitive challenge on delay discounting SO NEUROIMAGE LA English DT Article ID IMPULSIVE DECISION-MAKING; WORKING-MEMORY; PREFRONTAL CORTEX; SELF-CONTROL; INTERTEMPORAL CHOICE; NEURAL SYSTEMS; FMRI; REWARDS; MODEL; ADDICTION AB Recent findings suggest that the dorsolateral prefrontal cortex (DLPFC), a region consistently associated with impulse control, is vulnerable to transient suppression of its activity and attendant functions by excessive stress and/or cognitive demand. Using functional magnetic resonance imaging, we show that a capacity-exceeding cognitive challenge induced decreased DLPFC activity and correlated increases in the preference for immediately available rewards. Consistent with growing evidence of a link between working memory capacity and delay discounting, the effect was inversely proportional to baseline performance on a working memory task. Subjects who performed well on the working memory task had unchanged, or even decreased, delay discounting rates, suggesting that working memory ability may protect cognitive control from cognitive challenge. (C) 2015 Elsevier Inc. All rights reserved. C1 [Aranovich, Gabriel J.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [McClure, Samuel M.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA. [Fryer, Susanna; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Fryer, Susanna; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Aranovich, GJ (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. EM gabe.aranovich@ucsf.edu FU NIMH [R25MH060482, R01 MH076989]; NSF [1358507]; VA CSRD [IK2 CX001028] FX This work was supported by grants NIMH R25MH060482 (to G.J. Aranovich), NSF 1358507 (to S.M. McClure), VA CSR&D: and IK2 CX001028 (S. Fryer), and NIMH R01 MH076989 (to D.H. Mathalon). NR 44 TC 0 Z9 0 U1 3 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 BP 733 EP 739 DI 10.1016/j.neuroimage.2015.09.027 PN A PG 7 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY8GL UT WOS:000366646700068 PM 26394377 ER PT J AU Ahveninen, J Huang, S Ahlfors, SP Hamalainen, M Rossi, S Sams, M Jaaskelainen, IP AF Ahveninen, Jyrki Huang, Samantha Ahlfors, Seppo P. Hamalainen, Matti Rossi, Stephanie Sams, Mikko Jaaskelainen, Iiro P. TI Interacting parallel pathways associate sounds with visual identity in auditory cortices SO NEUROIMAGE LA English DT Article ID SUPERIOR TEMPORAL SULCUS; SHORT-TERM PLASTICITY; AUDIOVISUAL INTEGRATION; RHESUS-MONKEY; HUMAN BRAIN; MULTISENSORY INTERACTIONS; CROSSMODAL BINDING; SENSORY CORTICES; NEURAL SYNCHRONY; EEG-DATA AB Spatial and non-spatial information of sound events is presumably processed in parallel auditory cortex (AC) "what" and "where" streams, which are modulated by inputs from the respective visual-cortex subsystems. How these parallel processes are integrated to perceptual objects that remain stable across time and the source agent's movements is unknown. We recorded magneto-and electroencephalography (MEG/EEG) data while subjects viewed animated video clips featuring two audiovisual objects, a black cat and a gray cat. Adaptor-probe events were either linked to the same object (the black cat meowed twice in a row in the same location) or included a visually conveyed identity change (the black and then the gray cat meowed with identical voices in the same location). In addition to effects in visual (including fusiform, middle temporal or MT areas) and frontoparietal association areas, the visually conveyed object-identity change was associated with a release from adaptation of early (50-150 ms) activity in posterior ACs, spreading to left anterior ACs at 250-450 ms in our combined MEG/EEG source estimates. Repetition of events belonging to the same object resulted in increased theta-band (4-8 Hz) synchronization within the "what" and "where" pathways (e.g., between anterior AC and fusiform areas). In contrast, the visually conveyed identity changes resulted in distributed synchronization at higher frequencies (alpha and beta bands, 8-32 Hz) across different auditory, visual, and association areas. The results suggest that sound events become initially linked to perceptual objects in posterior AC, followed by modulations of representations in anterior AC. Hierarchical what and where pathways seem to operate in parallel after repeating audiovisual associations, whereas the resetting of such associations engages a distributed network across auditory, visual, and multisensory areas. (C) 2015 Elsevier Inc. All rights reserved. C1 [Ahveninen, Jyrki; Huang, Samantha; Ahlfors, Seppo P.; Hamalainen, Matti; Rossi, Stephanie] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA USA. [Hamalainen, Matti] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA. [Hamalainen, Matti] Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, Espoo, Finland. [Sams, Mikko; Jaaskelainen, Iiro P.] Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, Brain & Mind Lab, Espoo, Finland. RP Ahveninen, J (reprint author), MGH MIT HMS Martinos Ctr, Bldg 149 13th St, Charlestown, MA 02129 USA. EM jyrki@nmr.mgh.harvard.edu RI Sams, Mikko/G-7060-2012; Jaaskelainen, Iiro/C-7392-2012; Ahlfors, Seppo/P-3644-2016 OI Jaaskelainen, Iiro/0000-0001-6001-6950; FU National Institutes of Health (NIH) [R01MH083744, R21DC014134, R01HD040712, R01NS037462, 5R01EB009048]; Academy of Finland; NIH [P41EB015896, S10RR014978, S10RR021110, S10RR019307, S10RR014798, S10RR023401] FX In memory of our friend and mentor Dr. John W. Belliveau. We thank Nao Suzuki and Dr. Wei-Tang Chang for their advice and support. This work was supported by National Institutes of Health (NIH) Awards R01MH083744, R21DC014134, R01HD040712, R01NS037462, and 5R01EB009048, and by the Academy of Finland (authors IPJ and MS). The research environment was supported by the NIH awards P41EB015896, S10RR014978, S10RR021110, S10RR019307, S10RR014798, and S10RR023401. NR 106 TC 1 Z9 1 U1 3 U2 14 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 BP 858 EP 868 DI 10.1016/j.neuroimage.2015.09.044 PN A PG 11 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY8GL UT WOS:000366646700080 PM 26419388 ER PT J AU Ressler, KJ Smoller, JW AF Ressler, Kerry J. Smoller, Jordan W. TI Impact of Stress on the Brain: Pathology, Treatment and Prevention SO NEUROPSYCHOPHARMACOLOGY LA English DT Editorial Material C1 [Ressler, Kerry J.] Harvard Univ, McLean Hosp, Sch Med, Div Depress & Anxiety Disorders,James & Patricia, Belmont, MA 02178 USA. [Smoller, Jordan W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Psychiat & Neurodev Genet Unit, Dept Epidemiol,Harvard TH Chan Sch Publ Hlth,Stan, Boston, MA USA. RP Ressler, KJ (reprint author), Harvard Univ, McLean Hosp, Sch Med, Div Depress & Anxiety Disorders,James & Patricia, Belmont, MA 02178 USA. EM kressler@mclean.harvard.edu; jsmoller@hms.harvard.edu FU NIMH NIH HHS [K24 MH094614, K24MH094614, R01 MH094757, R01 MH096764, R01-MH079799, R01 MH079799] NR 21 TC 1 Z9 1 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 1 BP 1 EP 2 DI 10.1038/npp.2015.306 PG 2 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OP UT WOS:000366598400001 PM 26657948 ER PT J AU Besnard, A Sahay, A AF Besnard, Antoine Sahay, Amar TI Adult Hippocampal Neurogenesis, Fear Generalization, and Stress SO NEUROPSYCHOPHARMACOLOGY LA English DT Review ID DENTATE GRANULE CELLS; COMPLEMENTARY LEARNING-SYSTEMS; ENHANCED SYNAPTIC PLASTICITY; PATTERN SEPARATION PROCESSES; NEURAL PROGENITOR CELLS; GENOME-WIDE ASSOCIATION; MOSSY FIBER SYNAPSES; LONG-TERM-MEMORY; POSTTRAUMATIC-STRESS; CRITICAL PERIOD AB The generalization of fear is an adaptive, behavioral, and physiological response to the likelihood of threat in the environment. In contrast, the overgeneralization of fear, a cardinal feature of posttraumatic stress disorder (PTSD), manifests as inappropriate, uncontrollable expression of fear in neutral and safe environments. Overgeneralization of fear stems from impaired discrimination of safe from aversive environments or discernment of unlikely threats from those that are highly probable. In addition, the time-dependent erosion of episodic details of traumatic memories might contribute to their generalization. Understanding the neural mechanisms underlying the overgeneralization of fear will guide development of novel therapeutic strategies to combat PTSD. Here, we conceptualize generalization of fear in terms of resolution of interference between similar memories. We propose a role for a fundamental encoding mechanism, pattern separation, in the dentate gyrus (DG)-CA3 circuit in resolving interference between ambiguous or uncertain threats and in preserving episodic content of remote aversive memories in hippocampal-cortical networks. We invoke cellular-, circuit-, and systems-based mechanisms by which adult-born dentate granule cells (DGCs) modulate pattern separation to influence resolution of interference and maintain precision of remote aversive memories. We discuss evidence for how these mechanisms are affected by stress, a risk factor for PTSD, to increase memory interference and decrease precision. Using this scaffold we ideate strategies to curb overgeneralization of fear in PTSD. C1 [Besnard, Antoine; Sahay, Amar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA USA. [Sahay, Amar] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Sahay, Amar] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Sahay, Amar] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Sahay, A (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, 185 Cambridge St,CPZN 4242, Boston, MA 02114 USA. EM asahay@mgh.harvard.edu FU NARSAD Young Investigator Award; Bettencourt-Schueller Foundation; Philippe Foundation Award; US National Institutes of Health BRAINS [1-R01MH104175]; Ellison Medical Foundation; Whitehall Foundation; Inscopix Decode; Harvard Stem Cell Institute Development Grants FX The authors are supported by 2014 NARSAD Young Investigator Award, Bettencourt-Schueller Foundation and Philippe Foundation Award (to AB), the US National Institutes of Health BRAINS 1-R01MH104175, the Ellison Medical Foundation New Scholar in Aging, Whitehall Foundation, Inscopix Decode, and Harvard Stem Cell Institute Development Grants (to AS). We thank members of our laboratory for discussions and reviewers for their comments. NR 285 TC 15 Z9 17 U1 16 U2 34 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 1 BP 24 EP 44 DI 10.1038/npp.2015.167 PG 21 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OP UT WOS:000366598400003 PM 26068726 ER PT J AU Bowers, ME Yehuda, R AF Bowers, Mallory E. Yehuda, Rachel TI Intergenerational Transmission of Stress in Humans SO NEUROPSYCHOPHARMACOLOGY LA English DT Review ID ANTENATAL MATERNAL ANXIETY; GLUCOCORTICOID-RECEPTOR GENE; INFANT BIRTH-WEIGHT; HOLOCAUST SURVIVORS; PRENATAL STRESS; CORTISOL-LEVELS; NURTURING RELATIONSHIPS; CHERNOBYL EXPOSURE; TRAUMA EXPOSURE; PRETERM BIRTH AB The hypothesis that offspring are affected by parental trauma or stress exposure, first noted anecdotally, is now supported empirically by data from Holocaust survivor offspring cohorts and other populations. These findings have been extended to less extreme forms of stress, where differential physical, behavioral, and cognitive outcomes are observed in affected offspring. Parental stress-mediated effects in offspring could be explained by genetics or social learning theory. Alternatively, biological variations stemming from stress exposure in parents could more directly have an impact on offspring, a concept we refer to here as 'intergenerational transmission', via changes to gametes and the gestational uterine environment. We further extend this definition to include the transmission of stress to offspring via early postnatal care, as animal studies demonstrate the importance of early maternal care of pups in affecting offsprings' long-term behavioral changes. Here, we review clinical observations in offspring, noting that offspring of stress- or trauma-exposed parents may be at greater risk for physical, behavioral, and cognitive problems, as well as psychopathology. Furthermore, we review findings concerning offspring biological correlates of parental stress, in particular, offspring neuroendocrine, epigenetic, and neuroanatomical changes, in an attempt to determine the extent of parental stress effects. Although understanding the etiology of effects in offspring is currently impeded by methodological constraints, and limitations in our knowledge, we summarize current information and conclude by presenting hypotheses that have been prompted by recent studies in the field. C1 [Bowers, Mallory E.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Bronx, NY 10468 USA. [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, Bronx, NY USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY USA. RP Yehuda, R (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, JJP VAMC, 526 OOMH PTSD 116-A,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov NR 104 TC 15 Z9 15 U1 10 U2 38 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 1 BP 232 EP 244 DI 10.1038/npp.2015.247 PG 13 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OP UT WOS:000366598400015 PM 26279078 ER PT J AU Smoller, JW AF Smoller, Jordan W. TI The Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety Disorders SO NEUROPSYCHOPHARMACOLOGY LA English DT Review ID GENOME-WIDE ASSOCIATION; SEROTONIN TRANSPORTER GENE; ENVIRONMENTAL RISK-FACTORS; HURRICANE-EXPOSED ADULTS; SWEDISH NATIONAL TWIN; 2 INDEPENDENT SAMPLES; 22Q11.2 DELETION SYNDROME; DE-NOVO MUTATIONS; OF-THE-LITERATURE; RECEPTOR 1 GENE AB Research into the causes of psychopathology has largely focused on two broad etiologic factors: genetic vulnerability and environmental stressors. An important role for familial/heritable factors in the etiology of a broad range of psychiatric disorders was established well before the modern era of genomic research. This review focuses on the genetic basis of three disorder categories-posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and the anxiety disorders-for which environmental stressors and stress responses are understood to be central to pathogenesis. Each of these disorders aggregates in families and is moderately heritable. More recently, molecular genetic approaches, including genome-wide studies of genetic variation, have been applied to identify specific risk variants. In this review, I summarize evidence for genetic contributions to PTSD, MDD, and the anxiety disorders including genetic epidemiology, the role of common genetic variation, the role of rare and structural variation, and the role of gene-environment interaction. Available data suggest that stress-related disorders are highly complex and polygenic and, despite substantial progress in other areas of psychiatric genetics, few risk loci have been identified for these disorders. Progress in this area will likely require analysis of much larger sample sizes than have been reported to date. The phenotypic complexity and genetic overlap among these disorders present further challenges. The review concludes with a discussion of prospects for clinical translation of genetic findings and future directions for research. C1 [Smoller, Jordan W.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Smoller, Jordan W.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. RP Smoller, JW (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Simches Res Bldg,185 Cambridge St 6th Fl, Boston, MA 02114 USA. EM jsmoller@hms.harvard.edu FU NIMH grants [K24MH094614, R01MH101486] FX Supported in part by NIMH grants K24MH094614 and R01MH101486 to JWS. Dr Smoller is the Tepper Family MGH Research Scholar. Dr Smoller is an unpaid member of the Scientific Advisory Board of PsyBrain, Inc. For: 2016 Neuropsychopharmacology Reviews: The Next Generation of Progress Volume IX. Impact of Stress on the Brain: Pathology, Treatment and Prevention. Editors: Kerry Ressler, MD, PhD and Jordan Smoller, MD, ScD. NR 280 TC 16 Z9 17 U1 28 U2 88 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 1 BP 297 EP 319 DI 10.1038/npp.2015.266 PG 23 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OP UT WOS:000366598400019 PM 26321314 ER PT J AU Widge, AS Sahay, A AF Widge, Alik S. Sahay, Amar TI Closing the Loop in Deep Brain Stimulation for Psychiatric Disorders: Lessons from Motor Neural Prosthetics SO NEUROPSYCHOPHARMACOLOGY LA English DT Editorial Material C1 [Widge, Alik S.; Sahay, Amar] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Widge, Alik S.; Sahay, Amar] Harvard Univ, Sch Med, Boston, MA USA. [Widge, Alik S.] MIT, Picower Inst Learning & Memory, Cambridge, MA 02139 USA. [Sahay, Amar] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Sahay, Amar] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. RP Widge, AS (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM awidge@partners.org; asahay@mgh.harvard.edu FU NIMH NIH HHS [1-R01MH104175, R01 MH104175] NR 6 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 1 BP 379 EP 380 DI 10.1038/npp.2015.241 PG 3 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OP UT WOS:000366598400032 PM 26657958 ER PT J AU Vinogradov, S Herman, A AF Vinogradov, Sophia Herman, Alexander TI Psychiatric Illnesses as Oscillatory Connectomopathies SO NEUROPSYCHOPHARMACOLOGY LA English DT Editorial Material ID NETWORK OSCILLATIONS C1 [Vinogradov, Sophia; Herman, Alexander] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Vinogradov, Sophia] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. RP Vinogradov, S (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM sophia.vinogradov@ucsf.edu FU NIMH NIH HHS [MH68725, R01 MH068725] NR 6 TC 2 Z9 2 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 1 BP 387 EP 388 DI 10.1038/npp.2015.308 PG 3 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OP UT WOS:000366598400039 PM 26657965 ER PT J AU Haney, M Evins, AE AF Haney, Margaret Evins, A. Eden TI Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed SO NEUROPSYCHOPHARMACOLOGY LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; CONTEXTUAL FEAR MEMORY; 1ST EPISODE PSYCHOSIS; HIGH-POTENCY CANNABIS; FOLLOW-UP; ENDOCANNABINOID SYSTEM; 1ST-EPISODE PSYCHOSIS; SWEDISH CONSCRIPTS; MILITARY VETERANS; AVERSIVE MEMORIES AB There have been extensive policy shifts in the legality of recreational and therapeutic use of cannabis in the United States, as well as a steady increase in the number of people using the drug on a regular basis. Given these rapid societal changes, defining what is known scientifically about the consequences of cannabis use on mental health takes on added public health significance. The purpose of this circumspectives piece is to discuss evidence of cannabis' effects on two psychiatric conditions: post-traumatic stress disorder and psychotic disorders. Dr Haney and Dr Evins will discuss two viewpoints regarding the benefit and harm of cannabis use for these conditions, while outlining what remains unproven and requires further testing to move the field forward. C1 [Haney, Margaret] Columbia Univ, Med Ctr, Dept Psychiat, Div Substance Abuse, New York, NY 10032 USA. [Evins, A. Eden] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA. [Evins, A. Eden] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Haney, M (reprint author), Columbia Univ, Med Ctr, New York State Psychiat Inst, Neurobiol Psychiat, 1051 Riverside Dr,Unit 120, New York, NY 10032 USA. EM mh235@columbia.edu FU NIDA; Insys Therapeutics; Aelis Farma; Lifeloc Technologies; NIMH; NHLBI; Pfizer; Forum Pharmaceuticals; GSK FX Dr Haney's research is funded by NIDA. She has received research support from Insys Therapeutics, Aelis Farma and Lifeloc Technologies. Dr Evins' research is funded by NIDA, NIMH, and NHLBI. She has received research support from Pfizer, Forum Pharmaceuticals, and GSK. NR 113 TC 4 Z9 4 U1 13 U2 30 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 2 BP 393 EP 401 DI 10.1038/npp.2015.251 PG 9 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OZ UT WOS:000366599400002 PM 26286840 ER PT J AU Webb, CA Dillon, DG Pechtel, P Goer, FK Murray, L Huys, QJM Fava, M McGrath, PJ Weissman, M Parsey, R Kurian, BT Adams, P Weyandt, S Trombello, JM Grannemann, B Cooper, CM Deldin, P Tenke, C Trivedi, M Bruder, G Pizzagalli, DA AF Webb, Christian A. Dillon, Daniel G. Pechtel, Pia Goer, Franziska K. Murray, Laura Huys, Quentin J. M. Fava, Maurizio McGrath, Patrick J. Weissman, Myrna Parsey, Ramin Kurian, Benji T. Adams, Phillip Weyandt, Sarah Trombello, Joseph M. Grannemann, Bruce Cooper, Crystal M. Deldin, Patricia Tenke, Craig Trivedi, Madhukar Bruder, Gerard Pizzagalli, Diego A. TI Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study SO NEUROPSYCHOPHARMACOLOGY LA English DT Article ID DORSOLATERAL PREFRONTAL CORTEX; SUBGENUAL ANTERIOR CINGULATE; REWARD RESPONSIVENESS; MAJOR DEPRESSION; COGNITIVE CONTROL; CANDIDATE ENDOPHENOTYPES; INDIVIDUAL-DIFFERENCES; RESPONSE-INHIBITION; HUMAN BRAIN; PERSONALITY AB Major depressive disorder (MDD) is clinically, and likely pathophysiologically, heterogeneous. A potentially fruitful approach to parsing this heterogeneity is to focus on promising endophenotypes. Guided by the NIMH Research Domain Criteria initiative, we used source localization of scalp-recorded EEG resting data to examine the neural correlates of three emerging endophenotypes of depression: neuroticism, blunted reward learning, and cognitive control deficits. Data were drawn from the ongoing multi-site EMBARC study. We estimated intracranial current density for standard EEG frequency bands in 82 unmedicated adults with MDD, using Low-Resolution Brain Electromagnetic Tomography. Region-of-interest and whole-brain analyses tested associations between resting state EEG current density and endophenotypes of interest. Neuroticism was associated with increased resting gamma (36.5-44 Hz) current density in the ventral (subgenual) anterior cingulate cortex (ACC) and orbitofrontal cortex (OFC). In contrast, reduced cognitive control correlated with decreased gamma activity in the left dorsolateral prefrontal cortex (dlPFC), decreased theta (6.5-8 Hz) and alpha2 (10.5-12 Hz) activity in the dorsal ACC, and increased alpha2 activity in the right dlPFC. Finally, blunted reward learning correlated with lower OFC and left dlPFC gamma activity. Computational modeling of trial-by-trial reinforcement learning further indicated that lower OFC gamma activity was linked to reduced reward sensitivity. Three putative endophenotypes of depression were found to have partially dissociable resting intracranial EEG correlates, reflecting different underlying neural dysfunctions. Overall, these findings highlight the need to parse the heterogeneity of MDD by focusing on promising endophenotypes linked to specific pathophysiological abnormalities. C1 [Webb, Christian A.; Dillon, Daniel G.; Pechtel, Pia; Goer, Franziska K.; Murray, Laura; Pizzagalli, Diego A.] Harvard Univ, Dept Psychiat, Sch Med, Belmont, MA 02478 USA. [Webb, Christian A.; Dillon, Daniel G.; Pechtel, Pia; Goer, Franziska K.; Murray, Laura; Pizzagalli, Diego A.] McLean Hosp, Belmont, MA 02178 USA. [Huys, Quentin J. M.] Univ Zurich, Hosp Psychiat, Dept Psychiat Psychotherapy & Psychosomat, Ctr Addict Disorders, CH-8006 Zurich, Switzerland. [Huys, Quentin J. M.] Univ Zurich, Inst Biomed Engn, Translat Neuromodeling, CH-8006 Zurich, Switzerland. [Huys, Quentin J. M.] Swiss Fed Inst Technol, Zurich, Switzerland. [Fava, Maurizio] Massachusetts Gen Hosp, Clin Res Program, Boston, MA 02114 USA. [McGrath, Patrick J.; Weissman, Myrna; Adams, Phillip; Tenke, Craig; Bruder, Gerard] Columbia Univ, Dept Psychiat, New York State Psychiat Inst, New York, NY USA. [McGrath, Patrick J.; Weissman, Myrna; Adams, Phillip; Tenke, Craig; Bruder, Gerard] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Parsey, Ramin] SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA. [Kurian, Benji T.; Weyandt, Sarah; Trombello, Joseph M.; Grannemann, Bruce; Cooper, Crystal M.; Trivedi, Madhukar] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Deldin, Patricia] Univ Michigan Hlth Syst, Dept Psychiat, Ann Arbor, MI USA. RP Pizzagalli, DA (reprint author), Harvard Univ, McLean Hosp, Sch Med, Ctr Depress Anxiety & Stress Res, 115 Mill St, Belmont, MA 02478 USA. EM dap@mclean.harvard.edu RI Parsey, Ramin/J-8254-2014 FU National Institute of Mental Health of the National Institutes of Health [U01MH092221, U01MH092250]; NIMH [F32 MH099801, R00 MH094438, R01 MH068376]; EMBARC National Coordinating Center at UT Southwestern Medical Center; Targacept, Inc.; Pfizer, Inc.; Johnson Johnson; Evotec; Rexahn; Naurex; Forest Pharmaceuticals; Agency for Healthcare Research and Quality (AHRQ); Corcept Therapeutics, Inc.; Cyberonics, Inc.; National Alliance for Research in Schizophrenia and Depression; Novartis; Pharmacia Upjohn; Predix Pharmaceuticals (Epix); Solvay Pharmaceuticals, Inc.; National Institute of Mental Health; New York State Department of Mental Hygiene; Research Foundation for Mental Hygiene (New York State); F. Hoffman-LaRoche, Ltd.; Naurex Pharmaceuticals; Forest Research and Sunovion Pharmaceuticals; National Institute on Drug Abuse; National Alliance for Research on Schizophrenia and Depression; Sackler Foundation; Templeton Foundation; Advanced Neuro Technology North America; AstraZeneca; Otsuka America Pharmaceutical; Pfizer; Servier; Data Center at Columbia and Stony Brook Universities FX The EMBARC study was supported by the National Institute of Mental Health of the National Institutes of Health under award numbers U01MH092221 (Trivedi, M.H.) and U01MH092250 (McGrath, P.J., Parsey, R.V., Weissman, M. M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Drs. Webb, Dillon and Pizzagalli were supported by NIMH F32 MH099801, R00 MH094438, and R01 MH068376, respectively. Valeant Pharmaceuticals donated the Wellbutrin XL used in the study. This work was supported by the EMBARC National Coordinating Center at UT Southwestern Medical Center to Madhukar H. Trivedi, M.D., Coordinating PI, and the Data Center at Columbia and Stony Brook Universities. Dr Kurian has received grant support from the following additional sources: Targacept, Inc.; Pfizer, Inc.; Johnson & Johnson; Evotec; Rexahn; Naurex; and Forest Pharmaceuticals. Dr Trombello owns Merck and J&J stock. Dr Trivedi is or has been an advisor/consultant to: Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Fabre Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, SHIRE Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories. In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), Corcept Therapeutics, Inc., Cyberonics, Inc., National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, Novartis, Pharmacia & Upjohn, Predix Pharmaceuticals (Epix), and Solvay Pharmaceuticals, Inc. For a comprehensive list of lifetime disclosures of Dr Fava, see http://mghcme.org/faculty/faculty-detail/maurizio_fava. Over the past 3 years, Dr McGrath has received research support from the National Institute of Mental Health, the New York State Department of Mental Hygiene, the Research Foundation for Mental Hygiene (New York State), F. Hoffman-LaRoche, Ltd., Naurex Pharmaceuticals, Forest Research and Sunovion Pharmaceuticals. In the past 3 years, Dr Weissman received funding from the National Institute of Mental Health, the National Institute on Drug Abuse, the National Alliance for Research on Schizophrenia and Depression, the Sackler Foundation, and the Templeton Foundation; and received royalties from the Oxford University Press, Perseus Press, the American Psychiatric Association Press and MultiHealth Systems. Dr Weissman declares that none of these present a conflict of interest. Dr Grannemann declares that, except for income received from a primary employer and the above grant (U01MH092221), no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.; Over the past 3 years, Dr Pizzagalli has received honoraria/consulting fees from Advanced Neuro Technology North America, AstraZeneca, Otsuka America Pharmaceutical, Pfizer, and Servier for activities unrelated to this project. The remaining authors declare no conflict of interest. NR 61 TC 7 Z9 7 U1 8 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 2 BP 454 EP 463 DI 10.1038/npp.2015.165 PG 10 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OZ UT WOS:000366599400008 PM 26068725 ER PT J AU Curatolo, A Villiger, M Lorenser, D Wijesinghe, P Fritz, A Kennedy, BF Sampson, DD AF Curatolo, Andrea Villiger, Martin Lorenser, Dirk Wijesinghe, Philip Fritz, Alexander Kennedy, Brendan F. Sampson, David D. TI Ultrahigh-resolution optical coherence elastography SO OPTICS LETTERS LA English DT Article ID TOMOGRAPHY; MICROSCOPY AB Visualizing stiffness within the local tissue environment at the cellular and subcellular level promises to provide insight into the genesis and progression of disease. In this Letter, we propose ultrahigh-resolution optical coherence elastography (UHROCE), and demonstrate 3D imaging of local axial strain of tissues undergoing compressive loading. We combine optical coherence microscopy (OCM) and phase-sensitive detection of local tissue displacement to produce strain elastograms with resolution (x,y,z) of 2 x 2 x 15 mu m. We demonstrate this performance on a freshly excised mouse aorta and reveal the mechanical heterogeneity of vascular smooth muscle cells and elastin sheets, otherwise unresolved in a typical, lower resolution optical coherence elastography (OCE) system. (C) 2015 Optical Society of America C1 [Curatolo, Andrea; Lorenser, Dirk; Wijesinghe, Philip; Fritz, Alexander; Kennedy, Brendan F.; Sampson, David D.] Univ Western Australia, Opt Biomed Engn Lab, Crawley, WA 6009, Australia. [Villiger, Martin] Harvard Univ, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. [Villiger, Martin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sampson, David D.] Univ Western Australia, Ctr Microscopy Characterisat & Anal, Crawley, WA 6009, Australia. RP Curatolo, A (reprint author), Univ Western Australia, Opt Biomed Engn Lab, 35 Stirling Highway, Crawley, WA 6009, Australia. EM andrea.curatolo@uwa.edu.au RI Sampson, David/B-2931-2011 OI Sampson, David/0000-0001-6724-3873 FU Australian Research Council (ARC); National Breast Cancer Foundation (NBCF); National Health and Medical Research Council (NHMRC); University of Western Australia (UWA) FX Australian Research Council (ARC); National Breast Cancer Foundation (NBCF); National Health and Medical Research Council (NHMRC); University of Western Australia (UWA). NR 23 TC 11 Z9 11 U1 1 U2 10 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 0146-9592 EI 1539-4794 J9 OPT LETT JI Opt. Lett. PD JAN 1 PY 2016 VL 41 IS 1 BP 21 EP 24 DI 10.1364/OL.41.000021 PG 4 WC Optics SC Optics GA CY9WH UT WOS:000366756500006 PM 26696148 ER PT J AU Reddy, BG Dai, Q McNicholas, CM Fuller, CM Kappes, JC DeLucas, LJ AF Reddy, Bharat G. Dai, Qun McNicholas, Carmel M. Fuller, Catherine M. Kappes, John C. DeLucas, Lawrence J. TI Expression and purification of the alpha subunit of the epithelial sodium channel, ENaC SO PROTEIN EXPRESSION AND PURIFICATION LA English DT Article DE Epithelial sodium channel; ENaC; GFP; GFP Affinity Column; Membrane Protein Purification; Membrane Protein Expression ID CELL-SURFACE EXPRESSION; NA+ CHANNEL; MEMBRANE-PROTEINS; ION-CHANNEL; RETROVIRAL VECTORS; LENTIVIRAL VECTOR; GAMMA-SUBUNIT; AMILORIDE; STOICHIOMETRY; FLUORESCENCE AB The epithelial sodium channel (ENaC) plays a critical role in maintaining Na+ homeostasis in various tissues throughout the body. An understanding of the structure of the ENaC subunits has been developed from homology modeling based on the related acid sensing ion channel 1 (ASIC1) protein structure, as well as electrophysiological approaches. However, ENaC has several notable functional differences compared to ASIC1, thereby providing justification for determination of its three-dimensional structure. Unfortunately, this goal remains elusive due to several experimental challenges. Of the subunits that comprise a physiological hetero-trimeric alpha beta gamma ENaC, the alpha-subunit is unique in that it is capable of forming a homo-trimeric structure that conducts Na+ ions. Despite functional and structural interest in alpha ENaC, a key factor complicating structural studies has been its interaction with multiple other proteins, disrupting its homogeneity. In order to address this issue, a novel protocol was used to reduce the number of proteins that associate and co-purify with alpha ENaC. In this study, we describe a novel expression system coupled with a two-step affinity purification approach using NiNTA, followed by a GFP antibody column as a rapid procedure to improve the purity and yield of rat aENaC. (C) 2015 Elsevier Inc. All rights reserved. C1 [Dai, Qun; Kappes, John C.] Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35294 USA. [Dai, Qun; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [McNicholas, Carmel M.; Fuller, Catherine M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. [DeLucas, Lawrence J.] Univ Alabama Birmingham, Dept Optometry, Birmingham, AL 35294 USA. [Reddy, Bharat G.; Fuller, Catherine M.; Kappes, John C.; DeLucas, Lawrence J.] Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL 35233 USA. RP DeLucas, LJ (reprint author), Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA. EM duke2@uab.edu FU NIH [NIGMS R01GM095639, NIDDK R01DK037206, P30 AR048311]; Virology, Genetic Sequencing and Flow Cytometry Cores of the UAB Center for AIDS Research [P30 AI27767]; UAB CF Research & Translational Core Center [P30 DK072482] FX This research was supported by the following NIH Grants NIGMS R01GM095639 and NIDDK R01DK037206, and the Virology, Genetic Sequencing and Flow Cytometry Cores of the UAB Center for AIDS Research (P30 AI27767), and the UAB CF Research & Translational Core Center (P30 DK072482). They antibodies were made by RDCC Analytical Imaging and Immunoreagent Core with supported from NIH P30 AR048311. We would also Casey Weaver for the use of his hybridoma and Suman Bharara and Kevin Macon for their help in culturing the hybridoma to produce the GFP antibody. Finally we would like to thank the late Dale Benos, without whom, none of this would have been done. NR 62 TC 0 Z9 0 U1 2 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-5928 EI 1096-0279 J9 PROTEIN EXPRES PURIF JI Protein Expr. Purif. PD JAN PY 2016 VL 117 BP 67 EP 75 DI 10.1016/j.pep.2015.09.014 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA CZ0JU UT WOS:000366791900009 PM 26394093 ER PT J AU Bhatt, SP Wells, JM Kinney, GL Washko, GR Budoff, M Kim, YI Bailey, WC Nath, H Hokanson, JE Silverman, EK Crapo, J Dransfield, MT AF Bhatt, Surya P. Wells, James M. Kinney, Gregory L. Washko, George R., Jr. Budoff, Matthew Kim, Young-il Bailey, William C. Nath, Hrudaya Hokanson, John E. Silverman, Edwin K. Crapo, James Dransfield, Mark T. CA COPDGene Investigators TI beta-Blockers are associated with a reduction in COPD exacerbations SO THORAX LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; RISK; ASTHMA; HYPERTENSION; THERAPY; CLASSIFICATION; METAANALYSIS AB Background While some retrospective studies have suggested that beta-blocker use in patients with COPD is associated with a reduction in the frequency of acute exacerbations and lower mortality, there is concern that their use in patients with severe COPD on home oxygen may be harmful. Methods Subjects with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2-4 COPD participating in a prospective follow-up of the COPDGene cohort, a multicentre observational cohort of current and former smokers were recruited. Total and severe exacerbation rates were compared between groups categorised by beta-blocker use on longitudinal follow-up using negative binomial regression analyses, after adjustment for demographics, airflow obstruction, % emphysema on CT, respiratory medications, presence of coronary artery disease, congestive heart failure and coronary artery calcification, and after adjustment for propensity to prescribe beta-blockers. Results 3464 subjects were included. During a median of 2.1 years of follow-up, beta-blocker use was associated with a significantly lower rate of total (incidence risk ratio (IRR) 0.73, 95% CI 0.60 to 0.90; p=0.003) and severe exacerbations (IRR 0.67, 95% CI 0.48 to 0.93; p=0.016). In those with GOLD stage 3 and 4 and on home oxygen, use of beta-blockers was again associated with a reduction in the rate of total (IRR 0.33, 95% CI 0.19 to 0.58; p<0.001) and severe exacerbations (IRR 0.35, 95% CI 0.16 to 0.76; p=0.008). Exacerbation reduction was greatest in GOLD stage B. There was no difference in all-cause mortality with beta-blocker use. Conclusions beta-Blockers are associated with a significant reduction in COPD exacerbations regardless of severity of airflow obstruction. The findings of this study should be tested in a randomised, placebo-controlled trial. C1 [Bhatt, Surya P.; Wells, James M.; Bailey, William C.; Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Kinney, Gregory L.; Hokanson, John E.] Univ Colorado, Dept Epidemiol, Aurora, CO USA. [Washko, George R., Jr.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Budoff, Matthew] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Kim, Young-il] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL 35294 USA. [Nath, Hrudaya] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL 35294 USA. [Silverman, Edwin K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA. [Crapo, James] Natl Jewish Hlth, Div Pulm & Crit Care, Denver, CO USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Bhatt, SP (reprint author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, THT 422,1720,2nd Ave South, Birmingham, AL 35294 USA. EM spbhatt@uab.edu FU NIH [R01 HL089897, R01 HL089856, R01 HL122438]; TRDRP Award [20XT-0014] FX COPDGene is supported by NIH grant numbers R01 HL089897, R01 HL089856 and R01 HL122438. The coronary calcification data is supported by TRDRP Award No. 20XT-0014. NR 43 TC 13 Z9 15 U1 2 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 EI 1468-3296 J9 THORAX JI Thorax PD JAN PY 2016 VL 71 IS 1 BP 8 EP 14 DI 10.1136/thoraxjnl-2015-207251 PG 7 WC Respiratory System SC Respiratory System GA CY8TV UT WOS:000366682100004 PM 26283710 ER PT J AU Quittner, AL Abbott, J Georgiopoulos, AM Goldbeck, L Smith, B Hempstead, SE Marshall, B Sabadosa, KA Elborn, S AF Quittner, Alexandra L. Abbott, Janice Georgiopoulos, Anna M. Goldbeck, Lutz Smith, Beth Hempstead, Sarah E. Marshall, Bruce Sabadosa, Kathryn A. Elborn, Stuart CA Int Comm Mental Hlth TI International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety SO THORAX LA English DT Article ID QUALITY-OF-LIFE; SYMPTOMS; ADULTS; CARE; ADOLESCENTS; CHILDREN; ADHERENCE; ASSOCIATION; PREVALENCE; GUIDELINES AB Studies measuring psychological distress in individuals with cystic fibrosis (CF) have found high rates of both depression and anxiety. Psychological symptoms in both individuals with CF and parent caregivers have been associated with decreased lung function, lower body mass index, worse adherence, worse health-related quality of life, more frequent hospitalisations and increased healthcare costs. To identify and treat depression and anxiety in CF, the CF Foundation and the European CF Society invited a panel of experts, including physicians, psychologists, psychiatrists, nurses, social workers, a pharmacist, parents and an individual with CF, to develop consensus recommendations for clinical care. Over 18 months, this 22-member committee was divided into four workgroups: Screening; Psychological Interventions; Pharmacological Treatments and Implementation and Future Research, and used the Population, Intervention, Comparison, Outcome methodology to develop questions for literature search and review. Searches were conducted in PubMed, PsychINFO, ScienceDirect, Google Scholar, Psychiatry online and ABDATA by a methodologist at Dartmouth. The committee reviewed 344 articles, drafted statements and set an 80% acceptance for each recommendation statement as a consensus threshold prior to an anonymous voting process. Fifteen guideline recommendation statements for screening and treatment of depression and anxiety in individuals with CF and parent caregivers were finalised by vote. As these recommendations are implemented in CF centres internationally, the process of dissemination, implementation and resource provision should be closely monitored to assess barriers and concerns, validity and use. C1 [Quittner, Alexandra L.] Univ Miami, Coral Gables, FL 33146 USA. [Abbott, Janice] Univ Cent Lancashire, Sch Psychol, Preston PR1 2HE, Lancs, England. [Georgiopoulos, Anna M.] Massachusetts Gen Hosp, Dept Child & Adolescent Psychiat, Boston, MA 02114 USA. [Goldbeck, Lutz] Univ Hosp Ulm, Dept Child & Adolescent Psychiat Psychotherapy, Ulm, Germany. [Smith, Beth] SUNY Buffalo, Div Child & Adolescent Psychiat, Buffalo, NY 14260 USA. [Hempstead, Sarah E.; Sabadosa, Kathryn A.] Geisel Sch Med Dartmouth, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. [Marshall, Bruce] Cyst Fibrosis Fdn, Bethesda, MD USA. [Elborn, Stuart] Queens Univ Belfast, Belfast, Antrim, North Ireland. RP Quittner, AL (reprint author), Univ Miami, Dept Psychol, 5665 Ponce de Leon Blvd, Coral Gables, FL 33146 USA. EM aquittner@miami.edu OI elborn, joseph/0000-0002-2323-442X FU CFF; ECFS FX The authors received funding from the CFF and the ECFS. NR 41 TC 22 Z9 22 U1 5 U2 17 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 EI 1468-3296 J9 THORAX JI Thorax PD JAN PY 2016 VL 71 IS 1 BP 26 EP 34 DI 10.1136/thoraxjnl-2015-207488 PG 9 WC Respiratory System SC Respiratory System GA CY8TV UT WOS:000366682100006 PM 26452630 ER PT J AU Estock, JL Curinga, HK Li, A Grieve, LB Brackney, CR AF Estock, Jamie L. Curinga, Holly K. Li, Airan Grieve, Lorin B. Brackney, Christopher R. TI Comparison of chest compression interruption times across 2 automated devices: a randomized, crossover simulation study SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; OVER MANNEQUIN; TRIAL; SYSTEM; HELICOPTER; QUALITY; CPR AB Objective: The goal of this study was to compare chest compression interruption times required to apply, adjust, and remove 2 different automated chest compression (ACC) devices using the same evaluation protocol. Methods: Twenty-nine registered nurses and respiratory therapists used 2 ACC devices in separate resuscitation scenarios involving a patient manikin simulating a 45-year-old man in cardiac arrest in his intensive care unit room. Device presentation was randomized, with half of the participants using LUCAS 2 in the first scenario and the other half using AutoPulse in the first scenario. Results: The mean chest compression interruption time to apply the ACC device to the patient was significantly shorter for AutoPulse (mean [M] = 31.6 +/- 8.44) than for LUCAS 2 (M = 39.1 +/- 11.20; t(28) = 3.65, P = .001). The mean chest compression interruption time to remove the ACC device from the patient and resume manual compressions was also significantly shorter for AutoPulse (M = 6.5 +/- 3.65) than for LUCAS 2 (M = 10.1 +/- 3.97; t(26) = 3.36, P = .002). There was no difference in the mean chest compression interruption time to adjust the position of the ACC device on the patient between AutoPulse (M = 14.3 +/- 5.24) and LUCAS 2 (M = 12.5 +/- 3.89; t(23)= -1.45, P = .162). Conclusions: The results of this study trended in favor of AutoPulse. However, the interruption in chest compression to apply either device to the patient was notably longer than the maximum interruption time recommended by the American Heart Association. Published by Elsevier Inc. C1 [Estock, Jamie L.; Li, Airan] VA Pittsburgh Healthcare Syst, Ctr Med Prod End User Testing, Pittsburgh, PA USA. [Curinga, Holly K.; Brackney, Christopher R.] VA Pittsburgh Healthcare Syst, Crit Care Serv, Pittsburgh, PA USA. [Grieve, Lorin B.] VA Pittsburgh Healthcare Syst, Dept Educ, Pittsburgh, PA USA. RP Estock, JL (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C Res Bldg 30,G-39, Pittsburgh, PA 15240 USA. EM jamie.estock@va.gov OI Estock, Jamie/0000-0001-8279-2811 FU Medical Education and Patient Safety grant through the Veterans Research Foundation at VA Pittsburgh Healthcare System, Pittsburgh, PA FX The execution of this work was supported by a Medical Education and Patient Safety grant through the Veterans Research Foundation at VA Pittsburgh Healthcare System, Pittsburgh, PA. The sponsor of this research had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit this article for publication. NR 28 TC 0 Z9 0 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD JAN PY 2016 VL 34 IS 1 BP 57 EP 62 DI 10.1016/j.ajem.2015.09.011 PG 6 WC Emergency Medicine SC Emergency Medicine GA CY1IH UT WOS:000366159400012 PM 26472511 ER PT J AU Coe, TM Wilson, SE Chang, DC AF Coe, Taylor M. Wilson, Samuel E. Chang, David C. TI Do past mortality rates predict future hospital mortality? SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Surgical outcomes; Historical mortality rates; Outcomes prediction ID SURGICAL MORTALITY; UNITED-STATES; PERFORMANCE; VOLUME; OUTCOMES; SURGERY AB BACKGROUND: This study aimed to determine whether hospitals with higher historical mortality rates are independently associated with worse patient outcomes. METHODS: Observational study of in-hospital mortality in open abdominal aortic aneurysm repair, aortic valve replacement, and coronary artery bypass graft surgery in a California in-patient database was conducted. Hospitals' annual historical mortality rates between 1998 and 2010 were calculated based on 3 years of data before each year. Results were adjusted for race, sex, age, hospital teaching status, admission year, insurance status, and Charlson comorbidity index. RESULTS: Hospitals were divided into quartiles based on historical mortality rates. For abdominal aortic aneurysm repair, the odds ratio (OR) of in-hospital mortality for hospitals within the highest quartile of prior mortality was 1.30 compared with the lowest quartile (95% confidence interval [CI] 1.03 to 1.63). For aortic valve replacement, the OR was 1.41 for the 3rd quartile (95% CI 1.15 to 1.73) and 1.54 for the highest quartile (95% CI 1.27 to 1.87). For coronary artery bypass graft surgery, the OR was 1.33 for the 3rd (95% CI 1.2 to 1.49) and 1.58 for the highest (95% CI 1.41 to 1.76) quartiles. CONCLUSION: Patients presenting to hospitals with high historical mortality rates have a 30% to 60% increased mortality risk compared with patients presenting to hospitals with low historical mortality rates. (C) 2016 Elsevier Inc. All rights reserved. C1 [Coe, Taylor M.] Univ Calif San Diego, UC San Diego Hlth Syst, Dept Surg, La Jolla, CA 92093 USA. [Wilson, Samuel E.] Univ Calif Irvine, Irvine Med Ctr, Dept Surg, Orange, CA 92668 USA. [Chang, David C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA. RP Chang, DC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA. EM dchang8@mgh.harvard.edu FU NHLBI NIH HHS [T35 HL007491] NR 14 TC 1 Z9 1 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 EI 1879-1883 J9 AM J SURG JI Am. J. Surg. PD JAN PY 2016 VL 211 IS 1 BP 159 EP 165 DI 10.1016/j.amjsurg.2015.04.001 PG 7 WC Surgery SC Surgery GA CY2AH UT WOS:000366210500024 PM 26026336 ER PT J AU Butler, KL Chang, Y DeMoya, M Feinstein, A Ferrada, P Maduekwe, U Maung, AA Melo, N Odom, S Olasky, J Reinhorn, M Smink, DB Stassen, N Wilson, CT Fagenholz, P Kaafarani, H King, D Yeh, DD Velmahos, G Stefanidis, D AF Butler, Kathryn L. Chang, Yuchiao DeMoya, Marc Feinstein, Ara Ferrada, Paula Maduekwe, Ugwuji Maung, Adrian A. Melo, Nicolas Odom, Stephen Olasky, Jaisa Reinhorn, Michael Smink, Douglas B. Stassen, Nicole Wilson, Chad T. Fagenholz, Peter Kaafarani, Haytham King, David Yeh, Daniel D. Velmahos, George Stefanidis, Dimitrios TI Needs assessment for a focused radiology curriculum in surgical residency: a multicenter study SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE General surgery residency; Radiology; Resident education; Curricular design ID COMPUTED-TOMOGRAPHY SCANS; EMERGENCY-DEPARTMENT; TRAUMA; RADIOGRAPHS; PHYSICIANS AB BACKGROUND: Patient instability and limited radiology staffing may compel surgeons to make clinical decisions based on their independent interpretations of imaging studies. Despite potential implications for patients, no research to date has assessed the need for a diagnostic radiology curriculum in general surgery residency. METHODS: We performed a cross-sectional study of surgery faculty and residents at 13 teaching hospitals across the United States. Survey responses were summarized using frequency and percentage, and analyzed by chi-square, Mantel-Haenszel chi-square, and McNemar tests. RESULTS: Surveys were distributed to 465 faculty and 520 residents, with response rates of 26% and 30%, respectively. Most respondents reported making decisions based on their independent imaging interpretation at least sometimes, with higher frequency in acute scenarios. The majority voiced a need for a dedicated radiology curriculum, with teaching in chest x-rays, abdominal x-rays, abdominal computed tomography, chest computed tomography, and focused assessment with sonography in trauma examinations. CONCLUSIONS: Surgeons and surgical residents enact treatment plans based on their independent interpretation of imaging studies, especially during acute patient scenarios. Further curricular development efforts are warranted to ensure trainee accuracy in radiologic interpretation. (C) 2016 Elsevier Inc. All rights reserved. C1 [Butler, Kathryn L.; Chang, Yuchiao; DeMoya, Marc; Fagenholz, Peter; Kaafarani, Haytham; King, David; Yeh, Daniel D.; Velmahos, George] Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. [Feinstein, Ara] Banner Univ, Med Ctr, Trauma Crit Care & Acute Care Surg Div, Phoenix, AZ USA. [Ferrada, Paula] Virginia Commonwealth Univ, Dept Surg, Div Acute Care Surg, Richmond, VA USA. [Maduekwe, Ugwuji] Cambridge Hlth Alliance, Dept Surg, Cambridge, MA USA. [Maung, Adrian A.] Yale Univ, Sch Med, Dept Surg, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06510 USA. [Melo, Nicolas] Cedars Sinai Med Ctr, Dept Surg, Div Trauma Acute Care Surg & Crit Care, Los Angeles, CA 90048 USA. [Odom, Stephen] Beth Israel Deaconess Med Ctr, Dept Surg, Div Acute Care Surg, Boston, MA 02215 USA. [Olasky, Jaisa] Mt Auburn Hosp, Dept Surg, Cambridge, MA USA. [Reinhorn, Michael] Newton Wellesley Hosp, Dept Surg, Newton, MA USA. [Smink, Douglas B.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Stassen, Nicole] Univ Rochester, Med Ctr, Dept Surg, Rochester, NY 14642 USA. [Wilson, Chad T.] NYU, Sch Med, Dept Surg, Div Acute Care Surg, New York, NY USA. [Stefanidis, Dimitrios] Carolinas Healthcare Syst, Dept Surg, Charlotte, NC USA. RP Butler, KL (reprint author), Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge Suite 810, Boston, MA 02114 USA. EM klbutler@partners.org NR 15 TC 0 Z9 0 U1 2 U2 5 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 EI 1879-1883 J9 AM J SURG JI Am. J. Surg. PD JAN PY 2016 VL 211 IS 1 BP 279 EP 287 DI 10.1016/j.amjsurg.2015.05.027 PG 9 WC Surgery SC Surgery GA CY2AH UT WOS:000366210500037 PM 26329901 ER PT J AU Kil, KE Poutiainen, P Zhang, ZD Zhu, AJ Kuruppu, D Prabhakar, S Choi, JK Tannous, BA Brownell, AL AF Kil, Kun-Eek Poutiainen, Pekka Zhang, Zhaoda Zhu, Aijun Kuruppu, Darshini Prabhakar, Shilpa Choi, Ji-Kyung Tannous, Bakhos A. Brownell, Anna-Liisa TI Synthesis and evaluation of N-(methylthiophenyl)picolinamide derivatives as PET radioligands for metabotropic glutamate receptor subtype 4 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS LA English DT Article DE PET; Metabotropic glutamate receptor subtype 4 (mGlu(4)); Positive allosteric modulator (PAM) ID POSITIVE ALLOSTERIC MODULATOR; PARKINSONS-DISEASE; GROUP-III; MEDIATED MODULATION; RODENT MODELS; L-DOPA; MGLU(4); LOCALIZATION; RAT; RADIOSYNTHESIS AB In recent years, mGlu(4) has received great research attention because of the potential benefits of mGlu(4) activation in treating numerous brain disorders, such as Parkinson's disease (PD). A specific mGlu(4) PET radioligand could be an important tool in understanding the role of mGlu(4) in both healthy and disease conditions, and also for the development of new drugs. In this study, we synthesized four new N-(methylthiophenyl)picolinamide derivatives 11-14. Of these ligands, 11 and 14 showed high in vitro binding affinity for mGlu(4) with IC50 values of 3.4 nM and 3.1 nM, respectively, and suitable physicochemical parameters. Compound 11 also showed enhanced metabolic stability and good selectivity to other mGluRs. [C-11]11 and [C-11]14 were radiolabeled using the [C-11] methylation of the thiophenol precursors 20a and 20c with [C-11]CH3I in 19.0% and 34.8% radiochemical yields (RCY), and their specific activities at the end of synthesis (EOS) were 496 +/- 138 GBq/mu mol (n = 6) and 463 +/- 263 GBq/mu mol (n = 4), respectively. The PET studies showed that [C-11]11 accumulated fast into the brain and had higher uptake, slower washout and 25% better contrast than [C-11]2, indicating improved imaging characteristics as PET radiotracer for mGlu(4) compared to [C-11]2. Therefore, [C-11]11 will be a useful radioligand to investigate mGlu(4) in different biological applications. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Kil, Kun-Eek; Poutiainen, Pekka; Zhang, Zhaoda; Zhu, Aijun; Choi, Ji-Kyung; Brownell, Anna-Liisa] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA. [Kuruppu, Darshini] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Prabhakar, Shilpa; Tannous, Bakhos A.] Massachusetts Gen Hosp, Expt Therapeut & Mol Imaging Lab, Dept Neurol, Neurosci Ctr, Boston, MA 02114 USA. RP Brownell, AL (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, 149 13th St,Suite 2301, Charlestown, MA 02129 USA. EM abrownell@mgh.harvard.edu OI Kil, Kun-Eek/0000-0002-1113-2469 FU NIMH PDSP program [HHSN-271-2008-00025-C]; Orion Farmos Research Foundation; Saastamoinen Foundation; Sigrid Juselius Foundation; Osk Huttunen Foundation; Kuopio University Foundation; [1S10RR029495-01]; [1S10RR026666-01]; [1S10RR023452-01] FX The authors would like to thank the technical support of the PET/MRI and radiochemistry facility at the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital for the operation of cyclotron and synthesis modules. The authors are also grateful to Drs. Tanabe and Nakanishi's laboratory (Osaka Bioscience Institute, Osaka, Japan) for providing the vector of mGlu4 from the rat as a gift. The following supporting instrument Grants (1S10RR029495-01, 1S10RR026666-01, and 1S10RR023452-01) are also appreciated. The authors appreciate the generous help of the NIMH PDSP program (Contract # HHSN-271-2008-00025-C) led by Dr. Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and the Project Officer Jamie Driscol at NIMH, Bethesda MD, USA. Finally, the authors would like to express their appreciation of the financial support for P.P. from The Orion Farmos Research Foundation, Saastamoinen Foundation, Sigrid Juselius Foundation, Osk Huttunen Foundation and Kuopio University Foundation. NR 38 TC 0 Z9 0 U1 2 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-894X EI 1464-3405 J9 BIOORG MED CHEM LETT JI Bioorg. Med. Chem. Lett. PD JAN 1 PY 2016 VL 26 IS 1 BP 133 EP 139 DI 10.1016/j.bmcl.2015.11.015 PG 7 WC Chemistry, Medicinal; Chemistry, Organic SC Pharmacology & Pharmacy; Chemistry GA CY1JD UT WOS:000366161600026 PM 26602273 ER PT J AU Tirumani, SH Shinagare, AB O'Neill, AC Nishino, M Rosenthal, MH Ramaiya, NH AF Tirumani, Sree Harsha Shinagare, Atul B. O'Neill, Ailbhe C. Nishino, Mizuki Rosenthal, Michael H. Ramaiya, Nikhil H. TI Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients SO EUROPEAN RADIOLOGY LA English DT Article DE Gastrointestinal stromal tumour; Estimated volumtery; Sphere; Ellipsoid; RECIST ID CELL LUNG-CANCER; TERM-FOLLOW-UP; SOLID TUMORS; COMPUTED-TOMOGRAPHY; RADIATION-THERAPY; RESPONSE CRITERIA; RECTAL-CANCER; CT SCANS; RECIST; PREDICTION AB To validate estimated tumour volumetry in primary gastric gastrointestinal stromal tumours (GISTs) using semiautomated volumetry. In this IRB-approved retrospective study, we measured the three longest diameters in x, y, z axes on CTs of primary gastric GISTs in 127 consecutive patients (52 women, 75 men, mean age 61 years) at our institute between 2000 and 2013. Segmented volumes (Vsegmented) were obtained using commercial software by two radiologists. Estimate volumes (V1-V6) were obtained using formulae for spheres and ellipsoids. Intra- and interobserver agreement of Vsegmented and agreement of V1-6 with Vsegmented were analysed with concordance correlation coefficients (CCC) and Bland-Altman plots. Median Vsegmented and V1-V6 were 75.9, 124.9, 111.6, 94.0, 94.4, 61.7 and 80.3 cm(3), respectively. There was strong intra- and interobserver agreement for Vsegmented. Agreement with Vsegmented was highest for V6 (scalene ellipsoid, x not equal y not equal z), with CCC of 0.96 [95 % CI 0.95-0.97]. Mean relative difference was smallest for V6 (0.6 %), while it was -19.1 % for V5, +14.5 % for V4, +17.9 % for V3, +32.6 % for V2 and +47 % for V1. Ellipsoidal approximations of volume using three measured axes may be used to closely estimate Vsegmented when semiautomated techniques are unavailable. aEuro cent Estimation of tumour volume in primary GIST using mathematical formulae is feasible. aEuro cent Gastric GISTs are rarely spherical. aEuro cent Segmented volumes are highly concordant with three axis-based scalene ellipsoid volumes. aEuro cent Ellipsoid volume can be used as an alternative for automated tumour volumetry. C1 [Tirumani, Sree Harsha; Shinagare, Atul B.; Nishino, Mizuki; Rosenthal, Michael H.; Ramaiya, Nikhil H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA. [Tirumani, Sree Harsha; Shinagare, Atul B.; O'Neill, Ailbhe C.; Nishino, Mizuki; Rosenthal, Michael H.; Ramaiya, Nikhil H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. RP Tirumani, SH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA. EM Sreeharsha_Tirumani@DFCI.HARVARD.EDU FU NCI [1K23CA157631]; Radiologic Society of North America (RSNA) FX The scientific guarantor of this study is N.H.R. There is no grant support for the study. The investigator, M.N., has been awarded 1K23CA157631 (NCI) and has served as a consultant to Bristol-Myers Squibb. The investigator A.B..S. is a recipient of a Radiologic Society of North America (RSNA) research grant starting from July 2014. None of the other authors have any financial disclosures related to the content in the article. Some of the study subjects (72 patients) have been previously reported as part of another research study "Gastrointestinal stromal tumour: optimizing the use of cross-sectional chest imaging during follow-up" (Radiology Sep 5:132456, 2014. PMID: 25203129) NR 36 TC 3 Z9 3 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0938-7994 EI 1432-1084 J9 EUR RADIOL JI Eur. Radiol. PD JAN PY 2016 VL 26 IS 1 BP 286 EP 295 DI 10.1007/s00330-015-3829-6 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CX5EP UT WOS:000365725200034 PM 25991487 ER PT J AU Mancini, M Chiari, L Holmstrom, L Salarian, A Horak, FB AF Mancini, Martina Chiari, Lorenzo Holmstrom, Lars Salarian, Arash Horak, Fay B. TI Validity and reliability of an IMU-based method to detect APAs prior to gait initiation SO GAIT & POSTURE LA English DT Article DE Gait initiation; Inertial sensors; Force plates; Parkinson's disease ID ANTICIPATORY POSTURAL ADJUSTMENTS; PARKINSONS-DISEASE; STEP INITIATION; WEARABLE SENSORS; MOVEMENT; BALANCE; PERTURBATIONS; COORDINATION; STIMULATION; WALKING AB Anticipatory postural adjustments (APAs) prior to gait initiation have been largely studied in traditional, laboratory settings using force plates under the feet to characterize the displacement of the center of pressure. However clinical trials and clinical practice would benefit from a portable, inexpensive method for characterizing APAs. Therefore, the main objectives of this study were (1) to develop a novel, automatic IMU-based method to detect and characterize APAs during gait initiation and (2) to measure its test-retest reliability. Experiment I was carried out in the laboratory to determine the validity of the IMU-based method in 10 subjects with PD (OFF medication) and 12 control subjects. Experiment II was carried out in the clinic, to determine test-retest reliability of the IMU-based method in a different set of 17 early-to-moderate, treated subjects with PD (tested ON medication) and 17 age-matched control subjects. Results showed that gait initiation characteristics (both APAs and 1st step) detected with our novel method were significantly correlated to the characteristics calculated with a force plate and motion analysis system. The size of APAs measured with either inertial sensors or force plate was significantly smaller in subjects with PD than in control subjects (p < 0.05). Test-retest reliability for the gait initiation characteristics measured with inertial sensors was moderate-to-excellent (0.56 < ICC < 0.82) for both groups. Our findings support the feasibility of automatically characterizing postural preparation and gait initiation with body-worn inertial sensors that would be practical for unsupervised clinical and home settings. (C) 2015 Elsevier B.V. All rights reserved. C1 [Mancini, Martina; Salarian, Arash; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, Portland, OR 97201 USA. [Chiari, Lorenzo] Univ Bologna, Dept Elect Elect & Informat Engn Guglielmo Marcon, Bologna, Italy. [Holmstrom, Lars; Horak, Fay B.] APDM Inc, Portland, OR USA. [Horak, Fay B.] Portland VA Med Ctr, Dept Res, Portland, OR USA. RP Mancini, M (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, 3181 Sam Jackson Pk Rd, Portland, OR 97201 USA. EM mancinim@ohsu.edu; lorenzo.chiari@unibo.it; lars@apdm.com; arash.salarian@gmail.com; horakf@ohsu.edu RI Salarian, Arash/E-8311-2016; OI Salarian, Arash/0000-0001-7332-0062; Chiari, Lorenzo/0000-0002-2318-4370 FU NIH [RC1 NS068678, R42 HD071760-03] FX We thank Kelsey Priest for scheduling and helping with data collection. This publication was made possible with support from NIH RC1 NS068678 and R42 HD071760-03. NR 30 TC 4 Z9 4 U1 6 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 EI 1879-2219 J9 GAIT POSTURE JI Gait Posture PD JAN PY 2016 VL 43 BP 125 EP 131 DI 10.1016/j.gaitpost.2015.08.015 PG 7 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA CY1HW UT WOS:000366158300021 PM 26433913 ER PT J AU Bentley-Lewis, R Huynh, J Li, S Wenger, J Thadhani, R AF Bentley-Lewis, Rhonda Huynh, Jennifer Li, Sylvia Wenger, Julia Thadhani, Ravi TI Hypertension Risk Subsequent to Gestational Dysglycemia Is Modified by Race/Ethnicity SO HYPERTENSION LA English DT Article DE diabetes mellitus; ethnic groups; gestational; glucose intolerance; hypertension; pregnancy ID TYPE-2 DIABETES-MELLITUS; GLUCOSE-INTOLERANCE; METABOLIC SYNDROME; BLOOD-PRESSURE; YOUNG-WOMEN; US ADULTS; PREGNANCY; POPULATION; PREVALENCE; EDUCATION AB Gestational diabetes mellitus is associated with an increased risk of type 2 diabetes mellitus and hypertension. Additionally, gestational dysglycemia has been associated with an increased risk of type 2 diabetes mellitus but not yet associated with hypertension subsequent to pregnancy in long-term follow-up. Therefore, we set out to examine this relationship as well as the role of race/ethnicity in modifying this relationship. We analyzed a prospective observational cohort followed between 1998 and 2007. There were 17 655 women with self-reported race/ethnicity and full-term, live births. A 1-hour 50 g oral glucose-load test and a 3-hour 100 g oral glucose-tolerance test enabled third trimester stratification of women into 1 of 4 glucose-tolerance groups: (1) normal (n=15 056); (2) abnormal glucose-load test (n=1558); (3) abnormal glucose-load and -tolerance tests (n=520); and (4) gestational diabetes mellitus (n=521). Women were then followed for a mean +/- standard deviation of 4.1 +/- 2.9 years after delivery for the development of hypertension. Although gestational diabetes mellitus was associated with an increased risk of hypertension after pregnancy (odds ratio [95% confidence interval]: 1.58 [1.02, 2.45]; P=0.04), dysglycemia defined by an abnormal glucose-load test predicted hypertension only among black women (4.52 [1.24, 16.52]; P=0.02). The risk of hypertension after pregnancy among dysglycemia groups not meeting criteria for gestational diabetes mellitus varied based on the race/ethnicity of the population. Further research on the implications of the intersection of race/ethnicity and gestational dysglycemia on subsequent hypertension is warranted. C1 [Bentley-Lewis, Rhonda; Huynh, Jennifer; Li, Sylvia] Massachusetts Gen Hosp, Med Diabet Unit, Boston, MA 02114 USA. [Wenger, Julia; Thadhani, Ravi] Massachusetts Gen Hosp, Med Div Nephrol, Boston, MA 02114 USA. RP Bentley-Lewis, R (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Bulfinch 4-415, Boston, MA 02114 USA. EM rbentleylewis@mgh.harvard.edu FU National Institutes of Health (NIH) [R03DK096152]; Massachusetts General Hospital Executive Committee on Research/Multicultural Affairs Office Physician Scientist Development Award; NIH [K24 DK094872] FX This work was funded in part by the National Institutes of Health (NIH) R03DK096152 and Massachusetts General Hospital Executive Committee on Research/Multicultural Affairs Office Physician Scientist Development Award (R. Bentley-Lewis) and the NIH K24 DK094872 (R. Thadhani). NR 22 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD JAN PY 2016 VL 67 IS 1 BP 223 EP 228 DI 10.1161/HYPERTENSIONAHA.115.06360 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CY2RC UT WOS:000366254800032 PM 26573715 ER PT J AU Poelke, G Ventura, MI Byers, AL Yaffe, K Sudore, R Barnes, DE AF Poelke, Gina Ventura, Maria I. Byers, Amy L. Yaffe, Kristine Sudore, Rebecca Barnes, Deborah E. TI Leisure activities and depressive symptoms in older adults with cognitive complaints SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE leisure activities; depressive symptoms; mild cognitive impairment; aging ID PHYSICAL-ACTIVITY; CARDIOVASCULAR HEALTH; CONTROLLED-TRIAL; IMPAIRMENT; EXERCISE; INTERVENTIONS; PREVALENCE; COMMUNITY; DEMENTIA; DECLINE AB Background: Depressive symptoms are common in older adults and associated with increased risk of cognitive impairment. Leisure activities are often promoted for individuals with mood symptoms but few studies compare the effects of different types of leisure activities on reducing depressive symptoms. Methods: Data were analyzed from participants enrolled from 2008-2009 in the Mental Activity and eXercise (MAX) Trial, which examined the effects of physical plus mental activity over 12 weeks in inactive older adults with cognitive complaints. There were no significant differences between intervention groups on the primary outcome of cognitive function or the secondary outcome of depressive symptoms; therefore, all participants were combined for the current analyses in which we examined changes in leisure activity engagement (Community Healthy Activities Model Program for Seniors (CHAMPS)), and changes in depressive symptoms (Geriatric Depression Scale (GDS)) as a function of changes in leisure activity engagement from baseline to post-intervention. Results: Participants' mean age was 73.0 years, 61.6% were female, and 63.6% were non-Hispanic white. There was a significant change in total hours per week engaged in leisure activities from baseline (36.7 hours, SD = 12.7) to post-intervention (40.4 hours, SD = 15.7; paired t-test p = 0.02), and mean change in depressive symptoms was significantly inversely correlated with change in leisure activity hours such that increases in total leisure activity were associated with decreases in depressive symptoms (r = -0.21, p = 0.04). Conclusions: Increasing the total amount of leisure activity levels may help lower depressive symptoms in inactive older adults with cognitive complaints. C1 [Poelke, Gina; Ventura, Maria I.; Byers, Amy L.; Yaffe, Kristine; Sudore, Rebecca; Barnes, Deborah E.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94102 USA. RP Poelke, G (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 870 Market St,Suite 1123, San Francisco, CA 94102 USA. EM gpoelke@gmail.com FU Career Development Award from the National Institute on Aging [K01-AG024069]; Alzheimer's Association [IIRG-06-27306]; University of California School of Medicine; Institutes of Health/National Center for Research Resources/University of California; San Francisco - Clinical and Translational Science Institute [KL2 RR024130]; NIH [5-T32-AG000212] FX This study was supported in part by a Career Development Award from the National Institute on Aging (grant K01-AG024069), the Alzheimer's Association (grant IIRG-06-27306), the University of California School of Medicine, the Institutes of Health/National Center for Research Resources/University of California, San Francisco - Clinical and Translational Science Institute (grant KL2 RR024130) and NIH grant 5-T32-AG000212. NR 28 TC 0 Z9 0 U1 2 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD JAN PY 2016 VL 28 IS 1 BP 63 EP 69 DI 10.1017/S1041610215001246 PG 7 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA CY1WM UT WOS:000366198900009 PM 26299193 ER PT B AU Ginther, J McGahan, AM AF Ginther, John McGahan, Anita M. BE Godfrey, PC TI Healthcare in the Informal Economy SO MANAGEMENT, SOCIETY, AND THE INFORMAL ECONOMY SE Routledge Advances in Management and Business Studies LA English DT Article; Book Chapter ID MALARIA TREATMENT; MARKETS; MANAGEMENT; PROVIDERS; MEDICINE; NIGERIA C1 [Ginther, John] Univ Toronto, T HOPE Team, Toronto, ON M5S 1A1, Canada. [Ginther, John] World Bank, Washington, DC USA. [McGahan, Anita M.] Univ Toronto, Rotman Sch Management, Res, Toronto, ON M5S 1A1, Canada. [McGahan, Anita M.] Univ Toronto, Rotman Sch Management, Toronto, ON M5S 1A1, Canada. [McGahan, Anita M.] Univ Toronto, Rotman Sch Management, Management, Toronto, ON M5S 1A1, Canada. [McGahan, Anita M.] Munk Sch Global Affairs, Toronto, ON, Canada. [McGahan, Anita M.] Harvard Univ, Inst Strategy & Competitiveness, Cambridge, MA 02138 USA. [McGahan, Anita M.] Massachusetts Gen Hosp, Div Global Hlth & Human Rights, Boston, MA 02114 USA. RP Ginther, J (reprint author), Univ Toronto, T HOPE Team, Toronto, ON M5S 1A1, Canada. NR 23 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI ABINGDON PA 2 PARK SQ, MILTON PARK, ABINGDON OX14 4RN, OXFORD, ENGLAND BN 978-1-315-75744-5; 978-1-138-79706-2 J9 ROUTL ADV MANAG BUS PY 2016 VL 62 BP 115 EP 126 PG 12 WC Business; Management SC Business & Economics GA BD8ZX UT WOS:000364490100007 ER PT J AU Keator, DB van Erp, TGM Turner, JA Glover, GH Mueller, BA Liu, TT Voyvodic, JT Rasmussen, J Calhoun, VD Lee, HJ Toga, AW McEwen, S Ford, JM Mathalon, DH Diaz, M O'Leary, DS Bockholt, HJ Gadde, S Preda, A Wible, CG Stern, HS Belger, A McCarthy, G Ozyurt, B Potkin, SG AF Keator, David B. van Erp, Theo G. M. Turner, Jessica A. Glover, Gary H. Mueller, Bryon A. Liu, Thomas T. Voyvodic, James T. Rasmussen, Jerod Calhoun, Vince D. Lee, Hyo Jong Toga, Arthur W. McEwen, Sarah Ford, Judith M. Mathalon, Daniel H. Diaz, Michele O'Leary, Daniel S. Bockholt, H. Jeremy Gadde, Syam Preda, Adrian Wible, Cynthia G. Stern, Hal S. Belger, Aysenil McCarthy, Gregory Ozyurt, Burak Potkin, Steven G. CA FBIRN TI The Function Biomedical Informatics Research Network Data Repository SO NEUROIMAGE LA English DT Article ID MULTICENTER FMRI; CORTICAL THICKNESS; RATING-SCALE; SCHIZOPHRENIA; VARIABILITY; ACTIVATION; IDENTIFICATION; ABNORMALITIES; RELIABILITY; INSTRUMENT AB The Function Biomedical Informatics Research Network (FBIRN) developed methods and tools for conducting multi-scanner functional magnetic resonance imaging (fMRI) studies. Method and tool development were based on two major goals: 1) to assess the major sources of variation in fMRI studies conducted across scanners, including instrumentation, acquisition protocols, challenge tasks, and analysis methods, and 2) to provide a distributed network infrastructure and an associated federated database to host and query large, multi-site, fMRI and clinical data sets. In the process of achieving these goals the FBIRN test bed generated several multi-scanner brain imaging data sets to be shared with the wider scientific community via the BIRN Data Repository (BDR). The FBIRN Phase 1 data set consists of a traveling subject study of 5 healthy subjects, each scanned on 10 different 1.5 to 4 T scanners. The FBIRN Phase 2 and Phase 3 data sets consist of subjects with schizophrenia or schizoaffective disorder along with healthy comparison subjects scanned at multiple sites. In this paper, we provide concise descriptions of FBIRN's multi-scanner brain imaging data sets and details about the BIRN Data Repository instance of the Human Imaging Database (HID) used to publicly share the data. (C) 2015 Elsevier Inc. All rights reserved. C1 [Keator, David B.; van Erp, Theo G. M.; Rasmussen, Jerod; Preda, Adrian; Potkin, Steven G.] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92697 USA. [Turner, Jessica A.; Calhoun, Vince D.] Mind Res Networlc, Albuquerque, NM USA. [Turner, Jessica A.] Georgia State Univ, Dept Psychiat, Atlanta, GA 30303 USA. [Turner, Jessica A.] Georgia State Univ, Inst Neurosci, Atlanta, GA 30303 USA. [Glover, Gary H.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA. [Mueller, Bryon A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Liu, Thomas T.] Univ Calif San Diego, Ctr Funct MRI, San Diego, CA 92103 USA. [Voyvodic, James T.; Gadde, Syam] Duke Univ, Med Ctr, Brain Imaging & Anal Ctr, Durham, NC USA. [Calhoun, Vince D.; Bockholt, H. Jeremy] Univ New Mexico, Dept ECE, Albuquerque, NM 87131 USA. [Calhoun, Vince D.] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA. [Lee, Hyo Jong] Chonbuk Natl Univ, Dept Comp Sci & Engn, Jeonju, South Korea. [Toga, Arthur W.] Univ So Calif, Lab Neuro Imaging, Los Angeles, CA USA. [Toga, Arthur W.] Univ So Calif, Inst Neuroimaging & Informat, Los Angeles, CA USA. [Toga, Arthur W.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [McEwen, Sarah] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, Brain Imaging & EEG Lab, San Francisco, CA 94143 USA. [Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Diaz, Michele] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA. [O'Leary, Daniel S.; Bockholt, H. Jeremy] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA. [Wible, Cynthia G.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Wible, Cynthia G.] Brockton VAMC, Boston, MA USA. [Stern, Hal S.] Univ Calif Irvine, Dept Stat, Irvine, CA 92697 USA. [Belger, Aysenil] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Belger, Aysenil] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA. [McCarthy, Gregory] Yale Univ, Dept Psychol, New Haven, CT 06520 USA. [Ozyurt, Burak] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Keator, DB (reprint author), Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine Hall,Room 163, Irvine, CA 92697 USA. EM dbkeator@uci.edu RI Preda, Adrian /K-8889-2013 OI Preda, Adrian /0000-0003-3373-2438 FU National Center for Research Resources at the National Institutes of Health (Function Biomedical Informatics Research Network) [NIH 1 U24 RR021992]; National Center for Research Resources at the National Institutes of Health (Biomedical Informatics Research Network Coordinating Center) [NIH 1 U24 RR025736-01] FX We are thankful to Mrs. Liv McMillan for overall study coordination, to Ms. Shichun Ling for editorial assistance, and to the research subjects for their participation. This work was supported by the National Center for Research Resources at the National Institutes of Health (grant numbers: NIH 1 U24 RR021992) (Function Biomedical Informatics Research Network) and NIH 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; www.birncommunity.org). The funding sources had no role in the study design, data collection, or publication of the data. NR 54 TC 2 Z9 2 U1 1 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 SI SI BP 1074 EP 1079 DI 10.1016/j.neuroimage.2015.09.003 PN B PG 6 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY1FB UT WOS:000366151000003 PM 26364863 ER PT J AU Fan, QY Witzel, T Nummenmaa, A Van Dijk, KRA Van Horn, JD Drews, MK Somerville, LH Sheridan, MA Santillana, RM Snyder, J Hedden, T Shaw, EE Hollinshead, MO Renvall, V Zanzonico, R Keil, B Cauley, S Polimeni, JR Tisdall, D Buckner, RL Wedeen, V Wald, LL Toga, AW Rosen, BR AF Fan, Qiuyun Witzel, Thomas Nummenmaa, Aapo Van Dijk, Koene R. A. Van Horn, John D. Drews, Michelle K. Somerville, Leah H. Sheridan, Margaret A. Santillana, Rosario M. Snyder, Jenna Hedden, Trey Shaw, Emily E. Hollinshead, Marisa O. Renvall, Ville Zanzonico, Roberta Keil, Boris Cauley, Stephen Polimeni, Jonathan R. Tisdall, Dylan Buckner, Randy L. Wedeen, Van J. Wald, Lawrence L. Toga, Arthur W. Rosen, Bruce R. TI MGH-USC Human Connectome Project datasets with ultra-high b-value diffusion MRI SO NEUROIMAGE LA English DT Article DE Preprocessing; Multi-shell HARDI; Lifespan; Children; Adolescents; Older adults ID BRAIN; DECONVOLUTION; TRACTOGRAPHY AB The MGH-USC CONNECTOM MRI scanner housed at the Massachusetts General Hospital (MGH) is a major hardware innovation of the Human Connectome Project (HCP). The 3T CONNECTOM scanner is capable of producing a magnetic field gradient of up to 300 mT/m strength for in vivo human brain imaging, which greatly shortens the time spent on diffusion encoding, and decreases the signal loss due to T2 decay. To demonstrate the capability of the novel gradient system, data of healthy adult participants were acquired for this MGH-USC Adult Diffusion Dataset (N = 35), minimally preprocessed, and shared through the Laboratory of Neuro Imaging Image Data Archive (LONI IDA) and the WU-Minn Connectome Database (ConnectomeDB). Another purpose of sharing the data is to facilitate methodological studies of diffusion MRI (dMRI) analyses utilizing high diffusion contrast, which perhaps is not easily feasible with standard MR gradient system. In addition, acquisition of the MGH-Harvard-USC Lifespan Dataset is currently underway to include 120 healthy participants ranging from 8 to 90 years old, which will also be shared through LONI IDA and ConnectomeDB. Here we describe the efforts of the MGH-USC HCP consortium in acquiring and sharing the ultra-high b-value diffusion MRI data and provide a report on data preprocessing and access. We conclude with a demonstration of the example data, along with results of standard diffusion analyses, including q-ball Orientation Distribution Function (ODF) reconstruction and tractography. (C) 2015 Elsevier Inc. All rights reserved. C1 [Fan, Qiuyun; Witzel, Thomas; Nummenmaa, Aapo; Van Dijk, Koene R. A.; Drews, Michelle K.; Hedden, Trey; Shaw, Emily E.; Hollinshead, Marisa O.; Renvall, Ville; Zanzonico, Roberta; Keil, Boris; Cauley, Stephen; Polimeni, Jonathan R.; Tisdall, Dylan; Buckner, Randy L.; Wedeen, Van J.; Wald, Lawrence L.; Rosen, Bruce R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02129 USA. [Van Dijk, Koene R. A.; Drews, Michelle K.; Somerville, Leah H.; Hollinshead, Marisa O.; Buckner, Randy L.] Harvard Univ, Dept Psychol, Ctr Brain Sci, Cambridge, MA 02138 USA. [Van Horn, John D.; Toga, Arthur W.] Univ So Calif, Keck Sch Med, Dept Neurol, Lab Neuro Imaging,Inst Neuroimaging & Informat, Los Angeles, CA 90033 USA. [Sheridan, Margaret A.; Santillana, Rosario M.; Snyder, Jenna] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Dev Med, Boston, MA USA. [Renvall, Ville] Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, Espoo, Finland. [Wald, Lawrence L.; Rosen, Bruce R.] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Rosen, BR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, 149 13th St, Charlestown, MA 02129 USA. EM bruce@nmr.mgh.harvard.edu RI Renvall, Ville/M-4165-2013; Polimeni, Jonathan/P-1395-2014; Wald, Lawrence/D-4151-2009; Van Dijk, Koene/G-3317-2012 OI Renvall, Ville/0000-0002-4070-7030; Polimeni, Jonathan/0000-0002-1348-1179; Van Dijk, Koene/0000-0001-6137-4282 FU National Institutes of Health Blueprint Initiative for Neuroscience Research Grant [U01MH093765]; NIH NIBIB Grant [K99EB015445]; NIH NIA Grant [P50AG005134, K01AG040197]; NIH [5P41EB015922-16, 1U54EB020406-01]; [1S10RR023401]; [1S10RR019307]; [1S10RR023043] FX The authors thank Dr. Emmanuel Caruyer for providing help with b-vector calculations. The work is supported by funding from the National Institutes of Health Blueprint Initiative for Neuroscience Research Grant U01MH093765, NIH NIBIB Grant K99EB015445, NIH NIA Grant P50AG005134, NIH NIA Grant K01AG040197, and the Instrumentation Grants 1S10RR023401, 1S10RR019307, and 1S10RR023043. This work was also supported by NIH Grants 5P41EB015922-16 and 1U54EB020406-01 to AWT. NR 34 TC 3 Z9 3 U1 2 U2 14 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 SI SI BP 1108 EP 1114 DI 10.1016/j.neuroimage.2015.08.075 PN B PG 7 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY1FB UT WOS:000366151000010 PM 26364861 ER PT J AU Jernigan, TL Brown, TT Hagler, DJ Akshoomoff, N Bartsch, H Newman, E Thompson, WK Bloss, CS Murray, SS Schork, N Kennedy, DN Kuperman, JM McCabe, C Chung, YH Libiger, O Maddox, M Casey, BJ Chang, LD Ernst, TM Frazier, JA Gruen, JR Sowell, ER Kenet, T Kaufmann, WE Mostofsky, S Amaral, DG Dale, AM AF Jernigan, Terry L. Brown, Timothy T. Hagler, Donald J., Jr. Akshoomoff, Natacha Bartsch, Hauke Newman, Erik Thompson, Wesley K. Bloss, Cinnamon S. Murray, Sarah S. Schork, Nicholas Kennedy, David N. Kuperman, Joshua M. McCabe, Connor Chung, Yoonho Libiger, Ondrej Maddox, Melanie Casey, B. J. Chang, Linda Ernst, Thomas M. Frazier, Jean A. Gruen, Jeffrey R. Sowell, Elizabeth R. Kenet, Tal Kaufmann, Walter E. Mostofsky, Stewart Amaral, David G. Dale, Anders M. CA Pediat Imaging Neurocognition & Ge TI The Pediatric Imaging, Neurocognition, and Genetics (PING) Data Repository SO NEUROIMAGE LA English DT Article ID PROSPECTIVE MOTION CORRECTION; HUMAN CEREBRAL-CORTEX; MAGNETIC-RESONANCE IMAGES; SURFACE-BASED ANALYSIS; CORTICAL SURFACE; GEOMETRICALLY ACCURATE; ALZHEIMERS-DISEASE; COORDINATE SYSTEM; HUMAN GENOME; HUMAN BRAIN AB The main objective of the multi-site Pediatric Imaging, Neurocognition, and Genetics (PING) study was to create a large repository of standardized measurements of behavioral and imaging phenotypes accompanied by whole genome genotyping acquired from typically-developing children varying widely in age (3 to 20 years). This cross-sectional study produced sharable data from 1493 children, and these data have been described in several publications focusing on brain and cognitive development. Researchers may gain access to these data by applying for an account on the PING portal and filing a data use agreement. Here we describe the recruiting and screening of the children and give a brief overview of the assessments performed, the imaging methods applied, the genetic data produced, and the numbers of cases for whom different data types are available. We also cite sources of more detailed information about the methods and data. Finally we describe the procedures for accessing the data and for using the PING data exploration portal. (C) 2015 Elsevier Inc. All rights reserved. C1 [Jernigan, Terry L.; Akshoomoff, Natacha; Newman, Erik; Maddox, Melanie] Univ Calif San Diego, Ctr Human Dev, La Jolla, CA 92093 USA. [Jernigan, Terry L.; Dale, Anders M.] Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA. [Jernigan, Terry L.; Akshoomoff, Natacha; Newman, Erik; Thompson, Wesley K.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Brown, Timothy T.; Hagler, Donald J., Jr.; Bartsch, Hauke; Kuperman, Joshua M.; Dale, Anders M.] Univ Calif San Diego, Multimodal Imaging Lab, La Jolla, CA 92093 USA. [Brown, Timothy T.; Dale, Anders M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Hagler, Donald J., Jr.; Kuperman, Joshua M.; Dale, Anders M.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA. [Thompson, Wesley K.] Univ Calif San Diego, Stein Inst Res Aging, La Jolla, CA 92093 USA. [Bloss, Cinnamon S.; Libiger, Ondrej] Univ Calif San Diego, Qualcomm Inst, La Jolla, CA 92093 USA. [Murray, Sarah S.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA. [Schork, Nicholas] J Craig Venter Inst, Human Biol, La Jolla, CA USA. [Kennedy, David N.; Frazier, Jean A.] Univ Massachusetts, Sch Med, Dept Psychiat, Boston, MA 02125 USA. [McCabe, Connor] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Chung, Yoonho] Yale Univ, Dept Psychol, New Haven, CT 06520 USA. [Casey, B. J.] Weill Cornell Med Coll, Sackler Inst Dev Psychobiol, New York, NY USA. [Chang, Linda; Ernst, Thomas M.] Univ Hawaii, Dept Med, Queens Med Ctr, Honolulu, HI 96822 USA. [Gruen, Jeffrey R.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA. [Gruen, Jeffrey R.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Sowell, Elizabeth R.] Univ So Calif, Dept Pediat, Childrens Hosp Los Angeles, Los Angeles, CA 90089 USA. [Kenet, Tal] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Neurol, Charlestown, MA USA. [Kaufmann, Walter E.] Boston Childrens Hosp, Boston, MA USA. [Mostofsky, Stewart] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD USA. [Amaral, David G.] Univ Calif Davis, Dept Psychiat & Behav Sci, Davis, CA 95616 USA. RP Jernigan, TL (reprint author), Univ Calif San Diego, Ctr Human Dev, 9500 Gilman Dr,MC 0115, La Jolla, CA 92093 USA. EM tjernigan@ucsd.edu FU National Institute on Drug Abuse; Eunice Kennedy Shriver National Institute of Child Health and Human Development [RC2DA029475, R01 HD061414] FX The PING Project was supported by the National Institute on Drug Abuse and the Eunice Kennedy Shriver National Institute of Child Health and Human Development with the following awards: RC2DA029475 and R01 HD061414. NR 44 TC 12 Z9 12 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 SI SI BP 1149 EP 1154 DI 10.1016/j.neuroimage.2015.04.057 PN B PG 6 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY1FB UT WOS:000366151000017 PM 25937488 ER PT J AU Labus, JS Naliboff, B Kilpatrick, L Liu, C Ashe-McNalley, C dos Santos, IR Alaverdyan, M Woodworth, D Gupta, A Ellingson, BM Tillisch, K Mayer, EA AF Labus, Jennifer S. Naliboff, Bruce Kilpatrick, Lisa Liu, Cathy Ashe-McNalley, Cody dos Santos, Ivani R. Alaverdyan, Mher Woodworth, Davis Gupta, Arpana Ellingson, Benjamin M. Tillisch, Kirsten Mayer, Emeran A. TI Pain and Interoception Imaging Network (PAIN): A multimodal, multisite, brain-imaging repository for chronic somatic and visceral pain disorders SO NEUROIMAGE LA English DT Article DE Chronic pain; Neuroimaging data repository; Archived repository; Standardized repository; Large biological datasets; Multiple sites ID MAPP RESEARCH NETWORK; CHRONIC PELVIC PAIN; MRI AB The Pain and Interoception Imaging Network (PAIN) repository (painrepository.org) is a newly created NIH (NIDA/NCCAM) funded neuroimaging data repository that aims to accelerate scientific discovery regarding brain mechanisms in pain and to provide more rapid benefits to pain patients through the harmonization of efforts and data sharing. The PAIN Repository consists of two components, an Archived Repository and a Standardized Repository. Similar to other 'open' imaging repositories, neuroimaging researchers can deposit any dataset of chronic pain patients and healthy controls into the Archived Repository. Scans in the Archived Repository can be very diverse in terms of scanning procedures and clinical metadata, complicating the merging of datasets for analyses. The Standardized Repository overcomes these limitations through the use of standardized scanning protocols along with a standardized set of clinical metadata, allowing an unprecedented ability to perform pooled analyses. The Archived Repository currently includes 741 scans and is rapidly growing. The Standardized Repository currently includes 433 scans. Pain conditions currently represented in the PAIN repository include: irritable bowel syndrome, vulvodynia, migraine, chronic back pain, and inflammatory bowel disease. Both the PAIN Archived and Standardized Repositories promise to be important resources in the field of chronic pain research. The enhanced ability of the Standardized Repository to combine imaging, clinical and other biological datasets from multiple sites in particular make it a unique resource for significant scientific discoveries. (C) 2015 Elsevier Inc. All rights reserved. C1 [Labus, Jennifer S.; Naliboff, Bruce; Kilpatrick, Lisa; Liu, Cathy; Ashe-McNalley, Cody; dos Santos, Ivani R.; Alaverdyan, Mher; Woodworth, Davis; Gupta, Arpana; Ellingson, Benjamin M.; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Oppenheimer Family Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Kilpatrick, Lisa; Liu, Cathy; Ashe-McNalley, Cody; dos Santos, Ivani R.; Gupta, Arpana; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. [Tillisch, Kirsten] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Labus, Jennifer S.; Naliboff, Bruce; Kilpatrick, Lisa; Liu, Cathy; Ashe-McNalley, Cody; dos Santos, Ivani R.; Gupta, Arpana; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, PAIN, Los Angeles, CA 90095 USA. [Woodworth, Davis; Ellingson, Benjamin M.] Univ Calif Los Angeles, David Geffen Sch Med, Radiol, Los Angeles, CA 90095 USA. RP Mayer, EA (reprint author), Univ Calif Los Angeles, David Sch Med, Div Digest Dis, Oppenheimer Family Ctr Neurobiol Stress, CHS 42-210 MC737818,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM emayer@ucla.edu FU National Institutes of Health: NCCAM/NIDA [R01 AT007137, P30 DK041301, R01 DK048351, R01 HD076756] FX This research was supported in part by grants from the National Institutes of Health: NCCAM/NIDA: R01 AT007137 (KT, BN), P30 DK041301, R01 DK048351 (EAM), and R01 HD076756 (JSL). NR 13 TC 4 Z9 4 U1 2 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 SI SI BP 1232 EP 1237 DI 10.1016/j.neuroimage.2015.04.018 PN B PG 6 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY1FB UT WOS:000366151000029 PM 25902408 ER PT J AU McCullough, MB Petrakis, BA Gillespie, C Solomon, JL Park, AM Ourth, H Morreale, A Rose, AJ AF McCullough, Megan B. Petrakis, Beth Ann Gillespie, Christopher Solomon, Jeffrey L. Park, Angela M. Ourth, Heather Morreale, Anthony Rose, Adam J. TI Knowing the patient: A qualitative study on care-taking and the clinical pharmacist-patient relationship SO RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY LA English DT Article DE Knowing the patient; Pharmacist-patient communication; Pharmacist-patient relationship; Patient care; Time; Clinical pharmacy services ID COMMUNITY PHARMACIES; COMMUNICATION; INTERVENTIONS; THERAPY; WORKING; TEAMS AB Background: Previous studies have found clinical pharmacists (CPs) and clinical pharmacy specialists (CPSs) in direct patient care have positive effects across various patient outcomes. However, there are also other kinds of care-taking occurring in pharmacy-run clinic appointments that produce value for patients. Objective: To identify and characterize how CPs/CPSs in direct care clinics develop and practice caretaking behaviors which advance the pharmacist-patient relationship. Methods: Semi-structured CP/CPS interviews were conducted once per year for two years (46 year 1, 50 year 2) along with direct observations of clinical pharmacy work as part of an anticoagulation improvement intervention. Participants were from Veterans Health Administration (VHA) medical centers and VHA community-based outpatient clinics in the Northeastern U.S. Interviews were transcribed verbatim and thematically analyzed using NVIVO 10 software. Results: It was found that CPs/CPSs practice "knowing the patient" in ways related to, but distinct from this practice in the nursing literature. For CPs/CPSs, knowing the patient occurred over time, and it produced familiarity and trust between CPs/CPs and patients. A reciprocal relationship developed in which patients came to rely on CP/CPSs for other types of assistance. Patterns of knowing the patient and being known by the patient manifested in three distinct ways: 1) identifying the patient's unmet needs, 2) explaining other medications, and 3) helping the patient navigate the system. Conclusion: This research identifies an action, knowing the patient, whereby CPs use their knowledge of the patient to deliver individualized care. This study contributes to the developing literature on pharmacist-patient relationships and pharmacist-patient communication. Published by Elsevier Inc. C1 [McCullough, Megan B.; Petrakis, Beth Ann; Gillespie, Christopher; Solomon, Jeffrey L.; Rose, Adam J.] ENRM Vet Hosp 152, CHOIR, Bedford, MA 01730 USA. [Park, Angela M.] VA Boston Healthcare Syst, New England VERC, Jamaica Plain, MA 02130 USA. [Ourth, Heather] Dept Vet Affairs, Pharm Benefits Management Serv, Clin Pharm Practice Program & Outcomes Assessment, Ackworth, IA 50001 USA. [Morreale, Anthony] Dept Vet Affairs, Pharm Benefits Management VACO, Clin Pharm Serv, La Jolla, CA 92037 USA. [Morreale, Anthony] Dept Vet Affairs, Pharm Benefits Management VACO, Healthcare Serv Res, La Jolla, CA 92037 USA. [Rose, Adam J.] Boston Univ, Sch Med, Gen Internal Med Sect, Dept Med, Boston, MA 02118 USA. RP McCullough, MB (reprint author), ENRM Vet Hosp 152, CHOIR, 200 Springs Rd, Bedford, MA 01730 USA. EM Megan.McCullough@va.gov OI McCullough, Megan/0000-0002-3387-1967 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [SDP 12-249] FX Many thanks to the clinical pharmacists who have given generously of their time as well as shared with the research team their knowledge of clinical pharmacy care. Laurie Radwin's expert feedback and generosity is also noted and appreciated. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. Funding is from Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development SDP 12-249 (Rose, PI). NR 36 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7411 EI 1934-8150 J9 RES SOC ADMIN PHARM JI Res. Soc. Adm. Pharm. PD JAN-FEB PY 2016 VL 12 IS 1 BP 78 EP 90 DI 10.1016/j.sapharm.2015.04.005 PG 13 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA CY3HJ UT WOS:000366299500007 PM 26004019 ER PT J AU Scalia-Wilbur, J Colins, BL Penson, RT Dizon, DS AF Scalia-Wilbur, Jennifer Colins, Bradley L. Penson, Richard T. Dizon, Don S. TI Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2 SO SEMINARS IN RADIATION ONCOLOGY LA English DT Article ID PEUTZ-JEGHERS-SYNDROME; SUSCEPTIBILITY ALLELES; MUTATIONS; GENE; MODEL; PREDICTION; RECOMMENDATIONS; PREVALENCE; VALIDATION; MANAGEMENT AB The National Cancer Institute estimates that 12.3% of all women (about 1 in 8) would be diagnosed with breast cancer throughout their lifetime. In 2015, a projected 231,840 new cases are expected in:the United States, accompanied by 40,290 deaths. Presently, breast cancer is responsible for 6.8% of all cancer deaths, and roughly 30% of all cancers in women. Since the discovery of the BRCA gene in 1994, efforts have been made to develop effective screening methods for breast cancer detection. Although the BRCA gene certainly opened the door to breast cancer genetics, a wide variety of new genes have recently been linked to breast cancer risk, and the tools to screen for genes beyond just BRCA1 and BRCA2 are available. However, the indications for both screening and prevention of inherited predispositions beyond BRCA1 and BRCA2 are not entirely clear, and as a result, much of the ongoing work is aimed at determining the role of broader genetic screening in women deemed at sufficiently high risk for breast cancer based on family history. On this topic, we provide a brief overview of the genes associated with breast cancer risk as well as the technological platforms available to patients. We conclude by discussing recommendations of expert groups and what they practically mean for patients. (C) 2016 Elsevier Inc. All rights reserved. C1 [Scalia-Wilbur, Jennifer] Brown Univ, Women & Infants Hosp, Program Womens Oncol, Canc Risk & Prevent Program, Providence, RI USA. [Colins, Bradley L.] Harvard Univ, Sch Med, Boston, MA USA. [Penson, Richard T.; Dizon, Don S.] Massachusetts Gen Hosp, Ctr Canc, Gynecol Oncol Program, Boston, MA USA. [Penson, Richard T.; Dizon, Don S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Dizon, DS (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM ddizon@partners.org NR 33 TC 4 Z9 4 U1 1 U2 30 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-4296 EI 1532-9461 J9 SEMIN RADIAT ONCOL JI Semin. Radiat. Oncol. PD JAN PY 2016 VL 26 IS 1 BP 3 EP 8 DI 10.1016/j.semradonc.2015.09.004 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA CY2FK UT WOS:000366224000002 PM 26617204 ER PT J AU Braunstein, LZ Taghian, AG AF Braunstein, Lior Z. Taghian, Alphonse G. TI Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer SO SEMINARS IN RADIATION ONCOLOGY LA English DT Article ID 70-GENE PROGNOSIS-SIGNATURE; POLYMERASE CHAIN-REACTION; TUMOR GENE-EXPRESSION; POSITIVE LYMPH-NODES; DISTANT RECURRENCE; ONCOTYPE DX; POSTMENOPAUSAL PATIENTS; PROGESTERONE-RECEPTOR; CONSERVING THERAPY; ESTROGEN-RECEPTOR AB Molecular profiling has revealed that breast cancer is not a single disease entity, but rather a class of heterogeneous subtypes, each with its own inherent biology and natural history. As a result, different treatment approaches have been optimized for the various subtypes and, in turn, the ability to identify subtypes has become a critical element in the management of breast cancer. Comprehensive transcriptional profiling studies have revealed at least 4 principal subtypes that, in practice, are often distinguished by immunohistochemical staining of the estrogen receptor (ER), progesterone receptor (PR), and HER2, along with a determination of histologic grade or Ki-67 staining: lumina' A (ER+/HER2-/grade 1 or 2), luminal B (ER+/HER2-/grade 3), HER2 enriched (any HER2+ tumor), and basal like (ER-/PR-/HER2). Although these immunohistochemically derived subtypes show robust prognostic and predictive ability, there remain many cases that demand profiling that more closely approximates the original transcriptionally derived definitions of the intrinsic subtypes. The need for improved prognostication and risk stratification has led to the development of several multigene assays in breast cancer. Although there is little molecular overlap between current assays, they all rely heavily on quantifying the transcriptional output of ER signaling and proliferation-related genes. These data are typically then used in multivariate prediction models that incorporate other canonical risk factors such as the tumor size, lymph node involvement, and patient demographic parameters, among others. Indeed, the advent of scalable molecular profiling technologies has brought a number of assays into routine clinical use for optimizing risk prediction and treatment assignment. The landscape of these assays and the clinical utility of contemporary molecular profiles are the main focus of this overview. In addition to the clinical advances in transcriptional subtyping, recent reports have characterized the most common genomic and epigenomic alterations that are likely to drive certain breast cancers. The identification of these "driver" lesions has heralded an era of precision medicine in which vulnerable oncogenic pathways may be targeted to disrupt the etiologic lesion(s) of a specific tumor. A number of such early targeted approaches have yielded success in treating breast cancer, demonstrating the critical need for molecular diagnostics in this disease. (C) 2016 Elsevier Inc. All rights reserved. C1 [Braunstein, Lior Z.] Harvard Radiat Oncol Program, Boston, MA USA. [Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Taghian, AG (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Cox 302,100 Blossom St, Boston, MA 02114 USA. EM ATAGHIAN@mgh.harvard.edu NR 51 TC 0 Z9 0 U1 4 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-4296 EI 1532-9461 J9 SEMIN RADIAT ONCOL JI Semin. Radiat. Oncol. PD JAN PY 2016 VL 26 IS 1 BP 9 EP 16 DI 10.1016/j.semradonc.2015.08.002 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA CY2FK UT WOS:000366224000003 PM 26617205 ER PT J AU Wong, JS Warren, LEG Bellon, JR AF Wong, Julia S. Warren, Laura E. G. Bellon, Jennifer R. TI Management of the Regional Lymph Nodes in Early-Stage Breast Cancer SO SEMINARS IN RADIATION ONCOLOGY LA English DT Article ID INTERNAL MAMMARY NODES; RANDOMIZED CONTROLLED-TRIAL; EORTC 10981-22023 AMAROS; RADIATION-FIELD DESIGN; POSITIVE SENTINEL NODE; QUALITY-OF-LIFE; AXILLARY DISSECTION; ARM LYMPHEDEMA; RISK-FACTORS; FOLLOW-UP AB The management of regional nodes in early-stage invasive breast cancer continues to evolve. Improved systemic therapy has contributed to better local regional control, and at the same time it has drawn more attention to its importance. Axillary dissections have decreased, in part because of the increased efficacy of systemic therapy, and also because adjuvant therapy decisions are increasingly driven by biologic characterization of the tumor rather than pathologic nodal information. The trend toward less axillary surgery and a shift toward increased reliance on systemic and radiation therapy to address nodal disease has created interesting questions that were subsequently addressed in recent trials. We review the controversies in regional nodal management, the benefits of current treatment paradigms, the balance between less surgery and more radiation, and the potential tradeoffs vs toxicity. (C) 2016 Elsevier Inc. All rights reserved. C1 [Wong, Julia S.; Bellon, Jennifer R.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA. [Wong, Julia S.; Bellon, Jennifer R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Warren, Laura E. G.] Harvard Radiat Oncol Program, Boston, MA USA. RP Bellon, JR (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Yawkey 1472, Boston, MA 02215 USA. EM jbellon@lroc.harvard.edu NR 81 TC 0 Z9 0 U1 4 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-4296 EI 1532-9461 J9 SEMIN RADIAT ONCOL JI Semin. Radiat. Oncol. PD JAN PY 2016 VL 26 IS 1 BP 37 EP 44 DI 10.1016/j.semradonc.2015.08.003 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA CY2FK UT WOS:000366224000006 PM 26617208 ER PT J AU Bird, ER Gilmore, AK George, WH Lewis, MA AF Bird, Elizabeth R. Gilmore, Amanda K. George, William H. Lewis, Melissa A. TI The role of social drinking factors in the relationship between incapacitated sexual assault and drinking before sexual activity SO ADDICTIVE BEHAVIORS LA English DT Article DE Incapacitated sexual assault; Drinking motives; Drinking norms; Alcohol use; Sexual activity ID COLLEGE-STUDENTS; ALCOHOL-USE; SUBSTANCE USE; RISK-FACTORS; RECIPROCAL RELATIONSHIPS; CASUAL SEX; WOMEN; VICTIMIZATION; RAPE; CONSUMPTION AB White House Council on Women and Girls (2014) highlighted sexual assault prevention as a high priority issue in need of immediate attention. A risk factor associated with sexual assault victimization and revictimization is drinking before sexual activity. The current study examined the relationship between incapacitated sexual assault (ISA) and drinking before sexual activity. Given the typical social context of both drinking before sexual activity and sexual assault in college settings, social-related drinking factors including drinking to conform motives, social drinking motives, and perceived drinking norms were examined. Six hundred and three undergraduate college women completed a survey online assessing history of ISA, social factors associated with drinking, and frequency of drinking before sexual activity. Path analysis indicated that both ISA before college and since entering college were associated with higher perceived drinking norms, more social drinking motive endorsement, and more drinking to conform. However, only higher perceived drinking norms and more social drinking motive endorsement were associated with both more severe ISA histories and more frequent drinking before sexual activity. Thus, a more severe ISA history was indeed associated with more frequent drinking before sexual activity and social factors related to drinking played a significant role in this relationship. Social factors can be easily targeted through brief interventions and these findings can inform future programming to promote more careful use of alcohol in social and sexual situations. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Bird, Elizabeth R.; Gilmore, Amanda K.; George, William H.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Gilmore, Amanda K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lewis, Melissa A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Bird, ER (reprint author), Univ Washington, Dept Psychol, Box 351525, Seattle, WA 98195 USA. EM ebird@uw.edu FU National Institute for Alcohol Abuse and Alcoholism (NIAAA) [F31AA020134]; Alcohol and Drug Abuse Institute at the University of Washington [ADAI-0311-2]; University of Washington; NIAAA [R01AA016281, R01AA021379] FX Data collection and manuscript preparation were supported by grants from the National Institute for Alcohol Abuse and Alcoholism (NIAAA) awarded to A. K. Gilmore (F31AA020134) as well as a grant from the Alcohol and Drug Abuse Institute at the University of Washington (ADAI-0311-2), as well as the Bolles Fellowship and Hunt Fellowship from the University of Washington awarded to A. K. Gilmore. Manuscript preparation was also supported by grants from NIAAA awarded to W. H. George (R01AA016281) and to M. A. Lewis (R01AA021379). NR 59 TC 1 Z9 2 U1 7 U2 17 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD JAN PY 2016 VL 52 BP 28 EP 33 DI 10.1016/j.addbeh.2015.08.001 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CX0HI UT WOS:000365377100005 PM 26348279 ER PT J AU Grossbard, JR Leo, NRM Geisner, IM Atkins, D Ray, AE Kilmer, JR Mallett, K Larimer, ME Turrisi, R AF Grossbard, Joel R. Leo, Nadine R. Mastro Geisner, Irene Markman Atkins, David Ray, Anne E. Kilmer, Jason R. Mallett, Kimberly Larimer, Mary E. Turrisi, Rob TI Drinking norms, readiness to change, and gender as moderators of a combined alcohol intervention for first-year college students SO ADDICTIVE BEHAVIORS LA English DT Article DE Alcohol intervention; College students; Moderators; Readiness to change; Norms ID BRIEF MOTIVATIONAL INTERVENTIONS; PERSONALIZED NORMATIVE FEEDBACK; HEAVY-DRINKING; RANDOMIZED FACTORIAL; EMERGENCY-DEPARTMENT; CHANGE QUESTIONNAIRE; CONTROLLED-TRIAL; NATIONAL-SURVEY; NONMEDICAL USE; FOLLOW-UP AB Introduction: Alcohol interventions targeting college students and their parents have been shown to be efficacious. Little research has examined moderators of intervention efficacy to help tailor interventions for subgroups of students. Method: This study is a secondary data analysis of readiness to change, drinking norms, and gender as moderators of an efficacious peer- and parent-based intervention (Turrisi et al., 2009). Students (n = 680) were randomized to the combined peer and parent intervention (n = 342) or assessment-only control (n = 338). Results: The combined intervention reduced peak blood alcohol content (BAC) compared to control. Gender and norms did not moderate the relationship between the intervention and drinking. Significant interactions were found between gender, precontemplation, and intervention. Students in the combined condition with higher precontemplation had lower weekly drinking compared to those with lower precontemplation. This pattern was also found among men for peak BAC and alcohol-related consequences but not among women, indicating a three-way interaction. Conclusion: Interventions may need to consider readiness to change and gender to optimize effectiveness. Published by Elsevier Ltd. C1 [Grossbard, Joel R.] Vet Affairs Univ Washington, Dept Hlth Serv, Seattle, WA 98108 USA. [Leo, Nadine R. Mastro] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Geisner, Irene Markman; Atkins, David; Kilmer, Jason R.; Larimer, Mary E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA. [Ray, Anne E.] Rutgers State Univ, Ctr Alcohol Studies, Piscataway, NJ 08854 USA. [Mallett, Kimberly; Turrisi, Rob] Penn State Univ, Biobehav Hlth & Prevent Ctr, University Pk, PA 16802 USA. RP Grossbard, JR (reprint author), VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM joel.Grossbard@va.gov OI Atkins, David/0000-0002-5781-9880 FU National Institute on Alcohol Abuse and Alcoholism [R01 AA 12529] FX This research was supported in part by a grant from the National Institute on Alcohol Abuse and Alcoholism R01 AA 12529 awarded to Rob Turrisi. NR 74 TC 2 Z9 2 U1 7 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD JAN PY 2016 VL 52 BP 75 EP 82 DI 10.1016/j.addbeh.2015.07.028 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CX0HI UT WOS:000365377100012 PM 26363307 ER PT J AU Prodanov, L Jindal, R Bale, SS Hegde, M McCarty, WJ Golberg, I Bhushan, A Yarmush, ML Usta, OB AF Prodanov, Ljupcho Jindal, Rohit Bale, Shyam Sundhar Hegde, Manjunath McCarty, William J. Golberg, Inna Bhushan, Abhinav Yarmush, Martin L. Usta, Osman Berk TI Long-term maintenance of a microfluidic 3D human liver sinusoid SO BIOTECHNOLOGY AND BIOENGINEERING LA English DT Article DE liver-on-a-chip; microfludics; liver sinusoid; hepatocytes; 3D microtissue ID CELLS; EXPRESSION; DEVICES; CULTURE; U937 AB The development of long-term human organotypic liver-on-a-chip models for successful prediction of toxic response is one of the most important and urgent goals of the NIH/DARPA's initiative to replicate and replace chronic and acute drug testing in animals. For this purpose, we developed a microfluidic chip that consists of two microfluidic chambers separated by a porous membrane. The aim of this communication is to demonstrate the recapitulation of a liver sinusoid-on-a-chip, using human cells only for a period of 28 days. Using a step-by-step method for building a 3D microtissue on-a-chip, we demonstrate that an organotypic in vitro model that reassembles the liver sinusoid microarchitecture can be maintained successfully for a period of 28 days. In addition, higher albumin synthesis (synthetic) and urea excretion (detoxification) were observed under flow compared to static cultures. This human liver-on-a-chip should be further evaluated in drug-related studies. Biotechnol. Bioeng. 2016;113: 241-246. (c) 2015 Wiley Periodicals, Inc. C1 [Prodanov, Ljupcho; Jindal, Rohit; Bale, Shyam Sundhar; Hegde, Manjunath; McCarty, William J.; Golberg, Inna; Bhushan, Abhinav; Yarmush, Martin L.; Usta, Osman Berk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02144 USA. [Prodanov, Ljupcho; Jindal, Rohit; Bale, Shyam Sundhar; Hegde, Manjunath; McCarty, William J.; Golberg, Inna; Bhushan, Abhinav; Yarmush, Martin L.; Usta, Osman Berk] Shriners Hosp Children, Boston, MA 02144 USA. [Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA. RP Usta, OB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med, 51 Blossom St, Boston, MA 02144 USA. EM ireis@sbi.org; berkusta@gmail.com RI Hegde, Manjunath/M-3038-2014; OI Hegde, Manjunath/0000-0002-5396-2241; McCarty, William/0000-0002-3671-0616 FU NCATS [UH2TR000503]; NIDDK [F32DK098905, K99DK095984] FX Contract grant sponsor: NCATS; Contract grant number: UH2TR000503; Contract grant sponsor: NIDDK; Contract grant numbers: F32DK098905; K99DK095984 NR 28 TC 9 Z9 9 U1 7 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0006-3592 EI 1097-0290 J9 BIOTECHNOL BIOENG JI Biotechnol. Bioeng. PD JAN PY 2016 VL 113 IS 1 BP 241 EP 246 DI 10.1002/bit.25700 PG 6 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA CX5ES UT WOS:000365725500025 PM 26152452 ER PT B AU Devlin, PM AF Devlin, Phillip M. BE Devlin, PM TI Brachytherapy Applications and Techniques Second Edition Preface SO BRACHYTHERAPY: APPLICATIONS AND TECHNIQUES, SECOND EDITION LA English DT Editorial Material; Book Chapter C1 [Devlin, Phillip M.] Dana Farber Canc Inst, Div Brachytherapy, Boston, MA 02115 USA. [Devlin, Phillip M.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Devlin, PM (reprint author), Dana Farber Canc Inst, Div Brachytherapy, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-082-2 PY 2016 BP XV EP XXI PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BD9MP UT WOS:000364979300001 ER PT B AU Stewart, AJ Cormack, RA Held, KD AF Stewart, Alexandra J. Cormack, Robert A. Held, Kathryn D. BE Devlin, PM TI Radiobiologic Concepts for Brachytherapy SO BRACHYTHERAPY: APPLICATIONS AND TECHNIQUES, SECOND EDITION LA English DT Article; Book Chapter ID HIGH-DOSE-RATE; RATE INTRACAVITARY BRACHYTHERAPY; I-125 INTERSTITIAL BRACHYTHERAPY; PARTIAL BREAST IRRADIATION; EYE PLAQUE BRACHYTHERAPY; UTERINE CERVIX; PROGNOSTIC-FACTORS; RADIATION-THERAPY; PERMANENT BRACHYTHERAPY; TREATMENT PROLONGATION C1 [Stewart, Alexandra J.] Royal Surrey Cty Hosp, St Lukes Canc Ctr, Guildford, Surrey, England. [Stewart, Alexandra J.] Univ Surrey, Guildford GU2 5XH, Surrey, England. [Cormack, Robert A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Held, Kathryn D.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Held, Kathryn D.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Stewart, AJ (reprint author), Royal Surrey Cty Hosp, St Lukes Canc Ctr, Guildford, Surrey, England. NR 52 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-082-2 PY 2016 BP 37 EP 51 PG 15 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BD9MP UT WOS:000364979300003 ER PT B AU Bhagwat, MS Buzurovic, IM Damato, AL Friesen, SA Hansen, JL O'Farrell, DA Sugar, EN Cormack, RA AF Bhagwat, Mandar S. Buzurovic, Ivan M. Damato, Antonio L. Friesen, Scott A. Hansen, Jorgen L. O'Farrell, Desmond A. Sugar, Emily Neubauer Cormack, Robert A. BE Devlin, PM TI Technical Aspects of Brachytherapy SO BRACHYTHERAPY: APPLICATIONS AND TECHNIQUES, SECOND EDITION LA English DT Article; Book Chapter ID DOSE-RATE BRACHYTHERAPY; GYNECOLOGIC INTERSTITIAL BRACHYTHERAPY; CERVICAL-CANCER; PROSTATE-CANCER; INTRACAVITARY BRACHYTHERAPY; RADIATION-THERAPY; QUALITY-ASSURANCE; AAPM PROTOCOL; UNCERTAINTIES; TIME C1 [Bhagwat, Mandar S.; Buzurovic, Ivan M.; Damato, Antonio L.; Friesen, Scott A.; Hansen, Jorgen L.; O'Farrell, Desmond A.; Sugar, Emily Neubauer; Cormack, Robert A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. RP Bhagwat, MS (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. NR 60 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-082-2 PY 2016 BP 53 EP 78 PG 26 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BD9MP UT WOS:000364979300004 ER PT B AU Martin, AG Lacroix, F Niedermayr, T Nguyen, PL Orio, PF AF Martin, Andre-Guy Lacroix, Frederic Niedermayr, Thomas Nguyen, Paul L. Orio, Peter F., III BE Devlin, PM TI Genitourinary Brachytherapy SO BRACHYTHERAPY: APPLICATIONS AND TECHNIQUES, SECOND EDITION LA English DT Article; Book Chapter ID LOCALIZED PROSTATE-CANCER; DOSE-RATE BRACHYTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; PERMANENT INTERSTITIAL BRACHYTHERAPY; INFLAMMATORY-BOWEL-DISEASE; LONG-TERM OUTCOMES; SOCIETY CONSENSUS GUIDELINES; RANDOMIZED CONTROLLED-TRIAL; RELAPSE-FREE SURVIVAL; BODY-MASS INDEX C1 [Martin, Andre-Guy; Lacroix, Frederic] Univ Laval, Ctr Hosp Univ Quebec, Hotel Dieu Quebec, Dept Radiat Oncol, Quebec City, PQ, Canada. [Niedermayr, Thomas] Stanford Univ, Sch Med, Radiat Oncol Radiat Phys, Stanford, CA USA. [Nguyen, Paul L.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Nguyen, Paul L.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Orio, Peter F., III] Milford Reg Med Ctr, Dana Farber Brigham & Womens Hosp, Dept Radiat Oncol, Milford, MA USA. [Orio, Peter F., III] South Shore Hosp, Dana Farber Brigham & Womens Hosp Clin, Weymouth, MA USA. RP Martin, AG (reprint author), Univ Laval, Ctr Hosp Univ Quebec, Hotel Dieu Quebec, Dept Radiat Oncol, Quebec City, PQ, Canada. NR 167 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-082-2 PY 2016 BP 79 EP 137 PG 59 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BD9MP UT WOS:000364979300005 ER PT B AU Lee, LJ Damato, AL Viswanathan, AN AF Lee, Larissa J. Damato, Antonio L. Viswanathan, Akila N. BE Devlin, PM TI Gynecologic Brachytherapy SO BRACHYTHERAPY: APPLICATIONS AND TECHNIQUES, SECOND EDITION LA English DT Article; Book Chapter ID DOSE-RATE BRACHYTHERAPY; CERVICAL-CANCER BRACHYTHERAPY; RATE INTERSTITIAL BRACHYTHERAPY; POSITRON-EMISSION-TOMOGRAPHY; SOCIETY CONSENSUS GUIDELINES; PRIMARY VAGINAL-CARCINOMA; SQUAMOUS-CELL CARCINOMA; ENDOMETRIAL CANCER; RADIATION-THERAPY; AMERICAN BRACHYTHERAPY C1 [Lee, Larissa J.; Damato, Antonio L.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Lee, Larissa J.] Harvard Univ, Sch Med, Boston, MA USA. [Viswanathan, Akila N.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA. RP Lee, LJ (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. NR 111 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-082-2 PY 2016 BP 139 EP 164 PG 26 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BD9MP UT WOS:000364979300006 ER PT B AU Likhacheva, AO Devlin, PM Buzurovic, IM AF Likhacheva, Anna O. Devlin, Phillip M. Buzurovic, Ivan M. BE Devlin, PM TI Skin Brachytherapy SO BRACHYTHERAPY: APPLICATIONS AND TECHNIQUES, SECOND EDITION LA English DT Article; Book Chapter ID DOSE-RATE BRACHYTHERAPY; SQUAMOUS-CELL CARCINOMA; SURFACE APPLICATORS; CANCER; RADIATION; MOLDS; BASAL; THERAPY; SARCOMA; LESIONS C1 [Likhacheva, Anna O.] Banner MD Anderson Canc Ctr, Dept Radiat Oncol, Gilbert, AZ 85234 USA. [Likhacheva, Anna O.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Devlin, Phillip M.] Dana Farber Canc Inst, Div Brachytherapy, Boston, MA 02115 USA. [Devlin, Phillip M.] Harvard Univ, Sch Med, Boston, MA USA. [Buzurovic, Ivan M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. RP Likhacheva, AO (reprint author), Banner MD Anderson Canc Ctr, Dept Radiat Oncol, Gilbert, AZ 85234 USA. NR 26 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-082-2 PY 2016 BP 211 EP 233 PG 23 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BD9MP UT WOS:000364979300009 ER PT B AU Lukens, JN Hu, KS Levendag, PC Teguh, DN Busse, PM Harrison, LB AF Lukens, J. Nicholas Hu, Kenneth S. Levendag, Peter C. Teguh, David N. Busse, Paul M. Harrison, Louis B. BE Devlin, PM TI Head and Neck Brachytherapy SO BRACHYTHERAPY: APPLICATIONS AND TECHNIQUES, SECOND EDITION LA English DT Article; Book Chapter ID HIGH-DOSE-RATE; SQUAMOUS-CELL CARCINOMA; INTRAOPERATIVE RADIATION-THERAPY; RECURRENT NASOPHARYNGEAL CARCINOMA; QUALITY-OF-LIFE; RATE INTERSTITIAL BRACHYTHERAPY; SINGLE-INSTITUTION EXPERIENCE; EXTERNAL-BEAM IRRADIATION; TWICE-DAILY REIRRADIATION; T2 EPIDERMOID CARCINOMAS C1 [Lukens, J. Nicholas] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Hu, Kenneth S.] Mt Sinai Beth Israel Med Ctr, Dept Radiat Oncol, New York, NY USA. [Levendag, Peter C.; Teguh, David N.] Daniel Denhoed Canc Ctr, Erasmus Med Ctr, Dept Radiat Oncol, Rotterdam, Netherlands. [Busse, Paul M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Harrison, Louis B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL 33612 USA. RP Lukens, JN (reprint author), Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA. NR 133 TC 0 Z9 0 U1 0 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-082-2 PY 2016 BP 235 EP 292 PG 58 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BD9MP UT WOS:000364979300010 ER PT B AU Stockham, AL Arvold, ND AF Stockham, Abigail L. Arvold, Nils D. BE Devlin, PM TI Central Nervous System Brachytherapy SO BRACHYTHERAPY: APPLICATIONS AND TECHNIQUES, SECOND EDITION LA English DT Article; Book Chapter ID RECURRENT GLIOBLASTOMA-MULTIFORME; HIGH-ACTIVITY I-125; DOSE-RATE BRACHYTHERAPY; LOW-GRADE GLIOMA; BRAIN-TUMORS; INTERSTITIAL BRACHYTHERAPY; STEREOTACTIC BRACHYTHERAPY; GLIASITE BRACHYTHERAPY; SURGICAL RESECTION; RADIATION-THERAPY C1 [Stockham, Abigail L.] Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA. [Stockham, Abigail L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Arvold, Nils D.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Arvold, Nils D.] Harvard Univ, Sch Med, Boston, MA USA. RP Stockham, AL (reprint author), Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA. NR 70 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-082-2 PY 2016 BP 293 EP 318 PG 26 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BD9MP UT WOS:000364979300011 ER PT B AU Stewart, AJ Tselis, N Albert, M Thawani, N Myint, AS AF Stewart, Alexandra J. Tselis, Nikolaos Albert, Michele Thawani, Nitika Myint, Arthur Sun BE Devlin, PM TI Gastrointestinal Brachytherapy SO BRACHYTHERAPY: APPLICATIONS AND TECHNIQUES, SECOND EDITION LA English DT Article; Book Chapter ID DOSE-RATE BRACHYTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; RATE ENDORECTAL BRACHYTHERAPY; GUIDED INTERSTITIAL BRACHYTHERAPY; RATE INTRALUMINAL BRACHYTHERAPY; ANAL-CANAL CARCINOMA; STEREOTACTIC BODY RADIOTHERAPY; PRIMARY UNRESECTABLE CARCINOMA; SUPERFICIAL ESOPHAGEAL CANCER; MULTICENTER RANDOMIZED-TRIAL C1 [Stewart, Alexandra J.] Royal Surrey Cty Hosp, St Lukes Canc Ctr, Guildford, Surrey, England. [Stewart, Alexandra J.] Univ Surrey, Guildford GU2 5XH, Surrey, England. [Tselis, Nikolaos] Sana Klinikum Offenbach, Dept Radiat Oncol, Offenbach, Hessen, Germany. [Albert, Michele] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Albert, Michele] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Albert, Michele] St Annes Hosp, Reg Canc Ctr, Dept Radiat Oncol, Fall River, MA USA. [Thawani, Nitika] Scott & White Healthcare, Temple, TX USA. [Myint, Arthur Sun] Univ Liverpool, Wirral L64 7TE, Merseyside, England. [Myint, Arthur Sun] Int Contact Radiotherapy Network, Wirral, Merseyside, England. [Myint, Arthur Sun] GEC ESTRO Rectal & Anal Brachytherapy, Wirral, Merseyside, England. RP Stewart, AJ (reprint author), Royal Surrey Cty Hosp, St Lukes Canc Ctr, Guildford, Surrey, England. NR 122 TC 1 Z9 1 U1 1 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-082-2 PY 2016 BP 319 EP 353 PG 35 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BD9MP UT WOS:000364979300012 ER PT B AU Holloway, CL Raut, CP AF Holloway, Caroline L. Raut, Chandrajit P. BE Devlin, PM TI Soft Tissue Sarcoma Brachytherapy SO BRACHYTHERAPY: APPLICATIONS AND TECHNIQUES, SECOND EDITION LA English DT Article; Book Chapter ID HIGH-DOSE-RATE; EXTERNAL-BEAM RADIOTHERAPY; INTRAOPERATIVE RADIATION-THERAPY; PERIOPERATIVE INTERSTITIAL BRACHYTHERAPY; SINGLE INSTITUTION EXPERIENCE; LIMB-SPARING SURGERY; ADJUVANT BRACHYTHERAPY; RETROPERITONEAL SARCOMAS; I-125 BRACHYTHERAPY; SURFACE APPLICATORS C1 [Holloway, Caroline L.] Univ British Columbia, Dept Radiat Oncol, Victoria, BC, Canada. [Holloway, Caroline L.] British Columbia Canc Agcy, Vancouver Isl Ctr, Victoria, BC, Canada. [Raut, Chandrajit P.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Raut, Chandrajit P.] Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA. [Raut, Chandrajit P.] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA. RP Holloway, CL (reprint author), Univ British Columbia, Dept Radiat Oncol, Victoria, BC, Canada. NR 62 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-082-2 PY 2016 BP 355 EP 373 PG 19 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BD9MP UT WOS:000364979300013 ER PT J AU Leslie, RD Palmer, J Schloot, NC Lernmark, A AF Leslie, R. David Palmer, Jerry Schloot, Nanette C. Lernmark, Ake TI Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment SO DIABETOLOGIA LA English DT Review DE Autoantibodies; Genetic variants; LADA; MODY; Personalised medicine; Review; Tcells; Treatment; Type 1 diabetes; Type 2 diabetes ID BETA-CELL FUNCTION; INSULIN SENSITIVITY; GAD ANTIBODIES; RISK-FACTORS; LADA CHINA; C-PEPTIDE; TYPE-2; ONSET; ADULTS; AUTOIMMUNITY AB Diabetes is not a single homogeneous disease but composed of many diseases with hyperglycaemia as a common feature. Four factors have, historically, been used to identify this diversity: the age at onset; the severity of the disease, i.e. degree of loss of beta cell function; the degree of insulin resistance and the presence of diabetes-associated autoantibodies. Our broad understanding of the distinction between the two major types, type 1 diabetes mellitus and type 2 diabetes mellitus, are based on these factors, but it has become apparent that they do not precisely capture the different disease forms. Indeed, both major types of diabetes have common features, encapsulated by adult-onset autoimmune diabetes and maturity-onset diabetes of the young. As a result, there has been a repositioning of our understanding of diabetes. In this review, drawing on recent literature, we discuss the evidence that autoimmune type 1 diabetes has a broad clinical phenotype with diverse therapeutic options, while the term non-autoimmune type 2 diabetes obscures the optimal management strategy because it encompasses substantial heterogeneity. Underlying these developments is a general progression towards precision medicine with the need for precise patient characterisation, currently based on clinical phenotypes but in future augmented by laboratory-based tests. C1 [Leslie, R. David] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England. [Palmer, Jerry] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Schloot, Nanette C.] Univ Dusseldorf, German Diabet Ctr, Inst Clin Diabetol, Dusseldorf, Germany. [Schloot, Nanette C.] Lilly Deutschland GmbH, Bad Homburg, Germany. [Lernmark, Ake] Lund Univ, CRC, Dept Clin Sci, Malmo, Sweden. RP Leslie, RD (reprint author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England. EM r.d.g.leslie@qmul.ac.uk NR 45 TC 10 Z9 10 U1 3 U2 23 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD JAN PY 2016 VL 59 IS 1 BP 13 EP 20 DI 10.1007/s00125-015-3789-z PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CX6IN UT WOS:000365804500004 PM 26498592 ER PT J AU Bassi, R Fornoni, A Doria, A Fiorina, P AF Bassi, Roberto Fornoni, Alessia Doria, Alessandro Fiorina, Paolo TI CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease SO DIABETOLOGIA LA English DT Review DE B7-1; CD80; CTLA4-Ig; Diabetic kidney disease; Podocytes; Review ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; MINIMAL-CHANGE DISEASE; LONG-TERM SAFETY; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; RENAL-INSUFFICIENCY; URINARY CD80; ABATACEPT; PODOCYTES; NEPHROPATHY AB Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the Western world. Standard treatments have ultimately proven ineffective in blocking DKD progression, thus necessitating the design of new therapies to complement glycaemic and blood pressure control. High glucose levels upregulate the immune-related molecule B7-1 in podocytes, and such an event may play a relevant role in DKD onset, suggesting that B7-1 is a suitable therapeutic target for DKD. CTLA4-Ig is a clinically available fusion protein, approved for the treatment of some autoimmune diseases, which binds B7-1 and blocks its signalling. We have previously demonstrated that CTLA4-Ig restores the physiological structure and cellular motility of podocytes challenged with high glucose in vitro and abrogates the onset of proteinuria in murine models of DKD in vivo. Notably, these beneficial effects occurred independently of any systemic immunological effects of CTLA4-Ig. While the expression of B7-1 on podocytes raises questions regarding the very nature of the podocyte as we know it, the preliminary positive effect of CTLA4-Ig on proteinuria in preclinical models and the evidence of B7-1 expression in kidney biopsies of diabetic individuals suggest a potential novel indication for CTLA4-Ig in DKD. Nonetheless, recent reports of problems with detecting podocyte B7-1 and of inconsistent therapeutic efficacy of CTLA4-Ig in proteinuric patients highlight the necessity to establish uniformly accepted protocols for the detection of B7-1 and underline the need for randomised trials with CTLA4-Ig in kidney diseases. C1 [Bassi, Roberto; Fiorina, Paolo] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Nephrol, Boston, MA 02115 USA. [Bassi, Roberto; Fiorina, Paolo] Univ Milan, Osped San Raffaele, IRCCS, Dept Transplant Med, I-20127 Milan, Italy. [Fornoni, Alessia] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA. [Doria, Alessandro] Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA. RP Fiorina, P (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Div Nephrol, 300 Longwood Ave,Enders Bldg, Boston, MA 02115 USA. EM paolo.fiorina@childrens.harvard.edu FU AST Genentech/Novartis Clinical Science Fellowship grant; JDRF Post-Doctoral Fellowship grant; 'AMD-SID Pasquale di Coste' Award; American Heart Association; Italian Ministry of Health [RF-2010-2303119, RF-2010-2314794]; NIH [R01-DK090316, U24-DK076169, UL1-TR000460, U54-DK083912]; Katz Drug Discovery Center FX RB is the recipient of an AST Genentech/Novartis Clinical Science Fellowship grant, a JDRF Post-Doctoral Fellowship grant and an 'AMD-SID Pasquale di Coste' Award. PF is the recipient of an American Heart Association Grant-In-Aid; Italian Ministry of Health grant RF-2010-2303119 and RF-2010-2314794. AF is supported by NIH grants R01-DK090316, U24-DK076169, UL1-TR000460, U54-DK083912 and by the Katz Drug Discovery Center. NR 62 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD JAN PY 2016 VL 59 IS 1 BP 21 EP 29 DI 10.1007/s00125-015-3766-6 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CX6IN UT WOS:000365804500005 PM 26409459 ER PT J AU Polyzos, SA Aronis, KN Kountouras, J Raptis, DD Vasiloglou, MF Mantzoros, CS AF Polyzos, Stergios A. Aronis, Konstantinos N. Kountouras, Jannis Raptis, Dimitrios D. Vasiloglou, Maria F. Mantzoros, Christos S. TI Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis SO DIABETOLOGIA LA English DT Article DE Adipokine; Adipose tissue; Insulin resistance; Leptin; Meta-analysis; Metabolic syndrome; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Steatosis; Systematic review ID SERUM LEPTIN; INSULIN-RESISTANCE; ADIPOKINE CONCENTRATIONS; BARIATRIC SURGERY; CHRONIC HEPATITIS; OBESE-PATIENTS; STEATOHEPATITIS; ADIPONECTIN; FIBROSIS; SEVERITY AB Aims/hypothesis Clinical data regarding circulating leptin levels in patients with non-alcoholic fatty liver disease (NAFLD) are conflicting. The purpose of this meta-analysis was to compare leptin levels between the following groups: patients with biopsy-proven NAFLD vs controls; simple steatosis (SS) patients vs controls; non-alcoholic steatohepatitis (NASH) patients vs controls and NASH patients vs SS patients. Methods We performed a systematic search in PubMed, Scopus and the Cochrane Library. We analysed 33 studies, published between 1999 and 2014, including 2,612 individuals (775 controls and 1,837 NAFLD patients). Results Higher circulating leptin levels were observed in NAFLD patients vs controls (standardised mean difference [SMD] 0.640; 95% CI 0.422, 0.858), SS patients vs controls (SMD 0.358; 95% CI 0.043, 0.673), NASH patients vs controls (SMD 0.617; 95% CI 0.403, 0.832) and NASH patients vs SS patients (SMD 0.209; 95% CI 0.023, 0.395). These results remained essentially unchanged after excluding studies involving paediatric or adolescent populations and/or individuals undergoing bariatric surgery. There was moderate-to-severe heterogeneity among studies in all comparisons, but no significant publication bias was detected. Meta-regression analysis demonstrated that BMI was inversely associated with leptin SMD and accounted for 26.5% (p = 0.014) and 32.7% (p = 0.021) of the between-study variance in the comparison between NASH patients and controls and NAFLD patients and controls, respectively. However, when bariatric studies were excluded, BMI did not significantly explain the between-study variance. Conclusions/interpretation Circulating leptin levels were higher in patients with NAFLD than in controls. Higher levels of circulating leptin were associated with increased severity of NAFLD, and the association remained significant after the exclusion of studies involving paediatric or adolescent populations and morbidly obese individuals subjected to bariatric surgery. C1 [Polyzos, Stergios A.; Kountouras, Jannis; Raptis, Dimitrios D.; Vasiloglou, Maria F.] Aristotle Univ Thessaloniki, Med Clin 2, Ippokrat Hosp, Thessaloniki 54642, Greece. [Aronis, Konstantinos N.; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metabol,Dept Internal Med, Boston, MA 02215 USA. [Aronis, Konstantinos N.; Mantzoros, Christos S.] Boston Univ, Sch Med, Dept Med, Boston Med Ctr, Boston, MA 02118 USA. [Mantzoros, Christos S.] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Endocrinol Sect, Boston, MA USA. RP Polyzos, SA (reprint author), Aristotle Univ Thessaloniki, Med Clin 2, Ippokrat Hosp, 49 Konstantinoupoleos, Thessaloniki 54642, Greece. EM stergios@endo.gr RI Aronis, Konstantinos/F-3586-2012 OI Aronis, Konstantinos/0000-0001-7189-8434 FU Amgen; Aegerion FX CSM has served as a consultant for Astra Zeneca and has received research support through his Institution from Amgen and a lecture fee from Aegerion. All other authors declare that there is no duality of interest associated with their contribution to this manuscript. NR 48 TC 8 Z9 8 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD JAN PY 2016 VL 59 IS 1 BP 30 EP 43 DI 10.1007/s00125-015-3769-3 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CX6IN UT WOS:000365804500006 PM 26407715 ER PT J AU Du Bois, SN Sher, TG Grotkowski, K Aizenman, T Slesinger, N Cohen, M AF Du Bois, Steve N. Sher, Tamara G. Grotkowski, Karolina Aizenman, Talia Slesinger, Noel Cohen, Mariana TI Going the Distance: Health in Long-Distance Versus Proximal Relationships SO FAMILY JOURNAL LA English DT Article DE couples; relationships; long distance; health; relationship stress ID MARITAL-STATUS; MENTAL-HEALTH; RELATIONSHIP SATISFACTION; RELATIONSHIP QUALITY; SOCIAL-CONTROL; RELATIONSHIP MAINTENANCE; PSYCHOLOGICAL DISTRESS; SEXUAL SATISFACTION; STRESS; COUPLES AB Healthy romantic relationships are beneficial to an individual's physical and mental health. The prevalence of long-distance relationships (LDRs) is increasing; yet, no research has assessed whether the marriage-health association applies to individuals in LDRs. The present study investigated the marriage-health association in LDRs by comparing PR and LDR individuals on various health and relationship indices. Using both Qualtrics and Amazon's Mechanical Turk, we designed an online survey (N = 296 married, 21 years or older, English speakers). Health measures included the patient-reported outcomes measurement information system (PROMIS-29); Perceived Stress Scale; and substance use, diet, and exercise surveys. Relationship variables assessed included satisfaction, maintenance, relationship stress, and sex. Overall, results were mixed, with no clear relationship arrangement relating to better health or relationship variable ratings. Relationship satisfaction did not differ across groups; however, individuals in PRs reported better maintenance, higher sexual frequency, and lower relationship stress. In terms of health, LDR individuals reported better health on several indices: overall scores; lower anxiety, depression, and fatigue subscale scores; and better diet/exercise behaviors. PR individuals reported lower individual stress levels, better medication adherence, and higher physical functioning scores than their LDR counterparts. Regression analyses indicated being in a LDR predicted more individual and relationship stress but simultaneously better diet and exercise behaviors. This study challenges the popular notion that health and happiness in a relationship stem from partner proximity and provides potential points of intervention to improve relationship satisfaction and health for individuals in both PRs and LDRs. C1 [Du Bois, Steve N.] Adler Univ, Dept Psychol, Chicago, IL 60602 USA. [Sher, Tamara G.; Grotkowski, Karolina; Aizenman, Talia; Slesinger, Noel] Northwestern Univ, Family Inst, Chicago, IL 60611 USA. [Cohen, Mariana] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Du Bois, SN (reprint author), Adler Univ, Dept Psychol, Chicago, IL 60602 USA. EM dubois.steve@gmail.com NR 63 TC 0 Z9 0 U1 6 U2 12 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1066-4807 EI 1552-3950 J9 FAM J JI Fam. J. PD JAN PY 2016 VL 24 IS 1 BP 5 EP 14 DI 10.1177/1066480715616580 PG 10 WC Family Studies SC Family Studies GA CX5KV UT WOS:000365741400001 ER PT J AU Coutu, JP Goldblatt, A Rosas, HD Salat, DH AF Coutu, Jean-Philippe Goldblatt, Alison Rosas, H. Diana Salat, David H. CA ADNI TI White Matter Changes are Associated with Ventricular Expansion in Aging, Mild Cognitive Impairment, and Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; cerebral ventricles; diffusion tensor imaging; hippocampus; leukoaraiosis; mild cognitive impairment; white matter ID SMALL VESSEL DISEASE; VASCULAR RISK-FACTORS; CEREBRAL AMYLOID ANGIOPATHY; AD DEMENTIA; CEREBROVASCULAR-DISEASE; SPATIAL-DISTRIBUTION; CORTICAL SIGNATURE; BLOOD-FLOW; MRI; HYPERINTENSITIES AB White matter lesions are highly prevalent in individuals with Alzheimer's disease (AD). Although these lesions are presumed to be of vascular origin and linked to small vessel disease in older adults, little information exists about their relationship to markers of classical AD neurodegeneration. Thus, we examined the link between these white matter changes (WMC) segmented on T-1-weighted MRI and imaging markers presumed to be altered due to primary AD neurodegenerative processes. Tissue microstructure of WMC was quantified using diffusion tensor imaging and the relationship of WMC properties and volume to neuroimaging markers was examined in 219 cognitively healthy older adults and individuals with mild cognitive impairment and AD using data from the Alzheimer's Disease Neuroimaging Initiative. No significant group differences in WMC properties were found. However, there were strong associations between diffusivity of WMC and ventricular volume, volume of WMC and total WM volume. In comparison, group differences in parahippocampal white matter microstructure were found for all diffusion metrics and were largely explained by hippocampal volume. Factor analysis on neuroimaging markers suggested two independent sets of covarying degenerative changes, with potentially age-and vascular-mediated tissue damage contributing to one factor and classical neurodegenerative changes associated with AD contributing to a second factor. These data demonstrate two potentially distinct classes of degenerative change in AD, with one factor strongly linked to aging, ventricular expansion, and both volume and tissue properties of white matter lesions, while the other factor related to classical patterns of cortical and hippocampal neurodegeneration in AD. C1 [Coutu, Jean-Philippe; Goldblatt, Alison; Rosas, H. Diana; Salat, David H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA. [Coutu, Jean-Philippe] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Goldblatt, Alison; Salat, David H.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Rosas, H. Diana] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA USA. RP Coutu, JP (reprint author), MIT, Div Hlth Sci & Technol, Bldg E25-518,77 Massachusetts Ave, Cambridge, MA 02139 USA. EM coutu@nmr.mgh.harvard.edu FU NIH [R01NR010827, NS042861, NS058793]; Center for Functional Neuroimaging Technologies [P41RR14075]; Biomedical Technology Program of the National Center for Research Resources (NCRR), NIH; NCRR Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program [S10RR021110, S10RR023401, S10RR019307, S10RR019254, S10RR023043]; Fonds Quebecois de la Recherche - Sante; Peter C. Farrell Fund; Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; Takeda Pharmaceutical Company; Canadian Institutes of Health Research; Northern California Institute for Research and Education FX We would like to thank Paul J. Wilkens for his help with the processing of the diffusion images. This study was supported by the NIH grant R01NR010827 and by Biogen Idec using resources provided by NIH grants NS042861, NS058793 and by the Center for Functional Neuroimaging Technologies, P41RR14075, a P41 Regional Resource supported by the Biomedical Technology Program of the National Center for Research Resources (NCRR), NIH. This work also involved the use of instrumentation supported by the NCRR Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program; specifically, grant numbers S10RR021110, S10RR023401, S10RR019307, S10RR019254 and S10RR023043. J.P.C. was supported by the Fonds Quebecois de la Recherche - Sante and by the HST IDEA2 Program supported by the Peter C. Farrell (1967) Fund.; Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. NR 59 TC 2 Z9 2 U1 1 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 49 IS 2 BP 329 EP 342 DI 10.3233/JAD-150306 PG 14 WC Neurosciences SC Neurosciences & Neurology GA CX4ZV UT WOS:000365710600006 PM 26444767 ER PT J AU Shi, ZY Zhu, YB Wang, MJ Wu, YJ Cao, J Li, CB Xie, ZC Shen, Y AF Shi, Zhongyong Zhu, Yingbo Wang, Meijuan Wu, Yujie Cao, Jing Li, Chunbo Xie, Zhongcong Shen, Yuan TI The Utilization of Retinal Nerve Fiber Layer Thickness to Predict Cognitive Deterioration SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; conversion score; mild cognitive impairment; predictive model; retinal nerve fiber layer thickness ID ALZHEIMERS ASSOCIATION WORKGROUPS; MINI-MENTAL STATE; DIAGNOSTIC GUIDELINES; IMPAIRMENT PATIENTS; NATIONAL INSTITUTE; OPTIC-NERVE; DISEASE; CONVERSION; DEMENTIA; RECOMMENDATIONS AB Our previous studies have shown that longitudinal reduction in retinal nerve fiber layer (RNFL) thickness is associated with cognitive deterioration. However, whether the combination of longitudinal reduction in RNFL thickness with baseline episodic memory performance can better predict cognitive deterioration remains unknown. Therefore, we set out to re-analyze the data obtained from our previous studies with 78 elderly adults (mean age 74.4 +/- 3.83 years, 48.7% male) in the community over a 25-month period. The participants were categorized as either stable participants whose cognitive status did not change (n = 60) or converted participants whose cognitive status deteriorated (n = 18). A logistic regression analysis was applied to determine a conversion score for predicting the cognitive deterioration in the participants. We found that the area under the receiver operating characteristic curve (AUC) for the multivariable model was 0.854 (95% CI 0.762-0.947) using baseline story recall as a predictor, but the AUC increased to 0.915 (95% CI 0.849-0.981) with the addition of the longitudinal reduction of RNFL thickness in the inferior quadrant. The conversion score was significantly higher for the converted participants than the stable participants (0.59 +/- 0.30 versus 0.12 +/- 0.19, p < 0.001). Finally, the optimal cutoff value of the conversion score (0.134) was determined by the analysis of receiver operating characteristic curve, and this conversion score generated a sensitivity of 0.944 and a specificity of 0.767 in predicting the cognitive deterioration. These findings have established a system to perform a larger scale study to further test whether the longitudinal reduction in RNFL thickness could serve as a biomarker of Alzheimer's disease. C1 [Shi, Zhongyong; Wang, Meijuan; Wu, Yujie; Cao, Jing; Shen, Yuan] Tongji Univ, Peoples Hosp 10, Dept Psychiat, Shanghai 200072, Peoples R China. [Zhu, Yingbo] Tongji Univ, Sch Med, Shanghai 200072, Peoples R China. [Li, Chunbo] Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Dept Biol Psychiat, Sch Med, Shanghai 200030, Peoples R China. [Xie, Zhongcong] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, Charlestown, MA USA. [Xie, Zhongcong] Harvard Univ, Sch Med, Charlestown, MA USA. RP Shen, Y (reprint author), Tongji Univ, Peoples Hosp 10, Dept Psychiat, 301 Yanchang Rd,Bldg 9,Floor 4th,Room 4405, Shanghai 200072, Peoples R China. EM kmshy@sina.com FU National Natural Science Foundation of China [81571034, 81200833]; Shanghai Natural Science Foundation [12ZR1428600] FX This study was supported by grant 81571034, 81200833 from the National Natural Science Foundation of China and grant 12ZR1428600 from the Shanghai Natural Science Foundation. NR 27 TC 2 Z9 2 U1 0 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 49 IS 2 BP 399 EP 405 DI 10.3233/JAD-150438 PG 7 WC Neurosciences SC Neurosciences & Neurology GA CX4ZV UT WOS:000365710600012 PM 26484909 ER PT J AU Mehta, HB Mehta, V Tsai, CL Chen, H Aparasu, RR Johnson, ML AF Mehta, Hemalkumar B. Mehta, Vinay Tsai, Chu-Lin Chen, Hua Aparasu, Rajender R. Johnson, Michael L. TI Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Dementia; hypertension; prediction model; risk index; Type 2 diabetes ID CHARLSON COMORBIDITY INDEX; PRACTICE RESEARCH DATABASE; CHRONIC DISEASE SCORE; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; OLDER-ADULTS; ADJUSTMENT; MORTALITY; INDIVIDUALS; POPULATIONS AB Background: Elderly patients with type 2 diabetes mellitus and hypertension are at high risk for developing dementia. In addition to comorbid disease conditions (Dx), prescription drugs (Rx) are important risk factors for dementia. Objective: Develop and validate the RxDx-Dementia risk index by combining diagnosis and prescription information in a single risk index to predict incident dementia, and compare its performance with diagnosis-based Charlson comorbidity score (CCS) and prescription-based chronic disease score (CDS). Methods: Elderly patients diagnosed with type 2 diabetes mellitus and hypertension, and without prior dementia were identified from the Clinical Practice Research Datalink (2003-2012). A Cox proportional hazard model was constructed to model the time to dementia by incorporating age, gender, and 31 RxDx disease conditions as independent variables. Points were assigned to risk factors to obtain summary risk score. Discrimination and calibration of the risk index were evaluated. Different risk indices were compared against RxDx-Dementia risk index using c-statistic, net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: Of 133,176 patients with type 2 diabetes mellitus and hypertension, 3.42% patients developed dementia. The c-statistics value for RxDx-Dementia risk index was 0.806 (95% CI, 0.799-0.812). Based on the c-statistics, NRI and IDI values, the RxDx-Dementia risk index performed better compared to CCS, CDS, and their combinations. Conclusion: The RxDx-Dementia risk index can be a useful tool to identify hypertensive and diabetic patients who are at high risk of developing dementia. This has implications for clinical management of patients with multiple comorbid conditions as well as risk adjustment for database studies. C1 [Mehta, Hemalkumar B.] Univ Texas Med Branch, Dept Surg, Galveston, TX 77555 USA. [Mehta, Vinay] Merck & Co Inc, Kenilworth, NJ USA. [Tsai, Chu-Lin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. [Mehta, Hemalkumar B.; Chen, Hua; Aparasu, Rajender R.; Johnson, Michael L.] Univ Houston, Coll Pharm, Houston, TX 77030 USA. RP Mehta, HB (reprint author), Univ Texas Med Branch, Dept Surg, 301 Univ Blvd,RS6-616, Galveston, TX 77555 USA. EM hbmehta@utmb.edu RI CPRD, CPRD/B-9594-2017; OI TSAI, CHU-LIN/0000-0003-4639-1513 NR 37 TC 3 Z9 3 U1 1 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 49 IS 2 BP 423 EP 432 DI 10.3233/JAD-150466 PG 10 WC Neurosciences SC Neurosciences & Neurology GA CX4ZV UT WOS:000365710600014 PM 26519436 ER PT B AU Cavazos, JE AF Cavazos, Jose E. BE Husain, AM TI First-Generation Antiepileptic Drugs SO PRACTICAL EPILEPSY LA English DT Article; Book Chapter ID PARTIAL-ONSET SEIZURES; TONIC CLONIC SEIZURES; STATUS EPILEPTICUS; CARBAMAZEPINE; MONOTHERAPY; OUTCOMES; EPILEPSY; THERAPY C1 [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Cavazos, Jose E.] South Texas Vet Hlth Care Syst, San Antonio VA Epilepsy Ctr Excellence, San Antonio, TX USA. RP Cavazos, JE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. NR 9 TC 0 Z9 0 U1 0 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-029-7 PY 2016 BP 263 EP 276 PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA BD9PI UT WOS:000365049500026 ER PT J AU Kransdorf, MJ Rosenthal, DI AF Kransdorf, Mark J. Rosenthal, Daniel I. TI Untitled SO SKELETAL RADIOLOGY LA English DT Editorial Material C1 [Kransdorf, Mark J.] Mayo Clin, Phoenix, AZ USA. [Rosenthal, Daniel I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Rosenthal, DI (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM kransdorf.mark@mayo.edu; dirosenthal@partners.org NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2348 EI 1432-2161 J9 SKELETAL RADIOL JI Skeletal Radiol. PD JAN PY 2016 VL 45 IS 1 BP 1 EP 1 DI 10.1007/s00256-015-2285-3 PG 1 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA CX5VG UT WOS:000365770000001 PM 26572626 ER PT J AU Parajuli, S Fowler, JR Balasubramanian, E Reinus, WR Gaughan, JP Rosenthal, DI Khurana, JS AF Parajuli, Shobha Fowler, John R. Balasubramanian, Easwaran Reinus, William R. Gaughan, John P. Rosenthal, Daniel I. Khurana, Jasvir S. TI Problems with the pathological diagnosis of osteonecrosis SO SKELETAL RADIOLOGY LA English DT Article ID PRIMARY TOTAL HIP; FEMORAL-HEAD; AVASCULAR NECROSIS; OPERATIVE SPECIMENS; KNEE REPLACEMENT; CLASSIFICATION; BONE; REPRODUCIBILITY; RELIABILITY; MRI C1 [Parajuli, Shobha; Khurana, Jasvir S.] Temple Univ Hosp & Med Sch, Dept Pathol, Philadelphia, PA 19104 USA. [Fowler, John R.] Univ Pittsburgh, Dept Orthopaed, Pittsburgh, PA 15213 USA. [Balasubramanian, Easwaran] Temple Univ Hosp & Med Sch, Philadelphia, PA 19104 USA. [Reinus, William R.] Temple Univ Hosp & Med Sch, Dept Radiol, Philadelphia, PA 19104 USA. [Gaughan, John P.] Temple Univ, Sch Med, Biostat Consulting Ctr, Philadelphia, PA 19140 USA. [Rosenthal, Daniel I.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Khurana, JS (reprint author), Temple Univ Hosp & Med Sch, Dept Pathol, 3401 North Broad St, Philadelphia, PA 19104 USA. EM jkhurana@temple.edu RI Fowler, John/D-4849-2016 OI Fowler, John/0000-0002-2843-6725 NR 26 TC 0 Z9 0 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2348 EI 1432-2161 J9 SKELETAL RADIOL JI Skeletal Radiol. PD JAN PY 2016 VL 45 IS 1 BP 13 EP 17 DI 10.1007/s00256-015-2269-3 PG 5 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA CX5VG UT WOS:000365770000004 PM 26493194 ER PT J AU Li, QY Uygun, BE Geerts, S Ozer, S Scalf, M Gilpin, SE Ott, HC Yarmush, ML Smith, LM Welham, NV Frey, BL AF Li, Qiyao Uygun, Basak E. Geerts, Sharon Ozer, Sinan Scalf, Mark Gilpin, Sarah E. Ott, Harald C. Yarmush, Martin L. Smith, Lloyd M. Welham, Nathan V. Frey, Brian L. TI Proteomic analysis of naturally-sourced biological scaffolds SO BIOMATERIALS LA English DT Article DE Mass spectrometry; Proteomics; Matrisome; Matrigel; Decellularized rat liver; Decellularized human lung ID COLLAGEN GEL CULTURE; EXTRACELLULAR-MATRIX PROTEINS; MAMMARY EPITHELIAL-CELLS; PEROXIREDOXIN-I; PERFUSION DECELLULARIZATION; ORTHOTOPIC TRANSPLANTATION; QUANTITATIVE PROTEOMICS; ENDOTHELIAL-CELLS; URINARY-BLADDER; RAT HEPATOCYTES AB A key challenge to the clinical implementation of decellularized scaffold-based tissue engineering lies in understanding the process of removing cells and immunogenic material from a donor tissue/organ while maintaining the biochemical and biophysical properties of the scaffold that will promote growth of newly seeded cells. Current criteria for evaluating whole organ decellularization are primarily based on nucleic acids, as they are easy to quantify and have been directly correlated to adverse host responses. However, numerous proteins cause immunogenic responses and thus should be measured directly to further understand and quantify the efficacy of decellularization. In addition, there has been increasing appreciation for the role of the various protein components of the extracellular matrix (ECM) in directing cell growth and regulating organ function. We performed in-depth proteomic analysis on four types of biological scaffolds and identified a large number of both remnant cellular and ECM proteins. Measurements of individual protein abundances during the decellularization process revealed significant removal of numerous cellular proteins, but preservation of most structural matrix proteins. The observation that decellularized scaffolds still contain many cellular proteins, although at decreased abundance, indicates that elimination of DNA does not assure adequate removal of all cellular material. Thus, proteomic analysis provides crucial characterization of the decellularization process to create biological scaffolds for future tissue/organ replacement therapies. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Li, Qiyao; Scalf, Mark; Smith, Lloyd M.; Frey, Brian L.] Univ Wisconsin, Dept Chem, Madison, WI 53706 USA. [Uygun, Basak E.; Geerts, Sharon; Ozer, Sinan; Yarmush, Martin L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Shriners Hosp Children, Boston, MA 02114 USA. [Gilpin, Sarah E.; Ott, Harald C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA 02114 USA. [Welham, Nathan V.] Univ Wisconsin, Dept Surg, Div Otolaryngol, Sch Med & Publ Hlth, Madison, WI 53792 USA. RP Frey, BL (reprint author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA. EM welham@surgery.wisc.edu; bfrey@chem.wisc.edu RI Frey, Brian/M-5035-2015 OI Frey, Brian/0000-0002-0397-7269 FU National Institute on Deafness and Other Communication Disorders [R01 DC004428, R01 DC010777, R01 DC010777-S1]; National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK084053, R00 DK088962] FX This work was supported by the following grants: R01 DC004428 (to NVW), R01 DC010777 and R01 DC010777-S1 (to NVW and BLF) from the National Institute on Deafness and Other Communication Disorders; R01 DK084053 (to MLY) and R00 DK088962 (to BEU) from the National Institute of Diabetes and Digestive and Kidney Diseases. NR 79 TC 10 Z9 10 U1 15 U2 58 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 EI 1878-5905 J9 BIOMATERIALS JI Biomaterials PD JAN PY 2016 VL 75 BP 37 EP 46 DI 10.1016/j.biomaterials.2015.10.011 PG 10 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA CX0FV UT WOS:000365373200004 PM 26476196 ER PT J AU Unser, AM Mooney, B Corr, DT Tseng, YH Xie, YB AF Unser, Andrea M. Mooney, Bridget Corr, David T. Tseng, Yu-Hua Xie, Yubing TI 3D brown adipogenesis to create "Brown-Fat-in-Microstrands" SO BIOMATERIALS LA English DT Article DE Brown fat; Adipocyte; Alginate; Hydrogel; Stem cell; Adipose tissue engineering ID EMBRYONIC STEM-CELLS; ADIPOSE-TISSUE DEVELOPMENT; ADULT HUMANS; WHITE FAT; ENERGY-EXPENDITURE; COLD-EXPOSURE; OSTEOGENIC DIFFERENTIATION; MORPHOGENETIC PROTEIN-7; REGENERATIVE MEDICINE; BEIGE ADIPOCYTES AB The ability of brown adipocytes (fat cells) to dissipate energy as heat shows great promise for the treatment of obesity and other metabolic disorders. Employing pluripotent stem cells, with an emphasis on directed differentiation, may overcome many issues currently associated with primary fat cell cultures. In addition, three-dimensional (3D) cell culture systems are needed to better understand the role of brown adipocytes in energy balance and treating obesity. To address this need, we created 3D "Brown-Fat-in-Microstrands" by microfluidic synthesis of alginate hydrogel microstrands that encapsulated cells and directly induced cell differentiation into brown adipocytes, using mouse embryonic stem cells (ESCs) as a model of pluripotent stem cells, and brown preadipocytes as a positive control. Brown adipocyte differentiation within microstrands was confirmed by immunocytochemistry and qPCR analysis of the expression of the brown adipocyte-defining marker uncoupling protein 1 (UCP1), as well as other general adipocyte markers. Cells within microstrands were responsive to a beta-adrenergic agonist with an increase in gene expression of thermogenic UCP1, indicating that these "Brown-Fat-in-Microstrands" are functional. The ability to create "Brown-Fat-in-Microstrands" from pluripotent stem cells opens up a new arena to understanding brown adipogenesis and its implications in obesity and metabolic disorders. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Unser, Andrea M.; Mooney, Bridget; Xie, Yubing] SUNY Polytech Inst, Coll Nanoscale Sci, Albany, NY 12203 USA. [Unser, Andrea M.; Mooney, Bridget; Xie, Yubing] SUNY Polytech Inst, Coll Engn, Albany, NY 12203 USA. [Corr, David T.] Rensselaer Polytech Inst, Dept Biomed Engn, Troy, NY 12180 USA. [Tseng, Yu-Hua] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02215 USA. RP Xie, YB (reprint author), SUNY Polytech Inst, Coll Nanoscale Sci, 257 Fuller Rd, Albany, NY 12203 USA. EM YXie@sunypoly.edu FU NIH NIDDK [1R56DK088217]; NIH [R01 DK077097]; NSF [DBI-0922830]; Wendell Williams Memorial Fellowship for Excellence in Teaching and Mentoring FX This work was supported by NIH NIDDK 1R56DK088217, NIH R01 DK077097 (Tseng), NSF DBI-0922830, and The Wendell Williams Memorial Fellowship for Excellence in Teaching and Mentoring (AMU). Additional thanks to Dr. Nadine Hempel for advice on using the Seahorse XF243 Analyzer and comments on the manuscript during preparation. NR 121 TC 4 Z9 4 U1 8 U2 40 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 EI 1878-5905 J9 BIOMATERIALS JI Biomaterials PD JAN PY 2016 VL 75 BP 123 EP 134 DI 10.1016/j.biomaterials.2015.10.017 PG 12 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA CX0FV UT WOS:000365373200012 PM 26496384 ER PT B AU Zhang, QH Leung, PC AF Zhang, Qunhao Leung, Ping-Chung BE Leung, PC TI Practice and Research on Chinese Medicine Outside of China SO COMPREHENSIVE GUIDE TO CHINESE MEDICINE, 2ND EDITION LA English DT Article; Book Chapter ID ALTERNATIVE HEALTH-CARE; UNITED-STATES; PREVALENCE C1 [Zhang, Qunhao] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. [Leung, Ping-Chung] Chinese Univ Hong Kong, Inst Chinese Med, Hong Kong, Hong Kong, Peoples R China. RP Zhang, QH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. NR 34 TC 0 Z9 0 U1 0 U2 0 PU WORLD SCIENTIFIC PUBL CO PTE LTD PI SINGAPORE PA PO BOX 128 FARRER RD, SINGAPORE 9128, SINGAPORE BN 978-9814-667-08-1; 978-9814-667-07-4 PY 2016 BP 209 EP 238 PG 30 WC Integrative & Complementary Medicine; Medicine, General & Internal SC Integrative & Complementary Medicine; General & Internal Medicine GA BD7GR UT WOS:000363058000010 ER PT J AU Ehlinger, PP Blashill, AJ AF Ehlinger, Peter P. Blashill, Aaron J. TI Self-perceived vs. actual physical attractiveness: Associations with depression as a function of sexual orientation SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Appearance evaluation; Depression; Sexual minority; Body image; Physical appearance ID NATIONALLY REPRESENTATIVE SAMPLE; APPEARANCE SCHEMAS INVENTORY; BODY-IMAGE; OBJECTIFICATION THEORY; PSYCHIATRIC-DISORDERS; COMORBIDITY-SURVEY; ADOLESCENT BOYS; MINORITY STRESS; MENTAL-HEALTH; UNITED-STATES AB Objective: A commonly held belief about physical attractiveness is that attractive individuals are psychologically healthier than less attractive individuals (i.e., the "beauty is good" stereotype). To date, the data on this stereotype and its relationship with depression is limited, with a paucity of literature comparing subjective and objective appearance evaluations and depressive symptoms. Additionally, there is no known research on this relationship among sexual minorities (i.e., gay and bisexual individuals), a highly vulnerable population. The primary aims of the study were to assess the prediction of depression symptoms by subjective and objective appearance evaluation, and secondary aims were to assess the interaction of subjective and objective appearance with sexual orientation. Method: Participants were 4882 American emerging adults (M age =22 years; 2253 males, 2629 females) taken from a U.S. nationally representative dataset (Add Health) Results: Increased negative subjective appearance evaluation was associated with elevated rates of depressive symptoms (B=-.27, p <.001), while objective appearance evaluation was not significantly related to depressive symptoms. Sexual orientation significantly moderated the relationship between subjective appearance and depression (B=.19, p=.009), with a stronger positive association between negative appearance evaluation and depressive symptoms noted among sexual minority vs. heterosexual participants. Limitations: Limitations include cross-sectional design and self-report nature of questionnaires. Conclusions: Findings suggest that the 'beauty is good' stereotype may not be valid in regard to depressive symptoms, and that subjective appearance evaluation is a robust predictor of depression, particularly for sexual minority individuals. (C) 2015 Elsevier B.V. All rights reserved. C1 [Ehlinger, Peter P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Blashill, Aaron J.] San Diego State Univ, San Diego, CA 92120 USA. [Blashill, Aaron J.] SDSU UCSD Joint Doctoral Program Clin Psychol, San Diego, CA USA. RP Blashill, AJ (reprint author), San Diego State Univ, Dept Psychol, SDSU UCSD Joint Doctoral Program Clin Psychol, 6363 Alvarado Court,Suite 103, San Diego, CA 92120 USA. EM ablashill@mail.sdsu.edu FU National Institute of Mental Health [K23MH096647]; National Institute of Child Health and Human Development [P01-HD31921] FX Some of the author time was supported by the National Institute of Mental Health grant number K23MH096647 to Dr. Blashill. This research uses data from the National Longitudinal Study of Adolescent Health (Add Health)-a program project designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris that is funded by National Institute of Child Health and Human Development Grant P01-HD31921 with cooperative funding from 17 other agencies. Special acknowledgment is due to Ronald R. Rindfuss and Barbara Entwisle for assistance in the original design. Persons interested in obtaining data files from Add Health should contact Add Health, Carolina Population Center, 123 W. Franklin Street, Chapel Hill, North Carolina 27516-2524 (www.cpc.unc.edu/addhealth/contract.html). NR 64 TC 1 Z9 1 U1 8 U2 27 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN 1 PY 2016 VL 189 BP 70 EP 76 DI 10.1016/j.jad.2015.08.071 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CV3PD UT WOS:000364170200009 PM 26406971 ER PT J AU Bernstein, EE Rabideau, DJ Gigler, ME Nierenberg, AA Deckersbach, T Sylvia, LG AF Bernstein, Emily E. Rabideau, Dustin J. Gigler, Margaret E. Nierenberg, Andrew A. Deckersbach, Thilo Sylvia, Louisa G. TI Patient perceptions of physical health and bipolar symptoms: The intersection of mental and physical health SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Bipolar disorder; Quality of life; Physical health; Mood; Functioning ID QUALITY-OF-LIFE; TREATMENT ENHANCEMENT PROGRAM; GENERAL MEDICAL CONDITIONS; DISORDER STEP-BD; SURVEY SF-36; I-DISORDER; FORM; COMORBIDITIES; RELIABILITY; POPULATION AB Background: Affective symptoms and medical comorbidities have a negative impact on the course of bipolar disorder. The aim of this analysis was to examine how the perceptions of physical health and functioning in individuals with bipolar disorder relate to their mood symptoms. Methods: We analyzed longitudinal data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP BD) on the physical subscales of the Short Form Health Survey (SF 36) (physical functioning, role limitations due to physical problems, bodily pain, and general health). Results: Participants' perception of their overall physical health predicted severity of mania/hypomania, depression, and life satisfaction at concurrent and future visits. Perceptions of role limitations due to physical health problems predicted depressive symptoms and poor life satisfaction. Worse bodily pain predicted symptoms of mania/hypomania. Reports of specific or concrete physical limitations in daily life showed no associations with psychiatric symptoms at concurrent assessments, but did predict worse course of illness one year later. SF 36 scores showed significant, but small associations with the presence of medical comorbidities. Limitations: Perceptions of physical health and quality of life were self report, potentially lending themselves to transient negative biases, particularly among depressed participants. Additionally, the SF-36 was selected as a generic, widely used measure; as a result, it was not specific to the illness burden of bipolar disorder. Conclusion: Overall, broad perceptions of poor physical health were associated with worse course of illness over the 24 months of the study. Though further research is warranted, changes in subjective physical health related quality of life, even independent of objective health changes, may offer important insight into global wellbeing and be targets of psychotherapy treatment. (C) 2015 Elsevier B.V. All rights reserved. C1 [Bernstein, Emily E.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. [Rabideau, Dustin J.; Gigler, Margaret E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Nierenberg, Andrew A.; Deckersbach, Thilo; Sylvia, Louisa G.] Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. RP Bernstein, EE (reprint author), Harvard Univ, Dept Psychol, 1244 William James Hall,33 Kirkland St, Cambridge, MA 02138 USA. EM ebernstein@fas.harvard.edu FU NIMH NIH HHS [N01 MH080001] NR 30 TC 3 Z9 3 U1 5 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN 1 PY 2016 VL 189 BP 203 EP 206 DI 10.1016/j.jad.2015.09.052 PG 4 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CV3PD UT WOS:000364170200029 PM 26451504 ER PT J AU Ashrafioun, L Pigeon, WR Conner, KR Leong, SH Oslin, DW AF Ashrafioun, Lisham Pigeon, Wilfred R. Conner, Kenneth R. Leong, Shirley H. Oslin, David W. TI Prevalence and correlates of suicidal ideation and suicide attempts among veterans in primary care referred for a mental health evaluation SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Suicidal ideation; Suicide attempt; Primary care; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; COMPLETED SUICIDE; RECEIVING CARE; RISK-FACTORS; COMORBIDITY; DEPRESSION; SYSTEM; PTSD; METAANALYSIS; ASSOCIATION AB Background: The Veterans Health Administration has made concerted efforts to increase mental health services offered in primary care. However, few studies have evaluated correlates of suicidal ideation and suicide attempt in veterans in primary care-mental health integration (PCMHI). The purpose of the present study is to examine associations between suicidal ideation and suicide attempts as dependent variables and demographic and clinical factors as the independent variables. Methods: Veterans (n=3004) referred from primary care to PCMHI were contacted for further assessment, which included past-year severity of suicidal thoughts (none, low, high) and attempts using the Paykel Suicide Scale, mental health disorders, and illicit drug use. Multinomial logistic regression models were used to identify correlates of suicidal ideation and suicide attempts. Results: Thoughts of taking one's life was endorsed by 24% of participants and suicide attempts were reported in 2%. In adjusted models, depression, psychosis, mania, PTSD and generalized anxiety disorder were associated with high severity suicidal ideation, but not suicide attempt. Illicit drug use was not associated with suicidal ideation, but was the only variable associated with suicide attempt. Limitations: The study was cross-sectional, focused on one clinical setting, and the suicide attempt analyses had limited power. Conclusions: PCMHI is a critical setting to assess suicidal ideation and suicide attempt and researchers and clinicians should be aware that the differential correlates of these suicide-related factors. Future research is needed to identify prospective risk factors and assess the utility of follow-up care in preventing suicide. Published by Elsevier B.V. C1 [Ashrafioun, Lisham; Pigeon, Wilfred R.; Conner, Kenneth R.] Canandaigua VA Med Ctr, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. [Ashrafioun, Lisham; Pigeon, Wilfred R.; Conner, Kenneth R.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14627 USA. [Leong, Shirley H.; Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Leong, Shirley H.; Oslin, David W.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. RP Ashrafioun, L (reprint author), Canandaigua VA Med Ctr, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM Lisham.Ashrafioun@va.gov NR 50 TC 1 Z9 1 U1 6 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN 1 PY 2016 VL 189 BP 344 EP 350 DI 10.1016/j.jad.2015.09.014 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CV3PD UT WOS:000364170200051 PM 26474375 ER PT J AU Bruneau, S Wedel, J Fakhouri, F Nakayama, H Boneschansker, L Irimia, D Daly, KP Briscoe, DM AF Bruneau, Sarah Wedel, Johannes Fakhouri, Fadi Nakayama, Hironao Boneschansker, Leo Irimia, Daniel Daly, Kevin P. Briscoe, David M. TI Translational implications of endothelial cell dysfunction in association with chronic allograft rejection SO PEDIATRIC NEPHROLOGY LA English DT Review DE Graft survival; Graft rejection; Biomarkers; Preventative therapeutics; Endothelial cells; Vascular endothelial growth factor; mTOR-mediated signaling; miRNA ID ANTIBODY-MEDIATED REJECTION; NEUTROPHIL EXTRACELLULAR TRAPS; TO-MESENCHYMAL TRANSITION; HUMAN CARDIAC ALLOGRAFTS; GROWTH-FACTOR; IN-VIVO; INDUCED ANGIOGENESIS; VASCULAR INTEGRITY; INTRAGRAFT MICROENVIRONMENT; TRANSPLANT RECIPIENTS AB Advances in therapeutics have dramatically improved short-term graft survival, but the incidence of chronic rejection has not changed in the past 20 years. New insights into mechanism are sorely needed at this time and it is hoped that the development of predictive biomarkers will pave the way for the emergence of preventative therapeutics. In this review, we discuss a paradigm suggesting that sequential changes within graft endothelial cells (EC) lead to an intragraft microenvironment that favors the development of chronic rejection. Key initial events include EC injury, activation and uncontrolled leukocyte-induced angiogenesis. We propose that all of these early changes in the microvasculature lead to abnormal blood flow patterns, local tissue hypoxia, and an associated overexpression of HIF-1 alpha-inducible genes, including vascular endothelial growth factor. We also discuss how cell intrinsic regulators of mTOR-mediated signaling within EC are of critical importance in microvascular stability and may thus have a role in the inhibition of chronic rejection. Finally, we discuss recent findings indicating that miRNAs may regulate EC stability, and we review their potential as novel non-invasive biomarkers of allograft rejection. Overall, this review provides insights into molecular events, genes, and signals that promote chronic rejection and their potential as biomarkers that serve to support the future development of interruption therapeutics. C1 [Bruneau, Sarah; Wedel, Johannes; Nakayama, Hironao; Boneschansker, Leo; Daly, Kevin P.; Briscoe, David M.] Boston Childrens Hosp, Transplant Res Program, Boston, MA 02115 USA. [Bruneau, Sarah; Wedel, Johannes; Boneschansker, Leo; Daly, Kevin P.; Briscoe, David M.] Boston Childrens Hosp, Div Nephrol, Dept Med, Boston, MA 02115 USA. [Bruneau, Sarah; Wedel, Johannes; Boneschansker, Leo; Daly, Kevin P.; Briscoe, David M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Bruneau, Sarah; Fakhouri, Fadi] Univ Nantes, CHU Nantes, INSERM, UMR S1064,Inst Transplantat Urol Nephrol, Nantes, France. [Nakayama, Hironao] Boston Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA USA. [Nakayama, Hironao] Harvard Univ, Sch Med, Boston, MA USA. [Boneschansker, Leo; Irimia, Daniel] Harvard Univ, Sch Med, Dept Surg, BioMEMS Resource Ctr,Massachusetts Gen Hosp,Shrin, Boston, MA 02115 USA. RP Briscoe, DM (reprint author), Boston Childrens Hosp, Transplant Res Program, 300 Longwood Ave, Boston, MA 02115 USA. EM david.briscoe@childrens.harvard.edu OI Daly, Kevin/0000-0003-4327-1532 FU NIH [R01AI046756, R01AI92305, R21AI114223, T32DK007726, T32AI007529]; Pfizer ARTS grant; Casey Lee Ball Foundation; AST Fellowship grant; Fondation pour la Recherche Medicale [ARF20140129163]; German Research Foundation (DFG) FX The work cited in this review was supported by NIH Grants R01AI046756, R01AI92305, and R21AI114223 to DMB, by a Pfizer ARTS grant and by the Casey Lee Ball Foundation. LB was supported by NIH grants T32DK007726 and T32AI007529. SB was supported by an AST Fellowship grant and a grant from the Fondation pour la Recherche Medicale ARF20140129163. JW was supported by a fellowship grant from the German Research Foundation (DFG). NR 119 TC 2 Z9 2 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0931-041X EI 1432-198X J9 PEDIATR NEPHROL JI Pediatr. Nephrol. PD JAN PY 2016 VL 31 IS 1 BP 41 EP 51 DI 10.1007/s00467-015-3094-6 PG 11 WC Pediatrics; Urology & Nephrology SC Pediatrics; Urology & Nephrology GA CW6IG UT WOS:000365100500004 PM 25903640 ER PT B AU Greve, DN Brown, GG Mueller, BA Glover, GH Liu, TT AF Greve, Douglas N. Brown, Gregory G. Mueller, Bryon A. Glover, Gary H. Liu, Thomas T. BE Henly, SJ TI A SURVEY OF THE SOURCES OF NOISE IN fMRI SO ROUTLEDGE INTERNATIONAL HANDBOOK OF ADVANCED QUANTITATIVE METHODS IN NURSING RESEARCH SE Routledge International Handbooks LA English DT Article; Book Chapter ID EVENT-RELATED FMRI; INDEPENDENT COMPONENT ANALYSIS; MULTICENTER FUNCTIONAL MRI; BOLD HEMODYNAMIC-RESPONSES; MAGNETIC-RESONANCE; PHYSIOLOGICAL NOISE; TIME-SERIES; STATISTICAL-ANALYSIS; IMAGE REGISTRATION; HUMAN BRAIN C1 [Greve, Douglas N.] Massachusetts Gen Hosp, Martinos Ctr, Boston, MA 02114 USA. [Greve, Douglas N.] Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA. [Brown, Gregory G.] Univ Calif San Diego, Psychiat, San Diego, CA 92103 USA. [Brown, Gregory G.] Univ Calif San Diego, NeuroImaging & Behav Anal Lab, San Diego, CA 92103 USA. [Brown, Gregory G.] Amer Psychol Assoc, Washington, DC USA. [Mueller, Bryon A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Glover, Gary H.] Stanford Univ, Radiol, Stanford, CA 94305 USA. [Glover, Gary H.] Stanford Univ, Dept Radiol, Radiol Sci Lab, Stanford, CA 94305 USA. [Liu, Thomas T.] Univ Calif San Diego, Radiol & Bioengn, La Jolla, CA 92093 USA. [Liu, Thomas T.] Univ Calif San Diego, Ctr Funct Magnet Resonance Imaging FMRI, La Jolla, CA 92093 USA. RP Greve, DN (reprint author), Massachusetts Gen Hosp, Martinos Ctr, Boston, MA 02114 USA. NR 84 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI ABINGDON PA 2 PARK SQ, MILTON PARK, ABINGDON OX14 4RN, OXFORD, ENGLAND BN 978-1-315-88230-7; 978-0-415-52180-2 J9 ROUT INT HANDB PY 2016 BP 336 EP 357 PG 22 WC Social Sciences, Mathematical Methods; Nursing; Social Sciences, Interdisciplinary; Statistics & Probability SC Mathematical Methods In Social Sciences; Nursing; Social Sciences - Other Topics; Mathematics GA BD7HT UT WOS:000363111700024 ER PT J AU Bassir, SH Wisitrasameewong, W Raanan, J Ghaffarigarakani, S Chung, J Freire, M Andrada, LC Intini, G AF Bassir, Seyed Hossein Wisitrasameewong, Wichaya Raanan, Justin Ghaffarigarakani, Sasan Chung, Jamie Freire, Marcelo Andrada, Luciano C. Intini, Giuseppe TI Potential for Stem Cell-Based Periodontal Therapy SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Review ID DENTAL FOLLICLE CELLS; HUMAN BONE-MARROW; EXFOLIATED DECIDUOUS TEETH; AAP REGENERATION WORKSHOP; PLATELET-RICH PLASMA; TISSUE REGENERATION; IN-VITRO; STROMAL CELLS; ADIPOSE-TISSUE; EXTRACTION SOCKETS AB Periodontal diseases are highly prevalent and are linked to several systemic diseases. The goal of periodontal treatment is to halt the progression of the disease and regenerate the damaged tissue. However, achieving complete and functional periodontal regeneration is challenging because the periodontium is a complex apparatus composed of different tissues, including bone, cementum, and periodontal ligament. Stem cells may represent an effective therapeutic tool for periodontal regeneration due to their plasticity and their ability to regenerate different tissues. This review presents and critically analyzes the available information on stem cell-based therapy for the regeneration of periodontal tissues and suggests new avenues for the development of more effective therapeutic protocols. J. Cell. Physiol. 230: 50-61, 2016. (c) 2015 Wiley Periodicals, Inc. C1 [Bassir, Seyed Hossein; Wisitrasameewong, Wichaya; Raanan, Justin; Ghaffarigarakani, Sasan; Chung, Jamie; Freire, Marcelo; Andrada, Luciano C.; Intini, Giuseppe] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Div Periodontol, Boston, MA 02115 USA. [Wisitrasameewong, Wichaya] Chulalongkorn Univ, Fac Dent, Dept Periodontol, Bangkok, Thailand. [Wisitrasameewong, Wichaya] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA. [Freire, Marcelo] Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA USA. [Intini, Giuseppe] Harvard Stem Cell Inst, Boston, MA USA. RP Intini, G (reprint author), Harvard Univ, Sch Dent Med, Oral Med Infect & Immun, 188 Longwood Ave,REB403, Boston, MA 02115 USA. EM giuseppe_intini@hsdm.harvard.edu OI Freire, Marcelo/0000-0003-4906-7698 FU NIH/NIDCR [K99/R00 DE021069] FX Contract grant sponsor: NIH/NIDCR;; Contract grant number: K99/R00 DE021069 to Giuseppe Intini. NR 112 TC 4 Z9 5 U1 1 U2 56 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9541 EI 1097-4652 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD JAN PY 2016 VL 231 IS 1 BP 50 EP 61 DI 10.1002/jcp.25067 PG 12 WC Cell Biology; Physiology SC Cell Biology; Physiology GA CS6UH UT WOS:000362217800008 PM 26058394 ER PT J AU Walter, JE Armanios, M Shah, U Friedmann, AM Spitzer, T Sharatz, SM Hagen, C AF Walter, Jolan E. Armanios, Mary Shah, Uzma Friedmann, Alison M. Spitzer, Thomas Sharatz, Steven M. Hagen, Catherine TI Case 41-2015: A 14-Year-Old Boy with Immune and Liver Abnormalities SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID COMMON VARIABLE IMMUNODEFICIENCY; NODULAR REGENERATIVE HYPERPLASIA; LINKED DYSKERATOSIS-CONGENITA; HOYERAAL-HREIDARSSON-SYNDROME; BONE-MARROW-TRANSPLANTATION; REGULATORY T-CELLS; TELOMERE SYNDROMES; PULMONARY-FIBROSIS; DKC1 GENE; MUTATIONS C1 [Walter, Jolan E.] Massachusetts Gen Hosp, Div Pediat Allergy Immunol, Boston, MA 02114 USA. [Shah, Uzma] Massachusetts Gen Hosp, Div Pediat Gastroenterol, Boston, MA 02114 USA. [Friedmann, Alison M.] Massachusetts Gen Hosp, Div Pediat Hematol Oncol, Boston, MA 02114 USA. [Spitzer, Thomas] Massachusetts Gen Hosp, Div Bone Marrow Transplantat, Boston, MA 02114 USA. [Sharatz, Steven M.] Massachusetts Gen Hosp, Div Radiol, Boston, MA 02114 USA. [Hagen, Catherine] Massachusetts Gen Hosp, Div Pathol, Boston, MA 02114 USA. [Walter, Jolan E.; Shah, Uzma; Friedmann, Alison M.; Spitzer, Thomas] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Sharatz, Steven M.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Hagen, Catherine] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Armanios, Mary] Johns Hopkins Univ, Sch Med, Dept Med Oncol, Baltimore, MD USA. RP Walter, JE (reprint author), Massachusetts Gen Hosp, Div Pediat Allergy Immunol, Boston, MA 02114 USA. NR 45 TC 1 Z9 1 U1 7 U2 15 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 31 PY 2015 VL 373 IS 27 BP 2664 EP 2676 DI 10.1056/NEJMcpc1408595 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA CZ8UH UT WOS:000367374100013 PM 26716919 ER PT J AU Gimenez, F Mulik, S Veiga-Parga, T Bhela, S Rouse, BT AF Gimenez, Fernanda Mulik, Sachin Veiga-Parga, Tamara Bhela, Siddheshvar Rouse, Barry T. TI Robo 4 Counteracts Angiogenesis in Herpetic Stromal Keratitis SO PLOS ONE LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; CORNEAL NEOVASCULARIZATION; SIMPLEX-VIRUS; PATHOLOGICAL ANGIOGENESIS; IMMUNE PRIVILEGE; RECEPTOR; PATHOGENESIS; ROUNDABOUT AB The cornea is a complex tissue that must preserve its transparency to maintain optimal vision. However, in some circumstances, damage to the eye can result in neovascularization that impairs vision. This outcome can occur when herpes simplex virus type 1 (HSV-1) causes the immunoinflammatory lesion stromal keratitis (SK). Potentially useful measures to control the severity of SK are to target angiogenesis which with herpetic SK invariably involves VEGF. One such way to control angiogenesis involves the endothelial receptor Robo4 (R4), which upon interaction with another protein activates an antiangiogenic pathway that counteracts VEGF downstream signaling. In this study we show that mice unable to produce R4 because of gene knockout developed significantly higher angiogenesis after HSV-1 ocular infection than did infected wild type (WT) controls. Moreover, providing additional soluble R4 (sR4) protein by subconjunctival administration to R4 KO HSV-1 infected mice substantially rescued theWT phenotype. Finally, administration of sR4 to WT HSV-1 infected mice diminished the extent of corneal angiogenesis compared to WT control animals. Our results indicate that sR4 could represent a useful therapeutic tool to counteract corneal angiogenesis and help control the severity of SK. C1 [Gimenez, Fernanda; Mulik, Sachin; Veiga-Parga, Tamara; Bhela, Siddheshvar; Rouse, Barry T.] Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, Knoxville, TN 37996 USA. [Mulik, Sachin] Harvard Univ, Sch Med, Childrens Hosp Boston, Immune Dis Inst, Boston, MA USA. [Mulik, Sachin] Harvard Univ, Sch Med, Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA USA. RP Rouse, BT (reprint author), Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, 1414 Cumberland Ave, Knoxville, TN 37996 USA. EM btr@utk.edu OI Veiga-Parga, Tamara/0000-0002-5441-0959 FU National Institute of Allergy and Infectious Diseases [AI 06335]; National Institutes of Health [EY 005093] FX This study was supported by National Institute of Allergy and Infectious Diseases GrantAI 06335 and National Institutes of Health GrantEY 005093. NR 27 TC 2 Z9 2 U1 4 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 31 PY 2015 VL 10 IS 12 AR e0141925 DI 10.1371/journal.pone.0141925 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DA0TR UT WOS:000367510900003 PM 26720197 ER PT J AU Foster, GR Afdhal, N Roberts, SK Brau, N Gane, EJ Pianko, S Lawitz, E Thompson, A Shiffman, ML Cooper, C Towner, WJ Conway, B Ruane, P Bourliere, M Asselah, T Berg, T Zeuzem, S Rosenberg, W Agarwal, K Stedman, CAM Mo, H Dvory-Sobol, H Han, L Wang, J McNally, J Osinusi, A Brainard, DM McHutchison, JG Mazzotta, F Tran, TT Gordon, SC Patel, K Reau, N Mangia, A Sulkowski, M AF Foster, G. R. Afdhal, N. Roberts, S. K. Braeu, N. Gane, E. J. Pianko, S. Lawitz, E. Thompson, A. Shiffman, M. L. Cooper, C. Towner, W. J. Conway, B. Ruane, P. Bourliere, M. Asselah, T. Berg, T. Zeuzem, S. Rosenberg, W. Agarwal, K. Stedman, C. A. M. Mo, H. Dvory-Sobol, H. Han, L. Wang, J. McNally, J. Osinusi, A. Brainard, D. M. McHutchison, J. G. Mazzotta, F. Tran, T. T. Gordon, S. C. Patel, K. Reau, N. Mangia, A. Sulkowski, M. CA ASTRAL-2 & ASTRAL-3 Investigators TI Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID C VIRUS-INFECTION; RANDOMIZED-TRIAL AB BACKGROUND In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3. METHODS We conducted two randomized, phase 3, open-label studies involving patients who had received previous treatment for HCV genotype 2 or 3 and those who had not received such treatment, including patients with compensated cirrhosis. In one trial, patients with HCV genotype 2 were randomly assigned in a 1: 1 ratio to receive sofosbuvir-velpatasvir,in a once-daily, fixed-dose combination tablet (134 patients), or sofosbuvir plus weight-based ribavirin (132 patients) for 12 weeks. In a second trial, patients with HCV genotype 3 were randomly assigned in a 1: 1 ratio to receive sofosbuvir-velpatasvir for 12 weeks (277 patients) or sofosbuvir-ribavirin for 24 weeks (275 patients). The primary end point for the two trials was a sustained virologic response at 12 weeks after the end of therapy. RESULTS Among patients with HCV genotype 2, the rate of sustained virologic response in the sofosbuvir-velpatasvir group was 99% (95% confidence interval [CI], 96 to 100), which was superior to the rate of 94% (95% CI, 88 to 97) in the sofosbuvir-ribavirin group (P = 0.02). Among patients with HCV genotype 3, the rate of sustained virologic response in the sofosbuvir-velpatasvir group was 95% (95% CI, 92 to 98), which was superior to the rate of 80% (95% CI, 75 to 85) in the sofosbuvir-ribavirin group (P<0.001). The most common adverse events in the two studies were fatigue, headache, nausea, and insomnia. CONCLUSIONS Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment with sofosbuvir-ribavirin. C1 [Foster, G. R.] Queen Mary Univ London, London E1 4AT, England. [Rosenberg, W.] UCL, London WC1E 6BT, England. [Rosenberg, W.] Kings Coll Hosp London, London SE5 8RX, England. [Agarwal, K.] Inst Liver Studies, London, England. [Afdhal, N.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Roberts, S. K.] Alfred Hlth, Melbourne, Vic, Australia. [Roberts, S. K.] Monash Univ, Melbourne, Vic 3004, Australia. [Thompson, A.] St Vincents Hosp, Melbourne, Vic, Australia. [Pianko, S.] Monash Hlth, Clayton, Vic, Australia. [Pianko, S.] Monash Univ, Clayton, Vic, Australia. [Braeu, N.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Braeu, N.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Gane, E. J.] Auckland Clin Studies, Auckland, New Zealand. [Stedman, C. A. M.] Christchurch Clin Studies Trust & Univ Otago, Christchurch, New Zealand. [Lawitz, E.] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA. [Shiffman, M. L.] Liver Inst Virginia, Richmond, VA USA. [Cooper, C.] Univ Ottawa, Ottawa, ON, Canada. [Conway, B.] Vancouver Infect Dis Ctr, Vancouver, BC, Canada. [Towner, W. J.] Kaiser Permanente, Los Angeles, CA USA. [Ruane, P.] Ruane Med, Los Angeles, CA USA. [Tran, T. T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Berg, T.; Mo, H.; Dvory-Sobol, H.; Han, L.; Wang, J.; McNally, J.; Osinusi, A.; Brainard, D. M.; McHutchison, J. G.] Gilead Sci Inc, Foster City, CA 94404 USA. [Bourliere, M.] Hop St Joseph, Marseille, France. [Asselah, T.] Univ Paris Diderot, INSERM, UMR 1149, Hop Beaujon,Serv Hepatol, Clichy, France. [Berg, T.] Univ Hosp Leipzig, Leipzig, Germany. [Zeuzem, S.] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany. [Mazzotta, F.] Santa Maria Annunziata Hosp, Florence, Italy. [Mangia, A.] Casa Sollievo Sofferenza Hosp, San Giovanni Rotondo, Italy. [Gordon, S. C.] Henry Ford Hlth Syst, Detroit, MI USA. [Patel, K.] Duke Univ, Sch Med, Durham, NC USA. [Reau, N.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Sulkowski, M.] Johns Hopkins Univ, Baltimore, MD USA. RP Foster, GR (reprint author), Queen Mary Univ London, Liver Unit, 4 Newark St, London E1 4AT, England. EM g.r.foster@qmul.ac.uk RI Loustaud-Ratti, Veronique/A-5262-2017; Leggett, Barbara/D-3579-2011; OI Rosenberg, William/0000-0002-2732-2304 FU Gilead Sciences FX Funded by Gilead Sciences; ASTRAL-2 ClinicalTrials.gov number, NCT02220998; and ASTRAL-3, NCT02201953. NR 17 TC 108 Z9 109 U1 10 U2 27 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 31 PY 2015 VL 373 IS 27 BP 2608 EP 2617 DI 10.1056/NEJMoa1512612 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CZ8UH UT WOS:000367374100006 PM 26575258 ER PT J AU Greene, MF Ecker, JL AF Greene, Michael F. Ecker, Jeffrey L. TI Choosing Benefits while Balancing Risks SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Greene, Michael F.; Ecker, Jeffrey L.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. RP Greene, MF (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. NR 6 TC 0 Z9 0 U1 4 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 31 PY 2015 VL 373 IS 27 BP 2681 EP 2682 DI 10.1056/NEJMe1511068 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CZ8UH UT WOS:000367374100016 PM 26716920 ER PT J AU Buchy, L Seidman, LJ Cadenhead, KS Cannon, TD Cornblatt, BA McGlashan, TH Perkins, DO Stone, W Tsuang, MT Walker, EF Woods, SW Bearden, CE Mathalon, DH Addington, J AF Buchy, Lisa Seidman, Larry J. Cadenhead, Kristin S. Cannon, Tyrone D. Cornblatt, Barbara A. McGlashan, Thomas H. Perkins, Diana O. Stone, William Tsuang, Ming T. Walker, Elaine F. Woods, Scott W. Bearden, Carrie E. Mathalon, Daniel H. Addington, Jean TI Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis SO PSYCHIATRY RESEARCH LA English DT Article DE Age at onset; Alcohol; Cannabis; IQ; Prodrome; Schizophrenia ID 1ST ONSET PSYCHOSIS; 10-YEAR FOLLOW-UP; SCHIZOPHRENIC-PATIENTS; TOBACCO SMOKING; SUBSTANCE USE; NEUROPSYCHOLOGICAL PERFORMANCE; HEALTHY CONTROLS; INDIVIDUALS; METAANALYSIS; NEUROCOGNITION AB Among people with psychosis, those with a history of cannabis use show better cognitive performance than those who are cannabis naive. It is unknown whether this pattern is present in youth at clinical high risk (CHR) of psychosis. We evaluated relationships between IQ and cannabis use while controlling for use of other substances known to impact cognition in 678 CHR and 263 healthy control (HC) participants. IQ was estimated using the Vocabulary and Block Design subtests of the Wechsler Abbreviated Scale of Intelligence. Drug and alcohol use severity and frequency were assessed with the Alcohol and Drug Use Scale, and we inquired participants' age at first use. CHR were further separated into early and late age at onset of cannabis use sub-groups, and low-, moderate- and high-frequency sub-groups. No significant differences in IQ emerged between CHR or HC cannabis users vs. non-users, or between use frequency groups. CHR late-onset users showed significantly higher IQ than CHR early-onset users. Age at onset of cannabis use was significantly and positively correlated with IQ in CHR only. Results suggest that age at onset of cannabis may be a more important factor for IQ than use current use or use frequency in CHR. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Buchy, Lisa; Addington, Jean] Univ Calgary, Dept Psychiat, Calgary, AB T2N 4Z6, Canada. [Seidman, Larry J.; Stone, William] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Cadenhead, Kristin S.; Tsuang, Ming T.] UCSD, Dept Psychiat, La Jolla, CA USA. [Cannon, Tyrone D.] Yale Univ, Dept Psychol, New Haven, CT 06520 USA. [Cornblatt, Barbara A.; Woods, Scott W.] Zucker Hillside Hosp, Dept Psychiat, Long Isl City, NY USA. [McGlashan, Thomas H.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Perkins, Diana O.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Perkins, Diana O.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Walker, Elaine F.] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA. [Walker, Elaine F.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Bearden, Carrie E.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Bearden, Carrie E.] Univ Calif Los Angeles, Dept Biobehav Sci & Psychol, Los Angeles, CA USA. [Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Addington, J (reprint author), Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, 3280 Hosp Dr NW, Calgary, AB T2N 4Z6, Canada. EM jmadding@ucalgary.ca FU National Institute of Mental Health [U01MH081984, U01 MH081928, P50 MH080272, R01 MH60720, U01 MH082022, K24 MH76191, U01MH081902, P50 MH066286, U01MH082004, U01MH081988, U01MH082022, U01 MH081857-05]; National Institute of Mental Health (Commonwealth of Massachusetts) [SCDMH82101008006] FX This study was supported by the National Institute of Mental Health (Grant U01MH081984 to Dr Addington; Grants U01 MH081928; P50 MH080272; Commonwealth of Massachusetts SCDMH82101008006 to Dr Seidman; Grants R01 MH60720, U01 MH082022 and K24 MH76191 to Dr Cadenhead; Grant U01MH081902 to Dr Cannon; P50 MH066286 (Prodromal Core) to Dr Bearden; Grant U01MH082004 to Dr Perkins; Grant U01MH081988 to Dr Walker; Grant U01MH082022 to Dr Woods; and U01 MH081857-05 grant to Dr Cornblatt. The NIMH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 48 TC 2 Z9 2 U1 8 U2 22 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD DEC 30 PY 2015 VL 230 IS 3 BP 878 EP 884 DI 10.1016/j.psychres.2015.11.033 PG 7 WC Psychiatry SC Psychiatry GA DA5RT UT WOS:000367860900021 PM 26626949 ER PT J AU Jensen, R AF Jensen, Ralph TI Effects of Dopamine D2-Like Receptor Antagonists on Light Responses of Ganglion Cells in Wild-Type and P23H Rat Retinas SO PLOS ONE LA English DT Article ID RETINITIS-PIGMENTOSA; GABA(C) RECEPTORS; IMMUNOCYTOCHEMICAL LOCALIZATION; MAMMALIAN RETINA; D-1 RECEPTORS; RHO-SUBUNITS; MUTANT MOUSE; DEGENERATION; RELEASE; NEURONS AB In animal models of retinitis pigmentosa the dopaminergic system in the retina appears to be dysfunctional, which may contribute to the debilitated sight experienced by retinitis pigmentosa patients. Since dopamine D2-like receptors are known to modulate the activity of dopaminergic neurons, I examined the effects of dopamine D2-like receptor antagonists on the light responses of retinal ganglion cells (RGCs) in the P23H rat model of retinitis pigmentosa. Extracellular electrical recordings were made from RGCs in isolated transgenic P23H rat retinas and wild-type Sprague-Dawley rat retinas. Intensity-response curves to flashes of light were evaluated prior to and during bath application of a dopamine D2-like receptor antagonist. The dopamine D2/D3 receptor antagonists sulpiride and eticlopride and the D4 receptor antagonist L-745,870 increased light sensitivity of P23H rat RGCs but decreased light sensitivity in Sprague-Dawley rat RGCs. In addition, L-745,870, but not sulpiride or eticlopride, reduced the maximum peak responses of Sprague-Dawley rat RGCs. I describe for the first time ON-center RGCs in P23H rats that exhibit an abnormally long-latency (> 200 ms) response to the onset of a small spot of light. Both sulpiride and eticlopride, but not L-745,870, reduced this ON response and brought out a short-latency OFF response, suggesting that these cells are in actuality OFF-center cells. Overall, the results show that the altered dopaminergic system in degenerate retinas contributes to the deteriorated light responses of RGCs. C1 [Jensen, Ralph] VA Boston Healthcare Syst, Boston, MA 02130 USA. RP Jensen, R (reprint author), VA Boston Healthcare Syst, Mail Stop 151E,150 South Huntington Ave, Boston, MA 02130 USA. EM ralph.jensen@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service [1I01RX000341-01] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service (1I01RX000341-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 1 Z9 1 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 30 PY 2015 VL 10 IS 12 AR e0146154 DI 10.1371/journal.pone.0146154 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DA0TN UT WOS:000367510500138 PM 26717015 ER PT J AU Alawieh, A Elvington, A Zhu, H Yu, J Kindy, MS Atkinson, C Tomlinson, S AF Alawieh, Ali Elvington, Andrew Zhu, Hong Yu, Jin Kindy, Mark S. Atkinson, Carl Tomlinson, Stephen TI Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Ischemic stroke; Complement inhibition; Neuroinflammation; Neuroprotection ID MANNOSE-BINDING LECTIN; NEURAL PROGENITOR CELLS; FOCAL CEREBRAL-ISCHEMIA; SUBVENTRICULAR ZONE; BRAIN-INJURY; IN-VITRO; STROKE; NEUROGENESIS; RECEPTOR; SYSTEM AB Background: Complement promotes neuroinflammation and injury in models of stroke. However, complement is also being increasingly implicated in repair and regeneration after central nervous system (CNS) injury, and some complement deficiencies have been shown to provide acute, but not subacute, protection after murine stroke. Here, we investigate the dual role of complement in injury and repair after cerebral ischemia and reperfusion. Methods: We used complement-deficient mice and different complement inhibitors in a model of transient middle cerebral artery occlusion to investigate complement-dependent cellular and molecular changes that occur through the subacute phase after stroke. Results: C3 deficiency and site-targeted complement inhibition with either CR2-Crry (inhibits all pathways) or CR2-fH (inhibits alternative pathway) significantly reduced infarct size, reduced apoptotic cell death, and improved neurological deficit score in the acute phase after stroke. However, only in CR2-fH-treated mice was there sustained protection with no evolution of injury in the subacute phase. Whereas both inhibitors significantly reduced microglia/macrophage activation and astrogliosis in the subacute phase, only CR2-fH improved neurological deficit and locomotor function, maintained neurogenesis markers, enhanced neuronal migration, and increased VEGF expression. These findings in CR2-fH-treated mice correlated with improved performance in spatial learning and passive avoidance tasks. The complement anaphylatoxins have been implicated in repair and regenerative mechanisms after CNS injury, and in this context CR2-fH significantly reduced, but did not eliminate the generation of C5a within the brain, unlike CR2-Crry that completely blocked C5a generation. Gene expression profiling revealed that CR2-fH treatment downregulated genes associated with apoptosis, TGF beta signaling, and neutrophil activation, and decreased neutrophil infiltration was confirmed by immunohistochemistry. CR2-fH upregulated genes for neural growth factor and mediators of neurogenesis and neuronal migration. Live animal imaging demonstrated that following intravenous injection, CR2-fH targeted specifically to the post-ischemic brain, with a tissue half-life of 48.5 h. Finally, unlike C3 deficiency, targeted complement inhibition did not increase susceptibility to lethal post-stroke infection, an important consideration for stroke patients. Conclusions: Ischemic brain tissue-targeted and selective inhibition of alternative complement pathway provide self-limiting inhibition of complement activation and reduces acute injury while maintaining complement-dependent recovery mechanisms into the subacute phase after stroke. C1 [Alawieh, Ali; Elvington, Andrew; Atkinson, Carl; Tomlinson, Stephen] Med Univ S Carolina, Childrens Res Inst, Department Microbiol & Immunol, Charleston, SC 29425 USA. [Zhu, Hong; Yu, Jin; Kindy, Mark S.] Med Univ S Carolina, Inst Neurosci, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark S.; Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Childrens Res Inst, Department Microbiol & Immunol, 173 Ashley Ave BSB 201, Charleston, SC 29425 USA. EM tomlinss@musc.edu OI Alawieh, Ali/0000-0003-2601-8850 FU NIH [1P20GM109040]; Department of Veterans Affairs (Merit Award) [1I01RX001141, 1BX001218]; American Heart Association [15PRE25250009] FX This work was supported by grants from the NIH (1P20GM109040), the Department of Veterans Affairs (Merit Award 1I01RX001141 and 1BX001218), and an American Heart Association Pre-doctoral Fellowship to AA (15PRE25250009). NR 40 TC 2 Z9 2 U1 3 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD DEC 30 PY 2015 VL 12 AR 247 DI 10.1186/s12974-015-0464-8 PG 15 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DA0UG UT WOS:000367512400005 PM 26714866 ER PT J AU Mazzola, MA Raheja, R Murugaiyan, G Rajabi, H Kumar, D Pertel, T Regev, K Griffin, R Aly, L Kivisakk, P Nejad, P Patel, B Gwanyalla, N Hei, H Glanz, B Chitnis, T Weiner, HL Gandhi, R AF Mazzola, Maria Antonietta Raheja, Radhika Murugaiyan, Gopal Rajabi, Hasan Kumar, Deepak Pertel, Thomas Regev, Keren Griffin, Russell Aly, Lilian Kivisakk, Pia Nejad, Parham Patel, Bonny Gwanyalla, Nguendab Hei, Hillary Glanz, Bonnie Chitnis, Tanuja Weiner, Howard L. Gandhi, Roopali TI Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Multiple sclerosis; Fingolimod (FTY720); TCF-1; IFN-gamma; Granzyme B ID RELAPSING MULTIPLE-SCLEROSIS; HELPER 17 CELLS; ORAL FINGOLIMOD; IFN-GAMMA; INTERFERON-GAMMA; GENE-EXPRESSION; DIFFERENTIATION; BET; ACTIVATION; REPRESSION AB Background: Fingolimod (FTY720), the first oral treatment for multiple sclerosis (MS), blocks immune cell trafficking and prevents disease relapses by downregulation of sphingosine-1-phosphate receptor. We determined the effect of FTY720 on human T cell activation and effector function. Methods: T cells from MS patients and healthy controls were isolated to measure gene expression profiles in the presence or absence of FTY720 using nanostring and quantitative real-time polymerase chain reaction (qPCR). Cytokine protein expression was measured using luminex assay and flow cytometry analysis. Lentivirus vector carrying short hairpin RNA (shRNA) was used to knock down the expression of specific genes in CD4+ T cells. Chromatin immunoprecipitation was performed to assess T cell factor 1 (TCF-1) binding to promoter regions. Luciferase assays were performed to test the direct regulation of interferon gamma (IFN-gamma) and granzyme B (GZMB) by TCF-1. Western blot analysis was used to assess the phosphorylation status of Akt and GSK3 beta. Results: We showed that FTY720 treatment not only affects T cell trafficking but also T cell activation. Patients treated with FTY720 showed a significant reduction in circulating CD4 T cells. Activation of T cells in presence of FTY720 showed a less inflammatory phenotype with reduced production of IFN-gamma and GZMB. This decreased effector phenotype of FTY720-treated T cells was dependent on the upregulation of TCF-1. FTY720-induced TCF-1 downregulated the pathogenic cytokines IFN-gamma and GZMB by binding to their promoter/enhancer regions and mediating epigenetic modifications. Furthermore, we observed that TCF-1 expression was lower in T cells from multiple sclerosis patients than in those from healthy individuals, and FTY720 treatment increased TCF-1 expression in multiple sclerosis patients. Conclusions: These results reveal a previously unknown mechanism of the effect of FTY720 on human CD4+ T cell modulation in multiple sclerosis and demonstrate the role of TCF-1 in human T cell activation and effector function. C1 [Mazzola, Maria Antonietta; Raheja, Radhika; Murugaiyan, Gopal; Pertel, Thomas; Regev, Keren; Griffin, Russell; Aly, Lilian; Kivisakk, Pia; Nejad, Parham; Patel, Bonny; Gwanyalla, Nguendab; Hei, Hillary; Weiner, Howard L.; Gandhi, Roopali] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA. [Rajabi, Hasan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kumar, Deepak] Harvard Univ, Sch Med, Dept Mol Pharmacol & Biochem, Boston, MA 02115 USA. [Glanz, Bonnie; Chitnis, Tanuja; Weiner, Howard L.] Brigham & Womens Hosp, Partners MS Ctr, Brookline, MA 02445 USA. RP Gandhi, R (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA. EM rgandhi@rics.bwh.harvard.edu FU Novartis FX This study was supported by funding from Novartis. NR 68 TC 3 Z9 3 U1 2 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD DEC 30 PY 2015 VL 12 AR 245 DI 10.1186/s12974-015-0460-z PG 12 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DA0UG UT WOS:000367512400003 PM 26714756 ER PT J AU Chen, YX Zhu, WB Zhang, WR Libal, N Murphy, SJ Offner, H Alkayed, NJ AF Chen, Yingxin Zhu, Wenbin Zhang, Wenri Libal, Nicole Murphy, Stephanie J. Offner, Halina Alkayed, Nabil J. TI A novel mouse model of thromboembolic stroke SO JOURNAL OF NEUROSCIENCE METHODS LA English DT Article DE Cerebral ischemia; Stroke, Thromboembolic; Mouse; tPA; Optical microangiography ID CEREBRAL-ARTERY OCCLUSION; SPONTANEOUSLY HYPERTENSIVE-RATS; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; INTRALUMINAL SUTURE; EMBOLIC STROKE; BRAIN ISCHEMIA; INFARCT SIZE; REPERFUSION; MICE AB Background: We previously demonstrated that tissue plasminogen activator (tPA) reduces infarct size after mechanical middle cerebral artery occlusion (MCAO) in wild-type (WT) mice and transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). Clinically, tPA limits ischemic damage by dissolving the clot blocking blood flow through a cerebral artery. To mimic the clinical situation, we developed a new mouse model of thromboembolic stroke, and tested the efficacy of tPA in WT and DR2-Tg mice. New Method Autologous blood is withdrawn into a PE-8 catheter filled with 2 IU alpha-thrombin. After exposing the catheter briefly to air, the catheter is reintroduced into the external (ECA) and advanced into the internal carotid artery (ICA) to allow for intravascular injection of thrombin at the MCA bifurcation. To validate the model, we tested the effect of tPA on laser-Doppler perfusion (LDP) over the MCA territory and infarct size in WT and DR2-Tg mice. Results: The procedure results in a consistent drop in LDP, and leads to a highly reproducible ischemic lesion. When administered at 15 min after thrombosis, tPA restored LDP and resulted in a significant reduction in infarct size at 24 h after thrombosis in both WT and DR2-Tg. Comparison with Existing Methods: Our model significantly reduces surgery time, requires a single anesthesia exposure, and produces a consistent and predictable infarction, with low variability and mortality. Conclusion: We validated the efficacy of tPA in restoring blood flow and reducing infarct in a new model of endovascular thromboembolic stroke in the mouse. (C) 2015 Elsevier B.V. All rights reserved. C1 [Chen, Yingxin; Zhu, Wenbin; Zhang, Wenri; Libal, Nicole; Murphy, Stephanie J.; Offner, Halina; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. [Offner, Halina; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA. [Offner, Halina] Portland VA Med Ctr, Neuroimmunol Res, Portland, OR USA. RP Alkayed, NJ (reprint author), Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Dept Anesthesiol & Perioperat Med, UHN 2,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM alkayedn@ohsu.edu FU NIH [R42NS065515, R01NS070837] FX This project was supported by NIH grants R42NS065515 (Offner & Alkayed) and R01NS070837 (Alkayed). NR 40 TC 3 Z9 3 U1 9 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0270 EI 1872-678X J9 J NEUROSCI METH JI J. Neurosci. Methods PD DEC 30 PY 2015 VL 256 BP 203 EP 211 DI 10.1016/j.jneumeth.2015.09.013 PG 9 WC Biochemical Research Methods; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA CY7VW UT WOS:000366618400021 PM 26386284 ER PT J AU Cortese, BM Uhde, TW Brady, KT McClernon, FJ Yang, QX Collins, HR LeMatty, T Hartwell, KJ AF Cortese, Bernadette M. Uhde, Thomas W. Brady, Kathleen T. McClernon, F. Joseph Yang, Qing X. Collins, Heather R. LeMatty, Todd Hartwell, Karen J. TI The fMRI BOLD response to unisensory and multisensory smoking cues in nicotine-dependent adults SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Odors; Smoking; Tobacco dependence; Craving; Cue-reactivity; Neuroimaging ID ALCOHOL CUES; OLFACTORY FUNCTION; CIGARETTE-SMOKING; PREFRONTAL CORTEX; RISK DRINKERS; DRUG CUES; IN-VIVO; REACTIVITY; RELAPSE; SMOKERS AB Given that the vast majority of functional magnetic resonance imaging (fMRI) studies of drug cue reactivity use unisensory visual cues, but that multisensory cues may elicit greater craving-related brain responses, the current study sought to compare the fMRI BOLD response to unisensory visual and multisensory, visual plus odor, smoking cues in 17 nicotine-dependent adult cigarette smokers. Brain activation to smoking-related, compared to neutral, pictures was assessed under cigarette smoke and odorless odor conditions. While smoking pictures elicited a pattern of activation consistent with the addiction literature, the multisensory (odor+picture) smoking cues elicited significantly greater and more widespread activation in mainly frontal and temporal regions. BOLD signal elicited by the multisensory, but not unisensory cues, was significantly related to participants' level of control over craving as well. Results demonstrated that the co-presentation of cigarette smoke odor with smoking-related visual cues, compared to the visual cues alone, elicited greater levels of craving-related brain activation in key regions implicated in reward. These preliminary findings support future research aimed at a better understanding of multisensory integration of drug cues and craving. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Cortese, Bernadette M.; Uhde, Thomas W.; Brady, Kathleen T.; LeMatty, Todd; Hartwell, Karen J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Brady, Kathleen T.; Hartwell, Karen J.] Ralph H Johnson VAMC, Charleston, SC USA. [McClernon, F. Joseph] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Yang, Qing X.] Penn State Coll Med, Dept Radiol & Neurosurg, Ctr NMR Res, Hershey, PA USA. [Collins, Heather R.] Med Univ S Carolina, Dept Radiol & Radiol Sci, Ctr Biomed Imaging, Charleston, SC 29425 USA. RP Cortese, BM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, MSC 861, Charleston, SC 29425 USA. EM corteseb@musc.edu FU NIMH [K01MH090548]; NCATS [UL1 TR000062] FX Funding for this study was provided by NIMH Grant K01MH090548 (BMC), and by NCATS Grant UL1 TR000062 (pilot project to KJH and BMC). Study sponsors had no role in the study design, collection, analysis, interpretation of data, writing of the report, or the decision to submit the article for publication. NR 51 TC 0 Z9 0 U1 6 U2 17 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 EI 1872-7506 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD DEC 30 PY 2015 VL 234 IS 3 BP 321 EP 327 DI 10.1016/j.pscychresns.2015.10.008 PG 7 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CX9FU UT WOS:000366011200006 PM 26475784 ER PT J AU Moran-Jones, K Gloss, BS Murali, R Chang, DK Colvin, EK Jones, MD Yuen, S Howell, VM Brown, LM Wong, CW Spong, SM Scarlett, CJ Hacker, NF Ghosh, S Mok, SC Birrer, MJ Samimi, G AF Moran-Jones, Kim Gloss, Brian S. Murali, Rajmohan Chang, David K. Colvin, Emily K. Jones, Marc D. Yuen, Samuel Howell, Viive M. Brown, Laura M. Wong, Carol W. Spong, Suzanne M. Scarlett, Christopher J. Hacker, Neville F. Ghosh, Sue Mok, Samuel C. Birrer, Michael J. Samimi, Goli TI Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer SO ONCOTARGET LA English DT Article DE CTGF; FG-3019; metastasis; ovarian cancer; tumor microenvironment ID SURFACE EPITHELIUM; FACTOR CTGF/CCN2; TUMOR-GROWTH; EXPRESSION; CELLS; CARCINOMA; FEATURES; BINDING; MICROENVIRONMENT; TUMORIGENESIS AB Ovarian cancer is the most common cause of death among women with gynecologic cancer. We examined molecular profiles of fibroblasts from normal ovary and high-grade serous ovarian tumors to identify novel therapeutic targets involved in tumor progression. We identified 2,300 genes that are significantly differentially expressed in tumor-associated fibroblasts. Fibroblast expression of one of these genes, connective tissue growth factor (CTGF), was confirmed by immunohistochemistry. CTGF protein expression in ovarian tumor fibroblasts significantly correlated with gene expression levels. CTGF is a secreted component of the tumor microenvironment and is being pursued as a therapeutic target in pancreatic cancer. We examined its effect in in vitro and ex vivo ovarian cancer models, and examined associations between CTGF expression and clinico-pathologic characteristics in patients. CTGF promotes migration and peritoneal adhesion of ovarian cancer cells. These effects are abrogated by FG-3019, a human monoclonal antibody against CTGF, currently under clinical investigation as a therapeutic agent. Immunohistochemical analyses of high-grade serous ovarian tumors reveal that the highest level of tumor stromal CTGF expression was correlated with the poorest prognosis. Our findings identify CTGF as a promoter of peritoneal adhesion, likely to mediate metastasis, and a potential therapeutic target in high-grade serous ovarian cancer. These results warrant further studies into the therapeutic efficacy of FG-3019 in high-grade serous ovarian cancer. C1 [Moran-Jones, Kim; Gloss, Brian S.; Chang, David K.; Jones, Marc D.; Brown, Laura M.; Scarlett, Christopher J.; Samimi, Goli] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia. [Moran-Jones, Kim; Gloss, Brian S.; Chang, David K.; Jones, Marc D.; Brown, Laura M.; Scarlett, Christopher J.; Samimi, Goli] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia. [Moran-Jones, Kim; Gloss, Brian S.; Samimi, Goli] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia. [Murali, Rajmohan] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. [Murali, Rajmohan] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Colvin, Emily K.; Yuen, Samuel; Howell, Viive M.] Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, Sydney, NSW 2006, Australia. [Wong, Carol W.; Spong, Suzanne M.] FibroGen Inc, San Francisco, CA USA. [Scarlett, Christopher J.] Univ Newcastle, Sch Environm & Life Sci, Ourimbah, NSW, Australia. [Hacker, Neville F.] Univ New S Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia. [Hacker, Neville F.] Royal Hosp Women, Gynaecol Canc Ctr, Sydney, NSW, Australia. [Ghosh, Sue] Harvard Univ, Brigham & Womens Hosp, Sch Med, Lab Gynecol Oncol, Boston, MA 02115 USA. [Mok, Samuel C.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA. [Birrer, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. RP Samimi, G (reprint author), Kinghorn Canc Ctr, Darlinghurst, NSW, Australia. EM mbirrer@partners.org; g.samimi@garvan.org.au RI Murali, Rajmohan/A-7960-2008; OI Murali, Rajmohan/0000-0001-6988-4295; Jones, Marc/0000-0002-3078-8359 FU NIH [RO1CA133057]; Cancer Institute NSW FX This study was supported in part by NIH grant RO1CA133057 (S.C. Mok) and Fellowships from the Cancer Institute NSW (G. Samimi, B.S. Gloss, E.K. Colvin, C.J. Scarlett and D.K. Chang). NR 47 TC 3 Z9 3 U1 1 U2 3 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD DEC 29 PY 2015 VL 6 IS 42 BP 44551 EP 44562 PG 12 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DD4QX UT WOS:000369908800037 PM 26575166 ER PT J AU Jiang, RZ Lu, YT Ho, H Li, B Chen, JF Lin, M Li, FQ Wu, K Wu, HJ Lichterman, J Wan, HL Lu, CL OuYang, W Ni, M Wang, LL Li, GB Lee, T Zhang, XQ Yang, JT Rettig, M Chung, LWK Yang, HM Li, KC Hou, Y Tseng, HR Hou, S Xu, X Wang, J Posadas, EM AF Jiang, Runze Lu, Yi-Tsung Ho, Hao Li, Bo Chen, Jie-Fu Lin, Millicent Li, Fuqiang Wu, Kui Wu, Hanjie Lichterman, Jake Wan, Haolei Lu, Chia-Lun OuYang, William Ni, Ming Wang, Linlin Li, Guibo Lee, Tom Zhang, Xiuqing Yang, Jonathan Rettig, Matthew Chung, Leland W. K. Yang, Huanming Li, Ker-Chau Hou, Yong Tseng, Hsian-Rong Hou, Shuang Xu, Xun Wang, Jun Posadas, Edwin M. TI A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer SO ONCOTARGET LA English DT Article DE circulating tumor cell; prostate cancer; whole genome sequencing; liquid biopsy; cancer heterogeneity ID METASTATIC BREAST-CANCER; COPY-NUMBER; LUNG-CANCER; SINGLE-NUCLEOTIDE; PERIPHERAL-BLOOD; PD-1 BLOCKADE; MUTATIONS; EVOLUTION; DNA; REARRANGEMENTS AB Previous studies have demonstrated focal but limited molecular similarities between circulating tumor cells (CTCs) and biopsies using isolated genetic assays. We hypothesized that molecular similarity between CTCs and tissue exists at the single cell level when characterized by whole genome sequencing (WGS). By combining the NanoVelcro CTC Chip with laser capture microdissection (LCM), we developed a platform for single-CTC WGS. We performed this procedure on CTCs and tissue samples from a patient with advanced prostate cancer who had serial biopsies over the course of his clinical history. We achieved 30X depth and >= 95% coverage. Twenty-nine percent of the somatic single nucleotide variations (SSNVs) identified were founder mutations that were also identified in CTCs. In addition, 86% of the clonal mutations identified in CTCs could be traced back to either the primary or metastatic tumors. In this patient, we identified structural variations (SVs) including an intrachromosomal rearrangement in chr3 and an interchromosomal rearrangement between chr13 and chr15. These rearrangements were shared between tumor tissues and CTCs. At the same time, highly heterogeneous short structural variants were discovered in PTEN, RB1, and BRCA2 in all tumor and CTC samples. Using high-quality WGS on single-CTCs, we identified the shared genomic alterations between CTCs and tumor tissues. This approach yielded insight into the heterogeneity of the mutational landscape of SSNVs and SVs. It may be possible to use this approach to study heterogeneity and characterize the biological evolution of a cancer during the course of its natural history. C1 [Jiang, Runze; Li, Bo; Li, Fuqiang; Wu, Kui; Wu, Hanjie; Ni, Ming; Wang, Linlin; Li, Guibo; Yang, Huanming; Hou, Yong; Xu, Xun; Wang, Jun] Beijing Genome Inst Shenzhen, Shenzhen 51803, Peoples R China. [Lu, Yi-Tsung; Chen, Jie-Fu; Lichterman, Jake; Lu, Chia-Lun; Chung, Leland W. K.; Posadas, Edwin M.] Cedars Sinai Med Ctr, Urol Oncol Res Program, Los Angeles, CA 90048 USA. [Ho, Hao; Li, Ker-Chau] Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90095 USA. [Ho, Hao; Li, Ker-Chau] Acad Sinica, Inst Stat Sci, Taipei 11529, Taiwan. [Chen, Jie-Fu; Lin, Millicent; OuYang, William; Yang, Jonathan; Tseng, Hsian-Rong; Hou, Shuang] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Wan, Haolei] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Lee, Tom; Tseng, Hsian-Rong] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA. [Zhang, Xiuqing] BGI Shenzhen, Guangdong Enterprise Key Lab Human Dis Genom, Shenzhen 51803, Peoples R China. [Rettig, Matthew] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Rettig, Matthew] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA. [Rettig, Matthew] VA Greater Los Angeles Healthcare Syst, Div Hematol Oncol, Dept Med, Los Angeles, CA 90073 USA. [Yang, Huanming; Wang, Jun] King Abdulaziz Univ, Princess Al Jawhara Ctr Excellence Res Hereditary, Jeddah 21589, Saudi Arabia. [Yang, Huanming] Zhejiang Univ, James D Watson Inst Genome Sci, Hangzhou 310058, Zhejiang, Peoples R China. [Wang, Jun] Univ Copenhagen, Dept Biol, DK-1599 Copenhagen, Denmark. [Wang, Jun] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, DK-1599 Copenhagen, Denmark. RP Posadas, EM (reprint author), Cedars Sinai Med Ctr, Urol Oncol Res Program, Los Angeles, CA 90048 USA. EM HRTseng@mednet.ucla.edu; wangj@genomics.cn; Edwin.Posadas@csmc.edu FU National High Technology Research and Development Program of China-863 Program [2012AA02A201]; National Basic Research Program of China (973 program) [2011CB809202, 2011CB809203]; Key Laboratory Project - Shenzhen City [CXB201108250096A]; Major Industrial Technology Research Program of Shenzhen [BGI20100001]; Science, Technology and Innovation Committee of Shenzhen Municipality [JSGG20140702161347218]; China National GeneBank-Shenzhen; Prostate Cancer Foundation (PCF); UCLA Prostate Cancer SPORE Program; NIH/NCI Innovative Molecular Analysis Technologies (IMAT) Program [R21 CA151159, R33 CA157396]; DoD Idea Award [W81XWH-11-1-0422]; Steven Spielberg Discovery Fund in Prostate Cancer Research; PCF Young Investigator Award; St. Anthony Fund for Prostate Cancer Research; CD McKinnon Fund; Berns Family Fund for Prostate Cancer Research; Innovative Research Team Project of Guangdong; Guangdong Enterprise Key Laboratory of Human Disease Genomics [2011A060906007]; National Natural Science Fund [81272899, 81172510]; Discipline Booster Plan of Xi Jing Hospital [XJZT12Z07]; Danish Natural Science Research Council; Danish National Research Foundation; National Natural Science Foundation of China; Shenzhen Municipal Government; Local Government of the Yantian District of Shenzhen FX The work at BGI was supported by the National High Technology Research and Development Program of China-863 Program (No. 2012AA02A201), a National Basic Research Program of China (973 program No. 2011CB809202 and 2011CB809203), the Key Laboratory Project Supported by Shenzhen City (No. CXB201108250096A), Major Industrial Technology Research Program of Shenzhen (No. BGI20100001), the Science, Technology and Innovation Committee of Shenzhen Municipality (JSGG20140702161347218), and China National GeneBank-Shenzhen. The research endeavors at UCLA were supported by a Creativity Award from the Prostate Cancer Foundation (PCF), the UCLA Prostate Cancer SPORE Program, and research grants (R21 CA151159 and R33 CA157396) from the NIH/NCI Innovative Molecular Analysis Technologies (IMAT) Program. The research endeavors at Cedars-Sinai Medical Center were supported by a DoD Idea Award (W81XWH-11-1-0422), the Steven Spielberg Discovery Fund in Prostate Cancer Research, a PCF Young Investigator Award, the St. Anthony Fund for Prostate Cancer Research, the CD McKinnon Fund, and the Berns Family Fund for Prostate Cancer Research. This project was also supported by grants from the Innovative Research Team Project of Guangdong, the Guangdong Enterprise Key Laboratory of Human Disease Genomics (No. 2011A060906007), the National Natural Science Fund (81272899 and 81172510) and Discipline Booster Plan of Xi Jing Hospital (XJZT12Z07). We also acknowledge an Ole Romer grant from the Danish Natural Science Research Council, the Danish National Research Foundation, the National Natural Science Foundation of China, and funds from the Shenzhen Municipal Government and the Local Government of the Yantian District of Shenzhen. NR 53 TC 14 Z9 14 U1 6 U2 14 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD DEC 29 PY 2015 VL 6 IS 42 BP 44781 EP 44793 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DD4QX UT WOS:000369908800053 PM 26575023 ER PT J AU Benito, JM Godfrey, L Kojima, K Hogdal, L Wunderlich, M Geng, HM Marzo, I Harutyunyan, KG Golfman, L North, P Kerry, J Ballabio, E Ni Chonghaile, T Gonzalo, O Qiu, YH Jeremias, I Debose, L O'Brien, E Ma, HL Zhou, P Jacamo, R Park, E Coombes, KR Zhang, NAX Thomas, DA O'Brien, S Kantarjian, HM Leverson, JD Kornblau, SM Andreeff, M Muschen, M Zweidler-McKay, PA Mulloy, JC Letai, A Milne, TA Konopleva, M AF Benito, Juliana M. Godfrey, Laura Kojima, Kensuke Hogdal, Leah Wunderlich, Mark Geng, Huimin Marzo, Isabel Harutyunyan, Karine G. Golfman, Leonard North, Phillip Kerry, Jon Ballabio, Erica Ni Chonghaile, Triona Gonzalo, Oscar Qiu, Yihua Jeremias, Irmela Debose, LaKiesha O'Brien, Eric Ma, Helen Zhou, Ping Jacamo, Rodrigo Park, Eugene Coombes, Kevin R. Zhang, Nianxiang Thomas, Deborah A. O'Brien, Susan Kantarjian, Hagop M. Leverson, Joel D. Kornblau, Steven M. Andreeff, Michael Mueschen, Markus Zweidler-McKay, Patrick A. Mulloy, James C. Letai, Anthony Milne, Thomas A. Konopleva, Marina TI MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199 SO CELL REPORTS LA English DT Article ID MIXED-LINEAGE LEUKEMIA; ACUTE MYELOID-LEUKEMIA; IN-VIVO EFFICACY; TARGET; CELLS; CHROMATIN; COMPLEX; INHIBITION; DEPENDENCE; PROTEINS AB Targeted therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as the t(4;11) translocation cause aggressive leukemias that are refractory to conventional treatment. The t(4; 11) translocation produces an MLL/AF4 fusion protein that activates key target genes through both epigenetic and transcriptional elongation mechanisms. In this study, we show that t(4; 11) patient cells express high levels of BCL-2 and are highly sensitive to treatment with the BCL-2-specific BH3 mimetic ABT-199. We demonstrate that MLL/AF4 specifically upregulates the BCL-2 gene but not other BCL-2 family members via DOT1L-mediated H3K79me2/3. We use this information to show that a t(4; 11) cell line is sensitive to a combination of ABT-199 and DOT1L inhibitors. In addition, ABT-199 synergizes with standard induction-type therapy in a xenotransplant model, advocating for the introduction of ABT-199 into therapeutic regimens for MLL-rearranged leukemias. C1 [Benito, Juliana M.; Harutyunyan, Karine G.; Qiu, Yihua; Debose, LaKiesha; Ma, Helen; Zhou, Ping; Jacamo, Rodrigo; Thomas, Deborah A.; O'Brien, Susan; Kantarjian, Hagop M.; Kornblau, Steven M.; Andreeff, Michael; Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Godfrey, Laura; North, Phillip; Kerry, Jon; Ballabio, Erica; Milne, Thomas A.] Univ Oxford, NIHR Oxford Biomed Res Ctr Programme, Weatherall Inst Mol Med, Mol Haematol Unit, Oxford OX3 9DS, England. [Kojima, Kensuke] Saga Univ, Dept Internal Med, Fac Med, Div Hematol Resp Med & Oncol, Saga 8408502, Japan. [Hogdal, Leah; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Wunderlich, Mark; O'Brien, Eric; Mulloy, James C.] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA. [Geng, Huimin; Park, Eugene; Mueschen, Markus] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Marzo, Isabel; Gonzalo, Oscar] Univ Zaragoza, Dept Biochem Mol & Cell Biol, Zaragoza 50018, Spain. [Golfman, Leonard; Zweidler-McKay, Patrick A.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA. [Ni Chonghaile, Triona] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland. [Jeremias, Irmela] German Res Ctr Environm Hlth GmbH, D-85764 Neuherberg, Germany. [Coombes, Kevin R.; Zhang, Nianxiang] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA. [Leverson, Joel D.] AbbVie Inc, Dept Oncol Dev, N Chicago, IL 60064 USA. RP Milne, TA (reprint author), Univ Oxford, NIHR Oxford Biomed Res Ctr Programme, Weatherall Inst Mol Med, Mol Haematol Unit, Oxford OX3 9DS, England. EM thomas.milne@imm.ox.ac.uk; mkonople@mdanderson.org RI Milne, Tom/E-1872-2016; Marzo, Isabel/E-6918-2016 OI Milne, Tom/0000-0002-0413-4271; Marzo, Isabel/0000-0002-2315-9079 FU Medical Research Council (MRC) Molecular Haematology Unit [MC_UU_12009/6]; Wellcome Trust [090532/Z/09/Z]; AbbVie Inc.; NIH/NCI [P30 CA016672] FX The work in this grant performed by T.M., L.G., J.K., P.N., and E.B. was funded by Medical Research Council (MRC) Molecular Haematology Unit grant MC_UU_12009/6. We thank the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z) and the Computational Biology Research Group (CBRG), Radcliffe Department of Medicine, at the University of Oxford. This work was supported, in part, by AbbVie Inc. and by NIH/NCI grant P30 CA016672 to the University of Texas MD Anderson Cancer Center (MDACC). NR 45 TC 12 Z9 12 U1 3 U2 6 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD DEC 29 PY 2015 VL 13 IS 12 BP 2715 EP 2727 DI 10.1016/j.celrep.2015.12.003 PG 13 WC Cell Biology SC Cell Biology GA CZ8DU UT WOS:000367331200008 PM 26711339 ER PT J AU Zhang, J Zhang, L Hong, JX Wu, D Xu, JJ AF Zhang, Jing Zhang, Lu Hong, Jiaxu Wu, Dan Xu, Jianjiang TI Association of Common Variants in LOX with Keratoconus: A Meta-Analysis SO PLOS ONE LA English DT Article ID HAN CHINESE POPULATION; LYSYL OXIDASE; CANDIDATE GENE; ETHNIC-ORIGIN; IDENTIFICATION; POLYMORPHISMS; SEVERITY; DISEASE; LOCI AB Background Several case-control studies have been performed to examine the association of genetic variants in lysyl oxidase (LOX) with keratoconus. However, the results remained inconclusive and great heterogeneity might exist across populations. Method A comprehensive literature search for studies that published up to June 25, 2015 was performed. Summary odds ratios (OR) and 95% confidence intervals (CI) of each single nucleotide polymorphism (SNP) were estimated with fixed effects model when I-2<50% in the test for heterogeneity or random effects model when I-2>50%. Publication bias was evaluated using funnel plots and Egger's test. Results A total of four studies including 1,467 keratoconus cases and 4,490 controls were involved in this meta-analysis. SNPs rs2956540 and rs10519694 showed significant association with keratoconus, with ORs of 0.71 (95% CI: 0.63-0.80, P = 1.43E-08) and 0.77 (95% CI: 0.61-0.97, P = 0.026), respectively. In contrast, our study lacked sufficient evidences to support the association of rs1800449/rs2288393 with keratoconus across populations. Conclusion This meta-analysis suggested that two LOX variants, rs2956540 and rs10519694, may affect individual susceptibility to keratoconus, while distinct heterogeneity existed within this locus. Larger-scale and multi-ethnic genetic studies on keratoconus are required to further validate the results. C1 [Zhang, Jing] Fudan Univ, Res Ctr, Eye & ENT Hosp, Key Lab Myopia,Minist Hlth, Shanghai 200433, Peoples R China. [Hong, Jiaxu; Wu, Dan; Xu, Jianjiang] Fudan Univ, Dept Ophthalmol & Visual Sci, Eye & ENT Hosp, Key Lab Myopia,Minist Hlth, Shanghai 200433, Peoples R China. [Zhang, Lu] City Univ Hong Kong, Dept Comp Sci, Hong Kong, Hong Kong, Peoples R China. [Hong, Jiaxu] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. RP Xu, JJ (reprint author), Fudan Univ, Dept Ophthalmol & Visual Sci, Eye & ENT Hosp, Key Lab Myopia,Minist Hlth, Shanghai 200433, Peoples R China. EM jianjiangxu@126.com FU Key Clinic Medicine Research Program, the Ministry of Health, China [201302015]; National Science and Technology Research Program, the Ministry of Science and Technology, China [2012BAI08B01]; National Natural Science Foundation of China [81170817, 81200658, 81300735, 81270978, U1205025, 81330022]; Chinese Postdoctoral Fund [XMU135890]; Scientific Research Program, Science and Technology Commission of Shanghai Municipality, Shanghai [13441900900, 13430720400]; New Technology Joint Research Project in Shanghai Hospitals [SHDC12014114] FX The authors were supported by grants from the Key Clinic Medicine Research Program, the Ministry of Health, China (201302015); the National Science and Technology Research Program, the Ministry of Science and Technology, China (2012BAI08B01); the National Natural Science Foundation of China (81170817, 81200658, 81300735, 81270978, U1205025, and 81330022); the Chinese Postdoctoral Fund (XMU135890); and the Scientific Research Program, Science and Technology Commission of Shanghai Municipality, Shanghai (13441900900, 13430720400); New Technology Joint Research Project in Shanghai Hospitals (SHDC12014114). The sponsor or funding organization had no role in the design or conduct of this research. NR 24 TC 0 Z9 0 U1 3 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 29 PY 2015 VL 10 IS 12 AR e0145815 DI 10.1371/journal.pone.0145815 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DA0IX UT WOS:000367481900087 PM 26713757 ER PT J AU Partridge, AH AF Partridge, Ann H. TI Prevention of Premature Menopause and Preservation of Fertility in Young Cancer Survivors Hopeful Though Modest Long-term Results SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID PREMENOPAUSAL BREAST-CANCER; OVARIAN STIMULATION; CHEMOTHERAPY; SUPPRESSION; WOMEN C1 [Partridge, Ann H.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Partridge, Ann H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. RP Partridge, AH (reprint author), Dana Farber Canc Inst, Y1245,450 Brookline Ave, Boston, MA 02215 USA. EM ahpartridge@partners.org NR 16 TC 0 Z9 0 U1 2 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 29 PY 2015 VL 314 IS 24 BP 2625 EP 2627 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CZ2MR UT WOS:000366939800015 PM 26720024 ER PT J AU Holmes, DR Nishimura, RA Grover, FL Brindis, RG Carroll, JD Edwards, FH Peterson, ED Rumsfeld, JS Shahian, DM Thourani, VH Tuzcu, EM Vemulapalli, S Hewitt, K Michaels, J Fitzgerald, S Mack, MJ AF Holmes, David R., Jr. Nishimura, Rick A. Grover, Frederick L. Brindis, Ralph G. Carroll, John D. Edwards, Fred H. Peterson, Eric D. Rumsfeld, John S. Shahian, David M. Thourani, Vinod H. Tuzcu, E. Murat Vemulapalli, Sreekanth Hewitt, Kathleen Michaels, Joan Fitzgerald, Susan Mack, Michael J. CA STS ACC TVT Registry TI Annual Outcomes With Transcatheter Valve Therapy From the STS/ACC TVT Registry SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE aortic stenosis; aortic valve replacement; transcatheter aortic valve replacement; valvular heart disease; VARC ID CITY CARDIOMYOPATHY QUESTIONNAIRE; END-POINT DEFINITIONS; VASCULAR COMPLICATIONS; UNITED-STATES; HEALTH-STATUS; IMPLANTATION; REPLACEMENT; SURVEILLANCE; PACEMAKER; INFRASTRUCTURE AB BACKGROUND The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry has been a joint initiative of the STS and the ACC in concert with multiple stakeholders. The TVT Registry has important information regarding patient selection, delivery of care, science, education, and research in the field of structural valvular heart disease. OBJECTIVES This report provides an overview on current U.S. TVT practice and trends. The emphasis is on demographics, in-hospital procedural characteristics, and outcomes of patients having transcatheter aortic valve replacement (TAVR) performed at 348 U.S. centers. METHODS The TVT Registry captured 26,414 TAVR procedures as of December 31, 2014. Temporal trends between 2012 and 2013 versus 2014 were compared. RESULTS Comparison of the 2 time periods reveals that TAVR patients remain elderly (mean age 82 years), with multiple comorbidities, reflected by a high mean STS predicted risk of mortality (STS PROM) for surgical valve replacement (8.34%), were highly symptomatic (New York Heart Association functional class III/IV in 82.5%), frail (slow 5-m walk test in 81.6%), and have poor self-reported health status (median baseline Kansas City Cardiomyopathy Questionnaire score of 39.1). Procedure performance is changing, with an increased use of moderate sedation (from 1.6% to 5.1%) and increase in femoral access using percutaneous techniques (66.8% in 2014). Vascular complication rates are decreasing (from 5.6% to 4.2%), whereas site-reported stroke rates remain stable at 2.2%. CONCLUSIONS The TVT Registry provides important information on characteristics and outcomes of TAVR in contemporary U.S. clinical practice. It can be used to identify trends in practice and opportunities for quality improvement. (C) 2015 by the American College of Cardiology Foundation and The Society of Thoracic Surgeons. C1 [Holmes, David R., Jr.; Nishimura, Rick A.] Mayo Clin, Rochester, MN 55905 USA. [Grover, Frederick L.; Carroll, John D.] Univ Colorado, Denver, CO 80202 USA. [Brindis, Ralph G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Edwards, Fred H.] Univ Florida, Jacksonville, FL USA. [Peterson, Eric D.; Vemulapalli, Sreekanth] Duke Univ, Med Ctr, Durham, NC USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Shahian, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thourani, Vinod H.] Emory Univ, Atlanta, GA 30322 USA. [Tuzcu, E. Murat] Cleveland Clin, Cleveland, OH 44106 USA. [Hewitt, Kathleen; Michaels, Joan; Fitzgerald, Susan] Amer Coll Cardiol, Washington, DC USA. [Mack, Michael J.] Baylor Scott & White Hlth, Plano, TX USA. RP Holmes, DR (reprint author), Mayo Clin, 200 First St Southwest, Rochester, MN 55905 USA. EM holmes.david@mayo.edu NR 22 TC 32 Z9 32 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD DEC 29 PY 2015 VL 66 IS 25 BP 2813 EP 2823 DI 10.1016/j.jacc.2015.10.021 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CZ2PA UT WOS:000366945900001 PM 26652232 ER PT J AU Feldman, T Kar, S Elmariah, S Smart, SC Trento, A Siegel, RJ Apruzzese, P Fail, P Rinaldi, MJ Smalling, RW Hermiller, JB Heimansohn, D Gray, WA Grayburn, PA Mack, MJ Lim, DS Ailawadi, G Herrmann, HC Acker, MA Silvestry, FE Foster, E Wang, A Glower, DD Mauri, L AF Feldman, Ted Kar, Saibal Elmariah, Sammy Smart, Steven C. Trento, Alfredo Siegel, Robert J. Apruzzese, Patricia Fail, Peter Rinaldi, Michael J. Smalling, Richard W. Hermiller, James B. Heimansohn, David Gray, William A. Grayburn, Paul A. Mack, Michael J. Lim, D. Scott Ailawadi, Gorav Herrmann, Howard C. Acker, Michael A. Silvestry, Frank E. Foster, Elyse Wang, Andrew Glower, Donald D. Mauri, Laura CA EVEREST II Investigators TI Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation 5-Year Results of EVEREST II SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE mitral insufficiency; regurgitant lesion; valve therapy ID DOUBLE-ORIFICE TECHNIQUE; VALVE REPAIR; EVALVE MITRACLIP; TRIAL; DISEASE; OUTCOMES; THERAPY AB BACKGROUND In EVEREST II (Endovascular Valve Edge-to-Edge Repair Study), treatment of mitral regurgitation (MR) with a novel percutaneous device showed superior safety compared with surgery, but less effective reduction in MR at 1 year. OBJECTIVES This study sought to evaluate the final 5-year clinical outcomes and durability of percutaneous mitral valve (MV) repair with the MitraClip device compared with conventional MV surgery. METHODS Patients with grade 3+ or 4+ MR were randomly assigned to percutaneous repair with the device or conventional MV surgery in a 2: 1 ratio (178: 80). Patients prospectively consented to 5 years of follow-up. RESULTS At 5 years, the rate of the composite endpoint of freedom from death, surgery, or 3+ or 4+ MR in the as-treated population was 44.2% versus 64.3% in the percutaneous repair and surgical groups, respectively (p = 0.01). The difference was driven by increased rates of 3+ to 4+ MR (12.3% vs. 1.8%; p = 0.02) and surgery (27.9% vs. 8.9%; p = 0.003) with percutaneous repair. After percutaneous repair, 78% of surgeries occurred within the first 6 months. Beyond 6 months, rates of surgery and moderate-to-severe MR were comparable between groups. Five-year mortality rates were 20.8% and 26.8% (p = 0.4) for percutaneous repair and surgery, respectively. In multivariable analysis, treatment strategy was not associated with survival. CONCLUSIONS Patients treated with percutaneous repair more commonly required surgery for residual MR during the first year after treatment, but between 1-and 5-year follow-up, comparably low rates of surgery for MV dysfunction with either percutaneous or surgical therapy endorse the durability of MR reduction with both repair techniques. (EVEREST II Pivotal Study High Risk Registry; NCT00209274) (C) 2015 by the American College of Cardiology Foundation. C1 [Feldman, Ted; Smart, Steven C.] Evanston Hosp Corp, Div Cardiol, Dept Med, Evanston, IL 60201 USA. [Kar, Saibal; Siegel, Robert J.] Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Los Angeles, CA 90048 USA. [Elmariah, Sammy] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Elmariah, Sammy; Apruzzese, Patricia] Harvard Clin Res Inst, Dept Med, Div Cardiol, Boston, MA USA. [Trento, Alfredo] Cedars Sinai Med Ctr, Dept Surg, Div Cardiovasc Surg, Los Angeles, CA 90048 USA. [Fail, Peter] Terrebonne Gen Med Ctr, Dept Med, Div Cardiol, Houma, LA USA. [Rinaldi, Michael J.] Carolinas Med Ctr, Sanger Heart & Vasc Inst, Dept Med, Div Cardiol, Charlotte, NC 28203 USA. [Smalling, Richard W.] Mem Hermann Heart & Vasc Inst, Dept Med, Div Cardiol, Houston, TX USA. [Hermiller, James B.] St Vincent Med Grp, Dept Med, Div Cardiol, Indianapolis, IN USA. [Heimansohn, David] St Vincent Med Grp, Dept Surg, Div Cardiovasc Surg, Indianapolis, IN USA. [Gray, William A.] Columbia Univ, Dept Med, Med Ctr, Div Cardiol, New York, NY USA. [Grayburn, Paul A.] Baylor Univ, Dept Med, Div Cardiol, Dallas, TX USA. [Mack, Michael J.] Baylor Univ, Dept Surg, Div Cardiovasc Surg, Dallas, TX USA. [Lim, D. Scott] Univ Virginia, Dept Med, Div Cardiol, Charlottesville, VA USA. [Ailawadi, Gorav] Univ Virginia, Dept Surg, Div Cardiovasc Surg, Charlottesville, VA USA. [Herrmann, Howard C.; Silvestry, Frank E.] Univ Penn, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA. [Acker, Michael A.] Univ Penn, Dept Surg, Div Cardiovasc Surg, Philadelphia, PA 19104 USA. [Foster, Elyse] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA. [Wang, Andrew] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA. [Glower, Donald D.] Duke Univ, Med Ctr, Dept Surg, Div Cardiovasc Surg, Durham, NC 27710 USA. [Mauri, Laura] Brigham & Womens Hosp, Dept Med, Div Cardiol, Boston, MA USA. RP Feldman, T (reprint author), Evanston Hosp Corp, Div Cardiol, Walgreen Bldg 3rd Floor,2650 Ridge Ave, Evanston, IL 60201 USA. EM tfeldman@tfeldman.org NR 23 TC 29 Z9 30 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD DEC 29 PY 2015 VL 66 IS 25 BP 2844 EP 2854 DI 10.1016/j.jacc.2015.10.018 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CZ2PA UT WOS:000366945900006 PM 26718672 ER PT J AU Yin, J Leavenworth, JW Li, Y Luo, Q Xie, HF Liu, XH Huang, S Yan, H Fu, Z Zhang, LYY Zhang, LT Hao, JW Wu, XD Deng, XM Roberts, CWM Orkin, SH Cantor, H Wang, X AF Yin, Jie Leavenworth, Jianmei W. Li, Yang Luo, Qi Xie, Huafeng Liu, Xinhua Huang, Shan Yan, Han Fu, Zheng Zhang, Liyun Y. Zhang, Litao Hao, Junwei Wu, Xudong Deng, Xianming Roberts, Charles W. M. Orkin, Stuart H. Cantor, Harvey Wang, Xi TI Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE epigenetic regulation; NKG2D; hematopoietic stem and progenitor cells; histone modification; innate immunity ID POLYCOMB GROUP PROTEINS; INNATE LYMPHOID-CELLS; LINEAGE COMMITMENT; NK CELLS; CANCER; METHYLATION; HOMEOSTASIS; EXPRESSION; GENERATION; DEPENDENCE AB Changes of histone modification status at critical lineage-specifying gene loci in multipotent precursors can influence cell fate commitment. The contribution of these epigenetic mechanisms to natural killer (NK) cell lineage determination from common lymphoid precursors is not understood. Here we investigate the impact of histone methylation repressive marks (H3 Lys27 trimethylation; H3K27(me3)) on early NK cell differentiation. We demonstrate that selective loss of the histone-lysine N-methyltransferase Ezh2 (enhancer of zeste homolog 2) or inhibition of its enzymatic activity with small molecules unexpectedly increased generation of the IL-15 receptor (IL-15R) CD122(+) NK precursors and mature NK progeny from both mouse and human hematopoietic stem and progenitor cells. Mechanistic studies revealed that enhanced NK cell expansion and cytotoxicity against tumor cells were associated with up-regulation of CD122 and the C-type lectin receptor NKG2D. Moreover, NKG2D deficiency diminished the positive effects of Ezh2 inhibitors on NK cell commitment. Identification of the contribution of Ezh2 to NK lineage specification and function reveals an epigenetic-based mechanism that regulates NK cell development and provides insight into the clinical application of Ezh2 inhibitors in NK-based cancer immunotherapies. C1 [Yin, Jie; Li, Yang; Luo, Qi; Huang, Shan; Yan, Han; Wang, Xi] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Lab Epigenet Dev & Tumorigenesis, Dept Cell Biol,Tianjin Res Ctr Basic Med Sci,Tian, Tianjin 300070, Peoples R China. [Leavenworth, Jianmei W.; Cantor, Harvey] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02215 USA. [Leavenworth, Jianmei W.; Cantor, Harvey] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Div Immunol, Boston, MA 02115 USA. [Luo, Qi] Tianjin Med Univ, Dept Pharmacol, Tianjin 300070, Peoples R China. [Xie, Huafeng; Orkin, Stuart H.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Xie, Huafeng; Roberts, Charles W. M.; Orkin, Stuart H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. [Xie, Huafeng; Roberts, Charles W. M.; Orkin, Stuart H.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Liu, Xinhua] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin 300070, Peoples R China. [Fu, Zheng] Tianjin Med Univ, Dept Immunol, Tianjin 300070, Peoples R China. [Zhang, Liyun Y.] Shanxi Acad Med Sci, Shanxi Da Yi Hosp, Div Rheumatol, Taiyuan 030032, Shanxi, Peoples R China. [Zhang, Litao] Tianjin Acad Tradit Chinese Med, Affiliated Hosp, Dept Dermatol, Tianjin 300120, Peoples R China. [Hao, Junwei] Tianjin Med Univ, Gen Hosp, Dept Neurol, Tianjin 300052, Peoples R China. [Hao, Junwei] Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Tianjin 300052, Peoples R China. [Wu, Xudong] Tianjin Med Univ, Dept Cell Biol, Tianjin 300070, Peoples R China. [Deng, Xianming] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China. [Roberts, Charles W. M.; Orkin, Stuart H.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA. RP Leavenworth, JW (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02215 USA. EM Jianmei_Leavenworth@dfci.harvard.edu; harvey_cantor@dfci.harvard.edu; wangxi@tmu.edu.cn FU Ministry of Science and Technology of China [2014CB910100]; National Natural Science Foundation of China [81171899, 81372230, 81422045, 21272195, 81322018]; National Institutes of Health [AI048125, T32 CA070083, U01 CA105423, R01CA172152, R01CA113794]; U01NCI Mouse Models of Cancer Consortium award; Benacerraf Fellowship; Claudia Adams Barr Program for Innovative Cancer Research; Shanxi Scholarship Council of China [2012-089]; International Cooperation Project of Shan Xi Science and Technology Department Grant [2012081049]; Tianjin Natural Science Foundation Grant [12JCYBJC17200] FX We thank Dr. J. D. Leavenworth for editing; A. Angel for manuscript and figure preparation; Y. Shao (Dana-Farber Cancer Institute Microarray Facility) and Z. Zhu for flow cytometry; and Drs. Y. Shang, Z. Yao, Y. Wang, Z. Liu, and members of the laboratories of X. Wang., H.C., C.W.M.R., and S.H.O. for technical help, discussion, critical comments, and support. This work was supported in part by Ministry of Science and Technology of China Grant 2014CB910100 (to X. Wang and J. Y.); National Natural Science Foundation of China Grants 81171899 and 81372230 (to X. Wang), 81422045 and 21272195 (to X. D.), and 81322018 (to J. H.); National Institutes of Health Grants AI048125 (to H.C.), T32 CA070083 (to J.W.L.), U01 CA105423 (to S.H.O.), and R01CA172152 and R01CA113794 and a U01NCI Mouse Models of Cancer Consortium award (to C.W.M.R.); a gift from The LeRoy Schecter Research Foundation (to H.C.); the Benacerraf Fellowship and the Claudia Adams Barr Program for Innovative Cancer Research (J.W.L.); Shanxi Scholarship Council of China Grant 2012-089 and International Cooperation Project of Shan Xi Science and Technology Department Grant 2012081049 (to L.Y.Z.); and Tianjin Natural Science Foundation Grant 12JCYBJC17200 (to L.Z.). S.H.O. is a Howard Hughes Medical Institute investigator. H. X. was a Leukemia and Lymphoma Society fellow. NR 40 TC 9 Z9 9 U1 7 U2 15 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 29 PY 2015 VL 112 IS 52 BP 15988 EP 15993 DI 10.1073/pnas.1521740112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ6TU UT WOS:000367234700067 PM 26668377 ER PT J AU Bansback, N Keystone, E O'Dell, J Phibbs, CS Hannagan, K Brophy, M Anis, A AF Bansback, Nick Keystone, Edward O'Dell, James Phibbs, Ciaran S. Hannagan, Keri Brophy, Mary Anis, Aslam TI Making smart investment decisions in clinical research SO TRIALS LA English DT Editorial Material DE Rheumatoid arthritis; Randomized trials; Economics ID MODIFYING ANTIRHEUMATIC DRUGS; RHEUMATOID-ARTHRITIS; BIOLOGIC AGENTS; 3 MEDICATIONS; METHOTREXATE; TRIAL; COMBINATION; HYDROXYCHLOROQUINE; SULFASALAZINE; ETANERCEPT AB A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100's of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and research funders to make smarter investments in clinical research to save potential future costs. C1 [Bansback, Nick; Anis, Aslam] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada. [Bansback, Nick; Anis, Aslam] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada. [Bansback, Nick; Anis, Aslam] Arthrit Res Ctr Canada, Vancouver, BC, Canada. [Keystone, Edward] Univ Toronto, Toronto, ON, Canada. [Keystone, Edward] Mt Sinai Hosp, Rebecca MacDonald Ctr Arthrit & Autoimmune Dis, Toronto, ON M5G 1X5, Canada. [O'Dell, James] Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [O'Dell, James] Univ Nebraska Med Ctr, Omaha, NE USA. [Phibbs, Ciaran S.] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA. [Phibbs, Ciaran S.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. [Phibbs, Ciaran S.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA USA. [Phibbs, Ciaran S.] Stanford Univ, Sch Med, Ctr Primary Care Outcomes Res, Stanford, CA USA. [Hannagan, Keri; Brophy, Mary] Coordinating Ctr, VA Cooperat Studies Program, Boston, MA USA. [Brophy, Mary] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Bansback, N (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada. EM nick.bansback@ubc.ca OI Bansback, Nick/0000-0002-1510-3462 FU Canadian Institutes of Health Research NR 15 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD DEC 29 PY 2015 VL 16 AR 590 DI 10.1186/s13063-015-1123-1 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CZ6NC UT WOS:000367217000001 PM 26712327 ER PT J AU Ye, HY Tanenbaum, LM Na, YJ Mantzavinou, A Fulci, G del Carmen, MG Birrer, MJ Cima, MJ AF Ye, Hongye Tanenbaum, Laura M. Na, Young Jeong Mantzavinou, Aikaterini Fulci, Giulia del Carmen, Marcela G. Birrer, Michael J. Cima, Michael J. TI Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models SO JOURNAL OF CONTROLLED RELEASE LA English DT Article DE Drug delivery; Intraperitoneal; Continuous; Cisplatin; Ovarian cancer ID GYNECOLOGIC-ONCOLOGY-GROUP; STAGE-III OVARIAN; THERAPEUTIC-EFFICACY; CHEMOTHERAPY; PACLITAXEL; CYCLOPHOSPHAMIDE; PHARMACOKINETICS; COMPLICATIONS; CARBOPLATIN; DOCETAXEL AB Intraperitoneal (IP) chemotherapy for ovarian cancer treatment prolongs overall survival by 16 months compared to intravenous chemotherapy but is not widely practiced due to catheter-related complications and complexity of administration. An implantable, nonresorbable IP microdevice was used to release chemotherapeutic agent at a constant rate of approximately 1.3 mu/h in vitro and 1.0 mu g/h in vivo. Studies conducted in two orthotopic murine models bearing human xenografts (SKOV3 and UCI101) demonstrate that continuous dosing reduces tumor burden to the same extent as weekly IP bolus drug injections. Treatment-induced toxicity was quantified via body weight loss and complete blood count. The microdevice resulted in significantly less toxicity than IP bolus injections, despite administration of higher cumulative doses (total area under the concentration-time curve of 3049 ng day/mLwith the microdevice vs. 2118 ng-day/mL with IP bolus injections). This preclinical study supports the concept that reduced toxicity with similar efficacy outcomes can be achieved by continuous dosing in ovarian cancer patients currently treated with IP therapy. (C) 2015 Elsevier B.V. All rights reserved. C1 [Ye, Hongye; Tanenbaum, Laura M.; Mantzavinou, Aikaterini] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Ye, Hongye; Tanenbaum, Laura M.; Cima, Michael J.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Na, Young Jeong; Fulci, Giulia; Birrer, Michael J.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA. [del Carmen, Marcela G.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Birrer, Michael J.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Birrer, Michael J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Cima, Michael J.] MIT, Dept Mat Sci, Cambridge, MA 02139 USA. RP Cima, MJ (reprint author), MIT, Koch Inst Integrat Canc Res, 500 Main St,Bldg 76 Room 653, Cambridge, MA 02139 USA. EM mjcima@mit.edu FU Koch Institute Bridge Project; MIT Deshpande Center; Agency of Science, Technology and Research (Singapore); National Science Foundation (USA); Ludwig Center for Molecular Oncology Fund (USA) FX The research presented in this manuscript was funded by the Koch Institute Bridge Project and the MIT Deshpande Center. H.Y. received the National Science Scholarship from the Agency of Science, Technology and Research (Singapore). L.M.T. received the Graduate Research Fellowship from the National Science Foundation (USA). A.M. received the Ludwig Center for Molecular Oncology Graduate Fellowship from the Ludwig Center for Molecular Oncology Fund (USA). Funding organizations had no direct role in the development or submission of this manuscript. NR 32 TC 1 Z9 1 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-3659 EI 1873-4995 J9 J CONTROL RELEASE JI J. Control. Release PD DEC 28 PY 2015 VL 220 BP 358 EP 367 DI 10.1016/j.jconrel.2015.11.001 PN A PG 10 WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy SC Chemistry; Pharmacology & Pharmacy GA CY0TN UT WOS:000366119100039 PM 26548976 ER PT J AU Londino, JD Gulick, D Isenberg, JS Mallampalli, RK AF Londino, James D. Gulick, Dexter Isenberg, Jeffrey S. Mallampalli, Rama K. TI Cleavage of Signal Regulatory Protein alpha (SIRP alpha) Enhances Inflammatory Signaling SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMYLOID PRECURSOR PROTEIN; C-TERMINAL FRAGMENT; NF-KAPPA-B; CELL-MIGRATION; SECRETASE; ACTIVATION; CD47; SHPS-1; ADAM10; GROWTH AB Signal regulatory protein alpha (SIRP alpha) is a membrane glycoprotein immunoreceptor abundant in cells of monocyte lineage. SIRP alpha ligation by a broadly expressed transmembrane protein, CD47, results in phosphorylation of the cytoplasmic immunoreceptor tyrosine-based inhibitory motifs, resulting in the inhibition of NF-kappa B signaling in macrophages. Here we observed that proteolysis of SIRP alpha during inflammation is regulated by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10), resulting in the generation of a membrane-associated cleavage fragment in both THP-1 monocytes and human lung epithelia. We mapped a charge-dependent putative cleavage site near the membrane-proximal domain necessary for ADAM10-mediated cleavage. In addition, a secondary proteolytic cleavage within the membrane-associated SIRP alpha fragment by gamma-secretase was identified. Ectopic expression of a SIRP alpha mutant plasmid encoding a proteolytically resistant form in HeLa cells inhibited activation of the NF-kappa B pathway and suppressed STAT1 phosphorylation in response to TNF alpha to a greater extent than expression of wild-type SIRP alpha. Conversely, overexpression of plasmids encoding the proteolytically cleaved SIRP alpha fragments in cells resulted in enhanced STAT-1 and NF-kappa B pathway activation. Thus, the data suggest that combinatorial actions of ADAM10 and gamma-secretase on SIRP alpha cleavage promote inflammatory signaling. C1 [Londino, James D.; Gulick, Dexter; Isenberg, Jeffrey S.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol & Bioengn, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15213 USA. [Isenberg, Jeffrey S.] Univ Pittsburgh, Sch Med, Div Pulm,Allergy & Crit Care Med, Vasc Med Inst,Starzl Transplantat Inst,Dept Pharm, Pittsburgh, PA 15213 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Pulm Allergy & Crit Care Med, Dept Med, NW628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu RI Regan, Clinton/E-6250-2012 FU United States Department of Veterans Affairs Merit Review Award; National Institutes of Health [HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, HL114453, T32 5T32HL007563-28] FX This work was partially supported by a United States Department of Veterans Affairs Merit Review Award and partially by National Institutes of Health R01 Grants HL096376, HL097376, HL098174, HL081784, and 1UH2HL123502 and P01 Grant HL114453 (to R. K. M.) and Grant T32 5T32HL007563-28 (to J. D. L.). The authors declare no conflict of interests. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 42 TC 3 Z9 3 U1 1 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 25 PY 2015 VL 290 IS 52 BP 31113 EP 31125 DI 10.1074/jbc.M115.682914 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CZ6GK UT WOS:000367199000039 PM 26534964 ER PT J AU Liu, YB Tewari, A Salameh, J Arystarkhova, E Hampton, TG Brashear, A Ozelius, LJ Khodakhah, K Sweadner, KJ AF Liu, Yi Bessie Tewari, Ambika Salameh, Johnny Arystarkhova, Elena Hampton, Thomas G. Brashear, Allison Ozelius, Laurie J. Khodakhah, Kamran Sweadner, Kathleen J. TI A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin beta 1 subunit, Lamb1 SO ELIFE LA English DT Article ID EXTRACELLULAR-MATRIX; SYNAPTIC PLASTICITY; INTEGRIN BINDING; BASAL GANGLIA; ANIMAL-MODELS; H-REFLEX; MICE; INHIBITION; RECEPTORS; CHAINS AB A new mutant mouse (lamb1t) exhibits intermittent dystonic hindlimb movements and postures when awake, and hyperextension when asleep. Experiments showed co-contraction of opposing muscle groups, and indicated that symptoms depended on the interaction of brain and spinal cord. SNP mapping and exome sequencing identified the dominant causative mutation in the Lamb1 gene. Laminins are extracellular matrix proteins, widely expressed but also known to be important in synapse structure and plasticity. In accordance, awake recording in the cerebellum detected abnormal output from a circuit of two Lamb1-expressing neurons, Purkinje cells and their deep cerebellar nucleus targets, during abnormal postures. We propose that dystonia-like symptoms result from lapses in descending inhibition, exposing excess activity in intrinsic spinal circuits that coordinate muscles. The mouse is a new model for testing how dysfunction in the CNS causes specific abnormal movements and postures. C1 [Liu, Yi Bessie; Arystarkhova, Elena; Sweadner, Kathleen J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA. [Tewari, Ambika; Khodakhah, Kamran] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, New York, NY USA. [Salameh, Johnny] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA. [Hampton, Thomas G.] Mouse Specif Inc, Neurosci Discovery Core, Framingham, MA USA. [Brashear, Allison] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27103 USA. [Ozelius, Laurie J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. RP Sweadner, KJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA. EM sweadner@helix.mgh.harvard.edu FU National Institute of Neurological Disorders and Stroke [NS058949, NS058949S1, NS050808, NS079750, NS081558]; Congressionally Directed Medical Research Programs [PR100747] FX National Institute of Neurological Disorders and Stroke NS058949 to Allison Brashear, Laurie J Ozelius, Kathleen J Sweadner.; National Institute of Neurological Disorders and Stroke NS058949S1 to Allison Brashear, Laurie J Ozelius, Kamran Khodakhah, Kathleen J Sweadner.; National Institute of Neurological Disorders and Stroke NS050808 to Kamran Khodakhah.; National Institute of Neurological Disorders and Stroke NS079750 to Kamran Khodakhah.; Congressionally Directed Medical Research Programs PR100747 to Kathleen J Sweadner.; National Institute of Neurological Disorders and Stroke NS081558 to Kathleen J Sweadner. NR 72 TC 4 Z9 4 U1 1 U2 2 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD DEC 24 PY 2015 VL 4 AR e11102 DI 10.7554/eLife.11102 PG 25 WC Biology SC Life Sciences & Biomedicine - Other Topics GA DJ1HT UT WOS:000373954600001 ER PT J AU Anderson, H Patch, TC Reddy, PNG Hagedorn, EJ Kim, PG Soltis, KA Chen, MJ Tamplin, OJ Frye, M MacLean, GA Hubner, K Bauer, DE Kanki, JP Vogin, G Huston, NC Nguyen, M Fujiwara, Y Paw, BH Vestweber, D Zon, LI Orkin, SH Daley, GQ Shah, DI AF Anderson, Heidi Patch, Taylor C. Reddy, Pavankumar N. G. Hagedorn, Elliott J. Kim, Peter G. Soltis, Kathleen A. Chen, Michael J. Tamplin, Owen J. Frye, Maike MacLean, Glenn A. Huebner, Kathleen Bauer, Daniel E. Kanki, John P. Vogin, Guillaume Huston, Nicholas C. Minh Nguyen Fujiwara, Yuko Paw, Barry H. Vestweber, Dietmar Zon, Leonard I. Orkin, Stuart H. Daley, George Q. Shah, Dhvanit I. TI Hematopoietic stem cells develop in the absence of endothelial cadherin 5 expression SO BLOOD LA English DT Article ID VE-CADHERIN; MAMMALIAN-CELLS; FETAL LIVER; ZEBRAFISH; GENE; MUTATION; RUNX1; DIFFERENTIATION; IDENTIFICATION; REQUIREMENTS AB Rare endothelial cells in the aorta-gonad-mesonephros (AGM) transition into hematopoietic stem cells (HSCs) during embryonic development. Lineage tracing experiments indicate that HSCs emerge from cadherin 5 (Cdh5; vascular endothelial-cadherin)(+) endothelial precursors, and isolated populations of Cdh5(+) cells from mouse embryos and embryonic stem cells can be differentiated into hematopoietic cells. Cdh5 has also been widely implicated as a marker of AGM-derived hemogenic endothelial cells. Because Cdh5(-/-) mice embryos die before the first HSCs emerge, it is unknown whether Cdh5 has a direct role in HSC emergence. Our previous genetic screen yielded malbec (mlb(bw306)), a zebrafish mutant for cdh5, with normal embryonic and definitive blood. Using time-lapse confocal imaging, parabiotic surgical pairing of zebrafish embryos, and blastula transplantation assays, we show that HSCs emerge, migrate, engraft, and differentiate in the absence of cdh5 expression. By tracing Cdh5(-/-) green fluorescent protein (GFP)(+/+) cells in chimeric mice, we demonstrated that Cdh5(-/-) GFP(+/+) HSCs emerging from embryonic day 10.5 and 11.5 (E10.5 and E11.5) AGM or derived from E13.5 fetal liver not only differentiate into hematopoietic colonies but also engraft and reconstitute multilineage adult blood. We also developed a conditional mouse Cdh5 knockout (Cdh5(flox/flox) : Scl-Cre-ERT) and demonstrated that multipotent hematopoietic colonies form despite the absence of Cdh5. These data establish that Cdh5, a marker of hemogenic endothelium in the AGM, is dispensable for the transition of hemogenic endothelium to HSCs. C1 [Anderson, Heidi; Patch, Taylor C.; Soltis, Kathleen A.; Huebner, Kathleen; Vogin, Guillaume; Huston, Nicholas C.; Paw, Barry H.; Shah, Dhvanit I.] Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA. [Anderson, Heidi; Reddy, Pavankumar N. G.; Hagedorn, Elliott J.; Chen, Michael J.; Tamplin, Owen J.; MacLean, Glenn A.; Bauer, Daniel E.; Fujiwara, Yuko; Paw, Barry H.; Zon, Leonard I.; Orkin, Stuart H.; Daley, George Q.; Shah, Dhvanit I.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Reddy, Pavankumar N. G.; Hagedorn, Elliott J.; Kim, Peter G.; Chen, Michael J.; Tamplin, Owen J.; MacLean, Glenn A.; Bauer, Daniel E.; Minh Nguyen; Fujiwara, Yuko; Paw, Barry H.; Zon, Leonard I.; Orkin, Stuart H.; Daley, George Q.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Frye, Maike; Vestweber, Dietmar] Max Planck Inst Mol Biomed, D-48149 Munster, Germany. [Bauer, Daniel E.; Zon, Leonard I.; Orkin, Stuart H.; Daley, George Q.; Shah, Dhvanit I.] Harvard Stem Cell Inst, Cambridge, MA USA. [Kanki, John P.; Orkin, Stuart H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Zon, Leonard I.; Orkin, Stuart H.; Daley, George Q.] Howard Hughes Med Inst, Boston, MA 02115 USA. RP Shah, DI (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Harvard Stem Cell Inst,Div Hematol, Boston, MA 02115 USA. EM dshah@research.bwh.harvard.edu OI Reddy, Pavankumar N.G./0000-0001-5980-110X; Vestweber, Dietmar/0000-0002-3517-732X FU American Society of Hematology; Cooley's Anemia Foundation; National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [K01DK085217, R03DK100672]; Sigrid Juselius Foundation; Helen Hay Whitney Foundation; Alex's Lemonade Stand Foundation; NIH, NIDDK [K08DK093705, P30DK049216]; NIH, National Heart, Lung, and Blood Institute [P01HL032262]; Deutsche Forschungsgemeinschaft; Max Planck Society; NIH National Cancer Institute [R01CA103846]; National Heart, Lung, and Blood Institute [P01HL032262, R01HL04880, R01HL032259]; NIH National Heart, Lung and Blood Institute (Progenitor Cell Biology Consortium) [UO1-HL100001]; NIDDK [R24DK092760]; Alex's Lemonade Foundation; Boston Children's Hospital Stem Cell Program FX D.I.S. is supported by grants from the American Society of Hematology, the Cooley's Anemia Foundation, and the National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grants (K01DK085217 and R03DK100672). H.A. is supported by a fellowship from the Sigrid Juselius Foundation. E.J.H. is supported by a fellowship from the Helen Hay Whitney Foundation. P.N.G.R. is supported by a fellowship from the American Society of Hematology. O.J.T. is supported by a fellowship from the American Society of Hematology. G.A.M. is supported by a fellowship from the Alex's Lemonade Stand Foundation. D.E.B. is supported by a grant from the NIH, NIDDK (K08DK093705). B.H.P. is supported by a grant from the NIH, National Heart, Lung, and Blood Institute (P01HL032262). M.F. and D.V. are supported by grants from the Deutsche Forschungsgemeinschaft and the Max Planck Society. L.I.Z. is supported by grants from the NIH National Cancer Institute (R01CA103846) and National Heart, Lung, and Blood Institute (P01HL032262 and R01HL04880). S.H.O. is supported by grants from the NIH NIDDK (P30DK049216) and National Heart, Lung, and Blood Institute (R01HL032259 and P01HL032262). G.Q.D. is supported by grants from the NIH National Heart, Lung and Blood Institute (Progenitor Cell Biology Consortium UO1-HL100001) and NIDDK (R24DK092760), the Alex's Lemonade Foundation, and the Boston Children's Hospital Stem Cell Program. NR 46 TC 4 Z9 4 U1 2 U2 7 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 24 PY 2015 VL 126 IS 26 BP 2811 EP 2820 DI 10.1182/blood-2015-07-659276 PG 10 WC Hematology SC Hematology GA DB3RV UT WOS:000368430000014 PM 26385351 ER PT J AU Vervliet, B Indekeu, E AF Vervliet, Bram Indekeu, Ellen TI Low-Cost Avoidance Behaviors are Resistant to Fear Extinction in Humans SO FRONTIERS IN BEHAVIORAL NEUROSCIENCE LA English DT Article DE fear; extinction; avoidance; response prevention; exposure ID SAFETY BEHAVIOR; MODEL; OUTCOMES; ANXIETY; CONTEXT; RELAPSE; MEMORY AB Elevated levels of fear and avoidance are core symptoms across the anxiety disorders. It has long been known that fear serves to motivate avoidance. Consequently, fear extinction has been the primary focus in pre-clinical anxiety research for decades, under the implicit assumption that removing the motivator of avoidance (fear) would automatically mitigate the avoidance behaviors as well. Although this assumption has intuitive appeal, it has received little scientific scrutiny. The scarce evidence from animal studies is mixed, while the assumption remains untested in humans. The current study applied an avoidance conditioning protocol in humans to investigate the effects of fear extinction on the persistence of low-cost avoidance. Online danger-safety ratings and skin conductance responses documented the dynamics of conditioned fear across avoidance and extinction phases. Anxiety- and avoidance-related questionnaires explored individual differences in rates of avoidance. Participants first learned to click a button during a predictive danger signal, in order to cancel an upcoming aversive electrical shock (avoidance conditioning). Next, fear extinction was induced by presenting the signal in the absence of shocks while button-clicks were prevented (by removing the button in Experiment 1, or by instructing not to click the button in Experiment 2). Most importantly, post extinction availability of the button caused a significant return of avoidant button-clicks. In addition, trait-anxiety levels correlated positively with rates of avoidance during a predictive safety signal, and with the rate of pre- to post-extinction decrease during this signal. Fear measures gradually decreased during avoidance conditioning, as participants learned that button clicks effectively canceled the shock. Preventing button-clicks elicited a sharp increase in fear, which subsequently extinguished. Fear remained low during avoidance testing, but danger-safety ratings increased again when button-clicks were subsequently prevented. Together, these results show that low-cost avoidance behaviors can persist following fear extinction and induce increased threat appraisal. On the other hand, fear extinction did reduce augmented rates of unnecessary avoidance during safety in trait-anxious individuals, and instruction-based response prevention was more effective than removal of response cues. More research is needed to characterize the conditions under which fear extinction might mitigate avoidance. C1 [Vervliet, Bram] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Vervliet, Bram] Harvard Univ, Sch Med, Boston, MA USA. [Vervliet, Bram] Univ Leuven KU Leuven, Ctr Excellence Generalizat Hlth & Psychopathol, Leuven, Belgium. [Indekeu, Ellen] Univ Leuven KU Leuven, Dept Psychol, Leuven, Belgium. RP Vervliet, B (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM bram.vervliet@ppw.kuleuven.be FU European Community [PIOF-GA-2013-627743]; University of Leuven-KU Leuven [PF/10/005] FX This research was supported by a Marie Curie International Outgoing Fellowship within the 7th European Community Framework Programme (PIOF-GA-2013-627743) and by a Center for Excellence grant from the University of Leuven-KU Leuven (PF/10/005). NR 27 TC 3 Z9 3 U1 1 U2 10 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5153 J9 FRONT BEHAV NEUROSCI JI Front. Behav. Neurosci. PD DEC 24 PY 2015 VL 9 AR 351 DI 10.3389/fnbeh.2015.00351 PG 12 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA CZ8CK UT WOS:000367327500001 PM 26733837 ER PT J AU Khullar, D Jha, AK Jena, AB AF Khullar, Dhruv Jha, Ashish K. Jena, Anupam B. TI Reducing Diagnostic Errors - Why Now? SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Khullar, Dhruv; Jena, Anupam B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Jha, Ashish K.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA. [Jha, Ashish K.] Vet Affairs Boston Healthcare Syst, Boston, MA USA. [Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA. RP Khullar, D (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. FU NIH HHS [DP5 OD017897] NR 5 TC 10 Z9 10 U1 1 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 24 PY 2015 VL 373 IS 26 BP 2491 EP 2493 DI 10.1056/NEJMp1508044 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CZ7SG UT WOS:000367299700003 PM 26397948 ER PT J AU Singh, H Graber, ML AF Singh, Hardeep Graber, Mark L. TI Improving Diagnosis in Health Care - The Next Imperative for Patient Safety SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID ERRORS C1 [Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Graber, Mark L.] RTI Int, Raleigh, NC USA. [Graber, Mark L.] Soc Improve Diag Med, New York, NY USA. [Graber, Mark L.] SUNY Stony Brook, Stony Brook, NY 11794 USA. RP Singh, H (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Houston, TX 77030 USA. NR 5 TC 19 Z9 19 U1 1 U2 8 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 24 PY 2015 VL 373 IS 26 BP 2493 EP 2495 DI 10.1056/NEJMp1512241 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CZ7SG UT WOS:000367299700004 PM 26559457 ER PT J AU Sitbon, O Channick, R Chin, KM Frey, A Gaine, S Galie, N Ghofrani, HA Hoeper, MM Lang, IM Preiss, R Rubin, LJ Di Scala, L Tapson, V Adzerikho, I Liu, JM Moiseeva, O Zeng, XF Simonneau, G McLaughlin, VV AF Sitbon, Olivier Channick, Richard Chin, Kelly M. Frey, Aline Gaine, Sean Galie, Nazzareno Ghofrani, Hossein-Ardeschir Hoeper, Marius M. Lang, Irene M. Preiss, Ralph Rubin, Lewis J. Di Scala, Lilla Tapson, Victor Adzerikho, Igor Liu, Jinming Moiseeva, Olga Zeng, Xiaofeng Simonneau, Gerald McLaughlin, Vallerie V. CA GRIPHON Investigators TI Selexipag for the Treatment of Pulmonary Arterial Hypertension SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID PROSTACYCLIN RECEPTOR AGONIST; RANDOMIZED CONTROLLED-TRIAL; 5 INHIBITOR THERAPY; ORAL TREPROSTINIL; REVEAL REGISTRY; CLINICAL-TRIAL; DIAGNOSIS; ANTAGONIST; MANAGEMENT; SURVIVAL AB BACKGROUND In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension. METHODS In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patients with pulmonary arterial hypertension to receive placebo or selexipag in individualized doses (maximum dose, 1600 mu g twice daily). Patients were eligible for enrollment if they were not receiving treatment for pulmonary arterial hypertension or if they were receiving a stable dose of an endothelin-receptor antagonist, a phosphodiesterase type 5 inhibitor, or both. The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of the treatment period (defined for each patient as 7 days after the date of the last intake of selexipag or placebo). RESULTS A primary end-point event occurred in 397 patients -41.6% of those in the placebo group and 27.0% of those in the selexipag group (hazard ratio in the selexipag group as compared with the placebo group, 0.60; 99% confidence interval, 0.46 to 0.78; P< 0.001). Disease progression and hospitalization accounted for 81.9% of the events. The effect of selexipag with respect to the primary end point was similar in the subgroup of patients who were not receiving treatment for the disease at baseline and in the subgroup of patients who were already receiving treatment at baseline (including those who were receiving a combination of two therapies). By the end of the study, 105 patients in the placebo group and 100 patients in the selexipag group had died from any cause. Overall, 7.1% of patients in the placebo group and 14.3% of patients in the selexipag group discontinued their assigned regimen prematurely because of adverse events. The most common adverse events in the selexipag group were consistent with the known side effects of prostacyclin, including headache, diarrhea, nausea, and jaw pain. CONCLUSIONS Among patients with pulmonary arterial hypertension, the risk of the primary composite end point of death or a complication related to pulmonary arterial hypertension was significantly lower with selexipag than with placebo. There was no significant difference in mortality between the two study groups. (Funded by Actelion Pharmaceuticals; GRIPHON ClinicalTrials.gov number, NCT01106014.) C1 [Sitbon, Olivier; Simonneau, Gerald] Univ Paris Saclay, Univ Paris Sud, INSERM, Unite Mixte Rech Sante 999,Hop Bicetre,AP HP, Le Kremlin Bicetre, France. [Channick, Richard] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chin, Kelly M.] UT Southwestern Med Ctr, Dallas, TX USA. [Frey, Aline; Preiss, Ralph; Di Scala, Lilla] Actel Pharmaceut, Allschwil, Switzerland. [Gaine, Sean] Mater Misericordiae Univ Hosp, Natl Pulm Hypertens Unit, Dublin, Ireland. [Galie, Nazzareno] Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy. [Ghofrani, Hossein-Ardeschir] Univ Giessen, D-35390 Giessen, Germany. [Ghofrani, Hossein-Ardeschir] German Ctr Lung Res, Marburg Lung Ctr, Giessen, Germany. [Hoeper, Marius M.] Hannover Med Sch, Dept Resp Med, Hannover, Germany. [Hoeper, Marius M.] German Ctr Lung Res, Hannover, Germany. [Ghofrani, Hossein-Ardeschir] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2AZ, England. [Lang, Irene M.] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Allgemeines Krankenhaus, Vienna, Austria. [Rubin, Lewis J.] Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA. [Tapson, Victor] Cedars Sinai Med Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90048 USA. [Adzerikho, Igor] Minsk Reg Clin Hosp, Minsk, Byelarus. [Liu, Jinming] Shanghai Pulm Hosp, Dept Pulm Circulat, Shanghai, Peoples R China. [Zeng, Xiaofeng] Beijing Union Med Coll Hosp, Dept Rheumatol, Beijing, Peoples R China. [Moiseeva, Olga] Fed Almazov North West Med Res Ctr, St Petersburg, Russia. [McLaughlin, Vallerie V.] Univ Michigan Hlth Syst, Div Cardiovasc Med, Dept Internal Med, Ann Arbor, MI USA. RP Sitbon, O (reprint author), CHU Bicetre, Serv Pneumol & Soins Intensifs, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France. EM olivier.sitbon@bct.aphp.fr RI Chazova, Irina/B-8688-2017; OI Chazova, Irina/0000-0002-9822-4357; Soderberg, Stefan/0000-0001-9225-1306; Gaine, Sean/0000-0002-5941-684X; Schulman, Sam/0000-0002-8512-9043 FU Actelion Pharmaceuticals; Actelion; GlaxoSmithKline; Bayer; Pfizer; United Therapeutics; Gilead Sciences; GeNO; Daiichi Sankyo; Novartis; Daiichi-Sankyo; Merck; Arena; Lung Biotechnology; Janssen; Eli Lilly; Ikaria FX Supported by Actelion Pharmaceuticals.; Dr. Sitbon reports receiving fees for serving on a steering committee from Actelion, fees for writing assistance from Actelion and GlaxoSmithKline, consulting and lecture fees from Actelion, Bayer, GlaxoSmithKline, Pfizer, and United Therapeutics, and fees for serving on advisory boards and grant support from Actelion, Bayer, GlaxoSmithKline, and Pfizer; Dr. Channick, receiving fees for serving on advisory boards from Bayer and Actelion, consulting fees from Bayer, and grant support from United Therapeutics and Actelion; Dr. Chin, receiving consulting fees from Actelion, Bayer, and Gilead Sciences and grant support from Actelion, Gilead Sciences, and GeNO; Dr. Frey, Dr. Preiss, and Dr. Di Scalla, being employees of Actelion; Dr. Gaine, receiving fees for serving on advisory boards from Bayer, Actelion, Novartis, Pfizer, and Daiichi Sankyo, fees for serving on data and safety monitoring boards from GlaxoSmithKline, United Therapeutics, and Novartis, fees for serving on a steering committee from Actelion, lecture fees from Bayer, GlaxoSmithKline, United Therapeutics, and Actelion, and travel support from Bayer, GlaxoSmithKline, Actelion, Novartis, and Daiichi-Sankyo; Dr. Galie, receiving personal fees and grant support from Actelion, Bayer, GlaxoSmithKline, and Pfizer; Dr. Ghofrani, receiving fees for serving on steering committees from Bayer, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, and Pfizer, consulting fees from Actelion, Bayer, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, and Pfizer, lecture fees from Actelion, Bayer, GlaxoSmithKline, Novartis, and Pfizer, and grant support from Actelion, Bayer, Novartis, and Pfizer; Dr. Hoeper, receiving consulting and lecture fees from Pfizer, Bayer, and GlaxoSmithKline; Dr. Lang, receiving fees for serving on a data and safety monitoring board from Novartis, lecture fees from Actelion, Bayer, GlaxoSmithKline, and United Therapeutics, and grant support from Actelion, Bayer, and United Therapeutics; Dr. Rubin, receiving fees for serving on an advisory board from United Therapeutics and consulting fees and travel support from Actelion, Arena, GeNO, Lung Biotechnology, Gilead Sciences, and United Therapeutics; Dr. Tapson, receiving fees for serving on steering committees from Actelion, Bayer, and United Therapeutics, consulting fees from Actelion, Gilead Sciences, Bayer, Daiichi Sankyo, and Janssen, lecture fees from Gilead Sciences and Janssen, and grant support from Actelion, Bayer, United Therapeutics, and Janssen; Dr. Moiseeva, receiving lecture fees and grant support from Actelion and Bayer; Dr. Zeng, receiving grant and travel support and study drugs and equipment from Actelion; Dr. Simonneau, receiving consulting fees, lecture fees, and travel support from Actelion, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, and Pfizer, and grant support from Actelion and Bayer; and Dr. McLaughlin, receiving fees for serving on advisory boards and steering committees, consulting fees, and travel support from Bayer, Gilead Sciences, United Therapeutics, Actelion, and Ikaria, and grant support from Bayer, Actelion, Ikaria, and Novartis. No other potential conflict of interest relevant to this article was reported. NR 25 TC 59 Z9 63 U1 7 U2 30 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 24 PY 2015 VL 373 IS 26 BP 2522 EP 2533 DI 10.1056/NEJMoa1503184 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA CZ7SG UT WOS:000367299700008 PM 26699168 ER PT J AU Blinderman, CD Billings, JA AF Blinderman, Craig D. Billings, J. Andrew TI Comfort Care for Patients Dying in the Hospital SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Review ID OBSTRUCTIVE PULMONARY-DISEASE; OPIOID-INDUCED CONSTIPATION; OF-LIFE DISCUSSIONS; PALLIATIVE CARE; ADVANCED CANCER; DOUBLE-BLIND; CONTROLLED-TRIAL; RANDOMIZED-TRIAL; ADVANCED ILLNESS; CHRONIC COUGH C1 [Blinderman, Craig D.] Columbia Univ, Med Ctr, Adult Palliat Care Serv, Dept Med, New York, NY 10032 USA. [Billings, J. Andrew] Harvard Univ, Sch Med, Div Palliat Care, Massachusetts Gen Hosp,Dept Med, Boston, MA 02115 USA. [Billings, J. Andrew] Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA 02115 USA. RP Blinderman, CD (reprint author), Columbia Univ, Med Ctr, Adult Palliat Care Serv, Dept Med, 601 W 168th St,Suite 38, New York, NY 10032 USA. EM cdb21@columbis.edu NR 86 TC 15 Z9 17 U1 3 U2 10 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 24 PY 2015 VL 373 IS 26 BP 2549 EP 2561 DI 10.1056/NEJMra1411746 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA CZ7SG UT WOS:000367299700010 PM 26699170 ER PT J AU Shtasel, DL Freudenreich, O Baggett, TP AF Shtasel, Derri L. Freudenreich, Oliver Baggett, Travis P. TI Case 40-2015: A 40-Year-Old Homeless Woman with Headache, Hypertension, and Psychosis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID SCHIZOPHRENIA C1 [Shtasel, Derri L.; Freudenreich, Oliver] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Baggett, Travis P.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Shtasel, Derri L.; Freudenreich, Oliver] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Baggett, Travis P.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. RP Shtasel, DL (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. NR 13 TC 1 Z9 1 U1 0 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 24 PY 2015 VL 373 IS 26 BP 2563 EP 2570 DI 10.1056/NEJMcpc1405204 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CZ7SG UT WOS:000367299700012 PM 26699172 ER PT J AU McClay, JL Shabalin, AA Dozmorov, MG Adkins, DE Kumar, G Nerella, S Clark, SL Bergen, SE Hultman, CM Magnusson, PKE Sullivan, PF Aberg, KA van den Oord, EJCG AF McClay, Joseph L. Shabalin, Andrey A. Dozmorov, Mikhail G. Adkins, Daniel E. Kumar, Gaurav Nerella, Srilaxmi Clark, Shaunna L. Bergen, Sarah E. Hultman, Christina M. Magnusson, Patrik K. E. Sullivan, Patrick F. Aberg, Karolina A. van den Oord, Edwin J. C. G. CA Swedish Schizophrenia Consortium TI High density methylation QTL analysis in human blood via next-generation sequencing of the methylated genomic DNA fraction SO GENOME BIOLOGY LA English DT Article DE DNA methylation; next-generation sequencing; GWAS; single nucleotide polymorphism; quantitative trait loci; chromatin states ID METHYLOME-WIDE ASSOCIATION; ALLELE-SPECIFIC METHYLATION; HUMAN-DISEASES; ENCODE DATA; CPG ISLAND; RISK LOCI; SCHIZOPHRENIA; TRANSCRIPTION; COVERAGE; SNPS AB Background: Genetic influence on DNA methylation is potentially an important mechanism affecting individual differences in humans. We use next-generation sequencing to assay blood DNA methylation at approximately 4.5 million loci, each comprising 2.9 CpGs on average, in 697 normal subjects. Methylation measures at each locus are tested for association with approximately 4.5 million single nucleotide polymorphisms (SNPs) to exhaustively screen for methylation quantitative trait loci (meQTLs). Results: Using stringent false discovery rate control, 15 % of methylation sites show genetic influence. Most meQTLs are local, where the associated SNP and methylation site are in close genomic proximity. Distant meQTLs and those spanning different chromosomes are less common. Most local meQTLs encompass common SNPs that alter CpG sites (CpG-SNPs). Local meQTLs encompassing CpG-SNPs are enriched in regions of inactive chromatin in blood cells. In contrast, local meQTLs lacking CpG-SNPs are enriched in regions of active chromatin and transcription factor binding sites. Of 393 local meQTLs that overlap disease-associated regions from genome-wide studies, a high percentage encompass common CpG-SNPs. These meQTLs overlap active enhancers, differentiating them from CpG-SNP meQTLs in inactive chromatin. Conclusions: Genetic influence on the human blood methylome is common, involves several heterogeneous processes and is predominantly dependent on local sequence context at the meQTL site. Most meQTLs involve CpG-SNPs, while sequence-dependent effects on chromatin binding are also important in regions of active chromatin. An abundance of local meQTLs resulting from methylation of CpG-SNPs in inactive chromatin suggests that many meQTLs lack functional consequence. Integrating meQTL and Roadmap Epigenomics data could assist fine-mapping efforts. C1 [McClay, Joseph L.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA 23298 USA. [McClay, Joseph L.; Shabalin, Andrey A.; Adkins, Daniel E.; Kumar, Gaurav; Nerella, Srilaxmi; Clark, Shaunna L.; Aberg, Karolina A.; van den Oord, Edwin J. C. G.] Virginia Commonwealth Univ, Ctr Biomarker Res & Precis Med, Richmond, VA 23298 USA. [Dozmorov, Mikhail G.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA. [Bergen, Sarah E.; Hultman, Christina M.; Magnusson, Patrik K. E.; Sullivan, Patrick F.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Bergen, Sarah E.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Bergen, Sarah E.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Sullivan, Patrick F.] Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC USA. RP McClay, JL (reprint author), Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, 410 North 12th St, Richmond, VA 23298 USA. EM jlmcclay@vcu.edu; ashabalin@vcu.edu RI McClay, Joseph/C-9931-2009; Magnusson, Patrik/C-4458-2017 OI McClay, Joseph/0000-0002-3628-2447; FU National Institute of Mental Health [R01 MH097283]; NIMH [R01 MH077139]; Stanley Medical Research Institute; [K01 MH093731]; [K01 AA021266] FX This study was supported by the National Institute of Mental Health (grant R01 MH097283). The present study is part of a larger project entitled 'A Large-Scale Schizophrenia Association Study in Sweden' that is supported by grants from NIMH (R01 MH077139) and the Stanley Medical Research Institute. Institutions involved in this project are: University of North Carolina at Chapel Hill, Karolinska Institute, Icahn School of Medicine at Mount Sinai, Virginia Commonwealth University and Broad Institute of MIT and Harvard. Dr. Adkins was supported by grant K01 MH093731. Dr. Clark was supported by grant K01 AA021266. Library construction and next generation sequencing was performed by EdgeBio Gaithersburg, MD. Thanks to Lyon van den Oord for assistance with artwork. NR 64 TC 6 Z9 6 U1 4 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-6906 EI 1474-760X J9 GENOME BIOL JI Genome Biol. PD DEC 23 PY 2015 VL 16 AR 291 DI 10.1186/s13059-015-0842-7 PG 16 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA CZ8SE UT WOS:000367368600001 PM 26699738 ER PT J AU Sharma, A Hoover, DR Shi, QH Gustafson, D Plankey, MW Hershow, RC Tien, PC Golub, ET Anastos, K AF Sharma, Anjali Hoover, Donald R. Shi, Qiuhu Gustafson, Deborah Plankey, Michael W. Hershow, Ronald C. Tien, Phyllis C. Golub, Elizabeth T. Anastos, Kathryn TI Relationship between Body Mass Index and Mortality in HIV-Infected HAART Users in the Women's Interagency HIV Study SO PLOS ONE LA English DT Article ID STARTING ANTIRETROVIRAL THERAPY; ALL-CAUSE MORTALITY; IMMUNE CELL COUNTS; UNITED-STATES; DISEASE PROGRESSION; NUTRITIONAL-STATUS; PROSPECTIVE COHORT; BLACK ADULTS; OBESITY; IMPACT AB Background Early HIV studies suggested protective associations of overweight against mortality, yet data are lacking for the era of potent highly active antiretroviral therapy (HAART). We evaluated associations of pre-HAART initiation body mass index (BMI) with mortality among HAART-using women. Methods Prospective study of time to death after HAART initiation among continuous HAART users in the Women's Interagency HIV Study. Unadjusted Kaplan-Meier and adjusted proportional hazards survival models assessed time to AIDS and non-AIDS death by last measured pre-HAART BMI. Results Of 1428 continuous HAART users 39 (2.7%) were underweight, 521 (36.5%) normal weight, 441 (30.9%) overweight, and 427 (29.9%) obese at time of HAART initiation. A total of 322 deaths occurred during median follow-up of 10.4 years (IQR 5.9-14.6). Censoring at non-AIDS death, the highest rate of AIDS death was observed among underweight women (p = 0.0003 for all 4 categories). In multivariate models, women underweight prior to HAART died from AIDS more than twice as rapidly vs. normal weight women (aHR 2.04, 95% CI 1.03, 4.04); but being overweight or obese (vs. normal weight) was not independently associated with AIDS death. Cumulative incidence of non-AIDS death was similar across all pre-HAART BMI categories. Conclusions Among continuous HAART-using women, being overweight prior to initiation was not associated with lower risk of AIDS or non-AIDS death. Being underweight prior to HAART was associated with over double the rate of AIDS death in adjusted analyses. Although overweight and obesity may be associated with many adverse health conditions, neither was predictive of mortality among the HAART-using women. C1 [Sharma, Anjali; Anastos, Kathryn] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Shi, Qiuhu] New York Med Coll, Dept Epidemiol & Community Hlth, Valhalla, NY 10595 USA. [Gustafson, Deborah] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA. [Plankey, Michael W.] Georgetown Univ, Med Ctr, Dept Med, Div Infect Dis, Washington, DC 20007 USA. [Hershow, Ronald C.] Univ Illinois, Dept Epidemiol, Chicago, IL USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Golub, Elizabeth T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Sharma, A (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. EM anjali.sharma@einstein.yu.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI Grant) [UL1 RR024131]; National Institutes of Health [K23AR06199301] FX The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. This research was also supported by National Institutes of Health K23AR06199301 (AS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 1 Z9 1 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 23 PY 2015 VL 10 IS 12 AR e0143740 DI 10.1371/journal.pone.0143740 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ4SI UT WOS:000367092600009 PM 26699870 ER PT J AU Schneider, BP O'Neill, A Shen, F Sledge, GW Thor, AD Kahanic, SP Zander, PJ Davidson, NE AF Schneider, Bryan P. O'Neill, Anne Shen, Fei Sledge, George W. Thor, Ann D. Kahanic, Stephen P. Zander, Paul J. Davidson, Nancy E. TI Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198) SO BRITISH JOURNAL OF CANCER LA English DT Article DE HER2+; trastuzumab; congestive heart failure; breast cancer; adjuvant trial; duration of therapy ID PLUS TRASTUZUMAB; HEART-FAILURE; FOLLOW-UP; CHEMOTHERAPY; DOXORUBICIN; CARDIOTOXICITY; REVERSIBILITY; CAPECITABINE; EVENTS; B-31 AB Background: Blockade of human epidermal growth factor receptor type 2 (HER2) has dramatically improved outcome for patients with HER2-positive breast cancer. Trastuzumab, an anti-HER2 monoclonal antibody, has previously demonstrated improvement in overall survival (OS) in patients with metastatic and early stage HER2-positive breast cancer. However, trastuzumab can cause congestive heart failure (CHF) with an increased frequency for patients who have also received an anthracycline. The current trial was designed to evaluate the impact of the duration of trastuzumab on CHF. Methods: E2198 included 227 eligible women with histologically confirmed stage II or IIIA HER2-positive breast cancer. The patients were randomised to receive 12 weeks of paclitaxel and trastuzumab followed by four cycles of doxorubicin and cyclophosphamide (abbreviated Arm) or the aforementioned treatment with additional 1 year of trastuzumab (conventional Arm). The primary end point was to evaluate the safety of this variable duration of trastuzumab therapy, particularly cardiac toxicity defined as CHF or left ventricular ejection fraction decrease 410%. Secondary end points included disease-free survival (DFS) and OS. Results: Compared with 12-week treatment with trastuzumab, 1 year of trastuzumab-based therapy did not increase the frequency or severity of cardiac toxicity: three patients on the abbreviated Arm and four on the conventional Arm experienced CHF. The 5-year DFS was 76% and 73% for the abbreviated and conventional Arms, respectively, with a hazard ratio (HR) of 1.3 (95% CI: 0.82.1; P = 0.3). There was also no statistically significance difference in OS (HR, 1.4; P = 0.3). Conclusions: Compared with 12 weeks of treatment, 1 year of treatment with trastuzumab did not significantly increase the risk of cardiac toxicity. Although not powered for efficacy comparisons, the longer duration of trastuzumab therapy did not demonstrate a signal for marked superiority. C1 [Schneider, Bryan P.; Shen, Fei] Indiana Univ, Dept Med, Med Ctr, Indianapolis, IN 46033 USA. [O'Neill, Anne] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA. [Sledge, George W.] Stanford Univ, Dept Med, Stanford Med Ctr, Stanford, CA 94305 USA. [Thor, Ann D.] Univ Oklahoma, Dept Pathol, Hlth Sci Ctr, Oklahoma City, OK 73126 USA. [Kahanic, Stephen P.] Hematol Oncol Associates, Sioux City Mercy Med Ctr, Sioux City, IA 51101 USA. [Zander, Paul J.] Abbott NW Hosp, Dept Hematol & Oncol, Minneapolis, MN 55407 USA. [Davidson, Nancy E.] Univ Pittsburgh, Dept Med, Inst Canc, Pittsburgh, PA 15232 USA. [Davidson, Nancy E.] UMPC Canc Ctr, Pittsburgh, PA 15232 USA. RP Schneider, BP (reprint author), Indiana Univ, Dept Med, Med Ctr, Indianapolis, IN 46033 USA. EM bpschnei@iupui.edu FU Public Health Service [CA23318, CA66636, CA21115, CA180820, CA180794, CA49883, CA180795, CA180816, CA180798, CA35103, CA35267, CA17145, CA39229, CA180844, CA16116, CA180802]; National Cancer Institute, National Institutes of Health; Department of Health and Human Services FX This study was conducted by the ECOG-ACRIN Cancer Research Group (Robert L Comis, MD and Mitchell D Schnall, MD, PhD, Group Co-Chairs) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA180820, CA180794, CA49883, CA180795, CA180816, CA180798, CA35103, CA35267, CA17145, CA39229, CA180844, CA16116, CA180802 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. NR 26 TC 3 Z9 3 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0007-0920 EI 1532-1827 J9 BRIT J CANCER JI Br. J. Cancer PD DEC 22 PY 2015 VL 113 IS 12 BP 1651 EP 1657 DI 10.1038/bjc.2015.405 PG 7 WC Oncology SC Oncology GA DB3YJ UT WOS:000368449500002 PM 26625004 ER PT J AU Koo, H Choi, M Kim, E Hahn, SK Weissleder, R Yun, SH AF Koo, Heebeom Choi, Myunghwan Kim, Eunha Hahn, Sei Kwang Weissleder, Ralph Yun, Seok Hyun TI Bioorthogonal Click Chemistry-Based Synthetic Cell Glue SO SMALL LA English DT Article ID UNNATURAL AMINO-ACIDS; IN-VIVO; NANOPARTICLES; MEMBRANE; BINDING; CONJUGATION; ANTIBODIES; GLYCANS AB Artificial methods of cell adhesion can be effective in building functional cell complexes in vitro, but methods for in vivo use are currently lacking. Here, a chemical cell glue based on bioorthogonal click chemistry with high stability and robustness is introduced. Tetrazine (Tz) and trans-cyclooctene (TCO) conjugated to the cell surface form covalent bonds between cells within 10 min in aqueous conditions. Glued, homogeneous, or heterogeneous cell pairs remain viable and stably attached in a microfluidic flow channel at a shear stress of 20 dyn cm(-2). Upon intravenous injection of assembled Jurkat T cells into live mice, fluorescence microscopy shows the trafficking of cell pairs in circulation and their infiltration into lung tissues. These results demonstrate the promising potential of chemically glued cell pairs for various applications ranging from delivering therapeutic cells to studying cell-cell interactions in vivo. C1 [Koo, Heebeom; Choi, Myunghwan; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, 65 Landsdowne St,UP-5, Cambridge, MA 02139 USA. [Koo, Heebeom; Choi, Myunghwan; Yun, Seok Hyun] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Choi, Myunghwan] Sungkyunkwan Univ, Inst Basic Sci, Ctr Neurosci & Imaging Res, Dept Global Biomed Engn, Suwon 440746, Gyeonggi Do, South Korea. [Kim, Eunha; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Kim, Eunha; Weissleder, Ralph] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Kim, Eunha] Ajou Univ, Dept Mol Sci & Technol, Suwon 443749, South Korea. [Hahn, Sei Kwang] Pohang Univ Sci & Technol, Dept Mat Sci & Engn, Kyungbuk 790784, South Korea. RP Yun, SH (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 65 Landsdowne St,UP-5, Cambridge, MA 02139 USA. EM syun@hms.harvard.edu OI Choi, Myunghwan/0000-0002-4235-7003 FU US National Science Foundation [ECCS-1264356]; Department of Defense [FA9550-11-1-0331]; National Research Foundation of Korea [2012R1A2A2A06045773]; National IT Industry Promotion Agency (IT Consilience Creative Program) [NIPA-2014-H0201-14-1001]; Medical Discovery Postdoctoral Fellowship Award from MGH FX The authors thank Danny Cao and Scott Mordecai for their help in cytometry. This work was supported in part by the US National Science Foundation (ECCS-1264356), Department of Defense (FA9550-11-1-0331), and Mid-career Researcher Program through the National Research Foundation of Korea (2012R1A2A2A06045773), National IT Industry Promotion Agency (IT Consilience Creative Program, NIPA-2014-H0201-14-1001), and the Medical Discovery Postdoctoral Fellowship Award from MGH. NR 41 TC 1 Z9 1 U1 7 U2 37 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA POSTFACH 101161, 69451 WEINHEIM, GERMANY SN 1613-6810 EI 1613-6829 J9 SMALL JI Small PD DEC 22 PY 2015 VL 11 IS 48 BP 6458 EP 6466 DI 10.1002/smll.201502972 PG 9 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter SC Chemistry; Science & Technology - Other Topics; Materials Science; Physics GA DA6LY UT WOS:000367917500011 PM 26768353 ER PT J AU Chen, E Ahn, JS Sykes, DB Breyfogle, LJ Godfrey, AL Nangalia, J Ko, A DeAngelo, DJ Green, AR Mullally, A AF Chen, Edwin Ahn, Jong Sook Sykes, David B. Breyfogle, Lawrence J. Godfrey, Anna L. Nangalia, Jyoti Ko, Amy DeAngelo, Daniel J. Green, Anthony R. Mullally, Ann TI RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability SO CELL REPORTS LA English DT Article ID TYROSINE KINASE JAK2; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE DISORDERS; HEMATOPOIETIC STEM; MUTATION; NEOPLASM; MYELOFIBROSIS; HYDROXYUREA; PROGRESSION AB JAK2V617F is the most common oncogenic lesion in patients with myeloproliferative neoplasms (MPNs). Despite the ability of JAK2V617F to instigate DNA damage in vitro, MPNs are nevertheless characterized by genomic stability. In this study, we address this paradox by identifying the DNA helicase RECQL5 as a suppressor of genomic instability in MPNs. We report increased RECQL5 expression in JAK2V617F-expressing cells and demonstrate that RECQL5 is required to counteract JAK2V617F-induced replication stress. Moreover, RECQL5 depletion sensitizes JAK2V617F mutant cells to hydroxyurea (HU), a pharmacological inducer of replication stress and the most common treatment for MPNs. Using single-fiber chromosome combing, we show that RECQL5 depletion in JAK2V617F mutant cells impairs replication dynamics following HU treatment, resulting in increased double-stranded breaks and apoptosis. Cumulatively, these findings identify RECQL5 as a critical regulator of genome stability in MPNs and demonstrate that replication stress-associated cytotoxicity can be amplified specifically in JAK2V617F mutant cells through RECQL5-targeted synthetic lethality. C1 [Chen, Edwin; Breyfogle, Lawrence J.; Ko, Amy; Mullally, Ann] Harvard Univ, Sch Med, Dept Med, Div Hematol,Brigham & Womens Hosp, Boston, MA 02115 USA. [Chen, Edwin; Mullally, Ann] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02142 USA. [Ahn, Jong Sook; Godfrey, Anna L.; Nangalia, Jyoti; Green, Anthony R.] Univ Cambridge, Cambridge Inst Med Res, MRC, Wellcome Trust Stem Cell Inst, Cambridge CB2 0XY, England. [Ahn, Jong Sook; Godfrey, Anna L.; Nangalia, Jyoti; Green, Anthony R.] Univ Cambridge, Dept Haematol, Cambridge CB2 0XY, England. [Ahn, Jong Sook; Godfrey, Anna L.; Nangalia, Jyoti; Green, Anthony R.] Addenbrookes Hosp, Dept Haematol, Cambridge CB2 0XY, England. [Sykes, David B.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [DeAngelo, Daniel J.; Mullally, Ann] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Mullally, A (reprint author), Harvard Univ, Sch Med, Dept Med, Div Hematol,Brigham & Womens Hosp, Boston, MA 02115 USA. EM amullally@partners.org FU NIH [K08 HL109734]; MPN Research Foundation; Jeanne D. Housman Fund for Research on Myeloproliferative Disorders; Damon Runyon clinical investigator award; Lady Tata Memorial Trust Award; Bloodwise [13003]; Wellcome Trust [104710/Z/14/Z]; Medical Research Council; Kay Kendall Leukaemia Fund; Cambridge NIHR Biomedical Research Center; Cambridge Experimental Cancer Medicine Centre; Leukemia and Lymphoma Society of America [07037]; MRC FX A.M. is supported by the NIH (K08 HL109734), the MPN Research Foundation, and the Jeanne D. Housman Fund for Research on Myeloproliferative Disorders and is a recipient of a Damon Runyon clinical investigator award. E.C. is a recipient of a Lady Tata Memorial Trust Award. A.R.G. is supported by Bloodwise (13003), the Wellcome Trust (104710/Z/14/Z), the Medical Research Council, the Kay Kendall Leukaemia Fund, the Cambridge NIHR Biomedical Research Center, the Cambridge Experimental Cancer Medicine Centre, the Leukemia and Lymphoma Society of America (07037), and a core support grant from the Wellcome Trust and MRC to the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. We thank Drs. Benjamin Ebert and Steven Lane for critically reviewing the manuscript and Dr. Ross Levine for providing helpful insights during manuscript revision. NR 26 TC 1 Z9 1 U1 1 U2 3 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD DEC 22 PY 2015 VL 13 IS 11 BP 2345 EP 2352 DI 10.1016/j.celrep.2015.11.037 PG 8 WC Cell Biology SC Cell Biology GA CZ4VR UT WOS:000367101400004 PM 26686625 ER PT J AU Dilwali, S Landegger, LD Soares, VYR Deschler, DG Stankovic, KM AF Dilwali, Sonam Landegger, Lukas D. Soares, Vitor Y. R. Deschler, Daniel G. Stankovic, Konstantina M. TI Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage SO SCIENTIFIC REPORTS LA English DT Article ID FIBROBLAST-GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; INDUCED HEARING-LOSS; AUDITORY HAIR-CELLS; ACOUSTIC NEUROMAS; NEUROFIBROMATOSIS TYPE-2; NOISE EXPOSURE; EXPRESSION; ALPHA; VEGF AB Vestibular schwannomas (VSs) are the most common tumours of the cerebellopontine angle. Ninety-five percent of people with VS present with sensorineural hearing loss (SNHL); the mechanism of this SNHL is currently unknown. To establish the first model to study the role of VS-secreted factors in causing SNHL, murine cochlear explant cultures were treated with human tumour secretions from thirteen different unilateral, sporadic VSs of subjects demonstrating varied degrees of ipsilateral SNHL. The extent of cochlear explant damage due to secretion application roughly correlated with the subjects' degree of SNHL. Secretions from tumours associated with most substantial SNHL resulted in most significant hair cell loss and neuronal fibre disorganization. Secretions from VSs associated with good hearing or from healthy human nerves led to either no effect or solely fibre disorganization. Our results are the first to demonstrate that secreted factors from VSs can lead to cochlear damage. Further, we identified tumour necrosis factor alpha (TNF alpha) as an ototoxic molecule and fibroblast growth factor 2 (FGF2) as an otoprotective molecule in VS secretions. Antibody-mediated TNF alpha neutralization in VS secretions partially prevented hair cell loss due to the secretions. Taken together, we have identified a new mechanism responsible for SNHL due to VSs. C1 [Dilwali, Sonam; Landegger, Lukas D.; Soares, Vitor Y. R.; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA. [Dilwali, Sonam; Deschler, Daniel G.; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Dilwali, Sonam; Stankovic, Konstantina M.] Harvard MIT Program Hlth Sci & Technol, Cambridge, MA 02139 USA. [Landegger, Lukas D.] Med Univ Vienna, Dept Otorhinolaryngol Head & Neck Surg, A-1090 Vienna, Austria. [Landegger, Lukas D.; Soares, Vitor Y. R.; Deschler, Daniel G.; Stankovic, Konstantina M.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Soares, Vitor Y. R.] Univ Brasilia, SGAN, Fac Hlth Sci, Dept Otorhinolaryngol Head & Neck Surg, BR-70840050 Asa Norte, DF, Brazil. RP Stankovic, KM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Eaton Peabody Labs, 243 Charles St, Boston, MA 02114 USA. EM konstantina_stankovic@meei.harvard.edu OI Landegger, Lukas D./0000-0002-9660-2625 FU National Institute of Deafness and Other Communication Disorders [T32DC00038]; Department of Defense [W81XWH-14-1-0091]; Bertarelli Foundation; Nancy Sayles Day Foundation; Lauer Tinnitus Research Center FX We are grateful to Drs. Barker and Martuza for assisting in specimen collection. We would also like to thank Colin Fadzen for assistance with data analysis and manuscript review. This work was supported by the National Institute of Deafness and Other Communication Disorders grant T32DC00038 (S.D., K.M.S.), Department of Defense grant W81XWH-14-1-0091 (K.M.S.), the Bertarelli Foundation (K.M.S.), Nancy Sayles Day Foundation (K.M.S.) and the Lauer Tinnitus Research Center (K.M.S.). NR 43 TC 2 Z9 2 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD DEC 22 PY 2015 VL 5 AR 18599 DI 10.1038/srep18599 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ3VR UT WOS:000367032600001 PM 26690506 ER PT J AU Galea, E Morrison, W Hudry, E Arbel-Ornath, M Bacskai, BJ Gomez-Isla, T Stanley, HE Hyman, BT AF Galea, Elena Morrison, Will Hudry, Eloise Arbel-Ornath, Michal Bacskai, Brian J. Gomez-Isla, Teresa Stanley, H. Eugene Hyman, Bradley T. TI Topological analyses in APP/PS1 mice reveal that astrocytes do not migrate to amyloid-beta plaques SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE Alzheimer's disease; astrocyte; spatial analysis; sulforhodamine 101; two-photon ID ALZHEIMERS-DISEASE; REACTIVE ASTROCYTES; TRANSGENIC MICE; COLOCALIZATION; PROLIFERATION; ASSOCIATION; ACTIVATION; MICROSCOPY; RESPONSES; DEPOSITS AB Although the clustering of GFAP immunopositive astrocytes around amyloid-beta plaques in Alzheimer's disease has led to the widespread assumption that plaques attract astrocytes, recent studies suggest that astrocytes stay put in injury. Here we reexamine astrocyte migration to plaques, using quantitative spatial analysis and computer modeling to investigate the topology of astrocytes in 3D images obtained by two-photon microscopy of living APP/PS1 mice and WT littermates. In WT mice, cortical astrocyte topology fits a model in which a liquid of hard spheres exclude each other in a confined space. Plaques do not disturb this arrangement except at very large plaque loads, but, locally, cause subtle outward shifts of the astrocytes located in three tiers around plaques. These data suggest that astrocytes respond to plaque-induced neuropil injury primarily by changing phenotype, and hence function, rather than location. C1 [Galea, Elena] Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Spain. [Galea, Elena] Univ Autonoma Barcelona, Fac Med, Inst Neurociencies, E-08193 Barcelona, Spain. [Galea, Elena] Univ Autonoma Barcelona, Fac Med, Unitat Bioquim, E-08193 Barcelona, Spain. [Morrison, Will; Stanley, H. Eugene] Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA. [Morrison, Will; Stanley, H. Eugene] Boston Univ, Dept Phys, Boston, MA 02215 USA. [Hudry, Eloise; Arbel-Ornath, Michal; Bacskai, Brian J.; Gomez-Isla, Teresa; Hyman, Bradley T.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA. [Hudry, Eloise; Arbel-Ornath, Michal; Bacskai, Brian J.; Gomez-Isla, Teresa; Hyman, Bradley T.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Galea, E (reprint author), Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Spain. EM Elena.Galea@uab.cat; wzmorrison@gmail.com; hes@bu.edu RI Galea, Elena/E-1362-2011 FU Ministerio de Educacion, Cultura y Deporte [PR2011-0511]; Ministerio de Economia y Competitividad [BFU2012-38844]; NIH [EB000768, S10 RR025645, P50 AG005134, AG021133]; National Science Foundation [CMMI 1125290, PHY-1444389, PHY-0855161, PHY-1505000] FX We thank Ksenia Kastanenka and Christopher Williams of the Massachusetts General Hospital for their critical reading of the manuscript. This study was partially funded by Grant PR2011-0511 from the Ministerio de Educacion, Cultura y Deporte and Grant BFU2012-38844 from the Ministerio de Economia y Competitividad (to E.G.), a NIH Grants EB000768 and S10 RR025645 (to B.J.B.) and P50 AG005134 (to B.T.H.), and by NIH Grant AG021133 and National Science Foundation Grants CMMI 1125290, PHY-1444389, PHY-0855161, and PHY-1505000 (to W.M. and H.E.S). NR 39 TC 3 Z9 3 U1 1 U2 7 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 22 PY 2015 VL 112 IS 51 BP 15556 EP 15561 DI 10.1073/pnas.1516779112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ2DT UT WOS:000366916000031 PM 26644572 ER PT J AU Zhou, TL Li, J Zhao, PQ Liu, HJ Jia, DY Jia, H He, L Cang, Y Boast, S Chen, YH Thibault, H Scherrer-Crosbie, M Goff, SP Li, BJ AF Zhou, Tielin Li, Jing Zhao, Peiquan Liu, Huijuan Jia, Deyong Jia, Hao He, Lin Cang, Yong Boast, Sharon Chen, Yi-Han Thibault, Helene Scherrer-Crosbie, Marielle Goff, Stephen P. Li, Baojie TI Palmitoyl acyltransferase Aph2 in cardiac function and the development of cardiomyopathy SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE palmitoyl transferase; phospholamban; cardiac development; eye development; Aph2 gene ID HEART-FAILURE; DILATED CARDIOMYOPATHY; PHOSPHOLAMBAN ABLATION; PROTEIN PALMITOYLATION; CELL-SURFACE; C-ABL; GENE; RECEPTOR; HYPERTROPHY; MUTATION AB Protein palmitoylation regulates many aspects of cell function and is carried out by acyl transferases that contain zf-DHHC motifs. The in vivo physiological function of protein palmitoylation is largely unknown. Here we generated mice deficient in the acyl transferase Aph2 (Ablphilin 2 or zf-DHHC16) and demonstrated an essential role for Aph2 in embryonic/postnatal survival, eye development, and heart development. Aph2(-/-) embryos and pups showed cardiomyopathy and cardiac defects including bradycardia. We identified phospholamban, a protein often associated with human cardiomyopathy, as an interacting partner and a substrate of Aph2. Aph2-mediated palmitoylation of phospholamban on cysteine 36 differentially alters its interaction with PKA and protein phosphatase 1 a, augmenting serine 16 phosphorylation, and regulates phospholamban pentamer formation. Aph2 deficiency results in phospholamban hypophosphorylation, a hyperinhibitory form. Ablation of phospholamban in Aph2(-/-) mice histologically and functionally alleviated the heart defects. These findings establish Aph2 as a critical in vivo regulator of cardiac function and reveal roles for protein palmitoylation in the development of other organs including eyes. C1 [Zhou, Tielin; Liu, Huijuan; Jia, Hao; He, Lin; Li, Baojie] Shanghai Jiao Tong Univ, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, Bio X Inst, Shanghai 200240, Peoples R China. [Zhou, Tielin; Jia, Deyong] Proteos, Inst Mol & Cell Biol, Singapore 138673, Singapore. [Li, Jing; Zhao, Peiquan] Shanghai Jiao Tong Univ, XinHua Hosp, Shanghai 200092, Peoples R China. [Cang, Yong; Boast, Sharon; Goff, Stephen P.] Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA. [Cang, Yong] Zhejiang Univ, Life Sci Inst, Hangzhou 310058, Zhejiang, Peoples R China. [Boast, Sharon] UCL, Dept Anat & Dev Biol, London WC1E 6BT, England. [Chen, Yi-Han; Li, Baojie] Tongji Univ, Sch Med, East Hosp, Shanghai 200120, Peoples R China. [Thibault, Helene; Scherrer-Crosbie, Marielle] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. RP Goff, SP (reprint author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA. EM spg1@cumc.columbia.edu; libj@sjtu.edu.cn FU National Key Scientific Program [2012CB966901, 2014CB942902]; Shanghai Zhangjiang Stem Cell Research Project [ZJ2014-ZD-002, 2014-2016]; National Natural Science Foundation of China [81371063, 81130039, 81421061]; Howard Hughes Medical Institute FX We thank Yuh-Shin Chang, Hong Bo Xin, Wanjin Hong, Huangtian Yang, Yunfu Sun, Han Chen, and Kenneth Chien for helpful discussions; Zhuoshen Zhao, Quanhong Ma, and Zhongxin Wang for technical assistance; and Drs. David H. MacLennan, William C. Claycomb, Evangelia G. Kranias, and Jim Gulick for providing constructs, mouse strains, and reagents. This work was supported by the National Key Scientific Program (2012CB966901 and 2014CB942902), Shanghai Zhangjiang Stem Cell Research Project (ZJ2014-ZD-002, 2014-2016), National Natural Science Foundation of China (81371063, 81130039, and 81421061), and the Howard Hughes Medical Institute (to S.P.G.). NR 43 TC 1 Z9 1 U1 4 U2 22 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 22 PY 2015 VL 112 IS 51 BP 15666 EP 15671 DI 10.1073/pnas.1518368112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ2DT UT WOS:000366916000049 PM 26644582 ER PT J AU Killian, NJ Potter, SM Buffalo, EA AF Killian, Nathaniel J. Potter, Steve M. Buffalo, Elizabeth A. TI Saccade direction encoding in the primate entorhinal cortex during visual exploration SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE vision; spatial representation; medial temporal lobe; head direction; grid cell ID SPATIAL REPRESENTATION SYSTEM; FREELY MOVING RATS; HEAD-DIRECTION; GRID CELLS; SUBCORTICAL AFFERENTS; MACAQUE HIPPOCAMPUS; NEURONAL-ACTIVITY; MEMORY FORMATION; EYE-MOVEMENTS; PLACE CELLS AB We recently demonstrated that position in visual space is represented by grid cells in the primate entorhinal cortex (EC), suggesting that visual exploration of complex scenes in primates may employ signaling mechanisms similar to those used during exploration of physical space via movement in rodents. Here, we describe a group of saccade direction (SD) cells that encode eye movement information in the monkey EC during free-viewing of complex images. Significant saccade direction encoding was found in 20% of the cells recorded in the posterior EC. SD cells were generally broadly tuned and two largely separate populations of SD cells encoded future and previous saccade direction. Some properties of these cells resemble those of head-direction cells in rodent EC, suggesting that the same neural circuitry may be capable of performing homologous spatial computations under different exploratory contexts. C1 [Killian, Nathaniel J.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Killian, Nathaniel J.; Buffalo, Elizabeth A.] Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA. [Killian, Nathaniel J.; Potter, Steve M.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Lab Neuroengn, Atlanta, GA 30332 USA. [Killian, Nathaniel J.; Potter, Steve M.] Emory Univ, Sch Med, Atlanta, GA 30332 USA. [Buffalo, Elizabeth A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30332 USA. [Buffalo, Elizabeth A.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA. [Buffalo, Elizabeth A.] Washington Natl Primate Res Ctr, Seattle, WA 98195 USA. RP Buffalo, EA (reprint author), Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA. EM ebuffalo@uw.edu OI Killian, Nathaniel/0000-0002-4546-0516 FU National Institute of Mental Health [MH080007, MH093807]; National Center for Research Resources (Office of Research Infrastructure Programs/Office of the Director) [P51RR165, P51OD11132] FX The authors thank M. L. Jutras and K. Staikov for assistance with experiments; M. J. Jutras, D. Solyst, and M. Meister for helpful discussion; and S. Koenig for assistance with the analysis of image salience. Funding for this work was provided by National Institute of Mental Health Grants MH080007 (to E.A.B.) and MH093807 (to E.A.B.) and National Center for Research Resources Grant P51RR165 (currently Office of Research Infrastructure Programs/Office of the Director Grant P51OD11132). NR 52 TC 2 Z9 2 U1 0 U2 8 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 22 PY 2015 VL 112 IS 51 BP 15743 EP 15748 DI 10.1073/pnas.1417059112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ2DT UT WOS:000366916000062 PM 26644558 ER PT J AU Brivio, D Zygmanski, P Arnoldussen, M Hanlon, J Chell, E Sajo, E Makrigiorgos, GM Ngwa, W AF Brivio, D. Zygmanski, P. Arnoldussen, M. Hanlon, J. Chell, E. Sajo, E. Makrigiorgos, G. M. Ngwa, W. TI Kilovoltage radiosurgery with gold nanoparticles for neovascular age-related macular degeneration (AMD): a Monte Carlo evaluation SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article DE AMD; gold nanoparticles; Monte Carlo simulation; sterotactic radiosurgery; kilovoltage ID STEREOTACTIC RADIOSURGERY; DOSE ENHANCEMENT; BRACHYTHERAPY; RADIOSENSITIZATION; THERAPY; ENERGY AB This work uses Monte Carlo radiation transport simulation to assess the potential benefits of gold nanoparticles (AuNP) in the treatment of neovascular age-related macular degeneration with stereotactic radiosurgery. Clinically, a 100 kVp x-ray beam of 4 mm diameter is aimed at the macula to deliver an ablative dose in a single fraction. In the transport model, AuNP accumulated at the bottom of the macula are targeted with a source representative of the clinical beam in order to provide enhanced dose to the diseased macular endothelial cells. It is observed that, because of the AuNP, the dose to the endothelial cells can be significantly enhanced, allowing for greater sparing of optic nerve, retina and other neighboring healthy tissue. For 20 nm diameter AuNP concentration of 32 mg g(-1), which has been shown to be achievable in vivo, a dose enhancement ratio (DER) of 1.97 was found to be possible, which could potentially be increased through appropriate optimization of beam quality and/or AuNP targeting. A significant enhancement in dose is seen in the vicinity of the AuNP layer within 30 mu m, peaked at the AuNP-tissue interface. Different angular tilting of the 4 mm beam results in a similar enhancement. The DER inside and in the penumbra of the 4 mm irradiation-field are almost the same while the actual delivered dose is more than one order of magnitude lower outside the field leading to normal tissue sparing. The prescribed dose to macular endothelial cells can be delivered using almost half of the radiation allowing reduction of dose to the neighboring organs such as retina/optic nerve by 49% when compared to a treatment without AuNP. C1 [Brivio, D.; Zygmanski, P.; Makrigiorgos, G. M.; Ngwa, W.] Harvard Univ, Brigham & Womans Hosp, Sch Med, Boston, MA USA. [Brivio, D.; Zygmanski, P.; Makrigiorgos, G. M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Arnoldussen, M.; Hanlon, J.; Chell, E.] Oraya Therapeut Inc, Newark, CA 94560 USA. [Sajo, E.; Ngwa, W.] Univ Massachusetts, Lowell, MA USA. RP Brivio, D (reprint author), Harvard Univ, Brigham & Womans Hosp, Sch Med, Boston, MA USA. EM dbrivio@lroc.harvard.edu RI Brivio, Davide/R-1330-2016 OI Brivio, Davide/0000-0002-4127-9955 FU NIH [R41EY024197] FX This work was supported by NIH R41EY024197. NR 22 TC 1 Z9 1 U1 1 U2 1 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 EI 1361-6560 J9 PHYS MED BIOL JI Phys. Med. Biol. PD DEC 21 PY 2015 VL 60 IS 24 BP 9203 EP 9213 DI 10.1088/0031-9155/60/24/9203 PG 11 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA DJ2AO UT WOS:000374006300001 PM 26576672 ER PT J AU Olson, KA Beatty, AL Heidecker, B Regan, MC Brody, EN Foreman, T Kato, S Mehler, RE Singer, BS Hveem, K Dalen, H Sterling, DG Lawn, RM Schiller, NB Williams, SA Whooley, MA Ganz, P AF Olson, Kristoff A. Beatty, Alexis L. Heidecker, Bettina Regan, Mathilda C. Brody, Edward N. Foreman, Trudi Kato, Shintaro Mehler, Robert E. Singer, Britta S. Hveem, Kristian Dalen, Havard Sterling, David G. Lawn, Richard M. Schiller, Nelson B. Williams, Stephen A. Whooley, Mary A. Ganz, Peter TI Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts SO EUROPEAN HEART JOURNAL LA English DT Article DE Growth differentiation factor 11 and 8; Ageing; Cardiovascular outcomes; Epidemiology; Hypertrophy ID LEFT-VENTRICULAR MASS; SKELETAL-MUSCLE; DISEASE; FRAMINGHAM; FAILURE; AGE; DYSFUNCTION; SOCIETY; INDEX; RISK AB Aims Growth differentiation factor 11 and/or its homologue growth differentiation factor 8 (GDF11/8) reverses age-related cardiac hypertrophy and vascular ageing in mice. We investigated whether GDF11/8 associates with cardiovascular outcomes, left ventricular hypertrophy (LVH), or age in humans. Methods and results We measured plasma GDF11/8 levels in 928 participants with stable ischaemic heart disease in the Heart and Soul study. We adjudicated heart failure hospitalization, stroke, myocardial infarction, death, and their composite endpoint. Left ventricular hypertrophy was evaluated by echocardiography. We used multivariable Cox proportional hazards models to compare rates of cardiovascular events and death across GDF11/8 quartiles and logistic regression models to evaluate the association between GDF11/8 and LVH. Four hundred and fifty participants (48.5%) experienced a cardiovascular event or death during 8.9 years of follow-up. The adjusted risk of the composite endpoint was lower in the highest compared with the lowest GDF11/8 quartile [hazard ratio (HR), 0.45; 95% confidence interval (CI), 0.33-0.60; P < 0.001]. We replicated this relationship of GDF11/8 to adverse events in 971 participants in the HUNT3 cohort (adjusted HR, 0.34; 95% CI, 0.23-0.51; P < 0.001). Left ventricular hypertrophy was present in 368 participants (39.7%) at baseline. Participants in the highest quartile of GDF11/8 were less likely to have LVH than those in the lowest quartile (adjusted OR, 0.55; 95% CI, 0.35-0.86; P = 0.009). GDF11/8 levels were lower in older individuals (P < 0.001). Conclusion In patients with stable ischaemic heart disease, higher GDF11/8 levels are associated with lower risk of cardiovascular events and death. Our findings suggest that GDF11/8 has similar cardioprotective properties in humans to those demonstrated in mice. C1 [Olson, Kristoff A.; Beatty, Alexis L.; Heidecker, Bettina; Schiller, Nelson B.; Whooley, Mary A.; Ganz, Peter] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Beatty, Alexis L.] Vet Affairs Puget Sound Hlth Care Syst, Cardiol Sect, Seattle, WA USA. [Beatty, Alexis L.] Univ Washington, Dept Med, Seattle, WA USA. [Regan, Mathilda C.] Vet Hlth Res Inst, San Francisco, CA USA. [Brody, Edward N.; Foreman, Trudi; Mehler, Robert E.; Singer, Britta S.; Sterling, David G.; Lawn, Richard M.; Williams, Stephen A.] SomaLogic Inc, Boulder, CO USA. [Kato, Shintaro] NEC Corp Amer, Irving, TX 75063 USA. [Hveem, Kristian] Lifandis AS, Levanger, Norway. [Hveem, Kristian] NTNU, Dept Publ Hlth, HUNT Res Ctr, Trondheim, Norway. [Dalen, Havard] Nord Trondelag Hlth Trust, Levanger Hosp, Dept Med, Levanger, Norway. [Dalen, Havard] Norwegian Univ Sci & Technol, MI Lab, Trondheim, Norway. [Dalen, Havard] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Trondheim, Norway. [Whooley, Mary A.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Ganz, Peter] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA. RP Ganz, P (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM peter.ganz@ucsf.edu FU Department of Veterans Affairs (Epidemiology Merit Review Program); National Heart, Lung and Blood Institute [R01 HL079235]; Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program); Ischemia Research and Education Foundation; National Center for Advancing Translational Sciences [KL2TR000143]; SomaLogic FX This study was supported by grants from the Department of Veterans Affairs (Epidemiology Merit Review Program); the National Heart, Lung and Blood Institute (grant number: R01 HL079235); the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); the American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program); and the Ischemia Research and Education Foundation. None of these funding sources had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The contents of this research are solely the responsibility of the investigators and do not necessarily represent the official views of the NIH. A.L.B. is supported by the National Center for Advancing Translational Sciences (grant number: KL2TR000143). This study was also supported in part by a research grant to M.A.W. from SomaLogic. NR 18 TC 17 Z9 19 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD DEC 21 PY 2015 VL 36 IS 48 BP 3426 EP 3434 DI 10.1093/eurheartj/ehv385 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DE1GD UT WOS:000370373900010 PM 26294790 ER PT J AU Sunaguchi, N Yuasa, T Gupta, R Ando, M AF Sunaguchi, Naoki Yuasa, Tetsuya Gupta, Rajiv Ando, Masami TI An efficient reconstruction algorithm for differential phase-contrast tomographic images from a limited number of views SO APPLIED PHYSICS LETTERS LA English DT Article ID COMPUTED-TOMOGRAPHY; DARK-FIELD; RAY; ANALYZER; BREAST; CT AB The main focus of this paper is reconstruction of tomographic phase-contrast image from a set of projections. We propose an efficient reconstruction algorithm for differential phase-contrast computed tomography that can considerably reduce the number of projections required for reconstruction. The key result underlying this research is a projection theorem that states that the second derivative of the projection set is linearly related to the Laplacian of the tomographic image. The proposed algorithm first reconstructs the Laplacian image of the phase-shift distribution from the second-derivative of the projections using total variation regularization. The second step is to obtain the phase-shift distribution by solving a Poisson equation whose source is the Laplacian image previously reconstructed under the Dirichlet condition. We demonstrate the efficacy of this algorithm using both synthetically generated simulation data and projection data acquired experimentally at a synchrotron. The experimental phase data were acquired from a human coronary artery specimen using dark-field-imaging optics pioneered by our group. Our results demonstrate that the proposed algorithm can reduce the number of projections to approximately 33% as compared with the conventional filtered backprojection method, without any detrimental effect on the image quality. (C) 2015 AIP Publishing LLC. C1 [Sunaguchi, Naoki] Gunma Univ, Fac Sci & Technol, Kiryu, Gunma 3768515, Japan. [Yuasa, Tetsuya] Yamagata Univ, Grad Sch Engn & Sci, Yonezawa, Yamagata 9928510, Japan. [Gupta, Rajiv] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Gupta, Rajiv] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Ando, Masami] Tokyo Univ Sci, Res Inst Sci & Technol, Noda, Chiba 2788510, Japan. RP Sunaguchi, N (reprint author), Gunma Univ, Fac Sci & Technol, Kiryu, Gunma 3768515, Japan. FU Ministry of Education, Culture, Sports, Science, and Technology in Japan [23602002, 26350494, 26750142]; KEK [2008S2-002, 2011G-672, 2012G562, 2013G731] FX This research was partially supported by a Grant-In-Aid for Scientific Research (#23602002, #26350494, and #26750142) from the Ministry of Education, Culture, Sports, Science, and Technology in Japan. The experiment was performed under the auspices of KEK (2008S2-002, 2011G-672, 2012G562, and 2013G731). We would like to thank Dr. Kazuyuki Hyodo and Dr. Keiichi Hirano in KEK for the kind advices and preparing the CCD camera during this research. NR 17 TC 2 Z9 2 U1 1 U2 2 PU AMER INST PHYSICS PI MELVILLE PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA SN 0003-6951 EI 1077-3118 J9 APPL PHYS LETT JI Appl. Phys. Lett. PD DEC 21 PY 2015 VL 107 IS 25 AR 253701 DI 10.1063/1.4938211 PG 4 WC Physics, Applied SC Physics GA DB3VW UT WOS:000368442100045 ER PT J AU Kadakia, MB Rao, SV McCoy, L Choudhuri, PS Sherwood, MW Lilly, S Kobayashi, T Kolansky, DM Wilensky, RL Yeh, RW Giri, J AF Kadakia, Mitul B. Rao, Sunil V. McCoy, Lisa Choudhuri, Paramita S. Sherwood, Matthew W. Lilly, Scott Kobayashi, Taisei Kolansky, Daniel M. Wilensky, Robert L. Yeh, Robert W. Giri, Jay TI Transradial Versus Transfemoral Access in Patients Undergoing Rescue Percutaneous Coronary Intervention After Fibrinolytic Therapy SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE rescue PCI; STEMI; transradial access ID ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT-ELEVATION; FEMORAL ACCESS; THROMBOLYTIC THERAPY; RADIAL ACCESS; ACUITY TRIAL; OUTCOMES; REGISTRY; ANGIOPLASTY; ANGIOGRAPHY AB OBJECTIVES The purpose of this study was to assess usage patterns of transradial access in rescue percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) and associations between vascular access site choice and outcomes. BACKGROUND Transradial access reduces bleeding and mortality in STEMI patients undergoing primary PCI. Little is known about access site choice and outcomes in patients undergoing rescue PCI after receiving full-dose fibrinolytic therapy for STEMI. METHODS Patients in the National Cardiovascular Data Registry's CathPCI Registry undergoing rescue PCI for STEMI between 2009 and 2013 were studied. Patients were divided on the basis of access site. Patterns of access use and baseline demographics were noted. Unadjusted and propensity-matched analyses were performed comparing in-hospital bleeding, vascular complications, and mortality outcomes among transradial and transfemoral access patients. The falsification endpoint of gastrointestinal bleeding was specified to assess for persistent unmeasured confounding. RESULTS Transradial access was used in 14.2% of cases. In propensity-matched analyses, transradial rescue PCI was associated with significantly less bleeding than transfemoral access (odds ratio [OR]: 0.67; 95% confidence interval [CI]: 0.52 to 0.87; p = 0.003), but not mortality (OR: 0.81; 95% CI: 0.53 to 1.25; p = 0.35). Gastrointestinal bleeding was less frequent in the radial group (OR: 0.23; 95% CI: 0.05 to 0.98; p = 0.05). CONCLUSIONS In a large, "real-world" registry, transradial access was used in a minority of cases and was associated with significantly less bleeding than transfemoral access in patients undergoing rescue PCI. However, given persistent differences in a falsification endpoint, the influence of treatment-selection bias on these results cannot be ruled out. Further studies are needed to determine predictors of bleeding and mortality in this understudied high-risk group. (C) 2015 by the American College of Cardiology Foundation. C1 [Kadakia, Mitul B.; Kobayashi, Taisei; Kolansky, Daniel M.; Wilensky, Robert L.; Giri, Jay] Hosp Univ Penn, Cardiovasc Med Div, Philadelphia, PA 19104 USA. [Rao, Sunil V.; McCoy, Lisa; Choudhuri, Paramita S.; Sherwood, Matthew W.] Duke Clin Res Inst, Durham, NC USA. [Lilly, Scott] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA. [Yeh, Robert W.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Giri, J (reprint author), Hosp Univ Penn, Cardiovasc Med Div, Gates Pavil,9th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM giri.jay@gmail.com FU National Cardiovascular Data Registry FX Statistical support for this study was funded through a grant from the National Cardiovascular Data Registry. Dr. Rao is a consultant for Terumo Medical, Medtronic, and The Medicines Company (all modest); and has received an honorarium from Terumo Interventional Systems. Dr. Wilensky is a scientific advisory board member for Cardiostem, GenWay, Soteria, and Vascular Magnetics; and has equity interest in Johnson & Johnson. Dr. Yeh is an investigator for the Harvard Clinical Research Institute; has served on the advisory board of Abbott Vascular; and has served as a consultant for Gilead Sciences, Abbott Vascular, and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 33 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD DEC 21 PY 2015 VL 8 IS 14 BP 1868 EP 1876 DI 10.1016/j.jcin.2015.07.028 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CZ2OS UT WOS:000366945100019 PM 26718516 ER PT J AU Elphinstone, RE Riley, F Lin, T Higgins, S Dhabangi, A Musoke, C Cserti-Gazdewich, C Regan, RF Warren, HS Kain, KC AF Elphinstone, Robyn E. Riley, Frank Lin, Tian Higgins, Sarah Dhabangi, Aggrey Musoke, Charles Cserti-Gazdewich, Christine Regan, Raymond F. Warren, H. Shaw Kain, Kevin C. TI Dysregulation of the haem-haemopexin axis is associated with severe malaria in a case-control study of Ugandan children SO MALARIA JOURNAL LA English DT Article DE Severe malaria; Cerebral malaria; Severe malarial anaemia; Haemopexin; Haptoglobin; Haem; Haemoglobin; Experimental cerebral malaria ID SEVERE FALCIPARUM-MALARIA; CEREBRAL MALARIA; PATHOGENESIS; ACTIVATION; ANGIOPOIETIN-2; OXYGENASE-1; HEMOLYSIS; DISEASES; RECEPTOR; THERAPY AB Background: Malaria is associated with haemolysis and the release of plasma haem. Plasma haem can cause endothelial injury and organ dysfunction, and is normally scavenged by haemopexin to limit toxicity. It was hypothesized that dysregulation of the haem-haemopexin pathway contributes to severe and fatal malaria infections. Methods: Plasma levels of haemin (oxidized haem), haemopexin, haptoglobin, and haemoglobin were quantified in a case-control study of Ugandan children with Plasmodium falciparum malaria. Levels at presentation were compared in children with uncomplicated malaria (UM; n = 29), severe malarial anaemia (SMA; n = 27) or cerebral malaria (CM; n = 31), and evaluated for utility in predicting fatal (n = 19) vs non-fatal (n = 39) outcomes in severe disease. A causal role for haemopexin was assessed in a pre-clinical model of experimental cerebral malaria (ECM), following disruption of mouse haemopexin gene (hpx). Analysis was done using Kruskall Wallis tests, Mann-Whitney tests, log-rank tests for survival, and repeated measures ANOVA. Results: In Ugandan children presenting with P. falciparum malaria, haemin levels were higher and haemopexin levels were lower in SMA and CM compared to children with UM (haemin, p < 0.01; haemopexin, p < 0.0001). Among all cases of severe malaria, elevated levels of haemin and cell-free haemoglobin at presentation were associated with subsequent mortality (p < 0.05). Compared to ECM-resistant BALB/c mice, susceptible C57BL/6 mice had lower circulating levels of haemopexin (p < 0.01), and targeted deletion of the haemopexin gene, hpx, resulted in increased mortality compared to their wild type littermates (p < 0.05). Conclusions: These data indicate that plasma levels of haemin and haemopexin measured at presentation correlate with malaria severity and levels of haemin and cell-free haemoglobin predict outcome in paediatric severe malaria. Mechanistic studies in the ECM model support a causal role for the haem-haemopexin axis in ECM pathobiology. C1 [Elphinstone, Robyn E.; Higgins, Sarah; Kain, Kevin C.] Univ Hlth Network, Toronto Gen Hosp, Sandra Rotman Ctr Global Hlth, Toronto, ON, Canada. [Elphinstone, Robyn E.; Higgins, Sarah; Kain, Kevin C.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada. [Elphinstone, Robyn E.; Higgins, Sarah; Kain, Kevin C.] Univ Toronto, Dept Med, Trop Dis Unit, Toronto, ON, Canada. [Riley, Frank; Lin, Tian; Warren, H. Shaw] Massachusetts Gen Hosp, Dept Pediat, Infect Dis Unit, Boston, MA 02114 USA. [Dhabangi, Aggrey; Musoke, Charles] Makerere Univ, Coll Hlth Sci, Kampala, Uganda. [Cserti-Gazdewich, Christine] Univ Toronto, Univ Hlth Network, Lab Med Program Transfus Med, Toronto, ON, Canada. [Regan, Raymond F.] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA. RP Kain, KC (reprint author), Univ Hlth Network, Toronto Gen Hosp, Sandra Rotman Ctr Global Hlth, Toronto, ON, Canada. EM kevin.kain@uhn.ca FU Canadian Institutes of Health Research (CIHR) [MOP-13721, MOP-136813, MOP-115160]; Canada Research Chair in Molecular Parasitology; CIHR MD/PhD Studentship; Vanier Canada Graduate Scholarship; Defense Advanced Research Projects Agency (DARPA) [W9111NF-13-1-0070]; Shriners Hospital for Crippled Children [87200]; Tesari Foundation FX We acknowledge Dr. Frank Berger from the University of South Carolina for providing haemopexin breeding pairs to RR. This work was supported by a Canadian Institutes of Health Research (CIHR) [MOP-13721, MOP-136813, MOP-115160] to KCK, Canada Research Chair in Molecular Parasitology to KCK, a CIHR MD/PhD Studentship to REE, a Vanier Canada Graduate Scholarship to REE, Defense Advanced Research Projects Agency (DARPA) [Grant W9111NF-13-1-0070] to HSW, Shriners Hospital for Crippled Children [Grant 87200] to HSW, the Tesari Foundation, and a kind donation from Kim Kertland. NR 37 TC 2 Z9 2 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD DEC 21 PY 2015 VL 14 AR 511 DI 10.1186/s12936-015-1028-1 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CZ5MS UT WOS:000367147300003 PM 26691827 ER PT J AU Jung, JP Hu, DJ Domian, IJ Ogle, BM AF Jung, Jangwook P. Hu, Dongjian Domian, Ibrahim J. Ogle, Brenda M. TI An integrated statistical model for enhanced murine cardiomyocyte differentiation via optimized engagement of 3D extracellular matrices SO SCIENTIFIC REPORTS LA English DT Article ID PLURIPOTENT STEM-CELLS; NATIVE CHEMICAL LIGATION; HEART DEVELOPMENT; CARDIAC MYOCYTES; EMBRYOID BODIES; HYDROGELS; GENE; EXPRESSION; MYOGENESIS; CALCIUM AB The extracellular matrix (ECM) impacts stem cell differentiation, but identifying formulations supportive of differentiation is challenging in 3D models. Prior efforts involving combinatorial ECM arrays seemed intuitively advantageous. We propose an alternative that suggests reducing sample size and technological burden can be beneficial and accessible when coupled to design of experiments approaches. We predict optimized ECM formulations could augment differentiation of cardiomyocytes derived in vitro. We employed native chemical ligation to polymerize 3D poly (ethylene glycol) hydrogels under mild conditions while entrapping various combinations of ECM and murine induced pluripotent stem cells. Systematic optimization for cardiomyocyte differentiation yielded a predicted solution of 61%, 24%, and 15% of collagen type I, laminin-111, and fibronectin, respectively. This solution was confirmed by increased numbers of cardiac troponin T, alpha-myosin heavy chain and alpha-sarcomeric actinin-expressing cells relative to suboptimum solutions. Cardiomyocytes of composites exhibited connexin43 expression, appropriate contractile kinetics and intracellular calcium handling. Further, adding a modulator of adhesion, thrombospondin-1, abrogated cardiomyocyte differentiation. Thus, the integrated biomaterial platform statistically identified an ECM formulation best supportive of cardiomyocyte differentiation. In future, this formulation could be coupled with biochemical stimulation to improve functional maturation of cardiomyocytes derived in vitro or transplanted in vivo. C1 [Jung, Jangwook P.; Ogle, Brenda M.] Univ Minnesota Twin Cities, Dept Biomed Engn, Minneapolis, MN 55455 USA. [Jung, Jangwook P.; Ogle, Brenda M.] Univ Minnesota Twin Cities, Stem Cell Inst, Minneapolis, MN 55455 USA. [Hu, Dongjian; Domian, Ibrahim J.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Hu, Dongjian; Domian, Ibrahim J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Ogle, Brenda M.] Univ Minnesota Twin Cities, Masonic Canc Ctr, Minneapolis, MN 55455 USA. [Ogle, Brenda M.] Univ Minnesota Twin Cities, Lillehei Heart Inst, Minneapolis, MN 55455 USA. [Ogle, Brenda M.] Univ Minnesota Twin Cities, Inst Engn Med, Minneapolis, MN 55455 USA. RP Ogle, BM (reprint author), Univ Minnesota Twin Cities, Dept Biomed Engn, Minneapolis, MN 55455 USA. EM ogle@umn.edu FU National Science Foundation [1445650]; American Heart Association [13POST14080011] FX The authors thank Prof. Jonathan Marchant for helpful discussion on imaging Ca2+ transients and Prof. Deepak Srivastava for kindly providing miPSCs. The DIC and confocal imaging of Ca2+ transients was performed at the University Imaging Center of the University of Minnesota. Epifluorescence and MPLSM was performed in the Alford and the Provenzano lab, respectively. This work was supported by the National Science Foundation (1445650) and the American Heart Association Postdoctoral Fellowship (13POST14080011). NR 46 TC 2 Z9 2 U1 4 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD DEC 21 PY 2015 VL 5 AR 18705 DI 10.1038/srep18705 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ4MB UT WOS:000367076200002 PM 26687770 ER PT J AU Yin, ES Downing, NS Li, X Singer, SJ Curry, LA Li, J Krumholz, HM Jiang, LX AF Yin, Emily S. Downing, Nicholas S. Li, Xi Singer, Sara J. Curry, Leslie A. Li, Jing Krumholz, Harlan M. Jiang, Lixin TI Organizational culture in cardiovascular care in Chinese hospitals: a descriptive cross-sectional study SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Survey; Hospitals; Organizational learning; Healthcare workers; Positive response ID ACUTE MYOCARDIAL-INFARCTION; PATIENT SAFETY CULTURE; HEALTH-CARE; LEARNING ORGANIZATION; PERFORMANCE; MANAGEMENT; IMPLEMENTATION; ORIENTATION; IMPROVEMENT; STRATEGIES AB Background: Organizational learning, the process by which a group changes its behavior in response to newly acquired knowledge, is critical to outstanding organizational performance. In hospitals, strong organizational learning culture is linked with improved health outcomes for patients. This study characterizes the organizational learning culture of hospitals in China from the perspective of a cardiology service. Methods: Using a modified Abbreviated Learning Organization Survey (27 questions), we characterized organizational learning culture in a nationally representative sample of 162 Chinese hospitals, selecting 2 individuals involved with cardiovascular care at each hospital. Responses were analyzed at the hospital level by calculating the average of the two responses to each question. Responses were categorized as positive if they were 5+ on a 7-point scale or 4+ on a 5-point scale. Univariate and multiple regression analyses were used to assess the relationship between selected hospital characteristics and perceptions of organizational learning culture. Results: Of the 324 participants invited to take the survey, 316 responded (98 % response rate). Perceptions of organizational learning culture varied among items, among domains, and both among and within hospitals. Overall, the median proportion of positive responses was 82 % (interquartile range = 59 % to 93 %). "Training," "Performance Monitoring," and "Leadership that Reinforces Learning" were characterized as the most favorable domains, while "Time for Reflection" was the least favorable. Multiple regression analyses showed that region was the only factor significantly correlated with overall positive response rate. Conclusions: This nationally representative survey demonstrated variation in hospital organizational learning culture among hospitals in China. The variation was not substantially explained by hospital characteristics. Organizational learning culture domains with lower positive response rates reveal important areas for improvement. C1 [Yin, Emily S.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Downing, Nicholas S.; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA. [Li, Xi; Li, Jing; Jiang, Lixin] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Natl Clin Res Ctr Cardiovasc Dis,Fuwai Hosp, Beijing 100730, Peoples R China. [Li, Xi; Li, Jing; Jiang, Lixin] Peking Union Med Coll, Beijing 100021, Peoples R China. [Singer, Sara J.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Singer, Sara J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA. [Curry, Leslie A.; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06510 USA. [Curry, Leslie A.; Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. RP Krumholz, HM (reprint author), Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA. EM harlan.krumholz@yale.edu FU Research Special Fund for Public Welfare Industry of Health from the National Health and Family Planning Commission of China [201202025]; National Key Technology R&D Program from the Ministry of Science and Technology of China [2013BAI09B01]; Fuwai Hospital, Chinese Academy of Medical Sciences [2013-F11]; Peking Union Medical College; National Heart, Lung, and Blood Institute in Bethesda, Maryland [U01 HL105270-05] FX The authors wish to acknowledge the entire study team at the China Oxford Centre for International Health Research, especially Siming Wang, Ying Sun, and Pi Yi for survey administration and data collection, and Li Li and Jiamin Liu for conducting the in-person pilot interviews. We also appreciate the data interpretation contributed by Yuan Lu. The China PEACE study was partly supported by the Research Special Fund for Public Welfare Industry of Health (201202025) from the National Health and Family Planning Commission of China, and the National Key Technology R&D Program (2013BAI09B01) from the Ministry of Science and Technology of China. This survey study was also partially funded by the Young Scientist Research Fund (2013-F11) from Fuwai Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College. HK is supported by grant U01 HL105270-05 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute in Bethesda, Maryland. NR 56 TC 0 Z9 1 U1 5 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD DEC 21 PY 2015 VL 15 AR 569 DI 10.1186/s12913-015-1211-7 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CZ0LH UT WOS:000366795800001 PM 26689591 ER PT J AU Nedic, S Stufflebeam, SM Rondinoni, C Velasco, TR dos Santos, AC Leite, JP Gargaro, AC Mujica-Parodi, LR Ide, JS AF Nedic, Sanja Stufflebeam, Steven M. Rondinoni, Carlo Velasco, Tonicarlo R. dos Santos, Antonio C. Leite, Joao P. Gargaro, Ana C. Mujica-Parodi, Lilianne R. Ide, Jaime S. TI Using network dynamic fMRI for detection of epileptogenic foci SO BMC NEUROLOGY LA English DT Article DE Epilepsy; Seizure; fMRI; Power spectrum scale invariance; Autocorrelation function; Classification; Complexity; Chaos; Fractal ID TEMPORAL-LOBE EPILEPSY; STATE FUNCTIONAL CONNECTIVITY; SPECTRUM SCALE-INVARIANCE; BRAIN ACTIVITY; EEG-FMRI; MRI; DYSREGULATION; PATTERNS; SURGERY; SPIKES AB Background: Epilepsy is one of the most prevalent neurological disorders. It remains medically intractable for about one-third of patients with focal epilepsy, for whom precise localization of the epileptogenic zone responsible for seizure initiation may be critical for successful surgery. Existing fMRI literature points to widespread network disturbances in functional connectivity. Per previous scalp and intracranial EEG studies and consistent with excessive local synchronization during interictal discharges, we hypothesized that, relative to same regions in healthy controls, epileptogenic foci would exhibit less chaotic dynamics, identifiable via entropic analyses of resting state fMRI time series. Methods: In order to first validate this hypothesis on a cohort of patients with known ground truth, here we test individuals with well-defined epileptogenic foci (left mesial temporal lobe epilepsy). We analyzed voxel-wise resting-state fMRI time-series using the autocorrelation function (ACF), an entropic measure of regulation and feedback, and performed follow-up seed-to-voxel functional connectivity analysis. Disruptions in connectivity of the region exhibiting abnormal dynamics were examined in relation to duration of epilepsy and patients' cognitive performance using a delayed verbal memory recall task. Results: ACF analysis revealed constrained (less chaotic) functional dynamics in left temporal lobe epilepsy patients, primarily localized to ipsilateral temporal pole, proximal to presumed focal points. Autocorrelation decay rates differentiated, with 100 % accuracy, between patients and healthy controls on a subject-by-subject basis within a leave-one-subject out classification framework. Regions identified via ACF analysis formed a less efficient network in patients, as compared to controls. Constrained dynamics were linked with locally increased and long-range decreased connectivity that, in turn, correlated significantly with impaired memory (local left temporal connectivity) and epilepsy duration (left temporal - posterior cingulate cortex connectivity). Conclusions: Our current results suggest that data driven functional MRI methods that target network dynamics hold promise in providing clinically valuable tools for identification of epileptic regions. C1 [Nedic, Sanja; Mujica-Parodi, Lilianne R.; Ide, Jaime S.] SUNY Stony Brook, Sch Med, Dept Biomed Engn, Stony Brook, NY 11794 USA. [Nedic, Sanja; Stufflebeam, Steven M.; Mujica-Parodi, Lilianne R.; Ide, Jaime S.] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Rondinoni, Carlo; Velasco, Tonicarlo R.; dos Santos, Antonio C.; Leite, Joao P.; Gargaro, Ana C.] Univ Sao Paulo, Dep Neurosci & Behav, BR-14049 Ribeirao Preto, SP, Brazil. [Ide, Jaime S.] Univ Fed Sao Paulo, Dept Sci & Technol, BR-12231 Sao Jose Dos Campos, SP, Brazil. RP Mujica-Parodi, LR (reprint author), SUNY Stony Brook, Sch Med, Dept Biomed Engn, Stony Brook, NY 11794 USA. EM Lilianne.Strey@stonybrook.edu; Jaime.Ide@stonybrook.edu OI Mujica-Parodi, Lilianne/0000-0002-3752-5519 FU National Science Foundation [CBET 1264440]; Sao Paulo Research Foundation [FAPESP 11/08573-4] FX This research was supported by the National Science Foundation (CBET 1264440; LRMP) and the Sao Paulo Research Foundation (Young Investigators Awards FAPESP 11/08573-4; JSI). NR 71 TC 2 Z9 3 U1 4 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2377 J9 BMC NEUROL JI BMC Neurol. PD DEC 21 PY 2015 VL 15 AR 262 DI 10.1186/s12883-015-0514-y PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA CZ1WG UT WOS:000366896000001 PM 26689596 ER PT J AU Epstein, AJ Wong, YN Mitra, N Vachani, A Hin, S Yang, L Smith-McLallen, A Armstrong, K Groeneveld, PW AF Epstein, Andrew J. Wong, Yu-Ning Mitra, Nandita Vachani, Anil Hin, Sakhena Yang, Lin Smith-McLallen, Aaron Armstrong, Katrina Groeneveld, Peter W. TI Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID 21-GENE RECURRENCE SCORE; GENE-EXPRESSION; OLDER WOMEN; ASSAY; MODELS; RISK; RECOMMENDATIONS; MANAGEMENT; TAMOXIFEN; SOCIETY AB Purpose We assessed the associations between the 21-gene recurrence score assay (RS) receipt, subsequent chemotherapy use, and medical expenditures among patients with early-stage breast cancer. Patients and Methods Data from the Pennsylvania Cancer Registry were used to assemble a retrospective cohort of women with early-stage breast cancer from 2007 to 2010 who underwent initial surgical treatment. These data were merged with administrative claims from the 12-month periods before and after diagnosis to identify comorbidities, treatments, and expenditures (n = 7,287). Propensity score-weighted regression models were estimated to identify the effects of RS receipt on chemotherapy use and medical spending in the year after diagnosis. Results The associations between RS receipt and outcomes varied markedly by patient age. RS use was associated with lower chemotherapy use among women younger than 55 (19.2% lower; 95% CI, 10.6 to 27.9). RS use was associated with higher chemotherapy use among women 75 to 84 years old (5.7% higher; 95% CI, 0.4 to 11.0). RS receipt was associated with lower adjusted 1-year medical spending among women younger than 55 ($15,333 lower; 95% CI, $2,841 to $27,824) and with higher spending among women who were 75 to 84 years old ($3,489 higher; 95% CI, $857 to $6,122). Conclusion RS receipt was associated with reduced use of adjuvant chemotherapy and lower health care spending among women with breast cancer who were younger than 55. Conversely, among women 75 and older, RS testing was associated with a modest increase in chemotherapy use and slightly higher spending. From a population perspective, the impact of RS testing on breast cancer treatment and health care costs is much greater in younger women. (C) 2015 by American Society of Clinical Oncology C1 [Epstein, Andrew J.; Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Epstein, Andrew J.; Wong, Yu-Ning; Mitra, Nandita; Vachani, Anil; Hin, Sakhena; Yang, Lin; Groeneveld, Peter W.] Univ Penn, Philadelphia, PA 19104 USA. [Wong, Yu-Ning] Temple Univ Hlth Syst, Philadelphia, PA USA. [Smith-McLallen, Aaron] Independence Blue Cross, Philadelphia, PA USA. [Armstrong, Katrina] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Armstrong, Katrina] Harvard Univ, Sch Med, Boston, MA USA. RP Groeneveld, PW (reprint author), Univ Penn, Perelman Sch Med, 1201 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM petergro@upenn.edu FU Commonwealth of Pennsylvania-Department of Health [4100059202] FX Supported by a research grant from the Commonwealth of Pennsylvania-Department of Health (Grant No. 4100059202). NR 37 TC 3 Z9 3 U1 0 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 20 PY 2015 VL 33 IS 36 BP 4259 EP + DI 10.1200/JCO.2015.61.9023 PG 9 WC Oncology SC Oncology GA CY8GX UT WOS:000366647900005 PM 26598749 ER PT J AU Bellon, JR AF Bellon, Jennifer R. TI Personalized-Not Omitted-Radiation Oncology for Breast Cancer Reply SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Letter ID WOMEN C1 [Bellon, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bellon, Jennifer R.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Bellon, JR (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 5 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 20 PY 2015 VL 33 IS 36 BP 4314 EP 4314 DI 10.1200/JCO.2015.64.1373 PG 1 WC Oncology SC Oncology GA CY8GX UT WOS:000366647900015 PM 26527783 ER PT J AU Shukla, SK Cook, D Meyer, J Vernon, SD Le, T Clevidence, D Robertson, CE Schrodi, SJ Yale, S Frank, DN AF Shukla, Sanjay K. Cook, Dane Meyer, Jacob Vernon, Suzanne D. Le, Thao Clevidence, Derek Robertson, Charles E. Schrodi, Steven J. Yale, Steven Frank, Daniel N. TI Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) SO PLOS ONE LA English DT Article ID NITROSATIVE STRESS PATHWAYS; GRAM-NEGATIVE ENTEROBACTERIA; SYNDROME CFS; INFLAMMATORY PATHWAYS; LEAKY GUT; TRANSLOCATION; LPS; NORMALIZATION; RESPONSES; SYMPTOMS AB Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disease characterized by intense and debilitating fatigue not due to physical activity that has persisted for at least 6 months, post-exertional malaise, unrefreshing sleep, and accompanied by a number of secondary symptoms, including sore throat, memory and concentration impairment, headache, and muscle/joint pain. In patients with post-exertional malaise, significant worsening of symptoms occurs following physical exertion and exercise challenge serves as a useful method for identifying biomarkers for exertion intolerance. Evidence suggests that intestinal dysbiosis and systemic responses to gut microorganisms may play a role in the symptomology of ME/CFS. As such, we hypothesized that post-exertion worsening of ME/CFS symptoms could be due to increased bacterial translocation from the intestine into the systemic circulation. To test this hypothesis, we collected symptom reports and blood and stool samples from ten clinically characterized ME/CFS patients and ten matched healthy controls before and 15 minutes, 48 hours, and 72 hours after a maximal exercise challenge. Microbiomes of blood and stool samples were examined. Stool sample microbiomes differed between ME/CFS patients and healthy controls in the abundance of several major bacterial phyla. Following maximal exercise challenge, there was an increase in relative abundance of 6 of the 9 major bacterial phyla/genera in ME/CFS patients from baseline to 72 hours post-exercise compared to only 2 of the 9 phyla/genera in controls (p = 0.005). There was also a significant difference in clearance of specific bacterial phyla from blood following exercise with high levels of bacterial sequences maintained at 72 hours post-exercise in ME/CFS patients versus clearance in the controls. These results provide evidence for a systemic effect of an altered gut microbiome in ME/CFS patients compared to controls. Upon exercise challenge, there were significant changes in the abundance of major bacterial phyla in the gut in ME/CFS patients not observed in healthy controls. In addition, compared to controls clearance of bacteria from the blood was delayed in ME/CFS patients following exercise. These findings suggest a role for an altered gut microbiome and increased bacterial translocation following exercise in ME/CFS patients that may account for the profound post-exertional malaise experienced by ME/CFS patients. C1 [Shukla, Sanjay K.; Le, Thao; Schrodi, Steven J.] Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. [Cook, Dane; Meyer, Jacob] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Cook, Dane; Clevidence, Derek] Univ Wisconsin, Madison, WI USA. [Vernon, Suzanne D.] Bateman Horne Ctr Excellence, Salt Lake City, UT USA. [Robertson, Charles E.; Frank, Daniel N.] Univ Colorado Denver, Aurora, CO USA. [Yale, Steven] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. RP Shukla, SK (reprint author), Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. EM shukla.sanjay@mcrf.mfldclin.edu OI Schrodi, Steven/0000-0003-2304-8528 FU CFIDS Association of America; Marshfield Clinic Research Foundation FX This study was funded from a grant from The CFIDS Association of America to SKS and donors to the Marshfield Clinic Research Foundation. The funding agency has no role in the study design or in the preparation of the manuscript. NR 57 TC 4 Z9 4 U1 5 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 18 PY 2015 VL 10 IS 12 AR e0145453 DI 10.1371/journal.pone.0145453 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9KM UT WOS:000366725800078 PM 26683192 ER PT J AU Thirumurthy, H Hayashi, K Linnemayr, S Vreeman, RC Levin, IP Bangsberg, DR Brewer, NT AF Thirumurthy, Harsha Hayashi, Kami Linnemayr, Sebastian Vreeman, Rachel C. Levin, Irwin P. Bangsberg, David R. Brewer, Noel T. TI Time Preferences Predict Mortality among HIV-Infected Adults Receiving Antiretroviral Therapy in Kenya SO PLOS ONE LA English DT Article ID SUB-SAHARAN AFRICA; CIGARETTE SMOKERS; HEALTH BEHAVIORS; ALCOHOL; ADHERENCE; FUTURE AB Background Identifying characteristics of HIV-infected adults likely to have poor treatment outcomes can be useful for targeting interventions efficiently. Research in economics and psychology suggests that individuals' intertemporal time preferences, which indicate the extent to which they trade-off immediate vs. future cost and benefits, can influence various health behaviors. While there is empirical support for the association between time preferences and various non-HIV health behaviors and outcomes, the extent to which time preferences predict outcomes of those receiving antiretroviral therapy (ART) has not been examined previously. Methods HIV-infected adults initiating ART were enrolled at a health facility in Kenya. Participants' time preferences were measured at enrollment and used to classify them as having either a low or high discount rate for future benefits. At 48 weeks, we assessed mortality and ART adherence, as measured by Medication Event Monitoring System (MEMS). Logistic regression models adjusting for socio-economic characteristics and risk factors were used to determine the association between time preferences and mortality as well as MEMS adherence >= 90%. Results Overall, 44% (96/220) of participants were classified as having high discount rates. Participants with high discount rates had significantly higher 48-week mortality than participants with low discount rates (9.3% vs. 3.1%; adjusted odds ratio 3.84; 95% CI 1.03, 14.50). MEMS adherence >= 90% was similar for participants with high vs. low discount rates (42.3% vs. 49.6%, AOR 0.70; 95% CI 0.40, 1.25). Conclusion High discount rates were associated with significantly higher risk of mortality among HIV-infected patients initiating ART. Greater use of time preference measures may improve identification of patients at risk of poor clinical outcomes. More research is needed to further identify mechanisms of action and also to build upon and test the generalizability of this finding. C1 [Thirumurthy, Harsha] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA. [Thirumurthy, Harsha] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC USA. [Hayashi, Kami; Brewer, Noel T.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav, Chapel Hill, NC USA. [Linnemayr, Sebastian] RAND Corp, Santa Monica, CA USA. [Vreeman, Rachel C.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA. [Vreeman, Rachel C.] Acad Model Providing Access Healthcare, Eldoret, Kenya. [Levin, Irwin P.] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA. [Bangsberg, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Global Hlth, Boston, MA USA. RP Thirumurthy, H (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA. EM harsha@unc.edu FU World Bank Research Group - Bank Netherlands Partnership Program (BNPP) [7142349, 7144565]; United States Agency for International Development, President's Emergency Plan for AIDS Relief (PEPFAR); National Institute of Child Health & Human Development [K01HD061605] FX The World Bank Research Group provided financial support for this project under contracts 7142349 and 7144565 funded by the Bank Netherlands Partnership Program (BNPP). This research was also supported in part by a grant to the USAID-Academic Model Providing Access to Healthcare Partnership from the United States Agency for International Development as part of the President's Emergency Plan for AIDS Relief (PEPFAR). H. Thirumurthy received support from the National Institute of Child Health & Human Development (K01HD061605). NR 26 TC 1 Z9 1 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 18 PY 2015 VL 10 IS 12 AR e0145245 DI 10.1371/journal.pone.0145245 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9KM UT WOS:000366725800050 PM 26684298 ER PT J AU Bagnall, JS Byun, S Begum, S Miyamoto, DT Hecht, VC Maheswaran, S Stott, SL Toner, M Hynes, RO Manalis, SR AF Bagnall, Josephine Shaw Byun, Sangwon Begum, Shahinoor Miyamoto, David T. Hecht, Vivian C. Maheswaran, Shyamala Stott, Shannon L. Toner, Mehmet Hynes, Richard O. Manalis, Scott R. TI Deformability of Tumor Cells versus Blood Cells SO SCIENTIFIC REPORTS LA English DT Article ID EPITHELIAL-MESENCHYMAL TRANSITION; CANCER-CELLS; INITIATING CELLS; PROSTATE-CANCER; METASTASIS; PLATELETS; EMT; EXPRESSION; STIFFNESS; FRICTION AB The potential for circulating tumor cells (CTCs) to elucidate the process of cancer metastasis and inform clinical decision-making has made their isolation of great importance. However, CTCs are rare in the blood, and universal properties with which to identify them remain elusive. As technological advancements have made single-cell deformability measurements increasingly routine, the assessment of physical distinctions between tumor cells and blood cells may provide insight into the feasibility of deformability-based methods for identifying CTCs in patient blood. To this end, we present an initial study assessing deformability differences between tumor cells and blood cells, indicated by the length of time required for them to pass through a microfluidic constriction. Here, we demonstrate that deformability changes in tumor cells that have undergone phenotypic shifts are small compared to differences between tumor cell lines and blood cells. Additionally, in a syngeneic mouse tumor model, cells that are able to exit a tumor and enter circulation are not required to be more deformable than the cells that were first injected into the mouse. However, a limited study of metastatic prostate cancer patients provides evidence that some CTCs may be more mechanically similar to blood cells than to typical tumor cell lines. C1 [Bagnall, Josephine Shaw; Byun, Sangwon; Hecht, Vivian C.; Manalis, Scott R.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. [Bagnall, Josephine Shaw; Byun, Sangwon; Begum, Shahinoor; Hecht, Vivian C.; Hynes, Richard O.; Manalis, Scott R.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Begum, Shahinoor; Hynes, Richard O.] MIT, Howard Hughes Med Inst, Cambridge, MA USA. [Miyamoto, David T.; Maheswaran, Shyamala; Stott, Shannon L.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Miyamoto, David T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Maheswaran, Shyamala; Toner, Mehmet] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Stott, Shannon L.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA. [Stott, Shannon L.; Toner, Mehmet] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn & Med, Boston, MA USA. [Hynes, Richard O.] MIT, Dept Biol, Cambridge, MA USA. [Manalis, Scott R.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA. RP Manalis, SR (reprint author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM srm@mit.edu FU Janssen Pharmaceuticals, Inc.; Physical Sciences Oncology Center [U54CA143874]; CCNE-T grant [26697290-47281-A]; National Institute of Health P41 Biotechnology Resource Center; Koch Institute Support Grant from the National Cancer Institute [P30-CA14051]; Stand Up to Cancer FX We thank Katherine Broderick and Wooseok Kim for processing the patient blood samples at MGH. We also thank Eduardo Reategui for help in exploring alternative methods for CTC capture and validation, as well as Philipp Spuhler for help with initial validations of CTC-iChip-processed blood samples with the SMR. We especially appreciate all the patients who participated in this study. We also thank Xin Ye and Prof. Robert A. Weinberg for providing the MMTV-PyMT cell line as well as comments to the manuscript. We are also grateful to the Koch Institute Swanson Biotechnology Center, including Eliza Vasile at the Microscopy Core Facility and Michele Griffin at the Flow Cytometry Core Facility. This work was supported by Janssen Pharmaceuticals, Inc., Physical Sciences Oncology Center U54CA143874, CCNE-T grant 26697290-47281-A, Stand Up to Cancer, National Institute of Health P41 Biotechnology Resource Center, and Koch Institute Support Grant P30-CA14051 from the National Cancer Institute. NR 56 TC 11 Z9 11 U1 3 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD DEC 18 PY 2015 VL 5 AR 18542 DI 10.1038/srep18542 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ4FQ UT WOS:000367059300002 ER PT J AU Kataoka, A Scherrer-Crosbie, M Senior, R Gosselin, G Phaneuf, D Guzman, G Perna, G Lara, A Kedev, S Mortara, A El-Hajjar, M Shaw, LJ Reynolds, HR Picard, MH AF Kataoka, Akihisa Scherrer-Crosbie, Marielle Senior, Roxy Gosselin, Gilbert Phaneuf, Denis Guzman, Gabriela Perna, Gian Lara, Alfonso Kedev, Sasko Mortara, Andrea El-Hajjar, Mohammad Shaw, Leslee J. Reynolds, Harmony R. Picard, Michael H. TI The value of core lab stress echocardiography interpretations: observations from the ISCHEMIA Trial SO CARDIOVASCULAR ULTRASOUND LA English DT Article DE Stress echocardiography; ISCHEMIA Trial; Interpretation variability; Left ventricular myocardial ischemia; Image quality ID OPTIMAL MEDICAL THERAPY; MYOCARDIAL-INFARCTION; ADMISSION ELECTROCARDIOGRAM; EXERCISE ECHOCARDIOGRAPHY; LABORATORY INTERPRETATION; OBSERVER AGREEMENT; DISEASE; ASSOCIATION; TOMOGRAPHY; COURAGE AB Background: Stress echocardiography (SE) is dependent on subjective interpretations. As a prelude to the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial, potential sites were required to submit two SE, one with moderate or severe left ventricular (LV) myocardial ischemia and one with mild ischemia. We evaluated the concordance of site and core lab interpretations. Methods: Eighty-one SE were submitted from 41 international sites. Ischemia was classified by the number of new or worsening segmental LV wall motion abnormalities (WMA): none, mild (1 or 2) or moderate or severe (3 or more) by the sites and the core lab. Results: Core lab classified 6 SE as no ischemia, 35 mild and 40 moderate or greater. There was agreement between the site and core in 66 of 81 total cases (81 %, weighted kappa coefficient [K] = 0.635). Agreement was similar for SE type - 24 of 30 exercise (80 %, K = 0.571) vs. 41 of 49 pharmacologic (84 %, K = 0.685). The agreement between poor or fair image quality (27 of 36 cases, 75 %, K = 0.492) was not as good as for the good or excellent image quality cases (39 of 45 cases, 87 %, K = 0.755). Differences in concordance were noted for degree of ischemia with the majority of discordant interpretations (87 %) occurring in patients with no or mild LV myocardial ischemia. Conclusions: While site SE interpretations are largely concordant with core lab interpretations, this appears dependent on image quality and the extent of WMA. Thus core lab interpretations remain important in clinical trials where consistency of interpretation across a range of cases is critical. C1 [Kataoka, Akihisa; Scherrer-Crosbie, Marielle; Picard, Michael H.] Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA. [Kataoka, Akihisa; Scherrer-Crosbie, Marielle; Picard, Michael H.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Senior, Roxy] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Div Cardiol, Dept Cardiovasc Med, London SW3 6NP, England. [Gosselin, Gilbert] Montreal Heart Inst, Dept Med, Montreal, PQ H1T 1C8, Canada. [Phaneuf, Denis] CSSS Sud Lanaudiere, Dept Cardiol Res, Terrebonne, PQ J6V 2H2, Canada. [Guzman, Gabriela] Hosp Univ La Paz, Dept Cardiol, Madrid 28046, Spain. [Perna, Gian] Osped Riuniti Ancona, Cardiol Riabilitat & Prevent, I-60020 Ancona, Marche, Italy. [Lara, Alfonso] CRC IMSS, Ctr Med Nacl La Raza, Hosp Especialidades, Benito Juarez 3100, DF, Mexico. [Kedev, Sasko] Univ Clin Cardiol, Intervent Cardiol, Skopje, Macedonia. [Mortara, Andrea] Policlin Monza, Dept Clin Cardiol & Heart Failure, I-20900 Monza, MB, Italy. [El-Hajjar, Mohammad] Albany Med Coll, Div Cardiol, Internal Med, Albany, NY 12208 USA. [El-Hajjar, Mohammad] Stratton VA Med Ctr, Albany, NY 12208 USA. [Shaw, Leslee J.] Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA. [Reynolds, Harmony R.] NYU, Langone Med Ctr, Div Cardiol, Dept Med, New York, NY 10010 USA. RP Picard, MH (reprint author), Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St Yawkey 5E, Boston, MA 02114 USA. EM MHPICARD@mgh.harvard.edu OI Reynolds, Harmony/0000-0003-0284-0655; Picard, Michael/0000-0002-9264-3243 FU Japanese Society of Echocardiography Overseas Research Fellowship; Uehara Memorial Foundation Research Fellowship; National Heart, Lung, and Blood Institute [5U01HL105561-02, 1U01HL10556-01] FX This work was supported by grants from the Japanese Society of Echocardiography Overseas Research Fellowship and Uehara Memorial Foundation Research Fellowship (Dr. Kataoka), and the National Heart, Lung, and Blood Institute (5U01HL105561-02, 1U01HL10556-01). NR 21 TC 2 Z9 2 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-7120 J9 CARDIOVASC ULTRASOUN JI Cardiovasc. Ultrasound PD DEC 18 PY 2015 VL 13 AR 47 DI 10.1186/s12947-015-0043-2 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CZ0TF UT WOS:000366818200001 PM 26683627 ER PT J AU Meier, DT Tu, LH Zraika, S Hogan, MF Templin, AT Hull, RL Raleigh, DP Kahn, SE AF Meier, Daniel T. Tu, Ling-Hsien Zraika, Sakeneh Hogan, Meghan F. Templin, Andrew T. Hull, Rebecca L. Raleigh, Daniel P. Kahn, Steven E. TI Matrix Metalloproteinase-9 Protects Islets from Amyloid-induced Toxicity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID BETA-CELL APOPTOSIS; FIBRIL FORMATION; PANCREATIC-ISLETS; TRANSGENIC MOUSE; HUMAN AMYLIN; POLYPEPTIDE; DEPOSITION; INHIBITORS; CYTOTOXICITY; MECHANISM AB Deposition of human islet amyloid polypeptide (hIAPP, also known as amylin) as islet amyloid is a characteristic feature of the pancreas in type 2 diabetes, contributing to increased beta-cell apoptosis and reduced beta-cell mass. Matrix metalloproteinase-9 (MMP-9) is active in islets and cleaves hIAPP. We investigated whether hIAPP fragments arising from MMP-9 cleavage retain the potential to aggregate and cause toxicity, and whether over-expressing MMP-9 in amyloid-prone islets reduces amyloid burden and the resulting beta-cell toxicity. Synthetic hIAPP was incubated with MMP-9 and the major hIAPP fragments observed by MS comprised residues 1-15, 1-25, 16-37, 16-25, and 26-37. The fragments 1-15, 1-25, and 26-37 did not form amyloid fibrils in vitro and they were not cytotoxic when incubated with b cells. Mixtures of these fragments with full-length hIAPP did not modulate the kinetics of fibril formation by full-length hIAPP. In contrast, the 16-37 fragment formed fibrils more rapidly than full-length hIAPP but was less cytotoxic. Co-incubation of MMP-9 and fragment 16-37 ablated amyloidogenicity, suggesting that MMP-9 cleaves hIAPP 16-37 into non-amyloidogenic fragments. Consistent with MMP-9 cleavage resulting in largely non-amyloidogenic degradation products, adenoviral overexpression of MMP-9 in amyloid-prone islets reduced amyloid deposition and beta-cell apoptosis. These findings suggest that increasing islet MMP-9 activity might be a strategy to limit beta-cell loss in type 2 diabetes. C1 [Meier, Daniel T.; Zraika, Sakeneh; Hogan, Meghan F.; Templin, Andrew T.; Hull, Rebecca L.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Meier, Daniel T.; Zraika, Sakeneh; Hogan, Meghan F.; Templin, Andrew T.; Hull, Rebecca L.; Kahn, Steven E.] Univ Washington, Seattle, WA 98108 USA. [Tu, Ling-Hsien] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan. [Tu, Ling-Hsien; Raleigh, Daniel P.] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA. [Raleigh, Daniel P.] UCL, Dept Struct & Mol Biol, London WC1E 6BT, England. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@uw.edu RI Regan, Clinton/E-6250-2012; OI Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087 FU Dept. of Veterans Affairs [BX001060]; NIH [DK-007247, DK-017047, DK-020595, DK-080945, DK-088082, DK-098506, GM-078114, HL-007028]; Swiss National Foundation Fellowship; Dick and Julia McAbee Endowed Fellowship in Diabetes from the University of Washington; American Diabetes Association FX This work was supported by the Dept. of Veterans Affairs Grant BX001060, NIH Grants DK-007247, DK-017047, DK-020595, DK-080945, DK-088082, DK-098506, GM-078114, and HL-007028. The authors declare that they have no conflict of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; Supported by a Swiss National Foundation Fellowship and the Dick and Julia McAbee Endowed Fellowship in Diabetes from the University of Washington.; Supported by an American Diabetes Association Mentor-based Fellowship. NR 49 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 18 PY 2015 VL 290 IS 51 BP 30475 EP 30485 DI 10.1074/jbc.M115.676692 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CY9PG UT WOS:000366738200024 PM 26483547 ER PT J AU Shanmugam, NKN Chen, KJ Cherayil, BJ AF Shanmugam, Nanda Kumar N. Chen, Kejie Cherayil, Bobby J. TI Commensal Bacteria-induced Interleukin 1 beta (IL-1 beta) Secreted by Macrophages Up-regulates Hepcidin Expression in Hepatocytes by Activating the Bone Morphogenetic Protein Signaling Pathway SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; IRON HOMEOSTASIS; INTESTINAL INFLAMMATION; HORMONE HEPCIDIN; CROHNS-DISEASE; GUT MICROBIOTA; IN-VIVO; STAT3; FERROPORTIN; ANEMIA AB The liver hormone hepcidin is the central regulator of systemic iron metabolism. Its increased expression in inflammatory states leads to hypoferremia and anemia. Elucidation of the mechanisms that up-regulate hepcidin during inflammation is essential for developing rational therapies for this anemia. Using mouse models of inflammatory bowel disease, we have shown previously that colitis-associated hepcidin induction is influenced by intestinal microbiota composition. Here we investigate how two commensal bacteria, Bifidobacterium longum and Bacteroides fragilis, representative members of the gut microbiota, affect hepcidin expression. We found that supernatants of a human macrophage cell line infected with either of the bacteria up-regulated hepcidin when added to a human hepatocyte cell line. This activity was abrogated by neutralization of IL-1 beta. Moreover, purified IL-1 beta increased hepcidin expression when added to the hepatocyte line or primary human hepatocytes and when injected into mice. IL-1 beta activated the bone morphogenetic protein (BMP) signaling pathway in hepatocytes and in mouse liver, as indicated by increased phosphorylation of small mothers against decapentaplegic proteins. Activation of BMP signaling correlated with IL-1 beta -induced expression of BMP2in human hepatocytes and activinBin mouse liver. Treatment of hepatocytes with two different chemical inhibitors of BMP signaling or with a neutralizing antibody to BMP2 prevented IL-1 beta-induced up-regulation of hepcidin. Our results clarify how commensal bacteria affect hepcidin expression and reveal a novel connection between IL-1 beta and activation of BMP signaling. They also suggest that there may be differences between mice and humans with respect to the mechanism by which IL-1 beta up-regulates hepcidin. C1 [Shanmugam, Nanda Kumar N.; Chen, Kejie; Cherayil, Bobby J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr,Dept Pediat, Boston, MA 02129 USA. RP Cherayil, BJ (reprint author), Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, Bldg 114,16th St, Charlestown, MA 02129 USA. EM cherayil@helix.mgh.harvard.edu RI Regan, Clinton/E-6250-2012 FU National Institutes of Health [R01 AI089700]; China Scholarship Council FX This work was supported by National Institutes of Health Grant R01 AI089700 (to B. J. C.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; Supported by funding from the China Scholarship Council. NR 47 TC 6 Z9 6 U1 1 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 18 PY 2015 VL 290 IS 51 BP 30637 EP 30647 DI 10.1074/jbc.M115.689190 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CY9PG UT WOS:000366738200038 PM 26515063 ER PT J AU Zhang, G Zhang, Y AF Zhang, Gang Zhang, Yi TI "Mouse Clone Model" for evaluating the immunogenicity and tumorigenicity of pluripotent stem cells SO STEM CELL RESEARCH & THERAPY LA English DT Editorial Material ID IPS CELLS; MICE; GENERATION; LEUKEMIA; FETAL AB To investigate the immune-rejection and tumor-formation potentials of induced pluripotent stem cells and other stem cells, we devised a model-designated the "Mouse Clone Model" - which combined the theory of somatic animal cloning, tetraploid complementation, and induced pluripotent stem cells to demonstrate the applicability of stem cells for transplantation therapy. C1 [Zhang, Gang] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON M5S 3G5, Canada. [Zhang, Gang] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Dept Med, Toronto, ON M5T 2S8, Canada. [Zhang, Gang] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02129 USA. [Zhang, Yi] Univ Toronto, New Coll, Program Life Sci, Toronto, ON M5S 1C6, Canada. RP Zhang, G (reprint author), Univ Toronto, Dept Cell & Syst Biol, 25 Harbord St, Toronto, ON M5S 3G5, Canada. EM gang.zhang@utoronto.ca; yizhang.zhang@mail.utoronto.ca NR 29 TC 0 Z9 0 U1 3 U2 17 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1757-6512 J9 STEM CELL RES THER JI Stem Cell Res. Ther. PD DEC 18 PY 2015 VL 6 AR 255 DI 10.1186/s13287-015-0262-3 PG 4 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA CZ1VR UT WOS:000366894300005 PM 26687081 ER PT J AU Shenoy, ES Lai, PS Shepard, JAO Kradin, RL AF Shenoy, Erica S. Lai, Peggy S. Shepard, Jo-Anne O. Kradin, Richard L. TI Case 39-2015: A 22-Year-Old Man with Hypoxemia and Shock SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID PNEUMONIC TULAREMIA; PANDEMIC INFLUENZA; SEASONAL INFLUENZA; MARTHAS-VINEYARD; DEATH; RISK; COMPLICATIONS; INFECTION; OUTBREAK; ADULTS C1 [Shenoy, Erica S.; Lai, Peggy S.; Kradin, Richard L.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Shepard, Jo-Anne O.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Kradin, Richard L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Shenoy, Erica S.; Lai, Peggy S.; Kradin, Richard L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Shepard, Jo-Anne O.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Kradin, Richard L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Shenoy, ES (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. NR 23 TC 0 Z9 0 U1 0 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 17 PY 2015 VL 373 IS 25 BP 2456 EP 2466 DI 10.1056/NEJMcpc1507212 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CY5QD UT WOS:000366461400014 PM 26672848 ER PT J AU Brown, JR AF Brown, Jennifer R. TI Idelalisib has CLL on the run! SO BLOOD LA English DT Editorial Material AB In this issue of Blood, O'Brien et al report mature results of initial treatment of chronic lymphocytic leukemia (CLL) with the PI3K delta inhibitor idelalisib plus rituximab, and demonstrate that the combination is extremely effective with manageable toxicity in an older patient population.(1) C1 [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Brown, JR (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 10 TC 3 Z9 3 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 17 PY 2015 VL 126 IS 25 BP 2656 EP 2657 DI 10.1182/blood-2015-10-676890 PG 4 WC Hematology SC Hematology GA DB3RS UT WOS:000368429600003 PM 26679541 ER PT J AU Schmitz-Abe, K Ciesielski, SJ Schmidt, PJ Campagna, DR Rahimov, F Schilke, BA Cuijpers, M Rieneck, K Lausen, B Linenberger, ML Sendamarai, AK Guo, CS Hofmann, I Newburger, PE Matthews, D Shimamura, A Snijders, PJLM Towne, MC Niemeyer, CM Watson, HG Dziegiel, MH Heeney, MM May, A Bottomley, SS Swinkels, DW Markianos, K Craig, EA Fleming, MD AF Schmitz-Abe, Klaus Ciesielski, Szymon J. Schmidt, Paul J. Campagna, Dean R. Rahimov, Fedik Schilke, Brenda A. Cuijpers, Marloes Rieneck, Klaus Lausen, Birgitte Linenberger, Michael L. Sendamarai, Anoop K. Guo, Chaoshe Hofmann, Inga Newburger, Peter E. Matthews, Dana Shimamura, Akiko Snijders, Pieter J. L. M. Towne, Meghan C. Niemeyer, Charlotte M. Watson, Henry G. Dziegiel, Morten H. Heeney, Matthew M. May, Alison Bottomley, Sylvia S. Swinkels, Dorine W. Markianos, Kyriacos Craig, Elizabeth A. Fleming, Mark D. TI Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9 SO BLOOD LA English DT Article ID IRON; GENE; SSQ1; COUNTERPART; BIOGENESIS AB The congenital sideroblastic anemias (CSAs) are relatively uncommon diseases characterized by defects in mitochondrial heme synthesis, iron-sulfur (Fe-S) cluster biogenesis, or protein synthesis. Here we demonstrate that mutations in HSPA9, a mitochondrial HSP70 homolog located in the chromosome 5q deletion syndrome 5q33 critical deletion interval and involved in mitochondrial Fe-S biogenesis, result in CSA inherited as an autosomal recessive trait. In a fraction of patients with just 1 severe loss-of-function allele, expression of the clinical phenotype is associated with a common coding single nucleotide polymorphism in trans that correlates with reduced messenger RNA expression and results in a pseudodominant pattern of inheritance. C1 [Schmitz-Abe, Klaus; Rahimov, Fedik; Towne, Meghan C.; Markianos, Kyriacos] Boston Childrens Hosp, Div Genet & Genom, Boston, MA 02115 USA. [Schmitz-Abe, Klaus; Schmidt, Paul J.; Rahimov, Fedik; Sendamarai, Anoop K.; Guo, Chaoshe; Hofmann, Inga; Heeney, Matthew M.; Markianos, Kyriacos; Fleming, Mark D.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Ciesielski, Szymon J.; Schilke, Brenda A.; Craig, Elizabeth A.] Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA. [Schmidt, Paul J.; Campagna, Dean R.; Sendamarai, Anoop K.; Guo, Chaoshe; Fleming, Mark D.] Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. [Cuijpers, Marloes] Viecuri Med Ctr, Dept Internal Med, Venlo, Netherlands. [Rieneck, Klaus] Rigshosp, Copenhagen Univ Hosp, Dept Clin Immunol, DK-2100 Copenhagen, Denmark. [Lausen, Birgitte] Rigshosp, Copenhagen Univ Hosp, Dept Pediat & Adolescent Med, DK-2100 Copenhagen, Denmark. [Linenberger, Michael L.] Univ Washington, Div Hematol, Seattle, WA 98195 USA. [Hofmann, Inga] Dana Farber Canc Inst, Boston Childrens Ctr Canc & Blood Disorders, Dept Pediat, Boston, MA 02115 USA. [Newburger, Peter E.] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA. [Matthews, Dana; Shimamura, Akiko] Seattle Childrens Hosp, Div Hematol, Seattle, WA USA. [Snijders, Pieter J. L. M.] Huisartsenteam St Willebrord, St Willebrord, Netherlands. [Niemeyer, Charlotte M.] Univ Freiburg, Childrens Hosp, Pediat Hematol & Oncol Dept, D-79106 Freiburg, Germany. [Watson, Henry G.] Aberdeen Royal Infirm, Dept Haematol, Aberdeen, Scotland. [May, Alison] Cardiff Univ, Sch Med, Dept Haematol, Cardiff CF10 3AX, S Glam, Wales. [Bottomley, Sylvia S.] Univ Oklahoma, Coll Med, Dept Med, Hematol Oncol Sect, Oklahoma City, OK 73190 USA. [Swinkels, Dorine W.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Translat Metab Lab, NL-6525 ED Nijmegen, Netherlands. RP Fleming, MD (reprint author), Boston Childrens Hosp, 300 Longwood Ave,Bader 124-1, Boston, MA 02115 USA. EM mark.fleming@childrens.harvard.edu OI Newburger, Peter/0000-0002-8615-673X FU National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK087992]; NIH National Institute of Diabetes and Digestive and Kidney Diseases [R24 DK099808]; NIH National Institute of General Medical Sciences [R01 GM GM27870]; Llandough Haematology Development Fund; US Department of Veterans Affairs; Oklahoma Center for Advancement of Science and Technology FX M.D.F., K.M., and K.S.-A. were supported by grant R01 DK087992 from the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases. I.H., M.D.F., K.M., and A.S. were supported by grant R24 DK099808 from the NIH National Institute of Diabetes and Digestive and Kidney Diseases. E.A.C. and S.J.C. were supported by grant R01 GM GM27870 from the NIH National Institute of General Medical Sciences. A.M. was supported by the Llandough Haematology Development Fund, and S.S.B. was supported by grants from the US Department of Veterans Affairs and the Oklahoma Center for Advancement of Science and Technology. NR 17 TC 4 Z9 4 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 17 PY 2015 VL 126 IS 25 BP 2734 EP 2738 DI 10.1182/blood-2015-09-659854 PG 5 WC Hematology SC Hematology GA DB3RS UT WOS:000368429600016 PM 26491070 ER PT J AU Pedersen, MM Petersen, J Bean, JF Damkjaer, L Juul-Larsen, HG Andersen, O Beyer, N Bandholm, T AF Pedersen, Mette Merete Petersen, Janne Bean, Jonathan F. Damkjaer, Lars Juul-Larsen, Helle Gybel Andersen, Ove Beyer, Nina Bandholm, Thomas TI Feasibility of progressive sit-to-stand training among older hospitalized patients SO PEERJ LA English DT Article DE Older medical patients; Strength training; Cross continuum; Supervision; Physical therapy ID RANDOMIZED CONTROLLED-TRIAL; MEMORY-CONCENTRATION TEST; MUSCLE STRENGTH; FUNCTIONAL PERFORMANCE; PHYSICAL PERFORMANCE; SKELETAL-MUSCLE; HIP FRACTURE; RISK-FACTORS; LEG POWER; ADULTS AB Background. In older patients, hospitalization is associated with a decline in functional performance and loss of muscle strength. Loss of muscle strength and functional performance can be prevented by systematic strength training, but details are lacking regarding the optimal exercise program and dose for older patients. Therefore, our aim was to test the feasibility of a progression model for loaded sit-to-stand training among older hospitalized patients. Methods. This is a prospective cohort study conducted as a feasibility study prior to a full-scale trial. We included twenty-four older patients (>= 65 yrs) acutely admitted from their own home to the medical services of the hospital. We developed an 8-level progression model for loaded sit-to-stands, which we named STAND. We used STAND as a model to describe how to perform the sit-to-stand exercise as a strength training exercise aimed at reaching a relative load of 8-12 repetitions maximum (RM) for 8-12 repetitions. Weight could be added by the use of a weight vest when needed. The ability of the patients to reach the intended relative load (8-12 RM), while performing sit-to-stands following the STAND model, was tested once during hospitalization and once following discharge in their own homes. A structured interview including assessment of possible modifiers (cognitive status by the Short Orientation Memory test and mobility by the De Morton Mobility Index) was administered both on admission to the hospital and in the home setting. The STAND model was considered feasible if: (1) 75% of the assessed patients could perform the exercise at a given level of the model reaching 8-12 repetitions at a relative load of 8-12 RM for one set of exercise in the hospital and two sets of exercise at home; (2) no ceiling or floor effect was seen; (3) no indication of adverse events were observed. The outcomes assessed were: level of STAND attained, the number of sets performed, perceived exertion (the Borg scale), and pain (the Verbal Ranking Scale). Results. Twenty-four patients consented to participate. Twenty-three of the patients were tested in the hospital and 19 patients were also tested in their home. All three criteria for feasibility were met: (1) in the hospital, 83% could perform the exercise at a given level of STAND, reaching 8-12 repetitions at 8-12 RM for one set, and 79% could do so for two sets in the home setting; (2) for all assessed patients, a possibility of progression or regression was possible-no ceiling or floor effect was observed; (3) no indication of adverse events (pain) was observed. Also, those that scored higher on the De Morton Mobility Index performed the exercise at higher levels of STAND, whereas performance was independent of cognitive status. Conclusions. We found a simple progression model for loaded sit-to-stands (STAND) feasible in acutely admitted older medical patients (>= 65 yrs), based on our pre-specified criteria for feasibility. C1 [Pedersen, Mette Merete; Petersen, Janne; Juul-Larsen, Helle Gybel; Andersen, Ove; Bandholm, Thomas] Copenhagen Univ Hosp, Clin Res Ctr, Optimized Senior Patient Program Optimed, Hvidovre, Denmark. [Pedersen, Mette Merete; Juul-Larsen, Helle Gybel; Bandholm, Thomas] Copenhagen Univ Hosp, Dept Phys & Occupat Therapy, Phys Med & Rehabil Res Copenhagen PMRC, Hvidovre, Denmark. [Petersen, Janne] Univ Copenhagen, Dept Publ Hlth, Sect Biostat, Copenhagen, Denmark. [Bean, Jonathan F.] VA Boston Healthcare Syst, New England GRECC, Boston, MA USA. [Bean, Jonathan F.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Damkjaer, Lars] Copenhagen Municipal Hlth Adm, Dept Rehabil, Copenhagen, Denmark. [Beyer, Nina] Bispebjerg Hosp, Inst Sports Med, DK-2400 Copenhagen, Denmark. [Beyer, Nina] Bispebjerg Hosp, Musculoskeletal Rehabil Res Unit, DK-2400 Copenhagen, Denmark. [Bandholm, Thomas] Copenhagen Univ Hosp, Dept Orthopaed Surg, Hvidovre, Denmark. RP Pedersen, MM (reprint author), Copenhagen Univ Hosp, Clin Res Ctr, Optimized Senior Patient Program Optimed, Hvidovre, Denmark. EM mette.merete.pedersen@regionh.dk RI Bean, Jonathan/F-5798-2017 OI Bean, Jonathan/0000-0001-8385-8210 FU NICHD NIH HHS [K24 HD070966] NR 67 TC 1 Z9 1 U1 5 U2 8 PU PEERJ INC PI LONDON PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND SN 2167-8359 J9 PEERJ JI PeerJ PD DEC 17 PY 2015 VL 3 AR e1500 DI 10.7717/peerj.1500 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ5PO UT WOS:000367154700003 PM 26713248 ER PT J AU Mercier, FE Scadden, DT AF Mercier, Francois E. Scadden, David T. TI Not All Created Equal: Lineage Hard-Wiring in the Production of Blood SO CELL LA English DT Editorial Material ID STEM-CELL HIERARCHY AB The multiple cell types comprising blood have been thought to emerge from progenitors with progressively narrower lineage options. New data suggest that lineage fate may be determined earlier than thought and that myeloid progenitor populations are aggregates of individual lineage-restricted cells. C1 [Mercier, Francois E.; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med & Canc Ctr, Boston, MA 02114 USA. [Mercier, Francois E.; Scadden, David T.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Mercier, Francois E.; Scadden, David T.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. RP Scadden, DT (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med & Canc Ctr, 185 Cambridge St, Boston, MA 02114 USA. EM david_scadden@harvard.edu NR 7 TC 6 Z9 6 U1 0 U2 4 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD DEC 17 PY 2015 VL 163 IS 7 BP 1568 EP 1570 DI 10.1016/j.cell.2015.12.013 PG 4 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CZ1GN UT WOS:000366854200003 PM 26687347 ER PT J AU York, AG Williams, KJ Argus, JP Zhou, QD Brar, G Vergnes, L Gray, EE Zhen, AJ Wu, NC Yamada, DH Cunningham, CR Tarling, EJ Wilks, MQ Casero, D Gray, DH Yu, AK Wang, ES Brooks, DG Sun, R Kitchen, SG Wu, TT Reue, K Stetson, DB Bensinger, SJ AF York, Autumn G. Williams, Kevin J. Argus, Joseph P. Zhou, Quan D. Brar, Gurpreet Vergnes, Laurent Gray, Elizabeth E. Zhen, Anjie Wu, Nicholas C. Yamada, Douglas H. Cunningham, Cameron R. Tarling, Elizabeth J. Wilks, Moses Q. Casero, David Gray, David H. Yu, Amy K. Wang, Eric S. Brooks, David G. Sun, Ren Kitchen, Scott G. Wu, Ting-Ting Reue, Karen Stetson, Daniel B. Bensinger, Steven J. TI Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling SO CELL LA English DT Article ID FATTY-ACID SYNTHESIS; FOAM CELL-FORMATION; MYCOBACTERIUM-TUBERCULOSIS; ENDOPLASMIC-RETICULUM; RECEPTOR AGONISTS; INTERFERON; REPLICATION; MACROPHAGES; PATHWAY; 25-HYDROXYCHOLESTEROL AB Cellular lipid requirements are achieved through a combination of biosynthesis and import programs. Using isotope tracer analysis, we show that type I interferon (IFN) signaling shifts the balance of these programs by decreasing synthesis and increasing import of cholesterol and long chain fatty acids. Genetically enforcing this metabolic shift in macrophages is sufficient to render mice resistant to viral challenge, demonstrating the importance of reprogramming the balance of these two metabolic pathways in vivo. Unexpectedly, mechanistic studies reveal that limiting flux through the cholesterol biosynthetic pathway spontaneously engages a type I IFN response in a STING-dependent manner. The upregulation of type I IFNs was traced to a decrease in the pool size of synthesized cholesterol and could be inhibited by replenishing cells with free cholesterol. Taken together, these studies delineate a metabolic-inflammatory circuit that links perturbations in cholesterol biosynthesis with activation of innate immunity. C1 [York, Autumn G.; Argus, Joseph P.; Zhou, Quan D.; Brar, Gurpreet; Wu, Nicholas C.; Yu, Amy K.; Wang, Eric S.; Sun, Ren; Wu, Ting-Ting; Bensinger, Steven J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Williams, Kevin J.; Cunningham, Cameron R.; Gray, David H.; Bensinger, Steven J.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. [Casero, David; Bensinger, Steven J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Vergnes, Laurent; Reue, Karen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Zhen, Anjie; Kitchen, Scott G.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA. [Tarling, Elizabeth J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA. [Zhen, Anjie; Kitchen, Scott G.] UCLA AIDS Inst, Los Angeles, CA 90095 USA. [Zhen, Anjie; Kitchen, Scott G.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA. [Wu, Nicholas C.; Tarling, Elizabeth J.; Gray, David H.; Reue, Karen] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. [Stetson, Daniel B.] Univ Washington, Dept Immunol, Seattle, WA 98109 USA. [Wilks, Moses Q.] Massachusetts Gen Hosp, Dept Radiol, Ctr Adv Med Imaging Sci, Boston, MA 02114 USA. [Brooks, David G.] Univ Hlth Network, Princess Margaret Canc Ctr, Immune Therapy Program, Toronto, ON M5G 2M9, Canada. [Brooks, David G.] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada. [Brooks, David G.] Immunooncol Discovery Res, Spring House, PA 19477 USA. [Brooks, David G.] Janssen Res & Dev LLC, Spring House, PA 19477 USA. RP Bensinger, SJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. EM sbensinger@mednet.ucla.edu RI Wu, Nicholas/H-3822-2015; OI Wu, Nicholas/0000-0002-9078-6697; Casero, David/0000-0002-7347-3330 FU NCI Cancer Center Support Grant [P3016042-35]; California HIV/AIDS Research Program Training Fellowship [D12-LA-351]; UCLA Dissertation Year Fellowship; NIH CBI Grant [T32 GM008469]; UCLA Molecular Biology Philip Whitcome Pre-Doctoral Fellowship; Interdisciplinary Training in Virology and Gene Therapy Training Grant [NIH T32 AI 060567]; Cancer Research Institute Fellowship Program; NIH [HL 116181, P01 HL028481, P01 HL090553, AI093768, HL126556]; UCLA CTSI-DRC [UL1TR000124]; NCI [RO1 CA177322]; NIDCR [RO1 DE023519]; Lupus Research Institute; NIH NCRR [S10RR026744]; [R01 AI085043] FX We thank Drs. Peter Tontonoz, Stephen T. Smale, Jake Lusis, Caius Radu, Thotsophon "Todd'' Taechariyakul, Thuc Le, and Genhong Cheng (UCLA) for kindly providing reagents and thoughtful analysis. We thank the CFAR Virology Core Lab & Tissue Culture/PCR Facility at the UCLA AIDS Institute for their help with PBMC collection. We thank Dr. Robert Damoiseaux at the UCLA Molecular Screening Shared Resource (a core facility supported by the NCI Cancer Center Support Grant P3016042-35 to Judy Gasson). A.G.Y. was supported in part by California HIV/AIDS Research Program Training Fellowship (D12-LA-351) and UCLA Dissertation Year Fellowship. J.P.A. was supported in part by a NIH CBI Grant (T32 GM008469) and UCLA Dissertation Year Fellowship. N.C.W. was supported in part by UCLA Molecular Biology Philip Whitcome Pre-Doctoral Fellowship and UCLA Dissertation Year Fellowship. G.B. was supported by the Interdisciplinary Training in Virology and Gene Therapy Training Grant (NIH T32 AI 060567). E.E.G. was supported in part by Cancer Research Institute Fellowship Program. E.J.T. was supported in part by NIH HL 116181 and UCLA CTSI-DRC UL1TR000124. D.G.B. was supported by R01 AI085043. R.S. and T.-T.W. were supported by NCI RO1 CA177322 and NIDCR RO1 DE023519. K.R. and L.V. were supported in part by NIH P01 HL028481, NIH NCRR S10RR026744, and NIH P01 HL090553. S.J.B. was supported by NIH AI093768, HL126556, and the Lupus Research Institute. NR 46 TC 27 Z9 27 U1 7 U2 16 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD DEC 17 PY 2015 VL 163 IS 7 BP 1716 EP 1729 DI 10.1016/j.cell.2015.11.045 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CZ1GN UT WOS:000366854200018 PM 26686653 ER PT J AU Ruegsegger, GN Company, JM Toedebusch, RG Roberts, CK Roberts, MD Booth, FW AF Ruegsegger, Gregory N. Company, Joseph M. Toedebusch, Ryan G. Roberts, Christian K. Roberts, Michael D. Booth, Frank W. TI Rapid Alterations in Perirenal Adipose Tissue Transcriptomic Networks with Cessation of Voluntary Running SO PLOS ONE LA English DT Article ID GENE-EXPRESSION; ADIPOCYTE HYPERPLASIA; INSULIN-RESISTANCE; CHILDHOOD OBESITY; WEIGHT-REDUCTION; EPIDIDYMAL FAT; CELL-CYCLE; INFLAMMATION; PROTEIN; RATS AB In maturing rats, the growth of abdominal fat is attenuated by voluntary wheel running. After the cessation of running by wheel locking, a rapid increase in adipose tissue growth to a size that is similar to rats that have never run (i.e. catch-up growth) has been previously reported by our lab. In contrast, diet-induced increases in adiposity have a slower onset with relatively delayed transcriptomic responses. The purpose of the present study was to identify molecular pathways associated with the rapid increase in adipose tissue after ending 6 wks of voluntary running at the time of puberty. Age-matched, male Wistar rats were given access to running wheels from 4 to 10 weeks of age. From the 10th to 11th week of age, one group of rats had continued wheel access, while the other group had one week of wheel locking. Perirenal adipose tissue was extracted, RNA sequencing was performed, and bioinformatics analyses were executed using Ingenuity Pathway Analysis (IPA). IPA was chosen to assist in the understanding of complex ` omics data by integrating data into networks and pathways. Wheel locked rats gained significantly more fat mass and significantly increased body fat percentage between weeks 10-11 despite having decreased food intake, as compared to rats with continued wheel access. IPA identified 646 known transcripts differentially expressed (p < 0.05) between continued wheel access and wheel locking. In wheel locked rats, IPA revealed enrichment of transcripts for the following functions: extracellular matrix, macrophage infiltration, immunity, and pro-inflammatory. These findings suggest that increases in visceral adipose tissue that accompanies the cessation of pubertal physical activity are associated with the alteration of multiple pathways, some of which may potentiate the development of pubertal obesity and obesity-associated systemic low-grade inflammation that occurs later in life. C1 [Ruegsegger, Gregory N.; Company, Joseph M.; Toedebusch, Ryan G.; Roberts, Michael D.; Booth, Frank W.] Univ Missouri, Coll Vet Med, Dept Biomed Sci, Columbia, MO 65211 USA. [Roberts, Christian K.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Booth, Frank W.] Univ Missouri, Dept Med Pharmacol & Physiol, Columbia, MO USA. [Booth, Frank W.] Univ Missouri, Dept Nutr & Exercise Physiol, Columbia, MO USA. [Booth, Frank W.] Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO USA. RP Booth, FW (reprint author), Univ Missouri, Coll Vet Med, Dept Biomed Sci, Columbia, MO 65211 USA. EM boothf@missouri.edu NR 47 TC 3 Z9 3 U1 2 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 17 PY 2015 VL 10 IS 12 AR e0145229 DI 10.1371/journal.pone.0145229 PG 22 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9JO UT WOS:000366723400060 PM 26678390 ER PT J AU Shen, RZ Achenbach, J Shen, Y Palaia, J Rahkola, JT Nick, HJ Smythies, LE McConnell, M Fowler, MG Smith, PD Janoff, EN AF Shen, Ruizhong Achenbach, Jenna Shen, Yue Palaia, Jana Rahkola, Jeremy T. Nick, Heidi J. Smythies, Lesley E. McConnell, Michelle Fowler, Mary G. Smith, Phillip D. Janoff, Edward N. TI Mother-to-Child HIV-1 Transmission Events Are Differentially Impacted by Breast Milk and Its Components from HIV-1-Infected Women SO PLOS ONE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-ASSOCIATED HIV-1; TYPE-1 TRANSCYTOSIS; EPITHELIAL-CELLS; DENDRITIC CELLS; SECRETORY IGA; POSITIVE MOTHERS; FED INFANTS; R5 HIV-1; INFECTION AB Breast milk is a vehicle of infection and source of protection in post-natal mother-to-child HIV-1 transmission (MTCT). Understanding the mechanism by which breast milk limits vertical transmission will provide critical insight into the design of preventive and therapeutic approaches to interrupt HIV-1 mucosal transmission. However, characterization of the inhibitory activity of breast milk in human intestinal mucosa, the portal of entry in postnatal MTCT, has been constrained by the limited availability of primary mucosal target cells and tissues to recapitulate mucosal transmission ex vivo. Here, we characterized the impact of skimmed breast milk, breast milk antibodies (Igs) and non-Ig components from HIV-1-infected Ugandan women on the major events of HIV-1 mucosal transmission using primary human intestinal cells and tissues. HIV-1-specific IgG antibodies and non-Ig components in breast milk inhibited the uptake of Ugandan HIV-1 isolates by primary human intestinal epithelial cells, viral replication in and transport of HIV-1-bearing dendritic cells through the human intestinal mucosa. Breast milk HIV-1-specific IgG and IgA, as well as innate factors, blocked the uptake and transport of HIV-1 through intestinal mucosa. Thus, breast milk components have distinct and complementary effects in reducing HIV-1 uptake, transport through and replication in the intestinal mucosa and, therefore, likely contribute to preventing postnatal HIV-1 transmission. Our data suggests that a successful preventive or therapeutic approach would require multiple immune factors acting at multiple steps in the HIV-1 mucosal transmission process. C1 [Shen, Ruizhong; Nick, Heidi J.; Smythies, Lesley E.; Smith, Phillip D.] Univ Alabama Birmingham, Dept Med, Div Gastroenterol, Birmingham, AL 35294 USA. [Achenbach, Jenna; Palaia, Jana; Rahkola, Jeremy T.; Janoff, Edward N.] Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado MAVRC, Aurora, CO 80045 USA. [Shen, Yue] Auburn Univ, Dept Biol Sci, Auburn, AL 36849 USA. [Rahkola, Jeremy T.; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA. [McConnell, Michelle] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fowler, Mary G.] Makerere Univ Johns Hopkins Univ Res Collaborat, Kampala, Uganda. [Smith, Phillip D.] Vet Affairs Med Ctr, Birmingham, AL USA. RP Janoff, EN (reprint author), Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado MAVRC, Aurora, CO 80045 USA. EM rshen@uab.edu; Edward.Janoff@ucdenver.edu FU National Institutes of Health [AI093151, AI106395, AI083127, DK064400, AI41361, HD059527, AI083615]; UAB Center for AIDS Research (CFAR); Comprehensive Cancer Center Pilot Grant Program; amfAR; Foundation for AIDS Research [108015-49-RGRL]; Elisabeth Glaser Pediatric AIDS Foundations [MV-00-9-900-01432-0-00]; Research Service of the Veterans Administration FX National Institutes of Health grants AI093151 and AI106395 (RS), AI083127 and DK064400 (PDS), AI41361, HD059527 and AI083615 (ENJ); UAB Center for AIDS Research (CFAR) and Comprehensive Cancer Center Pilot Grant Program (RS); amfAR, the Foundation for AIDS Research 108015-49-RGRL (PDS); the Elisabeth Glaser Pediatric AIDS Foundations MV-00-9-900-01432-0-00 (ENJ); and the Research Service of the Veterans Administration (PDS and ENJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 0 Z9 0 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 17 PY 2015 VL 10 IS 12 AR e0145150 DI 10.1371/journal.pone.0145150 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9JO UT WOS:000366723400051 PM 26680219 ER PT J AU Singh, JA Qu, HY Yazdany, J Chatham, W Shewchuk, R AF Singh, Jasvinder A. Qu, Haiyan Yazdany, Jinoos Chatham, Winn Shewchuk, Richard TI Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making SO ARTHRITIS RESEARCH & THERAPY LA English DT Article DE Lupus; Systemic lupus erythematosus; Hispanic; African-American; Minorities; Race; Facilitators; Challenges; Immunosuppressive medication; Adherence ID QUALITY-OF-LIFE; TREATMENT ADHERENCE; RHEUMATIC-DISEASE; HEALTH-CARE; ERYTHEMATOSUS; COHORT; WOMEN AB Background: Medication decision-making poses a challenge for a significant proportion of patients. This is an even more challenging for patients who have complex, rare, immune conditions that affect them at a young age and are associated with the use of life-long treatment, perceived by some as having significant risk of side effects and toxicity. Introduction: The aim of our study was to examine the perspectives of women with lupus nephritis on facilitators to medication decision-making. Methods: We used the nominal group technique (NGT), a structured formative process to elicit patient perspectives. An NGT expert moderated eight patient group meetings. Participants (n = 52) responded to the question "What sorts of things make it easier for people to decide to take the medicines that doctors prescribe for treating their lupus kidney disease?" Patients nominated, discussed, and prioritized facilitators to medication decisional processes. Results: Fifty-two women with lupus nephritis participated in eight NGT meetings (27 African-American, 13 Hispanic, and 12 Caucasian). Average age was 40.6 years (standard deviation (SD) = 13.3), and disease duration was 11.8 years (SD = 8.3); 36.5 % obtained at least a college education, and 55.8 % had difficulty in reading health materials. Patients generated 280 decision-making facilitators (range of 26 to 42 per panel). Of these, 102 (36 %) facilitators were perceived by patients as having relatively more influence in decision-making processes than others. Prioritized facilitators included effective patient-physician communication regarding benefits/harms, patient desire to live a normal life and improve quality of life, concern for their dependents, experiencing benefits and few/infrequent/no harms with lupus medications, and their affordability. Relative to African-Americans, Caucasian and Hispanic patients endorsed a smaller percentage of facilitators as influential. Level of agreement with which patients within panels independently agreed in their selections of the three most influential facilitators ranged from 33 % to 60 %. Conclusions: We identified facilitators to lupus medication decision-making. This information will be used to populate a decision aid for lupus nephritis. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.; Chatham, Winn] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Chatham, Winn] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Coll Med, Rochester, MN 55905 USA. [Qu, Haiyan; Shewchuk, Richard] Univ Alabama Birmingham, Sch Hlth Profess, Dept Hlth Serv Adm, Birmingham, AL 35233 USA. [Yazdany, Jinoos] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, 510,20th St South,FOT 805B, Birmingham, AL 35233 USA. EM jassingh@uab.edu FU Patient-Centered Outcomes Research Institute [CE-1304-6631]; NIH [K23 AR060259]; Rosalind Russell Medical Research Center for Arthritis FX This material is the result of work supported by research contract CE-1304-6631 from the Patient-Centered Outcomes Research Institute. JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, AL, USA. JY is also supported by NIH K23 AR060259 and the Rosalind Russell Medical Research Center for Arthritis. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 23 TC 1 Z9 1 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD DEC 17 PY 2015 VL 17 AR 367 DI 10.1186/s13075-015-0883-z PG 11 WC Rheumatology SC Rheumatology GA CY8UD UT WOS:000366682900001 PM 26680561 ER PT J AU Stefan, DC Masalu, N Ngendahayo, L Amadori, D Botteghi, M Mendy, M Othieno-Aabinya, NA Ngoma, T Asirwa, F Balogun, O Ngwa, W Vuhahula, E Adesina, A AF Stefan, D. C. Masalu, N. Ngendahayo, L. Amadori, D. Botteghi, M. Mendy, M. Othieno-Aabinya, N. A. Ngoma, T. Asirwa, F. Balogun, O. Ngwa, W. Vuhahula, E. Adesina, A. TI Pathology and oncology in Africa: education and training for the future in cancer research-East African Regional Meeting SO INFECTIOUS AGENTS AND CANCER LA English DT Article DE Pathology; Oncology; Eastern Africa; Education; Research AB According to the World Health Organisation (WHO), deaths from non-communicable diseases (NCDs) will increase globally, with the largest increase being on the African continent. On our continent, projections have indicated that deaths from NCDs will exceed all combined communicable, maternal, perinatal and nutritional diseases as the most common causes of death by 2030. Hence, the importance of a functional and improved pathology system in the diagnosis of cancer cannot be debated. Recently, the African Organization for Research and Training in Cancer (AORTIC) organised its East African regional meeting in Mwanza, Tanzania on 25-26 June 2015, with the focus being 'Pathology and oncology: Education and training for the future in cancer research'. The main themes of the workshop were around improving cancer care and the role of twinning in Eastern Africa, in particular the Mwanza cancer project, telepathology, e-health and biobanking. The outcomes of a 2 day strategic meeting were developing an efficient and effective plan to guide the improvement in pathology training and cancer research in Africa. C1 [Stefan, D. C.] South African Med Res Council, ZA-7550 Cape Town, South Africa. [Masalu, N.] Bugando Med Ctr, Dept Oncol, Mwanza, Tanzania. [Ngendahayo, L.] Univ Burundi, Univ Teaching Hosp Kamenge, Dept Pathol, Bujumbura, Burundi. [Amadori, D.] IRST, Inst Canc Res & Care, Meldola, Italy. [Botteghi, M.] Italy Marche Univ, Dept Clin & Mol Sci, Vittorio Tison Assoc, Expt Pathol Res Grp, Ancona, Italy. [Mendy, M.] Int Agcy Res Canc, Lab Serv & Biobank Grp, F-69372 Lyon, France. [Othieno-Aabinya, N. A.] Univ Nairobi, Nairobi, Kenya. [Ngoma, T.; Vuhahula, E.] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania. [Asirwa, F.] Acad Model Providing Access Healthcare AMPATH, Eldoret, Kenya. [Balogun, O.] New York Presbyterian Weill Cornell Med Ctr, New York, NY USA. [Ngwa, W.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Adesina, A.] Baylor Coll Med, Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA. RP Stefan, DC (reprint author), South African Med Res Council, ZA-7550 Cape Town, South Africa. EM Cristina.stefan@mrc.ac.za FU AORTIC; IRST Bugando Medical Centre FX We would like to acknowledge AORTIC and IRST Bugando Medical Centre for their sponsorship. NR 5 TC 0 Z9 0 U1 3 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-9378 J9 INFECT AGENTS CANCER JI Infect. Agents Cancer PD DEC 17 PY 2015 VL 10 AR 48 DI 10.1186/s13027-015-0044-7 PG 7 WC Oncology; Immunology SC Oncology; Immunology GA CY5PK UT WOS:000366459400001 ER PT J AU Oldridge, DA Wood, AC Weichert-Leahey, N Crimmins, I Sussman, R Winter, C McDaniel, LD Diamond, M Hart, LS Zhu, SZ Durbin, AD Abraham, BJ Anders, L Tian, LF Zhang, SL Wei, JS Khan, J Bramlett, K Rahman, N Capasso, M Iolascon, A Gerhard, DS Auvil, JMG Young, RA Hakonarson, H Diskin, SJ Look, AT Maris, JM AF Oldridge, Derek A. Wood, Andrew C. Weichert-Leahey, Nina Crimmins, Ian Sussman, Robyn Winter, Cynthia McDaniel, Lee D. Diamond, Maura Hart, Lori S. Zhu, Shizhen Durbin, Adam D. Abraham, Brian J. Anders, Lars Tian, Lifeng Zhang, Shile Wei, Jun S. Khan, Javed Bramlett, Kelli Rahman, Nazneen Capasso, Mario Iolascon, Achille Gerhard, Daniela S. Auvil, Jaime M. Guidry Young, Richard A. Hakonarson, Hakon Diskin, Sharon J. Look, A. Thomas Maris, John M. TI Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism SO NATURE LA English DT Article ID CELL IDENTITY; HUMAN GENOME; TRANSCRIPTION; INHIBITION; LOCUS; SUSCEPTIBILITY; ASSOCIATION; DISEASE; CANCER; MYCN AB Neuroblastoma is a paediatric malignancy that typically arises in early childhood, and is derived from the developing sympathetic nervous system. Clinical phenotypes range from localized tumours with excellent outcomes to widely metastatic disease in which long-term survival is approximately 40% despite intensive therapy. A previous genome-wide association study identified common polymorphisms at the LMO1 gene locus that are highly associated with neuroblastoma susceptibility and oncogenic addiction to LMO1 in the tumour cells(1). Here we investigate the causal DNA variant at this locus and the mechanism by which it leads to neuroblastoma tumorigenesis. We first imputed all possible genotypes across the LMO1 locus and then mapped highly associated single nucleotide polymorphism (SNPs) to areas of chromatin accessibility, evolutionary conservation and transcription factor binding sites. We show that SNP rs2168101 G>T is the most highly associated variant (combined P = 7.47 x 10(-29), odds ratio 0.65, 95% confidence interval 0.60-0.70), and resides in a super-enhancer defined by extensive acetylation of histone H3 lysine 27 within the first intron of LMO1. The ancestral G allele that is associated with tumour formation resides in a conserved GATA transcription factor binding motif. We show that the newly evolved protective TATA allele is associated with decreased total LMO1 expression (P = 0.028) in neuroblastoma primary tumours, and ablates GATA3 binding (P < 0.0001). We demonstrate allelic imbalance favouring the G-containing strand in tumours heterozygous for this SNP, as demonstrated both by RNA sequencing (P < 0.0001) and reporter assays (P = 0.002). These findings indicate that a recently evolved polymorphism within a super-enhancer element in the first intron of LMO1 influences neuroblastoma susceptibility through differential GATA transcription factor binding and direct modulation of LMO1 expression in cis, and this leads to an oncogenic dependency in tumour cells. C1 [Oldridge, Derek A.; Crimmins, Ian; Sussman, Robyn; Winter, Cynthia; McDaniel, Lee D.; Diamond, Maura; Hart, Lori S.; Diskin, Sharon J.; Maris, John M.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA. [Oldridge, Derek A.; Crimmins, Ian; Sussman, Robyn; Winter, Cynthia; McDaniel, Lee D.; Diamond, Maura; Hart, Lori S.; Diskin, Sharon J.; Maris, John M.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA. [Oldridge, Derek A.] Univ Penn, Perelman Sch Med, Med Scientist Training Program, Philadelphia, PA 19104 USA. [Wood, Andrew C.] Univ Auckland, Dept Mol Med & Pathol, Auckland 1, Auckland Region, New Zealand. [Weichert-Leahey, Nina; Durbin, Adam D.; Look, A. Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. [Weichert-Leahey, Nina; Durbin, Adam D.; Look, A. Thomas] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA. [Zhu, Shizhen] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA. [Abraham, Brian J.; Anders, Lars; Young, Richard A.] Whitehead Inst Biomed Res, Boston, MA 02142 USA. [Abraham, Brian J.; Anders, Lars; Young, Richard A.] MIT, Boston, MA 02142 USA. [Tian, Lifeng; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA. [Zhang, Shile; Wei, Jun S.; Khan, Javed] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA. [Bramlett, Kelli] Thermo Fisher Sci, Austin, TX 78744 USA. [Rahman, Nazneen] Inst Canc Res, Sutton SM2 5NG, Surrey, England. [Capasso, Mario; Iolascon, Achille] Univ Naples 2, I-80131 Naples, Italy. [Capasso, Mario; Iolascon, Achille] CEINGE Biotecnol Avanzate, I-80131 Naples, Italy. [Gerhard, Daniela S.; Auvil, Jaime M. Guidry] NCI, Off Canc Genom, Bethesda, MD 20892 USA. [Hakonarson, Hakon; Diskin, Sharon J.; Maris, John M.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Diskin, Sharon J.; Maris, John M.] Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA. RP Maris, JM (reprint author), Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA. EM maris@chop.edu RI Capasso, Mario/D-1617-2014; Khan, Javed/P-9157-2014; Rahman, Nazneen/D-2802-2013; OI Khan, Javed/0000-0002-5858-0488; Rahman, Nazneen/0000-0003-4376-0440; Capasso, Mario/0000-0003-3306-1259 FU NIH [R01-CA124709, R01-CA180692, R00-CA151869, RC1MD004418, 1K99CA178189, T32-HG000046, R01-CA109901]; Giulio D'Angio Endowed Chair; PressOn Foundation; Andrew's Army Foundation; Abramson Family Cancer Research Institute; Brooke Mulford Foundation; University of Pennsylvania Genome Frontiers Institute; Alex's Lemonade Stand Foundation Innovation Award; Alex's Lemonade Stand Foundation; CureSearch for Children's Cancer Foundation; German Cancer Aid 110801; St Baldrick's Foundation Fellow award; George L. Ohrstrom Jr foundation; Wellcome Trust [100210/Z/12/Z]; NHS; Fondazione Italiana per la Lotta al Neuroblastoma; Associazione Oncologia Pediatrica e Neuroblastoma; Associazione Italiana per la Ricerca sul Cancro FX This work was supported in part by NIH grants R01-CA124709 (J.M.M.), R01-CA180692 (J.M.M. and A.T.L.), R00-CA151869 (S.J.D.), RC1MD004418 to the TARGET consortium, 1K99CA178189 (S.Z.), T32-HG000046 (D.A.O.), R01-CA109901 (R.A.Y.), the Giulio D'Angio Endowed Chair (J.M.M.), the PressOn Foundation (J.M.M.), Andrew's Army Foundation (J.M.M.), the Abramson Family Cancer Research Institute (J.M.M.), the Brooke Mulford Foundation (J.M.M.), the University of Pennsylvania Genome Frontiers Institute, an Alex's Lemonade Stand Foundation Innovation Award (A.T.L.), young investigator awards from Alex's Lemonade Stand Foundation (S.Z., A.C.W.) and the CureSearch for Children's Cancer Foundation (S.Z.), grant from the German Cancer Aid 110801 (N.W.-L.), St Baldrick's Foundation Fellow award (A.C.W.), George L. Ohrstrom Jr foundation (A.C.W.), Wellcome Trust Senior Investigator Award Ref: 100210/Z/12/Z (N.R.) and NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR (N.R.), Fondazione Italiana per la Lotta al Neuroblastoma (M.C.), Associazione Oncologia Pediatrica e Neuroblastoma (M.C.), and Associazione Italiana per la Ricerca sul Cancro (M.C.). We gratefully acknowledge the Children's Oncology Group (COG) for providing the specimens and clinical data from neuroblastoma patients and thank patients and families for participating in the COG, the UK-based Factors Associated with Childhood Tumors (FACT), and Italian cooperative group studies. We thank A. Renwick who performed the Taqman analyses and A. Zachariou for recruiting participants to the FACT study. We thank G. Blobel for scientific advice and discussion, and generously providing equipment and reagents for ChIP experiments, N. Saeki and H. Sasaki for providing the LMO1 cDNA clone, and Y. Nakatan for providing the lentiviral vector pOZ-FHN. NR 30 TC 26 Z9 27 U1 7 U2 23 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD DEC 17 PY 2015 VL 528 IS 7582 BP 418 EP + DI 10.1038/nature15540 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY8SM UT WOS:000366678600057 PM 26560027 ER PT J AU Calderone, SAL Raskin, KA Hornicek, F Schwab, JH AF Calderone, Santiago A. Lozano Raskin, Kevin A. Hornicek, Francis Schwab, Joseph H. TI What's New in Orthopaedic Oncology SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID GIANT-CELL TUMOR; ALLOGRAFT RECONSTRUCTION; EWING SARCOMA; LIMB SALVAGE; LOCAL RECURRENCE; BONE METASTASES; AFFECT SURVIVAL; EXPRESSION; CHORDOMA; OSTEOSARCOMA C1 [Calderone, Santiago A. Lozano; Raskin, Kevin A.; Hornicek, Francis; Schwab, Joseph H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Oncol Serv,Dept Orthopaed Surg, Boston, MA 02138 USA. RP Calderone, SAL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Oncol Serv,Dept Orthopaed Surg, Boston, MA 02138 USA. EM jhschwab@mgh.harvard.edu NR 59 TC 2 Z9 2 U1 0 U2 2 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 EI 1535-1386 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD DEC 16 PY 2015 VL 97A IS 24 BP 2061 EP 2067 DI 10.2106/JBJS.O.01015 PG 7 WC Orthopedics; Surgery SC Orthopedics; Surgery GA CZ3BW UT WOS:000366980100012 ER PT J AU Lelyveld, VS Bjorkbom, A Ransey, EM Sliz, P Szostak, JW AF Lelyveld, Victor S. Bjoerkbom, Anders Ransey, Elizabeth M. Sliz, Piotr Szostak, Jack W. TI Pinpointing RNA-Protein Cross-Links with Site-Specific Stable Isotope-Labeled Oligonucleotides SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY LA English DT Article ID MASS-SPECTROMETRY; RIBONUCLEIC-ACIDS; IDENTIFICATION; MECHANISMS; ASSIGNMENT; PEPTIDES; CELLS; CLIP AB High affinity RNA-protein interactions are critical to cellular function, but directly identifying the determinants of binding within these complexes is often difficult. Here, we introduce a stable isotope mass labeling technique to assign specific interacting nucleotides in an oligonudeotide-protein complex by photo-cross-linking. The method relies on generating site-specific oxygen-18-labeled phosphodiester linkages in oligonucleotides, such that covalent peptide-oligonucleotide cross-link sites arising from ultraviolet irradiation can be assigned to specific sequence positions in both RNA and protein simultaneously by mass spectrometry. Using Lin28A and a let-7 pre-element RNA, we demonstrate that mass labeling permits unambiguous identification of the cross-linked sequence positions in the RNA-protein complex. C1 [Lelyveld, Victor S.; Bjoerkbom, Anders; Szostak, Jack W.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Dept Mol Biol, Boston, MA 02114 USA. [Lelyveld, Victor S.; Bjoerkbom, Anders; Szostak, Jack W.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Szostak, Jack W.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. [Bjoerkbom, Anders] Abo Akad Univ, Dept Biosci, FI-20520 Turku, Finland. [Lelyveld, Victor S.; Bjoerkbom, Anders; Szostak, Jack W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Ransey, Elizabeth M.; Sliz, Piotr] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Sliz, Piotr] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Szostak, JW (reprint author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Dept Mol Biol, Boston, MA 02114 USA. EM szostak@molbio.mgh.harvard.edu FU Simons Foundation [290363]; National Cancer Institute [NIH R01CA163647]; Academy of Finland; National Science Foundation [DGE1144152]; UNCF-Merck Graduate Research Science Initiative FX J.W.S. is an Investigator of the Howard Hughes Medical Institute. This work was supported by grants from the Simons Foundation to J.W.S. (290363) and from the National Cancer Institute to P.S. (NIH R01CA163647). A.B. was supported by a fellowship from the Academy of Finland, and E.M.R. is supported by the National Science Foundation Graduate Research Fellowship (DGE1144152) and by the UNCF-Merck Graduate Research Science Initiative. We further thank Drs. L. Li, A. Pal, and A. Fahrenbach for helpful discussions. NR 23 TC 1 Z9 1 U1 3 U2 27 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0002-7863 J9 J AM CHEM SOC JI J. Am. Chem. Soc. PD DEC 16 PY 2015 VL 137 IS 49 BP 15378 EP 15381 DI 10.1021/jacs.5b10596 PG 4 WC Chemistry, Multidisciplinary SC Chemistry GA CZ1OH UT WOS:000366874700011 PM 26583201 ER PT J AU Gale, EM Atanasova, IP Blasi, F Ay, I Caravan, P AF Gale, Eric M. Atanasova, Iliyana P. Blasi, Francesco Ay, Ilknur Caravan, Peter TI A Manganese Alternative to Gadolinium for MRI Contrast SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY LA English DT Article ID NEPHROGENIC SYSTEMIC FIBROSIS; CHRONIC KIDNEY-DISEASE; MAGNETIC-RESONANCE ANGIOGRAPHY; HIGH SIGNAL INTENSITY; MN-DPDP; DENTATE NUCLEUS; METAL-COMPLEXES; IMAGING PROBES; AGENTS; FIBRIN AB Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) are routinely used to diagnose soft tissue and vascular abnormalities. However, safety concerns limit the use of iodinated and gadolinium (Gd)-based CT and MRI contrast media in renally compromised patients. With an estimated 14% of the US population suffering from chronic kidney disease (CKD), contrast media compatible with renal impairment is sorely needed. We present the new manganese(II) complex [Mn(PyC3A)(H2O)](-) as a Gd alternative. [Mn(PyC3A)(H2O)](-) is among the most stable Mn(II) complexes at pH 7.4 (log K-ML = 11.40). In the presence of 25 mol equiv of Zn at pH 6.0, 37 degrees C, [Mn(PyC3A)(H2O)](-) is 20-fold more resistant to dissociation than [Gd(DTPA)(H2O)](2-). Relaxivity of [Mn(PyC3A)(H2O)](-) in blood plasma is comparable to commercial Gd contrast agents. Biodistribution analysis confirms that [Mn(PyC3A)(H2O)](-) clears via a mixed renal/hepatobiliary pathway with >99% elimination by 24 h. [Mn(PyC3A)(H2O)](-) was modified to form a bifunctional chelator and 4 chelates were conjugated to a fibrin-specific peptide to give Mn-FBP. Mn-FBP binds the soluble fibrin fragment DD(E) with K-d = 110 nM. Per Mn relaxivity of Mn-FBP is 4-fold greater than [Mn(PyC3A)(H2O)](-) and increases 60% in the presence of fibrin, consistent with binding. Mn-FBP provided equivalent thrombus enhancement to the state of the art Gd analogue, EP-2104R, in a rat model of arterial thrombosis. Mn metabolite analysis reveals no evidence of dechelation and the probe was >99% eliminated after 24 h. [Mn(PyC3A)(H2O)](-) is a lead development candidate for an imaging probe that is compatible with renally compromised patients. C1 [Gale, Eric M.; Atanasova, Iliyana P.; Blasi, Francesco; Ay, Ilknur; Caravan, Peter] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging,Inst Inno, Charlestown, MA 02129 USA. RP Gale, EM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging,Inst Inno, 149 Thirteenth St,Suite 2301, Charlestown, MA 02129 USA. EM egale@nmr.mgh.harvard.edu; caravan@nmr.mgh.harvard.edu RI Blasi, Francesco/G-1055-2015 OI Blasi, Francesco/0000-0002-6616-8418 FU National Cancer Institute [T32CA009502, R01CA161221]; National Institute for Biomedical Imaging and Bioengineering [R01EB009062]; National Center for Research Resources; Office of the Director [RR14075, OD010650]; Comunidad de Madrid; Madrid MIT M+Vision Consortium FX This work was supported by grants from the National Cancer Institute (T32CA009502 to E.M.G, R01CA161221 to P.C.) and the National Institute for Biomedical Imaging and Bioengineering (R01EB009062 to P.C.) and instrumentation funded by the National Center for Research Resources and the Office of the Director (RR14075, OD010650). I.PA was supported by a fellowship from the Comunidad de Madrid and the Madrid MIT M+Vision Consortium. NR 59 TC 12 Z9 12 U1 18 U2 65 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0002-7863 J9 J AM CHEM SOC JI J. Am. Chem. Soc. PD DEC 16 PY 2015 VL 137 IS 49 BP 15548 EP 15557 DI 10.1021/jacs.5b10748 PG 10 WC Chemistry, Multidisciplinary SC Chemistry GA CZ1OH UT WOS:000366874700039 PM 26588204 ER PT J AU Vitor-Costa, M Okuno, NM Bortolotti, H Bertollo, M Boggio, PS Fregni, F Altimari, LR AF Vitor-Costa, Marcelo Okuno, Nilo Massaru Bortolotti, Henrique Bertollo, Maurizio Boggio, Paulo Sergio Fregni, Felipe Altimari, Leandro Ricardo TI Improving Cycling Performance: Transcranial Direct Current Stimulation Increases Time to Exhaustion in Cycling SO PLOS ONE LA English DT Article ID HUMAN MOTOR CORTEX; BRAIN ACTIVATION; FATIGUE; EXERCISE; EXCITABILITY; ENDURANCE; HUMANS; FORCE AB The central nervous system seems to have an important role in fatigue and exercise tolerance. Novel noninvasive techniques of neuromodulation can provide insights on the relationship between brain function and exercise performance. The purpose of this study was to determine the effects of transcranial direct current stimulation (tDCS) on physical performance and physiological and perceptual variables with regard to fatigue and exercise tolerance. Eleven physically active subjects participated in an incremental test on a cycle simulator to define peak power output. During 3 visits, the subjects experienced 3 stimulation conditions (anodal, cathodal, or sham tDCS-with an interval of at least 48 h between conditions) in a randomized, counterbalanced order to measure the effects of tDCS on time to exhaustion at 80% of peak power. Stimulation was administered before each test over 13 min at a current intensity of 2.0 mA. In each session, the Brunel Mood State questionnaire was given twice: after stimulation and after the time-to-exhaustion test. Further, during the tests, the electromyographic activity of the vastus lateralis and rectus femoris muscles, perceived exertion, and heart rate were recorded. RM-ANOVA showed that the subjects performed better during anodal primary motor cortex stimulation (491 +/- 100 s) compared with cathodal stimulation (443 +/- 11 s) and sham (407 +/- 69 s). No significant difference was observed between the cathodal and sham conditions. The effect sizes confirmed the greater effect of anodal M1 tDCS (anodal x cathodal = 0.47; anodal x sham = 0.77; and cathodal x sham = 0.29). Magnitude-based inference suggested the anodal condition to be positive versus the cathodal and sham conditions. There were no differences among the three stimulation conditions in RPE (p = 0.07) or heart rate (p = 0.73). However, as hypothesized, RM-ANOVA revealed a main effect of time for the two variables (RPE and HR: p < 0.001). EMG activity also did not differ during the test accross the different conditions. We conclude that anodal tDCS increases exercise tolerance in a cycling-based, constant-load exercise test, performed at 80% of peak power. Performance was enhanced in the absence of changes in physiological and perceptual variables. C1 [Vitor-Costa, Marcelo; Bortolotti, Henrique; Altimari, Leandro Ricardo] Univ Estadual Londrina, Grp Study & Res Neuromuscular Syst & Exercise, Londrina, PR, Brazil. [Vitor-Costa, Marcelo; Okuno, Nilo Massaru; Bortolotti, Henrique] Univ Estadual Ponta Grossa, Study Grp Physiol Responses & Adaptat Exercise, Ponta Grossa, PR, Brazil. [Bertollo, Maurizio] Univ G DAnnunzio, Behav Imaging & Neural Dynam Ctr, Dept Med & Aging Sci, Chieti, Italy. [Boggio, Paulo Sergio] Univ Prebiteriana Mackenzie, Cognit Neurosci Lab, Ctr Hlth & Biol Sci, Sao Paulo, Brazil. [Boggio, Paulo Sergio] Univ Prebiteriana Mackenzie, Dev Disorders Program, Ctr Hlth & Biol Sci, Sao Paulo, Brazil. [Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Neuromodulat Ctr, Spaulding Rehabil Hosp, Boston, MA USA. [Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Vitor-Costa, M (reprint author), Univ Estadual Londrina, Grp Study & Res Neuromuscular Syst & Exercise, Londrina, PR, Brazil. EM marcelovitordacosta@gmail.com RI Bertollo, Maurizio/K-5469-2013; Bortolotti, Henrique/I-5140-2012 OI Bertollo, Maurizio/0000-0002-0972-9178; Bortolotti, Henrique/0000-0002-1852-1395 FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes) FX Support was provided by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 2 Z9 2 U1 5 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 16 PY 2015 VL 10 IS 12 AR e0144916 DI 10.1371/journal.pone.0144916 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9JH UT WOS:000366722700072 PM 26674200 ER PT J AU Jensen, CG Lansner, J Petersen, A Vangkilde, SA Ringkobing, SP Frokjaer, VG Adamsen, D Knudsen, GM Denninger, JW Hasselbalch, SG AF Jensen, Christian G. Lansner, Jon Petersen, Anders Vangkilde, Signe A. Ringkobing, Signe P. Frokjaer, Vibe G. Adamsen, Dea Knudsen, Gitte M. Denninger, John W. Hasselbalch, Steen G. TI Open and Calm - A randomized controlled trial evaluating a public stress reduction program in Denmark SO BMC PUBLIC HEALTH LA English DT Article DE Stress reduction; Mental health promotion; Meditation; Cortisol; Attention ID SEROTONIN TRANSPORTER POLYMORPHISM; MENTAL-HEALTH PROMOTION; MAJOR DEPRESSION; MINDFULNESS MEDITATION; EMOTION REGULATION; VISUAL-ATTENTION; WAKING CORTISOL; METAANALYSIS; BURNOUT; COGNITION AB Background: Prolonged psychological stress is a risk factor for illness and constitutes an increasing public health challenge creating a need to develop public interventions specifically targeting stress and promoting mental health. The present randomized controlled trial evaluated health effects of a novel program: Relaxation-Response-based Mental Health Promotion (RR-MHP). Methods: The multimodal, meditation-based course was publicly entitled "Open and Calm" (OC) because it consistently trained relaxed and receptive ("Open") attention, and consciously non-intervening ("Calm") witnessing, in two standardized formats (individual or group) over nine weeks. Seventy-two participants who complained to their general practitioner about reduced daily functioning due to prolonged stress or who responded to an online health survey on stress were randomly assigned to OC formats or treatment as usual, involving e.g., unstandardized consultations with their general practitioner. Outcomes included perceived stress, depressive symptoms, quality of life, sleep disturbances, mental health, salivary cortisol, and visual perception. Control variables comprised a genetic stress-resiliency factor (serotonergic transporter genotype; 5-HTTLPR), demographics, personality, self-reported inattentiveness, and course format. Results: Intent-to-treat analyses showed significantly larger improvements in OC than in controls on all outcomes. Treatment effects on self-reported outcomes were sustained after 3 months and were not related to age, gender, education, or course format. The dropout rate was only 6 %. Conclusions: The standardized OC program reduced stress and improved mental health for a period of 3 months. Further testing of the OC program for public mental health promotion and reduction of stress-related illnesses is therefore warranted. A larger implementation is in progress. C1 [Jensen, Christian G.; Lansner, Jon; Ringkobing, Signe P.; Frokjaer, Vibe G.; Adamsen, Dea; Knudsen, Gitte M.; Hasselbalch, Steen G.] Rigshosp, Neurobiol Res Unit NRU, DK-2100 Copenhagen, Denmark. [Jensen, Christian G.; Lansner, Jon; Ringkobing, Signe P.; Frokjaer, Vibe G.; Adamsen, Dea; Knudsen, Gitte M.; Hasselbalch, Steen G.] Rigshosp, Ctr Integrated Mol Brain Imaging Cimbi, Neurosci Ctr, DK-2100 Copenhagen, Denmark. [Jensen, Christian G.; Lansner, Jon; Ringkobing, Signe P.; Frokjaer, Vibe G.; Adamsen, Dea; Knudsen, Gitte M.; Hasselbalch, Steen G.] Univ Copenhagen, DK-2100 Copenhagen, Denmark. [Petersen, Anders; Vangkilde, Signe A.] Univ Copenhagen, Dept Psychol, Ctr Visual Cognit, DK-1353 Copenhagen K, Denmark. [Denninger, John W.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA. [Hasselbalch, Steen G.] Copenhagen Univ Hosp, Danish Dementia Ctr, Copenhagen, Denmark. RP Jensen, CG (reprint author), Rigshosp, Neurobiol Res Unit NRU, Juliane Maries Vej 28,3rd Floor, DK-2100 Copenhagen, Denmark. EM cgj@cfps.dk FU Copenhagen University Hospital, The Capital Region of Denmark; Lundbeck Foundation Center for Integrated Molecular Brain Imaging (Cimbi); Nordea-fonden FX The study was funded by Nordea-fonden, Copenhagen University Hospital, The Capital Region of Denmark, and the Lundbeck Foundation Center for Integrated Molecular Brain Imaging (Cimbi). NR 84 TC 0 Z9 0 U1 3 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD DEC 16 PY 2015 VL 15 AR 1245 DI 10.1186/s12889-015-2588-2 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CY6XO UT WOS:000366552300005 PM 26673225 ER PT J AU Li, W Koster, J Xu, H Chen, CH Xiao, TF Liu, JS Brown, M Liu, XS AF Li, Wei Koester, Johannes Xu, Han Chen, Chen-Hao Xiao, Tengfei Liu, Jun S. Brown, Myles Liu, X. Shirley TI Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR SO GENOME BIOLOGY LA English DT Article DE CRISPR/Cas9; Screening; Maximum likelihood; Expectation-Maximization; Negative binomial; Data-driven documents; D3; Visualization; Quality control ID ACUTE MYELOID-LEUKEMIA; HUMAN-CELLS; FUNCTIONAL GENOMICS; ESSENTIAL GENES; SEQ DATA; ACTIVATION; CANCER; IDENTIFICATION; DESIGN; MOUSE AB High-throughput CRISPR screens have shown great promise in functional genomics. We present MAGeCK-VISPR, a comprehensive quality control (QC), analysis, and visualization workflow for CRISPR screens. MAGeCK-VISPR defines a set of QC measures to assess the quality of an experiment, and includes a maximum-likelihood algorithm to call essential genes simultaneously under multiple conditions. The algorithm uses a generalized linear model to deconvolute different effects, and employs expectation-maximization to iteratively estimate sgRNA knockout efficiency and gene essentiality. MAGeCK-VISPR also includes VISPR, a framework for the interactive visualization and exploration of QC and analysis results. MAGeCK-VISPR is freely available at http://bitbucket.org/liulab/mageck-vispr. C1 [Li, Wei; Koester, Johannes; Chen, Chen-Hao; Liu, X. Shirley] Harvard Univ, TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA. [Li, Wei; Koester, Johannes; Chen, Chen-Hao; Xiao, Tengfei; Brown, Myles; Liu, X. Shirley] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA. [Koester, Johannes; Xiao, Tengfei; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02215 USA. [Xu, Han] Broad Inst MIT& Harvard, Cambridge Ctr 7, Cambridge, MA 02142 USA. [Liu, Jun S.] Harvard Univ, Sci Ctr 715, Dept Stat, Cambridge, MA 02138 USA. [Brown, Myles] Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA. [Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Liu, X. Shirley] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China. RP Brown, M (reprint author), Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA. EM myles_brown@dfci.harvard.edu; xsliu@jimmy.harvard.edu OI Brown, Myles/0000-0002-8213-1658 FU NIH [U01 CA180980, R01 HG008728]; Department of Defense Synergistic Idea Development Award [PC140817, R01 GM113242-01]; NSF [DMS-1120368]; Claudia Adams Barr Award in Innovative Basic Cancer Research from the Dana-Farber Cancer Institute FX The project was supported by the NIH grant U01 CA180980 (to XSL), R01 HG008728 (to MB and XSL), Department of Defense Synergistic Idea Development Award PC140817 (to MB and XSL), R01 GM113242-01 (to JSL), NSF grant DMS-1120368 (to JSL), and the Claudia Adams Barr Award in Innovative Basic Cancer Research from the Dana-Farber Cancer Institute. NR 41 TC 2 Z9 2 U1 5 U2 18 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-6906 EI 1474-760X J9 GENOME BIOL JI Genome Biol. PD DEC 16 PY 2015 VL 16 AR 281 DI 10.1186/s13059-015-0843-6 PG 13 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA CZ1XE UT WOS:000366898400001 PM 26673418 ER PT J AU Duquette, M Sadow, PM Husain, A Sims, JN Antonello, ZA Fischer, AH Song, C Castellanos-Rizaldos, E Makrigiorgos, GM Kurebayashi, J Nose, V Van Hummelen, P Bronson, RT Vinco, M Giordano, TJ Dias-Santagata, D Pandolfi, PP Nucera, C AF Duquette, Mark Sadow, Peter M. Husain, Amjad Sims, Jennifer N. Antonello, Zeus A. Fischer, Andrew H. Song, Chen Castellanos-Rizaldos, Elena Makrigiorgos, G. Mike Kurebayashi, Junichi Nose, Vania Van Hummelen, Paul Bronson, Roderick T. Vinco, Michelle Giordano, Thomas J. Dias-Santagata, Dora Pandolfi, Pier Paolo Nucera, Carmelo TI Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAF(V600E) patient-derived papillary thyroid carcinoma preclinical model SO ONCOTARGET LA English DT Article DE BRAF(V600E) papillary thyroid cancer pre-clinical model; vemurafenib resisatnce; MCL1 and P16/CDKN2A somatic copy number; microenvironment ID ORTHOTOPIC MOUSE MODEL; REAL-TIME PCR; BRAF MUTATION; TUMOR INITIATION; CELL-LINE; CANCER; INHIBITION; ANGIOGENESIS; EXPRESSION; SURVIVAL AB BRAF(E)(V600) mutation exerts an essential oncogenic function in many tumors, including papillary thyroid carcinoma (PTC). Although BRAF(V600E) inhibitors are available, lack of response has been frequently observed. To study the mechanism underlying intrinsic resistance to the mutant BRAF(V600E) selective inhibitor vemurafenib, we established short-term primary cell cultures of human metastatic/recurrent BRAF(V600E)-PTC, intrathyroidal BRAF(V600E)-PTC, and normal thyroid (NT). We also generated an early intervention model of human BRAF(V600E)-PTC orthotopic mouse. We find that metastatic BRAF(V600E)-PTC cells elicit paracrine-signaling which trigger migration of pericytes, blood endothelial cells and lymphatic endothelial cells as compared to BRAF(WT)-PTC cells, and show a higher rate of invasion. We further show that vemurafenib therapy significantly suppresses these aberrant functions in non-metastatic BRAF(V600E)-PTC cells but lesser in metastatic BRAF(V600E)-PTC cells as compared to vehicle treatment. These results concur with similar folds of down-regulation of tumor microenvironment-associated pro-metastatic molecules, with no effects in BRAF(WT)-PTC and NT cells. Our early intervention preclinical trial shows that vemurafenib delays tumor growth in the orthotopic BRAF(WT/V600E)-PTC mice. Importantly, we identify high copy number gain of MCL1 (chromosome 1q) and loss of CDKN2A (P16, chromosome 9p) in metastatic BRAF(V600E)-PTC cells which are associated with resistance to vemurafenib treatment. Critically, we demonstrate that combined vemurafenib therapy with BCL2/MCL1 inhibitor increases metastatic BRAF(V600E)-PTC cell death and ameliorates response to vemurafenib treatment as compared to single agent treatment. In conclusion, short-term PTC and NT cultures offer a predictive model for evaluating therapeutic response in patients with PTC. Our PTC pre-clinical model suggests that combined targeted therapy might be an important therapeutic strategy for metastatic and refractory BRAF(V600E)-positive PTC. C1 [Duquette, Mark; Sims, Jennifer N.; Antonello, Zeus A.; Nucera, Carmelo] Harvard Univ, Beth Israel Deaconess Med Ctr, Lab Human Thyroid Canc Preclin & Translat Res,Med, Div Canc Biol & Angiogenesis,CRI,Canc Ctr,Dept Pa, Boston, MA 02215 USA. [Sadow, Peter M.; Nose, Vania] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Husain, Amjad; Nucera, Carmelo] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol,CVBR, Boston, MA 02215 USA. [Fischer, Andrew H.] Univ Massachusetts, Dept Pathol, Worcester, MA 01605 USA. [Song, Chen; Castellanos-Rizaldos, Elena; Makrigiorgos, G. Mike] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Kurebayashi, Junichi] Kawasaki Med Univ, Dept Breast & Thyroid Surg, Kurashiki, Okayama, Japan. [Van Hummelen, Paul] Harvard Univ, Sch Med, Dana Farber Canc Inst, CCGD, Boston, MA 02115 USA. [Bronson, Roderick T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Rodent Histopathol Unit, Boston, MA USA. [Vinco, Michelle; Giordano, Thomas J.] Univ Michigan, Dept Pathol, Ann Arbor, MI USA. [Dias-Santagata, Dora] Harvard Univ, Sch Med, Dept Pathol, Ctr Integrated Diagnost,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Dept Med, Div Canc Genet,CRI, Boston, MA USA. [Pandolfi, Pier Paolo] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol,Canc Ctr, Boston, MA 02215 USA. RP Nucera, C (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Lab Human Thyroid Canc Preclin & Translat Res,Med, Div Canc Biol & Angiogenesis,CRI,Canc Ctr,Dept Pa, Boston, MA 02215 USA. EM cnucera@bidmc.harvard.edu RI Song, Chen/H-6615-2015 OI Song, Chen/0000-0002-4439-4377 FU National Cancer Institute/National Institutes of Health [1R21CA165039-01A1, 1R01CA181183-01A1]; American Thyroid Association (ATA); ThyCa:Thyroid Cancer Survivors Association Inc. for Thyroid Cancer Research; Guido Berlucchi "Young Investigator" research award (Brescia, Italy); BIDMC/CAO Grant (Boston, MA); Roche FX Carmelo Nucera (Principal Investigator, Human Thyroid Cancers Preclinical and Translational Research at the Beth Israel Deaconess Medical Center (BIDMC)/Harvard Medical School) was awarded grants by the National Cancer Institute/National Institutes of Health (1R21CA165039-01A1 and 1R01CA181183-01A1), the American Thyroid Association (ATA) and ThyCa:Thyroid Cancer Survivors Association Inc. for Thyroid Cancer Research. Carmelo Nucera was also a recipient of the Guido Berlucchi "Young Investigator" research award 2013 (Brescia, Italy) and BIDMC/CAO Grant (Boston, MA). BIDMC was recipient of a grant by Roche (2011-2012). Roche had no role in the design of this study/manuscript, in the collection, analysis, or interpretation of the data, in the writing and publication of this manuscript. NR 51 TC 3 Z9 3 U1 3 U2 5 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD DEC 15 PY 2015 VL 6 IS 40 BP 42445 EP 42467 PG 23 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DD4QP UT WOS:000369907900005 PM 26636651 ER PT J AU Guo, F He, H Fu, ZC Huang, SP Chen, TT Papasian, CJ Morse, LR Xu, Y Battaglino, RA Yang, XF Jiang, ZS Xin, HB Fu, MG AF Guo, Fang He, Hui Fu, Zhi-Chao Huang, Shengping Chen, Tingtao Papasian, Christopher J. Morse, Leslie R. Xu, Yan Battaglino, Ricardo A. Yang, Xiao-Feng Jiang, Zhisheng Xin, Hong-Bo Fu, Mingui TI Adipocyte-derived PAMM suppresses macrophage inflammation by inhibiting MAPK signalling SO BIOCHEMICAL JOURNAL LA English DT Article DE adipocyte; anti-inflammation; macrophage; peroxiredoxin-like 2 activated in M-CSF-stimulated monocytes (PAMM); redox; secreted protein ID HYDROGEN-PEROXIDE; IMMUNE CELLS; PEROXIREDOXIN; OBESITY; RESPONSES; DISEASES AB Macrophages within adipose tissue play a key role in mediating inflammatory responses in adipose tissue that are associated with obesity-related metabolic complications. In an effort to identify novel proteins secreted from adipocytes that may negatively regulate macrophage inflammation, we found that peroxiredoxin (PRX)-like 2 activated in M-CSF stimulated monocytes (PAMM), a CXXC-type PRX-like 2 domain-containing redox regulatory protein, is a novel secreted protein with potent anti-inflammatory properties. PAMMis secreted from mature human adipocytes but not preadipocytes. Overexpression of PAMM significantly attenuated lipopolysaccharide (LPS)induced macrophage inflammation. Incubation of macrophages with adipocyte-conditional medium treated with anti-PAMM antibody significantly enhanced LPS-induced interleukin-12 (IL-12) expression in Raw264.7 cells. In addition, incubation of Raw264.7 cells with purified PAMM protein had a similar anti-inflammatory effect. Moreover, forced expression of PAMM in Raw264.7 cells resulted in decreased LPS-induced ERK1/2, p38 and c-Jun N-terminal kinase (JNK) phosphorylation, suggesting that PAMM exerted the anti-inflammatory function probably by suppressing the mitogen-activated protein kinase (MAPK) signalling pathway. Mutations in the CXXC motif of PAMM that suppressed its anti-redox activity were still able to suppress production of inflammatory cytokines in LPS-stimulated macrophages, suggesting that PAMM's anti-inflammatory properties may be independent of its antioxidant properties. Finally, PAMM was highly expressed in both white (WAT) and brown adipose tissues (BAT) and further increased in obesity status. Our results suggest that adipocyte-derived PAMM may suppressmacrophage activation by inhibitingMAPK signalling pathway. C1 [Guo, Fang; He, Hui; Jiang, Zhisheng] Univ South China, Inst Cardiovasc Dis, Dept Pathophysiol, Hengyang 421001, Hunan, Peoples R China. [Guo, Fang; He, Hui; Huang, Shengping; Papasian, Christopher J.; Fu, Mingui] Univ Missouri, Sch Med, Dept Basic Med Sci, Kansas City, MO 64108 USA. [Fu, Zhi-Chao; Chen, Tingtao; Xin, Hong-Bo] Nanchang Univ, Inst Translat Med, Nanchang 330031, Jiangxi, Peoples R China. [Morse, Leslie R.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02115 USA. [Xu, Yan; Battaglino, Ricardo A.] Forsyth Inst, Dept Mineralized Tissue Biol, Cambridge, MA 02142 USA. [Yang, Xiao-Feng] Temple Univ, Sch Med, Cardiovasc Res Ctr, Dept Pharmacol, Philadelphia, PA 19140 USA. RP Jiang, ZS (reprint author), Univ South China, Inst Cardiovasc Dis, Dept Pathophysiol, Hengyang 421001, Hunan, Peoples R China. EM zsjiang2005@163.com; hongbo.xin@yahoo.com; fum@umkc.edu RI Morse, Leslie/C-9442-2015; battaglino, ricardo/D-2892-2015 OI Morse, Leslie/0000-0002-7426-6341; FU School of Medicine, University of Missouri - Kansas City [DSF2014]; National Institute of Health [AI103618]; National Natural Foundation of China [91339113, 81270202, 81070095, 81470435, 81170277] FX This work was supported by the School of Medicine, University of Missouri - Kansas City [grant number DSF2014]; National Institute of Health [grant number AI103618 to (M.F.)]; and National Natural Foundation of China [(grant numbers 91339113, 81270202 and 81070095 to (H.X.), 81470435, 81170277 to (Z.J.)]. NR 28 TC 3 Z9 5 U1 4 U2 11 PU PORTLAND PRESS LTD PI LONDON PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND SN 0264-6021 EI 1470-8728 J9 BIOCHEM J JI Biochem. J. PD DEC 15 PY 2015 VL 472 BP 309 EP 318 DI 10.1042/BJ20150019 PN 3 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DC4EB UT WOS:000369172100007 PM 26438880 ER PT J AU Wong, SM Freedman, RA Sagara, Y Stamell, EF Desantis, SD Barry, WT Golshan, M AF Wong, Stephanie M. Freedman, Rachel A. Sagara, Yasuaki Stamell, Emily F. Desantis, Stephen D. Barry, William T. Golshan, Mehra TI The Effect of Paget Disease on Axillary Lymph Node Metastases and Survival in Invasive Ductal Carcinoma SO CANCER LA English DT Article DE breast neoplasms; cancer outcomes; Paget disease of the breast; prognosis; Surveillance; Epidemiology, and End Results; survival ID HER2-POSITIVE BREAST-CANCER; ADJUVANT CHEMOTHERAPY; NIPPLE; TRASTUZUMAB; MAMMARY; EXPERIENCE AB BACKGROUND: The objective of this study was to examine the effect of Paget disease (PD) on axillary lymph node metastases and survival in patients who had concomitant invasive ductal carcinoma (PD-IDC). METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify women who were diagnosed with PD-IDC from 2000 to 2011, comparing baseline demographic and tumor characteristics with those who were diagnosed with IDC alone during the same period. Multivariable logistic regression was used to examine the association of PD-IDC with axillary lymph node metastasis, and breast cancer-specific survival and overall survival were compared between the PD-IDC and IDC groups using the Kaplan-Meier method and Cox proportional hazards regression. RESULTS: The study cohort included 1102 patients with PD-IDC and 302,242 controls with IDC alone. PD-IDC tumors were more likely to be centrally located (26.9% vs 5.5%; P<.001), high grade (63.5% vs 40.3%; P<.001), > 2 cm in greatest dimension (47.1% vs 35.7%; P<.001), and estrogen/progesterone receptor-negative (45.2% vs 22.1%; P<.001). In adjusted analyses, patients with PD-IDC had higher odds of axillary lymph node metastasis (odds ratio, 1.83; P<.001). The unadjusted 10-year breast cancer-specific and overall survival rates were lower for the PD-IDC group compared with the IDC-alone group, although, after adjusting for disease stage, tumor characteristics, and local therapy, no significant differences in mortality risk were observed between the 2 groups (hazard ratio, 0.91; P = .24). CONCLUSIONS: PD-IDC is associated with an increased risk of axillary lymph node metastasis, but not with inferior survival, compared with IDC alone after adjustment for other disease factors. (C) 2015 American Cancer Society. C1 [Wong, Stephanie M.; Stamell, Emily F.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Wong, Stephanie M.] McGill Univ, Dept Surg, Ctr Hlth, Montreal, PQ H3A 2T5, Canada. [Freedman, Rachel A.; Stamell, Emily F.; Desantis, Stephen D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Sagara, Yasuaki; Desantis, Stephen D.; Golshan, Mehra] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Surg, Boston, MA 02115 USA. [Barry, William T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Golshan, M (reprint author), Dana Farber Canc Inst, Dept Surg, 450 Brookline Ave, Boston, MA 02115 USA. EM mgolshan@partners.org FU Henry R. Shibata Fellowship from Cedars Cancer Institute FX Dr. Wong was supported by a Henry R. Shibata Fellowship from the Cedars Cancer Institute. NR 29 TC 3 Z9 3 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD DEC 15 PY 2015 VL 121 IS 24 BP 4333 EP 4340 DI 10.1002/cncr.29687 PG 8 WC Oncology SC Oncology GA DA7LD UT WOS:000367984700010 PM 26376021 ER PT J AU Aizer, AA Bi, WL Kandola, MS Lee, EQ Nayak, L Rinne, ML Norden, AD Beroukhim, R Reardon, DA Wen, PY Al-Mefty, O Arvold, ND Dunn, IF Alexander, BM AF Aizer, Ayal A. Bi, Wenya Linda Kandola, Manjinder S. Lee, Eudocia Q. Nayak, Lakshmi Rinne, Mikael L. Norden, Andrew D. Beroukhim, Rameen Reardon, David A. Wen, Patrick Y. Al-Mefty, Ossama Arvold, Nils D. Dunn, Ian F. Alexander, Brian M. TI Extent of Resection and Overall Survival for Patients With Atypical and Malignant Meningioma SO CANCER LA English DT Article DE anaplastic; atypical; death; extent of resection; gross total; malignant; meningioma; mortality; surgery; survival ID ANAPLASTIC MENINGIOMAS; PROGNOSTIC-FACTORS; CLINICOPATHOLOGICAL FEATURES; INTRACRANIAL MENINGIOMAS; ADJUVANT RADIOTHERAPY; RADIATION-THERAPY; CLINICAL ARTICLE; SURGERY; RECURRENCE; BRAIN AB BACKGROUND: The prognosis for patients with atypical and malignant meningioma is guarded; whether the extent of resection is associated with survival-based outcomes in this population remains poorly defined. This study investigated the association between gross total resection (GTR) and all-cause mortality in patients with atypical and malignant meningioma. METHODS: The Surveillance, Epidemiology, and End Results program was used to identify 575 and 64 patients betweens the ages of 18 and 70 years who were diagnosed with atypical and malignant meningioma, respectively, between 2004 and 2009. Multivariate Cox proportional hazards regression was used to assess the adjusted impact of GTR versus subtotal resection on all-cause mortality. RESULTS: Baseline patient characteristics were similar for patients who did undergo GTR and patients who did not undergo GTR. The 5-year overall survival rates were 91.3% (95% confidence interval [CI], 86.2%-94.5%) and 78.2% (95% CI, 70.0%-84.3%) for patients with atypical meningioma who did and did not undergo GTR, respectively, and 64.5% (95% CI, 45.9%-78.1%) and 41.1% (95% CI, 17.9%-63.1%) for patients with malignant meningioma who did and did not undergo GTR, respectively. After adjustments for available, pertinent confounding variables, GTR was associated with lower all-cause mortality in patients with atypical (hazard ratio, 0.39; 95% CI, 0.23-0.67; P<.001) and malignant meningioma (hazard ratio, 0.35; 95% CI, 0.15-0.81; P=.01). CONCLUSIONS: The extent of resection is a powerful predictor of outcome for patients with atypical and malignant meningioma. These data highlight the hazard associated with the presence of gross tumor bulk after surgery and suggest a value for more extensive resections that should be balanced against the additional potential morbidity. (C) 2015 American Cancer Society. C1 [Aizer, Ayal A.; Arvold, Nils D.; Alexander, Brian M.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Bi, Wenya Linda; Al-Mefty, Ossama; Dunn, Ian F.] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Kandola, Manjinder S.] Harvard Univ, Sch Med, Boston, MA USA. [Lee, Eudocia Q.; Nayak, Lakshmi; Rinne, Mikael L.; Norden, Andrew D.; Beroukhim, Rameen; Reardon, David A.; Wen, Patrick Y.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. RP Alexander, BM (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM idunn@partners.org; brian_alexander@dfci.harvard.edu FU Midatech; Celldex Therapeutics; Incyte; Agios; AngioChem; Astra Zeneca; Exelixis; Genentech/Roche; GlaxoSmithKline; Karyopharm; Novartis; Sanofi-Aventis; Regeneron Pharmaceuticals; Vascular Biogenics FX Lakshmi Nayak is on the advisory board for Amgen. David A. Reardon is on advisory boards and speakers bureaus for AbbVie Pharmaceuticals, Cavion, Genentech/Roche, Merck, Midatech, Momenta Pharmaceuticals, Novartis, Novocure, Regeneron Pharmaceuticals, and Stemline Therapeutics and reports research support from Midatech, Celldex Therapeutics, and Incyte outside the submitted work. Patrick Y. Wen is on advisory boards and speakers bureaus for Genentech/Roche, Novartis, Vascular Biogenics, AbbVie Pharmaceuticals, Cavion, Celldex, Cubist, Midatech, Momenta, Novacure, Sigma-Tau, and Merck and reports research support from Agios, AngioChem, Astra Zeneca, Exelixis, Genentech/Roche, GlaxoSmithKline, Karyopharm, Novartis, Sanofi-Aventis, Regeneron Pharmaceuticals, and Vascular Biogenics outside the submitted work. Rameen Beroukhim reports grants and personal fees from Novartis outside the submitted work. NR 29 TC 10 Z9 10 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD DEC 15 PY 2015 VL 121 IS 24 BP 4376 EP 4381 DI 10.1002/cncr.29639 PG 6 WC Oncology SC Oncology GA DA7LD UT WOS:000367984700015 PM 26308667 ER PT J AU Govindan, R Mandrekar, SJ Gerber, DE Oxnard, GR Dahlberg, SE Chaft, J Malik, S Mooney, M Abrams, JS Janne, PA Gandara, DR Ramalingam, SS Vokes, EE AF Govindan, Ramaswamy Mandrekar, Sumithra J. Gerber, David E. Oxnard, Geoffrey R. Dahlberg, Suzanne E. Chaft, Jamie Malik, Shakun Mooney, Margaret Abrams, Jeffrey S. Jaenne, Pasi A. Gandara, David R. Ramalingam, Suresh S. Vokes, Everett E. TI ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer SO CLINICAL CANCER RESEARCH LA English DT Review ID VINORELBINE PLUS CISPLATIN; CHEMOTHERAPY; GEFITINIB; PLACEBO; EGFR; ADENOCARCINOMA; MULTICENTER; CRIZOTINIB; ERLOTINIB; PHASE-3 AB The treatment of patients with metastatic non-small cell lung cancer (NSCLC) is slowly evolving from empirical cytotoxic chemotherapy to personalized treatment based on specific molecular alterations. Despite this 10-year evolution, targeted therapies have not been studied adequately in patients with resected NSCLC who have clearly defined actionable mutations. The advent of next-generation sequencing has now made it possible to characterize genomic alterations in unprecedented detail. The efforts begun by The Cancer Genome Atlas project to understand the complexities of the genomic landscape of lung cancer will be supplemented further by studying a large number of tumor specimens. The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) is an NCI-sponsored national clinical trials network (NCTN) initiative to address the needs to refine therapy for early-stage NSCLC. This program will screen several thousand patients with operable lung adenocarcinoma to determine whether their tumors contain specific molecular alterations [epidermal growth factor receptor mutation (EGFR) and anaplastic lymphoma kinase rearrangement (ALK)], making them eligible for treatment trials that target these alterations. Patients with EGFR mutation or ALK gene rearrangement in their tumor will be randomized to placebo versus erlotinib or crizotinib, respectively, after completion of their standard adjuvant therapy. ALCHEMIST will also contain a large discovery component that will provide an opportunity to incorporate genomic studies to fully understand the clonal architecture, clonal evolution, and mechanisms of resistance to therapy. In this review, we describe the concept, rationale, and outline of ALCHEMIST and the plan for genomic studies in patients with lung adenocarcinoma. (C)2015 AACR. C1 [Govindan, Ramaswamy] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA. [Mandrekar, Sumithra J.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Gerber, David E.] UT Southwestern Med Ctr, Div Hematol & Oncol, Dallas, TX USA. [Oxnard, Geoffrey R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA. [Dahlberg, Suzanne E.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Chaft, Jamie] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [Malik, Shakun; Mooney, Margaret; Abrams, Jeffrey S.] NCI, Clin Invest Branch, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA. [Jaenne, Pasi A.] Harvard Univ, Sch Med, Lowe Ctr Thorac Oncol, Boston, MA USA. [Jaenne, Pasi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02115 USA. [Gandara, David R.] Univ Calif Davis, Ctr Comprehens Canc, Div Hematol & Oncol, Sacramento, CA USA. [Ramalingam, Suresh S.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA. [Vokes, Everett E.] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA. [Vokes, Everett E.] Univ Chicago, Comprehens Canc Res Ctr, Chicago, IL 60637 USA. RP Govindan, R (reprint author), Washington Univ, Sch Med, Campus Box 8056, St Louis, MO 63110 USA. EM rgovinda@dom.wustl.edu OI Chaft, Jamie/0000-0002-5838-9982 FU NCI of the NIH [U10CA180821, U10CA18088]; [CA180820]; [CA180794]; [CA180870]; [CA180864]; [P30CA008748] FX This work was supported in part by the NCI of the NIH under award numbers U10CA180821 and U10CA18088 (to Alliance for Clinical Trials in Oncology); CA180820, CA180794, CA180870, and CA180864 (to S.E. Dahlberg); and P30CA008748 (to J. Chaft, through her institution). NR 23 TC 9 Z9 9 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD DEC 15 PY 2015 VL 21 IS 24 BP 5439 EP 5444 DI 10.1158/1078-0432.CCR-15-0354 PG 6 WC Oncology SC Oncology GA DA1HK UT WOS:000367546700008 PM 26672084 ER PT J AU Tewari, KS Sill, MW Monk, BJ Penson, RT Long, HJ Poveda, A Landrum, LM Leitao, MM Brown, J Reid, TJA Michael, HE Moore, DH AF Tewari, Krishnansu S. Sill, Michael W. Monk, Bradley J. Penson, Richard T. Long, Harry J., III Poveda, Andres Landrum, Lisa M. Leitao, Mario M. Brown, Jubilee Reid, Thomas J. A. Michael, Helen E. Moore, David H. TI Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study SO CLINICAL CANCER RESEARCH LA English DT Article ID SQUAMOUS-CELL CARCINOMA; GYNECOLOGIC-ONCOLOGY; RANDOMIZED-TRIAL; PHASE-III; RECURRENT; PERSISTENT; CISPLATIN; SURVIVAL; DISPARITIES; IFOSFAMIDE AB Purpose: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. Experimental Design: Potential negative factors included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval < 365 days. Risk categories included low-risk (0-1 factor), mid-risk (2-3 factors), and high-risk (4-5 factors). Each test of association was conducted at the 5% level of significance. Logistic regression and survival analysis was used to determine whether factors were prognostic or could be used to guide therapy. Results: For the entire population (n = 452), high-risk patients had significantly worse OS (P < 0.0001). The HRs of death for treating with topotecan in low-risk, mid-risk, and high-risk subsets are 1.18 [95% confidence interval (CI), 0.63-2.24], 1.11 (95% CI, 0.82-1.5), and 0.84 (95% CI, 0.50-1.42), respectively. The HRs of death for treating with bevacizumab in low-risk, mid-risk, and high-risk subsets are 0.96 (95% CI, 0.51-1.83; P = 0.9087), 0.673 (95% CI, 0.5-0.91; P = 0.0094), and 0.536 (95% CI, 0.32-0.905; P = 0.0196), respectively. Conclusions: This is the first prospectively validated scoring system in cervical cancer. The Moore criteria have real-world clinical applicability. Toxicity concerns may justify omission of bevacizumab in some low-risk patients where survival benefit is small. The benefit to receiving bevacizumab appears to be greatest in the moderate-and high-risk subgroups (5.8-month increase in median OS). (C) 2015 AACR. C1 [Tewari, Krishnansu S.] Univ Calif Irvine, Med Ctr, Orange, CA 92868 USA. [Sill, Michael W.] Roswell Pk Canc Inst, NRG Oncol GOG Stat & Data Management Ctr, Buffalo, NY 14263 USA. [Monk, Bradley J.] Creighton Univ, St Josephs Hosp, Phoenix, AZ USA. [Monk, Bradley J.] Med Ctr, Phoenix, AZ USA. [Penson, Richard T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Long, Harry J., III] Mayo Clin, Rochester, MN USA. [Poveda, Andres] Fdn Inst Valenciano Oncol, Valencia, Spain. [Landrum, Lisa M.] Univ Oklahoma, Hlth Sci Ctr, Norman, OK 73019 USA. [Leitao, Mario M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Brown, Jubilee] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Reid, Thomas J. A.] Univ Cincinnati, Womens Canc Ctr Kettering, Kettering, OH USA. [Michael, Helen E.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Moore, David H.] Franciscan St Francis Hlth, Indianapolis, IN USA. RP Tewari, KS (reprint author), Univ Calif Irvine, Med Ctr, Div Gynecol Oncol, 101 City Dr South,Bldg 56, Orange, CA 92868 USA. EM ktewari@uci.edu FU National Cancer Institute [CA 27469, CA 37517]; NRG Oncology Group Grant [1 U10 CA180822] FX This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517) and NRG Oncology Group Grant 1 U10 CA180822. NR 30 TC 3 Z9 3 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD DEC 15 PY 2015 VL 21 IS 24 BP 5480 EP 5487 DI 10.1158/1078-0432.CCR-15-1346 PG 8 WC Oncology SC Oncology GA DA1HK UT WOS:000367546700013 PM 26672085 ER PT J AU Wang, XD Huang, Y Christie, A Bowden, M Lee, GSM Kantoff, PW Sweeney, CJ AF Wang, Xiaodong Huang, Ying Christie, Amanda Bowden, Michaela Lee, Gwo-Shu Mary Kantoff, Philip W. Sweeney, Christopher J. TI Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity SO CLINICAL CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR-I; MEDULLARY-THYROID CANCER; ANDROGEN-RECEPTOR; PROGRESSION; CELLS; AXIS; MECHANISMS; EXPRESSION; RESISTANCE; THERAPY AB Purpose: Abiraterone improves the overall survival of men with metastatic castration-resistant prostate cancer. However, de novo or adaptive resistance to abiraterone limits its activity. Rational combinations of drugs with different mechanisms of action that overcome resistance mechanisms may improve the efficacy of therapy. To that end, we studied the molecular and phenotypic effects of the combination of cabozantinib plus abiraterone. Experimental Design: Three prostate cancer cell lines were used to interrogate the in vitro molecular and antiproliferative effects of the single agents and combination of cabozantinib and abiraterone. The in vivo impact of the combination was assessed using the LAPC4-CR xenograft mouse model. Results: In vitro proliferation studies demonstrated single-agent doses between 2 mu mol/L and 10 mu mol/L for abiraterone and cabozantinib inhibit prostate cancer cell proliferation in a dose-dependent manner, and the anticancer activity of abiraterone is enhanced when combined with cabozantinib. In vivo LAPC4-CR xenograft mouse studies also showed that cabozantinib can improve the antitumor activity of abiraterone. Cabozantinib, a multiple receptor tyrosine kinase inhibitor, enhances the ability of abiraterone to inhibit AR activity in a cell line-dependent manner. In addition, our cell line studies demonstrate abiraterone-stimulated insulin-like growth factor I receptor (IGFIR) phosphorylation with downstream activation of MEK1/2 and ERK1/2, and that this potential adaptive resistance mechanism was inhibited by cabozantinib. Conclusions: Cabozantinib can enhance the efficacy of abiraterone by blocking multiple compensatory survival mechanisms, including IGFIR activation, and supports the assessment of the combination in a clinical trial. (C)2015 AACR. C1 [Wang, Xiaodong; Lee, Gwo-Shu Mary; Kantoff, Philip W.; Sweeney, Christopher J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. [Huang, Ying; Bowden, Michaela] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA. [Christie, Amanda] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Sweeney, CJ (reprint author), Dana Farber Canc Inst, 44 Binney St,Room 1230, Boston, MA 02115 USA. EM Philip_Kantoff@dfci.harvard.edu; Christopher_Sweeney@dfci.harvard.edu OI Huang, Ying/0000-0003-1145-3606 FU Exelixis, Inc. in South San Francisco, CA FX This work was funded in part by grants from Exelixis, Inc. in South San Francisco, CA. NR 45 TC 3 Z9 3 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD DEC 15 PY 2015 VL 21 IS 24 BP 5578 EP 5587 DI 10.1158/1078-0432.CCR-15-0824 PG 10 WC Oncology SC Oncology GA DA1HK UT WOS:000367546700022 PM 26289068 ER PT J AU Rothenberg, SM Daniels, GH Wirth, LJ AF Rothenberg, S. Michael Daniels, Gilbert H. Wirth, Lori J. TI Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response SO CLINICAL CANCER RESEARCH LA English DT Letter C1 [Rothenberg, S. Michael; Daniels, Gilbert H.; Wirth, Lori J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Rothenberg, S. Michael; Daniels, Gilbert H.; Wirth, Lori J.] Harvard Univ, Sch Med, Boston, MA USA. [Rothenberg, S. Michael; Daniels, Gilbert H.; Wirth, Lori J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Daniels, Gilbert H.] Massachusetts Gen Hosp, Thyroid Unit, Boston, MA 02114 USA. RP Wirth, LJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Yawkey 7B,55 Fruit St, Boston, MA 02114 USA. EM lwirth@partners.org NR 4 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD DEC 15 PY 2015 VL 21 IS 24 BP 5640 EP 5641 DI 10.1158/1078-0432.CCR-15-2298 PG 2 WC Oncology SC Oncology GA DA1HK UT WOS:000367546700029 PM 26672087 ER PT J AU Wang, K Smith, ZM Buxton, RB Swenson, ER Dubowitz, DJ AF Wang, Kang Smith, Zachary M. Buxton, Richard B. Swenson, Erik R. Dubowitz, David J. TI Acetazolamide during acute hypoxia improves tissue oxygenation in the human brain SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE cerebral oxygen metabolism; cerebral oxygenation; cerebral blood flow; acetazolamide; hypoxia; magnetic resonance imaging ID ACUTE MOUNTAIN-SICKNESS; CEREBRAL-BLOOD-FLOW; CARBON-DIOXIDE; HIGH-ALTITUDE; TRUST MRI; EXERCISE; METABOLISM; PREVENTION; PERFUSION; METAANALYSIS AB Low doses of the carbonic anhydrase inhibitor acetazolamide provides accelerated acclimatization to high-altitude hypoxia and prevention of cerebral and other symptoms of acute mountain sickness. We previously observed increases in cerebral O-2 metabolism (CMRO2) during hypoxia. In this study, we investigate whether low-dose oral acetazolamide (250 mg) reduces this elevated CMRO2 and in turn might improve cerebral tissue oxygenation (Pti(O2)) during acute hypoxia. Six normal human subjects were exposed to 6 h of normobaric hypoxia with and without acetazolamide prophylaxis. We determined CMRO2 and cerebral Pti(O2) from MRI measurements of cerebral blood flow (CBF) and cerebral venous O-2 saturation. During normoxia, low-dose acetazolamide resulted in no significant change in CBF, CMRO2, or Pti(O2). During hypoxia, we observed increases in CBF [48.5 (SD 12.4) (normoxia) to 65.5 (20.4) ml.100 ml(-1).min(-1) (hypoxia), P < 0.05] and CMRO2 [1.54 (0.19) to 1.79 (0.25) mu mol.ml(-1).min(-1), P < 0.05] and a dramatic decline in Pti(O2) [25.0 to 11.4 (2.7) mmHg, P < 0.05]. Acetazolamide prophylaxis mitigated these rises in CBF [53.7 (20.7) ml.100 ml(-1).min(-1) (hypoxia + acetazolamide)] and CMRO2 [1.41 (0.09) mu mol.ml(-1).min(-1) (hypoxia + acetazolamide)] associated with acute hypoxia but also reduced O-2 delivery [6.92 (1.45) (hypoxia) to 5.60 (1.14) mmol/min (hypoxia + acetazolamide), P < 0.05]. The net effect was improved cerebral tissue Pti(O2) during acute hypoxia [11.4 (2.7) (hypoxia) to 16.5 (3.0) mmHg (hypoxia + acetazolamide), P < 0.05]. In addition to its renal effect, low-dose acetazolamide is effective at the capillary endothelium, and we hypothesize that local interruption in cerebral CO2 excretion accounts for the improvements in CMRO2 and ultimately in cerebral tissue oxygenation during hypoxia. This study suggests a potentially pivotal role of cerebral CO2 and pH in modulating CMRO2 and Pti(O2) during acute hypoxia. C1 [Wang, Kang; Smith, Zachary M.; Buxton, Richard B.; Dubowitz, David J.] Univ Calif San Diego, Dept Radiol, Ctr Funct MRI, San Diego, CA 92103 USA. [Wang, Kang] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Swenson, Erik R.] Univ Washington, Dept Med, Seattle, WA USA. [Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Dubowitz, DJ (reprint author), UCSD Ctr Funct MRI, 9500 Gilman Dr,MC 0677, La Jolla, CA 92093 USA. EM dubowitz@ucsd.edu FU National Institute of Neurological Disorders and Stroke [R01-NS-053934, R21-NS-075812, R01-NS-036722] FX This work was supported by National Institute of Neurological Disorders and Stroke Grants R01-NS-053934, R21-NS-075812, and R01-NS-036722. NR 49 TC 5 Z9 5 U1 2 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD DEC 15 PY 2015 VL 119 IS 12 BP 1494 EP 1500 DI 10.1152/japplphysiol.00117.2015 PG 7 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA DA2BP UT WOS:000367600600016 PM 26472861 ER PT J AU Langenau, DM Sweet-Cordero, A Wechsler-Reya, RJ Dyer, MA AF Langenau, David M. Sweet-Cordero, Alejandro Wechsler-Reya, Robert J. Dyer, Michael A. TI Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer SO CANCER RESEARCH LA English DT Review ID ACUTE LYMPHOBLASTIC-LEUKEMIA; PROPAGATING CELL FREQUENCY; ENGAGING BASIC SCIENTISTS; T-CELL; EMBRYONAL RHABDOMYOSARCOMA; TRANSGENIC ZEBRAFISH; MOUSE MODELS; IN-VIVO; FAMILIAL NEUROBLASTOMA; DRUG DEVELOPMENT AB Despite improvements in survival rates for children with cancer since the 1960s, progress for many pediatric malignancies has slowed over the past two decades. With the recent advances in our understanding of the genomic landscape of pediatric cancer, there is now enthusiasm for individualized cancer therapy based on genomic profiling of patients' tumors. However, several obstacles to effective personalized cancer therapy remain. For example, relatively little data from prospective clinical trials demonstrate the selective efficacy of molecular-targeted therapeutics based on somatic mutations in the patient's tumor. In this commentary, we discuss recent advances in preclinical testing for pediatric cancer and provide recommendations for providing scientific justification and translational relevance for novel therapeutic combinations for childhood cancer. Establishing rigorous criteria for defining and validating druggable mutations will be essential for the success of ongoing and future clinical genomic trials for pediatric malignancies. (C) 2015 AACR. C1 [Langenau, David M.] Massachusetts Gen Hosp, Ctr Canc, Mol Pathol, Boston, MA USA. [Langenau, David M.] Massachusetts Gen Hosp, Regenerat Med, Boston, MA 02114 USA. [Langenau, David M.] Harvard Stem Cell Inst, Cambridge, MA USA. [Sweet-Cordero, Alejandro] Stanford Univ, Pediat, Sch Med, Stanford, CA 94305 USA. [Wechsler-Reya, Robert J.] Sanford Burnham Prebys Med Discovery Inst, Tumor Initiat & Maintenance Program, NCI Designated Canc Ctr, La Jolla, CA USA. [Dyer, Michael A.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA. [Dyer, Michael A.] Howard Hughes Med Inst, Chevy Chase, MD USA. RP Dyer, MA (reprint author), St Jude Childrens Res Hosp, Div Dev Biol, Mail Stop 323,332 N Lauderdale, Memphis, TN 38105 USA. EM michael.dyer@stjude.org FU NCI [CA21765, CA168875, CA159859]; NIH [EY014867, EY018599, U54CA168512, R01CA154923]; American Lebanese Syrian Associated Charities; Alex's Lemonade Stand Foundation; Howard Hughes Medical Institute; Live Like Bella Foundation; Leadership Award from the California Institute of Regenerative Medicine [LA1-01747] FX This work was supported by NCI grants [CA21765 and CA168875 (M.A. Dyer); CA159859 (R. Wechsler-Reya)], NIH grants [EY014867 and EY018599 (M.A. Dyer); U54CA168512 and R01CA154923 (D.M. Langenau)], the American Lebanese Syrian Associated Charities (M.A. Dyer), Alex's Lemonade Stand Foundation, Howard Hughes Medical Institute (M.A. Dyer), the Live Like Bella Foundation (D.M. Langenau), and a Leadership Award from the California Institute of Regenerative Medicine (LA1-01747 to R. Wechsler-Reya). NR 73 TC 1 Z9 1 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD DEC 15 PY 2015 VL 75 IS 24 BP 5176 EP 5186 DI 10.1158/0008-5472.CAN-15-1308 PG 11 WC Oncology SC Oncology GA DA1JL UT WOS:000367552000002 PM 26627009 ER PT J AU An, NF Xiong, Y LaRue, AC Kraft, AS Cen, B AF An, Ningfei Xiong, Ying LaRue, Amanda C. Kraft, Andrew S. Cen, Bo TI Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors SO CANCER RESEARCH LA English DT Article ID ACQUIRED-RESISTANCE; PROSTATE-CANCER; GENE AMPLIFICATION; RECEPTOR; CELLS; TRANSLATION; PROTEIN; GROWTH; CRIZOTINIB; INITIATION AB Mesenchymal-epithelial transition (MET) blockade offers a new targeted therapy particularly in those cancers with MET amplification. However, the efficacy and the duration of the response to MET inhibitors are limited by the emergence of drug resistance. Here, we report that resistance to small-molecule inhibitors of MET can arise from increased expression of the prosurvival Pim protein kinases. This resistance mechanism was documented in non-small cell lung cancer and gastric cancer cells with MET amplification. Inhibition of Pim kinases enhanced cell death triggered by short-term treatment with MET inhibitors. Pim kinases control the translation of anti-apoptotic protein Bcl-2 at an internal ribosome entry site and this mechanism was identified as the basis for Pim-mediated resistance to MET inhibitors. Protein synthesis was increased in drug-resistant cells, secondary to a Pim-mediated increase in cap-independent translation. In cells rendered drug resistant by chronic treatment with MET inhibitors, genetic or pharmacologic inhibition of Pim kinases was sufficient to restore sensitivity in vitro and in vivo. Taken together, our results rationalize Pim inhibition as a strategy to augment responses and blunt acquired resistance to MET inhibitors in cancer. (C)2015 AACR. C1 [An, Ningfei; Cen, Bo] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [An, Ningfei; Xiong, Ying; LaRue, Amanda C.; Cen, Bo] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Xiong, Ying; LaRue, Amanda C.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [LaRue, Amanda C.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Kraft, Andrew S.] Univ Arizona, Ctr Canc, Tucson, AZ USA. RP Cen, B (reprint author), Med Univ S Carolina, Dept Med, 86 Jonathan Lucas St, Charleston, SC 29425 USA. EM akraft@uacc.arizona.edu; cen@musc.edu FU NIH [1K01DK085196, 1R01CA173200]; DOD [W81XWH-12-10560] FX This work was supported by NIH grants 1K01DK085196 (B. Cen), 1R01CA173200 (A.S. Kraft), and DOD grant W81XWH-12-10560 (A.S. Kraft). NR 40 TC 2 Z9 2 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD DEC 15 PY 2015 VL 75 IS 24 BP 5318 EP 5328 DI 10.1158/0008-5472.CAN-15-0544 PG 11 WC Oncology SC Oncology GA DA1JL UT WOS:000367552000017 PM 26670562 ER PT J AU Grant, IM Balcha, D Hao, T Shen, Y Trivedi, P Patrushev, I Fortriede, JD Karpinka, JB Liu, LM Zorn, AM Stukenberg, PT Hill, DE Gilchrist, MJ AF Grant, Ian M. Balcha, Dawit Hao, Tong Shen, Yun Trivedi, Prasad Patrushev, Ilya Fortriede, Joshua D. Karpinka, John B. Liu, Limin Zorn, Aaron M. Stukenberg, P. Todd Hill, David E. Gilchrist, Michael J. TI The Xenopus ORFeome: A resource that enables functional genomics SO DEVELOPMENTAL BIOLOGY LA English DT Article DE Gateway; Recombinational cloning; ORFeome; Xenopus; Open reading frame; Gene annotation ID OPEN READING FRAMES; GENE COLLECTION; VERSION 1.1; SYSTEMATIC IDENTIFICATION; CAENORHABDITIS-ELEGANS; EXPRESSION CLONING; TROPICALIS; LAEVIS; CHROMOSOMES; VERTEBRATES AB Functional characterisation of proteins and large-scale, systems-level studies are enabled by extensive sets of cloned open reading frames (ORFs) in an easily-accessible format that enables many different applications. Here we report the release of the first stage of the Xenopus ORFeome, which contains 8673 ORFs from the Xeno pus Gene Collection (XGC) for Xenopus laevis, cloned into a Gateway (R) donor vector enabling rapid in-frame transfer of the ORFs to expression vectors. This resource represents an estimated 7871 unique genes, approximately 40% of the non-redundant X. laevis gene complement, and includes 2724 genes where the human ortholog has an association with disease. Transfer into the Gateway system was validated by 5' and 3' end sequencing of the entire collection and protein expression of a set of test clones. In a parallel process, the underlying ORF predictions from the original XGC collection were re-analysed to verify quality and full-length status, identifying those proteins likely to exhibit truncations when translated. These data are integrated into Xenbase, the Xenopus community database, which associates genomic, expression, function and human disease model metadata to each ORF, enabling end-users to search for ORFeome clones with links to commercial distributors of the collection. When coupled with the experimental advantages of Xenopus eggs and embryos, the ORFeome collection represents a valuable resource for functional genomics and disease modelling. (C) 2015 The Authors. Published by Elsevier Inc. C1 [Grant, Ian M.; Patrushev, Ilya; Gilchrist, Michael J.] Francis Crick Inst, Mill Hill Lab, London NW7 1AA, England. [Balcha, Dawit; Hao, Tong; Shen, Yun; Hill, David E.] Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA. [Balcha, Dawit; Hao, Tong; Shen, Yun; Hill, David E.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Fortriede, Joshua D.; Zorn, Aaron M.] Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Xenbase, Cincinnati, OH 45229 USA. [Karpinka, John B.] Univ Calgary, Dept Biol Sci, Xenbase, Calgary, AB, Canada. [Trivedi, Prasad; Liu, Limin; Stukenberg, P. Todd] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. RP Hill, DE (reprint author), Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA. EM David_Hill@dfci.harvard.edu; mike.gilchrist@crick.ac.uk OI Grant, Ian/0000-0001-6960-6762; Stukenberg, Todd/0000-0002-6788-2111 FU NIH grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development [R01HD069352]; Cancer Research UK; UK Medical Research Council; Wellcome Trust; Francis Crick Institute FX This work was supported by NIH grant R01HD069352 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development awarded to M.J.G., D.E.H., P.T.S., and A.M.Z. In addition, M.J.G. and I.M.G. were supported by the Francis Crick Institute which receives its core funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust. NR 46 TC 5 Z9 6 U1 1 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0012-1606 EI 1095-564X J9 DEV BIOL JI Dev. Biol. PD DEC 15 PY 2015 VL 408 IS 2 SI SI BP 345 EP 357 DI 10.1016/j.ydbio.2015.09.004 PG 13 WC Developmental Biology SC Developmental Biology GA CZ2TG UT WOS:000366956900015 PM 26391338 ER PT J AU Pikor, NB Astarita, JL Summers-Deluca, L Galicia, G Qu, J Ward, LA Armstrong, S Dominguez, CX Malhotra, D Heiden, B Kay, R Castanov, V Touil, H Boon, L O'Connor, P Bar-Or, A Prat, A Ramaglia, V Ludwin, S Turley, SJ Gommerman, JL AF Pikor, Natalia B. Astarita, Jillian L. Summers-Deluca, Leslie Galicia, Georgina Qu, Joy Ward, Lesley A. Armstrong, Susan Dominguez, Claudia X. Malhotra, Deepali Heiden, Brendan Kay, Robert Castanov, Valera Touil, Hanane Boon, Louis O'Connor, Paul Bar-Or, Amit Prat, Alexandre Ramaglia, Valeria Ludwin, Samuel Turley, Shannon J. Gommerman, Jennifer L. TI Integration of Th17-and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation SO IMMUNITY LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FIBROBLASTIC RETICULAR CELLS; MULTIPLE-SCLEROSIS; LYMPHOID FOLLICLES; DENDRITIC CELLS; B-CELLS; BETA; DISEASE; SYSTEM; DEMYELINATION AB Tertiary lymphoid tissues (TLTs) have been observed in the meninges of multiple sclerosis (MS) patients, but the stromal cells and molecular signals that support TLTs remain unclear. Here, we show that T helper 17 (Th17) cells induced robust TLTs within the brain meninges that were associated with local demyelination during experimental autoimmune encephalitis (EAE). Th17-cell-induced TLTs were underpinned by a network of stromal cells producing extracellular matrix proteins and chemokines, enabling leukocytes to reside within, rather than simply transit through, the meninges. Within the CNS, interactions between lymphotoxin ab (LT alpha beta) on Th17 cells and LT beta R on meningeal radio-resistant cells were necessary for the propagation of de novo interleukin-17 responses, and activated T cells from MS patients expressed elevated levels of LTbR ligands. Therefore, input from both Th17 cells and the lymphotoxin pathway induce the formation of an immune-competent stromal cell niche in the meninges. C1 [Pikor, Natalia B.; Summers-Deluca, Leslie; Galicia, Georgina; Qu, Joy; Ward, Lesley A.; Armstrong, Susan; Kay, Robert; Castanov, Valera; Gommerman, Jennifer L.] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada. [Astarita, Jillian L.; Malhotra, Deepali; Heiden, Brendan; Turley, Shannon J.] Dana Farber Canc Inst, Dept Canc Immunol, Boston, MA 02115 USA. [Astarita, Jillian L.; Malhotra, Deepali; Heiden, Brendan; Turley, Shannon J.] Dana Farber Canc Inst, AIDS, Boston, MA 02115 USA. [Astarita, Jillian L.; Malhotra, Deepali; Heiden, Brendan; Turley, Shannon J.] Harvard Univ, Sch Med, Div Med Sci, Boston, MA 02115 USA. [Astarita, Jillian L.; Dominguez, Claudia X.; Turley, Shannon J.] Genentech Inc, Dept Canc Immunol, San Francisco, CA 94080 USA. [Touil, Hanane; Bar-Or, Amit] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada. [Boon, Louis] EPIRUS Biopharmaceut Netherlands, NL-3584 CM Utrecht, Netherlands. [O'Connor, Paul] Univ Toronto, Dept Med, Toronto, ON M5B 1W8, Canada. [O'Connor, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Prat, Alexandre] CHU Montreal, Ctr Rech, Neuroimmunol Res Lab, Montreal, PQ H2L 4M1, Canada. [Ludwin, Samuel] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada. [Ramaglia, Valeria] Acad Med Ctr, Dept Genome Anal, NL-1105 AZ Noord Holland, Netherlands. RP Gommerman, JL (reprint author), Univ Toronto, Dept Immunol, 100 Coll St, Toronto, ON M5S 1A8, Canada. EM jen.gommerman@utoronto.ca FU MS Society of Canada (Operating Grant EGID) [1553]; Canadian Institutes of Health Research (MOG) [67157]; NIH [RO1 DK074500, PO1 AIO45757]; National Science Foundation; MS Society of Canada FX We would like to acknowledge Biogen Idec for providing LT beta R-Ig, control antibodies, and BBF6 for this study, as well as Genentech Inc. for providing anti-IL-17A, anti-IL-17F, and anti-IL-22. We would also like to acknowledge Dr. Jeff Browning for helpful advice on the choice of control antibodies for i.c.v. treatments. This work was supported in part by the MS Society of Canada (Operating Grant EGID no. 1553 to J.L.G., Doctoral Studentships to N.P. and H.T., and Collaborative Research Grant to A.B.O., A.P., and J.L.G), the Canadian Institutes of Health Research (MOG no. 67157 to J.L.G.), the NIH (grants RO1 DK074500 and PO1 AIO45757 to S.J.T.), and the National Science Foundation (Graduate Research Fellowship to J.L.A.). S.J.T., J.L.A., and C.X.D. are employees of Genentech Inc., and V.R. is a cofounder of Regenesance BV. NR 29 TC 14 Z9 14 U1 0 U2 7 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1074-7613 EI 1097-4180 J9 IMMUNITY JI Immunity PD DEC 15 PY 2015 VL 43 IS 6 BP 1160 EP 1173 DI 10.1016/j.immuni.2015.11.010 PG 14 WC Immunology SC Immunology GA CZ1DS UT WOS:000366846600019 PM 26682987 ER PT J AU Schoenfeld, JD Mahadevan, A Floyd, SR Dyer, MA Catalano, PJ Alexander, BM McDermott, DF Kaplan, ID AF Schoenfeld, Jonathan D. Mahadevan, Anand Floyd, Scott R. Dyer, Michael A. Catalano, Paul J. Alexander, Brian M. McDermott, David F. Kaplan, Irving D. TI Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review SO JOURNAL FOR IMMUNOTHERAPY OF CANCER LA English DT Review DE Melanoma; Ipilimumab; Immunotherapy; Radiation; Abscopal effect; Brain metastases; Stereotactic radiosurgery ID BRAIN METASTASES; STEREOTACTIC RADIOSURGERY; IPILIMUMAB AB Background: Ipilimumab improves survival in metastatic melanoma patients. This population frequently develops brain metastases, which have been associated with poor survival and are often treated with radiation. Therefore, outcomes following ipilimumab and radiation are of interest, especially given case reports and animal studies suggest combined treatment may generate abscopal responses outside the radiation field. Findings: We reviewed sixteen consecutive melanoma patients who received 1 to 8 courses of radiation, with a sum total of 51, systematically evaluating abscopal responses by following the largest extra-cranial lesion. We also reviewed other series of patients treated with cranial radiation and ipilimumab. Our patients received between 1 and 8 courses of cranial radiation. Four patients received radiation concurrently with ipilimumab. Median survival was 14 months, and 17 months in patients initially treated with SRS. Interestingly, after radiotherapy, there was a 2.8-fold increased likelihood that the rate of extra-cranial index lesion response improved that didn't reach statistical significance (p = 0.07); this was more pronounced when ipilimumab was administered within three months of radiation (p < 0.01). Conclusion: Our experience and review of recently published series suggest ipilimumab and cranial radiation is well tolerated and can result in prolonged survival. Timing of ipilimumab administration in relation to radiation may impact outcomes. Additionally, our results demonstrate a trend for favorable systemic response following radiotherapy worthy of further evaluation in studies powered to detect potential synergies between radiation and immunotherapy. C1 [Schoenfeld, Jonathan D.; Catalano, Paul J.; Alexander, Brian M.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Schoenfeld, Jonathan D.; Catalano, Paul J.; Alexander, Brian M.] Dana Farber Canc Inst, Boston, MA 02114 USA. [Mahadevan, Anand; Floyd, Scott R.; Kaplan, Irving D.] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA USA. [McDermott, David F.] Dept Med Oncol, Boston, MA USA. [Dyer, Michael A.] Harvard Radiat Oncol Program, Boston, MA USA. [Floyd, Scott R.] Duke Med Sch, Dept Radiat Oncol, Durham, NC USA. RP Schoenfeld, JD (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 450 Brookline Ave,L2-57, Boston, MA 02114 USA. EM jdschoenfeld@partners.org NR 21 TC 9 Z9 9 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2051-1426 J9 J IMMUNOTHER CANCER JI J. Immunother. Cancer PD DEC 15 PY 2015 VL 3 AR 50 DI 10.1186/s40425-015-0095-8 PG 6 WC Oncology SC Oncology GA CZ5QQ UT WOS:000367157500001 PM 26672895 ER PT J AU Connor, K Cheng, E Siebens, HC Lee, ML Mittman, BS Ganz, DA Vickrey, B AF Connor, Karen Cheng, Eric Siebens, Hilary C. Lee, Martin L. Mittman, Brian S. Ganz, David A. Vickrey, Barbara TI Study protocol of "CHAPS": a randomized controlled trial protocol of Care Coordination for Health Promotion and Activities in Parkinson's Disease to improve the quality of care for individuals with Parkinson's disease SO BMC NEUROLOGY LA English DT Article DE Care coordination; Parkinson's disease; Behavioral intervention; Clinical trial; Quality of health care; Nursing care management ID DOMAIN MANAGEMENT MODEL; INCREASE FUNCTIONAL INDEPENDENCE; CHRONIC ILLNESS; INPATIENT REHABILITATION; DEMENTIA CAREGIVERS; COLLABORATIVE CARE; DISCHARGE RATE; INTERVENTION; VALIDATION; VALIDITY AB Background: Parkinson's disease, the second most common neurodegenerative disease, is diagnostically defined by motor impairments, but also includes often under-recognized impairments in cognition, mood, sleep, and the autonomic nervous system. These problems can severely affect individuals' quality of life. In our prior research, we have developed indicators to measure the quality of care delivered to patients with Parkinson's disease, and we identified gaps in delivering evidence-based treatments for this population. Effective strategies to close these gaps are needed to improve patient quality of life. Methods/design: Building on prior research we developed a multi-faceted proactive implementation program called Care Coordination for Health Promotion and Activities in Parkinson's Disease (CHAPS). To be eligible, patients had to have at least two visits with a primary diagnosis of idiopathic Parkinson's disease (ICD-9 code: 332.0) at one of five Veterans Affairs Medical Centers in the southwestern United States from 2010 to 2014. The program consists of telephone assessments, evidence-based protocols, and tools to enhance patient self-management, care planning, and coordination of care across providers, including an electronic database to support and track coordination of care. Our mixed-methods study employs a randomized, controlled trial design to test whether the CHAPS intervention improves performance in 38 quality measures among an analytic sample of 346 patients. The 38 qualitymeasures are categorized into overarching areas of communication, education, and continuity; regulatory reporting; diagnosis; periodic assessment; medication use; management of motor and non-motor symptoms; use of non-pharmacological approaches and therapies; palliative care; and health maintenance. Secondary outcomes are patient health-related quality of life, self-efficacy, and perceptions of care quality. We are also evaluating the extent of the CHAPS Program implementation and measuring program costs and impacts on health services utilization, in order to perform a analysis of the CHAPS program from the perspective of the Veterans Health Administration (VA). Outcomes are assessed by interviewer-administered surveys collected at baseline and at 6, 12, and 18 months, and by medical record chart abstractions. Analyses will be intention-to-treat. Discussion: The CHAPS Program is poised for dissemination within the VA National Parkinson's Disease Research, Education, and Clinical Center Consortium if demonstrated efficacious. C1 [Connor, Karen; Cheng, Eric; Vickrey, Barbara] VA Greater Los Angeles Healthcare Syst, PADRECC Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Connor, Karen; Cheng, Eric; Vickrey, Barbara] Univ Calif Los Angeles, Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Siebens, Hilary C.] Siebens Patient Care Commun, Seal Beach, CA 90740 USA. [Lee, Martin L.] VA Greater Los Angeles Healthcare Syst, Sepulveda VA Ambulatory Care Ctr, North Hills, CA 91343 USA. [Lee, Martin L.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Mittman, Brian S.] Vet Affairs Greater Los Angeles Healthcare Syst 1, CIPRS, Sepulveda, CA 91343 USA. [Ganz, David A.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA 90073 USA. RP Connor, K (reprint author), VA Greater Los Angeles Healthcare Syst, PADRECC Parkinsons Dis Res Educ & Clin Ctr, 11301 Wilshire Blvd,B500,ML 127, Los Angeles, CA 90073 USA. EM Karen.Connor@va.gov FU Department of Veteran Affairs, Veterans Health Administration, Health Services Research and Development Service [NRI 11-126] FX The research reported here was supported by the Department of Veteran Affairs, Veterans Health Administration, Health Services Research and Development Service (NRI 11-126). Dr. Karen Connor is a Health Scientist at the Parkinson's Disease Research, Education, and Clinical Center (PADRECC), VA Greater Los Angeles Healthcare System. The authors wish to thank the CHAPS Advisory Board: Dr. Robert Ruff, Dr. Jeff Bronstein, Dr. Sharon Valente, Dr. Fran Weaver, Dr. Peter Schmidt, Michele Popadynec RN MPS, John Ball, Edna Ball and the CHAPS Steering Committee: Dr. Dorothee Cole, Dr. Evelyn Tecoma, Dr. Denson Fujikawa, Dr. Emad Farag, Virginia Janovsky, Dr. Steven Schreiber, Dr. Selina Parveen, Dr. Donna McNeese-Smith, Dr. Donna Benton, Ms. Jo Rosen. We wish to thank Virginia Janovsky MN, MS, RN and Erik Ernst DNP who provided nursing practice expertise in the CHAPS Program design. We wish to thank Michael McGowan and Lisa Edwards for their contributions to the ongoing research study. We wish to acknowledge Megan Connor's programming expertise in the CHAPS care management tool development. NR 59 TC 0 Z9 0 U1 10 U2 23 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2377 J9 BMC NEUROL JI BMC Neurol. PD DEC 15 PY 2015 VL 15 AR 258 DI 10.1186/s12883-015-0506-y PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA CZ1WE UT WOS:000366895800002 PM 26670300 ER PT J AU Bouts, MJRJ Westmoreland, SV de Crespigny, AJ Liu, YT Vangel, M Dijkhuizen, RM Wu, O D'Arceuil, HE AF Bouts, Mark. J. R. J. Westmoreland, Susan. V. de Crespigny, Alex J. Liu, Yutong Vangel, Mark Dijkhuizen, Rick M. Wu, Ona D'Arceuil, Helen E. TI Magnetic resonance imaging-based cerebral tissue classification reveals distinct spatiotemporal patterns of changes after stroke in non-human primates SO BMC NEUROSCIENCE LA English DT Article DE ISODATA; Tissue signatures; Non-human primates; Stroke; Temporal ischemic tissue evolution; Diffusion-tensor imaging ID ISCHEMIC-STROKE; DIFFUSION TENSOR; ARTERY OCCLUSION; TEMPORAL PROFILE; ISODATA ANALYSIS; FOCAL ISCHEMIA; SYMPTOM ONSET; WHITE-MATTER; BRAIN EDEMA; MRI AB Background: Spatial and temporal changes in brain tissue after acute ischemic stroke are still poorly understood. Aims of this study were three-fold: (1) to determine unique temporal magnetic resonance imaging (MRI) patterns at the acute, subacute and chronic stages after stroke in macaques by combining quantitative T-2 and diffusion MRI indices into MRI 'tissue signatures', (2) to evaluate temporal differences in these signatures between transient (n = 2) and permanent (n = 2) middle cerebral artery occlusion, and (3) to correlate histopathology findings in the chronic stroke period to the acute and subacute MRI derived tissue signatures. Results: An improved iterative self-organizing data analysis algorithm was used to combine T-2, apparent diffusion coefficient (ADC), and fractional anisotropy (FA) maps across seven successive timepoints (1, 2, 3, 24, 72, 144, 240 h) which revealed five temporal MRI signatures, that were different from the normal tissue pattern (P < 0.001). The distribution of signatures between brains with permanent and transient occlusions varied significantly between groups (P < 0.001). Qualitative comparisons with histopathology revealed that these signatures represented regions with different histopathology. Two signatures identified areas of progressive injury marked by severe necrosis and the presence of gitter cells. Another signature identified less severe but pronounced neuronal and axonal degeneration, while the other signatures depicted tissue remodeling with vascular proliferation and astrogliosis. Conclusion: These exploratory results demonstrate the potential of temporally and spatially combined voxel-based methods to generate tissue signatures that may correlate with distinct histopathological features. The identification of distinct ischemic MRI signatures associated with specific tissue fates may further aid in assessing and monitoring the efficacy of novel pharmaceutical treatments for stroke in a pre-clinical and clinical setting. C1 [Bouts, Mark. J. R. J.; de Crespigny, Alex J.; Liu, Yutong; Vangel, Mark; Wu, Ona; D'Arceuil, Helen E.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Bouts, Mark. J. R. J.; Dijkhuizen, Rick M.] Univ Med Ctr Utrecht, Image Sci Inst, Biomed MR Imaging & Spect Grp, Utrecht, Netherlands. [Westmoreland, Susan. V.] New England Primate Res Ctr, Pathol, Southborough, MA USA. [Liu, Yutong] Univ Nebraska Med Ctr, Dept Radiol, Omaha, NE USA. RP Wu, O (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St CNY 2301, Charlestown, MA 02129 USA. EM ona@nmr.mgh.harvard.edu OI Dijkhuizen, Rick/0000-0002-4623-4078 FU National Institutes of Health [R01NS041285, R01NS59775, R01NS063925, NIBIB [P41EB015896], P50NS051343-01]; American Heart Association; Royal Netherlands Academy of Arts and Sciences FX This study was supported in part by grants from the National Institutes of Health (R01NS041285, R01NS59775, R01NS063925, NIBIB [P41EB015896], P50NS051343-01), the American Heart Association, and the Royal Netherlands Academy of Arts and Sciences. NR 37 TC 0 Z9 0 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2202 J9 BMC NEUROSCI JI BMC Neurosci. PD DEC 15 PY 2015 VL 16 AR 91 DI 10.1186/s12868-015-0226-7 PG 13 WC Neurosciences SC Neurosciences & Neurology GA CY8WT UT WOS:000366690100002 PM 26666889 ER PT J AU Satpute, AB Kang, J Bickart, KC Yardley, H Wager, TD Barrett, LF AF Satpute, Ajay B. Kang, Jian Bickart, Kevin C. Yardley, Helena Wager, Tor D. Barrett, Lisa F. TI Involvement of Sensory Regions in Affective Experience: A Meta-Analysis SO FRONTIERS IN PSYCHOLOGY LA English DT Article DE emotion; fMRI; meta-analysis; perception; affect ID FUNCTIONAL NEUROIMAGING DATA; CONDITIONED TASTE-AVERSION; OLD-WORLD MONKEY; VISUAL-CORTEX; AUDITORY-CORTEX; HUMAN AMYGDALA; HUMAN BRAIN; PREFRONTAL CORTEX; EMOTIONAL AROUSAL; MACAQUE MONKEY AB A growing body of work suggests that sensory processes may also contribute to affective experience. In this study, we performed a meta-analysis of affective experiences driven through visual, auditory, olfactory, gustatory, and somatosensory stimulus modalities including study contrasts that compared affective stimuli to matched neutral control stimuli. We found, first, that limbic and paralimbic regions, including the amygdala, anterior insula, pre-supplementary motor area, and portions of orbitofrontal cortex were consistently engaged across two or more modalities. Second, early sensory input regions in occipital, temporal, piriform, mid insular, and primary sensory cortex were frequently engaged during affective experiences driven by visual, auditory, olfactory, gustatory, and somatosensory inputs. A classification analysis demonstrated that the pattern of neural activity across a contrast map diagnosed the stimulus modality driving the affective experience. These findings suggest that affective experiences are constructed from activity that is distributed across limbic and paralimbic brain regions and also activity in sensory cortical regions. C1 [Satpute, Ajay B.] Pomona Coll, Dept Psychol, Claremont, CA 91711 USA. [Kang, Jian] Emory Univ, Atlanta, GA 30322 USA. [Bickart, Kevin C.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA. [Yardley, Helena] Univ Colorado, Dept Intergrat Physiol, Boulder, CO 80309 USA. [Yardley, Helena; Wager, Tor D.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA. [Barrett, Lisa F.] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA. [Barrett, Lisa F.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Satpute, AB (reprint author), Pomona Coll, Dept Psychol, Claremont, CA 91711 USA. EM ajay.satpute@pomona.edu FU National institute of Health Director's Pioneer Award [DP1OD003312]; U.S. Army Research Institute for the Behavioral and Social Sciences [W5J9CQ-11-C-0046] FX This work was supported by National institute of Health Director's Pioneer Award (DP1OD003312) and by the U.S. Army Research Institute for the Behavioral and Social Sciences (contract W5J9CQ-11-C-0046) awarded to LB. The views, opinion, and/or findings contained in this article are solely of the authors and should not be construed as an official Department of the Army of DOD position, policy, or decision. NR 115 TC 5 Z9 5 U1 3 U2 15 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-1078 J9 FRONT PSYCHOL JI Front. Psychol. PD DEC 15 PY 2015 VL 6 AR 1860 DI 10.3389/fpsyg.2015.01860 PG 14 WC Psychology, Multidisciplinary SC Psychology GA CZ2HG UT WOS:000366925100001 PM 26696928 ER PT J AU Scott, JL Cunningham, MA Naga, OS Wirth, JR Eudaly, JG Gilkeson, GS AF Scott, Jennifer L. Cunningham, Melissa A. Naga, Osama S. Wirth, Jena R. Eudaly, Jackie G. Gilkeson, Gary S. TI Estrogen Receptor alpha Deficiency Modulates TLR Ligand-Mediated PDC-TREM Expression in Plasmacytoid Dendritic Cells in Lupus-Prone Mice SO JOURNAL OF IMMUNOLOGY LA English DT Article ID I INTERFERON; MURINE LUPUS; DIFFERENTIATION; ERYTHEMATOSUS; TRANSCRIPTION; PROMOTES; DISEASE; MOUSE; LY49Q; AUTOIMMUNITY AB Female lupus-prone NZM2410 estrogen receptor alpha (ER alpha)-deficient mice are protected from renal disease and have prolonged survival compared with wild-type littermates; however, the mechanism of protection is unknown. Plasmacytoid dendritic cells (pDCs) and type I IFN drive lupus pathogenesis. Estrogen acting via ER alpha enhances both pDC development and IFN production. The objectives for this study were to determine if ER alpha modulates pDC function and IFN activity in predisease NZM2410 mice as a possible protective mechanism of ER alpha deficiency in lupus-prone mice. We measured the effect of ER alpha deficiency on spleen pDC frequency, number, maturation, and activation state. ER alpha deficiency reduced type I IFN activity and the frequency of MHC class II+ pDCs in the spleen without altering overall pDC frequency, number, or maturation state. Additionally, ER alpha-deficient NZM2410 mice had a significantly decreased frequency of pDCs expressing PDC-TREM, a modulator of TLR-mediated IFN production. After in vitro TLR9 stimulation, ER alpha deficiency significantly reduced the expression of PDC-TREM on pDCs from both NZM2410 and C57BL/6 mice. Thus, we have identified a significant effect of ER alpha deficiency on pDCs in predisease NZM2410 mice, which may represent a mechanism by which ER alpha deficiency protects NZM2410 mice from lupuslike disease. C1 [Scott, Jennifer L.] Med Univ S Carolina, Coll Grad Studies, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Scott, Jennifer L.; Cunningham, Melissa A.; Naga, Osama S.; Wirth, Jena R.; Eudaly, Jackie G.; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Gilkeson, Gary S.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29403 USA. RP Gilkeson, GS (reprint author), Med Univ S Carolina, Dept Med, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA. EM gilkeson@musc.edu FU Veterans Affairs Merit Review Grant [BX000470]; National Institutes of Health Grant [UT1 TR000062]; American Association of Immunology Careers in Immunology Fellowship; Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center; Medical University of South Carolina [P30 CA138313]; National Institutes of Health-National Institute of General Medical Sciences Grant [P30 GM103342] FX This work was supported by Veterans Affairs Merit Review Grant BX000470, the National Institutes of Health Grant UT1 TR000062, and an American Association of Immunology Careers in Immunology Fellowship. This work was supported in part by the Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, and Medical University of South Carolina (Grant P30 CA138313). This study used the services of the Medical University of South Carolina Flow Cytometry Facility, which is supported by National Institutes of Health-National Institute of General Medical Sciences Grant P30 GM103342 to the South Carolina Center of Biomedical Research Excellence for Developmentally Based Cardiovascular Diseases. NR 36 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD DEC 15 PY 2015 VL 195 IS 12 BP 5561 EP 5571 DI 10.4049/jimmunol.1500315 PG 11 WC Immunology SC Immunology GA CY9OB UT WOS:000366735100006 PM 26553076 ER PT J AU Heatwole, C Johnson, N Bode, R Dekdebrun, J Dilek, N Hilbert, JE Luebbe, E Martens, W McDermott, MP Quinn, C Rothrock, N Thornton, C Vickrey, BG Victorson, D Moxley, RT AF Heatwole, Chad Johnson, Nicholas Bode, Rita Dekdebrun, Jeanne Dilek, Nuran Hilbert, James E. Luebbe, Elizabeth Martens, William McDermott, Michael P. Quinn, Christine Rothrock, Nan Thornton, Charles Vickrey, Barbara G. Victorson, David Moxley, Richard T., III TI Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2) SO NEUROLOGY LA English DT Article ID FACIOSCAPULOHUMERAL DYSTROPHY; CHRONIC PAIN; CEREBRAL INVOLVEMENT; DAYTIME SLEEPINESS; WORKSHOP REPORT; DYSFUNCTION; INTENSITY AB Objective:To determine the frequency and relative importance of the most life-affecting symptoms in myotonic dystrophy type 2 (DM2) and to identify the factors that have the strongest association with these symptoms.Methods:We conducted a cross-sectional study of adult patients with DM2 from a National Registry of DM2 Patients to assess the prevalence and relative importance of 310 symptoms and 21 symptomatic themes. Participant responses were compared by age categories, sex, educational attainment, employment status, and duration of symptoms.Results:The symptomatic themes with the highest prevalence in DM2 were the inability to do activities (94.4%), limitations with mobility or walking (89.2%), hip, thigh, or knee weakness (89.2%), fatigue (89.2%), and myotonia (82.6%). Participants identified the inability to do activities and fatigue as the symptomatic themes that have the greatest overall effect on their lives. Unemployment, a longer duration of symptoms, and less education were associated with a higher average prevalence of all symptomatic themes (p < 0.01). Unemployment, a longer duration of symptoms, sex, and increased age were associated with a higher average effect of all symptomatic themes among patients with DM2 (p < 0.01).Conclusions:The lives of patients with DM2 are affected by a variety of symptoms. These symptoms have different levels of significance and prevalence in this population and vary across DM2 subgroups in different demographic categories. C1 [Heatwole, Chad; Dekdebrun, Jeanne; Dilek, Nuran; Hilbert, James E.; Luebbe, Elizabeth; Martens, William; McDermott, Michael P.; Thornton, Charles; Moxley, Richard T., III] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA. [McDermott, Michael P.] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA. [Quinn, Christine] Univ Rochester, Med Ctr, James P Wilmot Canc Inst, Rochester, NY 14642 USA. [Johnson, Nicholas] Univ Utah, Salt Lake City, UT USA. [Bode, Rita; Rothrock, Nan; Victorson, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Vickrey, Barbara G.] Univ Calif Los Angeles, Med Ctr, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Vickrey, Barbara G.] Greater Los Angeles VA HealthCare Syst, Los Angeles, CA USA. RP Heatwole, C (reprint author), Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA. EM Chad_Heatwole@urmc.rochester.edu FU Goldberg Nathan Foundation for Myotonic Dystrophy Type-2 Research; National Institute of Arthritis and Musculoskeletal and Skin Disorders [1K23AR055947]; Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center [U54NS48843-01]; Muscular Dystrophy Association; New York State Empire Clinical Research Investigator Program; Saunders Family Fund; University of Rochester Clinical Translational Science Institute FX Support for PRISM-2 was provided by the Goldberg Nathan Foundation for Myotonic Dystrophy Type-2 Research, the National Institute of Arthritis and Musculoskeletal and Skin Disorders (1K23AR055947), the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center (U54NS48843-01), the Muscular Dystrophy Association, the New York State Empire Clinical Research Investigator Program, the Saunders Family Fund, and the University of Rochester Clinical Translational Science Institute. NR 28 TC 1 Z9 1 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD DEC 15 PY 2015 VL 85 IS 24 BP 2136 EP 2146 DI 10.1212/WNL.0000000000002225 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA CY5QI UT WOS:000366461900008 PM 26581301 ER PT J AU Forsyth, JK Bachman, P Mathalon, DH Roach, BJ Asarnow, RF AF Forsyth, Jennifer K. Bachman, Peter Mathalon, Daniel H. Roach, Brian J. Asarnow, Robert F. TI Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE D-cycloserine; NMDA receptor; neuroplasticity; long-term potentiation; learning ID LONG-TERM POTENTIATION; COGNITIVE-BEHAVIORAL THERAPY; NONEMOTIONAL MEMORY TASKS; D-CYCLOSERINE; SYNAPTIC PLASTICITY; BASAL GANGLIA; PSYCHIATRIC-DISORDERS; EVOKED-POTENTIALS; VISUAL-CORTEX; SCHIZOPHRENIA AB Experience-dependent plasticity is a fundamental property of the brain. It is critical for everyday function, is impaired in a range of neurological and psychiatric disorders, and frequently depends on long-term potentiation (LTP). Preclinical studies suggest that augmenting N-methyl-D-aspartate receptor (NMDAR) signaling may promote experience-dependent plasticity; however, a lack of noninvasive methods has limited our ability to test this idea in humans until recently. We examined the effects of enhancing NMDAR signaling using D-cycloserine (DCS) on a recently developed LTP EEG paradigm that uses high-frequency visual stimulation (HFvS) to induce neural potentiation in visual cortex neurons, as well as on three cognitive tasks: a weather prediction task (WPT), an information integration task (IIT), and a n-back task. The WPT and IIT are learning tasks that require practice with feedback to reach optimal performance. The n-back assesses working memory. Healthy adults were randomized to receive DCS (100 mg; n = 32) or placebo (n = 33); groups were similar in IQ and demographic characteristics. Participants who received DCS showed enhanced potentiation of neural responses following repetitive HFvS, as well as enhanced performance on the WPT and IIT. Groups did not differ on the n-back. Augmenting NMDAR signaling using DCS therefore enhanced activity-dependent plasticity in human adults, as demonstrated by lasting enhancement of neural potentiation following repetitive HFvS and accelerated acquisition of two learning tasks. Results highlight the utility of considering cellular mechanisms underlying distinct cognitive functions when investigating potential cognitive enhancers. C1 [Forsyth, Jennifer K.; Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Bachman, Peter] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mathalon, Daniel H.; Roach, Brian J.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Asarnow, RF (reprint author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. EM rasarnow@mednet.ucla.edu FU Della Martin Foundation; National Science Foundation FX We thank Dr. Gregory Ashby and Dr. Vivian Valentin for consultation on implementation and modeling of the IIT and Dr. Barbara Knowlton for consultation on implementation of the WPT. We also thank Elissa Ye, Cheryl Li, Heather Hansen, Devin Deer, and Chantelle Kinzel for assistance with data collection, data processing, and/or programming. This work was supported by the Della Martin Foundation and a National Science Foundation Graduate Research Fellowship (to J.K.F.). NR 56 TC 5 Z9 5 U1 0 U2 1 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 15 PY 2015 VL 112 IS 50 BP 15331 EP 15336 DI 10.1073/pnas.1509262112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY4UN UT WOS:000366404200046 PM 26621715 ER PT J AU Zhang, CY Li, XT Adelmant, G Dobbins, J Geisen, C Oser, MG Wucherpfenning, KW Marto, JA Kaelin, WG AF Zhang, Cuiyan Li, Xiaotong Adelmant, Guillaume Dobbins, Jessica Geisen, Christoph Oser, Matthew G. Wucherpfenning, Kai W. Marto, Jarrod A. Kaelin, William G., Jr. TI Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE degradation; ubiquitylation; cell cycle; G0; pRB ID NUCLEAR RECEPTOR SHP; EMBRYONIC STEM-CELLS; FAMILY-MEMBER; RETINOBLASTOMA PROTEIN; UBIQUITIN LIGASES; INHIBITS TRANSACTIVATION; E1A-LIKE INHIBITOR; DIFFERENTIATION; IDENTIFICATION; GENE AB EP300-interacting inhibitor of differentiation 1 (EID1) belongs to a protein family implicated in the control of transcription, differentiation, DNA repair, and chromosomal maintenance. EID1 has a very short half-life, especially in G0 cells. We discovered that EID1 contains a peptidic, modular degron that is necessary and sufficient for its polyubiquitylation and proteasomal degradation. We found that this degron is recognized by an Skp1, Cullin, and F-box (SCF)-containing ubiquitin ligase complex that uses the F-box Only Protein 21 (FBXO21) as its substrate recognition subunit. SCFFBXO21 polyubiquitylates EID1 both in vitro and in vivo and is required for the efficient degradation of EID1 in both cycling and quiescent cells. The EID1 degron partially overlaps with its retinoblastoma tumor suppressor protein-binding domain and is congruent with a previously defined melanoma-associated antigen-binding motif shared by EID family members, suggesting that binding to retinoblastoma tumor suppressor and melanoma-associated antigen family proteins could affect the polyubiquitylation and turnover of EID family members in cells. C1 [Zhang, Cuiyan; Geisen, Christoph; Oser, Matthew G.; Kaelin, William G., Jr.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Zhang, Cuiyan; Geisen, Christoph; Oser, Matthew G.; Kaelin, William G., Jr.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02215 USA. [Li, Xiaotong] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China. [Adelmant, Guillaume; Marto, Jarrod A.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Adelmant, Guillaume; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02215 USA. [Adelmant, Guillaume; Marto, Jarrod A.] Harvard Univ, Dept Biol Chem & Mol Pharmacol, Sch Med, Boston, MA 02215 USA. [Dobbins, Jessica; Wucherpfenning, Kai W.] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02215 USA. [Dobbins, Jessica; Wucherpfenning, Kai W.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02215 USA. [Geisen, Christoph; Kaelin, William G., Jr.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. RP Kaelin, WG (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. EM william_kaelin@dfci.harvard.edu OI Dobbins, Jessica/0000-0002-6074-5595 FU NIH; Dana-Farber Strategic Research Initiative; NINDS FX We thank Gang Lu for the luciferase fusion reporter plasmids and members of the W.G.K. laboratory for useful discussions and careful reading of the manuscript. This work was supported by an NIH grant (to W.G.K.) and Dana-Farber Strategic Research Initiative and NINDS (JAM.). W.G.K. is a Howard Hughes Medical Institute investigator. NR 39 TC 1 Z9 1 U1 1 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 15 PY 2015 VL 112 IS 50 BP 15372 EP 15377 DI 10.1073/pnas.1522006112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY4UN UT WOS:000366404200053 PM 26631746 ER PT J AU Lynn, DA Dalton, HM Sowa, JN Wang, MC Soukas, AA Curran, SP AF Lynn, Dana A. Dalton, Hans M. Sowa, Jessica N. Wang, Meng C. Soukas, Alexander A. Curran, Sean P. TI Omega-3 and-6 fatty acids allocate somatic and germline lipids to ensure fitness during nutrient and oxidative stress in Caenorhabditis elegans SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE soma; germline; trade-off; lipids; survival ID EXTEND LIFE-SPAN; C-ELEGANS; LONGEVITY; SKN-1; PATHWAYS; REPRODUCTION; METABOLISM; DROSOPHILA; EVOLUTION; AUTOPHAGY AB Animals in nature are continually challenged by periods of feast and famine as resources inevitably fluctuate, and must allocate somatic reserves for reproduction to abate evolutionary pressures. We identify an age-dependent lipid homeostasis pathway in Caenorhabditis elegans that regulates the mobilization of lipids from the soma to the germline, which supports fecundity but at the cost of survival in nutrient-poor and oxidative stress environments. This trade-off is responsive to the levels of dietary carbohydrates and organismal oleic acid and is coupled to activation of the cyto-protective transcription factor SKN-1 in both laboratory-derived and natural isolates of C. elegans. The homeostatic balance of lipid stores between the somatic and germ cells is mediated by arachidonic acid (omega-6) and eicosapentaenoic acid (omega-3) precursors of eicosanoid signaling molecules. Our results describe a mechanism for resource reallocation within intact animals that influences reproductive fitness at the cost of somatic resilience. C1 [Lynn, Dana A.; Dalton, Hans M.; Curran, Sean P.] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA 90089 USA. [Lynn, Dana A.; Dalton, Hans M.; Curran, Sean P.] Univ So Calif, Dept Mol & Computat Biol, Dornsife Coll Letters Arts & Sci, Los Angeles, CA 90089 USA. [Sowa, Jessica N.; Wang, Meng C.] Baylor Coll Med, Huffington Ctr Aging, Dept Mol & Human Genet, Houston, TX 77030 USA. [Soukas, Alexander A.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Soukas, Alexander A.] Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA. RP Curran, SP (reprint author), Univ So Calif, Davis Sch Gerontol, Los Angeles, CA 90089 USA. EM spcurran@usc.edu FU National Institutes of Health's Office of Research Infrastructure Programs [P40 OD010440]; National Institutes of Health [T32AG000037, R00AG032308, R01 GM109028]; American Heart Association; Ellison New Scholar Award; American Federation for Aging Research FX We thank L. Thomas and J. Dietrich for technical support and A. Pradhan and J. Lo for a critical reading of the manuscript. We also thank the Caenorhabditis Genetics Center, funded by the National Institutes of Health's Office of Research Infrastructure Programs (P40 OD010440), for providing some strains. Support for this work was provided by the National Institutes of Health (Grant T32AG000037, to D.A.L.; R00AG032308, to S.P.C.; and R01 GM109028, to S.P.C.), the American Heart Association (S.P.C.), an Ellison New Scholar Award (S.P.C.), and the American Federation for Aging Research (S.P.C.). NR 48 TC 7 Z9 7 U1 1 U2 14 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 15 PY 2015 VL 112 IS 50 BP 15378 EP 15383 DI 10.1073/pnas.1514012112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY4UN UT WOS:000366404200054 PM 26621724 ER PT J AU Tashima, KT Smeaton, LM Fichtenbaum, CJ Andrade, A Eron, JJ Gandhi, RT Johnson, VA Klingman, KL Ritz, J Hodder, S Santana, JL Wilkin, T Haubrich, RH AF Tashima, Karen T. Smeaton, Laura M. Fichtenbaum, Carl J. Andrade, Adriana Eron, Joseph J. Gandhi, Rajesh T. Johnson, Victoria A. Klingman, Karin L. Ritz, Justin Hodder, Sally Santana, Jorge L. Wilkin, Timothy Haubrich, Richard H. CA A5241 Study Team TI HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors A Randomized, Controlled Trial SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID ANTIRETROVIRAL REGIMENS; INFECTION; RITONAVIR; EFFICACY; SAFETY; MORTALITY; RALTEGRAVIR; 2ND-LINE; ADULTS; NORTH AB Background: Nucleoside reverse transcriptase inhibitors (NRTIs) are often included in antiretroviral regimens in treatment-experienced patients in the absence of data from randomized trials. Objective: To compare treatment success between participants who omit versus those who add NRTIs to an optimized antiretroviral regimen of 3 or more agents. Design: Multicenter, randomized, controlled trial. (ClinicalTrials.gov: NCT00537394) Setting: Outpatient HIV clinics. Participants: Treatment-experienced patients with HIV infection and viral resistance. Intervention: Open-label optimized regimens (not including NRTIs) were selected on the basis of treatment history and susceptibility testing. Participants were randomly assigned to omit or add NRTIs. Measurements: The primary efficacy outcome was regimen failure through 48 weeks using a noninferiority margin of 15%. The primary safety outcome was time to initial episode of a severe sign, symptom, or laboratory abnormality before discontinuation of NRTI assignment. Results: 360 participants were randomly assigned, and 93% completed a 48-week visit. The cumulative probability of regimen failure was 29.8% in the omit-NRTIs group versus 25.9% in the add-NRTIs group (difference, 3.2 percentage points [95% CI, -6.1 to 12.5 percentage points]). No significant between-group differences were found in the primary safety end points or the proportion of participants with HIV RNA level less than 50 copies/mL. No deaths occurred in the omit-NRTIs group compared with 7 deaths in the add-NRTIs group. Limitation: Unblinded study design, and the study may not be applicable to resource-poor settings. Conclusion: Treatment-experienced patients with HIV infection starting a new optimized regimen can safely omit NRTIs without compromising virologic efficacy. Omitting NRTIs will reduce pill burden, cost, and toxicity in this patient population. C1 [Tashima, Karen T.] Brown Univ, Alpert Med Sch, Miriam Hosp, Providence, RI 02906 USA. [Smeaton, Laura M.; Ritz, Justin] Harvard Univ, TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA. [Gandhi, Rajesh T.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Fichtenbaum, Carl J.] Univ Cincinnati, Coll Med, Cincinnati, OH 45267 USA. [Andrade, Adriana] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Eron, Joseph J.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC USA. [Johnson, Victoria A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. [Klingman, Karin L.] NIAID, Therapeut Res Program, HIV Res Branch, Bethesda, MD 20892 USA. [Hodder, Sally] W Virginia Univ, Sch Med, Morgantown, WV 26506 USA. [Santana, Jorge L.] Univ Puerto Rico, San Juan, PR 00936 USA. [Wilkin, Timothy] Weill Cornell Med Coll, Ctr Special Studies HIV AIDS, New York, NY 10065 USA. [Haubrich, Richard H.] Gilead Sci Inc, Foster City, CA 94404 USA. RP Tashima, KT (reprint author), Brown Univ, Alpert Med Sch, Miriam Hosp, 164 Summit Ave, Providence, RI 02906 USA. EM ktashima@lifespan.org FU National Institute of Allergy and Infectious Diseases; Boehringer Ingelheim; Janssen; Merck; ViiV Healthcare; Roche; Monogram Biosciences (LabCorp) FX National Institute of Allergy and Infectious Diseases, Boehringer Ingelheim, Janssen, Merck, ViiV Healthcare, Roche, and Monogram Biosciences (LabCorp). NR 21 TC 2 Z9 2 U1 1 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 15 PY 2015 VL 163 IS 12 BP 908 EP + DI 10.7326/M15-0949 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA CY4BS UT WOS:000366354200016 PM 26595748 ER PT J AU Agenor, M Potter, JE Austin, SB AF Agenor, Madina Potter, Jennifer E. Austin, S. Bryn TI Sexual Orientation Identity Disparities in Awareness and Initiation of the Human Papillomavirus Vaccine RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID WOMEN C1 [Agenor, Madina; Austin, S. Bryn] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Agenor, Madina] Dana Farber Canc Inst, Boston, MA 02115 USA. [Potter, Jennifer E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Potter, Jennifer E.] Fenway Hlth, Boston, MA USA. [Austin, S. Bryn] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA. RP Agenor, M (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. FU NCI NIH HHS [R25 CA057711] NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 15 PY 2015 VL 163 IS 12 BP 960 EP 961 DI 10.7326/L15-5183 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CY4BS UT WOS:000366354200029 PM 26666790 ER PT J AU Ladha, KS Eikermann, M AF Ladha, Karim S. Eikermann, Matthias TI Codifying healthcare - big data and the issue of misclassification SO BMC ANESTHESIOLOGY LA English DT Editorial Material AB The rise of electronic medical records has led to a proliferation of large observational studies that examine the perioperative period. In contrast to randomized controlled trials, these studies have the ability to provide quick, cheap and easily obtainable information on a variety of patients and are reflective of everyday clinical practice. However, it is important to note that the data used in these studies are often generated for billing or documentation purposes such as insurance claims or the electronic anesthetic record. The reliance on codes to define diagnoses in these studies may lead to false inferences or conclusions. Researchers should specify the code assignment process and be aware of potential error sources when undertaking studies using secondary data sources. While misclassification may be a short-coming of using large databases, it does not prevent their use in conducting meaningful effectiveness research that has direct consequences on medical decision making. C1 [Ladha, Karim S.] Toronto Gen Hosp, Dept Anesthesia, Toronto, ON M5G 2C4, Canada. [Ladha, Karim S.] Univ Toronto, Toronto, ON M5G 2C4, Canada. [Eikermann, Matthias] Harvard Univ, Dept Anesthesia Crit Care & Pain Med, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. RP Ladha, KS (reprint author), Toronto Gen Hosp, Dept Anesthesia, Toronto, ON M5G 2C4, Canada. EM Karim.Ladha@uhn.ca NR 9 TC 1 Z9 1 U1 2 U2 14 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2253 J9 BMC ANESTHESIOL JI BMC Anesthesiol. PD DEC 15 PY 2015 VL 15 AR 179 DI 10.1186/s12871-015-0165-y PG 2 WC Anesthesiology SC Anesthesiology GA CY2VP UT WOS:000366266600001 PM 26667619 ER PT J AU Collins, GT France, CP AF Collins, Gregory T. France, Charles P. TI Determinants of conditioned reinforcing effectiveness: Dopamine D-2-like receptor agonist-stimulated responding for cocaine-associated stimuli SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Article DE Conditioned reinforcement; Dopamine D2-like receptors; Pramipexole; Cocaine self-administration ID DRUG-SEEKING BEHAVIOR; PROGRESSIVE-RATIO SCHEDULES; CUE-INDUCED REINSTATEMENT; EXTENDED ACCESS; IMPULSE CONTROL; D-3 RECEPTORS; ADDICTION; REWARD; PRAMIPEXOLE; ANTAGONISTS AB Environmental stimuli associated with drug use can take on conditioned properties capable of promoting drug-seeking behaviors during abstinence. This study investigated the relative importance of the amount of reinforced responding, number of cocaine-stimulus pairings, total cocaine intake, and reinforcing effectiveness of the self-administered dose of cocaine to the conditioned reinforcing effectiveness of cocaine-associated stimuli (CS). Male rats were trained to self-administer cocaine (0.1 [small] or 1.0 mg/kg/ inf [large]) under a fixed ratio schedule of reinforcement. A progressive ratio (PR) schedule was used to quantify the reinforcing effectiveness of each dose of cocaine, as well as the conditioned reinforcing effectiveness of the CS following treatment with saline or the dopamine D2-like receptor agonist pramipexole (0.1-3.2 mg/kg). The large dose of cocaine maintained larger final ratios and greater levels of cocaine intake, whereas the small dose resulted in more cocaine-CS pairings. The total amount of responding was comparable between groups. During PR tests of conditioned reinforcement, pramipexole increased responding for CS presentations in both groups; however, the final ratio completed was significantly greater in large-as compared to small-dose group. In addition to highlighting a central role for dopamine D2-like receptors in modulating the effectiveness of cocaine-paired stimuli to reinforce behavior, these results suggest that conditioned reinforcing effectiveness is primarily determined by the reinforcing effectiveness of the self-administered dose of cocaine and/or total cocaine intake, and not the total amount of responding or number cocaine-stimulus pairings. These findings have implications for understanding how different patterns of drug-taking might impact vulnerability to relapse. Published by Elsevier B.V. C1 [Collins, Gregory T.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Collins, Gregory T.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. RP Collins, GT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM collinsg@uthscsa.edu RI Collins, Gregory/K-3125-2012 FU National Institute on Drug Abuse Senior Scientist Award [K05 DA017918] FX CPF is supported by a National Institute on Drug Abuse Senior Scientist Award (K05 DA017918) NR 39 TC 2 Z9 2 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 EI 1879-0712 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD DEC 15 PY 2015 VL 769 BP 242 EP 249 DI 10.1016/j.ejphar.2015.11.024 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CY1AG UT WOS:000366137800030 PM 26593427 ER PT J AU Dhabangi, A Ainomugisha, B Cserti-Gazdewich, C Ddungu, H Kyeyune, D Musisi, E Opoka, R Stowell, CP Dzik, WH AF Dhabangi, Aggrey Ainomugisha, Brenda Cserti-Gazdewich, Christine Ddungu, Henry Kyeyune, Dorothy Musisi, Ezra Opoka, Robert Stowell, Christopher P. Dzik, Walter H. TI Effect of Transfusion of Red Blood Cells With Longer vs Shorter Storage Duration on Elevated Blood Lactate Levels in Children With Severe Anemia The TOTAL Randomized Clinical Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID IN-VITRO MARKERS; CRITICALLY-ILL; CEREBRAL OXYGENATION; TISSUE OXYGENATION; AFRICAN CHILDREN; LACTIC-ACIDOSIS; AGE; DEFORMABILITY; METAANALYSIS; CLEARANCE AB IMPORTANCE Although millions of transfusions are given annually worldwide, the effect of red blood cell (RBC) unit storage duration on oxygen delivery is uncertain. OBJECTIVE To determine if longer-storage RBC units are not inferior to shorter-storage RBC units for tissue oxygenation as measured by reduction in blood lactate levels and improvement in cerebral tissue oxygen saturation among children with severe anemia. DESIGN, SETTING, AND PARTICIPANTS Randomized noninferiority trial of 290 children (aged 6-60 months), most with malaria or sickle cell disease, presenting February 2013 through May 2015 to a university-affiliated national referral hospital in Kampala, Uganda, with a hemoglobin level of 5 g/dL or lower and a lactate level of 5 mmol/L or higher. INTERVENTIONS Patients were randomly assigned to receive RBC units stored 25 to 35 days (longer-storage group; n = 145) vs 1 to 10 days (shorter-storage group; n = 145). All units were leukoreduced prior to storage. All patients received 10 mL/kg of RBCs during hours 0 through 2 and, if indicated per protocol, an additional 10 mL/kg during hours 4 through 6. MAIN OUTCOMES AND MEASURES The primary outcome was the proportion of patients with a lactate level of 3 mmol/L or lower at 8 hours using a margin of noninferiority equal to an absolute difference of 25%. Secondary measures included noninvasive cerebral tissue oxygen saturation during the first transfusion, clinical and laboratory changes up to 24 hours, and survival and health at 30 days after transfusion. Adverse events were monitored up to 24 hours. RESULTS In the total population of 290 children, the mean (SD) presenting hemoglobin level was 3.7 g/dL (1.3) and mean lactate level was 9.3 mmol/L (3.4). Median (interquartile range) RBC unit storage was 8 days (7-9) for shorter storage vs 32 days (30-34) for longer storage without overlap. The proportion achieving the primary end point was 0.61(95% Cl, 0.52 to 0.69) in the longer-storage group vs 0.58 (95% Cl, 0.49 to 0.66) in the shorter-storage group (between-group difference, 0.03 [95% Cl, -0.07 tool, P < .001), meeting the prespecified margin of noninferiority. Mean lactate levels were not statistically different between the 2 groups at 0, 2, 4, 6, 8, or 24 hours. Kaplan-Meier analysis and global nonlinear regression revealed no statistical difference in lactate reduction between the 2 groups. Clinical assessment, cerebral oxygen saturation, electrolyte abnormalities, adverse events, survival, and 30-day recovery were also not significantly different between the groups. CONCLUSIONS AND RELEVANCE Among children with lactic acidosis due to severe anemia, transfusion of longer-storage compared with shorter-storage RBC units did not result in inferior reduction of elevated blood lactate levels. These findings have relevance regarding the efficacy of stored RBC transfusion for patients with critical tissue hypoxia and lactic acidosis due to anemia. C1 [Dhabangi, Aggrey] Makerere Univ, Child Hlth & Dev Ctr, Kampala, Uganda. [Ainomugisha, Brenda] Mulago Hosp, Kampala, Uganda. [Cserti-Gazdewich, Christine] Univ Toronto, Univ Hlth Network, Lab Med Program, Toronto, ON, Canada. [Ddungu, Henry] Makerere Univ, Uganda Canc Inst, Kampala, Uganda. [Kyeyune, Dorothy; Musisi, Ezra] Uganda Natl Blood Transfus Serv, Kampala, Uganda. [Opoka, Robert] Makerere Univ, Mulago Hosp, Dept Paediat, Kampala, Uganda. [Stowell, Christopher P.; Dzik, Walter H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Blood Transfus Serv, Boston, MA 02114 USA. RP Dzik, WH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Blood Transfus Serv, 55 Fruit St,Room J-224, Boston, MA 02114 USA. EM sdzik@mgh.harvard.edu FU National Institutes of Health [1R21HL109518-01A1] FX The study was fully funded by grant 1R21HL109518-01A1 from the National Institutes of Health. Nonin Corporation supplied the equipment used for noninvasive cerebral oxygen measurements. NR 31 TC 39 Z9 39 U1 5 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 15 PY 2015 VL 314 IS 23 BP 2514 EP 2523 DI 10.1001/jama.2015.13977 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CY4PV UT WOS:000366391500018 PM 26637812 ER PT J AU Friedman, DJ Singh, JP Curtis, JP Tang, WHW Bao, HK Spatz, ES Hernandez, AF Patel, UD Al-Khatib, SM AF Friedman, Daniel J. Singh, Jagmeet P. Curtis, Jeptha P. Tang, W. H. Wilson Bao, Haikun Spatz, Erica S. Hernandez, Adrian F. Patel, Uptal D. Al-Khatib, Sana M. TI Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE biventricular; cardiomyopathy; chronic kidney disease; pacemaker ID CARDIAC-RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DATA REGISTRY; GLOMERULAR-FILTRATION-RATE; HEART-FAILURE; RENAL-INSUFFICIENCY; MORTALITY AB BACKGROUND Patients with moderate-to-severe chronic kidney disease (CKD) are poorly represented in clinical trials of cardiac resynchronization therapy (CRT). OBJECTIVES This study sought to assess the real-world comparative effectiveness of CRT with defibrillator (CRT-D) versus implantable cardioverter-defibrillator (ICD) alone in CRT-eligible patients with moderate-to-severe CKD. METHODS We conducted an inverse probability-weighted analysis of 10,946 CRT-eligible patients (ejection fraction <35%, QRS >120 ms, New York Heart Association functional class III/IV) with stage 3 to 5 CKD in the National Cardiovascular Data Registry (NCDR) ICD Registry, comparing outcomes between patients who received CRT-D (n = 9,525) versus ICD only (n = 1,421). Outcomes were obtained via Medicare claims and censored at 3 years. The primary endpoint of heart failure (HF) hospitalization or death and the secondary endpoint of death were assessed with Cox proportional hazards models. HF hospitalization, device explant, and progression to end-stage renal disease were assessed using Fine-Gray models. RESULTS After risk adjustment, CRT-D use was associated with a reduction in HF hospitalization or death (hazard ratio [HR]: 0.84; 95% confidence interval [CI]: 0.78 to 0.91; p < 0.0001), death (HR: 0.85; 95% CI: 0.77 to 0.93; p < 0.0004), and HF hospitalization alone (subdistribution HR: 0.84; 95% CI: 0.76 to 0.93; p < 0.009). Subgroup analyses suggested that CRT was associated with a reduced risk of HF hospitalization and death across CKD classes. The incidence of in-hospital, short-term, and mid-term device-related complications did not vary across CKD stages. CONCLUSIONS In a nationally representative population of HF and CRT-eligible patients, use of CRT-D was associated with a significantly lower risk of the composite endpoint of HF hospitalization or death among patients with moderate-to-severe CKD in the setting of acceptable complication rates. (C) 2015 by the American College of Cardiology Foundation. C1 [Friedman, Daniel J.; Hernandez, Adrian F.; Al-Khatib, Sana M.] Duke Univ Hosp, Div Cardiol, Durham, NC USA. [Singh, Jagmeet P.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Curtis, Jeptha P.; Bao, Haikun; Spatz, Erica S.] Yale Univ, Sch Med, New Haven, CT USA. [Tang, W. H. Wilson] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA. [Hernandez, Adrian F.; Patel, Uptal D.; Al-Khatib, Sana M.] Duke Clin Res Inst, Durham, NC 27715 USA. [Patel, Uptal D.] Duke Univ Hosp, Div Nephrol, Durham, NC USA. RP Al-Khatib, SM (reprint author), Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA. EM alkha001@mc.duke.edu OI Friedman, Daniel /0000-0001-5791-1954 FU American College of Cardiology's National Cardiovascular Data Registry (NCDR); Boston Scientific; Medtronic; St. Jude Medical; Sorin Group; Amgen; Merck; Novartis; AstraZeneca; BMS; Portola; Eli Lilly FX This research was supported by the American College of Cardiology's National Cardiovascular Data Registry (NCDR). The views expressed in this manuscript represent those of the authors, and do not necessarily represent the official views of the NCDR or its associated professional societies identified at CVQuality.ACC.org/NCDR. ICD Registry is an initiative of the American College of Cardiology with partnering support from the Heart Rhythm Society. Dr. Friedman has received educational grants from Boston Scientific. Dr. Singh has received research grants from Medtronic, St. Jude Medical, Boston Scientific, and Sorin Group; and has served as a consultant for Respicardia, CardioInsight, Medtronic, St. Jude Medical, Boston Scientific, and Sorin Group. Dr. Curtis owns stock in Medtronic. Dr. Hernandez has received honoraria and research grants from Amgen, Merck, and Novartis; research grants from AstraZeneca, BMS, Medtronic, and Portola; and has served as a consultant for AstraZeneca, Bayer, and Janssen. Dr. Patel has received honoraria from Amgen and Hospira; has received research grants from Amgen and Eli Lilly; and has served on data safety monitoring boards for studies for Angion Biomedica, CSL Limited, and Gilead. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 25 TC 6 Z9 6 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD DEC 15 PY 2015 VL 66 IS 23 BP 2618 EP 2629 DI 10.1016/j.jacc.2015.09.097 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CY0KO UT WOS:000366095200007 PM 26670062 ER PT J AU Batra, A Berkowitz, A AF Batra, Ayush Berkowitz, Aaron TI Clinical Reasoning: A 50-year-old man with headache and cognitive decline SO NEUROLOGY LA English DT Editorial Material ID SPONTANEOUS INTRACRANIAL HYPOTENSION; REVERSIBLE FRONTOTEMPORAL DEMENTIA AB A 50-year-old man presented with headache and cognitive decline 10 weeks after undergoing matched-donor peripheral blood stem cell transplantation for treatment of mixed-phenotype acute leukemia. His pretransplant treatment included systemic chemotherapy (cyclophosphamide, daunorubicin, vincristine, prednisone, l-asparaginase, dasatinib, and cytarabine), intrathecal chemotherapy (methotrexate), and total body irradiation. His posttransplant course had been complicated by cutaneous graft-vs-host disease. Over 1 month, he developed holocephalic, throbbing, temporal headache worse when standing and reported feeling confused. His family members reported progressively withdrawn affect, depressed mood, and decreased spontaneous activity. Before his illness, he worked in a cognitively demanding profession with no history of cognitive deficit. C1 [Batra, Ayush; Berkowitz, Aaron] Harvard Univ, Brigham & Womens Hosp, Dept Neurol, Sch Med, Boston, MA 02115 USA. [Batra, Ayush] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. RP Batra, A (reprint author), Harvard Univ, Brigham & Womens Hosp, Dept Neurol, Sch Med, Boston, MA 02115 USA. EM abatra@partners.org NR 10 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD DEC 15 PY 2015 VL 85 IS 24 BP E182 EP E186 DI 10.1212/WNL.0000000000002222 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA CY5QR UT WOS:000366462800001 PM 26668243 ER PT J AU Peters, AT Shankman, SA Deckersbach, T West, AE AF Peters, Amy T. Shankman, Stewart A. Deckersbach, Thilo West, Amy E. TI Predictors of first-episode unipolar major depression in individuals with and without sub-threshold depressive symptoms: A prospective, population-based study SO PSYCHIATRY RESEARCH LA English DT Article DE Depression; Sub-threshold; Risk factors ID NATIONAL EPIDEMIOLOGIC SURVEY; PERSONALITY-DISORDERS; ANXIETY DISORDERS; ONSET DEPRESSION; RISK-FACTORS; ADULTS; CHILDHOOD; ADOLESCENTS; ALCOHOL; STRESS AB Background: The aim of this study is to assess predictors of first-episode major depression in a community-based sample of adults with and without sub-threshold depression. Method: Data were from Waves 1 and 2 of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). Participants meeting criteria for a sub-threshold depressive episode (sMDE; n=3901) reported lifetime depressed mood/loss of interest lasting at least two weeks and at least two of the seven other DSM-IV symptoms of MDD. Predictors of MDE 3 years later were compared in those with and without (n=31022) sMDE. Results: Being female, history of alcohol or substance use, and child abuse increased the odds of developing MDD to a greater degree in individuals without sMDE relative to those with sMDE. Among those with sMDE and additional risk factors (low education, substance use), younger age was associated with marginally increased risk of MDD. Conclusion: Several demographic risk factors may help identify individuals at risk for developing MDD in individuals who have not experienced an sMDE who may be candidates for early intervention. Future work should assess whether preventative interventions targeting substance/alcohol use and child abuse could reduce the risk of depression. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Peters, Amy T.; Shankman, Stewart A.; West, Amy E.] Univ Illinois, Dept Psychiat, Chicago, IL 60614 USA. [Peters, Amy T.; Shankman, Stewart A.; West, Amy E.] Univ Illinois, Dept Psychol, Chicago, IL 60614 USA. [Deckersbach, Thilo] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Deckersbach, Thilo] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. RP West, AE (reprint author), Univ Illinois, 1747W Roosevelt Rd, Chicago, IL 60614 USA. EM Awest@psych.uic.edu FU National Institute of Mental Health (NIMH) [T32 MH067631] FX This work was supported by a National Institute of Mental Health (NIMH) T32 MH067631 (ATP). NR 35 TC 0 Z9 0 U1 3 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD DEC 15 PY 2015 VL 230 IS 2 BP 150 EP 156 DI 10.1016/j.psychres.2015.08.030 PG 7 WC Psychiatry SC Psychiatry GA CY0DV UT WOS:000366077400005 PM 26343831 ER PT J AU Dewey, D McDonald, MK Brown, WJ Boyd, SJ Bunnell, BE Schuldberg, D AF Dewey, Daniel McDonald, Molly K. Brown, Wilson J. Boyd, Steven J. Bunnell, Brian E. Schuldberg, David TI The impact of ecological momentary assessment on posttraumatic stress symptom trajectory SO PSYCHIATRY RESEARCH LA English DT Article DE Posttraumatic stress disorder; Ecological momentary assessment; Self-monitoring; Traumatic stress ID RANDOMIZED CONTROLLED-TRIAL; PSYCHOMETRIC PROPERTIES; TRAUMA EXPOSURE; DISORDER; DISTRESS AB Ecological momentary assessment includes continuous, real-time gathering of self-report data in a participant's natural environment. The current study evaluated the possible impact of this assessment strategy on severity of posttraumatic stress (PTS) in a sample of participants who reported experiencing a past traumatic event. Participants with clinically elevated PTS symptoms reported symptom severity at three time-points: during an initial screening, following an unmonitored period, and following two weeks of monitoring. During the monitoring period, participants carried an Android device which prompted them to report PTS symptoms and negative emotions six times daily. PTS severity scores were then compared across these three time-points. Results indicated that participating in the ecological momentary assessment protocol was associated with a significant reduction in PTS severity, whereas significant changes were not noted over the unmonitored control condition. The authors conclude that ecological momentary assessment may have therapeutic value even when not combined with formal intervention, and it may be a useful tool for improving the efficiency of a stepped-care approach to treating PTS symptoms. Published by Elsevier Ireland Ltd. C1 [Dewey, Daniel; Brown, Wilson J.; Boyd, Steven J.; Bunnell, Brian E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Dewey, Daniel; McDonald, Molly K.; Schuldberg, David] Univ Montana, Dept Psychol, Missoula, MT 59812 USA. RP Dewey, D (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116,109 Bee St, Charleston, SC 29401 USA. EM daniel.dewey@va.gov NR 19 TC 0 Z9 0 U1 4 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD DEC 15 PY 2015 VL 230 IS 2 BP 300 EP 303 DI 10.1016/j.psychres.2015.09.009 PG 4 WC Psychiatry SC Psychiatry GA CY0DV UT WOS:000366077400026 PM 26381184 ER PT J AU Freed, RD Tompson, MC Otto, MW Nierenberg, AA Henin, A AF Freed, Rachel D. Tompson, Martha C. Otto, Michael W. Nierenberg, Andrew A. Henin, Aude TI A latent class analysis of parental bipolar disorder: Examining associations with offspring psychopathology SO PSYCHIATRY RESEARCH LA English DT Article DE Risk factors; High-risk Offspring; Mood disorder; Anxiety disorder ID STRESSFUL LIFE EVENTS; COMORBIDITY SURVEY REPLICATION; TREATMENT ENHANCEMENT PROGRAM; MAJOR DEPRESSIVE DISORDER; I DISORDER; MOOD DISORDERS; FOLLOW-UP; DSM-IV; STEP-BD; PREDOMINANT POLARITY AB Bipolar disorder (BD) is highly heterogeneous, and course variations are associated with patient outcomes. This diagnostic complexity challenges identification of patients in greatest need of intervention. Additionally, course variations have implications for offspring risk. First, latent class analysis (LCA) categorized parents with BD based on salient illness characteristics: BD type, onset age, polarity of index episode, pole of majority of episodes, rapid cycling, psychosis, anxiety comorbidity, and substance dependence. Fit indices favored three parental classes with some substantively meaningful patterns. Two classes, labeled "Earlier-Onset Bipolar-I" (EO-I) and "Earlier-Onset Bipolar-II" (EO-II), comprised parents who had a mean onset age in mid-adolescence, with EO-I primarily BD-I parents and EO-II entirely BD-II parents. The third class, labeled "Later-Onset BD" (LO) had an average onset age in adulthood. Classes also varied on probability of anxiety comorbidity, substance dependence, psychosis, rapid cycling, and pole of majority of episodes. Second, we examined rates of disorders in offspring (ages 4-33, Mage=13.46) based on parental latent class membership. Differences emerged for offspring anxiety disorders only such that offspring of EO-I and EO-II parents had higher rates, compared to offspring of LO parents, particularly for daughters. Findings may enhance understanding of BD and its nosology (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Freed, Rachel D.; Tompson, Martha C.; Otto, Michael W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Nierenberg, Andrew A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Henin, Aude] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Freed, RD (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, Pediat Mood & Anxiety Disorders Program, 1240 Pk Ave, New York, NY 10029 USA. EM rfreed@bu.edu OI Tompson, Martha /0000-0003-0557-7856 FU Brain & Behavior Research Foundation; Brain & Behavior Research Foundation Young Investigator Award; SHINE Initiative; MGH Claflin Award FX This study was funded by two Brain & Behavior Research Foundation (formerly NARSAD) Independent Investigator Awards (PI: Nierenberg), a Brain & Behavior Research Foundation Young Investigator Award (PI: Henin) generously supported in part by the SHINE Initiative, and an MGH Claflin Award (PI: Henin). We thank David A. Langer, Ph.D., Thomas M. Olino, Ph.D., and Meredith Lotz Wallace, Ph.D. for their consultation. NR 82 TC 1 Z9 1 U1 2 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD DEC 15 PY 2015 VL 230 IS 2 BP 314 EP 322 DI 10.1016/j.psychres.2015.09.011 PG 9 WC Psychiatry SC Psychiatry GA CY0DV UT WOS:000366077400028 PM 26394919 ER PT J AU Ramin, C Wang, W Prescott, J Rosner, B Simon, NM De Vivo, I Okereke, OI AF Ramin, Cody Wang, Wei Prescott, Jennifer Rosner, Bernard Simon, Naomi M. De Vivo, Immaculata Okereke, Olivia I. TI A prospective study of leukocyte telomere length and risk of phobic anxiety among women SO PSYCHIATRY RESEARCH LA English DT Article DE Epidemiology; Anxiety disorders; Phobic anxiety; Panic disorder; Agoraphobia; Social phobia; Specific phobia; Crown-Crisp Index score; Telomere length; Finite mixture modeling ID POSTTRAUMATIC-STRESS-DISORDER; NUTRITION EXAMINATION SURVEY; OXIDATIVE STRESS; MENTAL-DISORDERS; OLDER-ADULTS; PHYSICAL-ACTIVITY; QUANTITATIVE PCR; NATIONAL-HEALTH; UNITED-STATES; CANCER-RISK AB We prospectively examined the relation of relative telomere lengths (RTLs), a marker of biological aging, to phobic anxiety in later-life. RTLs in peripheral blood leukocytes were measured among 3194 women in the Nurses' Health Study who provided blood samples in 1989/90. The Crown-Crisp Phobic Index (CCI, range=0-16) was assessed in 1988 and 2004. Only participants with CCI <= 3 (consistent with no meaningful anxiety symptoms) in 1988 were included. We related baseline RTLs to odds ratios (ORs) of incident high phobic anxiety symptoms (CCI 6). To enhance clinical relevance, we used finite mixture modeling (FMM) to relate baseline RTLs to latent classes of CCI in 2004. RTLs were not significantly associated with high phobic anxiety symptoms after 16 years of follow-up. However, FMM identified 3 groups of phobic symptoms in later-life: severe, minimal/intermediate, and non-anxious. The severe group had non-significantly shorter multivariable-adjusted mean RTLs than the minimal/intermediate and non-anxious groups. Women with shorter telomeres vs. longest telomeres had non-significantly higher likelihood of being in the severe vs. non-anxious group. Overall, there was no significant association between RTLs and incident phobic anxiety symptoms. Further work is required to explore potential connections of telomere length and emergence of severe phobic anxiety symptoms during laterlife. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Ramin, Cody; Prescott, Jennifer; Rosner, Bernard; De Vivo, Immaculata; Okereke, Olivia I.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Ramin, Cody; Prescott, Jennifer; Rosner, Bernard; De Vivo, Immaculata; Okereke, Olivia I.] Harvard Univ, Sch Med, Boston, MA USA. [Wang, Wei] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA. [Wang, Wei] Brigham & Womens Hosp, Dept Med & Neurol, Boston, MA 02115 USA. [Prescott, Jennifer; De Vivo, Immaculata] Harvard Univ, Sch Publ Hlth, Program Genet Epidemiol & Stat Genet, Boston, MA 02115 USA. [Rosner, Bernard] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Simon, Naomi M.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Anxiety & Traumat Stress Disorders, Boston, MA 02114 USA. [Okereke, Olivia I.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Okereke, Olivia I.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. RP Okereke, OI (reprint author), Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA. EM olivia.okereke@channing.harvard.edu RI Okereke, Olivia/R-9934-2016 FU National Institutes of Health (NIH) [R01 MH096776, P01 CA87969, R01 CA49449, R01 HL034594, R01 HL088521, R01 CA065725, R01 CA082838, R03 CA132190, R03 CA139586, R03 CA1321905, R01 CA163451, R01 AR059073, K07 CA140790] FX This work was supported by the National Institutes of Health (NIH) (Grant numbers - R01 MH096776, P01 CA87969, R01 CA49449, R01 HL034594, R01 HL088521, R01 CA065725, R01 CA082838, R03 CA132190, R03 CA139586, R03 CA1321905, R01 CA163451, R01 AR059073, and K07 CA140790). NR 69 TC 0 Z9 0 U1 3 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD DEC 15 PY 2015 VL 230 IS 2 BP 545 EP 552 DI 10.1016/j.psychres.2015.10.002 PG 8 WC Psychiatry SC Psychiatry GA CY0DV UT WOS:000366077400061 PM 26603336 ER PT J AU Dekel, S Levin, Y Solomon, Z AF Dekel, Sharon Levin, Yafit Solomon, Zahava TI Posttraumatic growth among spouses of combat veterans: Adaptive or maladaptive for adjustment? SO PSYCHIATRY RESEARCH LA English DT Article DE Posttraumatic growth; Secondary traumatization; Longitudinal study ID STRESS-DISORDER; SECONDARY TRAUMATIZATION; SURVIVORS; TRAUMA; ASSAULT; BENEFIT; EVENTS; HEALTH; IMPACT; WIVES AB We examined the relationship between posttraumatic growth (PTG) and distress in spouses of trauma survivors. A sample of spouses of combat veterans of the 1973 Yom Kippur War were assessed using questionnaires pertaining to PIG, depression, anxiety, and posttraumatic stress, in 2004 and 2011. Applying cross-lagged modeling strategy, higher PIG levels predicted higher depression and anxiety levels above and beyond initial distress. Thus, psychological growth in spouses of survivors appears to signify subsequent distress. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Dekel, Sharon] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Dekel, Sharon] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Levin, Yafit; Solomon, Zahava] Tel Aviv Univ, Bob Shapell Sch Social Work, IL-69978 Tel Aviv, Israel. [Solomon, Zahava] I Core Res Ctr Mass Trauma, Tel Aviv, Israel. RP Dekel, S (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 120 Second Ave, Boston, MA 02129 USA. EM sdekel@mgh.harvard.edu NR 32 TC 0 Z9 0 U1 4 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD DEC 15 PY 2015 VL 230 IS 2 BP 712 EP 715 DI 10.1016/j.psychres.2015.09.018 PG 4 WC Psychiatry SC Psychiatry GA CY0DV UT WOS:000366077400086 PM 26384572 ER PT J AU Bertero, T Cottrill, KA Annis, S Bhat, B Gochuico, BR Osorio, JC Rosas, I Haley, KJ Corey, KE Chung, RT Chau, BN Chan, SY AF Bertero, Thomas Cottrill, Katherine A. Annis, Sofia Bhat, Balkrishen Gochuico, Bernadette R. Osorio, Juan C. Rosas, Ivan Haley, Kathleen J. Corey, Kathleen E. Chung, Raymond T. Chau, B. Nelson Chan, Stephen Y. TI A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions SO SCIENTIFIC REPORTS LA English DT Article ID MATRIX-METALLOPROTEINASE INHIBITORS; PROMOTES PULMONARY-HYPERTENSION; HIPPO SIGNALING PATHWAY; GROWTH-FACTOR; CANCER; EXPRESSION; MIR-29; YAP; PROGRESSION; FIBROBLASTS AB The molecular origins of fibrosis affecting multiple tissue beds remain incompletely defined. Previously, we delineated the critical role of the control of extracellular matrix (ECM) stiffening by the mechanosensitive microRNA-130/301 family, as activated by the YAP/TAZ co-transcription factors, in promoting pulmonary hypertension (PH). We hypothesized that similar mechanisms may dictate fibrosis in other tissue beds beyond the pulmonary vasculature. Employing an in silico combination of microRNA target prediction, transcriptomic analysis of 137 human diseases and physiologic states, and advanced gene network modeling, we predicted the microRNA-130/301 family as a master regulator of fibrotic pathways across a cohort of seemingly disparate diseases and conditions. In two such diseases (pulmonary fibrosis and liver fibrosis), inhibition of microRNA-130/301 prevented the induction of ECM modification, YAP/TAZ, and downstream tissue fibrosis. Thus, mechanical forces act through a central feedback circuit between microRNA-130/301 and YAP/TAZ to sustain a common fibrotic phenotype across a network of human physiologic and pathophysiologic states. Such re-conceptualization of interconnections based on shared systems of disease and non-disease gene networks may have broad implications for future convergent diagnostic and therapeutic strategies. C1 [Bertero, Thomas; Cottrill, Katherine A.; Annis, Sofia; Chan, Stephen Y.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA. [Bertero, Thomas; Cottrill, Katherine A.; Annis, Sofia; Chan, Stephen Y.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Network Med, Boston, MA 02115 USA. [Bhat, Balkrishen; Chau, B. Nelson] Regulus Therapeut, San Diego, CA USA. [Gochuico, Bernadette R.] NIH, Bethesda, MD 20892 USA. [Osorio, Juan C.; Rosas, Ivan; Haley, Kathleen J.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Corey, Kathleen E.; Chung, Raymond T.] Massachusetts Gen Hosp, Liver Ctr & Gastrointestinal Div, Boston, MA 02114 USA. RP Chan, SY (reprint author), Univ Pittsburgh, Pittsburgh Heart Lung & Blood Vasc Med Inst, Ctr Pulm Vasc Biol & Med, Div Cardiol,Dept Med,Med Ctr, BST1704-2 200 Lothrop St, Pittsburgh, PA 15260 USA. EM chansy@pitt.edu OI Osorio, Juan C/0000-0001-8090-1551; BERTERO, Thomas/0000-0002-4801-9902 FU NIH [HL096834, HL124021, DK099422, DK078772]; Pulmonary Hypertension Association; American Heart Association; Foundation Bettencourt-Schueller FX We thank J.W. Snow, S.K. Chan, R. Wang, J. Androsavich, and J. Loscalzo for manuscript advice. This work was supported by the NIH [grants HL096834, HL124021 (S.Y.C.); DK099422 (K.E.C.); DK078772 (R.T.C.); intramural research program (B.R.G.)]; Pulmonary Hypertension Association; American Heart Association (T.B.); and Foundation Bettencourt-Schueller (T.B). NR 63 TC 6 Z9 6 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD DEC 15 PY 2015 VL 5 AR 18277 DI 10.1038/srep18277 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY4NU UT WOS:000366385700001 PM 26667495 ER PT J AU Francisco, CD Beltrame, T Ferraresi, C Parizotto, NA Bagnato, VS Silva, AB Benze, BG Porta, A Catai, AM AF Francisco, Cristina de Oliveira Beltrame, Thomas Ferraresi, Cleber Parizotto, Nivaldo Antonio Bagnato, Vanderlei Salvador Silva, Audrey Borghi Benze, Benedito Galvao Porta, Alberto Catai, Aparecida Maria TI Evaluation of acute effect of light-emitting diode (LED) phototherapy on muscle deoxygenation and pulmonary oxygen uptake kinetics in patients with diabetes mellitus: study protocol for a randomized controlled trial SO TRIALS LA English DT Article DE Type 2 diabetes mellitus; phototherapy; light-emitting diode; oxygen uptake; physical exercise; oxygen uptake kinetics ID LEVEL LASER THERAPY; SKELETAL-MUSCLE; EXERCISE; MICROCIRCULATION; INDIVIDUALS; IRRADIATION; RESPONSES; WOMEN AB Background: Type 2 diabetes mellitus (DM) is responsible for a significant reduction in the quality of life due to its negative impact on functional capacity. Cardiopulmonary fitness impairment in DM patients has been associated with limited tissue oxygenation. Phototherapy is widely utilized to treat several disorders due to expected light-tissue interaction. This type of therapy may help to improve muscular oxygenation, thereby increasing aerobic fitness and functional capacity. Methods/Design: This study is a randomized, double-blind, placebo-controlled crossover trial approved by the Ethics Committee of the Federal University of Sao Carlos and registered at ClinicalTrials.gov. Four separate tests will be performed to evaluate the acute effect of phototherapy. All participants will receive both interventions in random order: light-emitting diode therapy (LEDT) and placebo, with a minimum 14-day interval between sessions (washout period). Immediately after the intervention, participants will perform moderate constant workload cycling exercise corresponding to 80 % of the pulmonary oxygen uptake (p(V) over dotO(2)) during the gas exchange threshold (GET). LEDT will be administered with a multidiode cluster probe (50 GaAIA LEDs, 850 eta m, 75 mW each diode, and 3 J per point) before each exercise session. Pulmonary oxygen uptake, muscle oxygenation, heart rate, and arterial pressure will be measured using a computerized metabolic cart, a near-infrared spectrometer, an electrocardiogram, and a photoplethysmography system, respectively. Discussion: The main objective of this study is to evaluate the acute effects of muscular pre-conditioning using LED phototherapy on pulmonary oxygen uptake, muscle oxygenation, heart rate, and arterial pressure dynamics during dynamic moderate exercise. We hypothesize that phototherapy may be beneficial to optimize aerobic fitness in the DM population. Data will be published after the study is completed. C1 [Francisco, Cristina de Oliveira; Parizotto, Nivaldo Antonio; Silva, Audrey Borghi; Catai, Aparecida Maria] Univ Fed Sao Carlos, Dept Physiotherapy, BR-13565905 Sao Paulo, Brazil. [Beltrame, Thomas] Univ Waterloo, Fac Appl Hlth Sci, Waterloo, ON N2L 3G1, Canada. [Ferraresi, Cleber] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Bagnato, Vanderlei Salvador] Univ Sao Paulo, Sao Carlos Inst Phys, BR-13566590 Sao Paulo, Brazil. [Benze, Benedito Galvao] Univ Fed Sao Carlos, Dept Stat, BR-13565905 Sao Paulo, Brazil. [Porta, Alberto] Univ Milan, Dept Biomed Sci Hlth, I-20122 Milan, Italy. [Porta, Alberto] Policlin San Donato, Dept Cardiothorac Vasc Anesthesia & Intens Care, IRCCS, Milan, Italy. RP Catai, AM (reprint author), Univ Fed Sao Carlos, Dept Physiotherapy, Rod Washington Luis,Km 235, BR-13565905 Sao Paulo, Brazil. EM mcatai@ufscar.br RI Porta, Alberto/K-4390-2016; Sao Carlos Institute of Physics, IFSC/USP/M-2664-2016; USP, CePOF/J-3608-2015; Bagnato, Vanderlei/C-3133-2012 OI Porta, Alberto/0000-0002-6720-9824; FU Sao Paulo State Research Foundation - FAPESP [2013/08183-7, 2013/07953-3] FX This study has the financial support of Sao Paulo State Research Foundation - FAPESP (grant 2013/08183-7 to COF and 2013/07953-3 to AMC). NR 34 TC 0 Z9 0 U1 0 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD DEC 15 PY 2015 VL 16 AR 572 DI 10.1186/s13063-015-1093-3 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CY2RE UT WOS:000366255000002 ER PT J AU Orrell, C Cohen, K Mauff, K Bangsberg, DR Maartens, G Wood, R AF Orrell, Catherine Cohen, Karen Mauff, Katya Bangsberg, David R. Maartens, Gary Wood, Robin TI A Randomized Controlled Trial of Real-Time Electronic Adherence Monitoring With Text Message Dosing Reminders in People Starting First-Line Antiretroviral Therapy SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE real-time adherence monitoring; antiretroviral therapy; mobile phone use; text message; virological failure ID SUB-SAHARAN AFRICA; TREATMENT INTERRUPTIONS; SOUTH-AFRICA; IMPROVE ADHERENCE; RURAL UGANDA; HIV EVIDENCE; FAILURE; INTERVENTIONS; SUPPRESSION; MANAGEMENT AB Background:There are conflicting findings about whether mobile phone text message reminders impact on antiretroviral adherence. We hypothesized that text reminders sent when dosing was late would improve adherence and HIV viral suppression.Methods:Antiretroviral therapy (ART)-naive participants, from a South African outpatient ART clinic, were randomized to standard of care (SoC, 3 pretreatment education sessions), or intervention (SoC and automated text reminders if dosing >30 minutes late). Dosing time was recorded by real-time electronic adherence monitoring devices, given to participants at ART start. CD4 cell count and HIV RNA were determined at baseline, 16 and 48 weeks. Primary outcome was cumulative adherence execution by electronic adherence monitoring device. HIV-1 viral suppression (<40 copies/mL) at week 48 and count of treatment interruptions (TIs) >72 hours were secondary outcomes. Analysis was by intention to treat (missing = failure). Registration was with the Pan-African Clinical Trials Registry: PACTR201311000641402.Results:A total of 230 participants were randomly assigned to control (n = 115) or intervention (n = 115) arms. Median adherence was 82.1% (interquartile range, 56.6%-94.6%) in the intervention arm, compared with 80.4% (interquartile range, 52.8%-93.8%) for SoC [adjusted odds ratio for adherence 1.08; 95% confidence interval (CI): 0.77 to 1.52]. Suppressed HIV RNA (<40 copies/mL) occurred in 80 (69.6%) of control and 75 (65.2%) of intervention (adjusted odds ratio for virological failure in intervention arm 0.77; 95% CI: 0.42 to 1.40). In the intervention arm, the count of TIs of >72 hours was reduced (adjusted incident rate ratio, 0.84; 95% CI: 0.75 to 0.94).Conclusions:Text message reminders linked to late doses detected by real-time adherence monitoring reduced the number of prolonged TIs, but did not significantly improve adherence or viral suppression. C1 [Orrell, Catherine; Wood, Robin] Univ Cape Town, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa. [Orrell, Catherine; Wood, Robin] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa. [Cohen, Karen; Maartens, Gary] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa. [Mauff, Katya] Univ Cape Town, Dept Stat Sci, ZA-7925 Cape Town, South Africa. [Bangsberg, David R.] Harvard Univ, Sch Med, Boston, MA USA. [Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. [Bangsberg, David R.] Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02114 USA. RP Orrell, C (reprint author), Univ Cape Town, Fac Hlth Sci, Desmond Tutu HIV Ctr, Werner Beit Bldg North,Anzio Rd, ZA-7925 Cape Town, South Africa. EM catherine.orrell@hiv-research.org.za RI Maartens, Gary/F-3836-2014; Emchi, Karma/Q-1952-2016; Cohen, Karen/D-4036-2017; OI Maartens, Gary/0000-0003-3080-6606; Cohen, Karen/0000-0002-1892-4207 FU European and Developing Countries Clinical Trials Partnership (EDCTP) [TA.2011.40200.015]; Discovery Foundation FX Supported by the European and Developing Countries Clinical Trials Partnership (EDCTP; TA.2011.40200.015) and the Discovery Foundation. NR 43 TC 12 Z9 12 U1 3 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 15 PY 2015 VL 70 IS 5 BP 495 EP 502 DI 10.1097/QAI.0000000000000770 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CX3LO UT WOS:000365600500005 PM 26218411 ER PT J AU Pitman, RK AF Pitman, Roger K. TI Harnessing Reconsolidation to Treat Mental Disorders SO BIOLOGICAL PSYCHIATRY LA English DT Editorial Material ID PROTEIN-SYNTHESIS; MECHANISMS; STRESS; FEAR; MEMORIES; RETURN C1 [Pitman, Roger K.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Pitman, Roger K.] Harvard Univ, Sch Med, Boston, MA USA. RP Pitman, RK (reprint author), MGH East,120 Second Ave, Charlestown, MA 02129 USA. EM roger_pitman@hms.harvard.edu NR 10 TC 0 Z9 0 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD DEC 15 PY 2015 VL 78 IS 12 BP 819 EP 820 DI 10.1016/j.biopsych.2015.10.002 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CW5OX UT WOS:000365047000003 PM 26589491 ER PT J AU Wegmann, S Maury, EA Kirk, MJ Saqran, L Roe, A Devos, SL Nicholls, S Fan, ZY Takeda, S Cagsal-Getkin, O William, CM Spires-Jones, TL Pitstick, R Carlson, GA Pooler, AM Hyman, BT AF Wegmann, Susanne Maury, Eduardo A. Kirk, Molly J. Saqran, Lubna Roe, Allyson Devos, Sarah L. Nicholls, Samantha Fan, Zhanyun Takeda, Shuko Cagsal-Getkin, Ozge William, Christopher M. Spires-Jones, Tara L. Pitstick, Rose Carlson, George A. Pooler, Amy M. Hyman, Bradley T. TI Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity SO EMBO JOURNAL LA English DT Article DE Alzheimer's disease; neurodegeneration; neurofibrillary tangles; P301L tau; prion-like ID UNFOLDED PROTEIN RESPONSE; HOST PRION PROTEIN; ALZHEIMERS-DISEASE; MOUSE MODEL; IN-VIVO; NEURODEGENERATIVE DISEASES; PATHOLOGY; TAUOPATHY; MICE; MEMORY AB In Alzheimer's disease and tauopathies, tau protein aggregates into neurofibrillary tangles that progressively spread to synaptically connected brain regions. A prion-like mechanism has been suggested: misfolded tau propagating through the brain seeds neurotoxic aggregation of soluble tau in recipient neurons. We use transgenic mice and viral tau expression to test the hypotheses that trans-synaptic tau propagation, aggregation, and toxicity rely on the presence of endogenous soluble tau. Surprisingly, mice expressing human P301Ltau in the entorhinal cortex showed equivalent tau propagation and accumulation in recipient neurons even in the absence of endogenous tau. We then tested whether the lack of endogenous tau protects against misfolded tau aggregation and toxicity, a second prion model paradigm for tau, using P301Ltau-overexpressing mice with severe tangle pathology and neurodegeneration. Crossed onto tau-null background, these mice had similar tangle numbers but were protected against neurotoxicity. Therefore, misfolded tau can propagate across neural systems without requisite templated misfolding, but the absence of endogenous tau markedly blunts toxicity. These results show that tau does not strictly classify as a prion protein. C1 [Wegmann, Susanne; Maury, Eduardo A.; Kirk, Molly J.; Saqran, Lubna; Roe, Allyson; Devos, Sarah L.; Nicholls, Samantha; Fan, Zhanyun; Takeda, Shuko; Cagsal-Getkin, Ozge; William, Christopher M.; Pooler, Amy M.; Hyman, Bradley T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA. [Spires-Jones, Tara L.] Univ Edinburgh, Ctr Cognit & Neural Syst, Edinburgh, Midlothian, Scotland. [Spires-Jones, Tara L.] Univ Edinburgh, Euan MacDonald Ctr, Edinburgh, Midlothian, Scotland. [Pitstick, Rose; Carlson, George A.] McLaughlin Res Inst, Great Falls, MT USA. [Pooler, Amy M.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Basic & Clin Neurosci, London WC2R 2LS, England. RP Hyman, BT (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA. EM bhyman@mgh.harvard.edu OI William, Christopher/0000-0001-8933-1639 FU German Research Association (DFG); Alzheimer's Research UK; Chief Scientist's Office, Scotland; NIH [NS41997, AG 26249]; Massachusetts General Hospital FX We thank Dr. Marc Diamond for the HEK293 CFP-/YFP-TauRD cell line. AAVs were produced by Ry Xiao at MEEI vector core in Boston. This research was funded by Massachusetts General Hospital, NIH AG 26249, the German Research Association (DFG), Alzheimer's Research UK, and the Chief Scientist's Office, Scotland. Mapt0/0 congenic strains were produced with funding by NIH program project grant NS41997. NR 55 TC 13 Z9 13 U1 5 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0261-4189 EI 1460-2075 J9 EMBO J JI Embo J. PD DEC 14 PY 2015 VL 34 IS 24 BP 3028 EP 3041 DI 10.15252/embj.201592748 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DA6MD UT WOS:000367918000006 PM 26538322 ER PT J AU Jena, AB Schoemaker, L Bhattacharya, J Seabury, SA AF Jena, Anupam B. Schoemaker, Lena Bhattacharya, Jay Seabury, Seth A. TI PHYSICIAN SPENDING AND RISK OF MALPRACTICE CLAIMS Reply SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Letter C1 [Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Jena, Anupam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jena, Anupam B.; Bhattacharya, Jay] Natl Bur Econ Res, Cambridge, MA 02138 USA. [Schoemaker, Lena; Bhattacharya, Jay] Stanford Univ, Ctr Primary Care & Outcomes Res, Sch Med, Stanford, CA 94305 USA. [Seabury, Seth A.] Univ So Calif, Dept Emergency Med, Los Angeles, CA USA. [Seabury, Seth A.] Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA. RP Jena, AB (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. EM jena@hcp.med.harvard.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD DEC 14 PY 2015 VL 351 AR h6774 DI 10.1136/bmj.h6774 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CZ4KY UT WOS:000367073200031 PM 26668033 ER PT J AU Olenski, AR Abola, MV Jena, AB AF Olenski, Andrew R. Abola, Matthew V. Jena, Anupam B. TI CHRISTMAS 2015: POLITICAL SCIENCE Do heads of government age more quickly? Observational study comparing mortality between elected leaders and runners-up in national elections of 17 countries SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Editorial Material AB Objectives To determine whether being elected to head of government is associated with accelerated mortality by studying survival differences between people elected to office and unelected runner-up candidates who never served. Design Observational study. Setting Historical survival data on elected and runner-up candidates in parliamentary or presidential elections in Australia, Austria, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, New Zealand, Norway, Poland, Spain, Sweden, United Kingdom, and United States, from 1722 to 2015. Participants Elected and runner-up political candidates. Main outcome measure Observed number of years alive after each candidate's last election, relative to what would be expected for an average person of the same age and sex as the candidate during the year of the election, based on historical French and British life tables. Observed post-election life years were compared between elected candidates and runners-up, adjusting for life expectancy at time of election. A Cox proportional hazards model (adjusted for candidate's life expectancy at the time of election) considered years until death (or years until end of study period for those not yet deceased by 9 September 2015) for elected candidates versus runners-up. Results The sample included 540 candidates: 279 winners and 261 runners-up who never served. A total of 380 candidates were deceased by 9 September 2015. Candidates who served as a head of government lived 4.4 (95% confidence interval 2.1 to 6.6) fewer years after their last election than did candidates who never served (17.8 v 13.4 years after last election; adjusted difference 2.7 (0.6 to 4.8) years). In Cox proportional hazards analysis, which considered all candidates (alive or deceased), the mortality hazard for elected candidates relative to runners-up was 1.23 (1.00 to 1.52). Conclusions Election to head of government is associated with a substantial increase in mortality risk compared with candidates in national elections who never served. C1 [Olenski, Andrew R.; Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Abola, Matthew V.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. [Jena, Anupam B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA. RP Jena, AB (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM jena@hcp.med.harvard.edu FU Office of the Director, National Institutes of Health (NIH early independence award) [1DP5OD017897-01] FX ABJ had support from the Office of the Director, National Institutes of Health (NIH early independence award, grant 1DP5OD017897-01). The research conducted was independent of any involvement from the sponsors of the study. Study sponsors were not involved in study design, data interpretation, writing of the manuscript, or the decision to submit the article for publication. NR 12 TC 1 Z9 1 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD DEC 14 PY 2015 VL 351 AR h6424 DI 10.1136/bmj.h6424 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CZ4KY UT WOS:000367073200009 PM 26666894 ER PT J AU Tateishi, K Wakimoto, H Iafrate, AJ Tanaka, S Loebe, F Lelic, N Wiederschain, D Bedel, O Deng, GJ Zhang, BL He, T Shi, X Gerszten, RE Zhang, YY Yeh, JRJ Curry, WT Zhao, D Sundaram, S Nigim, F Koerner, MVA Ho, Q Fisher, DE Roider, EM Kemeny, LV Samuels, Y Flaherty, KT Batchelor, TT Chi, AS Cahill, DP AF Tateishi, Kensuke Wakimoto, Hiroaki Iafrate, A. John Tanaka, Shota Loebe, Franziska Lelic, Nina Wiederschain, Dmitri Bedel, Olivier Deng, Gejing Zhang, Bailin He, Timothy Shi, Xu Gerszten, Robert E. Zhang, Yiyun Yeh, Jing-Ruey J. Curry, William T. Zhao, Dan Sundaram, Sudhandra Nigim, Fares Koerner, Mara V. A. Ho, Quan Fisher, David E. Roider, Elisabeth M. Kemeny, Lajos V. Samuels, Yardena Flaherty, Keith T. Batchelor, Tracy T. Chi, Andrew S. Cahill, Daniel P. TI Extreme Vulnerability of IDH1 Mutant Cancers to NAD plus Depletion SO CANCER CELL LA English DT Article ID ISOCITRATE DEHYDROGENASE 1; ACUTE MYELOID-LEUKEMIA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; GLUTAMINE-METABOLISM; GLIOMA-CELLS; ONCOMETABOLITE 2-HYDROXYGLUTARATE; PROMOTES DIFFERENTIATION; REDUCTIVE CARBOXYLATION; ALPHA-KETOGLUTARATE; PATHWAY MUTATIONS AB Heterozygous mutation of IDH1 in cancers modifies IDH1 enzymatic activity, reprogramming metabolite flux and markedly elevating 2-hydroxyglutarate (2-HG). Here, we found that 2-HG depletion did not inhibit growth of several IDH1 mutant solid cancer types. To identify other metabolic therapeutic targets, we systematically profiled metabolites in endogenous IDH1 mutant cancer cells after mutant IDH1 inhibition and discovered a profound vulnerability to depletion of the coenzyme NAD+. Mutant IDH1 lowered NAD+ levels by downregulating the NAD+ salvage pathway enzyme nicotinate phosphoribosyltransferase (Naprt1), sensitizing to NAD+ depletion via concomitant nicotinamide phosphoribosyltransferase (NAMPT) inhibition. NAD+ depletion activated the intracellular energy sensor AMPK, triggered autophagy, and resulted in cytotoxicity. Thus, we identify NAD+ depletion as a metabolic susceptibility of IDH1 mutant cancers. C1 [Tateishi, Kensuke; Wakimoto, Hiroaki; Loebe, Franziska; Lelic, Nina; Curry, William T.; Nigim, Fares; Koerner, Mara V. A.; Cahill, Daniel P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg,Translat Neurooncol Lab, Boston, MA 02114 USA. [Tanaka, Shota; Zhao, Dan; Sundaram, Sudhandra; Batchelor, Tracy T.; Chi, Andrew S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neurooncol, Boston, MA 02114 USA. [Tanaka, Shota; Zhao, Dan; Sundaram, Sudhandra; Batchelor, Tracy T.; Chi, Andrew S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Div Hematol Oncol,Translat Neurooncol, Boston, MA 02114 USA. [Iafrate, A. John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol,Translat Neurooncol Lab, Boston, MA 02114 USA. [Flaherty, Keith T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol Oncol, Boston, MA 02114 USA. [Wiederschain, Dmitri; Bedel, Olivier; Deng, Gejing; Zhang, Bailin; He, Timothy] Sanofi Oncol, Cambridge, MA 02139 USA. [Shi, Xu; Gerszten, Robert E.; Zhang, Yiyun; Yeh, Jing-Ruey J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr,Dept Med,Div Cardiol, Boston, MA 02114 USA. [Fisher, David E.; Roider, Elisabeth M.; Kemeny, Lajos V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA. [Samuels, Yardena] Weizmann Inst Sci, IL-7610001 Rehovot, Israel. RP Chi, AS (reprint author), NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY 10016 USA. EM chia01@nyumc.org; cahill@mgh.harvard.edu FU Richard B. Simches Scholars Award; MGH Glioblastoma Research Fund; Burroughs Wellcome Fund Career Award; NIH [P50CA165962-01A1, K24 CA125440-06, R01CA140188]; Society of Nuclear Medicine and Molecular Imaging Wagner-Torizuka Fellowship; Japan Brain Foundation; American Heart Association Established Investigator Award; MGH Cardiology Hassenfeld Scholar Award; KANAE Foundation for the Promotion of Medical Science FX A.C. is supported by a Richard B. Simches Scholars Award and the MGH Glioblastoma Research Fund in memory of David M. King, Kirit N. Patel, Sarah E. Rippetoe, and Eric W. Schwartz. D.C. is supported by a Burroughs Wellcome Fund Career Award. A.C., D.C., H.W., and T.B. are supported by NIH P50CA165962-01A1 (TB., PI). T.B. is supported by NIH K24 CA125440-06. K.T. is supported by a Society of Nuclear Medicine and Molecular Imaging Wagner-Torizuka Fellowship, the Japan Brain Foundation, and the KANAE Foundation for the Promotion of Medical Science. R.G. is supported by an American Heart Association Established Investigator Award. J.-R.Y. is supported by NIH R01CA140188 and the MGH Cardiology Hassenfeld Scholar Award. D.W., O.B., G.D., B.Z., and T.H. are full-time employees of Sanofi. We thank NovaBioAssays LLC for the 2-HG quantitation. NR 61 TC 22 Z9 22 U1 4 U2 14 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 EI 1878-3686 J9 CANCER CELL JI Cancer Cell PD DEC 14 PY 2015 VL 28 IS 6 BP 773 EP 784 DI 10.1016/j.ccell.2015.11.006 PG 12 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CZ2RK UT WOS:000366952100011 PM 26678339 ER PT J AU Ballard, ME Dean, AC Mandelkern, MA London, ED AF Ballard, Michael E. Dean, Andy C. Mandelkern, Mark A. London, Edythe D. TI Striatal Dopamine D-2/D-3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users SO PLOS ONE LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; REFERENCE TISSUE MODEL; PREFRONTAL CORTEX; COGNITIVE PERFORMANCE; DISTRIBUTION VOLUME; COCAINE ADDICTION; D-2 RECEPTORS; BRAIN IMAGES; DEFICITS; ABUSERS AB Background Dopamine D-2/D-3 receptor availability in the striatum has been linked with executive function in healthy individuals, and is below control levels among drug addicts, possibly contributing to diminished executive function in the latter group. This study tested for an association of striatal D-2/D-3 receptor availability with a measure of executive function among research participants who met DSM-IV criteria for methamphetamine dependence. Methods Methamphetamine users and non-user controls (n = 18 per group) completed the Wisconsin Card Sorting Test and positron emission tomography with [F-18]fallypride. Results The methamphetamine users displayed significantly lower striatal D-2/D-3 receptor availability on average than controls after controlling for age and education (p = 0.008), but they did not register greater proportions of either perseverative or non-perseverative errors when controlling for education (both ps >= 0.622). The proportion of non-perseverative, but not perseverative, errors was negatively correlated with striatal D2/D3 receptor availability among controls (r = -0.588, p = 0.010), but not methamphetamine users (r = 0.281, p = 0.258), and the group-wise interaction was significant (p = 0.030). Conclusions These results suggest that cognitive flexibility, as measured by perseverative errors on the Wisconsin Card Sorting Test, is not determined by signaling through striatal D-2/D-3 receptors in healthy controls, and that in stimulant abusers, who have lower D-2/D-3 receptor availability, compensation can effectively maintain other executive functions, which are associated with D-2/D-3 receptor signaling in controls. C1 [Ballard, Michael E.; Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Ballard, Michael E.; Mandelkern, Mark A.; London, Edythe D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. [London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. RP London, ED (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. EM elondon@mednet.ucla.edu RI Ballard, Michael/F-9146-2013 OI Ballard, Michael/0000-0002-2651-6588 FU National Institutes of Health [R01 DA020726, P20 DA022539, K23 DA027734, M0I RR00865]; Marjorie M. Greene Trust; Thomas P. and Katherine K. Pike Chair in Addiction Studies; [T32 DA024635] FX The research was supported by National Institutes of Health grants R01 DA020726 (EDL), P20 DA022539 (EDL), K23 DA027734 (ACD), M0I RR00865 (UCLA GCRC), by endowments from the Thomas P. and Katherine K. Pike Chair in Addiction Studies (EDL), and the Marjorie M. Greene Trust. MEB was supported by T32 DA024635. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 70 TC 0 Z9 0 U1 6 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 14 PY 2015 VL 10 IS 12 AR e0143510 DI 10.1371/journal.pone.0143510 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9GR UT WOS:000366715900012 PM 26657223 ER PT J AU Orwoll, BE Spicer, AC Zinter, MS Alkhouli, MF Khemani, RG Flori, HR Neuhaus, JM Calfee, CS Matthay, MA Sapru, A AF Orwoll, Benjamin E. Spicer, Aaron C. Zinter, Matt S. Alkhouli, Mustafa F. Khemani, Robinder G. Flori, Heidi R. Neuhaus, John M. Calfee, Carolyn S. Matthay, Michael A. Sapru, Anil TI Elevated soluble thrombomodulin is associated with organ failure and mortality in children with acute respiratory distress syndrome (ARDS): a prospective observational cohort study SO CRITICAL CARE LA English DT Article ID ACUTE LUNG INJURY; DISSEMINATED INTRAVASCULAR COAGULATION; ENDOTHELIAL-CELL INJURY; VON-WILLEBRAND-FACTOR; DYSFUNCTION SYNDROME; CIRCULATING THROMBOMODULIN; FACTOR ANTIGEN; SEVERE SEPSIS; PROTEIN-C; PLASMA AB Introduction: The significance of endothelial injury in children with the acute respiratory distress syndrome (ARDS) has not been well studied. Plasma levels of soluble thrombomodulin (sTM), an endothelial surface protein involved in coagulation, have been associated with endothelial injury. We hypothesized that elevated plasma sTM would correlate with mortality and organ failure in children with ARDS. Methods: We conducted a multicenter prospective observational study of pediatric patients with ARDS between 2008 and 2014. sTM was measured in plasma collected less than 24 hours from ARDS diagnosis. Outcomes were intensive care unit mortality and organ dysfunction by pediatric logistic organ dysfunction scores. Logistic regression was used to adjust for clinically relevant covariates. Results: Plasma sTM was higher in patients with indirect lung injury compared to direct lung injury (100 ng/mL vs. 86 ng/mL, p = 0.02). Increased sTM levels were correlated with more organ dysfunction in the entire study population (Spearman's rho = 0.37, p < 0.01). Overall mortality was 16 %. sTM levels were associated with increased mortality in patients with indirect lung injury (OR 2.7 per log(sTM), p = 0.02). These relationships were independent of age, oxygenation defect, or presence of acute kidney injury. Conclusion: Elevated plasma sTM levels are associated with organ dysfunction in children with ARDS and with higher mortality in children with indirect lung injury. These findings highlight the importance of endothelial injury in children with ARDS and may guide the development of future therapies targeted toward endothelial stabilization, repair, or functional replacement in this population. C1 [Orwoll, Benjamin E.; Zinter, Matt S.; Alkhouli, Mustafa F.; Sapru, Anil] Univ Calif San Francisco, Dept Pediat, Div Crit Care, Benioff Childrens Hosp, San Francisco, CA 94143 USA. [Orwoll, Benjamin E.; Zinter, Matt S.; Flori, Heidi R.] Univ Calif San Francisco, Div Pediat Crit Care, Benioff Childrens Hosp, Oakland, CA 94609 USA. [Spicer, Aaron C.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Khemani, Robinder G.] Childrens Hosp Los Angeles, Dept Anesthesiol & Crit Care Med, Los Angeles, CA 90027 USA. [Neuhaus, John M.] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA. [Calfee, Carolyn S.; Matthay, Michael A.] Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, San Francisco, CA 94158 USA. [Calfee, Carolyn S.; Matthay, Michael A.] Univ Calif San Francisco, Dept Anesthesia, Cardiovasc Res Inst, San Francisco, CA 94158 USA. RP Orwoll, BE (reprint author), Univ Calif San Francisco, Dept Pediat, Div Crit Care, Benioff Childrens Hosp, 550 16th St,Box 0106, San Francisco, CA 94143 USA. EM orwoll@ucsf.edu RI Spicer, Aaron/D-1829-2014 OI Orwoll, Benjamin/0000-0002-5023-3385; Spicer, Aaron/0000-0001-7713-0565 FU NIH [NHLBI HL085526 (K23), NHLBI HL114484 (R01), NHLBI R37HL51856] FX Funds provided through NIH grants NHLBI HL085526 (K23) (Sapru), NHLBI HL114484 (R01) (Sapru), and NHLBI R37HL51856 (Matthay). Thanks to Victoria Lo, Elizabeth Colglazier, and Izabella Damm for help with initial study sample collection and processing. We would also like to thank Dr. Patrick McQuillen for his comments and manuscript review. NR 41 TC 5 Z9 6 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X EI 1364-8535 J9 CRIT CARE JI Crit. Care PD DEC 14 PY 2015 VL 19 AR 435 DI 10.1186/s13054-015-1145-9 PG 9 WC Critical Care Medicine SC General & Internal Medicine GA CY3ZR UT WOS:000366348900001 PM 26652251 ER PT J AU Sudore, R Le, GM McMahon, R Feuz, M Katen, M Barnes, DE AF Sudore, Rebecca Le, Gem M. McMahon, Ryan Feuz, Mariko Katen, Mary Barnes, Deborah E. TI The advance care planning PREPARE study among older Veterans with serious and chronic illness: study protocol for a randomized controlled trial SO TRIALS LA English DT Article DE advance care planning; aging; medical decision-making; randomized trial; chronic disease management; geriatrics; veterans; health behavior; advance directive; vulnerable populations ID MENTAL STATUS QUESTIONNAIRE; LIMITED HEALTH LITERACY; QUALITY-OF-LIFE; DECISION-MAKING; ADMINISTRATIVE DATA; ADVANCED CANCER; BEHAVIOR-CHANGE; MEDICAL-CARE; ADULTS; VALIDATION AB Background: Advance care planning (ACP) is a process whereby patients prepare for medical decision-making. The traditional objective of ACP has focused on the completion of advance directives. We have developed a new paradigm of ACP focused on preparing patients and their loved ones for communication and informed medical decision-making. To operationalize this new paradigm of ACP, we created an interactive, patient-centered website called PREPARE (www.prepareforyourcare.org) designed for diverse older adults. Methods/Design: This randomized controlled trial with blinded outcome assessment is designed to determine the efficacy of PREPARE to engage older Veterans in the ACP process. Veterans who are >= 60 years of age, have >= two medical conditions, and have seen a primary care physician >= two times in the last year are being randomized to one of two study arms. The PREPARE study arm reviews the PREPARE website and an easy-to-read advance directive. The control arm only reviews the advance directive. The primary outcome is documentation of an advance directive and ACP discussions. Other clinically important outcomes using validated surveys include ACP behavior change process measures (knowledge, contemplation, self-efficacy, and readiness) and a full range of ACP action measures (identifying a surrogate, identifying values and goals, choosing leeway or flexibility for the surrogate, communicating with clinicians and surrogates, and documenting one's wishes). We will also assess satisfaction with decision-making and Veteran activation within primary care visits by direct audio recording. To examine the outcomes at 1 week, 3 months, and 6 months between the two study arms, we will use mixed effects linear, Poisson, or negative binomial regression and mixed effects logistic regression. Discussion: This study will determine whether PREPARE increases advance directive completion rates and engagement with the ACP process. If PREPARE is efficacious, it could prove to be an easy and effective intervention to help older adults engage in the ACP process within or outside of the medical environment. PREPARE may also help older adults communicate their medical wishes and goals to their loved ones and clinicians, improve medical decision-making, and ensure their wishes are honored over the life course. C1 [Sudore, Rebecca; Le, Gem M.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Sudore, Rebecca; McMahon, Ryan; Feuz, Mariko; Katen, Mary] San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. [Le, Gem M.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, Ctr Vulnerable Populat, San Francisco, CA 94110 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Sudore, R (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 3333 Calif St,Suite 380, San Francisco, CA 94143 USA. EM rebecca.sudore@ucsf.edu FU Veterans Affairs Health Services Research Development [11-110-2] FX The Veterans Affairs Health Services Research & Development is the primary funder of this study (#11-110-2). The funder has no role in the study design, the interpretation of data, or the publication of results. NR 60 TC 1 Z9 1 U1 5 U2 17 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD DEC 12 PY 2015 VL 16 AR 570 DI 10.1186/s13063-015-1055-9 PG 16 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CY2RB UT WOS:000366254700001 PM 26654250 ER PT J AU Klann, JG Phillips, LC Turchin, A Weiler, S Mandl, KD Murphy, SN AF Klann, Jeffrey G. Phillips, Lori C. Turchin, Alexander Weiler, Sarah Mandl, Kenneth D. Murphy, Shawn N. TI A numerical similarity approach for using retired Current Procedural Terminology (CPT) codes for electronic phenotyping in the Scalable Collaborative Infrastructure for a Learning Health System (SCILHS) SO BMC MEDICAL INFORMATICS AND DECISION MAKING LA English DT Article DE CPT codes; Biomedical ontologies; Medical informatics; Phenotype; Data mining/methods; Biomedical research/methods; Electronic health records/trends AB Background: Interoperable phenotyping algorithms, needed to identify patient cohorts meeting eligibility criteria for observational studies or clinical trials, require medical data in a consistent structured, coded format. Data heterogeneity limits such algorithms' applicability. Existing approaches are often: not widely interoperable; or, have low sensitivity due to reliance on the lowest common denominator (ICD-9 diagnoses). In the Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS) we endeavor to use the widely-available Current Procedural Terminology (CPT) procedure codes with ICD-9. Unfortunately, CPT changes drastically year-to-year - codes are retired/replaced. Longitudinal analysis requires grouping retired and current codes. BioPortal provides a navigable CPT hierarchy, which we imported into the Informatics for Integrating Biology and the Bedside (i2b2) data warehouse and analytics platform. However, this hierarchy does not include retired codes. Methods: We compared BioPortal's 2014AA CPT hierarchy with Partners Healthcare's SCILHS datamart, comprising three-million patients' data over 15 years. 573 CPT codes were not present in 2014AA (6.5 million occurrences). No existing terminology provided hierarchical linkages for these missing codes, so we developed a method that automatically places missing codes in the most specific "grouper" category, using the numerical similarity of CPT codes. Two informaticians reviewed the results. We incorporated the final table into our i2b2 SCILHS/PCORnet ontology, deployed it at seven sites, and performed a gap analysis and an evaluation against several phenotyping algorithms. Results: The reviewers found the method placed the code correctly with 97 % precision when considering only miscategorizations ("correctness precision") and 52 % precision using a gold-standard of optimal placement ("optimality precision"). High correctness precision meant that codes were placed in a reasonable hierarchal position that a reviewer can quickly validate. Lower optimality precision meant that codes were not often placed in the optimal hierarchical subfolder. The seven sites encountered few occurrences of codes outside our ontology, 93 % of which comprised just four codes. Our hierarchical approach correctly grouped retired and non-retired codes in most cases and extended the temporal reach of several important phenotyping algorithms. Conclusions: We developed a simple, easily-validated, automated method to place retired CPT codes into the BioPortal CPT hierarchy. This complements existing hierarchical terminologies, which do not include retired codes. The approach's utility is confirmed by the high correctness precision and successful grouping of retired with non-retired codes. C1 [Klann, Jeffrey G.; Turchin, Alexander; Weiler, Sarah; Mandl, Kenneth D.; Murphy, Shawn N.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Klann, Jeffrey G.; Phillips, Lori C.; Turchin, Alexander; Murphy, Shawn N.] Partners Healthcare, Boston, MA USA. [Klann, Jeffrey G.; Murphy, Shawn N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Turchin, Alexander] Brigham & Womens Hosp, Boston, MA 02115 USA. [Turchin, Alexander] Harvard Clin Res Inst, Boston, MA USA. [Mandl, Kenneth D.] Boston Childrens Hosp, Computat Hlth Informat Program, Boston, MA USA. RP Klann, JG (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA. EM jeff.klann@mgh.harvard.edu FU Patient-Centered Outcomes Research Institute (PCORI) Award for development of the National Patient-Centered Clinical Research Network, known as PCORnet [282364.5077585.0007, CDRN-1306-04608]; Instrumenting i2b2 for Improved Medication Research: Adding the Patient Voice [R01 GM104303] FX Thanks to the entire SCILHS team. Special thanks go to Vijay Raghavan, who managed deployment and implementation of this work at our sites and reported back successes and difficulties. Also, thanks go to: Jessica Lyons, who is spearheading our network's phenotyping algorithms; and Mike Mendis, who leads development and implementation of i2b2 in our network. This work funded by: a Patient-Centered Outcomes Research Institute (PCORI) Award CDRN-1306-04608 (282364.5077585.0007) for development of the National Patient-Centered Clinical Research Network, known as PCORnet; and, by R01 GM104303 - Instrumenting i2b2 for Improved Medication Research: Adding the Patient Voice. NR 23 TC 0 Z9 0 U1 3 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6947 J9 BMC MED INFORM DECIS JI BMC Med. Inform. Decis. Mak. PD DEC 11 PY 2015 VL 15 AR 104 DI 10.1186/s12911-015-0223-x PG 12 WC Medical Informatics SC Medical Informatics GA CY5OD UT WOS:000366456100001 PM 26655696 ER PT J AU Lyons, BE Austin, D Seelye, A Petersen, J Yeargers, J Riley, T Sharma, N Mattek, N Dodge, H Wild, K Kaye, JA AF Lyons, Bayard E. Austin, Daniel Seelye, Adriana Petersen, Johanna Yeargers, Jonathan Riley, Thomas Sharma, Nicole Mattek, Nora Dodge, Hiroko Wild, Katherine Kaye, Jeffrey A. TI Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy (vol 7, 102, 2015) SO FRONTIERS IN AGING NEUROSCIENCE LA English DT Correction DE Alzheimer's disease (AD); dementia; mild cognitive impairment (MCI); home monitoring; OHSU; ORCATECH; Layton Aging and Alzheimer's Disease Center C1 [Lyons, Bayard E.; Austin, Daniel; Seelye, Adriana; Petersen, Johanna; Yeargers, Jonathan; Riley, Thomas; Sharma, Nicole; Mattek, Nora; Dodge, Hiroko; Wild, Katherine; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. [Lyons, Bayard E.; Seelye, Adriana; Mattek, Nora; Dodge, Hiroko; Wild, Katherine; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Austin, Daniel; Petersen, Johanna; Yeargers, Jonathan; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA. [Kaye, Jeffrey A.] Portland VA Med Ctr, Neurol Serv, Portland, OR USA. RP Lyons, BE (reprint author), Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. EM lyonsb@ohsu.edu FU NIA NIH HHS [R01 AG024059, R01 AG042191, K01 AG023014, P30 AG008017, P30 AG024978, R01 AG033581] NR 1 TC 0 Z9 0 U1 0 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1663-4365 J9 FRONT AGING NEUROSCI JI Front. Aging Neurosci. PD DEC 11 PY 2015 VL 7 AR 232 DI 10.3389/fnagi.2015.00232 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA CY7ND UT WOS:000366594500001 PM 26696884 ER PT J AU Pallais, JC McInnis, M Saylor, PJ Wu, RI AF Pallais, J. Carl McInnis, Micheal Saylor, Philip J. Wu, Roseann I. TI Case 38-2015: A 21-Year-Old Man with Fatigue and Weight Loss SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID HUMAN CHORIONIC-GONADOTROPIN; GERM-CELL TUMORS; BETA-SUBUNIT; HYPERTHYROIDISM; THYROTOXICOSIS; GYNECOMASTIA; NEOPLASMS; BIOLOGY; UTILITY; CANCER C1 [Pallais, J. Carl] Massachusetts Gen Hosp, Dept Endocrinol, Boston, MA 02114 USA. [McInnis, Micheal] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Saylor, Philip J.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. [Wu, Roseann I.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Pallais, J. Carl] Harvard Univ, Sch Med, Dept Endocrinol, Boston, MA 02115 USA. [McInnis, Micheal] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Saylor, Philip J.] Harvard Univ, Sch Med, Dept Hematol Oncol, Boston, MA 02115 USA. [Wu, Roseann I.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Pallais, JC (reprint author), Massachusetts Gen Hosp, Dept Endocrinol, Boston, MA 02114 USA. NR 28 TC 1 Z9 1 U1 1 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 10 PY 2015 VL 373 IS 24 BP 2358 EP 2369 DI 10.1056/NEJMcpc1506821 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA CY0QW UT WOS:000366111600012 PM 26650156 ER PT J AU Devine, SM Owzar, K Blum, W Mulkey, F Stone, RM Hsu, JW Champlin, RE Chen, YB Vij, R Slack, J Soiffer, RJ Larson, RA Shea, TC Hars, V Sibley, AB Giralt, S Carter, S Horowitz, MM Linker, C Alyea, EP AF Devine, Steven M. Owzar, Kouros Blum, William Mulkey, Flora Stone, Richard M. Hsu, Jack W. Champlin, Richard E. Chen, Yi-Bin Vij, Ravi Slack, James Soiffer, Robert J. Larson, Richard A. Shea, Thomas C. Hars, Vera Sibley, Alexander B. Giralt, Sergio Carter, Shelly Horowitz, Mary M. Linker, Charles Alyea, Edwin P. TI Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID STEM-CELL TRANSPLANTATION; VERSUS-HOST-DISEASE; RISK MYELODYSPLASTIC SYNDROME; ACUTE MYELOGENOUS LEUKEMIA; UNRELATED DONORS; CHRONIC GRAFT; HEMATOLOGIC MALIGNANCIES; EUROPEAN LEUKEMIANET; TREATMENT OUTCOMES; BONE-MARROW AB Purpose Long-term survival rates for older patients with newly diagnosed acute myeloid leukemia (AML) are extremely low. Previous observational studies suggest that allogeneic hematopoietic stem-cell transplantation (HSCT) may improve overall survival (OS) because of lower rates of relapse. We sought to prospectively determine the value of HSCT for older patients with AML in first complete remission. Patients and Methods We conducted a prospective multicenter phase II study to assess the efficacy of reduced-intensity conditioning HSCT for patients between the ages of 60 and 74 years with AML in first complete remission. The primary end point was disease-free survival at 2 years after HSCT. Secondary end points included nonrelapse mortality (NRM), graft-versus-host disease (GVHD), relapse, and OS. Results In all, 114 patients with a median age of 65 years received transplantations. The majority (52%) received transplantations from unrelated donors and were given antithymocyte globulin for GVHD prophylaxis. Disease-free survival and OS at 2 years after transplantation were 42% (95% CI, 33% to 52%) and 48% (95% CI, 39% to 58%), respectively, for the entire group and 40% (95% CI, 29% to 55%) and 50% (95% CI, 38% to 64%) for the unrelated donor group. NRM at 2 years was 15% (95% CI, 8% to 21%). Grade 2 to 4 acute GVHD occurred in 9.6% (95% CI, 4% to 15%) of patients, and chronic GVHD occurred in 28% (95% CI, 19% to 36%) of patients. The cumulative incidence of relapse at 2 years was 44% (95% CI, 35% to 53%). Conclusion Reduced-intensity conditioning HSCT to maintain remission in selected older patients with AML is relatively well tolerated and appears to provide superior outcomes when compared with historical patients treated without HSCT. GVHD and NRM rates were lower than expected. Future transplantation studies in these patients should focus on further reducing the risk of relapse. (C) 2015 by American Society of Clinical Oncology C1 [Devine, Steven M.; Blum, William] Ohio State Univ, Columbus, OH 43210 USA. [Owzar, Kouros; Mulkey, Flora; Hars, Vera; Sibley, Alexander B.] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA. [Shea, Thomas C.] Univ N Carolina, Chapel Hill, NC USA. [Stone, Richard M.; Soiffer, Robert J.; Alyea, Edwin P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hsu, Jack W.] Univ Florida, Gainesville, FL USA. [Champlin, Richard E.] MD Anderson Canc Res Ctr, Houston, TX USA. [Vij, Ravi] Washington Univ, St Louis, MO USA. [Slack, James] Mayo Clin, Scottsdale, AZ USA. [Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA. [Giralt, Sergio] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Carter, Shelly] EMMES Corp, Bethesda, MD USA. [Horowitz, Mary M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Linker, Charles] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Devine, SM (reprint author), Ohio State Univ, B316 Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA. EM steven.devine@osumc.edu FU National Cancer Institute, National Institutes of Health (NIH) [U10CA180821, U10CA180882, 1U10CA180850, 1U10CA180867, 1U10CA180858, 1U10CA180833, 1U10CA180790, 1U10CA180836, 1U10CA180838, 1U10CA180791]; National Heart, Lung, and Blood Institute [U10HL069294]; National Cancer Institute (NIH); Genzyme FX Supported in part by Grants No. U10CA180821 and U10CA180882 (Alliance for Clinical Trials in Oncology) and 1U10CA180850, 1U10CA180867, 1U10CA180858, 1U10CA180833, 1U10CA180790, 1U10CA180836, 1U10CA180838, and 1U10CA180791 from the National Cancer Institute, National Institutes of Health (NIH), by Grant No. U10HL069294 from the National Heart, Lung, and Blood Institute and the National Cancer Institute (NIH), and by Genzyme. NR 42 TC 17 Z9 17 U1 0 U2 9 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 10 PY 2015 VL 33 IS 35 BP 4167 EP + DI 10.1200/JCO.2015.62.7273 PG 14 WC Oncology SC Oncology GA CX9JG UT WOS:000366021200010 PM 26527780 ER PT J AU Hatcher, JM Bahcall, M Choi, HG Gao, Y Sim, T George, R Janne, PA Gray, NS AF Hatcher, John M. Bahcall, Magda Choi, Hwan Geun Gao, Yang Sim, Taebo George, Rani Jaenne, Pasi A. Gray, Nathanael S. TI Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID CELL LUNG-CANCER; ACTIVATING MUTATIONS; ALK REARRANGEMENTS; TYROSINE KINASE; CRIZOTINIB; NEUROBLASTOMA; IDENTIFICATION; CHEMOTHERAPY; EXPRESSION; RECEPTOR AB The treatment of patients with advanced non-small-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small-molecule inhibitor of ALK, ROS1, and MET. However, resistance to crizotinib inevitably develops through a variety of mechanisms, leading to relapse both systemically and in the central nervous system (CNS). This has motivated the development of "second-generation" ALK inhibitors, including alectinib and ceritinib, that overcome some of the mutations leading to resistance. However, most of the reported ALK inhibitors do not show inhibition of the G1202R mutant, which is one of the most common mutations. Herein, we report the development of a structural analogue of alectinib (JH-VIII-157-02) that is potent against the G1202R mutant as well as a variety of other frequently observed mutants. In addition, JET-VIII-157-02 is capable of penetrating the CNS of mice following oral dosing. C1 [Hatcher, John M.; Choi, Hwan Geun; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Bahcall, Magda; Jaenne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA. [Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02115 USA. [Hatcher, John M.; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Gao, Yang; George, Rani] Dana Farber Canc Inst, Dept Pediat Haematol & Oncol, Boston, MA 02115 USA. [Gao, Yang; George, Rani] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA 02215 USA. [Sim, Taebo] Korea Inst Sci & Technol, Chem Kinom Res Ctr, Seoul 136791, South Korea. [Sim, Taebo] Korea Univ, KU KIST Grad Sch Converging Sci & Technol, Seoul 136713, South Korea. RP Gray, NS (reprint author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave, Boston, MA 02115 USA. EM Nathanael_Gray@dfci.harvard.edu FU National Institutes of Health (NIH) [R01 CA136851-07]; National Research Foundation of Korea [NRF-2011-0028676] FX Funding for this work was received from the National Institutes of Health (NIH) (Grant R01 CA136851-07) (P.A.J. and N.S.G.) and the creative/challenging research program of the National Research Foundation of Korea (Grant NRF-2011-0028676) NR 29 TC 6 Z9 6 U1 5 U2 16 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 EI 1520-4804 J9 J MED CHEM JI J. Med. Chem. PD DEC 10 PY 2015 VL 58 IS 23 BP 9296 EP 9308 DI 10.1021/acs.jmedchem.5b01136 PG 13 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA CY3WG UT WOS:000366340000016 PM 26568289 ER PT J AU Carrizosa, E Mempel, TR AF Carrizosa, Esteban Mempel, Thorsten R. TI IMMUNOLOGY In the right place at the right time SO NATURE LA English DT Editorial Material ID T-CELLS; TCR C1 [Carrizosa, Esteban] Harvard Univ, Sch Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA. RP Carrizosa, E (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA. EM tmempel@mgh.harvard.edu NR 9 TC 0 Z9 0 U1 2 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD DEC 10 PY 2015 VL 528 IS 7581 BP 205 EP 206 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CX9VH UT WOS:000366053300029 PM 26605531 ER PT J AU Cheloufi, S Elling, U Hopfgartner, B Jung, YL Murn, J Ninova, M Hubmann, M Badeaux, AI Ang, CE Tenen, D Wesche, DJ Abazova, N Hogue, M Tasdemir, N Brumbaugh, J Rathert, P Jude, J Ferrari, F Blanco, A Fellner, M Wenzel, D Zinner, M Vidal, SE Bell, O Stadtfeld, M Chang, HY Almouzni, G Lowe, SW Rinn, J Wernig, M Aravin, A Shi, Y Park, PJ Penninger, JM Zuber, J Hochedlinger, K AF Cheloufi, Sihem Elling, Ulrich Hopfgartner, Barbara Jung, Youngsook L. Murn, Jernej Ninova, Maria Hubmann, Maria Badeaux, Aimee I. Ang, Cheen Euong Tenen, Danielle Wesche, Daniel J. Abazova, Nadezhda Hogue, Max Tasdemir, Nilgun Brumbaugh, Justin Rathert, Philipp Jude, Julian Ferrari, Francesco Blanco, Andres Fellner, Michaela Wenzel, Daniel Zinner, Marietta Vidal, Simon E. Bell, Oliver Stadtfeld, Matthias Chang, Howard Y. Almouzni, Genevieve Lowe, Scott W. Rinn, John Wernig, Marius Aravin, Alexei Shi, Yang Park, Peter J. Penninger, Josef M. Zuber, Johannes Hochedlinger, Konrad TI The histone chaperone CAF-1 safeguards somatic cell identity SO NATURE LA English DT Article ID DIFFERENTIAL EXPRESSION ANALYSIS; DNA-BINDING PROTEINS; NUCLEAR TRANSFER; STEM-CELLS; IN-VIVO; CHROMATIN; GENOME; MOUSE; HETEROCHROMATIN; PLURIPOTENCY AB Cellular differentiation involves profound remodelling of chromatic landscapes, yet the mechanisms by which somatic cell identity is subsequently maintained remain incompletely understood. To further elucidate regulatory pathways that safeguard the somatic state, we performed two comprehensive RNA interference (RNAi) screens targeting chromatin factors during transcription-factor-mediated reprogramming of mouse fibroblasts to induced pluripotent stem cells (iPS cells). Subunits of the chromatin assembly factor-1 (CAF-1) complex, including Chaf1a and Chaf1b, emerged as the most prominent hits from both screens, followed by modulators of lysine sumoylation and heterochromatin maintenance. Optimal modulation of both CAF-1 and transcription factor levels increased reprogramming efficiency by several orders of magnitude and facilitated iPS cell formation in as little as 4 days. Mechanistically, CAF-1 suppression led to a more accessible chromatin structure at enhancer elements early during reprogramming. These changes were accompanied by a decrease in somatic heterochromatin domains, increased binding of Sox2 to pluripotency-specific targets and activation of associated genes. Notably, suppression of CAF-1 also enhanced the direct conversion of B cells into macrophages and fibroblasts into neurons. Together, our findings reveal the histone chaperone CAF-1 to be a novel regulator of somatic cell identity during transcription-factor-induced cell-fate transitions and provide a potential strategy to modulate cellular plasticity in a regenerative setting. C1 [Cheloufi, Sihem; Wesche, Daniel J.; Abazova, Nadezhda; Hogue, Max; Brumbaugh, Justin; Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Canc, Dept Mol Biol, Boston, MA 02114 USA. [Cheloufi, Sihem; Wesche, Daniel J.; Abazova, Nadezhda; Hogue, Max; Brumbaugh, Justin; Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Cheloufi, Sihem; Tenen, Danielle; Wesche, Daniel J.; Abazova, Nadezhda; Hogue, Max; Brumbaugh, Justin; Rinn, John; Hochedlinger, Konrad] Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Cheloufi, Sihem; Tenen, Danielle; Wesche, Daniel J.; Abazova, Nadezhda; Hogue, Max; Brumbaugh, Justin; Rinn, John; Hochedlinger, Konrad] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Cheloufi, Sihem; Wesche, Daniel J.; Abazova, Nadezhda; Hogue, Max; Brumbaugh, Justin; Chang, Howard Y.; Lowe, Scott W.; Hochedlinger, Konrad] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. [Elling, Ulrich; Hubmann, Maria; Wenzel, Daniel; Zinner, Marietta; Bell, Oliver; Penninger, Josef M.] Austrian Acad Sci IMBA, Inst Mol Biotechnol, Vienna Bioctr VBC, A-1030 Vienna, Austria. [Hopfgartner, Barbara; Rathert, Philipp; Jude, Julian; Fellner, Michaela; Zuber, Johannes] Res Inst Mol Pathol IMP, Vienna Bioctr VBC, A-1030 Vienna, Austria. [Jung, Youngsook L.; Ferrari, Francesco; Park, Peter J.] Harvard Univ, Sch Med, Dept Biomed Informat, Boston, MA 02115 USA. [Jung, Youngsook L.; Ferrari, Francesco; Park, Peter J.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. [Murn, Jernej; Badeaux, Aimee I.; Blanco, Andres; Shi, Yang] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Murn, Jernej; Badeaux, Aimee I.; Blanco, Andres; Shi, Yang] Boston Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA. [Ninova, Maria; Aravin, Alexei] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA. [Ang, Cheen Euong; Wernig, Marius] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Dept Pathol, Stanford, CA 94305 USA. [Ang, Cheen Euong; Wernig, Marius] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA. [Tenen, Danielle; Rinn, John] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02142 USA. [Tasdemir, Nilgun; Lowe, Scott W.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA. [Vidal, Simon E.; Stadtfeld, Matthias] NYU, Sch Med, Skirball Inst Biomol Med, Helen L & Martin S Kimmel Ctr Biol & Med,Dept Cel, New York, NY 10016 USA. [Chang, Howard Y.] Stanford Univ, Sch Med, Ctr Personal Dynam Regulomes, Stanford, CA 94305 USA. [Chang, Howard Y.] Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA. [Almouzni, Genevieve] Inst Curie, Ctr Rech, F-75248 Paris, France. RP Hochedlinger, K (reprint author), Massachusetts Gen Hosp, Ctr Canc, Dept Mol Biol, Boston, MA 02114 USA. EM johannes.zuber@imp.ac.at; khochedlinger@mgh.harvard.edu RI Ferrari, Francesco/H-5007-2012; Penninger, Josef/I-6860-2013; OI Ferrari, Francesco/0000-0002-9811-3753; Penninger, Josef/0000-0002-8194-3777; Bell, Oliver/0000-0002-7639-5948; Ninova, Maria/0000-0001-5051-5502; Stadtfeld, Matthias/0000-0002-5852-9906 FU PRCRP at the Department of Defense [CA 120212]; NIH [P50-HG007735, R01 HD058013-06]; IMBA; Austrian National Foundation; cancer center support grant; NCI; ERC GA [341036]; Innovator Award/Era of Hope Award [W81XWH-12-1-0093]; ERC [336860]; Boehringer Ingelheim; MGH; HHMI; Gerald and Darlene Jordan Chair in Regenerative Medicine FX We thank B. Kingston, C. Vakoc, M. Tolstorukov and G. Hannon for guidance and discussions, B. Bernstein, K. Plath, K. Chronis, Y. Shen and O. Tam for advice on the ATAC-seq analysis, P. Brown for providing the Dot1l inhibitor, B. Stillman for sharing the Chaf1b antibody and T. Graf for sharing the C10 cell line. We thank C. Nakada and Y. Kiyota (Nikon) for providing software to quantify iPS cell formation and A. Huebner for help with transdifferentiation experiments. We are grateful to H. Hock and the HSCI-CRM flow cytometry core for help with flow data analysis and to W. Mallard for initial RNA-sequencing analysis. We further thank B. Ma, S. Muller, M. Weissenboeck and the IMP/IMBA Biooptics and Transgenic core facility as well the CSF NGS laboratory for technical assistance and all members of the Hochedlinger, Zuber, Penninger, Elling, Shi and Kingston laboratories for their feedback on various aspects of this project. We thank A. Stark, A. Deaton and L. Barrett for critical reading of the manuscript. S. C. was supported by the PRCRP at the Department of Defense (CA 120212). H. Y. C. by was supported by NIH P50-HG007735. U.E. was funded by grants from IMBA and the Austrian National Foundation. S. W. L. was supported by a cancer center support grant and program project grant from the NCI and is an HHMI investigator. J.M.P. was supported by IMBA, ERC GA (number 341036) and the Innovator Award/Era of Hope Award Number W81XWH-12-1-0093. J.Z. was funded by an ERC starting grant (number 336860) and generous institutional funding from Boehringer Ingelheim. K. H. was supported by funds from the MGH, HHMI, NIH (R01 HD058013-06) and the Gerald and Darlene Jordan Chair in Regenerative Medicine. NR 54 TC 23 Z9 24 U1 5 U2 27 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD DEC 10 PY 2015 VL 528 IS 7581 BP 218 EP + DI 10.1038/nature15749 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CX9VH UT WOS:000366053300032 PM 26659182 ER PT J AU Redfield, MM Anstrom, KJ Levine, JA Koepp, GA Borlaug, BA Chen, HH LeWinter, MM Joseph, SM Shah, SJ Semigran, MJ Felker, GM Cole, RT Reeves, GR Tedford, RJ Tang, WHW McNulty, SE Velazquez, EJ Shah, MR Braunwald, E AF Redfield, Margaret M. Anstrom, Kevin J. Levine, James A. Koepp, Gabe A. Borlaug, Barry A. Chen, Horng H. LeWinter, Martin M. Joseph, Susan M. Shah, Sanjiv J. Semigran, Marc J. Felker, G. Michael Cole, Robert T. Reeves, Gordon R. Tedford, Ryan J. Tang, W. H. Wilson McNulty, Steven E. Velazquez, Eric J. Shah, Monica R. Braunwald, Eugene CA NHLBI Heart Failure Clinical Res TI Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID EXERCISE CAPACITY; PHYSICAL-ACTIVITY; ENERGY-EXPENDITURE; SEDENTARY TIME; DOUBLE-BLIND; TRIAL; THERAPY; ACCELEROMETRY; INTOLERANCE; INHIBITION AB BACKGROUND Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients. METHODS In this multicenter, double-blind, crossover study, 110 patients with heart failure and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen of isosorbide mononitrate (from 30 mg to 60 mg to 120 mg once daily) or placebo, with subsequent crossover to the other group for 6 weeks. The primary end point was the daily activity level, quantified as the average daily accelerometer units during the 120-mg phase, as assessed by patient-worn accelerometers. Secondary end points included hours of activity per day during the 120-mg phase, daily accelerometer units during all three dose regimens, quality-of-life scores, 6-minute walk distance, and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with the placebo group, there was a nonsignificant trend toward lower daily activity (-381 accelerometer units; 95% confidence interval [CI], -780 to 17; P = 0.06) and a significant decrease in hours of activity per day (-0.30 hours; 95% CI, -0.55 to -0.05; P = 0.02). During all dose regimens, activity in the isosorbide mononitrate group was lower than that in the placebo group (-439 accelerometer units; 95% CI, -792 to -86; P = 0.02). Activity levels decreased progressively and significantly with increased doses of isosorbide mononitrate (but not placebo). There were no significant between-group differences in the 6-minute walk distance, quality-of-life scores, or NT-proBNP levels. CONCLUSIONS Patients with heart failure and a preserved ejection fraction who received isosorbide mononitrate were less active and did not have better quality of life or submaximal exercise capacity than did patients who received placebo. C1 [Redfield, Margaret M.; Borlaug, Barry A.; Chen, Horng H.] Mayo Clin, Rochester, MN 55905 USA. [Anstrom, Kevin J.; McNulty, Steven E.; Velazquez, Eric J.] Duke Clin Res Inst, Durham, NC USA. [Felker, G. Michael] Duke Univ, Med Ctr, Durham, NC USA. [Levine, James A.; Koepp, Gabe A.] Mayo Clin, Scottsdale, AZ USA. [LeWinter, Martin M.] Univ Vermont, Med Ctr, Burlington, VT 05405 USA. [Joseph, Susan M.] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Shah, Sanjiv J.] Northwestern Univ, Chicago, IL 60611 USA. [Semigran, Marc J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Braunwald, Eugene] Harvard Univ, Sch Med, Boston, MA USA. [Cole, Robert T.] Emory Univ, Atlanta, GA 30322 USA. [Reeves, Gordon R.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Tedford, Ryan J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Shah, Monica R.] NHLBI, Bethesda, MD 20892 USA. [Tang, W. H. Wilson] Cleveland Clin Fdn, Cleveland, OH USA. RP Redfield, MM (reprint author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA. EM redfield.margaret@mayo.edu FU National Heart, Lung, and Blood Institute (NHLBI) [U10 HL084904, U01 HL084861, U10 HL110312, U109 HL110337, U01 HL084889, U01 HL084890, U01 HL084891, U10 HL110342, U10 HL110262, U01 HL084931, U10 HL110297, U10 HL110302, U10 HL110309, U10 HL110336, U10 HL110338] FX Supported by grants from the National Heart, Lung, and Blood Institute (NHLBI) (coordinating center: U10 HL084904; regional clinical centers: U01 HL084861, U10 HL110312, U109 HL110337, U01 HL084889, U01 HL084890, U01 HL084891, U10 HL110342, U10 HL110262, U01 HL084931, U10 HL110297, U10 HL110302, U10 HL110309, U10 HL110336, and U10 HL110338). NR 36 TC 42 Z9 44 U1 4 U2 13 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 10 PY 2015 VL 373 IS 24 BP 2314 EP 2324 DI 10.1056/NEJMoa1510774 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CY0QW UT WOS:000366111600006 PM 26549714 ER PT J AU Musher, DM Abers, MS AF Musher, Daniel M. Abers, Michael S. TI Community-Acquired Pneumonia Requiring Hospitalization SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Musher, Daniel M.] Baylor Coll Med, Houston, TX 77030 USA. [Abers, Michael S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Musher, DM (reprint author), Baylor Coll Med, Houston, TX 77030 USA. EM daniel.musher@va.gov NR 5 TC 0 Z9 0 U1 0 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 10 PY 2015 VL 373 IS 24 BP 2381 EP 2381 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CY0QW UT WOS:000366111600019 PM 26650162 ER PT J AU Revuelta, GJ Embry, A Elm, JJ Gregory, C Delambo, A Kautz, S Hinson, VK AF Revuelta, Gonzalo J. Embry, Aaron Elm, Jordan J. Gregory, Chris Delambo, Amy Kautz, Steve Hinson, Vanessa K. TI Pilot study of atomoxetine in patients with Parkinson's disease and dopa-unresponsive Freezing of Gait SO TRANSLATIONAL NEURODEGENERATION LA English DT Article DE Parkinson's disease; Freezing of gait; Noradrenaline; Atomoxetine; Dopa-response ID ATTENTION AB Background: Freezing of gait (FoG) is a common and debilitating condition in Parkinson's disease (PD) associated with executive dysfunction. A subtype of FoG does not respond to dopaminergic therapy and may be related to noradrenergic deficiency. This pilot study explores the effects of atomoxetine on gait in PD patients with dopaunresponsive FoG using a novel paradigm for objective gait assessment. Findings: Ten patients with PD and dopa-unresponsive FoG were enrolled in this eight-week open label pilot study. Assessments included an exploratory gait analysis protocol that quantified spatiotemporal parameters during straight-away walking and turning, while performing a dual task. Clinical, and subjective assessments of gait, quality of life, and safety were also administered. The primary outcome was a validated subjective assessment for FoG (FOG-Q). Atomoxetine was well tolerated, however, no significant change was observed in the primary outcome. The gait analysis protocol correlated well with clinical scales, but not with subjective assessments. DBS patients were more likely to increase gait velocity (p = 0.033), and improved in other clinical assessments. Conclusions: Objective gait analysis protocols assessing gait while dual tasking are feasible and useful for this patient population, and may be superior correlates of FoG severity than subjective measures. These findings can inform future trials in this population. C1 [Revuelta, Gonzalo J.; Delambo, Amy; Hinson, Vanessa K.] Med Univ S Carolina, Coll Med, Dept Neurol, Movement Disorders Div, Charleston, SC 29425 USA. [Embry, Aaron; Gregory, Chris; Kautz, Steve] Med Univ S Carolina, Coll Hlth Profess, Ctr Rehabil Res Neurol Condit, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Elm, Jordan J.] Med Univ S Carolina, Dept Publ Hlth Sci, Coll Med, Charleston, SC 29425 USA. [Gregory, Chris; Kautz, Steve] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Revuelta, GJ (reprint author), Med Univ S Carolina, Coll Med, Dept Neurol, Movement Disorders Div, 208B Rutledge Ave,MSC 108, Charleston, SC 29425 USA. EM revuelta@musc.edu FU NCATS NIH HHS [UL1 TR000062]; NINDS NIH HHS [K23 NS091391] NR 12 TC 1 Z9 1 U1 3 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2047-9158 J9 TRANSL NEURODEGENER JI Transl. Neurodegener. PD DEC 10 PY 2015 VL 4 AR UNSP 24 DI 10.1186/s40035-015-0047-8 PG 4 WC Neurosciences SC Neurosciences & Neurology GA CY3OK UT WOS:000366318900001 PM 26693006 ER PT J AU Spence, T De Souza, R Dou, YN Stapleton, S Reilly, RM Allen, C AF Spence, Tara De Souza, Raquel Dou, Yannan Stapleton, Shawn Reilly, Raymond M. Allen, Christine TI Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies SO JOURNAL OF CONTROLLED RELEASE LA English DT Article DE Nanomedicine; Tumor microenvironment; Functional imaging; Molecular imaging; Response assessment; Patient stratification; Companion diagnostic imaging ID POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; PEGYLATED LIPOSOMAL DOXORUBICIN; METASTATIC BREAST-CANCER; TUMOR XENOGRAFT MODEL; CONTRAST-ENHANCED MRI; INTEGRIN ALPHA(V)BETA(3) EXPRESSION; MESOPOROUS SILICA NANOPARTICLES; TEMPERATURE-SENSITIVE LIPOSOMES; INTENSITY FOCUSED ULTRASOUND AB Functional andmolecular imaging has become increasingly used to evaluate interpatient and intrapatient tumor heterogeneity. Imaging allows for assessment of microenvironment parameters including tumor hypoxia, perfusion and proliferation, as well as tumor metabolism and the intratumoral distribution of specific molecular markers. Imaging information may be used to stratify patients for targeted therapies, and to define patient populations that may benefit from alternative therapeutic approaches. It also provides a method for non-invasive monitoring of treatment response at earlier time-points than traditional cues, such as tumor shrinkage. Further, companion diagnostic imaging techniques are becoming progressively more important for development and clinical implementation of targeted therapies. Imaging-based companion diagnostics are likely to be essential for the validation and FDA approval of targeted nanotherapies and macromolecular medicines. This review describes recent clinical advances in the use of functional and molecular imaging to evaluate the tumor microenvironment. Additionally, this article focuses on image-based assessment of distribution and anti-tumor effect of nano-and macromolecular systems. (C) 2015 Elsevier B.V. All rights reserved. C1 [Spence, Tara; De Souza, Raquel; Dou, Yannan; Reilly, Raymond M.; Allen, Christine] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada. [Stapleton, Shawn] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Reilly, Raymond M.] Univ Toronto, Dept Med Imaging, Toronto, ON M5S 3E2, Canada. RP Allen, C (reprint author), Univ Toronto, Leslie Dan Fac Pharm, 144 Coll St, Toronto, ON M5S 3M2, Canada. EM cj.allen@utoronto.ca FU CIHR operating grant FX The authors extend their gratitude to Huang Huang for helpful discussions and information on inorganic nanoparticles. C. Allen acknowledges funding from a CIHR operating grant and GSK for a chair in pharmaceutics and drug delivery. NR 235 TC 1 Z9 1 U1 11 U2 31 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-3659 EI 1873-4995 J9 J CONTROL RELEASE JI J. Control. Release PD DEC 10 PY 2015 VL 219 BP 295 EP 312 DI 10.1016/j.jconrel.2015.09.036 PG 18 WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy SC Chemistry; Pharmacology & Pharmacy GA CX3HK UT WOS:000365587800025 PM 26403800 ER PT J AU Uno, H Tian, L Claggett, B Wei, LJ AF Uno, Hajime Tian, Lu Claggett, Brian Wei, L. J. TI A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves SO STATISTICS IN MEDICINE LA English DT Article DE logrank test; perturbation resampling method; proportional hazards; robust tests ID LOG-RANK STATISTICS; CENSORED-DATA; LARGE SAMPLE; TIME; DISTRIBUTIONS; MODELS; TRIALS; LINE AB With censored event time observations, the logrank test is the most popular tool for testing the equality of two underlying survival distributions. Although this test is asymptotically distribution free, it may not be powerful when the proportional hazards assumption is violated. Various other novel testing procedures have been proposed, which generally are derived by assuming a class of specific alternative hypotheses with respect to the hazard functions. The test considered by Pepe and Fleming (1989) is based on a linear combination of weighted differences of the two Kaplan-Meier curves over time and is a natural tool to assess the difference of two survival functions directly. In this article, we take a similar approach but choose weights that are proportional to the observed standardized difference of the estimated survival curves at each time point. The new proposal automatically makes weighting adjustments empirically. The new test statistic is aimed at a one-sided general alternative hypothesis and is distributed with a short right tail under the null hypothesis but with a heavy tail under the alternative. The results from extensive numerical studies demonstrate that the new procedure performs well under various general alternatives with a caution of a minor inflation of the type I error rate when the sample size is small or the number of observed events is small. The survival data from a recent cancer comparative study are utilized for illustrating the implementation of the process. Copyright (c) 2015 John Wiley & Sons, Ltd. C1 [Uno, Hajime] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Uno, Hajime] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Tian, Lu] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Claggett, Brian] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA. [Wei, L. J.] Harvard Univ, Dept Biostat, Boston, MA 02115 USA. RP Uno, H (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, 450 Brookline Ave, Boston, MA 02115 USA. EM huno@jimmy.harvard.edu FU NIH [R01-HL089778, R01-GM079330, R01-AI024643, UM1AI068616, UM1AI068634] FX The authors are grateful to the reviewers for insightful comments/suggestions on the manuscript. They also thank the Eastern Cooperative Oncology Group for permission to use the data. This work was supported in part by grants R01-HL089778, R01-GM079330, R01-AI024643, UM1AI068616 and UM1AI068634 from the NIH. NR 34 TC 2 Z9 2 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD DEC 10 PY 2015 VL 34 IS 28 BP 3680 EP 3695 DI 10.1002/sim.6591 PG 16 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA CV0KX UT WOS:000363940700004 PM 26194988 ER PT J AU Senger, S Sapone, A Fiorentino, MR Mazzarella, G Lauwers, GY Fasano, A AF Senger, Stefania Sapone, Anna Fiorentino, Maria Rosaria Mazzarella, Giuseppe Lauwers, Gregory Y. Fasano, Alessio TI Celiac Disease Histopathology Recapitulates Hedgehog Downregulation, Consistent with Wound Healing Processes Activation SO PLOS ONE LA English DT Article ID RESTRICTED T-CELLS; STEM-CELLS; SMALL-INTESTINE; SMOOTH-MUSCLE; INTERFERON-GAMMA; GENE-EXPRESSION; MOUSE INTESTINE; SONIC HEDGEHOG; IN-VITRO; CRYPT AB Background In celiac disease (CD), intestinal epithelium damage occurs secondary to an immune insult and is characterized by blunting of the villi and crypt hyperplasia. Similarities between Hedgehog (Hh)/BMP4 downregulation, as reported in a mouse model, and CD histopathology, suggest mechanistic involvement of Hh/BMP4/WNT pathways in proliferation and differentiation of immature epithelial cells in the context of human intestinal homeostasis and regeneration after damage. Herein we examined the nature of intestinal crypt hyperplasia and involvement of Hh/BMP4 in CD histopathology. Methods and Findings Immunohistochemistry, qPCR and in situ hybridization were used to study a cohort of 24 healthy controls (HC) and 24 patients with diagnosed acute celiac disease (A-CD) intestinal biopsies. In A-CD we observed an increase in cells positive for Leucin-rich repeat-containing G protein-coupled receptor 5 (LGR5), an epithelial stem cell specific marker and expansion of WNT responding compartment. Further, we observed alteration in number and distribution of mesenchymal cells, predicted to be part of the intestinal stem cells niche. At the molecular level we found downregulation of indian hedgehog (IHH) and other components of the Hh pathway, but we did not observe a concurrent downregulation of BMP4. However, we observed upregulation of BMPs antagonists, gremlin 1 and gremlin 2. Conclusions Our data suggest that acute CD histopathology partially recapitulates the phenotype reported in Hh knockdown models. Specifically, Hh/BMP4 paradigm appears to be decoupled in CD, as the expansion of the immature cell population does not occur consequent to downregulation of BMP4. Instead, we provide evidence that upregulation of BMP antagonists play a key role in intestinal crypt hyperplasia. This study sheds light on the molecular mechanisms underlying CD histopathology and the limitations in the use of mouse models for celiac disease. C1 [Senger, Stefania; Sapone, Anna; Fiorentino, Maria Rosaria; Fasano, Alessio] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mucosal Immunol & Biol Res,Children & Celiac, Charlestown, MA 02129 USA. [Sapone, Anna] Beth Israel Deaconess Med Ctr, Celiac Ctr, Div Gastroenterol, Dept Med, Boston, MA 02215 USA. [Sapone, Anna] Harvard Univ, Sch Med, Boston, MA USA. [Mazzarella, Giuseppe] CNR, Inst Food Sci, I-83100 Avellino, Italy. [Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Fasano, A (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mucosal Immunol & Biol Res,Children & Celiac, Charlestown, MA 02129 USA. EM afasano@mgh.harvard.edu OI Fiorentino, Maria R/0000-0001-5318-7313 FU NIH grant [R01DK048373] FX The authors declare that the study entitled: "Celiac Disease Histopathology Recapitulates Hedgehog Downregulation, Consistent with Wound Healing Processes Activation" was funded exclusively by NIH grant, R01DK048373 to AF and there was no additional external funding received for this study. NR 42 TC 2 Z9 2 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 9 PY 2015 VL 10 IS 12 AR e0144634 DI 10.1371/journal.pone.0144634 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ1YX UT WOS:000366903300063 PM 26649570 ER PT J AU Dalela, M Shrivastav, TG Kharbanda, S Singh, H AF Dalela, Manu Shrivastav, T. G. Kharbanda, Surender Singh, Harpal TI pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice SO ACS APPLIED MATERIALS & INTERFACES LA English DT Article DE poly(styrene-co-maleic acid); paclitaxel; pharmacokinetics; EAT; BALB/c mice ID CELL LUNG-CANCER; PHASE-II TRIAL; IN-VIVO EVALUATION; LOADED NANOPARTICLES; CREMOPHOR-FREE; GENEXOL-PM; CONTROLLED-RELEASE; VITRO; FORMULATION; TAXOL AB In the present study, we have synthesized poly(styrene-co-maleic anhydride), a biocompatible copolymer that was further conjugated with paclitaxel (PTX) via ester linkage and self-assembled to form poly(styrene-co-maleic acid)-paclitaxel (PSMAC-PTX) nanopartides (NPs). The in vitro release of PTX from PSMAC-PTX NPs showed a higher release at lower pH than at the physiological pH of 7.4, confirming its pH-dependent release. The cell viability of PSMAC-PTX nanopartides was evaluated using MTT assay. IC50 values of 9.05-18.43 ng/mL of PTX equivalent were observed in various cancer cell lines after 72 h of incubation. Confocal microscopy, Western blotting, and Flow cytometry results further supported that the cellular uptake and apoptosis of cancer cells with PSMAC-PTX NPs. Pharmacokinetic studies revealed that the conjugation of PTX to the PSMAC copolymer not only increased the plasma and tumor C-max of PTX but also prolonged its plasma half-life and retention in tumor via enhanced permeability and retention (EPR) effect. Administration of PSMAC-PTX NPs showed significant tumor growth inhibition with improved apoptosis effects in vivo on Ehrlich Ascites Tumor (EAT)-bearing BALB/c syngeneic mice in comparison with Taxol, without showing any cytotoxicity. On the basis of preliminary results, no subacute toxicity was observed in major organs, tissues and hematological system up to a dosage of 60 mg/kg body weight in mice. Therefore, PSMAC-PTX NPs may be considered as an alternative nanodrug delivery system for the delivery of PTX in solid tumors. C1 [Dalela, Manu; Singh, Harpal] Indian Inst Technol, Ctr Biomed Engn, New Delhi 110016, India. [Dalela, Manu; Singh, Harpal] All India Inst Med Sci, Biomed Engn Unit, New Delhi 110029, India. [Shrivastav, T. G.] Natl Inst Hlth & Family Welfare, Dept Reprod Biomed, Delhi 110067, India. [Kharbanda, Surender] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. RP Singh, H (reprint author), Indian Inst Technol, Ctr Biomed Engn, New Delhi 110016, India. EM harpal@cbme.iitd.ac.in FU UGC; Department of Science and Technology, Government of India [RPO 2467] FX M.D. acknowledges UGC for SRF fellowship and the Department of Science and Technology (Project No. RPO 2467), Government of India, for financial support. Thanks to Dr. Sandeep Kumar Dixit (Department of Chemistry, Delhi University) for help in conjugation studies, Dr. Gaurav Verma (CSIR-IGIB, New Delhi) for help with Western Blotting experiments, and Dr. Ashish Kumar for help with the XPS studies at CSIR-IICT Hyderabad. NR 53 TC 4 Z9 4 U1 8 U2 38 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1944-8244 J9 ACS APPL MATER INTER JI ACS Appl. Mater. Interfaces PD DEC 9 PY 2015 VL 7 IS 48 BP 26530 EP 26548 DI 10.1021/acsami.5b07764 PG 19 WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Science & Technology - Other Topics; Materials Science GA CY3VX UT WOS:000366339100024 PM 26528585 ER PT J AU Delgado, C Grimes, BA Glidden, DV Shlipak, M Sarnak, MJ Johansen, KL AF Delgado, Cynthia Grimes, Barbara A. Glidden, David V. Shlipak, Michael Sarnak, Mark J. Johansen, Kirsten L. TI Association of Frailty based on self-reported physical function with directly measured kidney function and mortality SO BMC NEPHROLOGY LA English DT Article DE Self-report frailty; Kidney function and mortality ID BODY-COMPOSITION; RENAL-DISEASE; OLDER-ADULTS; HEMODIALYSIS; HEALTH; PERFORMANCE; PROGRESSION; PREVALENT; PROTEIN AB Background: Use of serum creatinine to estimate GFR may lead to underestimation of the association between self-reported frailty and kidney function. Our objectives were to evaluate the association of measured GFR (mGFR) with self-reported frailty among patients with CKD and to determine whether self-reported frailty was associated with death after adjusting for mGFR. Methods: Participants in the Modification of Diet in Renal Disease study (1989-1993) had GFR measured using iothalamate clearance (mGFR), and GFR was estimated based on the CKD-EPI creatinine (eGFRcr) and cystatin C (eGFRcys) equations. We defined self-reported frailty as three or more of: exhaustion, poor physical function, low physical activity, and low body weight. Death was ascertained through 2007 using the National Death Index and the United States Renal Data System. Results: Eight hundred twelve MDRD participants (97 %) had complete data on self-reported frailty (16 % prevalence, N = 130) and mGFR (mean (SD) 33.1 +/- 11.7 ml/min/1.73 m(2)). Higher GFR was associated with lower odds of self-reported frailty based on mGFR, (OR 0.71, 95 % CI 0.60-0.86 per 10 ml/min/1.73 m(2)), eGFRcr (OR 0.80, 95 % CI 0.67-0.94 per 10 ml/min/1.73 m2), and eGFRcys (OR 0.75, 95 % CI 0.62-0.90 per 10 ml/min/1.73 m(2)). Median follow-up was 17 (IQR 11-18) years, with 371 deaths. Self-reported frailty was associated with a higher risk of death (HR 1.71, 95 % CI 1.26-2.30), which was attenuated to a similar degree when mGFR (HR 1.48, 95 % CI 1.08-2.00), eGFRcr (HR 1.57, 95 % CI 1.15-2.10), or eGFRcys (HR 1.51, 95 % CI 1.10-2.10) was included as an indicator of kidney function. Conclusions: We found an inverse association between kidney function and self-reported frailty that was similar for mGFR, eGFR and eGFRcys. In this relatively healthy cohort of clinical trial participants with CKD, using serum creatinine to estimate GFR did not substantially alter the association of GFR with self-reported frailty or of self-reported frailty with death. C1 [Delgado, Cynthia; Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Grimes, Barbara A.; Glidden, David V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. RP Delgado, C (reprint author), San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. EM Cynthia.Delgado@ucsf.edu FU United States Department of Veteran Affairs, Clinical Science Research and Development Program [1IK2CX000527-01A2]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [1K24DK085153]; National Institute of Aging (NIA) [R01AG027002] FX Cynthia Delgado MD's work was supported by Career Development Award # 1IK2CX000527-01A2 from the United States Department of Veteran Affairs, Clinical Science Research and Development Program; Dr. Johansen is supported by 1K24DK085153 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).; Drs. Shlipak and Sarnak are supported by R01AG027002 from the National Institute of Aging (NIA). NR 21 TC 1 Z9 1 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD DEC 9 PY 2015 VL 16 AR 203 DI 10.1186/s12882-015-0202-6 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA CY1NE UT WOS:000366173000001 PM 26645070 ER PT J AU Tripathi, S Pohl, MO Zhou, YY Rodriguez-Frandsen, A Wang, GJ Stein, DA Moulton, HM DeJesus, P Che, JW Mulder, LCF Yenguez, E Andenmatten, D Pache, L Manicassamy, B Albrecht, RA Gonzalez, MG Nguyen, Q Brass, A Elledge, S White, M Shapira, S Hacohen, N Karlas, A Meyer, TF Shales, M Gatorano, A Johnson, JR Jang, G Johnson, T Verschueren, E Sanders, D Krogan, N Shaw, M Konig, R Stertz, S Garcia-Sastre, A Chanda, SK AF Tripathi, Shashank Pohl, Marie O. Zhou, Yingyao Rodriguez-Frandsen, Ariel Wang, Guojun Stein, David A. Moulton, Hong M. DeJesus, Paul Che, Jianwei Mulder, Lubbertus C. F. Yangueez, Emilio Andenmatten, Dario Pache, Lars Manicassamy, Balaji Albrecht, Randy A. Gonzalez, Maria G. Nguyen, Quy Brass, Abraham Elledge, Stephen White, Michael Shapira, Sagi Hacohen, Nir Karlas, Alexander Meyer, Thomas F. Shales, Michael Gatorano, Andre Johnson, Jeffrey R. Jang, Gwen Johnson, Tasha Verschueren, Erik Sanders, Doug Krogan, Nevan Shaw, Megan Koenig, Renate Stertz, Silke Garcia-Sastre, Adolfo Chanda, Sumit K. TI Meta- and Orthogonal Integration of Influenza "OMICs'' Data Defines a Role for UBR4 in Virus Budding SO CELL HOST & MICROBE LA English DT Article ID HOST FACTORS; REPLICATION; INFECTION; PROTEIN; SCREEN; ENTRY; COMPLEXES; AUTOPHAGY; PATHWAY; GENOME AB Several systems-level datasets designed to dissect host-pathogen interactions during influenza A infection have been reported. However, apparent discordance among these data has hampered their full utility toward advancing mechanistic and therapeutic knowledge. To collectively reconcile these datasets, we performed a meta-analysis of data from eight published RNAi screens and integrated these data with three protein interaction datasets, including one generated within the context of this study. Further integration of these data with global virus-host interaction analyses revealed a functionally validated biochemical landscape of the influenza-host interface, which can be queried through a simplified and customizable web portal (http://www.metascape.org/IAV). Follow-up studies revealed that the putative ubiquitin ligase UBR4 associates with the viral M2 protein and promotes apical transport of viral proteins. Taken together, the integrative analysis of influenza OMICs datasets illuminates a viral-host network of high-confidence human proteins that are essential for influenza A virus replication. C1 [Tripathi, Shashank; Wang, Guojun; Mulder, Lubbertus C. F.; Manicassamy, Balaji; Albrecht, Randy A.; Gonzalez, Maria G.; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA. [Tripathi, Shashank; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA. [Pohl, Marie O.; Yangueez, Emilio; Andenmatten, Dario] Univ Zurich, Inst Med Virol, CH-8057 Zurich, Switzerland. [Zhou, Yingyao; Che, Jianwei] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA. [Rodriguez-Frandsen, Ariel; DeJesus, Paul; Pache, Lars; Nguyen, Quy; Gatorano, Andre; Koenig, Renate; Chanda, Sumit K.] Sanford Burnham Prebys Med Discovery Inst, Immun & Pathogenesis Program, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA. [Stein, David A.; Moulton, Hong M.] Oregon State Univ, Coll Vet Med, Dept Biomed Sci, Corvallis, OR 97331 USA. [Brass, Abraham] Univ Massachusetts, Sch Med, Microbiol & Physiol Syst MaPS Dept, Worcester, MA 01605 USA. [Elledge, Stephen] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Genet, Boston, MA 02127 USA. [Elledge, Stephen] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. [White, Michael] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Shapira, Sagi] Columbia Univ, Dept Syst Biol, New York, NY 10032 USA. [Shapira, Sagi] Dept Microbiol & Immunol, New York, NY 10032 USA. [Hacohen, Nir] Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Karlas, Alexander; Meyer, Thomas F.] Max Planck Inst Infect Biol, D-10117 Berlin, Germany. [Shales, Michael; Johnson, Jeffrey R.; Jang, Gwen; Johnson, Tasha; Verschueren, Erik; Sanders, Doug; Krogan, Nevan] Univ Calif San Francisco, San Francisco, CA 94158 USA. [Koenig, Renate] Paul Ehrlich Inst, Host Pathogen Interact, D-63225 Langen, Germany. [Koenig, Renate] German Ctr Infect Res DZIF, D-63225 Langen, Germany. [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA. RP Konig, R (reprint author), Sanford Burnham Prebys Med Discovery Inst, Immun & Pathogenesis Program, Infect & Inflammatory Dis Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA. EM renate.koenig@pei.de; stertz.silke@virology.uzh.ch; adolfo.garcia-sastre@mssm.edu; schanda@sbpdiscovery.org RI Stertz, Silke/D-5254-2015; Rodriguez, Ariel/B-3908-2013; OI Rodriguez, Ariel/0000-0001-6850-5003; Albrecht, Randy/0000-0003-4008-503X; Garcia-Sastre, Adolfo/0000-0002-6551-1827; Meyer, Thomas F./0000-0002-6120-8679 FU NIAID [U19 AI106754]; Swiss National Science Foundation [31003A_135278]; AXA Research Fund; NIH [P50 GM085764]; National Institute of Allergy and Infectious Diseases of the NIH [1R01AI091786]; Burroughs Wellcome Fund; Bill and Melinda Gates Foundation FX We thank Andrea Gamarnik and David Leib for providing luciferase reporter viruses. Microscopy and FACS experiments were performed at the Microscopy Center of Research Excellence (CORE) and Flow Cytometry Core of the Icahn School of Medicine at Mount Sinai (ISMMS). We thank Rumana Huq and Lauren O'Rourke for their help in microscopy. We thank Tom Moran for providing anti-M2 E10 and anti-HA PY102 antibodies and Patricia Nigg and Nina Hein-Fuchs for help with figure graphics. These studies were partially supported by NIAID research grant U19 AI106754 to A.G.-S., R.A.A., D.S., H.M., P.D., L.P., S.K.C., N.K., and M.S. This work was also supported by a grant from the Swiss National Science Foundation (31003A_135278) to S. Stertz. M.O.P. is the beneficiary of a doctoral grant from the AXA Research Fund. Additionally, this work was supported by the NIH P50 GM085764 (S.K.C.). A.B. is supported by a grant (1R01AI091786) from the National Institute of Allergy and Infectious Diseases of the NIH, the Burroughs Wellcome Fund, and the Bill and Melinda Gates Foundation. S.E. is an Investigator with the Howard Hughes Medical Institute. NR 41 TC 23 Z9 23 U1 2 U2 14 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1931-3128 EI 1934-6069 J9 CELL HOST MICROBE JI Cell Host Microbe PD DEC 9 PY 2015 VL 18 IS 6 BP 723 EP 735 DI 10.1016/j.chom.2015.11.002 PG 13 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA CY1AL UT WOS:000366138400014 PM 26651948 ER PT J AU Kumar, DKV Eimer, WA Ramakrishnan, S AF Kumar, Deepak Kumar Vijaya Eimer, William A. Ramakrishnan, Sreejith TI Specificity of Toll-Like Receptor 2 and Dectin-1 Signaling in CNS Macrophages SO JOURNAL OF NEUROSCIENCE LA English DT Editorial Material ID BLOOD-BRAIN-BARRIER; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; NEUROTOXICITY; INFLAMMATION; MICROGLIA C1 [Kumar, Deepak Kumar Vijaya; Eimer, William A.] Massachusetts Gen Hosp, Dept Neurol, Genet & Aging Res Unit, Charlestown, MA 02129 USA. [Kumar, Deepak Kumar Vijaya; Eimer, William A.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Ramakrishnan, Sreejith] Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA. [Ramakrishnan, Sreejith] Stanford Univ, Dept Genet, Stanford, CA 94305 USA. RP Kumar, DKV (reprint author), 114 16th St, Charlestown, MA 02129 USA. EM kumar.deepak@mgh.harvard.edu NR 15 TC 0 Z9 0 U1 4 U2 4 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD DEC 9 PY 2015 VL 35 IS 49 BP 16015 EP 16017 DI 10.1523/JNEUROSCI.3453-15.2015 PG 3 WC Neurosciences SC Neurosciences & Neurology GA CX9WQ UT WOS:000366057000001 ER PT J AU Pereira, PJS Machado, GDB Danesi, GM Canevese, FF Reddy, VB Pereira, TCB Bogo, MR Cheng, YC Laedermann, C Talbot, S Lerner, EA Campos, MM AF Pereira, Paula J. S. Machado, Gustavo D. B. Danesi, Giuliano M. Canevese, Francesca F. Reddy, Vemuri B. Pereira, Talita C. B. Bogo, Mauricio R. Cheng, Yung-Chih Laedermann, Cedric Talbot, Sebastien Lerner, Ethan A. Campos, Maria M. TI GRPR/PI3K gamma: Partners in Central Transmission of Itch SO JOURNAL OF NEUROSCIENCE LA English DT Article DE AS605240; dry skin; GRPR; itch; PI3K gamma; spinal cord ID GASTRIN-RELEASING-PEPTIDE; SPINAL-CORD; SCRATCHING BEHAVIOR; BOMBESIN RECEPTORS; DISEASE STATES; MICE LACKING; MOUSE MODEL; PAIN; INHIBITION; RESPONSES AB The gastrin-releasing peptide (GRP) and its receptor (GRPR) are important components of itch transmission. Upstream, but not downstream, aspects of GRPR signaling have been investigated extensively. We hypothesize that GRPR signals in part through the PI3K gamma/Akt pathway. We used pharmacological, electrophysiological, and behavioral approaches to further evaluate GRPR downstream signaling pathways. Our data show that GRP directly activates small-size capsaicin-sensitive DRG neurons, an effect that translates into transient calcium flux and membrane depolarization (similar to 20 mV). GRPR activation also induces Akt phosphorylation, a proxy for PI3K gamma activity, in ex vivo naive mouse spinal cords and in GRPR transiently expressing HEK293 cells. The intrathecal injection of GRP led to intense scratching, an effect largely reduced by either GRPR antagonists or PI3K gamma inhibitor. Scratching behavior was also induced by the intrathecal injection of an Akt activator. In a dry skin model of itch, we show that GRPR blockade or PI3K gamma inhibition reversed the scratching behavior. Altogether, these findings are highly suggestive that GRPR is expressed by the central terminals of DRG nociceptive afferents, which transmit itch via the PI3K gamma/Akt pathway. C1 [Pereira, Paula J. S.; Bogo, Mauricio R.] Pontificia Univ Catolica Rio Grande Do Sul, Programa Posgrad Biol Celular & Mol, BR-90619900 Porto Alegre, RS, Brazil. [Machado, Gustavo D. B.; Danesi, Giuliano M.; Canevese, Francesca F.] Pontificia Univ Catolica Rio Grande Do Sul, Fac Med & Ciencias Saude, BR-90619900 Porto Alegre, RS, Brazil. [Pereira, Paula J. S.; Machado, Gustavo D. B.; Danesi, Giuliano M.; Canevese, Francesca F.; Bogo, Mauricio R.; Campos, Maria M.] Pontificia Univ Catolica Rio Grande Do Sul, Inst Pharmacol & Toxicol, BR-90619900 Porto Alegre, RS, Brazil. [Pereira, Talita C. B.; Campos, Maria M.] Pontificia Univ Catolica Rio Grande Do Sul, Programa Posgrad Med & Ciencias Saude, BR-90619900 Porto Alegre, RS, Brazil. [Campos, Maria M.] Pontificia Univ Catolica Rio Grande Do Sul, Fac Odontol, BR-90619900 Porto Alegre, RS, Brazil. [Pereira, Paula J. S.; Reddy, Vemuri B.; Lerner, Ethan A.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Boston, MA 02114 USA. [Pereira, Paula J. S.; Reddy, Vemuri B.; Lerner, Ethan A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Cheng, Yung-Chih; Laedermann, Cedric; Talbot, Sebastien] Childrens Hosp Boston, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA. RP Campos, MM (reprint author), Pontificia Univ Catolica Rio Grande Do Sul, Inst Pharmacol & Toxicol, Ave Ipiranga 6681, BR-90619900 Porto Alegre, RS, Brazil. EM elerner@partners.org; maria.campos@pucrs.br RI Bogo, Mauricio/D-7537-2013 OI Bogo, Mauricio/0000-0002-5728-9576 FU Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul [FAPERGS/2012-2525-0]; National Institutes of Health [R01AR057744, R21AR067399]; Canadian Institute of Health and Research; Programa de Doutorado Sanduiche no Exterior - Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior; National Council for Scientific and Technological Development of Brazil FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (Grant FAPERGS/2012-2525-0 to M.M.C.), the National Institutes of Health (Grants R01AR057744 and R21AR067399 to E.A.L.), the Canadian Institute of Health and Research (S.T.), and the Programa de Doutorado Sanduiche no Exterior, sponsored by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (P.J.S.P.). M.M.C. is a research career awardee of the National Council for Scientific and Technological Development of Brazil. We thank Rafael F. Zanin and Tuanlian Luo for their respective assistance with flow cytometry and technical input. NR 45 TC 0 Z9 0 U1 1 U2 4 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD DEC 9 PY 2015 VL 35 IS 49 BP 16272 EP 16281 DI 10.1523/JNEUROSCI.2310-15.2015 PG 10 WC Neurosciences SC Neurosciences & Neurology GA CX9WQ UT WOS:000366057000021 PM 26658875 ER PT J AU Anderson, CD Charidimou, A AF Anderson, Christopher D. Charidimou, Andreas TI Small DWI lesions after intracerebral hemorrhage Are perivascular spaces the missing link? SO NEUROLOGY LA English DT Editorial Material ID CEREBRAL AMYLOID ANGIOPATHY; SUPERFICIAL SIDEROSIS C1 [Anderson, Christopher D.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Anderson, Christopher D.] Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Boston, MA 02114 USA. [Charidimou, Andreas] Massachusetts Gen Hosp, Hemorrhag Stroke Res Program, Boston, MA 02114 USA. [Charidimou, Andreas] UCL, Inst Neurol, London, England. [Charidimou, Andreas] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England. RP Anderson, CD (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. EM cdanderson@mgh.harvard.edu NR 10 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD DEC 8 PY 2015 VL 85 IS 23 BP 2004 EP 2005 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA DF8WV UT WOS:000371642200006 PM 26546631 ER PT J AU Chen, DH Meneret, A Friedman, JR Korvatska, O Gad, A Bonkowski, ES Stessman, HA Doummar, D Mignot, C Anheim, M Bernes, S Davis, MY Damon-Perriere, N Degos, B Grabli, D Gras, D Hisama, FM Mackenzie, KM Swanson, PD Tranchant, C Vidailhet, M Winesett, S Trouillard, O Amendola, LM Dorschner, MO Weiss, M Eichler, EE Torkamani, A Roze, E Bird, TD Raskind, WH AF Chen, Dong-Hui Meneret, Aurelie Friedman, Jennifer R. Korvatska, Olena Gad, Alona Bonkowski, Emily S. Stessman, Holly A. Doummar, Diane Mignot, Cyril Anheim, Mathieu Bernes, Saunder Davis, Marie Y. Damon-Perriere, Nathalie Degos, Bertrand Grabli, David Gras, Domitille Hisama, Fuki M. Mackenzie, Katherine M. Swanson, Phillip D. Tranchant, Christine Vidailhet, Marie Winesett, Steven Trouillard, Oriane Amendola, Laura M. Dorschner, Michael O. Weiss, Michael Eichler, Evan E. Torkamani, Ali Roze, Emmanuel Bird, Thomas D. Raskind, Wendy H. TI ADCY5-related dyskinesia Broader spectrum and genotype-phenotype correlations SO NEUROLOGY LA English DT Article ID BENIGN HEREDITARY CHOREA; TYPE-5 ADENYLYL-CYCLASE; FACIAL MYOKYMIA FDFM; FAMILIAL DYSKINESIA; ADCY5 MUTATIONS; FOLLOW-UP; DYSTONIA; DYSFUNCTION; MICE AB Objective: To investigate the clinical spectrum and distinguishing features of adenylate cyclase 5 (ADCY5)-related dyskinesia and genotype-phenotype relationship. Methods: We analyzed ADCY5 in patients with choreiform or dystonic movements by exome or targeted sequencing. Suspected mosaicism was confirmed by allele-specific amplification. We evaluated clinical features in our 50 new and previously reported cases. Results: We identified 3 new families and 12 new sporadic cases with ADCY5 mutations. These mutations cause a mixed hyperkinetic disorder that includes dystonia, chorea, and myoclonus, often with facial involvement. The movements are sometimes painful and show episodic worsening on a fluctuating background. Many patients have axial hypotonia. In 2 unrelated families, a p.A726T mutation in the first cytoplasmic domain (C1) causes a relatively mild disorder of prominent facial and hand dystonia and chorea. Mutations p.R418W or p.R418Q in C1, de novo in 13 individuals and inherited in 1, produce a moderate to severe disorder with axial hypotonia, limb hypertonia, paroxysmal nocturnal or diurnal dyskinesia, chorea, myoclonus, and intermittent facial dyskinesia. Somatic mosaicism is usually associated with a less severe phenotype. In one family, a p.M1029K mutation in the C2 domain causes severe dystonia, hypotonia, and chorea. The progenitor, whose childhood-onset episodic movement disorder almost disappeared in adulthood, was mosaic for the mutation. Conclusions: ADCY5-related dyskinesia is a childhood-onset disorder with a wide range of hyperkinetic abnormal movements. Genotype-specific correlations and mosaicism play important roles in the phenotypic variability. Recurrent mutations suggest particular functional importance of residues 418 and 726 in disease pathogenesis. C1 [Chen, Dong-Hui; Bonkowski, Emily S.; Davis, Marie Y.; Swanson, Phillip D.; Weiss, Michael; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Korvatska, Olena; Raskind, Wendy H.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Stessman, Holly A.; Eichler, Evan E.] Univ Washington, Dept Genom Sci, Seattle, WA 98195 USA. [Hisama, Fuki M.; Amendola, Laura M.; Raskind, Wendy H.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Dorschner, Michael O.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Eichler, Evan E.] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] INSERM, U 1127, Paris, France. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] CNRS, UMR 7225, Paris, France. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] Univ Paris 06, Sorbonne Univ, UMR S 1127, Paris, France. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] ICM, Inst Cerveau & Moe Epiniere, Paris, France. [Meneret, Aurelie; Degos, Bertrand; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France. [Meneret, Aurelie; Degos, Bertrand; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] Hop La Pitie Salpetriere, AP HP, Dept Genet, Paris, France. [Friedman, Jennifer R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Friedman, Jennifer R.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA. [Friedman, Jennifer R.] Rady Childrens Hosp, San Diego, CA USA. [Gad, Alona] Tel Aviv Med Sch, Tel Aviv Brill Community Mental Hlth Ctr, Tel Aviv, Israel. [Doummar, Diane] Hop Trousseau, AP HP, Serv Neuropediat, F-75571 Paris, France. [Doummar, Diane] Ctr Reference Mouvements Anormaux Enfant Adulte, Paris, France. [Mignot, Cyril] Ctr Deficiences Intellectuelles Causes Rares, Paris, France. [Anheim, Mathieu; Tranchant, Christine] Hospices Civils Strasbourg, Dept Neurol, Illkirch Graffenstaden, France. [Anheim, Mathieu; Tranchant, Christine] Univ Strasbourg, FMTS, Illkirch Graffenstaden, France. [Anheim, Mathieu; Tranchant, Christine] Univ Strasbourg, CNRS UMR7104, INSERM U964, IGBMC, Illkirch Graffenstaden, France. [Bernes, Saunder] Phoenix Childrens Hosp, Phoenix, AZ USA. [Damon-Perriere, Nathalie] CHU Bordeaux, Explorat Fonct Syst Nerveux, Paris, France. [Gras, Domitille] Hop Robert Debre, AP HP, Serv Neuropediat, F-75019 Paris, France. [Mackenzie, Katherine M.] Stanford Univ, Lucile Packard Childrens Hosp, Dept Child Neurol, Palo Alto, CA 94304 USA. [Winesett, Steven] Johns Hopkins All Childrens Hosp, St Petersburg, FL USA. [Torkamani, Ali] Scripps Hlth, Scripps Translat Sci Inst, San Diego, CA USA. [Torkamani, Ali] Scripps Res Inst, San Diego, CA USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Raskind, Wendy H.] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. RP Raskind, WH (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM tomnroz@uw.edu; wendyrun@uw.edu FU NIH [R01 NS069719, R01 MH101221, U01 HG006476]; NIH (Clinical and Translational Science Award (CTSA) [UL1 TR001114-03]; Journees de Neurologie en Langue Francaise; INSERM (COSSEC); AP-HP (DRC-PHRC); Fondation pour la Recherche sur le Cerveau (FRC); DHOS-INSERM; ANR (French National Institutes); AMADYS; Alliance France Dystonie; Department of Veterans Affairs FX Supported in part by funds from the NIH (R01 NS069719) to W. H. R., R01 MH101221 to E. E. E., U01 HG006476 to A. T., Clinical and Translational Science Award (CTSA; UL1 TR001114-03) to A. T., Journees de Neurologie en Langue Francaise to A. M., INSERM (COSSEC) to E. R., AP-HP (DRC-PHRC) to E. R., Fondation pour la Recherche sur le Cerveau (FRC) to E. R., DHOS-INSERM to M. V., ANR (French National Institutes) to M. V., AMADYS to M. V., Alliance France Dystonie to A. M., and the Department of Veterans Affairs (T.D.B., W.H.R.). NR 30 TC 13 Z9 13 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD DEC 8 PY 2015 VL 85 IS 23 BP 2026 EP 2035 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DF8WV UT WOS:000371642200010 PM 26537056 ER PT J AU Augsberger, A Yeung, A Dougher, M Hahm, HC AF Augsberger, Astraea Yeung, Albert Dougher, Meaghan Hahm, Hyeouk Chris TI Factors influencing the underutilization of mental health services among Asian American women with a history of depression and suicide SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Asian Americans; Depression; Suicide; Help-seeking behaviors; Mental health utilization; Stigma; Women's health ID CHINESE-AMERICANS; HELP-SEEKING; COLLEGE-STUDENTS; ILLNESS STIGMA; UNITED-STATES; HIV RISK; CARE; IMMIGRANT; ATTITUDES; DISORDERS AB Background: Despite the substantially high prevalence of depression, suicidal ideation and suicide attempts among Asian American women who are children of immigrants, little is known about the prevalence of mental health utilization and the perceived barriers to accessing care. Methods: The data were from the Asian American Women's Sexual Health Initiative Project (AWSHIP), a 5-year mixed methods study at Boston University. The quantitative analysis examined the differential proportion of mental health utilization among 701 survey participants based on their mental health risk profile determined by current moderate to severe depression symptoms and lifetime history of suicidality. Mental health risk groups were created based on participants' current depression symptoms and history of suicide behaviors: Group 1-low-risk; Group 2-medium-risk; Group 3-high-risk. Mental health care utilization outcomes were measured by any mental health care, minimally adequate mental health care, and intensive mental health care. The qualitative analysis explored the perceived barriers to mental health care among 17 participants from the medium and high-risk groups. Results: Among 701 participants, 43 % of women (n = 299) reported that they either suffered from current moderate to severe depression symptoms or a lifetime history of suicidal ideation or suicide attempt. Although the high-risk group demonstrated statistically significant higher mental health utilization compared to the low and medium-risk groups, more than 60 % of the high-risk group did not access any mental health care, and more than 80 % did not receive minimally adequate care. The qualitative analysis identified three underutilization factors: Asian family contributions to mental health stigma, Asian community contributions to mental health stigma, and a mismatch between cultural needs and available services. Conclusions: Despite the high prevalence of depression and suicidal behaviors among young Asian American women in the sample, the proportion of mental health care utilization was extremely low. The qualitative analysis underscores the influence of Asian family and community stigma on mental health utilization and the lack of culturally appropriate mental health interventions. Prevention and intervention efforts should focus on raising mental health awareness in the Asian American community and offering culturally sensitive services. C1 [Augsberger, Astraea; Dougher, Meaghan; Hahm, Hyeouk Chris] Boston Univ, Sch Social Work, Boston, MA 02215 USA. [Yeung, Albert] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Yeung, Albert] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Augsberger, A (reprint author), Boston Univ, Sch Social Work, Boston, MA 02215 USA. EM augsberg@bu.edu FU National Institute of Mental Health [1K01 MH 086366-01A1, 1R34MH099943-01A1] FX This study was supported by grants 1K01 MH 086366-01A1, a Mentored Research Scientist Development Award, and 1R34MH099943-01A1, a Clinical Trial Planning Grant, both from the National Institute of Mental Health. We thank all the Asian American women for participating in the "Asian-American Women's Health Initiative Project (AWSHIP)" project and sharing their vivid and candid stories with us. We thank them for their openness, courage, and contributions to science. NR 51 TC 2 Z9 2 U1 7 U2 18 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD DEC 8 PY 2015 VL 15 AR 542 DI 10.1186/s12913-015-1191-7 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CY4CE UT WOS:000366355400001 PM 26645481 ER PT J AU Bellinger, AM Arteaga, CL Force, T Humphreys, BD Demetri, GD Druker, BJ Moslehi, JJ AF Bellinger, Andrew M. Arteaga, Carlos L. Force, Thomas Humphreys, Benjamin D. Demetri, George D. Druker, Brian J. Moslehi, Javid J. TI Cardio-Oncology How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery SO CIRCULATION LA English DT Review DE cardiotoxicity; drug evaluation; molecular targeted therapy; pre-eclampsia; protein-tyrosine kinases; translational medical research ID TOLL-LIKE RECEPTOR-4; ALTERNATIVELY SPLICED FORMS; EXTRA DOMAIN; CELLULAR FIBRONECTIN; REPERFUSION INJURY; ISCHEMIC-STROKE; EIIIA SEGMENT; BRAIN-DAMAGE; RAT; INFLAMMATION AB Cardio-oncology (the cardiovascular care of cancer patients) has developed as a new translational and clinical field based on the expanding repertoire of mechanism-based cancer therapies. Although these therapies have changed the natural course of many cancers, several may also lead to cardiovascular complications. Many new anticancer drugs approved over the past decade are " targeted" kinase inhibitors that interfere with intracellular signaling contributing to tumor progression. Unexpected cardiovascular and cardiometabolic effects of patient treatment with these inhibitors have provided unique insights into the role of kinases in human cardiovascular biology. Today, an ever-expanding number of cancer therapies targeting novel kinases and other specific cellular and metabolic pathways are being developed and tested in oncology clinical trials. Some of these drugs may affect the cardiovascular system in detrimental ways and others perhaps in beneficial ways. We propose that the numerous ongoing oncology clinical trials are an opportunity for closer collaboration between cardiologists and oncologists to study the cardiovascular and cardiometabolic changes caused by the modulation of these pathways in patients. In this regard, cardio-oncology represents an opportunity and a novel platform for basic and translational investigation and can serve as a potential avenue for optimization of anticancer therapies and for cardiovascular research and drug discovery. C1 Univ Iowa, Dept Internal Med, Iowa City, IA USA. [Bellinger, Andrew M.; Demetri, George D.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Arteaga, Carlos L.; Moslehi, Javid J.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA. [Force, Thomas; Moslehi, Javid J.] Vanderbilt Univ, Sch Med, Div Cardiovasc, Nashville, TN 37212 USA. [Arteaga, Carlos L.; Force, Thomas; Moslehi, Javid J.] Vanderbilt Univ, Sch Med, Cardiooncol Program, Nashville, TN 37232 USA. [Humphreys, Benjamin D.; Moslehi, Javid J.] Washington Univ, Dept Med, Med Ctr, St Louis, MO USA. [Demetri, George D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Demetri, George D.] Harvard Univ, Sch Med, Ludwig Ctr Harvard, Boston, MA 02115 USA. [Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA. RP Moslehi, JJ (reprint author), Vanderbilt Univ, Med Ctr, Cardiooncol Program, 2220 Pierce Ave, Nashville, TN 37232 USA. EM javid.moslehi@vanderbilt.edu OI Force, Thomas/0000-0002-0450-8659 FU National Institutes of Health [T32 5T32HL007604-29]; Ludwig Center at Harvard; Pan Mass Challenge; Russo Family Fund for GIST Research; Gastrointestinal Cancer SPORE grant at the Dana-Farber Cancer Institute from the US National Cancer Institute [1P50CA127003-05] FX Dr Bellinger was supported in part by National Institutes of Health grant T32 5T32HL007604-29. Dr Druker is an investigator for the Howard Hughes Medical Institute. Dr Demetri is supported by the following: Ludwig Center at Harvard, The Pan Mass Challenge via Paul's Posse, the Russo Family Fund for GIST Research, and Gastrointestinal Cancer SPORE grant 1P50CA127003-05 at the Dana-Farber Cancer Institute from the US National Cancer Institute. NR 34 TC 13 Z9 13 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 8 PY 2015 VL 132 IS 23 BP 2248 EP 2258 DI 10.1161/CIRCULATIONAHA.115.010484 PG 11 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX7DH UT WOS:000365861100009 PM 26644247 ER PT J AU Redfield, MM Anstrom, KJ Levine, JA Borlaug, B Chen, H LeWinter, MM Joseph, SM Shah, SJ Semigran, MJ Felker, GM Cole, RT Reeves, G Tedford, RJ Tang, W McNulty, SE Velazquez, EJ Shah, MR Braunwald, E AF Redfield, Margaret M. Anstrom, Kevin J. Levine, James A. Borlaug, Barry Chen, Horng LeWinter, Martin M. Joseph, Susan M. Shah, Sanjiv J. Semigran, Marc J. Felker, G. M. Cole, Robert T. Reeves, Gordon Tedford, Ryan J. Tang, Wilson McNulty, Steven E. Velazquez, Eric J. Shah, Monica R. Braunwald, Eugene CA NHLBI Heart Failure Clinical Rsch TI Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction (NEAT-HFpEF) SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium CY NOV 15-19, 2015 CL Chicago, IL SP Amer Heart Assoc C1 [Redfield, Margaret M.; Borlaug, Barry; Chen, Horng] Mayo Clin & Mayo Fdn, Cardiovasc Dis, Rochester, MN USA. [Anstrom, Kevin J.; McNulty, Steven E.; Velazquez, Eric J.] Duke Clin Rsch Inst, Outcomes, Durham, NC USA. [Levine, James A.] Mayo Clin & Mayo Fdn, Cardiovasc Dis, Scottsdale, AZ USA. [LeWinter, Martin M.] Univ Vermont, Med Ctr, Div Cardiol, Burlington, VT USA. [Joseph, Susan M.] Washington Univ, Sch Med, Div Cardiol, St Louis, MO USA. [Shah, Sanjiv J.] Northwestern Univ, Div Cardiol, Chicago, IL 60611 USA. [Semigran, Marc J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Felker, G. M.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA. [Cole, Robert T.] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA. [Reeves, Gordon] Thomas Jefferson Univ, Div Cardiol, Philadelphia, PA 19107 USA. [Tedford, Ryan J.] Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD USA. [Tang, Wilson] Cleveland Clin Fdn, Cardiovasc Dis, Cleveland, OH 44195 USA. [Shah, Monica R.] NHLBI, NIH, Bethesda, MD 20892 USA. [Braunwald, Eugene] Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 8 PY 2015 VL 132 IS 23 MA 13362 BP 2268 EP 2268 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX7DH UT WOS:000365861100014 ER PT J AU Teerlink, JR Felker, GM McMurray, JJV Solomon, SD Monsalvo, ML Legg, J Malik, FI Honarpour, N AF Teerlink, John R. Felker, G. Michael McMurray, John J. V. Solomon, Scott D. Monsalvo, Maria Laura Legg, Jason Malik, Fady I. Honarpour, Narimon CA COSMIC-HF Investigators TI Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): Final Results from a Double-blind, Randomized, Placebo-controlled, Multicenter Study SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium CY NOV 15-19, 2015 CL Chicago, IL SP Amer Heart Assoc C1 [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Felker, G. Michael] Duke Univ, Sch Med, Durham, NC USA. [McMurray, John J. V.] Univ Glasgow, Glasgow, Lanark, Scotland. [Solomon, Scott D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Solomon, Scott D.] Harvard Univ, Sch Med, Boston, MA USA. [Monsalvo, Maria Laura; Legg, Jason; Honarpour, Narimon] Amgen Inc, Thousand Oaks, CA 91320 USA. [Malik, Fady I.] Cytokinetics Inc, San Francisco, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 8 PY 2015 VL 132 IS 23 MA 24294 BP 2269 EP 2269 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX7DH UT WOS:000365861100017 ER PT J AU Bonaca, MP Bhatt, DL Ophuis, TO Steg, PG Storey, R Cohen, M Kuder, J Im, K Magnani, G Budaj, A Theroux, P Hamm, C Spinar, J Kiss, R Dalby, A Ardissino, D Kontny, F Aylward, P Jensen, EC Held, P Sabatine, MS AF Bonaca, Marc P. Bhatt, Deepak L. Ophuis, Ton Oude Steg, P. Gabriel Storey, Robert Cohen, Marc Kuder, Julia Im, KyungAh Magnani, Giulia Budaj, Andrej Theroux, Pierre Hamm, Christian Spinar, Jindrich Kiss, Robert Dalby, Anthony Ardissino, Diego Kontny, Frederic Aylward, Philip Jensen, Eva C. Held, Peter Sabatine, Marc S. TI Long-Term Tolerability of Ticagrelor in the PEGASUS-TIMI 54 Trial SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium CY NOV 15-19, 2015 CL Chicago, IL SP Amer Heart Assoc DE Ticagrelor; Coronary heart disease; Antiplatelet drugs; Prevention; Myocardial infarction C1 [Bonaca, Marc P.; Bhatt, Deepak L.; Kuder, Julia; Im, KyungAh; Magnani, Giulia; Sabatine, Marc S.] Brigham & Womens Hosp, TIMI Study Grp, CARDIOVASC MED, Med, Boston, MA 02115 USA. [Ophuis, Ton Oude] CWZ Hosp, Nijmegen, Netherlands. [Steg, P. Gabriel] Hop Bichat Claude Bernard, AP HP, Dept Cardiol, F-75877 Paris, France. [Storey, Robert] Univ Sheffield, Sheffield, S Yorkshire, England. [Cohen, Marc] Mt Sinai Sch Med, Beth Israel Med Ctr, Dept Med, Div Cardiovasc, New York, NY USA. [Budaj, Andrej] Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland. [Theroux, Pierre] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Hamm, Christian] Kerckhoff Heart Ctr, Cardiol, Bad Nauheim, Germany. [Spinar, Jindrich] Univ Hosp, Internal Cardiol Dept, Brno, Czech Republic. [Spinar, Jindrich] Fac Med, Brno, Czech Republic. [Kiss, Robert] Mil Hosp, Cardiol, Budapest, Hungary. [Dalby, Anthony] Milpark Hosp, Cardiol, Johannesburg, South Africa. [Ardissino, Diego] Univ Parma, Azienda Hosp, Cardiol, I-43100 Parma, Italy. [Kontny, Frederic] Stavanger Univ Hosp, Dept Cardiol, Stavanger, Norway. [Aylward, Philip] Flinders Med Ctr, Div Med, Cardiac Serv, Bedford Pk, SA, Australia. [Aylward, Philip] Flinders Med Ctr, Crit Care Serv, Bedford Pk, SA, Australia. [Jensen, Eva C.; Held, Peter] AstraZeneca, R&D, Molndal, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 8 PY 2015 VL 132 IS 23 MA 19689 BP 2272 EP 2272 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX7DH UT WOS:000365861100025 ER PT J AU Yeh, RW Secemsky, E Kereiakes, DJ Gershlick, A Cohen, DJ Spertus, JA Steg, PG Cutlip, DE Apruzzese, PK Massaro, JM Mauri, L AF Yeh, Robert W. Secemsky, Eric Kereiakes, Dean J. Gershlick, Anthony Cohen, David J. Spertus, John A. Steg, Philippe G. Cutlip, Donald E. Apruzzese, Patricia K. Massaro, Joseph M. Mauri, Laura TI Individualizing Treatment Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: An Analysis of the DAPT Study SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium CY NOV 15-19, 2015 CL Chicago, IL SP Amer Heart Assoc C1 [Yeh, Robert W.; Secemsky, Eric] Massachusetts Gen Hosp, Cardiol, Boston, MA 02114 USA. [Kereiakes, Dean J.] Christ Hosp, Heart & Vasc Ctr, Lindner Rsch Ctr, Cincinnati, OH 45219 USA. [Gershlick, Anthony] Univ Leicester, Cardiovasc Sci, Leicester, Leics, England. [Cohen, David J.] St Lukes Mid Amer Heart Inst, Cardiol, Kansas City, MO USA. [Spertus, John A.] St Lukes Mid Amer Heart Inst, Cardiovasc Rsch, Kansas City, MO USA. [Steg, Philippe G.] Univ Paris Diderot, Med, Paris, France. [Cutlip, Donald E.] Harvard Clin Rsch Inst, Clin Invest, Boston, MA USA. [Apruzzese, Patricia K.] Harvard Clin Rsch Inst, Biostat, Boston, MA USA. [Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Biostat, Boston, MA USA. [Mauri, Laura] Brigham & Womens Hosp, Med, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 8 PY 2015 VL 132 IS 23 MA 20297 BP 2272 EP 2273 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX7DH UT WOS:000365861100026 ER PT J AU Lei, C Berra, L Rezoagli, E Yu, BL Strelow, S Nordio, F Bonventre, J Xiong, LZ Zapol, W AF Lei, Chong Berra, Lorenzo Rezoagli, Emanuele Yu, Binglan Strelow, Sabrina Nordio, Francesco Bonventre, Joseph Xiong, Lize Zapol, Warren TI Prevention of Acute Kidney Injury by Nitric Oxide During and After Prolonged Cardiopulmonary Bypass. A Double Blind Randomized Controlled Trial SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium CY NOV 15-19, 2015 CL Chicago, IL SP Amer Heart Assoc C1 [Lei, Chong; Xiong, Lize] Xijing Hosp, Anesthesia, Xian, Peoples R China. [Berra, Lorenzo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Rezoagli, Emanuele] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Anesthesia Crit Care & Pain Med, Boston, MA USA. [Yu, Binglan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Anesthesia Ctr Crit Care Rsch, Boston, MA USA. [Strelow, Sabrina] Massachusetts Gen Hosp, Anesthesia, Boston, MA 02114 USA. [Nordio, Francesco] Harvard Univ, Sch Med, Brigham Women Hosp, Med, Boston, MA USA. [Bonventre, Joseph] Brigham & Womens Hosp, Div Renal, Med, Boston, MA 02115 USA. [Zapol, Warren] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 8 PY 2015 VL 132 IS 23 MA 20991 BP 2274 EP 2275 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX7DH UT WOS:000365861100032 ER PT J AU Goldstein, D Ailawadi, G Moskowitz, A Perrault, LP Parides, M Gelijns, A Hung, J Dagenais, F Goldfarb, AM Thourani, V Argenziano, M Gammie, J Mack, M Demers, P Atluri, P Rose, EA O'Sullivan, K Williams, D Bagiella, E Michler, R Weisel, R Miller, M Taddei-Peters, WC Smith, PK Moquete, E O'Gara, P Overbey, JR Kron, I Acker, MA AF Goldstein, Daniel Ailawadi, Gorav Moskowitz, Alan Perrault, Louis P. Parides, Michael Gelijns, Annetine Hung, Judy Dagenais, Francois Goldfarb, A. Marc Thourani, Vinod Argenziano, Michael Gammie, James Mack, Michael Demers, Philippe Atluri, Pavan Rose, Eric A. O'Sullivan, Karen Williams, Deborah Bagiella, Emilia Michler, Robert Weisel, Richard Miller, Marissa Taddei-Peters, Wendy C. Smith, Peter K. Moquete, Ellen O'Gara, Patrick Overbey, Jessica R. Kron, Irving Acker, Michael A. CA CTSN Investigators TI Two-Year Outcomes following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium CY NOV 15-19, 2015 CL Chicago, IL SP Amer Heart Assoc DE Cardiac surgery; Mitral regurgitation; Ischemic heart disease C1 [Goldstein, Daniel] Montefiore Med Ctr, Cardiothorac Surg, Bronx, NY 10467 USA. [Ailawadi, Gorav; Kron, Irving] Univ Virginia Hlth Syst, Cardiothorac Surg, Charlottesville, VA USA. [Moskowitz, Alan; Parides, Michael; Gelijns, Annetine; Rose, Eric A.; Williams, Deborah; Moquete, Ellen; Overbey, Jessica R.] Icahn Sch Med Mt Sinai, Populat Hlth Sci & Policy, New York, NY 10029 USA. [Perrault, Louis P.; Demers, Philippe] Montreal Heart Inst, Surg, Montreal, PQ H1T 1C8, Canada. [Hung, Judy] Massachusetts Gen Hosp, Cardiol, Boston, MA 02114 USA. [Dagenais, Francois] Inst Univ Cardiol & Pneumol Quebec, Cardiothorac Surg, Quebec City, PQ, Canada. [Goldfarb, A. Marc] Cleveland Clin, Thorac & Cardiovasc Surg, Cleveland, OH 44106 USA. [Thourani, Vinod] Emory Univ, Hosp Midtown, Cardiothorac Surg, Atlanta, GA 30322 USA. [Argenziano, Michael] Columbia Univ, Med Ctr, NewYork Presbyterian Hosp, Cardiac Surg, New York, NY USA. [Gammie, James] Univ Maryland, Cardiac Surg, Baltimore, MD 21201 USA. [Mack, Michael] Baylor Rsch Inst, Cardiovasc Med, Plano, TX USA. [Atluri, Pavan; Acker, Michael A.] Univ Penns Hlth Syst, Cardiovasc Surg, Philadelphia, PA USA. [O'Sullivan, Karen; Bagiella, Emilia] Icahn Sch Med Mt Sinai, Hlth Evidence & Policy, New York, NY 10029 USA. [Michler, Robert] Montefiore Einstein Heart Ctr, Cardiothorac Surg, Bronx, NY USA. [Weisel, Richard] Toronto Gen Hosp, Cardiovasc Surg, Toronto, ON, Canada. [Miller, Marissa] NHLBI, Cardiovasc Sci, NIH, Bethesda, MD 20892 USA. [Taddei-Peters, Wendy C.] NHLBI, Cardiovasc Sci, Bethesda, MD 20892 USA. [Smith, Peter K.; O'Gara, Patrick] Duke Univ, Surg, Durham, NC USA. [O'Gara, Patrick] Brigham & Womens Hosp, Cardiovasc Surg, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 8 PY 2015 VL 132 IS 23 MA 23690 BP 2276 EP 2276 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX7DH UT WOS:000365861100036 ER PT J AU El-Jawahri, A Paasche-Orlow, M Matlock, D Stevenson, L Lewis, E Stewart, G Chiang, YC Semigran, M Walker-Corkery, B Parks, K Bohossian, H Ooi, H Mann, E Volandes, A AF El-Jawahri, Areej Paasche-Orlow, Michael Matlock, Daniel Stevenson, Lynne Lewis, Eldrin Stewart, Garrick Chiang, Yuchiao Semigran, Marc Walker-Corkery, Beth Parks, Kimberly Bohossian, Hacho Ooi, Henry Mann, Eileen Volandes, Angelo TI A Randomized Controlled Trial of a Video Decision Support Tool to Depict Goals of Care and Resuscitation Options for Patients With Advanced Heart Failurec SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium CY NOV 15-19, 2015 CL Chicago, IL SP Amer Heart Assoc DE Cardiopulmonary resuscitation; Quality of medical care; Patient education/teaching psychosocial aspects C1 [El-Jawahri, Areej; Chiang, Yuchiao; Semigran, Marc; Walker-Corkery, Beth; Parks, Kimberly; Mann, Eileen; Volandes, Angelo] Massachusetts Gen Hosp, Med, Boston, MA 02114 USA. [Paasche-Orlow, Michael] Boston Med Ctr, Med, Boston, MA USA. [Matlock, Daniel] Univ Colorado, Med, Denver, CO 80202 USA. [Stevenson, Lynne; Lewis, Eldrin; Stewart, Garrick] Brigham & Womens Hosp, Med, Boston, MA 02115 USA. [Bohossian, Hacho] Newton Wellesley Hosp, Med, Newton, MA USA. [Ooi, Henry] Vanderbilt Univ, Med, Nashville, TN 37235 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 8 PY 2015 VL 132 IS 23 MA 18002 BP 2279 EP 2279 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX7DH UT WOS:000365861100043 ER PT J AU Aragam, KG Seth, M Gurm, HS AF Aragam, Krishna G. Seth, Milan Gurm, Hitinder S. TI REPLY: The Gaps in Cardiac Rehabilitation Referral The Elephant in the Room SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Letter ID PERCUTANEOUS CORONARY INTERVENTION; SYSTEM C1 [Aragam, Krishna G.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Aragam, KG (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB 8-852, Boston, MA 02114 USA. EM karagam@gmail.com NR 4 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD DEC 8 PY 2015 VL 66 IS 22 BP 2574 EP 2575 DI 10.1016/j.jacc.2015.09.064 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CY0KH UT WOS:000366094500020 PM 26653636 ER PT J AU Bong, KW Kim, JJ Cho, HS Lim, E Doyle, PS Irimia, D AF Bong, Ki Wan Kim, Jae Jung Cho, Hansang Lim, Eugene Doyle, Patrick S. Irimia, Daniel TI Synthesis of Cell-Adhesive Anisotropic Multifunctional Particles by Stop Flow Lithography and Streptavidin-Biotin Interactions SO LANGMUIR LA English DT Article ID MICROPARTICLES; PROTEIN; 3D; MICROSTRUCTURES; MICROARRAYS; CAPILLARY; TRANSPORT; RELEASE AB Cell-adhesive particles are of significant interest in biotechnology, the bioengineering of complex tissues, and biomedical research. Their applications range from platforms to increase the efficiency of anchorage-dependent cell culture to building blocks to loading cells in heterogeneous structures to clonal-population growth monitoring to cell sorting. Although useful, currently available cell-adhesive particles can accommodate only homogeneous cell culture. Here, we report the design of anisotropic hydrogel microparticles with tunable cell-adhesive regions as first step toward micropatterned cell cultures on particles. We employed stop flow lithography (SFL), the coupling reaction between amine and N-hydroxysuccinimide (NHS) and streptavidin biotin chemistry to adjust the localization of conjugated collagen and poly-L-lysine on the surface of microscale particles. Using the new particles, we demonstrate the attachment and formation of tight junctions between brain endothelial cells. We also demonstrate the geometric patterning of breast cancer cells on particles with heterogeneous collagen coatings. This new approach avoids the exposure of cells to potentially toxic photoinitiators and ultraviolet light and decouples in time the microparticle synthesis and the cell culture steps to take advantage of the most recent advances in cell patterning available for traditional culture substrates. C1 [Bong, Ki Wan; Cho, Hansang; Lim, Eugene; Irimia, Daniel] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Charlestown, MA 02129 USA. [Bong, Ki Wan] Korea Univ, Dept Chem & Biol Engn, Seoul 136713, South Korea. [Kim, Jae Jung; Doyle, Patrick S.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. RP Doyle, PS (reprint author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM pdoyle@mit.edu; dirimia@mgh.harvard.edu FU National Institutes of Health [GM092804]; National Science Foundation [CMMI-1120724, DMR-1006147]; Samsung FX We gratefully acknowledge support from the National Institutes of Health (GM092804), the National Science Foundation (CMMI-1120724 and DMR-1006147), and a Samsung Scholarship to J.J.K. We also thank Lynna Chen and Rathi Srinivas for insightful discussions. NR 34 TC 4 Z9 4 U1 4 U2 27 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0743-7463 J9 LANGMUIR JI Langmuir PD DEC 8 PY 2015 VL 31 IS 48 BP 13165 EP 13171 DI 10.1021/acs.langmuir.5b03501 PG 7 WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science, Multidisciplinary SC Chemistry; Materials Science GA CY2FD UT WOS:000366223300013 PM 26545155 ER PT J AU Fischer, M Quaas, M Nickel, A Engeland, K AF Fischer, Martin Quaas, Marianne Nickel, Annina Engeland, Kurt TI Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex SO ONCOTARGET LA English DT Article DE p53; CDKN1A; DREAM; CDE-CHR; p53-p21-DREAM-CDE/CHR pathway ID POLO-LIKE KINASE; INDUCED DOWN-REGULATION; SUPPRESSOR PROTEIN P53; HUMAN CANCER-CELLS; SCF-BETA-TRCP; DNA-DAMAGE; PLK1-DEPENDENT PHOSPHORYLATION; MITOTIC PROGRESSION; SPINDLE ORIENTATION; INDUCED APOPTOSIS AB The transcription factor p53 is central to cell cycle control by downregulation of cell cycle-promoting genes upon cell stress such as DNA damage. Survivin (BIRC5), CDC25C, and PLK1 encode important cell cycle regulators that are repressed following p53 activation. Here, we provide evidence that p53-dependent repression of these genes requires activation of p21 (CDKN1A, WAF1, CIP1). Chromatin immunoprecipitation (ChIP) data indicate that promoter binding of B-MYB switches to binding of E2F4 and p130 resulting in a replacement of the MMB (Myb-MuvB) by the DREAM complex. We demonstrate that this replacement depends on p21. Furthermore, transcriptional repression by p53 requires intact DREAM binding sites in the target promoters. The CDE and CHR cell cycle promoter elements are the sites for DREAM binding. These elements as well as the p53 response of Survivin, CDC25C, and PLK1 are evolutionarily conserved. No binding of p53 to these genes is detected by ChIP and mutation of proposed p53 binding sites does not alter the p53 response. Thus, a mechanism for direct p53-dependent transcriptional repression is not supported by the data. In contrast, repression by DREAM is consistent with most previous findings and unifies models based on p21-, E2F4-, p130-, and CDE/CHR-dependent repression by p53. In conclusion, the presented data suggest that the p53-p21-DREAM-CDE/CHR pathway regulates p53-dependent repression of Survivin, CDC25C, and PLK1. C1 [Fischer, Martin; Quaas, Marianne; Nickel, Annina; Engeland, Kurt] Univ Leipzig, Sch Med, Mol Oncol, D-04109 Leipzig, Germany. [Fischer, Martin] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med Oncol,Dana Farber Canc Inst,Dept Med, Boston, MA 02115 USA. RP Engeland, K (reprint author), Univ Leipzig, Sch Med, Mol Oncol, D-04109 Leipzig, Germany. EM engeland@medizin.uni-leipzig.de RI Fischer, Martin/I-4825-2014 OI Fischer, Martin/0000-0002-3429-1876 FU German Research Foundation (DFG); Universitat Leipzig within the program of Open Access Publishing; Freistaat Sachsen; Faculty of Medicine, University of Leipzig; Fritz Thyssen Foundation; Bundesministerium fur Bildung und Forschung (BMBF) through Interdisciplinary Center for Clinical Research (IZKF) at the University of Leipzig FX We are indebted to Carola Koschke and Andrea Rothe for expert technical assistance as well as Andreas Losche and Kathrin Jager at the IZKF Leipzig core unit for performing flow cytometry. We thank Bert Vogelstein for the kind gift of HCT116 cell lines, Larissa Litovchick and James DeCaprio for the LIN9 antibody. We thank Christine E. Engeland and Gerd Muller for critical reading of the manuscript. We acknowledge support from the German Research Foundation (DFG) and Universitat Leipzig within the program of Open Access Publishing.r This work was supported through a graduate fellowship provided by the Freistaat Sachsen and a junior research grant from the Faculty of Medicine, University of Leipzig (to MQ); a postdoctoral fellowship provided by the Fritz Thyssen Foundation (to MF); the Bundesministerium fur Bildung und Forschung (BMBF) through grants by the Interdisciplinary Center for Clinical Research (IZKF) at the University of Leipzig (to KE). NR 128 TC 5 Z9 5 U1 1 U2 9 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD DEC 8 PY 2015 VL 6 IS 39 BP 41402 EP 41417 PG 16 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CY0TR UT WOS:000366119600003 PM 26595675 ER PT J AU Bersani, F Lee, E Kharchenko, PV Xu, AW Liu, M Xega, K MacKenzie, OC Brannigan, BW Wittner, BS Jung, H Ramaswamy, S Park, PJ Maheswaran, S Ting, DT Haber, DA AF Bersani, Francesca Lee, Eunjung Kharchenko, Peter V. Xu, Andrew W. Liu, Mingzhu Xega, Kristina MacKenzie, Olivia C. Brannigan, Brian W. Wittner, Ben S. Jung, Hyunchul Ramaswamy, Sridhar Park, Peter J. Maheswaran, Shyamala Ting, David T. Haber, Daniel A. TI Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE satellites; reverse transcription; repeats; cancer ID NONCODING RNAS; HEAT-SHOCK; CELLS; TRANSCRIPTION; HYBRIDS; RETROTRANSPOSITION; HYPOMETHYLATION; HETEROCHROMATIN; CENTROMERES; ACTIVATION AB Aberrant transcription of the pericentromeric human satellite II (HSATII) repeat is present in a wide variety of epithelial cancers. In deriving experimental systems to study its deregulation, we observed that HSATII expression is induced in colon cancer cells cultured as xenografts or under nonadherent conditions in vitro, but it is rapidly lost in standard 2D cultures. Unexpectedly, physiological induction of endogenous HSATII RNA, as well as introduction of synthetic HSATII transcripts, generated cDNA intermediates in the form of DNA/RNA hybrids. Single molecule sequencing of tumor xenografts showed that HSATII RNA-derived DNA (rdDNA) molecules are stably incorporated within pericentromeric loci. Suppression of RT activity using small molecule inhibitors reduced HSATII copy gain. Analysis of whole-genome sequencing data revealed that HSATII copy number gain is a common feature in primary human colon tumors and is associated with a lower overall survival. Together, our observations suggest that cancer-associated derepression of specific repetitive sequences can promote their RNA-driven genomic expansion, with potential implications on pericentromeric architecture. C1 [Bersani, Francesca; Liu, Mingzhu; Xega, Kristina; MacKenzie, Olivia C.; Brannigan, Brian W.; Wittner, Ben S.; Ramaswamy, Sridhar; Maheswaran, Shyamala; Ting, David T.; Haber, Daniel A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Charlestown, MA 02129 USA. [Lee, Eunjung; Kharchenko, Peter V.; Xu, Andrew W.; Park, Peter J.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA. [Lee, Eunjung; Park, Peter J.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. [Kharchenko, Peter V.] Childrens Hosp, Hematol Oncol Program, Boston, MA 02115 USA. [Liu, Mingzhu; Haber, Daniel A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. [Jung, Hyunchul] Samsung Med Ctr, Seoul 135710, South Korea. [Ramaswamy, Sridhar; Ting, David T.; Haber, Daniel A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Park, Peter J.] Childrens Hosp, Informat Program, Boston, MA 02115 USA. [Maheswaran, Shyamala] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Ting, DT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Charlestown, MA 02129 USA. EM dting1@mgh.harvard.edu; dhaber@mgh.harvard.edu FU Howard Hughes Medical Institute; National Foundation for Cancer Research; National Cancer Institute [R01CA129933]; Burroughs Wellcome Trust; NIH [K12CA087723-11A1]; Department of Defense [W81XWH-13-1-0237]; Warshaw Institute for Pancreatic Cancer Research; Verville Family Pancreatic Cancer Research Fund; Eleanor and Miles Shore Fellowship; William Randolph Hearst Fund; Susan G. Komen for the Cure [KG09042]; NCI Federal Share Program and Income FX We thank M. Miri from the Massachusetts General Hospital (MGH) Tissue Repository for providing pathological specimens. We also thank N. J. Dyson and M. R. Motamedi for critically revising the manuscript, as well as R. Taulli and all laboratory members for helpful discussions. This work was supported by the Howard Hughes Medical Institute (D.A.H.), the National Foundation for Cancer Research (D.A.H.), National Cancer Institute (NCI) Grant R01CA129933 (to D.A.H. and F.B.), the Burroughs Wellcome Trust (D.T.T.), NIH Grant K12CA087723-11A1 (to D.T.T.), Department of Defense Grant W81XWH-13-1-0237 (to D.T.T.), the Warshaw Institute for Pancreatic Cancer Research (D.T.T.), the Verville Family Pancreatic Cancer Research Fund (D.T.T.), the Eleanor and Miles Shore Fellowship (to E.L.), the William Randolph Hearst Fund (E.L.), Susan G. Komen for the Cure Grant KG09042 (to S.M.), and the NCI Federal Share Program and Income (S.M.). NR 33 TC 9 Z9 9 U1 4 U2 8 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 8 PY 2015 VL 112 IS 49 BP 15148 EP 15153 DI 10.1073/pnas.1518008112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CX8YA UT WOS:000365989800049 PM 26575630 ER PT J AU Tanne, A Muniz, LR Puzio-Kuter, A Leonova, KI Gudkov, AV Ting, DT Monasson, R Cocco, S Levine, AJ Bhardwaj, N Greenbaum, BD AF Tanne, Antoine Muniz, Luciana R. Puzio-Kuter, Anna Leonova, Katerina I. Gudkov, Andrei V. Ting, David T. Monasson, Remi Cocco, Simona Levine, Arnold J. Bhardwaj, Nina Greenbaum, Benjamin D. TI Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE noncoding RNA; genome evolution; cancer immunology ID TOLL-LIKE RECEPTORS; VIRUS ATTENUATION; DNA METHYLATION; DENDRITIC CELLS; IMMUNE-SYSTEM; INNATE; REPEATS; MACROPHAGES; EPIGENETICS; RECOGNITION AB Recent studies have demonstrated abundant transcription of a set of noncoding RNAs (ncRNAs) preferentially within tumors as opposed to normal tissue. Using an approach from statistical physics, we quantify global transcriptome-wide motif use for the first time, to our knowledge, in human and murine ncRNAs, determining that most have motif use consistent with the coding genome. However, an outlier subset of tumor-associated ncRNAs, typically of recent evolutionary origin, has motif use that is often indicative of pathogen-associated RNA. For instance, we show that the tumor-associated human repeat human satellite repeat II (HSATII) is enriched in motifs containing CpG dinucleotides in AU-rich contexts that most of the human genome and human adapted viruses have evolved to avoid. We demonstrate that a key subset of these ncRNAs functions as immunostimulatory "self-agonists" and directly activates cells of the mononuclear phagocytic system to produce proinflammatory cytokines. These ncRNAs arise from endogenous repetitive elements that are normally silenced, yet are often very highly expressed in cancers. We propose that the innate response in tumors may partially originate from direct interaction of immunogenic ncRNAs expressed in cancer cells with innate pattern recognition receptors, and thereby assign a previously unidentified danger-associated function to a set of dark matter repetitive elements. These findings potentially reconcile several observations concerning the role of ncRNA expression in cancers and their relationship to the tumor microenvironment. C1 [Tanne, Antoine; Muniz, Luciana R.; Bhardwaj, Nina; Greenbaum, Benjamin D.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med Hematol & Med Oncol, New York, NY 10029 USA. [Puzio-Kuter, Anna; Levine, Arnold J.] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA. [Leonova, Katerina I.; Gudkov, Andrei V.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Ting, David T.] Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Monasson, Remi] CNRS, Lab Phys Theor, F-75005 Paris, France. [Monasson, Remi; Cocco, Simona] Ecole Normale Super, F-75005 Paris, France. [Cocco, Simona] CNRS, Lab Phys Stat, F-75005 Paris, France. [Levine, Arnold J.; Greenbaum, Benjamin D.] Princeton Univ Sch Nat Sci, Simons Ctr Syst Biol, Inst Adv Study, Princeton, NJ 08540 USA. [Greenbaum, Benjamin D.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA. RP Levine, AJ (reprint author), Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA. EM alevine@ias.edu; benjamin.greenbaum@mssm.edu OI Ting, David/0000-0002-3261-2322 FU NIH [National Cancer Institute (NCI)] [5P01CA087497-13]; NIH (NIAID) [5R01AI081848-05]; NCI [1R01CA180913-01A1]; Cancer Research Institute; NIH (NCI) [K12CA087723-11A1]; Department of Defense (US Army) [W81XWH-13-1-0237]; Burroughs Welcome Fund; L'Agence Nationale de la Recherche [ANR-13-BS04-0012-01] FX We thank Dr. K. Fitzgerald (University of Massachusetts Medical School), Dr. R. Vance (University of California, Berkeley), Dr. G. Barton (University of California, Berkeley), and the Biodefense and Emerging Infections Research Resources Repository [American Type Culture Collection/National Institute of Allergy and Infectious Diseases (NIAID)] for helping us collect murine immortalized macrophages. We also thank Dr. N. Vabret for many helpful discussions and A. Munk for all of his assistance. B.D.G. was supported by NIH [National Cancer Institute (NCI)] Grant 5P01CA087497-13; N.B. was supported by NIH (NIAID) Grants 5R01AI081848-05 and 5R01AI081848-05, NCI Grant 1R01CA180913-01A1, and the Cancer Research Institute; D.T.T. was supported by NIH (NCI) Grant K12CA087723-11A1, Department of Defense (US Army) Grant W81XWH-13-1-0237, and the Burroughs Welcome Fund; and R.M. and S.C. were supported by L'Agence Nationale de la Recherche Grant ANR-13-BS04-0012-01. NR 48 TC 10 Z9 11 U1 3 U2 16 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 8 PY 2015 VL 112 IS 49 BP 15154 EP 15159 DI 10.1073/pnas.1517584112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CX8YA UT WOS:000365989800050 PM 26575629 ER PT J AU Kijlstra, JD Hu, DJ Mittal, N Kausel, E van der Meer, P Garakani, A Domian, IJ AF Kijlstra, Jan David Hu, Dongjian Mittal, Nikhil Kausel, Eduardo van der Meer, Peter Garakani, Arman Domian, Ibrahim J. TI Integrated Analysis of Contractile Kinetics, Force Generation, and Electrical Activity in Single Human Stem Cell-Derived Cardiomyocytes SO STEM CELL REPORTS LA English DT Article ID MYOCYTE SHAPE; CARDIOTOXICITY; HEART; MODULATION; DYNAMICS; PLATFORM; VOLTAGE AB The quantitative analysis of cardiomyocyte function is essential for stem cell-based approaches for the in vitro study of human cardiac physiology and pathophysiology. We present a method to comprehensively assess the function of single human pluripotent stem cell-derived cardiomyocyte (hPSC-CMs) through simultaneous quantitative analysis of contraction kinetics, force generation, and electrical activity. We demonstrate that statistical analysis of movies of contracting hPSC-CMs can be used to quantify changes in cellular morphology over time and compute contractile kinetics. Using a biomechanical model that incorporates substrate stiffness, we calculate cardiomyocyte force generation at single-cell resolution and validate this approach with conventional traction force microscopy. The addition of fluorescent calcium indicators or membrane potential dyes allows the simultaneous analysis of contractility and calcium handling or action potential morphology. Accordingly, our approach has the potential for broad application in the study of cardiac disease, drug discovery, and cardiotoxicity screening. C1 [Kijlstra, Jan David; Hu, Dongjian; Domian, Ibrahim J.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Kijlstra, Jan David; Hu, Dongjian; Domian, Ibrahim J.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Kijlstra, Jan David; van der Meer, Peter] Univ Groningen, Univ Med Ctr Groningen, NL-9713 GZ Groningen, Netherlands. [Hu, Dongjian] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. [Mittal, Nikhil] Inst Bioengn & Nanotechnol, Singapore 138669, Singapore. [Kausel, Eduardo] MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA. [Garakani, Arman] Reify Corp, Saratoga, CA 95070 USA. [Domian, Ibrahim J.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Domian, IJ (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. EM domian@mgh.harvard.edu OI Mittal, Nikhil/0000-0002-2360-7134 FU NIH/National Heart, Lung, and Blood Institute [U01HL100408-01, 1K08 HL091209]; Dutch Heart Foundation [2013SB013] FX We thank the Massachusetts General Hospital Program in the Membrane Biology Microscopy Core Facility for contributions to the setup and image acquisition on the Nikon A1R. We thank Reify Corporation for the use of the Visible software. We thank C. Cowan from the Harvard Stem Cell Institute for the generous gift of the HUES-9 cell line and D. Eliot from the Murdoch Children's Research Institute for the generous gift of the HES-3 NKX2-5 eGFP/w cell line. We thank Nikita Shah for assistance with the data analysis and isolation of adult murine cardiomyocytes. This work was supported by grants from the NIH/National Heart, Lung, and Blood Institute (U01HL100408-01 and 1K08 HL091209) and a grant from the Dutch Heart Foundation (2013SB013). A.G. is a founder of Reify. NR 40 TC 5 Z9 5 U1 2 U2 6 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2213-6711 J9 STEM CELL REP JI Stem Cell Rep. PD DEC 8 PY 2015 VL 5 IS 6 BP 1226 EP 1238 DI 10.1016/j.stemcr.2015.10.017 PG 13 WC Cell & Tissue Engineering; Cell Biology SC Cell Biology GA CY1BY UT WOS:000366142900025 PM 26626178 ER PT J AU Dhaliwal, G AF Dhaliwal, Gurpreet TI The Greatest Generation SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID PHYSICIANS C1 [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Dhaliwal, G (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM gurpreet.dhaliwal@ucsf.edu NR 7 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 8 PY 2015 VL 314 IS 22 BP 2353 EP 2354 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CX8XT UT WOS:000365989100006 PM 26647253 ER PT J AU Incio, J Suboj, P Chin, SM Vardam-Kaur, T Liu, H Hato, T Babykutty, S Chen, I Deshpande, V Jain, RK Fukumura, D AF Incio, Joao Suboj, Priya Chin, Shan M. Vardam-Kaur, Trupti Liu, Hao Hato, Tai Babykutty, Suboj Chen, Ivy Deshpande, Vikram Jain, Rakesh K. Fukumura, Dai TI Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages SO PLOS ONE LA English DT Article ID HIGH-ENERGY DIET; ANTIDIABETIC DRUG METFORMIN; SP TRANSCRIPTION-FACTORS; IN-VIVO; DUCTAL ADENOCARCINOMA; MESENCHYMAL TRANSITION; CHRONIC INFLAMMATION; INSULIN-RESISTANCE; DIABETES-MELLITUS; CARCINOMA GROWTH AB Background Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic tumor with a dismal prognosis for most patients. Fibrosis and inflammation are hallmarks of tumor desmoplasia. We have previously demonstrated that preventing the activation of pancreatic stellate cells (PSCs) and alleviating desmoplasia are beneficial strategies in treating PDAC. Metformin is a widely used glucose-lowering drug. It is also frequently prescribed to diabetic pancreatic cancer patients and has been shown to associate with a better outcome. However, the underlying mechanisms of this benefit remain unclear. Metformin has been found to modulate the activity of stellate cells in other disease settings. In this study, we examine the effect of metformin on PSC activity, fibrosis and inflammation in PDACs. Methods/Results In overweight, diabetic PDAC patients and pre-clinical mouse models, treatment with metformin reduced levels of tumor extracellular matrix (ECM) components, in particular hyaluronan (HA). In vitro, we found that metformin reduced TGF-beta signaling and the production of HA and collagen-I in cultured PSCs. Furthermore, we found that metformin alleviates tumor inflammation by reducing the expression of inflammatory cytokines including IL-1 beta as well as infiltration and M2 polarization of tumor-associated macrophages (TAMs) in vitro and in vivo. These effects on macrophages in vitro appear to be associated with a modulation of the AMPK/STAT3 pathway by metformin. Finally, we found in our preclinical models that the alleviation of desmoplasia by metformin was associated with a reduction in ECM remodeling, epithelial-to-mesenchymal transition (EMT) and ultimately systemic metastasis. Conclusion Metformin alleviates the fibro-inflammatory microenvironment in obese/diabetic individuals with pancreatic cancer by reprogramming PSCs and TAMs, which correlates with reduced disease progression. Metformin should be tested/explored as part of the treatment strategy in overweight diabetic PDAC patients. C1 [Incio, Joao; Suboj, Priya; Chin, Shan M.; Vardam-Kaur, Trupti; Liu, Hao; Hato, Tai; Babykutty, Suboj; Chen, Ivy; Jain, Rakesh K.; Fukumura, Dai] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Res Inst, Edwin L Steele Labs,Dept Radiat Oncol, Boston, MA 02115 USA. [Incio, Joao] Hosp Sao Joao, Dept Internal Med, Oporto, Portugal. [Incio, Joao] Univ Porto, Fac Med, Inst Innovat & Res Heath,I3S, Metab Nutr & Endocrinol Grp,Dept Biochem, P-4100 Oporto, Portugal. [Suboj, Priya] St Xaviers Coll, Dept Bot & Biotechnol, Trivandrum, Kerala, India. [Liu, Hao] Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA. [Hato, Tai] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan. [Babykutty, Suboj] Mar Ivanios Coll, Dept Zool, Trivandrum, Kerala, India. [Chen, Ivy] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Deshpande, Vikram] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA. RP Jain, RK (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Res Inst, Edwin L Steele Labs,Dept Radiat Oncol, Boston, MA 02115 USA. EM jain@steele.mgh.harvard.edu; dai@steele.mgh.harvard.edu FU National Institutes of Health [R35-CA197743, CA80124, CA85140, CA96915, CA115767, CA126642]; Lustgarten Foundation; Foundation for Science and Technology (Portugal) FX This work was supported by National Institutes of Health (http://nih.gov/; R35-CA197743, CA80124, CA85140, CA96915, CA115767, and CA126642 to RKJ and DF), the Lustgarten Foundation (http://www.lustgarten.org/; research grant to RKJ) and the Foundation for Science and Technology (http://www.fct.pt/; Portugal, POPH/FSE funding program, fellowship and research grant to JI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 97 TC 17 Z9 17 U1 4 U2 24 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 7 PY 2015 VL 10 IS 12 AR e0141392 DI 10.1371/journal.pone.0141392 PG 23 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ1YS UT WOS:000366902700004 PM 26641266 ER PT J AU Kelly, VJ Winkler, T Venegas, JG Kone, M Hamilos, DL Afshar, R Cho, JL Luster, AD Medoff, BD Harris, RS AF Kelly, Vanessa J. Winkler, Tilo Venegas, Jose G. Kone, Mamary Hamilos, Daniel L. Afshar, Roshi Cho, Josalyn L. Luster, Andrew D. Medoff, Benjamin D. Harris, R. Scott TI Allergic Non-Asthmatic Adults Have Regional Pulmonary Responses to Segmental Allergen Challenge SO PLOS ONE LA English DT Article ID BRAIN TRANSFER CONSTANTS; BLOOD-FLOW DISTRIBUTION; TIME UPTAKE DATA; GRAPHICAL EVALUATION; VENTILATION DEFECTS; AIRWAY RESPONSE; F-18-FDG UPTAKE; ATOPIC ASTHMA; GAS-EXCHANGE; INFLAMMATION AB Background Allergic non-asthmatic (ANA) adults experience upper airway symptoms of allergic disease such as rhinorrhea, congestion and sneezing without symptoms of asthma. The aim of this study was to utilize PET-CT functional imaging to determine whether allergen challenge elicits a pulmonary response in ANA subjects or whether their allergic disease is truly isolated to the upper airways. Methods In 6 ANA subjects, bronchoalveolar lavages (BAL) were performed at baseline and 24h after instillation of an allergen and a diluent in separate lung lobes. After instillation (10h), functional imaging was performed to quantify and compare regional perfusion, ventilation, fractional gas content (Fgas), and glucose uptake rate (Ki) between the baseline, diluent and allergen lobes. BAL cell counts were also compared. Results In ANA subjects, compared to the baseline and diluent lobes, perfusion and ventilation were significantly lower in the allergen lobe (median [inter-quartile range], baseline vs. diluent vs. allergen: Mean-normalized perfusion; 0.87 [0.85-0.97] vs. 0.90 [0.86-0.98] vs. 0.59 [0.55-0.67]; p<0.05. Mean-normalized ventilation 0.89 [0.88-0.98] vs. 0.95 [0.89-1.02] vs. 0.63 [0.52-0.67], p< 0.05). In contrast, no significant differences were found in Fgas between baseline, diluent and allergen lobes or in Ki. Total cell counts, eosinophil and neutrophil cell counts (cells/ml BAL) were significantly greater in the allergen lobe compared to the baseline lobe (all P<0.05). Conclusions Despite having no clinical symptoms of a lower airway allergic response (cough and wheeze) allergic non-asthmatic subjects have a pulmonary response to allergen exposure which manifests as reduced ventilation and perfusion. C1 [Kelly, Vanessa J.; Kone, Mamary; Hamilos, Daniel L.; Afshar, Roshi; Cho, Josalyn L.; Luster, Andrew D.; Medoff, Benjamin D.; Harris, R. Scott] Massachusetts Gen Hosp, Dept Med, Div Pulm, Boston, MA 02114 USA. [Kelly, Vanessa J.; Kone, Mamary; Hamilos, Daniel L.; Afshar, Roshi; Cho, Josalyn L.; Luster, Andrew D.; Medoff, Benjamin D.; Harris, R. Scott] Massachusetts Gen Hosp, Dept Med, Div Crit Care & Rheumatol, Boston, MA 02114 USA. [Kelly, Vanessa J.; Kone, Mamary; Hamilos, Daniel L.; Afshar, Roshi; Cho, Josalyn L.; Luster, Andrew D.; Medoff, Benjamin D.; Harris, R. Scott] Massachusetts Gen Hosp, Dept Med, Div Allergy, Boston, MA 02114 USA. [Kelly, Vanessa J.; Kone, Mamary; Hamilos, Daniel L.; Afshar, Roshi; Cho, Josalyn L.; Luster, Andrew D.; Medoff, Benjamin D.; Harris, R. Scott] Massachusetts Gen Hosp, Dept Med, Div Immunol, Boston, MA 02114 USA. [Kelly, Vanessa J.; Winkler, Tilo; Venegas, Jose G.; Kone, Mamary; Hamilos, Daniel L.; Afshar, Roshi; Cho, Josalyn L.; Luster, Andrew D.; Medoff, Benjamin D.; Harris, R. Scott] Harvard Univ, Sch Med, Boston, MA USA. [Winkler, Tilo; Venegas, Jose G.] Massachusetts Gen Hosp, Dept Anaesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Afshar, Roshi; Cho, Josalyn L.; Luster, Andrew D.; Medoff, Benjamin D.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA. RP Harris, RS (reprint author), Massachusetts Gen Hosp, Dept Med, Div Pulm, Boston, MA 02114 USA. EM rsharris@mgh.harvard.edu RI Winkler, Tilo/B-5337-2009 OI Winkler, Tilo/0000-0002-7276-5550 FU National Institutes of Health [HL088297, AI040618, AI095261, HL086717]; American Heart Association [12POST11820025] FX This work was supported by National Institutes of Health: BDM HL088297, ADL AI040618 and AI095261, RSH HL086717; and American Heart Association, VJK 12POST11820025. NR 31 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 7 PY 2015 VL 10 IS 12 AR e0143976 DI 10.1371/journal.pone.0143976 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ1YS UT WOS:000366902700038 PM 26640951 ER PT J AU Whaley, C Reed, M Hsu, J Fung, V AF Whaley, Christopher Reed, Mary Hsu, John Fung, Vicki TI Functional Limitations, Medication Support, and Responses to Drug Costs among Medicare Beneficiaries SO PLOS ONE LA English DT Article ID HEALTH-INSURANCE; PART-D; CLINICAL EVENTS; SOCIAL SUPPORT; COVERAGE GAP; CARE; ADHERENCE; BENEFITS; ADULTS; NEEDS AB Objective Standard Medicare Part D prescription drug benefits include substantial and complex cost-sharing. Many beneficiaries also have functional limitations that could affect self-care capabilities, including managing medications, but also have varying levels of social support to help with these activities. We examined the associations between drug cost responses, functional limitations, and social support. Data Sources and Study Setting We conducted telephone interviews in a stratified random sample of community-dwelling Medicare Advantage beneficiaries (N = 1,201, response rate = 70.0%). Participants reported their functional status (i.e., difficulty with activities of daily living) and social support (i.e., receiving help with medications). Drug cost responses included cost-reducing behaviors, cost-related non-adherence, and financial stress. Study Design We used multivariate logistic regression to assess associations among functional status, help with medications, and drug cost responses, adjusting for patient characteristics. Principal Findings Respondents with multiple limitations who did not receive help with their medications were more likely to report cost-related non-adherence (OR = 3.2, 95% CI: 1.2-8.5) and financial stress (OR = 2.4, 95% CI: 1.3-4.5) compared to subjects with fewer limitations and no help; however, those with multiple limitations and with medication help had similar odds of unfavorable cost responses as those with fewer limitations. Conclusion The majority of beneficiaries with functional limitations did not receive help with medications. Support with medication management for beneficiaries who have functional limitations could improve adherence and outcomes. C1 [Whaley, Christopher] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Whaley, Christopher; Reed, Mary] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Hsu, John; Fung, Vicki] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Hsu, John; Fung, Vicki] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Hsu, John] Dept Hlth Care Policy, Boston, MA USA. RP Whaley, C (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. EM cwhaley@berkeley.edu; mary.e.reed@kp.org FU Kaiser Permanente Community Benefits; National Institute of Mental Health [R01MH090284] FX This study was supported by Kaiser Permanente Community Benefits, recipient: John Hsu; National Institute of Mental Health, grant # R01MH090284, recipient: Vicki Fung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 0 Z9 0 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 7 PY 2015 VL 10 IS 12 AR e0144236 DI 10.1371/journal.pone.0144236 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ1YS UT WOS:000366902700081 PM 26642195 ER PT J AU Singh, SP Schwartz, MP Tokuda, EY Luo, Y Rogers, RE Fujita, M Ahn, NG Anseth, KS AF Singh, S. P. Schwartz, M. P. Tokuda, E. Y. Luo, Y. Rogers, R. E. Fujita, M. Ahn, N. G. Anseth, K. S. TI A synthetic modular approach for modeling the role of the 3D microenvironment in tumor progression SO SCIENTIFIC REPORTS LA English DT Article ID CELL-MIGRATION; 3-DIMENSIONAL CULTURE; MALIGNANT PHENOTYPE; MATRIX STIFFNESS; DRUG-RESISTANCE; GENE-EXPRESSION; ELASTIC-MODULI; CANCER; HYDROGELS; INVASION AB Here, we demonstrate the flexibility of peptide-functionalized poly(ethylene glycol) (PEG) hydrogels for modeling tumor progression. The PEG hydrogels were formed using thiol-ene chemistry to incorporate a matrix metalloproteinase-degradable peptide crosslinker (KKCGGPQG down arrow IWGQGCKK) permissive to proteolytic remodeling and the adhesive CRGDS peptide ligand. Tumor cell function was investigated by culturing WM239A melanoma cells on PEG hydrogel surfaces or encapsulating cells within the hydrogels, and either as monocultures or indirect (non-contact) cocultures with primary human dermal fibroblasts (hDFs). WM239A cluster size and proliferation rate depended on the shear elastic modulus for cells cultured on PEG hydrogels, while growth was inhibited by coculture with hDFs regardless of hydrogel stiffness. Cluster size was also suppressed by hDFs for WM239A cells encapsulated in PEG hydrogels, which is consistent with cells seeded on top of hydrogels. Notably, encapsulated WM239A clusters and single cells adopted invasive phenotypes in the hDF coculture model, which included single cell and collective migration modes that resembled invasion from human melanoma patient-derived xenograft tumors encapsulated in equivalent PEG hydrogels. Our combined results demonstrate that peptide-functionalized PEG hydrogels provide a useful platform for investigating aspects of tumor progression in 2D and 3D microenvironments, including single cell migration, cluster growth and invasion. C1 [Singh, S. P.; Tokuda, E. Y.; Anseth, K. S.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA. [Singh, S. P.; Tokuda, E. Y.; Anseth, K. S.] Univ Colorado, BioFrontiers Inst, Boulder, CO 80309 USA. [Schwartz, M. P.] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA. [Luo, Y.; Fujita, M.] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA. [Rogers, R. E.] Texas A&M Hlth Sci Ctr, Coll Med, Bryan, TX USA. [Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Ahn, N. G.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA. [Anseth, K. S.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA. RP Anseth, KS (reprint author), Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA. EM kristi.anseth@colorado.edu RI Schwartz, Michael/B-3417-2008; Schwartz, Mike/O-7963-2016 OI Schwartz, Michael/0000-0003-3785-6606; Schwartz, Mike/0000-0003-3785-6606 FU Howard Hughes Medical Institute; National Institutes of Health [RO1 CA132633-02, T32 GM-065103] FX The authors acknowledge the Howard Hughes Medical Institute and the National Institutes of Health (RO1 CA132633-02) for funding this work. SPS acknowledges the biophysics training program (NIH grant T32 GM-065103) for fellowship support. MPS acknowledges a donation in the memory of Gerald E. Whitbeck (generously provided by his family and Follett Corp). NR 66 TC 1 Z9 1 U1 10 U2 31 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD DEC 7 PY 2015 VL 5 AR 17814 DI 10.1038/srep17814 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CX7CB UT WOS:000365857300001 PM 26638791 ER PT J AU Gobin, RL Green, KE Iverson, KM AF Gobin, Robyn L. Green, Kelly E. Iverson, Katherine M. TI Alcohol Misuse Among Female Veterans: Exploring Associations With Interpersonal Violence and Mental Health SO SUBSTANCE USE & MISUSE LA English DT Article DE Alcohol misuse; veterans; interpersonal violence; mental health ID INTIMATE PARTNER VIOLENCE; POSTTRAUMATIC-STRESS-DISORDER; MILITARY SEXUAL TRAUMA; IDENTIFICATION TEST AUDIT; WOMEN VETERANS; PRIMARY-CARE; HAZARDOUS DRINKING; GENDER-DIFFERENCES; CONTROLLED-TRIAL; SUBSTANCE USE AB Background: The correlates of alcohol misuse among female Veterans are not well understood. The present study explored associations among alcohol misuse, demographic/military-related characteristics, interpersonal violence exposure, and posttraumatic stress disorder (PTSD) and depression symptom severity. Method: Participants were 369 female Veteran patients of the VA New England Healthcare System. Participants completed a paper-and-pencil mail survey that included validated assessments of alcohol misuse, interpersonal violence, and psychological distress. Results: Younger age, adulthood physical abuse, military sexual trauma, past-year psychological aggression by an intimate partner, and PTSD and depression symptom severity showed significant univariate associations with alcohol misuse (as indicated by unsafe drinking levels, presence or incipience of an alcohol use disorder, intrapersonal alcohol-related concerns, and/or interpersonal alcohol-related concerns). A couple of these associations remained significant when examined in logistic regression models. Conclusions: Findings suggest that female Veterans who are at risk for alcohol use disorders and/or are experiencing alcohol-related problems may benefit from screening and intervention efforts that take into account interpersonal violence exposures and mental health symptoms on a case-by-case basis. Results also suggest the importance of future research examining correlates and risk factors for substance misuse among female Veterans. C1 [Gobin, Robyn L.] VA San Diego Healthcare Syst, Dept Psychol, San Diego, CA 92161 USA. [Green, Kelly E.] St Edwards Univ, Dept Psychol, Austin, TX 78704 USA. [Green, Kelly E.] VA Boston Healthcare Syst, Dual Diag Intens Outpatient Treatment Program, Boston, MA USA. [Iverson, Katherine M.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, Boston, MA USA. RP Gobin, RL (reprint author), VA San Diego Healthcare Syst, Psychol, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM robyngobin@gmail.com FU U.S. Department of Veterans Affairs [CDA 10-029] FX This work was supported by the U.S. Department of Veterans Affairs [grant number CDA 10-029]. NR 57 TC 0 Z9 0 U1 4 U2 12 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1082-6084 EI 1532-2491 J9 SUBST USE MISUSE JI Subst. Use Misuse PD DEC 6 PY 2015 VL 50 IS 14 BP 1765 EP 1777 DI 10.3109/10826084.2015.1037398 PG 13 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA CY9QZ UT WOS:000366742700004 PM 26642782 ER PT J AU Najavits, LM de Haan, H Kok, T AF Najavits, Lisa M. de Haan, Hein Kok, Tim TI How Do Females With PTSD and Substance Abuse View 12-Step Groups? An Empirical Study of Attitudes and Attendance Patterns SO SUBSTANCE USE & MISUSE LA English DT Article DE PTSD; substance abuse; 12-step groups; self-help; attitudes; females ID COCAINE-DEPENDENT PATIENTS; POSTTRAUMATIC-STRESS-DISORDER; HELP GROUP ATTENDANCE; SEEKING-SAFETY; WOMEN; PARTICIPATION; OUTCOMES; ALCOHOLISM; HEALTH; TRIAL AB Background. Self-help groups are beneficial for many people with addiction, predominantly through 12-step models. Yet obstacles to attendance also occur. Objectives. We explored attendance patterns and attitudes toward self-help groups by 165 outpatient females with co-occurring posttraumatic stress disorder (PTSD) and substance use disorder (SUD), the first study of its kind. Methods. Cross-sectional self-report data compared adults versus adolescents, and those currently attending self-help versus not attending. We also explored attendance in relation to perceptions of the PTSD/SUD relationship and symptom severity. Results. Adults reported higher attendance at self-help than adolescents, both lifetime and currently. Among current attendees, adults also attended more weekly groups than adolescents. Yet only a minority of both age cohorts attended any self-help in the past week. Adults perceived a stronger relationship between PTSD and SUD than adolescents, but both age groups gave low ratings to the fact that self-help groups do not address PTSD. That item also had low ratings by both those currently attending and not attending self-help. Analysis of those not currently attending identified additional negative attitudes toward self-help (spirituality, addiction as a life-long illness, sayings, and the fellowship). Symptom severity was not associated with attendance, but may reflect a floor effect. Finally, a surprising finding was that all-female groups were not preferred by any subsample. Conclusions/Importance. Creative solutions are needed to address obstacles to self-help among this population. Addressing trauma and PTSD, not just SUD, was valued by females we surveyed, and may be more helpful than all-female groups per se. C1 [Najavits, Lisa M.] Boston Univ, Sch Med, Boston, MA 02118 USA. [de Haan, Hein; Kok, Tim] Tactus Addict Treatment, Deventer, Netherlands. RP Najavits, LM (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA. EM najavits@bu.edu FU U.S. Department of Defense [W81XWH-10-2-0173] FX This work was supported by the U.S. Department of Defense [grant number W81XWH-10-2-0173]. NR 42 TC 0 Z9 0 U1 2 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1082-6084 EI 1532-2491 J9 SUBST USE MISUSE JI Subst. Use Misuse PD DEC 6 PY 2015 VL 50 IS 14 BP 1786 EP 1794 DI 10.3109/10826084.2015.1050111 PG 9 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA CY9QZ UT WOS:000366742700006 PM 26606541 ER PT J AU Murray, E Cho, JH Goodwin, D Ku, T Swaney, J Kim, SY Choi, H Park, YG Park, JY Hubbert, A Mccue, M Vassallo, S Bakh, N Frosch, MP Wedeen, VJ Seung, HS Chung, K AF Murray, Evan Cho, Jae Hun Goodwin, Daniel Ku, Taeyun Swaney, Justin Kim, Sung-Yon Choi, Heejin Park, Young-Gyun Park, Jeong-Yoon Hubbert, Austin McCue, Margaret Vassallo, Sara Bakh, Naveed Frosch, Matthew P. Wedeen, Van J. Seung, H. Sebastian Chung, Kwanghun TI Simple, Scalable Proteomic Imaging for High-Dimensional Profiling of Intact Systems SO CELL LA English DT Article ID GLUTARALDEHYDE FIXATION; PYRAMIDAL NEURONS; CELL-MEMBRANE; BRAIN; CALRETININ; FORMALDEHYDE; PARVALBUMIN; RESOLUTION; CALBINDIN; TISSUES AB Combined measurement of diverse molecular and anatomical traits that span multiple levels remains a major challenge in biology. Here, we introduce a simple method that enables proteomic imaging for scalable, integrated, high-dimensional phenotyping of both animal tissues and human clinical samples. This method, termed SWITCH, uniformly secures tissue architecture, native biomolecules, and antigenicity across an entire system by synchronizing the tissue preservation reaction. The heat-and chemical-resistant nature of the resulting framework permits multiple rounds (>20) of relabeling. We have performed 22 rounds of labeling of a single tissue with precise co-registration of multiple datasets. Furthermore, SWITCH synchronizes labeling reactions to improve probe penetration depth and uniformity of staining. With SWITCH, we performed combinatorial protein expression profiling of the human cortex and also interrogated the geometric structure of the fiber pathways in mouse brains. Such integrated high-dimensional information may accelerate our understanding of biological systems at multiple levels. C1 [Murray, Evan; McCue, Margaret; Chung, Kwanghun] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Murray, Evan; Ku, Taeyun; Kim, Sung-Yon; Choi, Heejin; Park, Young-Gyun; Park, Jeong-Yoon; Vassallo, Sara; Chung, Kwanghun] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA. [Cho, Jae Hun; Swaney, Justin; Hubbert, Austin; Bakh, Naveed; Chung, Kwanghun] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Ku, Taeyun; Choi, Heejin; Park, Young-Gyun; Park, Jeong-Yoon; McCue, Margaret; Vassallo, Sara; Chung, Kwanghun] MIT, Picower Inst Learning & Memory, Cambridge, MA 02139 USA. [Goodwin, Daniel; Seung, H. Sebastian] Simons Ctr Data Anal, New York, NY 10010 USA. [Frosch, Matthew P.] Massachusetts Gen Hosp, Dept Pathol, CS Kubik Lab Neuropathol, Boston, MA 02114 USA. [Frosch, Matthew P.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Wedeen, Van J.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA. [Wedeen, Van J.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Seung, H. Sebastian] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA. [Seung, H. Sebastian] Princeton Univ, Dept Comp Sci, Princeton, NJ 08544 USA. [Chung, Kwanghun] Harvard Univ, Broad Inst, Cambridge, MA 02142 USA. [Chung, Kwanghun] MIT, Cambridge, MA 02142 USA. RP Chung, K (reprint author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA. EM khchung@mit.edu RI Swaney, Justin/H-1437-2016; OI Swaney, Justin/0000-0002-4830-9133; Kim, Sung-Yon/0000-0003-0791-7308 FU Simons Postdoctoral Fellowship; Life Sciences Research Foundation; Burroughs Wellcome Fund Career Awards at the Scientific Interface; Searle Scholars Program; Michael J. Fox Foundation; DARPA; JPB Foundation (PIIF and PNDRF); NIH [1-U01-NS090473-01]; Massachusetts Alzheimer Disease Research Center [5 P50 AG005134] FX We thank the entire Chung laboratory for support and helpful discussions. S.-Y.K. was supported by the Simons Postdoctoral Fellowship and the Life Sciences Research Foundation. K.C. was supported by Burroughs Wellcome Fund Career Awards at the Scientific Interface, the Searle Scholars Program, the Michael J. Fox Foundation, DARPA, the JPB Foundation (PIIF and PNDRF), and NIH (1-U01-NS090473-01). M.P.F. was supported in part by the Massachusetts Alzheimer Disease Research Center (5 P50 AG005134). Resources that may help enable general users to establish the methodology are freely available online. (www.chunglabresources.org). NR 43 TC 28 Z9 28 U1 6 U2 27 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD DEC 6 PY 2015 VL 163 IS 6 BP 1500 EP 1514 DI 10.1016/j.cell.2015.11.025 PG 15 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CX9SE UT WOS:000366044800022 PM 26638076 ER PT J AU Gaublomme, JT Yosef, N Lee, Y Gertner, RS Yang, LV Wu, C Pandolfi, PP Mak, T Satija, R Shalek, AK Kuchroo, VK Park, H Regev, A AF Gaublomme, Jellert T. Yosef, Nir Lee, Youjin Gertner, Rona S. Yang, Li V. Wu, Chuan Pandolfi, Pier Paolo Mak, Tak Satija, Rahul Shalek, Alex K. Kuchroo, Vijay K. Park, Hongkun Regev, Aviv TI Single-Cell Genomics Unveils Critical Regulators of Th17 Cell Pathogenicity SO CELL LA English DT Article ID HEMATOPOIETIC STEM-CELLS; T-CELLS; T(H)17 CELLS; MOLECULAR SIGNATURE; MULTIPLE-SCLEROSIS; FLOW-CYTOMETRY; SELF-RENEWAL; RNA-SEQ; DIFFERENTIATION; DISEASE AB Extensive cellular heterogeneity exists within specific immune-cell subtypes classified as a single lineage, but its molecular underpinnings are rarely characterized at a genomic scale. Here, we use single-cell RNA-seq to investigate the molecular mechanisms governing heterogeneity and pathogenicity of Th17 cells isolated from the central nervous system (CNS) and lymph nodes (LN) at the peak of autoimmune encephalomyelitis (EAE) or differentiated in vitro under either pathogenic or nonpathogenic polarization conditions. Computational analysis relates a spectrum of cellular states in vivo to in-vitro-differentiated Th17 cells and unveils genes governing pathogenicity and disease susceptibility. Using knockout mice, we validate four new genes: Gpr65, Plzp, Toso, and Cd5l (in a companion paper). Cellular heterogeneity thus informs Th17 function in autoimmunity and can identify targets for selective suppression of pathogenic Th17 cells while potentially sparing non-pathogenic tissueprotective ones. C1 [Gaublomme, Jellert T.; Yosef, Nir; Lee, Youjin; Satija, Rahul; Shalek, Alex K.; Kuchroo, Vijay K.; Park, Hongkun; Regev, Aviv] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA. [Gaublomme, Jellert T.; Gertner, Rona S.; Park, Hongkun] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. [Gaublomme, Jellert T.; Gertner, Rona S.; Park, Hongkun] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA. [Yosef, Nir] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA. [Yosef, Nir] Univ Calif Berkeley, Ctr Computat Biol, Berkeley, CA 94720 USA. [Lee, Youjin; Wu, Chuan; Kuchroo, Vijay K.] Harvard Univ, Sch Med, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA. [Lee, Youjin; Wu, Chuan; Kuchroo, Vijay K.] Brigham & Womens Hosp, Harvard Inst Med, Boston, MA 02115 USA. [Yang, Li V.] E Carolina Univ, Brody Sch Med, Dept Internal Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA. [Pandolfi, Pier Paolo] Harvard Univ, Canc Res Inst, Dept Med & Pathol,Beth Israel Deaconess Med Ctr, Beth Israel Deaconess Canc Ctr,Med Sch, Boston, MA 02215 USA. [Mak, Tak] Princess Margaret Hosp, Ontario Canc Ctr, Toronto, ON M5G 2M9, Canada. [Satija, Rahul] New York Genome Ctr, New York, NY 10013 USA. [Satija, Rahul] NYU, Ctr Genom & Syst Biol, New York, NY 10012 USA. [Shalek, Alex K.] MIT, Inst Med Engn & Sci, Cambridge, MA 02142 USA. [Shalek, Alex K.] MIT, Dept Chem, Cambridge, MA 02142 USA. [Shalek, Alex K.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02139 USA. [Shalek, Alex K.] Harvard Univ, Boston, MA 02139 USA. [Regev, Aviv] MIT, Howard Hughes Med Inst, Cambridge, MA 02142 USA. [Regev, Aviv] MIT, Dept Biol, David H Koch Inst Integrat Canc Biol, Cambridge, MA 02142 USA. RP Park, H (reprint author), Broad Inst MIT & Harvard, 415 Main St, Cambridge, MA 02142 USA. EM hongkun_park@harvard.edu; aregev@broadinstitute.org FU Klarman Cell Observatory at the Broad Institute; NIH [P50 HG006193, NS030843, AI039671, NS076410, AI056299, 4R00AI110649]; Koch Institute Support (core) grant from the National Cancer Institute [P30-CA14051]; National MS Society, New York; Crohn's and Colitis Foundation of America; National Multiple Sclerosis Society [TA3059-A-2]; NIH NSRA grant [F32 HD075541] FX We thank J.E. Coligan for providing Toso-/- mice; J. Shuga for scientific discussions; D. Kozoriz, T. Rogers, and M. Tam for assistance with cell sorting; T.J. Diefenbach for assistance with the Imagestream system; C. Wu for help with EAE experiments; O. Rozenblatt-Rosen, E. Shefler, J. Lee, and C. Guiducci for project management; the Broad Genomics Platform for all sequencing work; and L. Gaffney for help with artwork. Work was supported by the Klarman Cell Observatory at the Broad Institute (A.R., H.P., and V.K.K.), an NIH grant P50 HG006193 (A.R. and H.P.), and by the Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute (A.R.). V.K.K. was supported by NIH grants NS030843, AI039671, NS076410, AI056299, National MS Society, New York, and Crohn's and Colitis Foundation of America. C.W. was supported by a Career Transition Award from the National Multiple Sclerosis Society (TA3059-A-2) and NIH grant 4R00AI110649. R.S. was supported by NIH NSRA grant F32 HD075541. A.R. is an Investigator of the Howard Hughes Medical Institute. During the course of the research, V.K.K. had an ownership interest in Tempero Pharmaceuticals, a company that was working in the area of Treg-Th17 biology and developing treatments for autoimmune diseases in areas related to this research. V.K.K.'s ownership ended in October 2014. V.K.K.'s interests were reviewed and managed by the Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies. A.R. is a paid consultant for Driver Group and a member of the SAB of ThermoFisher Scientific and Syros Pharmaceuticals. A.R.'s interests were reviewed and managed by the Broad Institute according to its conflict of interest policies. NR 53 TC 43 Z9 46 U1 10 U2 32 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD DEC 6 PY 2015 VL 163 IS 6 DI 10.1016/j.cell.2015.11.009 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CX9SE UT WOS:000366044800005 PM 26607794 ER PT J AU Hart, T Chandrashekhar, M Aregger, M Steinhart, Z Brown, KR MacLeod, G Mis, M Zimmermann, M Fradet-Turcotte, A Sun, S Mero, P Dirks, P Sidhu, S Roth, FP Rissland, OS Durocher, D Angers, S Moffat, J AF Hart, Traver Chandrashekhar, Megha Aregger, Michael Steinhart, Zachary Brown, Kevin R. MacLeod, Graham Mis, Monika Zimmermann, Michal Fradet-Turcotte, Amelie Sun, Song Mero, Patricia Dirks, Peter Sidhu, Sachdev Roth, Frederick P. Rissland, Olivia S. Durocher, Daniel Angers, Stephane Moffat, Jason TI High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities SO CELL LA English DT Article ID SACCHAROMYCES-CEREVISIAE GENOME; MITOCHONDRIAL PROTEIN-SYNTHESIS; HUMAN-CELLS; RNAI SCREENS; INHIBITION; MAP; P53; VULNERABILITIES; OXAZOLIDINONES; ENDONUCLEASE AB The ability to perturb genes in human cells is crucial for elucidating gene function and holds great potential for finding therapeutic targets for diseases such as cancer. To extend the catalog of human core and context-dependent fitness genes, we have developed a high-complexity second-generation genome-scale CRISPR-Cas9 gRNA library and applied it to fitness screens in five human cell lines. Using an improved Bayesian analytical approach, we consistently discover 5-fold more fitness genes than were previously observed. We present a list of 1,580 human core fitness genes and describe their general properties. Moreover, we demonstrate that context-dependent fitness genes accurately recapitulate pathway-specific genetic vulnerabilities induced by known oncogenes and reveal cell-type-specific dependencies for specific receptor tyrosine kinases, even in oncogenic KRAS backgrounds. Thus, rigorous identification of human cell line fitness genes using a high-complexity CRISPR-Cas9 library affords a high-resolution view of the genetic vulnerabilities of a cell. C1 [Hart, Traver; Chandrashekhar, Megha; Aregger, Michael; Brown, Kevin R.; Sun, Song; Mero, Patricia; Sidhu, Sachdev; Roth, Frederick P.; Moffat, Jason] Donnelly Ctr, Toronto, ON M5S 3E1, Canada. [Chandrashekhar, Megha; Sun, Song; Dirks, Peter; Sidhu, Sachdev; Roth, Frederick P.; Rissland, Olivia S.; Durocher, Daniel; Moffat, Jason] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A1, Canada. [Steinhart, Zachary; MacLeod, Graham; Mis, Monika; Angers, Stephane] Univ Toronto, Dept Pharmaceut Sci, Toronto, ON M5S 1A1, Canada. [Steinhart, Zachary; MacLeod, Graham; Mis, Monika; Angers, Stephane] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 1A1, Canada. [Angers, Stephane] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A1, Canada. [Zimmermann, Michal; Fradet-Turcotte, Amelie; Roth, Frederick P.; Durocher, Daniel] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada. [Rissland, Olivia S.] Hosp Sick Children, Res Inst, Mol Struct & Funct Program, Toronto, ON M5G 0A4, Canada. [Sun, Song] Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden. [Dirks, Peter] Hosp Sick Children, Div Neurosurg, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada. [Sun, Song; Roth, Frederick P.] Univ Toronto, Dept Comp Sci, Toronto, ON M5G 1X8, Canada. [Roth, Frederick P.; Moffat, Jason] Canadian Inst Adv Res, Toronto, ON M5G 1Z8, Canada. [Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02215 USA. RP Moffat, J (reprint author), Donnelly Ctr, 160 Coll St, Toronto, ON M5S 3E1, Canada. EM j.moffat@utoronto.ca RI Durocher, Daniel/A-7733-2010; Roth, Frederick/H-6308-2011; OI Durocher, Daniel/0000-0003-3863-8635; Aregger, Michael/0000-0001-6443-9870; Roth, Frederick/0000-0002-6628-649X FU Swiss National Science Foundation; CIHR; Swedish Research Council; Ontario Research Fund; Ontario Institute for Cancer Research ITV Program; Canadian Foundation for Innovation; Canada Research Chairs program; Krembil Foundation; Canadian Institutes for Health Research operating grant [CIHR-342551]; [FDN 143343] FX We thank Michael Costanzo, Amy Tong, Charlie Boone, and Brenda Andrews for helpful discussions and comments on the manuscript. We thank Olga Sizova and Amy Tong for technical assistance, Sachin Kumar for providing plasmids, all the members of the Moffat and Angers labs for helpful discussions, Peggy Wang for graphic design, and Aaron Schimmer for chemicals. We thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison (http://exac.broadinstitute.org/about). We also thank Dax Torti at the Donnelly Sequencing Centre for assistance with sequencing. M.A. holds a postdoctoral fellowship from the Swiss National Science Foundation, A.F.-T. holds a CIHR postdoctoral fellowship, M.Z. is an EMBO Long-Term postdoctoral fellow, and S. Sun holds an international post-doc grant from the Swedish Research Council. This work was supported by grants from the Ontario Research Fund (J.M.), Ontario Institute for Cancer Research ITV Program (J.M.), Canadian Foundation for Innovation (J.M.), Canada Research Chairs program (J.M., S.A., and D.D.), Krembil Foundation (D.D.), a Canadian Institutes for Health Research operating grant to J.M. (CIHR-342551), and foundation grant to D.D. (FDN 143343). D.D. is a Tier 1 Canada Research Chair in Molecular Mechanisms of Genome Integrity, S.A. is a Tier 2 Canada Research Chair in Functional Architecture of Signal Transduction, and J.M. is a Tier 2 Canada Research Chair in Functional Genomics of Cancer. NR 47 TC 61 Z9 61 U1 17 U2 64 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD DEC 6 PY 2015 VL 163 IS 6 DI 10.1016/j.cell.2015.11.015 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CX9SE UT WOS:000366044800004 PM 26627737 ER PT J AU Forouzanfar, MH Alexander, L Anderson, HR Bachman, VF Biryukov, S Brauer, M Burnett, R Casey, D Coates, MM Cohen, A Delwiche, K Estep, K Frostad, JJ Astha, KC Kyu, HH Moradi-Lakeh, M Ng, M Slepak, EL Thomas, BA Wagner, J Aasvang, GM Abbafati, C Ozgoren, AA Abd-Allah, F Abera, SF Aboyans, V Abraham, B Abraham, JP Abubakar, I Abu-Rmeileh, NME Aburto, TC Achoki, T Adelekan, A Adofo, K Adou, AK Adsuar, JC Afshin, A Agardh, EE Al Khabouri, MJ Al Lami, FH Alam, SS Alasfoor, D Albittar, MI Alegretti, MA Aleman, AV Alemu, ZA Alfonso-Cristancho, R Alhabib, S Ali, R Ali, MK Alla, F Allebeck, P Allen, PJ Alsharif, U Alvarez, E Alvis-Guzman, N Amankwaa, AA Amare, AT Ameh, EA Ameli, O Amini, H Ammar, W Anderson, BO Antonio, CAT Anwari, P Cunningham, SA Arnlov, J Arsenijevic, VSA Artaman, A Asghar, RJ Assadi, R Atkins, LS Atkinson, C Avila, MA Awuah, B Badawi, A Bahit, MC Bakfalouni, T Balakrishnan, K Balalla, S Balu, RK Banerjee, A Barber, RM Barker-Collo, SL Barquera, S Barregard, L Barrero, LH Barrientos-Gutierrez, T Basto-Abreu, AC Basu, A Basu, S Basulaiman, MO Ruvalcaba, CB Beardsley, J Bedi, N Bekele, T Bell, ML Benjet, C Bennett, DA Benzian, H Bernabe, E Beyene, TJ Bhala, N Bhalla, A Bhutta, ZQA Bikbov, B Bin Abdulhak, AA Blore, JD Blyth, FM Bohensky, MA Basara, BB Borges, G Bornstein, NM Bose, D Boufous, S Bourne, RR Brainin, M Brazinova, A Breitborde, NJ Brenner, H Briggs, ADM Broday, DM Brooks, PM Bruce, NG Brugha, TS Brunekreef, B Buchbinder, R Bui, LN Bukhman, G Bulloch, AG Burch, M Burney, PGJ Campos-Nonato, IR Campuzano, JC Cantoral, AJ Caravanos, J Cardenas, R Cardis, E Carpenter, DO Caso, V Castaneda-Orjuela, CA Castro, RE Catala-Lopez, F Cavalleri, F Ccedil;avlin, A Chadha, VK Chang, JC Charlson, FJ Chen, HL Chen, WQ Chen, ZM Chiang, PP Chimed-Ochir, O Chowdhury, R Christophi, CA Chuang, TW Chugh, SS Cirillo, M Classen, TKD Colistro, V Colomar, M Colquhoun, SM Contreras, AG Cooper, C Cooperrider, K Cooper, LT Coresh, J Courville, KJ Criqui, MH Cuevas-Nasu, L Damsere-Derry, J Danawi, H Dandona, L Dandona, R Dargan, PI Davis, A Davitoiu, DV Dayama, A de Castro, EF De la Cruz-Gongora, V De Leo, D de Lima, G Degenhardt, L del Pozo-Cruz, B Dellavalle, RP Deribe, K Derrett, S Jarlais, DCD Dessalegn, M deVeber, GA Devries, KM Dharmaratne, SD Dherani, MK Dicker, D Ding, EL Dokova, K Dorsey, ER Driscoll, TR Duan, L Durrani, AM Ebel, BE Ellenbogen, RG Elshrek, YM Endres, M Ermakov, SP Erskine, HE Eshrati, B Esteghamati, A Fahimi, S Faraon, EJA Farzadfar, F Fay, DFJ Feigin, VL Feigl, AB Fereshtehnejad, SM Ferrari, AJ Ferri, CP Flaxman, AD Fleming, TD Foigt, N Foreman, KJ Paleo, UF Franklin, RC Gabbe, B Gaffikin, L Gakidou, E Gamkrelidze, A Gankpe, FG Gansevoort, RT Garcia-Guerra, FA Gasana, E Geleijnse, JM Gessner, BD Gething, P Gibney, KB Gillum, RF Ginawi, IAM Giroud, M Giussani, G Goenka, S Goginashvili, K Dantes, HG Gona, P de Cosio, TG Gonzalez-Castell, D Gotay, CC Goto, A Gouda, HN Guerrant, RL Gugnani, HC Guillemin, F Gunnell, D Gupta, R Gupta, R Gutierrez, RA Hafezi-Nejad, N Hagan, H Hagstromer, M Halasa, YA Hamadeh, RR Hammami, M Hankey, GJ Hao, YT Harb, HL Haregu, TN Haro, JM Havmoeller, R Hay, SI Hedayati, MT Heredia-Pi, IB Hernandez, L Heuton, KR Heydarpour, P Hijar, M Hoek, HW Man, HJH Hornberger, JC Hosgood, HD Hoy, DG Hsairi, M Hu, GQ Hu, H Huang, C Huang, JJ Hubbell, BJ Huiart, L Husseini, A Iannarone, ML Iburg, KM Idrisov, BT Ikeda, N Innos, K Inoue, M Islami, F Ismayilova, S Jacobsen, KH Jansen, HA Jarvis, DL Jassal, SK Jauregui, A Jayaraman, S Jeemon, P Jensen, PN Jha, V Jiang, F Jiang, GH Jiang, Y Jonas, JB Juel, K Kan, HD Roseline, SSK Karam, NE Karch, A Karema, CK Karthikeyan, G Kaul, A Kawakami, N Kazi, DS Kemp, AH Kengne, AP Keren, A Khader, YS Khalifa, SEAH Khan, EA Khang, YH Khatibzadeh, S Khonelidze, I Kieling, C Kim, D Kim, S Kim, Y Kimokoti, RW Kinfu, Y Kinge, JM Kissela, BM Kivipelto, M Knibbs, LD Knudsen, AK Kokubo, Y Kose, MR Kosen, S Kraemer, A Kravchenko, M Krishnaswami, S Kromhout, H Ku, T Defo, BK Bicer, BK Kuipers, EJ Kulkarni, C Kulkarni, VS Kumar, GA Kwan, GF Lai, T Balaji, AL Lalloo, R Lallukka, T Lam, H Lan, Q Lansingh, VC Larson, HJ Larsson, A Laryea, DO Lavados, PM Lawrynowicz, AE Leasher, JL Lee, JT Leigh, J Leung, R Levi, M Li, Y Li, Y Liang, J Liang, XF Lim, SS Lindsay, MP Lipshultz, SE Liu, SW Liu, Y Lloyd, BK Logroscino, G London, SJ Lopez, N Lortet-Tieulent, J Lotufo, PA Lozano, R Lunevicius, R Ma, JX Ma, S Machado, VMP MacIntyre, MF Magis-Rodriguez, C Mahdi, AA Majdan, M Malekzadeh, R Mangalam, S Mapoma, CC Marape, M Marcenes, W Margolis, DJ Margono, C Marks, GB Martin, RV Marzan, MB Mashal, MT Masiye, F Mason-Jones, AJ Matsushita, K Matzopoulos, R Mayosi, BM Mazorodze, TT Mckay, AC Mckee, M McLain, A Meaney, PA Medina, C Mehndiratta, MM Mejia-Rodriguez, F Mekonnen, W Melaku, YA Meltzer, M Memish, ZA Mendoza, W Mensah, GA Meretoja, A Mhimbira, FA Micha, R Miller, TR Mills, EJ Misganaw, A Mishra, S Ibrahim, NM Mohammad, KA Mokdad, AH Mola, GL Monasta, L Hernandez, JCM Montico, M Moore, AR Morawska, L Mori, R Moschandreas, J Moturi, WN Arian, DM Mueller, UO Mukaigawara, M Mullany, EC Murthy, KS Naghavi, M Nahas, Z Naheed, A Naidoo, KS Naldi, L Nand, D Nangia, V Narayan, KMV Nash, D Neal, B Nejjari, C Neupane, SP Newton, CR Ngalesoni, FN Ngirabega, JD Nguyen, G Nguyen, NT Nieuwenhuijsen, MJ Nisar, MI Nogueira, JR Nolla, JM Nolte, S Norheim, OF Norman, RE Norrving, B Nyakarahuka, L Oh, IH Ohkubo, T Olusanya, BO Omer, SB Opio, JN Orozco, R Pagcatipunan, RS Pain, AW Pandian, JD Panelo, CIA Papachristou, C Park, EK Parry, CD Caicedo, AJP Patten, SB Paul, VK Pavlin, BI Pearce, N Pedraza, LS Pedroza, A Stokic, LP Pekericli, A Pereira, DM Perez-Padilla, R Perez-Ruiz, F Perico, N Perry, SAL Pervaiz, A Pesudovs, K Peterson, CB Petzold, M Phillips, MR Phua, HP Plass, D Poenaru, D Polanczyk, GV Polinder, S Pond, CD Pope, CA Pope, D Popova, S Pourmalek, F Powles, J Prabhakaran, D Prasad, NM Qato, DM Quezada, AD Quistberg, DAA Racape L Rafay, A Rahimi, K Rahimi-Movaghar, V Rahman, SU Raju, M Rakovac, I Rana, SM Rao, M Razavi, H Reddy, KS Refaat, AH Rehm, J Remuzzi, G Ribeiro, AL Riccio, PM Richardson, L Riederer, A Robinson, M Roca, A Rodriguez, A Rojas-Rueda, D Romieu, I Ronfani, L Room, R Roy, N Ruhago, GM Rushton, L Sabin, N Sacco, RL Saha, S Sahathevan, R Sahraian, MA Salomon, JA Salvo, D Sampson, UK Sanabria, JR Sanchez, LM Sanchez-Pimienta, TG Sanchez-Riera, L Sandar, L Santos, IS Sapkota, A Satpathy, M Saunders, JE Sawhney, M Saylan, MI Scarborough, P Schmidt, JC Schneider, IJC Schottker, B Schwebel, DC Scott, JG Seedat, S Sepanlou, SG Serdar, B Servan-Mori, EE Shaddick, G Shahraz, S Levy, TS Shangguan, S She, J Sheikhbahaei, S Shibuya, K Shin, HH Shinohara, Y Shiri, R Shishani, K Shiue, I Sigfusdottir, ID Silberberg, DH Simard, EP Sindi, S Singh, A Singh, GM Singh, JA Skirbekk, V Sliwa, K Soljak, M Soneji, S Soreide, K Soshnikov, S Sposato, LA Sreeramareddy, CT Stapelberg, NJC Stathopoulou, V Steckling, N Stein, DJ Stein, MB Stephens, N Stockl, H Straif, K Stroumpoulis, K Sturua, L Sunguya, BF Swaminathan, S Swaroop, M Sykes, BL Tabb, KM Takahashi, K Talongwa, RT Tandon, N Tanne, D Tanner, M Tavakkoli, M Ao, BJT Teixeira, CM Rojo, MMT Terkawi, AS Texcalac-Sangrador, JL Thackway, SV Thomson, B Thorne-Lyman, AL Thrift, AG Thurston, GD Tillmann, T Tobollik, M Tonelli, M Topouzis, F Towbin, JRA Toyoshima, H Traebert, JE Tran, BX Trasande, L Trillini, M Trujillo, U Dimbuene, ZT Tsilimbaris, M Tuzcu, EM Uchendu, US Ukwaja, KN Uzun, SB van de Vijver, S Van Dingenen, R Van Gool, CH Van Os, J Varakin, YY Vasankari, TJ Vasconcelos, AMN Vavilala, MS Veerman, LJ Velasquez-Melendez, G Venketasubramanian, N Vijayakumar, L Villalpando, S Violante, FS Vlassov, VV Vollset, SE Wagner, GR Waller, SG Wallin, MT Wan, X Wang, HD Wang, JL Wang, LH Wang, WZ Wang, YP Warouw, TS Watts, CH Weichenthal, S Weiderpass, E Weintraub, RG Werdecker, A Wessells, KR Westerman, R Whiteford, HA Wilkinson, JD Williams, HC Williams, TN Woldeyohannes, SM Wolfe, CDA Wong, JQ Woolf, AD Wright, JL Wurtz, B Xu, G Yan, LJL Yang, GH Yano, Y Ye, PP Yenesew, M Yentur, GK Yip, P Yonemoto, N Yoon, SJ Younis, MZ Younoussi, Z Yu, CH Zaki, ME Zhao, Y Zheng, YF Zhou, MG Zhu, J Zhu, SK Zou, XN Zunt, JR Lopez, AD Vos, T Murray, CJ AF Forouzanfar, Mohammad H. Alexander, Lily Anderson, H. Ross Bachman, Victoria F. Biryukov, Stan Brauer, Michael Burnett, Richard Casey, Daniel Coates, Matthew M. Cohen, Aaron Delwiche, Kristen Estep, Kara Frostad, Joseph J. Astha, K. C. Kyu, Hmwe H. Moradi-Lakeh, Maziar Ng, Marie Slepak, Erica Leigh Thomas, Bernadette A. Wagner, Joseph Aasvang, Gunn Marit Abbafati, Cristiana Ozgoren, Ayse Abbasoglu Abd-Allah, Foad Abera, Semaw F. Aboyans, Victor Abraham, Biju Abraham, Jerry Puthenpurakal Abubakar, Ibrahim Abu-Rmeileh, Niveen M. E. Aburto, Tania C. Achoki, Tom Adelekan, Ademola Adofo, Koranteng Adou, Arsene K. Adsuar, Jose C. Afshin, Ashkan Agardh, Emilie E. Al Khabouri, Mazin J. Al Lami, Faris H. Alam, Sayed Saidul Alasfoor, Deena Albittar, Mohammed I. Alegretti, Miguel A. Aleman, Alicia V. Alemu, Zewdie A. Alfonso-Cristancho, Rafael Alhabib, Samia Ali, Raghib Ali, Mohammed K. Alla, Francois Allebeck, Peter Allen, Peter J. Alsharif, Ubai Alvarez, Elena Alvis-Guzman, Nelson Amankwaa, Adansi A. Amare, Azmeraw T. Ameh, Emmanuel A. Ameli, Omid Amini, Heresh Ammar, Walid Anderson, Benjamin O. Antonio, Carl Abelardo T. Anwari, Palwasha Cunningham, Solveig Argeseanu Arnlov, Johan Arsenijevic, Valentina S. Arsic Artaman, Al Asghar, Rana J. Assadi, Reza Atkins, Lydia S. Atkinson, Charles Avila, Marco A. Awuah, Baffour Badawi, Alaa Bahit, Maria C. Bakfalouni, Talal Balakrishnan, Kalpana Balalla, Shivanthi Balu, Ravi Kumar Banerjee, Amitava Barber, Ryan M. Barker-Collo, Suzanne L. Barquera, Simon Barregard, Lars Barrero, Lope H. Barrientos-Gutierrez, Tonatiuh Basto-Abreu, Ana C. Basu, Arindam Basu, Sanjay Basulaiman, Mohammed O. Ruvalcaba, Carolina Batis Beardsley, Justin Bedi, Neeraj Bekele, Tolesa Bell, Michelle L. Benjet, Corina Bennett, Derrick A. Benzian, Habib Bernabe, Eduardo Beyene, Tariku J. Bhala, Neeraj Bhalla, Ashish Bhutta, Zulfi Qar A. Bikbov, Boris Bin Abdulhak, Aref A. Blore, Jed D. Blyth, Fiona M. Bohensky, Megan A. Basara, Berrak Bora Borges, Guilherme Bornstein, Natan M. Bose, Dipan Boufous, Soufiane Bourne, Rupert R. Brainin, Michael Brazinova, Alexandra Breitborde, Nicholas J. Brenner, Hermann Briggs, Adam D. M. Broday, David M. Brooks, Peter M. Bruce, Nigel G. Brugha, Traolach S. Brunekreef, Bert Buchbinder, Rachelle Bui, Linh N. Bukhman, Gene Bulloch, Andrew G. Burch, Michael Burney, Peter G. J. Campos-Nonato, Ismael R. Campuzano, Julio C. Cantoral, Alejandra J. Caravanos, Jack Cardenas, Rosario Cardis, Elisabeth Carpenter, David O. Caso, Valeria Castaneda-Orjuela, Carlos A. Castro, Ruben E. Catala-Lopez, Ferran Cavalleri, Fiorella Cavlin, Alanur Chadha, Vineet K. Chang, Jung-chen Charlson, Fiona J. Chen, Honglei Chen, Wanqing Chen, Zhengming Chiang, Peggy P. Chimed-Ochir, Odgerel Chowdhury, Rajiv Christophi, Costas A. Chuang, Ting-Wu Chugh, Sumeet S. Cirillo, Massimo Classen, Thomas K. D. Colistro, Valentina Colomar, Mercedes Colquhoun, Samantha M. Contreras, Alejandra G. Cooper, Cyrus Cooperrider, Kimberly Cooper, Leslie T. Coresh, Josef Courville, Karen J. Criqui, Michael H. Cuevas-Nasu, Lucia Damsere-Derry, James Danawi, Hadi Dandona, Lalit Dandona, Rakhi Dargan, Paul I. Davis, Adrian Davitoiu, Dragos V. Dayama, Anand de Castro, E. Filipa De la Cruz-Gongora, Vanessa De Leo, Diego de Lima, Graca Degenhardt, Louisa del Pozo-Cruz, Borja Dellavalle, Robert P. Deribe, Kebede Derrett, Sarah Jarlais, Don C. Des Dessalegn, Muluken deVeber, Gabrielle A. Devries, Karen M. Dharmaratne, Samath D. Dherani, Mukesh K. Dicker, Daniel Ding, Eric L. Dokova, Klara Dorsey, E. Ray Driscoll, Tim R. Duan, Leilei Durrani, Adnan M. Ebel, Beth E. Ellenbogen, Richard G. Elshrek, Yousef M. Endres, Matthias Ermakov, Sergey P. Erskine, Holly E. Eshrati, Babak Esteghamati, Alireza Fahimi, Saman Faraon, Emerito Jose A. Farzadfar, Farshad Fay, Derek F. J. Feigin, Valery L. Feigl, Andrea B. Fereshtehnejad, Seyed-Mohammad Ferrari, Alize J. Ferri, Cleusa P. Flaxman, Abraham D. Fleming, Thomas D. Foigt, Nataliya Foreman, Kyle J. Paleo, Urbano Fra Franklin, Richard C. Gabbe, Belinda Gaffikin, Lynne Gakidou, Emmanuela Gamkrelidze, Amiran Gankpe, Fortune G. Gansevoort, Ron T. Garcia-Guerra, Francisco A. Gasana, Evariste Geleijnse, Johanna M. Gessner, Bradford D. Gething, Pete Gibney, Katherine B. Gillum, Richard F. Ginawi, Ibrahim A. M. Giroud, Maurice Giussani, Giorgia Goenka, Shifalika Goginashvili, Ketevan Dantes, Hector Gomez Gona, Philimon de Cosio, Teresita Gonzalez Gonzalez-Castell, Dinorah Gotay, Carolyn C. Goto, Atsushi Gouda, Hebe N. Guerrant, Richard L. Gugnani, Harish C. Guillemin, Francis Gunnell, David Gupta, Rahul Gupta, Rajeev Gutierrez, Reyna A. Hafezi-Nejad, Nima Hagan, Holly Hagstromer, Maria Halasa, Yara A. Hamadeh, Randah R. Hammami, Mouhanad Hankey, Graeme J. Hao, Yuantao Harb, Hilda L. Haregu, Tilahun Nigatu Haro, Josep Maria Havmoeller, Rasmus Hay, Simon I. Hedayati, Mohammad T. Heredia-Pi, Ileana B. Hernandez, Lucia Heuton, Kyle R. Heydarpour, Pouria Hijar, Martha Hoek, Hans W. Man, Howard J. Hoff Hornberger, John C. Hosgood, H. Dean Hoy, Damian G. Hsairi, Mohamed Hu, Guoqing Hu, Howard Huang, Cheng Huang, John J. Hubbell, Bryan J. Huiart, Laetitia Husseini, Abdullatif Iannarone, Marissa L. Iburg, Kim M. Idrisov, Bulat T. Ikeda, Nayu Innos, Kaire Inoue, Manami Islami, Farhad Ismayilova, Samaya Jacobsen, Kathryn H. Jansen, Henrica A. Jarvis, Deborah L. Jassal, Simerjot K. Jauregui, Alejandra Jayaraman, Sudha Jeemon, Panniyammakal Jensen, Paul N. Jha, Vivekanand Jiang, Fan Jiang, Guohong Jiang, Ying Jonas, Jost B. Juel, Knud Kan, Haidong Roseline, Sidibe S. Kany Karam, Nadim E. Karch, Andre Karema, Corine K. Karthikeyan, Ganesan Kaul, Anil Kawakami, Norito Kazi, Dhruv S. Kemp, Andrew H. Kengne, Andre P. Keren, Andre Khader, Yousef S. Khalifa, Shams Eldin Ali Hassan Khan, Ejaz A. Khang, Young-Ho Khatibzadeh, Shahab Khonelidze, Irma Kieling, Christian Kim, Daniel Kim, Sungroul Kim, Yunjin Kimokoti, Ruth W. Kinfu, Yohannes Kinge, Jonas M. Kissela, Brett M. Kivipelto, Miia Knibbs, Luke D. Knudsen, Ann Kristin Kokubo, Yoshihiro Kose, M. Rifat Kosen, Soewarta Kraemer, Alexander Kravchenko, Michael Krishnaswami, Sanjay Kromhout, Hans Ku, Tiffany Defo, Barthelemy Kuate Bicer, Burcu Kucuk Kuipers, Ernst J. Kulkarni, Chanda Kulkarni, Veena S. Kumar, G. Anil Kwan, Gene F. Lai, Taavi Balaji, Arjun Lakshmana Lalloo, Ratilal Lallukka, Tea Lam, Hilton Lan, Qing Lansingh, Van C. Larson, Heidi J. Larsson, Anders Laryea, Dennis O. Lavados, Pablo M. Lawrynowicz, Alicia E. Leasher, Janet L. Lee, Jong-Tae Leigh, James Leung, Ricky Levi, Miriam Li, Yichong Li, Yongmei Liang, Juan Liang, Xiaofeng Lim, Stephen S. Lindsay, M. Patrice Lipshultz, Steven E. Liu, Shiwei Liu, Yang Lloyd, Belinda K. Logroscino, Giancarlo London, Stephanie J. Lopez, Nancy Lortet-Tieulent, Joannie Lotufo, Paulo A. Lozano, Rafael Lunevicius, Raimundas Ma, Jixiang Ma, Stefan Machado, Vasco M. P. MacIntyre, Michael F. Magis-Rodriguez, Carlos Mahdi, Abbas A. Majdan, Marek Malekzadeh, Reza Mangalam, Srikanth Mapoma, Christopher C. Marape, Marape Marcenes, Wagner Margolis, David J. Margono, Christopher Marks, Guy B. Martin, Randall V. Marzan, Melvin B. Mashal, Mohammad T. Masiye, Felix Mason-Jones, Amanda J. Matsushita, Kunihiro Matzopoulos, Richard Mayosi, Bongani M. Mazorodze, Tasara T. Mckay, Abigail C. Mckee, Martin McLain, Abigail Meaney, Peter A. Medina, Catalina Mehndiratta, Man Mohan Mejia-Rodriguez, Fabiola Mekonnen, Wubegzier Melaku, Yohannes A. Meltzer, Michele Memish, Ziad A. Mendoza, Walter Mensah, George A. Meretoja, Atte Mhimbira, Francis Apolinary Micha, Renata Miller, Ted R. Mills, Edward J. Misganaw, Awoke Mishra, Santosh Ibrahim, Norlinah Mohamed Mohammad, Karzan A. Mokdad, Ali H. Mola, Glen L. Monasta, Lorenzo Hernandez, Julio C. Montaez Montico, Marcella Moore, Ami R. Morawska, Lidia Mori, Rintaro Moschandreas, Joanna Moturi, Wilkister N. Arian, Dariush Mozaff Mueller, Ulrich O. Mukaigawara, Mitsuru Mullany, Erin C. Murthy, Kinnari S. Naghavi, Mohsen Nahas, Ziad Naheed, Aliya Naidoo, Kovin S. Naldi, Luigi Nand, Devina Nangia, Vinay Narayan, K. M. Venkat Nash, Denis Neal, Bruce Nejjari, Chakib Neupane, Sudan P. Newton, Charles R. Ngalesoni, Frida N. Ngirabega, Jean de Dieu Nguyen, Grant Nguyen, Nhung T. Nieuwenhuijsen, Mark J. Nisar, Muhammad I. Nogueira, Jose R. Nolla, Joan M. Nolte, Sandra Norheim, Ole F. Norman, Rosana E. Norrving, Bo Nyakarahuka, Luke Oh, In-Hwan Ohkubo, Takayoshi Olusanya, Bolajoko O. Omer, Saad B. Opio, John Nelson Orozco, Ricardo Pagcatipunan, Rodolfo S., Jr. Pain, Amanda W. Pandian, Jeyaraj D. Panelo, Carlo Irwin A. Papachristou, Christina Park, Eun-Kee Parry, Charles D. Caicedo, Angel J. Paternina Patten, Scott B. Paul, Vinod K. Pavlin, Boris I. Pearce, Neil Pedraza, Lilia S. Pedroza, Andrea Stokic, Ljiljana Pejin Pekericli, Ayfer Pereira, David M. Perez-Padilla, Rogelio Perez-Ruiz, Fernando Perico, Norberto Perry, Samuel A. L. Pervaiz, Aslam Pesudovs, Konrad Peterson, Carrie B. Petzold, Max Phillips, Michael R. Phua, Hwee Pin Plass, Dietrich Poenaru, Dan Polanczyk, Guilherme V. Polinder, Suzanne Pond, Constance D. Pope, C. Arden Pope, Daniel Popova, Svetlana Pourmalek, Farshad Powles, John Prabhakaran, Dorairaj Prasad, Noela M. Qato, Dima M. Quezada, Amado D. Quistberg, D. Alex A. Racape, Lionel Rafay, Anwar Rahimi, Kazem Rahimi-Movaghar, Vafa Rahman, Sajjad Ur Raju, Murugesan Rakovac, Ivo Rana, Saleem M. Rao, Mayuree Razavi, Homie Reddy, K. Srinath Refaat, Amany H. Rehm, Juergen Remuzzi, Giuseppe Ribeiro, Antonio L. Riccio, Patricia M. Richardson, Lee Riederer, Anne Robinson, Margaret Roca, Anna Rodriguez, Alina Rojas-Rueda, David Romieu, Isabelle Ronfani, Luca Room, Robin Roy, Nobhojit Ruhago, George M. Rushton, Lesley Sabin, Nsanzimana Sacco, Ralph L. Saha, Sukanta Sahathevan, Ramesh Sahraian, Mohammad Ali Salomon, Joshua A. Salvo, Deborah Sampson, Uchechukwu K. Sanabria, Juan R. Sanchez, Luz Maria Sanchez-Pimienta, Tania G. Sanchez-Riera, Lidia Sandar, Logan Santos, Itamar S. Sapkota, Amir Satpathy, Maheswar Saunders, James E. Sawhney, Monika Saylan, Mete I. Scarborough, Peter Schmidt, Juergen C. Schneider, Ione J. C. Schoettker, Ben Schwebel, David C. Scott, James G. Seedat, Soraya Sepanlou, Sadaf G. Serdar, Berrin Servan-Mori, Edson E. Shaddick, Gavin Shahraz, Saeid Levy, Teresa Shamah Shangguan, Siyi She, Jun Sheikhbahaei, Sara Shibuya, Kenji Shin, Hwashin H. Shinohara, Yukito Shiri, Rahman Shishani, Kawkab Shiue, Ivy Sigfusdottir, Inga D. Silberberg, Donald H. Simard, Edgar P. Sindi, Shireen Singh, Abhishek Singh, Gitanjali M. Singh, Jasvinder A. Skirbekk, Vegard Sliwa, Karen Soljak, Michael Soneji, Samir Soreide, Kjetil Soshnikov, Sergey Sposato, Luciano A. Sreeramareddy, Chandrashekhar T. Stapelberg, Nicolas J. C. Stathopoulou, Vasiliki Steckling, Nadine Stein, Dan J. Stein, Murray B. Stephens, Natalie Stoeckl, Heidi Straif, Kurt Stroumpoulis, Konstantinos Sturua, Lela Sunguya, Bruno F. Swaminathan, Soumya Swaroop, Mamta Sykes, Bryan L. Tabb, Karen M. Takahashi, Ken Talongwa, Roberto T. Tandon, Nikhil Tanne, David Tanner, Marcel Tavakkoli, Mohammad Ao, Braden J. Te Teixeira, Carolina M. Rojo, Martha M. Tellez Terkawi, Abdullah S. Texcalac-Sangrador, Jose Luis Thackway, Sarah V. Thomson, Blake Thorne-Lyman, Andrew L. Thrift, Amanda G. Thurston, George D. Tillmann, Taavi Tobollik, Myriam Tonelli, Marcello Topouzis, Fotis Towbin, Jeff Rey A. Toyoshima, Hideaki Traebert, Jeff Erson Tran, Bach X. Trasande, Leonardo Trillini, Matias Trujillo, Ulises Dimbuene, Zacharie Tsala Tsilimbaris, Miltiadis Tuzcu, Emin Murat Uchendu, Uche S. Ukwaja, Kingsley N. Uzun, Selen B. van de Vijver, Steven Van Dingenen, Rita Van Gool, Coen H. Van Os, Jim Varakin, Yuri Y. Vasankari, Tommi J. Vasconcelos, Ana Maria N. Vavilala, Monica S. Veerman, Lennert J. Velasquez-Melendez, Gustavo Venketasubramanian, N. Vijayakumar, Lakshmi Villalpando, Salvador Violante, Francesco S. Vlassov, Vasiliy Victorovich Vollset, Stein Emil Wagner, Gregory R. Waller, Stephen G. Wallin, Mitchell T. Wan, Xia Wang, Haidong Wang, JianLi Wang, Linhong Wang, Wenzhi Wang, Yanping Warouw, Tati S. Watts, Charlotte H. Weichenthal, Scott Weiderpass, Elisabete Weintraub, Robert G. Werdecker, Andrea Wessells, K. Ryan Westerman, Ronny Whiteford, Harvey A. Wilkinson, James D. Williams, Hywel C. Williams, Thomas N. Woldeyohannes, Solomon M. Wolfe, Charles D. A. Wong, John Q. Woolf, Anthony D. Wright, Jonathan L. Wurtz, Brittany Xu, Gelin Yan, Lijing L. Yang, Gonghuan Yano, Yuichiro Ye, Pengpeng Yenesew, Muluken Yentuer, Goekalp K. Yip, Paul Yonemoto, Naohiro Yoon, Seok-Jun Younis, Mustafa Z. Younoussi, Zourkaleini Yu, Chuanhua Zaki, Maysaa E. Zhao, Yong Zheng, Yingfeng Zhou, Maigeng Zhu, Jun Zhu, Shankuan Zou, Xiaonong Zunt, Joseph R. Lopez, Alan D. Vos, Theo Murray, Christopher J. CA GBD 2013 Risk Factors TI Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 SO LANCET LA English DT Article ID BODY-MASS INDEX; CORONARY-HEART-DISEASE; CAUSE-SPECIFIC MORTALITY; FINE PARTICULATE MATTER; OUTDOOR AIR-POLLUTION; MALE BRITISH DOCTORS; ALL-CAUSE MORTALITY; LONG-TERM EXPOSURE; BLOOD-PRESSURE; TOBACCO SMOKING AB Background The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity to update the comparative risk assessment with new data for exposure, relative risks, and evidence on the appropriate counterfactual risk distribution. Methods Attributable deaths, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) have been estimated for 79 risks or clusters of risks using the GBD 2010 methods. Risk-outcome pairs meeting explicit evidence criteria were assessed for 188 countries for the period 1990-2013 by age and sex using three inputs: risk exposure, relative risks, and the theoretical minimum risk exposure level (TMREL). Risks are organised into a hierarchy with blocks of behavioural, environmental and occupational, and metabolic risks at the first level of the hierarchy. The next level in the hierarchy includes nine clusters of related risks and two individual risks, with more detail provided at levels 3 and 4 of the hierarchy. Compared with GBD 2010, six new risk factors have been added: handwashing practices, occupational exposure to trichloroethylene, childhood wasting, childhood stunting, unsafe sex, and low glomerular filtration rate. For most risks, data for exposure were synthesised with a Bayesian meta-regression method, DisMod-MR 2.0, or spatial-temporal Gaussian process regression. Relative risks were based on meta-regressions of published cohort and intervention studies. Attributable burden for clusters of risks and all risks combined took into account evidence on the mediation of some risks such as high body-mass index (BMI) through other risks such as high systolic blood pressure and high cholesterol. Findings All risks combined account for 57.2% (95% uncertainty interval [UI] 55.8-58.5) of deaths and 41.6% (40.1-43.0) of DALYs. Risks quantified account for 87.9% (86.5-89.3) of cardiovascular disease DALYs, ranging to a low of 0% for neonatal disorders and neglected tropical diseases and malaria. In terms of global DALYs in 2013, six risks or clusters of risks each caused more than 5% of DALYs: dietary risks accounting for 11.3 million deaths and 241.4 million DALYs, high systolic blood pressure for 10.4 million deaths and 208.1 million DALYs, child and maternal malnutrition for 1.7 million deaths and 176.9 million DALYs, tobacco smoke for 6.1 million deaths and 143.5 million DALYs, air pollution for 5.5 million deaths and 141.5 million DALYs, and high BMI for 4.4 million deaths and 134.0 million DALYs. Risk factor patterns vary across regions and countries and with time. In sub-Saharan Africa, the leading risk factors are child and maternal malnutrition, unsafe sex, and unsafe water, sanitation, and handwashing. In women, in nearly all countries in the Americas, north Africa, and the Middle East, and in many other high-income countries, high BMI is the leading risk factor, with high systolic blood pressure as the leading risk in most of Central and Eastern Europe and south and east Asia. For men, high systolic blood pressure or tobacco use are the leading risks in nearly all high-income countries, in north Africa and the Middle East, Europe, and Asia. For men and women, unsafe sex is the leading risk in a corridor from Kenya to South Africa. Interpretation Behavioural, environmental and occupational, and metabolic risks can explain half of global mortality and more than one-third of global DALYs providing many opportunities for prevention. Of the larger risks, the attributable burden of high BMI has increased in the past 23 years. In view of the prominence of behavioural risk factors, behavioural and social science research on interventions for these risks should be strengthened. Many prevention and primary care policy options are available now to act on key risks. C1 [Forouzanfar, Mohammad H.; Alexander, Lily; Bachman, Victoria F.; Biryukov, Stan; Brauer, Michael; Casey, Daniel; Coates, Matthew M.; Cohen, Aaron; Delwiche, Kristen; Estep, Kara; Frostad, Joseph J.; Kyu, Hmwe H.; Moradi-Lakeh, Maziar; Ng, Marie; Slepak, Erica Leigh; Thomas, Bernadette A.; Wagner, Joseph; Achoki, Tom; Atkinson, Charles; Barber, Ryan M.; Cooperrider, Kimberly; Dandona, Lalit; Dicker, Daniel; Flaxman, Abraham D.; Fleming, Thomas D.; Foreman, Kyle J.; Gakidou, Emmanuela; Hay, Simon I.; Heuton, Kyle R.; Iannarone, Marissa L.; Ku, Tiffany; Larson, Heidi J.; Lim, Stephen S.; Lozano, Rafael; MacIntyre, Michael F.; Margono, Christopher; McLain, Abigail; Mokdad, Ali H.; Mullany, Erin C.; Naghavi, Mohsen; Nguyen, Grant; Pain, Amanda W.; Richardson, Lee; Robinson, Margaret; Sandar, Logan; Stephens, Natalie; Thomson, Blake; Wan, Xia; Wurtz, Brittany; Lopez, Alan D.; Vos, Theo; Murray, Christopher J.] Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. [Ebel, Beth E.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA. [Ellenbogen, Richard G.] Univ Washington, Harborview UW Med, Seattle, WA 98195 USA. [Wright, Jonathan L.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Alfonso-Cristancho, Rafael; Anderson, Benjamin O.; Jensen, Paul N.; Quistberg, D. Alex A.; Riederer, Anne; Vavilala, Monica S.; Zunt, Joseph R.] Univ Washington, Seattle, WA 98195 USA. [Anderson, H. Ross] Univ London, St Georges, London, England. [Pourmalek, Farshad] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada. [Brauer, Michael; Gotay, Carolyn C.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Burnett, Richard; Shin, Hwashin H.; Weichenthal, Scott] Hlth Canada, Ottawa, ON K1A 0L2, Canada. [Cohen, Aaron] Hlth Effects Inst, Boston, MA USA. [Moradi-Lakeh, Maziar] Iran Univ Med Sci, Dept Community Med, Tehran, Iran. [Knudsen, Ann Kristin] Norwegian Inst Publ Hlth, Dept Hlth Registries, Oslo, Norway. [Aasvang, Gunn Marit; Kinge, Jonas M.; Skirbekk, Vegard; Vollset, Stein Emil] Norwegian Inst Publ Hlth, Oslo, Norway. [Abbafati, Cristiana] Univ Roma La Sapienza, I-00185 Rome, Italy. [Ozgoren, Ayse Abbasoglu; Cavlin, Alanur] Hacettepe Univ, Inst Populat Studies, Ankara, Turkey. [Bicer, Burcu Kucuk] Hacettepe Univ, Inst Publ Hlth, Ankara, Turkey. [Abd-Allah, Foad] Cairo Univ, Fac Med, Cairo, Egypt. [Abera, Semaw F.] Mekelle Univ, Sch Publ Hlth, Coll Hlth Sci, Mekelle, Ethiopia. [Melaku, Yohannes A.] Mekelle Univ, Mekelle, Ethiopia. [Abera, Semaw F.] Kilte Awlaelo Hlth & Demog Surveillance Site, Mekelle, Ethiopia. [Aboyans, Victor] Dupuytren Univ Hosp, Limoges, France. [Abraham, Biju] Govt Coll Munnar, Munnar, India. [Abraham, Jerry Puthenpurakal] Univ So Calif, Calif Hosp, Family Med Residency Program, Los Angeles, CA USA. [Abraham, Jerry Puthenpurakal] Harvard Univ, Inst Global Hlth, Boston, MA 02115 USA. [Thorne-Lyman, Andrew L.] Harvard Univ, Dept Nutr, Boston, MA 02115 USA. [Ding, Eric L.; Fahimi, Saman; Khatibzadeh, Shahab; Wagner, Gregory R.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Bukhman, Gene] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA. [Campos-Nonato, Ismael R.; Feigl, Andrea B.; Salomon, Joshua A.] Harvard Univ, Boston, MA 02115 USA. [Benzian, Habib] UCL, Dept Epidemiol & Publ Hlth, London, England. [Abubakar, Ibrahim] UCL, London, England. [Abu-Rmeileh, Niveen M. E.] Birzeit Univ, Inst Community & Publ Hlth, Ramallah, Pakistan. [Aburto, Tania C.; Avila, Marco A.; Barquera, Simon; Barrientos-Gutierrez, Tonatiuh; Campos-Nonato, Ismael R.; Campuzano, Julio C.; Cantoral, Alejandra J.; Contreras, Alejandra G.; Cuevas-Nasu, Lucia; De la Cruz-Gongora, Vanessa; Garcia-Guerra, Francisco A.; Dantes, Hector Gomez; de Cosio, Teresita Gonzalez; Gonzalez-Castell, Dinorah; Heredia-Pi, Ileana B.; Hernandez, Lucia; Jauregui, Alejandra; Lozano, Rafael; Medina, Catalina; Mejia-Rodriguez, Fabiola; Hernandez, Julio C. Montaez; Pedraza, Lilia S.; Pedroza, Andrea; Quezada, Amado D.; Salvo, Deborah; Sanchez, Luz Maria; Sanchez-Pimienta, Tania G.; Servan-Mori, Edson E.; Levy, Teresa Shamah; Rojo, Martha M. Tellez; Villalpando, Salvador] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico. [Adelekan, Ademola] Publ Hlth Promot Alliance, Osogbo, Nigeria. [Adofo, Koranteng] Kwame Nkrumah Univ Sci, Kumasi, Ghana. [Adou, Arsene K.] Assoc Ivoirienne Bien Etre Familial, Abidjan, Cote Ivoire. [Adsuar, Jose C.; Paleo, Urbano Fra] Univ Extremadura, Caceres, Spain. [Afshin, Ashkan; Micha, Renata; Arian, Dariush Mozaff] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA USA. [Shahraz, Saeid; Shangguan, Siyi] Tufts Univ, Tufts Med Ctr, Boston, MA USA. [Agardh, Emilie E.] Inst Publ Hlth Sci, Stockholm, Sweden. [Al Khabouri, Mazin J.] Minist Hlth, Muscat, Oman. [Al Lami, Faris H.] Baghdad Coll Med, Baghdad, Iraq. [Alam, Sayed Saidul; Naheed, Aliya] icddr b, Dhaka, Bangladesh. [Alasfoor, Deena] Minist Hlth, Al Khuwair, Oman. [Albittar, Mohammed I.] Independent, Damascus, Syria. [Alegretti, Miguel A.] Univ Republica, Dept Prevent & Social Med, Montevideo, Uruguay. [Cavalleri, Fiorella] Univ Republica, Fac Med, Montevideo, Uruguay. [Alemu, Zewdie A.] Debre Markos Univ, Addis Ababa, Ethiopia. [Alhabib, Samia] King Abdullah Bin Abdulaziz Univ Hosp, Riyadh, Saudi Arabia. [Chen, Zhengming] Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England. [Gething, Pete] Univ Oxford, Dept Zool, Oxford, England. [Ali, Raghib; Bennett, Derrick A.; Briggs, Adam D. M.; Hay, Simon I.; Rahimi, Kazem; Scarborough, Peter] Univ Oxford, Oxford, England. [Singh, Gitanjali M.] Tufts Univ, Boston, MA USA. [Aleman, Alicia V.; Colistro, Valentina] Univ Republica, Montevideo, Uruguay. [Simard, Edgar P.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA USA. [Ali, Mohammed K.; Cunningham, Solveig Argeseanu; Liu, Yang; Narayan, K. M. Venkat; Omer, Saad B.] Emory Univ, Atlanta, GA USA. [Alla, Francois; Guillemin, Francis] Univ Lorraine, Nancy, France. [Allebeck, Peter; Roy, Nobhojit] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. [Kivipelto, Miia] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden. [Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Fereshtehnejad, Seyed-Mohammad] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden. [Havmoeller, Rasmus; Sindi, Shireen] Karolinska Inst, Stockholm, Sweden. [Allen, Peter J.] Minist Hlth, Belmopan, Belize. [Alsharif, Ubai; Endres, Matthias; Nolte, Sandra; Papachristou, Christina] Charite, Berlin, Germany. [Alvarez, Elena] Govt, Madrid, Spain. [Alvis-Guzman, Nelson; Caicedo, Angel J. Paternina] Univ Cartagena, Cartagena De Indias, Colombia. [Amankwaa, Adansi A.] Albany State Univ, Albany, GA 31705 USA. [Amare, Azmeraw T.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Hoek, Hans W.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands. [Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Amare, Azmeraw T.] Bahir Dar Univ, Coll Med & Hlth Sci, Bahir Dar, Ethiopia. [Yenesew, Muluken] Bahir Dar Univ, Bahir Dar, Ethiopia. [Ameh, Emmanuel A.] Ahmadu Bello Univ, Zaria, Nigeria. [Ameli, Omid] Boston Univ, Boston, MA USA. [Amini, Heresh] Kurdistan Univ Med Sci, Kurdistan Environm Hlth Res Ctr, Sanandaj, Iran. [Amini, Heresh] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland. [Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Amini, Heresh] Univ Basel, Basel, Switzerland. [Ammar, Walid; Harb, Hilda L.] Minist Publ Hlth, Beirut, Lebanon. [Faraon, Emerito Jose A.] Univ Philippines Manila, Coll Publ Hlth, Manila, Philippines. [Antonio, Carl Abelardo T.] Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, Philippines. [Panelo, Carlo Irwin A.] Univ Philippines Manila, Manila, Philippines. [Arnlov, Johan] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Larsson, Anders] Uppsala Univ, Uppsala, Sweden. [Arnlov, Johan] Dalarna Univ, Falun, Sweden. [Arsenijevic, Valentina S. Arsic] Univ Belgrade, Inst Microbiol & Immunol, Sch Med, Belgrade, Serbia. [Arsenijevic, Valentina S. Arsic] Univ Childrens Hosp Belgrade, Belgrade, Serbia. [Asghar, Rana J.] South Asian Publ Hlth Forum, Islamabad, Pakistan. [Assadi, Reza] Mashhad Univ Med Sci, Mashhad, Iran. [Atkins, Lydia S.] Minist Hlth, Wellness Human Serv & Gender Relat, St Lucia, Qld, Australia. [Awuah, Baffour; Laryea, Dennis O.] Komfo Anokye Teaching Hosp, Kumasi, Ghana. [Badawi, Alaa] Publ Hlth Agcy Canada, Toronto, ON, Canada. [Bahit, Maria C.] INECO Neurociencias, Rosario, Argentina. [Bakfalouni, Talal] Minist Hlth, Damascus, Syria. [Balakrishnan, Kalpana] Sri Ramachandra Univ, Madras, Tamil Nadu, India. [Balalla, Shivanthi; Feigin, Valery L.] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand. [Ao, Braden J. Te] Auckland Univ Technol, Auckland, New Zealand. [Balu, Ravi Kumar; Dandona, Lalit; Dandona, Rakhi; Goenka, Shifalika; Kumar, G. Anil; Murthy, Kinnari S.; Reddy, K. Srinath] Publ Hlth Fdn India, Delhi, India. [Banerjee, Amitava] Univ Birmingham, Birmingham, W Midlands, England. [Barker-Collo, Suzanne L.] Univ Auckland, Sch Psychol, Auckland, New Zealand. [del Pozo-Cruz, Borja] Univ Auckland, Auckland, New Zealand. [Barregard, Lars] Univ Gothenburg, Dept Occupat & Environm Hlth, Gothenburg, Sweden. [Barrero, Lope H.] Pontificia Univ Javeriana, Dept Ind Engn, Bogota, Colombia. [Basto-Abreu, Ana C.; Ruvalcaba, Carolina Batis; de Castro, E. Filipa; Lopez, Nancy; Texcalac-Sangrador, Jose Luis] Natl Inst Publ Hlth, Mexico City, DF, Mexico. [Basu, Arindam] Univ Canterbury, Sch Hlth Sci, Christchurch, New Zealand. [Gaffikin, Lynne] Stanford Univ, Sch Med, Stanford, CA USA. [Basu, Sanjay] Stanford Univ, Stanford, CA 94305 USA. [Basulaiman, Mohammed O.; Memish, Ziad A.] Minist Hlth, Riyadh, Saudi Arabia. [Beardsley, Justin] Univ Oxford, Ho Hi Minh City, Vietnam. [Bedi, Neeraj] Coll Publ Hlth & Trop Med, Jazan, Saudi Arabia. [Bekele, Tolesa] Madawalabu Univ, Bale Robe, Ethiopia. [Bell, Michelle L.] Yale Univ, New Haven, CT USA. [Benjet, Corina; Borges, Guilherme; Gutierrez, Reyna A.; Orozco, Ricardo] Natl Inst Psychiat Ramon Fuente Muniz, Mexico City, DF, Mexico. [Benzian, Habib] NYU, Coll Dent, Dept Epidemiol & Hlth Promot, New York, NY 10003 USA. [Trasande, Leonardo] NYU, Sch Med, New York, NY USA. [Hagan, Holly] NYU, New York, NY 10003 USA. [Bernabe, Eduardo; Wolfe, Charles D. A.] Kings Coll London, London, England. [Beyene, Tariku J.] Addis Ababa Univ, Debre Zeyit, Ethiopia. [Bhala, Neeraj] Queen Elizabeth Hosp, Birmingham, W Midlands, England. [Bhala, Neeraj] Univ Otago, Capital & Coast District Hlth Board, Wellington, New Zealand. [Derrett, Sarah] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Wellington, New Zealand. [Bhalla, Ashish; Jha, Vivekanand] Postgrad Inst Med Educ & Res, Chandigarh, India. [Bhutta, Zulfi Qar A.] Aga Khan Univ, Med Ctr, Karachi, Pakistan. [Nisar, Muhammad I.] Aga Khan Univ, Karachi, Pakistan. [Bikbov, Boris] AI Evdokimov Moscow State Univ Med & Dent, Moscow, Russia. [Bikbov, Boris] Acad VI Shumakov Fed Res Ctr Transplantol & Artif, Moscow, Russia. [Bin Abdulhak, Aref A.] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. [Vijayakumar, Lakshmi] Univ Melbourne, Ctr Youth Mental Hlth, Melbourne, Vic, Australia. [Chiang, Peggy P.] Univ Melbourne, Gen Practice & Primary Hlth Care Acad Ctr, Melbourne, Vic, Australia. [Blore, Jed D.; Brooks, Peter M.; Colquhoun, Samantha M.; Balaji, Arjun Lakshmana; Weintraub, Robert G.; Lopez, Alan D.] Univ Melbourne, Melbourne, Vic, Australia. [Blyth, Fiona M.] Univ Sydney, Concord, NSW, Australia. [Meretoja, Atte] Univ Melbourne, Dept Florey, Parkville, Vic, Australia. [Meretoja, Atte] Univ Melbourne, Dept Med, Parkville, Vic, Australia. [Bohensky, Megan A.] Univ Melbourne, Parkville, Vic, Australia. [Basara, Berrak Bora; Yentuer, Goekalp K.] Minist Hlth, Gen Directorate Hlth Res, Ankara, Turkey. [Kose, M. Rifat; Pekericli, Ayfer; Uzun, Selen B.] Minist Hlth, Ankara, Turkey. [Bornstein, Natan M.] Tel Aviv Saurasky Med Ctr, Tel Aviv, Israel. [Bose, Dipan] World Bank, Washington, DC USA. [Boufous, Soufiane] Univ New S Wales, Transport & Rd Safety, Sydney, NSW, Australia. [Degenhardt, Louisa] Univ New S Wales, Sydney, NSW, Australia. [Bourne, Rupert R.] Anglia Ruskin Univ, Cambridge, England. [Brainin, Michael] Danube Univ Krems, Krems, Austria. [Brazinova, Alexandra; Majdan, Marek] Trnava Univ, Fac Hlth Sci & Social Work, Trnava, Slovakia. [Breitborde, Nicholas J.] Ohio State Univ, Columbus, OH USA. [Breitborde, Nicholas J.] Univ Arizona, Tucson, AZ USA. [Schoettker, Ben] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Brenner, Hermann] German Canc Res Ctr, Heidelberg, Germany. [Broday, David M.] Technion, Haifa, Israel. [Lunevicius, Raimundas] Univ Liverpool, Sch Med, Liverpool, Merseyside, England. [Bruce, Nigel G.; Dherani, Mukesh K.; Pope, Daniel] Univ Liverpool, Liverpool, Merseyside, England. [Brugha, Traolach S.] Univ Leicester, Leicester, Leics, England. [Brunekreef, Bert; Kromhout, Hans] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands. [Buchbinder, Rachelle] Cabrini Inst, Monash Dept Clin Epidemiol, Melbourne, Vic, Australia. [Buchbinder, Rachelle] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia. [Gabbe, Belinda; Gibney, Katherine B.; Thrift, Amanda G.] Monash Univ, Melbourne, Vic, Australia. [Bui, Linh N.; Nguyen, Nhung T.] Hanoi Sch Publ Hlth, Hanoi, Vietnam. [Bulloch, Andrew G.; Patten, Scott B.; Tonelli, Marcello; Wang, JianLi] Univ Calgary, Calgary, AB, Canada. [Burch, Michael] Great Ormond St Hosp Sick Children, London, England. [Burney, Peter G. J.; Foreman, Kyle J.; Jarvis, Deborah L.; Rodriguez, Alina; Rushton, Lesley; Soljak, Michael; Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, London, England. [Caravanos, Jack; Nash, Denis] CUNY, Sch Publ Hlth, New York, NY USA. [Cardenas, Rosario] Univ Autonoma Metropolitana, Mexico City, DF, Mexico. [Cardis, Elisabeth; Nieuwenhuijsen, Mark J.; Rojas-Rueda, David] Ctr Res Environm Epidemiol, Barcelona, Spain. [Carpenter, David O.; Leung, Ricky] SUNY Albany, Rensselaer, NY USA. [Caso, Valeria] Univ Perugia, Stroke Unit, Perugia, Italy. [Castaneda-Orjuela, Carlos A.] Colombian Natl Hlth Observ, Inst Nacl Salud, Bogota, Colombia. [Castaneda-Orjuela, Carlos A.] Univ Nacl Colombia, Dept Publ Hlth, Epidemiol & Publ Hlth Evaluat Grp, Bogota, Colombia. [Castro, Ruben E.] Univ Diego Portales, Santiago, Chile. [Catala-Lopez, Ferran] Spanish Med & Healthcare Prod Agcy, Minist Hlth, Div Pharmacoepidemiol & Pharmacovigilance, Madrid, Spain. [Catala-Lopez, Ferran] Univ Valencia, Dept Med, CIBERSAM, Valencia, Spain. [Chadha, Vineet K.] Natl TB Inst, Bangalore, Karnataka, India. [Chang, Jung-chen] Natl Taiwan Univ, Taipei, Taiwan. [Scott, James G.] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia. [Hoy, Damian G.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia. [Knibbs, Luke D.] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia. [Charlson, Fiona J.; Erskine, Holly E.; Ferrari, Alize J.; Gouda, Hebe N.; Veerman, Lennert J.; Whiteford, Harvey A.] Univ Queensland, Brisbane, Qld, Australia. [Chen, Wanqing; Zou, Xiaonong] Chinese Acad Med Sci, Canc Inst, Beijing, Peoples R China. [Wan, Xia] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing, Peoples R China. [Chen, Honglei; London, Stephanie J.] NIEHS, Div Intramural Res, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC USA. [Jiang, Ying] Univ Occupat & Environm Hlth, Dept Hlth Dev, Kitakyushu, Fukuoka 807, Japan. [Takahashi, Ken] Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Kitakyushu, Fukuoka 807, Japan. [Chimed-Ochir, Odgerel] Univ Occupat & Environm Hlth, Dept Environm Epidemiol, Kitakyushu, Fukuoka 807, Japan. [Chowdhury, Rajiv; Powles, John] Univ Cambridge, Cambridge, England. [Christophi, Costas A.] Cyprus Univ Technol, Limassol, Cyprus. [Chuang, Ting-Wu] Taipei Med Univ, Taipei, Taiwan. [Chugh, Sumeet S.] Cedars Sinai Med Ctr, Los Angeles, CA USA. [Cirillo, Massimo] Univ Salerno, Baronissi, Italy. [Classen, Thomas K. D.] Univ Bielefeld, Dept Environm & Hlth, Bielefeld, Germany. [Kraemer, Alexander; Tobollik, Myriam] Univ Bielefeld, Sch Publ Hlth, Bielefeld, Germany. [Colomar, Mercedes] UNICEM, Montevideo, Uruguay. [Colquhoun, Samantha M.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Cooper, Cyrus] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England. [Cooper, Leslie T.] Mayo Clin, Rochester, MN USA. [Coresh, Josef; Matsushita, Kunihiro] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. [Tran, Bach X.] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Courville, Karen J.] Hosp Dr Gustavo N Collado, Chitre, Panama. [Criqui, Michael H.; Stein, Murray B.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Damsere-Derry, James] Bldg & Rd Res Inst, Kumasi, Ghana. [Danawi, Hadi; Refaat, Amany H.] Walden Univ, Minneapolis, MN USA. [Dargan, Paul I.] Guys & St Thomas NHS Fdn Trust, London, England. [Davis, Adrian; Fay, Derek F. J.; Schmidt, Juergen C.] Publ Hlth England, London, England. [Davitoiu, Dragos V.] Univ Med & Pharm Bucharest, Bucharest, Romania. [Dayama, Anand] Jacobi Med Ctr, Dept Surg, Atlanta, GA USA. [De Leo, Diego] Griffith Univ, Brisbane, Qld, Australia. [de Lima, Graca] Local Hlth Unit Matosinhos, Matosinhos, Portugal. [de Lima, Graca; Machado, Vasco M. P.] Northern Reg Hlth Adm, Dept Publ Hlth, Oporto, Portugal. [Nogueira, Jose R.; Teixeira, Carolina M.] Northern Reg Hlth Adm, Oporto, Portugal. [Dellavalle, Robert P.] Eastern Colorado Healthcare Syst, US Dept Vet Affairs, Denver, CO USA. [Deribe, Kebede] Brighton & Sussex Med Sch, Brighton, E Sussex, England. [Deribe, Kebede] Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, Ethiopia. [Mekonnen, Wubegzier] Univ Addis Ababa, Addis Ababa, Ethiopia. [Derrett, Sarah] Massey Univ, Coll Hlth, Sch Publ Hlth, Palmerston North, New Zealand. [Jarlais, Don C. Des] Mt Sinai Beth Israel, New York, NY USA. [Jarlais, Don C. Des] Icahn Sch Med Mt Sinai, New York, NY USA. [Dessalegn, Muluken] Africa Med & Res Fdn Ethiopia, Addis Ababa, Ethiopia. [deVeber, Gabrielle A.] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada. [Lindsay, M. Patrice] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Hu, Howard] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Devries, Karen M.; Larson, Heidi J.; Mckee, Martin; Pearce, Neil; Stoeckl, Heidi; Tillmann, Taavi; Watts, Charlotte H.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England. [Dharmaratne, Samath D.] Univ Peradeniya, Peradeniya, Sri Lanka. [Dokova, Klara] Med Univ Varna, Fac Publ Hlth, Dept Social Med, Varna, Bulgaria. [Dorsey, E. Ray] Univ Rochester, Med Ctr, Rochester, NY USA. [Driscoll, Tim R.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia. [Marks, Guy B.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia. [Leigh, James] Univ Sydney, Sydney, NSW 2006, Australia. [Duan, Leilei; Li, Yichong; Liu, Shiwei; Ma, Jixiang; Wang, Linhong; Ye, Pengpeng; Zhou, Maigeng] Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China. [Durrani, Adnan M.] Natl Inst Hlth, Montgomery Village, MD USA. [Elshrek, Yousef M.] Univ Tripoli, Fac Agr, Dept Food Sci, Tripoli, Libya. [Ermakov, Sergey P.] Russian Acad Sci, Inst Social & Econ Studies Populat, Moscow, Russia. [Ermakov, Sergey P.; Soshnikov, Sergey] Minist Hlth Russian Federat, Fed Res Inst Hlth Org & Informat, Moscow, Russia. [Liang, Xiaofeng] China CDC, Beijing, Peoples R China. [Eshrati, Babak] Arak Univ Med Sci & Hlth Affairs, Arak, Iran. [Farzadfar, Farshad] Univ Tehran Med Sci, NonCommunicable Dis Res Ctr, Tehran, Iran. [Heydarpour, Pouria; Sahraian, Mohammad Ali] Univ Tehran Med Sci, Multiple Sclerosis Res Ctr, Neurosci Inst, Tehran, Iran. [Sepanlou, Sadaf G.] Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran. [Rahimi-Movaghar, Vafa] Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, Iran. [Ferri, Cleusa P.] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Foigt, Nataliya] Acad Med Sci, Inst Gerontol, Kiev, Ukraine. [Franklin, Richard C.] James Cook Univ, Townsville, Qld, Australia. [Gamkrelidze, Amiran; Khonelidze, Irma; Sturua, Lela] Natl Ctr Dis Control & Publ Hlth, Tbilisi, Rep of Georgia. [Gankpe, Fortune G.] Leras Afrique, Cotonou, Benin. [Gankpe, Fortune G.] CHU Hassan II, Fes, Morocco. [Gasana, Evariste] Rwanda Biomed Ctr, TB & Other Respir Dis Div, Kigali, Rwanda. [Sabin, Nsanzimana] Rwanda Biomed Ctr, Kigali, Rwanda. [Geleijnse, Johanna M.] Wageningen Univ, Div Human Nutr, Wageningen, Netherlands. [Gessner, Bradford D.] Agence Med Prevent, Paris, France. [Gibney, Katherine B.] Melbourne Hlth, Parkville, Vic, Australia. [Gillum, Richard F.] Howard Univ, Washington, DC USA. [Ginawi, Ibrahim A. M.] Univ Hail, Coll Med, Hailsham, E Sussex, England. [Giroud, Maurice] Univ Hosp Dijon, Dijon, France. [Giussani, Giorgia] IRCCS Mario Negri Inst Pharmacol Res, Milan, Italy. [Goginashvili, Ketevan] Minist Labour Hlth & Social Affairs, Tbilisi, Rep of Georgia. [Esteghamati, Alireza; Hafezi-Nejad, Nima; Sheikhbahaei, Sara] Univ Tehran Med Sci, Endocrinol & Metab Res Inst, Tehran, Iran. [Gona, Philimon] Univ Massachusetts Boston, Boston, MA USA. [Goto, Atsushi] Tokyo Womens Med Univ, Dept Publ Hlth, Tokyo, Japan. [Guerrant, Richard L.] Univ Virginia, Sch Med, Charlottesville, VA USA. [Terkawi, Abdullah S.] Univ Virginia, Dept Anesthesiol, Charlottesville, VA USA. [Gugnani, Harish C.] St James Sch Med, Kralendijk, Netherlands. [Gunnell, David] Univ Bristol, Bristol, Avon, England. [Gupta, Rahul] West Virginia Bur Publ Hlth, Charleston, WV USA. [Gupta, Rajeev] Fortis Escorts Hosp, Jaipur, Rajasthan, India. [Hagstromer, Maria] Karolinska Inst, Huddinge, Sweden. [Halasa, Yara A.; Idrisov, Bulat T.] Brandeis Univ, Waltham, MA USA. [Hamadeh, Randah R.] Arabian Gulf Univ, Manama, Bahrain. [Hammami, Mouhanad] Wayne Cty Dept Hlth & Human Serv, Detroit, MI USA. [Hankey, Graeme J.] Univ Western Australia, Perth, WA, Australia. [Hao, Yuantao] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China. [Zheng, Yingfeng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China. [Haregu, Tilahun Nigatu; van de Vijver, Steven] African Populat & Hlth Res Ctr, Nairobi, Kenya. [Haro, Josep Maria] CIBERSAM, Parc Sanitari St Joan de Deu, Sant Boi De Llobregat, Spain. [Haro, Josep Maria] Univ Barcelona, Barcelona, Spain. [Hedayati, Mohammad T.] Mazandaran Univ Med Sci, Sari, Mazandaran, Iran. [Hijar, Martha] Fdn Entornos AC, Cuernavaca, Morelos, Mexico. [Hoek, Hans W.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Man, Howard J. Hoff] Natl Inst Deafness & Other Commun Disorders, Epidemiol & Stat Program, NIH, Bethesda, MD USA. [Mensah, George A.] NIH, Ctr Translat Res & Implementat Sci, Bethesda, MD USA. [Sampson, Uchechukwu K.] NIH, NHLBI, Bethesda, MD USA. [Hornberger, John C.] Cedar Associates, Menlo Pk, CA USA. [Hosgood, H. Dean] Albert Einstein Coll Med, Bronx, NY USA. [Hsairi, Mohamed] Natl Inst Publ Hlth, Tunis, Tunisia. [Hoy, Damian G.] Secretariat Pacific Community, Publ Hlth Div, Noumea, New Caledonia. [Hu, Guoqing] Cent S Univ, Changsha, Peoples R China. [Huang, Cheng] George Washington Univ, Washington, DC USA. [Hubbell, Bryan J.] US EPA, Res Triangle Pk, NC USA. [Huiart, Laetitia; Racape, Lionel] CHU La Reunion, Saint Denis, France. [Husseini, Abdullatif] Qatar Univ, Doha, Qatar. [Iburg, Kim M.] Aarhus Univ, Aarhus, Denmark. [Ikeda, Nayu] Natl Inst Hlth Nutr, Tokyo, Japan. [Innos, Kaire] Natl Inst Hlth Dev, Tallinn, Estonia. [Inoue, Manami] Univ Tokyo, Grad Sch Med, Tokyo, Japan. [Kawakami, Norito] Univ Tokyo, Sch Publ Hlth, Tokyo, Japan. [Shibuya, Kenji] Univ Tokyo, Tokyo, Japan. [Islami, Farhad] Amer Canc Soc, New York, NY USA. [Jacobsen, Kathryn H.] George Mason Univ, Fairfax, VA USA. [Jansen, Henrica A.] UNFPA Asia & Pacific Reg Off, Bangkok, Thailand. [Jassal, Simerjot K.] Univ Calif San Diego, San Diego, CA USA. [Jayaraman, Sudha] Virginia Commonwealth Univ, Richmond, VA USA. [Jeemon, Panniyammakal; Prabhakaran, Dorairaj] Ctr Chron Dis Control, New Delhi, India. [Jiang, Fan] Shanghai Childrens Med Ctr, Tianjin, Peoples R China. [Jiang, Guohong] Tianjin Ctr Dis Control & Prevent, Tianjin, Peoples R China. [Phillips, Michael R.] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China. [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany. [Juel, Knud] Natl Inst Publ Hlth, Copenhagen, Denmark. [She, Jun] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China. [Kan, Haidong] Fudan Univ, Shanghai, Peoples R China. [Roseline, Sidibe S. Kany] MARIKANI, Bamako, Mali. [Karam, Nadim E.] Univ Balamand, Beirut, Lebanon. [Karch, Andre] Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, Germany. [Karch, Andre] German Ctr Infect Res, Hannover Braunschweig Site, Braunschweig, Germany. [Karema, Corine K.] Minist Hlth, Malaria & Other Parasit Dis Div, Kigali City, Rwanda. [Karthikeyan, Ganesan; Paul, Vinod K.; Satpathy, Maheswar; Tandon, Nikhil] All India Inst Med Sci, New Delhi, India. [Kaul, Anil] Oklahoma State Univ, Tulsa, OK USA. [Kazi, Dhruv S.] Univ Calif San Francisco, San Francisco, CA USA. [Kemp, Andrew H.; Lotufo, Paulo A.; Polanczyk, Guilherme V.; Santos, Itamar S.] Univ Sao Paulo, Sao Paulo, Brazil. [Kemp, Andrew H.] Univ Sydney, Camperdown, NSW, Australia. [Kengne, Andre P.; Matzopoulos, Richard; Parry, Charles D.] South African Med Res Council, Cape Town, South Africa. [Sliwa, Karen] Univ Cape Town, Fac Hlth Sci, Hatter Inst Cardiovasc Res Africa, Cape Town, South Africa. [Matzopoulos, Richard] Univ Cape Town, Sch Publ Hlth & Family Med, Cape Town, South Africa. [Kengne, Andre P.; Mayosi, Bongani M.; Stein, Dan J.] Univ Cape Town, Cape Town, South Africa. [Keren, Andre] Hadassah Kerem Univ Hosp, Cardiol, Jerusalem, Israel. [Khader, Yousef S.] Jordan Univ Sci & Technol, Irbid, Jordan. [Khalifa, Shams Eldin Ali Hassan] Supreme Council Hlth, Doha, Qatar. [Khan, Ejaz A.] Hlth Serv Acad, Islamabad, Pakistan. [Khan, Ejaz A.] Expanded Programme Immunizat, Islamabad, Pakistan. [Khang, Young-Ho] Seoul Natl Univ, Coll Med, Seoul, South Korea. [Kieling, Christian] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil. [Kim, Daniel] Northeastern Univ, Boston, MA USA. [Kim, Sungroul] Soonchunhyang Univ, Seoul, South Korea. [Kim, Yunjin] Southern Univ Coll, Johor Baharu, Malaysia. [Kimokoti, Ruth W.] Simmons Coll, Boston, MA USA. [Kinfu, Yohannes] Univ Canberra, Canberra, ACT, Australia. [Kissela, Brett M.] Univ Cincinnati, Cincinnati, OH USA. [Kokubo, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Suita, Osaka, Japan. [Kosen, Soewarta] Minist Hlth Indonesia, NIHRD, Ctr Community Empowerment Hlth Policy & Human, Jakarta, Indonesia. [Warouw, Tati S.] Minist Hlth Indonesia, NIHRD, Jakarta, Indonesia. [Kravchenko, Michael] Res Ctr Neurol, Moscow, Russia. [Krishnaswami, Sanjay] Oregon Hlth & Sci Univ, Portland, OR USA. [Defo, Barthelemy Kuate] Univ Montreal, Montreal, PQ, Canada. [Kuipers, Ernst J.] Univ Med Ctr, Erasmus MC, Rotterdam, Netherlands. [Kulkarni, Chanda] Rajrajeswari Med Coll & Hosp, Bangalore, Karnataka, India. [Kulkarni, Veena S.] Arkansas State Univ, State Univ, AR USA. [Kwan, Gene F.] Boston Med Ctr, Boston, MA USA. [Lai, Taavi] Fourth View Consulting, Tallinn, Estonia. [Lalloo, Ratilal] Griffith Univ, Sch Dent & Oral Hlth, Gold Coast, Qld, Australia. [Lalloo, Ratilal] Univ Adelaide, Sch Dent, Australian Res Ctr Populat Oral Hlth, Adelaide, SA, Australia. [Lallukka, Tea] Finnish Inst Occupat Hlth, Disabil Prevent Res Ctr, Helsinki, Finland. [Shiri, Rahman] Finnish Inst Occupat Hlth, Helsinki, Finland. [Lallukka, Tea] Univ Helsinki, Fac Med, Helsinki, Finland. [Lam, Hilton] NIH, Inst Hlth Policy & Dev Studies, Manila, Philippines. [Lan, Qing] NCI, Rockville, MD USA. [Lansingh, Van C.] Help Me See Inc, New York, NY USA. [Lansingh, Van C.] Inst Mexicano Oftalmol, Queretaro, Mexico. [Lavados, Pablo M.] Univ Desarrollo, Serv Neurol, Clin Alemana, Santiago, Chile. [Lawrynowicz, Alicia E.] Inst Nacl Epidemiol Dr Juan H Jara, Mar Del Plata, Buenos Aires, Argentina. [Leasher, Janet L.] Nova SE Univ, Coll Optometry, Ft Lauderdale, FL USA. [Lee, Jong-Tae; Yoon, Seok-Jun] Korea Univ, Seoul, South Korea. [Levi, Miriam] Tuscany Reg Ctr Occupat Injuries & Dis, Florence, Italy. [Li, Yichong] Anolinx LLC, Salt Lake City, UT USA. [Liang, Juan; Wang, Yanping; Zhu, Jun] Sichuan Univ, West China Univ Hosp 2, Natl Off Maternal & Child Hlth Surveillance, Chengdu, Peoples R China. [Lindsay, M. Patrice] Heart & Stroke Fdn Canada, Ottawa, ON, Canada. [Lipshultz, Steven E.] Wayne State Univ, Detroit, MI USA. [Lloyd, Belinda K.] Monash Univ, Eastern Hlth Clin Sch, Fitzroy, Vic, Australia. [Lloyd, Belinda K.; Room, Robin] Eastern Hlth, Turning Point Alcohol & Drug Ctr, Fitzroy, Vic, Australia. [Logroscino, Giancarlo] Univ Bari, Bari, Italy. [Lortet-Tieulent, Joannie] Amer Canc Soc, Atlanta, GA USA. [Lunevicius, Raimundas] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England. [Ma, Stefan; Phua, Hwee Pin] Minist Hlth Singapore, Singapore, Singapore. [Ma, Stefan] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore. [Magis-Rodriguez, Carlos] Secretaria Salud Mexico, Ctr Nacl Prevenc & Control VIH SIDA, Mexico City, DF, Mexico. [Mahdi, Abbas A.] King Georges Med Univ, Lucknow, Uttar Pradesh, India. [Malekzadeh, Reza] Shariati Hosp, Digest Dis Reseach Inst, Tehran, Iran. [Malekzadeh, Reza] Shiraz Univ Med Sci, Shiraz, Iran. [Mangalam, Srikanth] Tech Stand & Safety Author, Toronto, ON, Canada. [Masiye, Felix] Univ Zambia, Lusaka, Zambia. [Marape, Marape] Botswana Baylor Childrens Clin Ctr Excellence, Gaborone, Botswana. [Marcenes, Wagner] Queen Mary Univ London, London, England. [Meaney, Peter A.] Univ Penn, Pereleman Sch Med, Philadelphia, PA USA. [Martin, Randall V.] Dalhousie Univ, Halifax, NS, Canada. [Marzan, Melvin B.] Univ East Ramon Magsaysay Memorial, Med Ctr, Quezon City, Philippines. [Mashal, Mohammad T.] Minist Publ Hlth, Kabul, Afghanistan. [Mason-Jones, Amanda J.] Univ York, York, N Yorkshire, England. [Mazorodze, Tasara T.] Automot Ind Dev Ctr Eastern Cape, Port Elizabeth, South Africa. [Mckay, Abigail C.] EmergentCorp, Belize City, Belize. [Meaney, Peter A.] Childrens Hosp Philadelphia, Philadelphia, PA USA. [Mehndiratta, Man Mohan] Janakpuri Superspecialty Hosp, New Delhi, India. [Meltzer, Michele] Thomas Jefferson Univ, Philadelphia, PA USA. [Mendoza, Walter] United Nations Populat Fund, Lima, Peru. [Meretoja, Atte] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland. [Mhimbira, Francis Apolinary] Ifakara Hlth Inst, Bagamoyo, Tanzania. [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Miller, Ted R.] Curtin Univ, Ctr Populat Hlth, Perth, WA, Australia. [Mills, Edward J.] Univ Ottawa, Ottawa, ON, Canada. [Margolis, David J.; Silberberg, Donald H.] Univ Penn, Philadelphia, PA USA. [Mishra, Santosh] SNDT Womens Univ, Populat Educ Resource Ctr, Dept Continuing & Adult Educ & Extens, Bombay, Maharashtra, India. [Ibrahim, Norlinah Mohamed] Univ Kebangsaan Malaysia, Med Ctr, Dept Med, Bandar Tun Razak, Malaysia. [Mohammad, Karzan A.] Univ Salahaddin, Erbil, Iraq. [Mola, Glen L.] Univ Papua New Guinea, Boroko, Papua N Guinea. [Monasta, Lorenzo; Montico, Marcella; Ronfani, Luca] Inst Maternal & Child Hlth, IRCCS Burlo Garofolo, Trieste, Italy. [Moore, Ami R.] Univ N Texas, Denton, TX USA. [Morawska, Lidia] Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld, Australia. [Norman, Rosana E.] Queensland Univ Technol, Inst Hlth Biomed Innovat, Brisbane, Qld, Australia. [Mori, Rintaro] Natl Ctr Child Hlth & Dev, Setagaya Ku, Tokyo, Japan. [Tsilimbaris, Miltiadis] Univ Crete, Dept Med, Iraklion, Greece. [Moschandreas, Joanna] Univ Crete, Iraklion, Greece. [Moturi, Wilkister N.] Egerton Univ, Egerton, Kenya. [Werdecker, Andrea] Competence Ctr Mortal Follow Up German Natl Cohor, Heidelberg, Germany. [Mueller, Ulrich O.; Westerman, Ronny] Fed Inst Populat Res, Wiesbaden, Germany. [Mukaigawara, Mitsuru] Okinawa Chubu Hosp, Okinawa, Japan. [Nahas, Ziad] Amer Univ Beirut, Med Ctr, Beirut, Lebanon. [Naidoo, Kovin S.] Univ KwaZulu Natal, Durban, South Africa. [Naldi, Luigi] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy. [Nand, Devina] Minist Hlth Fiji, Suva, Fiji. [Nangia, Vinay] Suraj Eye Inst, Nagpur, Maharashtra, India. [Neal, Bruce] George Inst Global Hlth, Sydney, NSW, Australia. [Nejjari, Chakib] Fac Med, Fes, Morocco. [Neupane, Sudan P.] Univ Oslo, Oslo, Norway. [Ngalesoni, Frida N.] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania. [Ngirabega, Jean de Dieu] East African Community Hlth Res Commiss, Kigali, Rwanda. [Nolla, Joan M.] Hosp Univ Bellvitge, Lhospitalet De Llobregat, Spain. [Nolte, Sandra] Deakin Univ, Melbourne, Vic, Australia. [Vollset, Stein Emil] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway. [Norheim, Ole F.] Univ Bergen, Bergen, Norway. [Norrving, Bo] Lund Univ, Dept Clin Sci, Lund, Sweden. [Nyakarahuka, Luke] Makerere Univ, Kampala, Uganda. [Oh, In-Hwan] Kyung Hee Univ, Seoul, South Korea. [Ohkubo, Takayoshi] Teikyo Univ, Sch Med, Tokyo, Japan. [Olusanya, Bolajoko O.] Ctr Hlth Start Initiat, Ikoyi, Nigeria. [Opio, John Nelson] Lira Municipal Council, Lira Dist Local Govt, Lira, Uganda. [Pagcatipunan, Rodolfo S., Jr.] United Lab Inc, Mandaluyong City, Philippines. [Pandian, Jeyaraj D.] Christian Med Coll Ludhiana, Ludhiana, Punjab, India. [Park, Eun-Kee] Kosin Univ, Coll Med, Busan, South Korea. [Stein, Dan J.] South African Med Res Council, Unit Anxiety & Stress Disorders, Cape Town, South Africa. [Parry, Charles D.] South African Med Res Council, Cape Town, South Africa. [Parry, Charles D.; Seedat, Soraya] Univ Stellenbosch, Cape Town, South Africa. [Stokic, Ljiljana Pejin] Econ Inst, Belgrade, Serbia. [Pereira, David M.] Univ Porto, REQUIMTE, Fac Farm, Dept Quim,Lab Farmacognosia, Oporto, Portugal. [Perez-Padilla, Rogelio] Natl Inst Resp Dis, Mexico City, DF, Mexico. [Perez-Ruiz, Fernando] Hosp Univ Cruces, OSI EE Cruces, Baracaldo, Spain. [Perez-Ruiz, Fernando] Biocruces Hlth Res Inst, Baracaldo, Spain. [Perico, Norberto; Remuzzi, Giuseppe; Trillini, Matias] IRCCS Mario Negri Inst Pharmacol Res, Bergamo, Italy. [Perry, Samuel A. L.] Washington State Dept Hlth, Kent, WA USA. [Pervaiz, Aslam] Postgrad Med Inst, Lahore, Pakistan. [Pesudovs, Konrad] Flinders Univ S Australia, Adelaide, SA, Australia. [Peterson, Carrie B.] Aalborg Univ, Aalborg Esst, Denmark. [Petzold, Max] Hlth Metr Unit, Gothenburg, Sweden. [Petzold, Max] Univ Witwatersrand, Johannesburg, South Africa. [Phillips, Michael R.] Emory Univ, Atlanta, GA USA. [Plass, Dietrich] Fed Environm Agcy, Sect Exposure Assessment & Environm Hlth Indicato, Berlin, Germany. [Poenaru, Dan] McGill Univ, Montreal Childrens Hosp, Montreal, PQ, Canada. [Poenaru, Dan] MyungSung Med Coll, Addis Ababa, Ethiopia. [Pond, Constance D.] Univ Newcastle, Callaghan, NSW 2308, Australia. [Pope, C. Arden] Brigham Young Univ, Provo, UT USA. [Popova, Svetlana; Rehm, Juergen] Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Prasad, Noela M.] Fred Hollows Fdn, Sydney, NSW, Australia. [Qato, Dima M.] Univ Illinois, Coll Pharm, Chicago, IL USA. [Rafay, Anwar; Rana, Saleem M.] Contech Int Hlth Consultants, Lahore, Pakistan. [Rafay, Anwar; Rana, Saleem M.] Contech Sch Publ Hlth, Lahore, Pakistan. [Rahman, Sajjad Ur] Hamad Med Corp, Doha, Qatar. [Raju, Murugesan] Univ Missouri, Columbia, MO USA. [Rakovac, Ivo] WHO Reg Off Europe, Copenhagen, Denmark. [Rao, Mayuree] Brown Univ, Warren Alpert Med Sch, Providence, RI USA. [Razavi, Homie] Ctr Dis Anal, Louisville, CO USA. [Refaat, Amany H.] Suez Canal Univ, Ismailia, Egypt. [Ribeiro, Antonio L.] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil. [Velasquez-Melendez, Gustavo] Univ Fed Minas Gerais, Escola Enfermagem, Belo Horizonte, MG, Brazil. [Riccio, Patricia M.; Sposato, Luciano A.] Univ Western Ontario, Dept Clin Neurol Sci, London Hlth Sci Ctr, London, ON, Canada. [Riederer, Anne] George Washington Univ, Washington, DC USA. [Roca, Anna] MRC Unit, Fajara, Gambia. [Rodriguez, Alina] Mid Sweden Univ, Stersund, Sweden. [Romieu, Isabelle; Straif, Kurt] WHO, IARC, Lyon, France. [Roy, Nobhojit] HBNI Univ, BARC Hosp, Bombay, Maharashtra, India. [Ruhago, George M.; Sunguya, Bruno F.] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania. [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Miami, FL USA. [Saha, Sukanta] Pk Ctr Mental Hlth, Queensland Ctr Mental Hlth Res, Brisbane, Qld, Australia. [Sahathevan, Ramesh] Univ Kebangsaan Malaysia, Med Ctr, Kuala Lumpur, Malaysia. [Sahathevan, Ramesh] Calvary Healthcare Bruce, Canberra, ACT, Australia. [Sanabria, Juan R.] Case Western Reserve Univ, Cleveland, OH USA. [Sanabria, Juan R.] RFU Chicago Med Sch, Canc Treatment Ctr Amer, N Chicago, IL USA. [Sanchez-Riera, Lidia] Univ Zurich, Ctr Ageing & Mobil, Zurich, Switzerland. [Sanchez-Riera, Lidia] City Hosp Waid, Zurich, Switzerland. [Sapkota, Amir] Univ Maryland, Sch Publ Hlth, College Pk, MD USA. [Saunders, James E.] Dartmouth Coll, Dartmouth Hitchcock Med Ctr, Lebanon, NH USA. [Soneji, Samir] Dartmouth Coll, Lebanon, NH USA. [Sawhney, Monika] Marshall Univ, Huntington, WV USA. [Saylan, Mete I.] Novartis Turkey, Istanbul, Turkey. [Schneider, Ione J. C.] Univ Fed Santa Catarina, Florianopolis, SC, Brazil. [Schwebel, David C.; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Serdar, Berrin] Univ Colorado, Aurora, CO USA. [Shaddick, Gavin] Univ Bath, Bath BA2 7AY, Avon, England. [Shangguan, Siyi] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Shinohara, Yukito] Tachikawa Hosp, Tokyo, Japan. [Shiri, Rahman] Univ Tampere, Sch Hlth Sci, Tampere, Finland. [Shishani, Kawkab] Washington State Univ, Spokane, WA USA. [Shiue, Ivy] Northumbria Univ, Hlth & Life Sci, Newcastle Upon Tyne, Tyne & Wear, England. [Shiue, Ivy] Univ Edinburgh, Alzheimer Scotland Dementia Res Ctr, Edinburgh, Midlothian, Scotland. [Sigfusdottir, Inga D.] Reykjavik Univ, Reykjavik, Iceland. [Singh, Abhishek] Int Inst Populat Sci, Bombay, Maharashtra, India. [Soreide, Kjetil] Stavanger Univ Hosp, Stavanger, Norway. [Sreeramareddy, Chandrashekhar T.] Univ Tunku Abdul Rahman, Fac Med & Hlth Sci, Kajang, Cheras, Malaysia. [Stapelberg, Nicolas J. C.] Griffith Univ, Southport, Qld, Australia. [Stathopoulou, Vasiliki] Attikon Univ Hosp, Athens, Greece. [Steckling, Nadine] Univ Hosp Munich, Inst & Outpatient Clin Occupat Social & Environm, Munich, Germany. [Stroumpoulis, Konstantinos] Alexandra Gen Hosp Athens, Athens, Greece. [Stroumpoulis, Konstantinos] Ctr Hosp Publ Cotentin, Cherbourg, France. [Swaminathan, Soumya] Natl Inst Res TB, Madras, Tamil Nadu, India. [Swaroop, Mamta; Yano, Yuichiro] Northwestern Univ, Chicago, IL USA. [Sykes, Bryan L.] Univ Calif Irvine, Irvine, CA USA. [Tabb, Karen M.] Univ Illinois, Champaign, IL USA. [Talongwa, Roberto T.] Minist Hlth, MINSANTE, Yaounde, Cameroon. [Tanne, David] Chaim Sheba Med Ctr, Tel Hashomer, Israel. [Tanne, David] Tel Aviv Univ, Tel Hashomer, Israel. [Tavakkoli, Mohammad] Westchester Med Ctr, Valhalla, NY USA. [Terkawi, Abdullah S.] Outcomes Res Consortium, Cleveland, OH USA. [Terkawi, Abdullah S.] King Fahad Med City, Dept Anesthesiol, Riyadh, Saudi Arabia. [Thackway, Sarah V.] New South Wales Hlth, Sydney, NSW, Australia. [Thurston, George D.] NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY USA. [Topouzis, Fotis] Aristotle Univ Thessaloniki, Thessaloniki, Greece. [Towbin, Jeff Rey A.] Bonheur Childrens Hosp, Memphis, TN USA. [Towbin, Jeff Rey A.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN USA. [Toyoshima, Hideaki] Anjo Kosei Hosp, Hlth Care Ctr, Anjo City, Japan. [Traebert, Jeff Erson] Univ Southern Santa Catarina, Palhoca, Brazil. [Tran, Bach X.] Hanoi Med Univ, Hanoi, Vietnam. [Trujillo, Ulises] Serv Canario Salud, Tenerife, Spain. [Dimbuene, Zacharie Tsala] Univ Kinshasa, Fac Econ & Management, Dept Populat Sci & Dev, Kinshasa, Zaire. [Tuzcu, Emin Murat] Cleveland Clin, Cleveland, OH USA. [Uchendu, Uche S.] Dept Vet Affairs, Washington, DC USA. [Ukwaja, Kingsley N.] Fed Teaching Hosp, Dept Internal Med, Abakaliki, Nigeria. [Van Dingenen, Rita] European Commiss, Joint Res Ctr, Ispra, Italy. [Van Gool, Coen H.] Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands. [Van Os, Jim] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Vasankari, Tommi J.] UKK Inst Hlth Promot Res, Tampere, Finland. [Vasconcelos, Ana Maria N.] Univ Brasilia, Brasilia, DF, Brazil. [Vijayakumar, Lakshmi] VHS SNEHA, Madras, Tamil Nadu, India. [Violante, Francesco S.] Univ Bologna, Bologna, Italy. [Vlassov, Vasiliy Victorovich] Higher Sch Econ, Moscow, Russia. [Wagner, Gregory R.] Natl Inst Occupat Safety & Hlth, Washington, DC USA. [Waller, Stephen G.] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA. [Wallin, Mitchell T.] Georgetown Univ, Dept Neurol, Arlington, VA USA. [Wallin, Mitchell T.] VA Med Ctr, Washington, DC USA. [Wang, Wenzhi] Beijing Neurosurg Inst, Beijing, Peoples R China. [Weintraub, Robert G.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Wessells, K. Ryan] Univ Calif Davis, Davis, CA USA. [Westerman, Ronny] German Natl Cohort Consortium, Heidelberg, Germany. [Wilkinson, James D.] Wayne State Univ, Detroit, MI USA. [Williams, Hywel C.] Univ Nottingham, Nottingham, England. [Woldeyohannes, Solomon M.] Univ Gondar, Inst Publ Hlth, Gondar, Ethiopia. [Wong, John Q.] Manila Univ, Ateneo Sch Med & Publ Hlth, Pasig, Philippines. [Woolf, Anthony D.] Royal Cornwall Hosp, Truro, Cornwall, England. [Xu, Gelin] Nanjing Univ, Sch Med, Jinling Hosp, Nanjing, Peoples R China. [Yan, Lijing L.] Duke Kunshan Univ, Kunshan, Peoples R China. [Yang, Gonghuan] Peking Union Med Coll, Beijing, Peoples R China. [Yano, Yuichiro] Jichi Med Sch, Tochigi, Japan. [Yip, Paul] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Yonemoto, Naohiro] Natl Ctr Neurol & Psychiat, Kodaira, Tokyo, Japan. [Younis, Mustafa Z.] Jackson State Univ, Jackson, MS USA. [Younoussi, Zourkaleini] Univ Niamey, Niamey, Niger. [Yu, Chuanhua] Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Peoples R China. [Yu, Chuanhua] Wuhan Univ, Global Hlth Inst, Wuhan, Peoples R China. [Zaki, Maysaa E.] Mansoura Fac Med, Mansoura, Egypt. [Zhao, Yong] Chongqing Med Univ, Chongqing, Peoples R China. [Zhu, Shankuan] Zhejiang Univ, Sch Publ Hlth, Hangzhou, Peoples R China. RP Murray, CJ (reprint author), Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA. EM cjlm@uw.edu RI Balakrishnan, Kalpana/B-6653-2015; Davis, Adrian/E-6022-2015; Nieuwenhuijsen, Mark/C-3914-2017; Alsharif, Ubai/C-6527-2017; Amini, Heresh/B-3076-2010; Lotufo, Paulo/A-9843-2008; Karch, Andre/D-6973-2017; Hedayati, Mohammad T./E-2304-2017; Scott, James/D-5900-2012; Franklin, Richard/H-1731-2012; Giussani, Giorgia/E-8057-2017; Ermakov, Sergey/G-1709-2016; Pereira, David/M-9286-2013; Parry, Charles/A-2906-2009; Kravchenko, Michael/B-2596-2012; Nolte, Sandra/B-7498-2008; Stein, Dan/A-1752-2008; Tonelli, Marcello/B-3028-2009; Lalloo, Ratilal/O-5624-2014; Tillmann, Taavi/R-6026-2016; Salomon, Joshua/D-3898-2009; Beyene, Tariku Jibat/A-6875-2017; Varakin, Yuriy/C-8634-2012; Brenner, Hermann/B-4627-2017; Majdan, Marek/K-5017-2012; Cardis, Elisabeth/C-3904-2017; Sepanlou, Sadaf/H-9343-2016; Ferri, Cleusa/B-2922-2010; Devries, Karen/K-1083-2016; Jacobsen, Kathryn/B-5857-2008; LOGROSCINO, GIANCARLO/K-5148-2016; wang, YA XING/K-9671-2016; Ribeiro, Antonio/C-2707-2009; Hay, Simon/F-8967-2015; Naldi, Luigi/K-6343-2016; Thrift, Amanda/I-6251-2012; Weiderpass, Elisabete/M-4029-2016; Dokova, Klara/N-2448-2016; Montico, Marcella/B-5290-2013; Haro, Josep Maria/D-1423-2011; Monasta, Lorenzo/B-1388-2012; Degenhardt, Louisa/D-4515-2012; Martin, Randall/C-1205-2014; Hankey, Graeme /H-4968-2014; Kaul, Anil/B-2075-2016; Rakovac, Ivo/A-7678-2013; Banerjee, Amitava/D-4381-2014; NORMAN, ROSANA/F-2774-2010; Charlson, Fiona/F-5290-2011; Patten, Scott/B-4434-2011; Fra.Paleo, Urbano/B-8088-2016; OI Balakrishnan, Kalpana/0000-0002-5905-1801; Newton, Charles/0000-0002-6999-5507; Aburto, Tania/0000-0002-6932-9344; Moradi-Lakeh, Maziar/0000-0001-7381-5305; Mhimbira, Francis/0000-0001-8989-6832; Olusanya, Bolajoko/0000-0002-3826-0583; Castaneda-Orjuela, Carlos/0000-0002-8735-6223; Heredia-Pi, Ileana Beatriz/0000-0002-9998-9239; Soreide, Kjetil/0000-0001-7594-4354; Stockl, Heidi/0000-0002-0907-8483; Vlassov, Valentin/0000-0003-2845-2992; Davis, Adrian/0000-0001-7134-7528; Paternina-Caicedo, Angel/0000-0002-6332-5174; Leasher, Janet/0000-0002-8779-5162; Hu, Howard/0000-0002-3676-2707; Nieuwenhuijsen, Mark/0000-0001-9461-7981; Alsharif, Ubai/0000-0002-4024-3950; Amini, Heresh/0000-0002-4825-1322; Lotufo, Paulo/0000-0002-4856-8450; Karch, Andre/0000-0003-3014-8543; Hedayati, Mohammad T./0000-0001-6415-4648; Scott, James/0000-0002-0744-0688; Franklin, Richard/0000-0003-1864-4552; Ermakov, Sergey/0000-0003-1072-1162; Pereira, David/0000-0003-0384-7592; Parry, Charles/0000-0001-9787-2785; Kravchenko, Michael/0000-0001-5187-5518; Nolte, Sandra/0000-0001-6185-9423; Stein, Dan/0000-0001-7218-7810; Lalloo, Ratilal/0000-0001-5822-1269; Tillmann, Taavi/0000-0002-8428-3719; Salomon, Joshua/0000-0003-3929-5515; Beyene, Tariku Jibat/0000-0002-7474-1966; Brenner, Hermann/0000-0002-6129-1572; Majdan, Marek/0000-0001-8037-742X; Sepanlou, Sadaf/0000-0002-3669-5129; Ferri, Cleusa/0000-0002-1815-7685; Devries, Karen/0000-0001-8935-2181; Jacobsen, Kathryn/0000-0002-4198-6246; LOGROSCINO, GIANCARLO/0000-0003-0423-3242; wang, YA XING/0000-0003-2749-7793; Ribeiro, Antonio/0000-0002-2740-0042; Hay, Simon/0000-0002-0611-7272; Naldi, Luigi/0000-0002-3160-2835; Thrift, Amanda/0000-0001-8533-4170; Weiderpass, Elisabete/0000-0003-2237-0128; Montico, Marcella/0000-0003-0377-8232; Haro, Josep Maria/0000-0002-3984-277X; Monasta, Lorenzo/0000-0001-7774-548X; Degenhardt, Louisa/0000-0002-8513-2218; Martin, Randall/0000-0003-2632-8402; Hankey, Graeme /0000-0002-6044-7328; Rakovac, Ivo/0000-0003-3462-2636; Banerjee, Amitava/0000-0001-8741-3411; NORMAN, ROSANA/0000-0002-9742-1957; Charlson, Fiona/0000-0003-2876-5040; Patten, Scott/0000-0001-9871-4041; Fra.Paleo, Urbano/0000-0001-6192-7684; Chen, Honglei/0000-0003-3446-7779; Perez-Ruiz, Fernando/0000-0002-5268-1894; Kissela, Brett/0000-0002-9773-4013; Catala-Lopez, Ferran/0000-0002-3833-9312; Broday, David/0000-0002-6525-3979; Gouda, Hebe/0000-0002-5709-4509; Xu, Gelin/0000-0002-6194-0341; Goto, Atsushi/0000-0003-0669-654X; Kieling, Christian/0000-0001-7691-4149; Goenka, Shifalika/0000-0001-6993-2883; Sreeramareddy, Chandrashekhar/0000-0002-5693-7631; Soshnikov, Sergey/0000-0002-6983-7066; assadi, reza/0000-0002-5016-2994; Heydarpour, Pouria/0000-0001-5644-7555; Vlassov, Vasiliy/0000-0001-5203-549X; Hoek, Hans/0000-0001-6353-5465; Santos, Itamar/0000-0003-3212-8466; Villalpando, Salvador/0000-0001-6429-3816; Borges, Guilherme/0000-0002-3269-0507; Miller, Ted/0000-0002-0958-2639; Giussani, Giorgia/0000-0003-2460-3095; Leung, Ricky/0000-0002-2852-6771; London, Stephanie/0000-0003-4911-5290; Sindi, Shireen/0000-0002-3786-0552; Gething, Peter/0000-0001-6759-5449; Husseini, Abdullatif/0000-0001-8767-5956; Benjet, Corina/0000-0002-4569-6094; Gabbe, Belinda/0000-0001-7096-7688; Bernabe, Eduardo/0000-0002-1858-3713; Prabhakaran, Dorairaj/0000-0002-3172-834X; Neupane, Sudan Prasad/0000-0002-7389-4178; Khang, Young-Ho/0000-0002-9585-8266; Kemp, Andrew/0000-0003-1146-3791; Erskine, Holly/0000-0003-3119-9211; Aboyans, Victor/0000-0002-0322-9818 FU Bill AMP; Melinda Gates Foundation FX Funding Bill & Melinda Gates Foundation. NR 86 TC 238 Z9 252 U1 124 U2 294 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD DEC 5 PY 2015 VL 386 IS 10010 BP 2287 EP 2323 DI 10.1016/S0140-6736(15)00128-2 PG 37 WC Medicine, General & Internal SC General & Internal Medicine GA CX8ZB UT WOS:000365993200031 ER PT J AU Vajjhala, PR Lu, A Brown, DL Pang, SW Sagulenko, V Sester, DP Cridland, SO Hill, JM Schroder, K Stow, JL Wu, H Stacey, KJ AF Vajjhala, Parimala R. Lu, Alvin Brown, Darren L. Pang, Siew Wai Sagulenko, Vitaliya Sester, David P. Cridland, Simon O. Hill, Justine M. Schroder, Kate Stow, Jennifer L. Wu, Hao Stacey, Katryn J. TI The Inflammasome Adaptor ASC Induces Procaspase-8 Death Effector Domain Filaments SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID APOPTOTIC CELL-DEATH; CRYSTAL-STRUCTURE; SIGNALING COMPLEX; CD95-INDUCED APOPTOSIS; NLRP3 INFLAMMASOMES; PYRIN INFLAMMASOME; SELF-ASSOCIATION; CYTOPLASMIC DNA; MELANOMA 2; C-FLIP AB Inflammasomes mediate inflammatory and cell death responses to pathogens and cellular stress signals via activation of procaspases-1 and -8. During inflammasome assembly, activated receptors of the NLR or PYHIN family recruit the adaptor protein ASC and initiate polymerization of its pyrin domain (PYD) into filaments. We show that ASC filaments in turn nucleate procaspase-8 death effector domain (DED) filaments in vitro and in vivo. Interaction between ASC PYD and procaspase-8 tandem DEDs optimally required both DEDs and represents an unusual heterotypic interaction between domains of the death fold superfamily. Analysis of ASC PYD mutants showed that interaction surfaces that mediate procaspase-8 interaction overlap with those required for ASC self-association and interaction with the PYDs of inflammasome initiators. Our data indicate that multiple types of death fold domain filaments form at inflammasomes and that PYD/DED and homotypic PYD interaction modes are similar. Interestingly, we observed condensation of procaspase-8 filaments containing the catalytic domain, suggesting that procaspase-8 interactions within and/or between filaments may be involved in caspase-8 activation. Procaspase-8 filaments may also be relevant to apoptosis induced by death receptors. C1 [Vajjhala, Parimala R.; Pang, Siew Wai; Sagulenko, Vitaliya; Sester, David P.; Cridland, Simon O.; Hill, Justine M.; Stacey, Katryn J.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia. [Brown, Darren L.; Schroder, Kate; Stow, Jennifer L.; Stacey, Katryn J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia. [Lu, Alvin; Wu, Hao] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Lu, Alvin; Wu, Hao] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. RP Wu, H (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Biol Chem & Mol Pharmacol,Program Cellular &, 3 Blackfan Circle,Rm 3099, Boston, MA 02115 USA. EM hao.wu@childrens.harvard.edu; katryn.stacey@uq.edu.au RI Regan, Clinton/E-6250-2012; Schroder, Kate/C-6132-2008; OI Schroder, Kate/0000-0001-9261-3805; Lu, Alvin/0000-0003-2353-848X; Stow, Jennifer/0000-0002-5409-9101 FU National Health and Medical Research Council (NHMRC) [1050651]; ACRF [FT130100361]; NHMRC [606788, 1003021, 1059729]; National Institutes of Health [AI050872] FX This work was supported by National Health and Medical Research Council (NHMRC) Grant 1050651 (to K. J. S. and K. S.). The Australian Cancer Research Foundation (ACRF)/Institute for Molecular Bioscience Cancer Biology Imaging Facility was established with the support of the ACRF. The authors declare that they have no conflicts of interest with the contents of this article.; Supported by Australian Research Council Fellowship FT130100361.; Supported by NHMRC Grant 606788 and Fellowship 1003021.; Supported by National Institutes of Health RO1 Grant AI050872. To whom correspondence may be addressed: Dept. of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Program in Cellular and Molecular Medicine, Boston Children's Hospital, 3 Blackfan Circle, Rm. 3099, Boston, MA 02115. Tel.: 617-713-8160; Fax: 617-713-8161; E-mail: hao.wu@childrens.harvard.edu.; Supported by NHMRC Fellowship 1059729. To whom correspondence may be addressed: School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Queensland 4072, Australia. Tel.: 61-7-33654640; Fax: 61-7-33654273; E-mail: katryn.stacey@uq.edu.au. NR 67 TC 8 Z9 8 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 4 PY 2015 VL 290 IS 49 BP 29217 EP 29230 DI 10.1074/jbc.M115.687731 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CY7TY UT WOS:000366613400009 PM 26468282 ER PT J AU Lew, RA Liang, MH Doros, G AF Lew, Robert A. Liang, Matthew H. Doros, Gheorghe TI Statistical considerations for stopping systemic lupus erythematosus clinical trials earlier SO ARTHRITIS RESEARCH & THERAPY LA English DT Review AB Group sequential designs are used to potentially shorten randomized clinical trials and thereby reduce subject burden, improve safety, and save time and resources. Clinical trials comparing treatments for systemic lupus erythematosus (SLE) might adopt such designs if the ordinal outcome scales for SLE, such as the Systemic Lupus Activity Measure and Systemic Lupus Erythematosus Disease Activity Index, were more like continuous outcome scales with interval properties. After describing the basic features of sequential trials and highlighting some major issues in their design, we propose approaches that mitigate these issues. In particular, high-speed computing has accelerated advances in sequential design, making available a variety of designs that can be implemented with minimal technical support. The challenge now is to understand the concepts behind such flexible designs and then to apply them to improve studies of SLE. C1 [Lew, Robert A.; Doros, Gheorghe] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Lew, Robert A.; Liang, Matthew H.; Doros, Gheorghe] VA Boston Healthcare Syst, VA Cooperat Studies Program, Boston, MA 02115 USA. [Liang, Matthew H.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Sect Clin Sci, Boston, MA 02115 USA. [Liang, Matthew H.] VA Boston Healthcare Syst, Rheumatol Sect, Boston, MA 02115 USA. RP Lew, RA (reprint author), Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. EM Robert.lew2@va.gov NR 19 TC 1 Z9 1 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD DEC 4 PY 2015 VL 17 AR 345 DI 10.1186/s13075-015-0874-0 PG 7 WC Rheumatology SC Rheumatology GA CY4DP UT WOS:000366359100001 PM 26634344 ER PT J AU Berry, RH Qu, J John, SWM Howell, GR Jakobs, TC AF Berry, Ryan H. Qu, Juan John, Simon W. M. Howell, Gareth R. Jakobs, Tatjana C. TI Synapse Loss and Dendrite Remodeling in a Mouse Model of Glaucoma SO PLOS ONE LA English DT Article ID RETINAL GANGLION-CELLS; CLASSICAL COMPLEMENT CASCADE; DBA/2J MICE; OPTIC-NERVE; POSTSYNAPTIC DENSITIES; QUANTITATIVE-ANALYSIS; AMPA RECEPTORS; PROTEINS; PSD-95; DEGENERATION AB It has been hypothesized that synaptic pruning precedes retinal ganglion cell degeneration in glaucoma, causing early dysfunction to retinal ganglion cells. To begin to assess this, we studied the excitatory synaptic inputs to individual ganglion cells in normal mouse retinas and in retinas with ganglion cell degeneration from glaucoma (DBA/2J), or following an optic nerve crush. Excitatory synapses were labeled by AAV2-mediated transfection of ganglion cells with PSD-95-GFP. After both insults the linear density of synaptic inputs to ganglion cells decreased. In parallel, the dendritic arbors lost complexity. We did not observe any cells that had lost dendritic synaptic input while preserving a normal or near-normal morphology. Within the temporal limits of these observations, dendritic remodeling and synapse pruning thus appear to occur near-simultaneously. C1 [Berry, Ryan H.; Qu, Juan; Jakobs, Tatjana C.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [John, Simon W. M.; Howell, Gareth R.] Jackson Lab, Bar Harbor, ME 04609 USA. [John, Simon W. M.] Howard Hughes Med Inst, Jackson Lab, Bar Harbor, ME USA. [John, Simon W. M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA. RP Howell, GR (reprint author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA. EM Gareth.Howell@jax.org; Tatjana_Jakobs@meei.harvard.edu OI Jakobs, Tatjana/0000-0002-8104-9206 FU National Eye Institute [EY019703, EY021525, EY14104]; Research to Prevent Blindness; Massachusetts Lions Eye Research Fund FX National Eye Institute (http://www.nei.nih.gov/) grant EY019703 (TJ); National Eye Institute grant EY021525 (GH); National Eye Institute core grant EY14104 (MEEI); Grants from Research to Prevent Blindness (http://www.rpbusa.org/rpb/) and the Massachusetts Lions Eye Research Fund (http://www.masslionseyeresearch.org/). SJ is an investigator of the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 56 TC 4 Z9 4 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 4 PY 2015 VL 10 IS 12 AR e0144341 DI 10.1371/journal.pone.0144341 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY1CH UT WOS:000366143800078 PM 26637126 ER PT J AU Labadorf, A Hoss, AG Lagomarsino, V Latourelle, JC Hadzi, TC Bregu, J MacDonald, ME Gusella, JF Chen, JF Akbarian, S Weng, ZP Myers, RH AF Labadorf, Adam Hoss, Andrew G. Lagomarsino, Valentina Latourelle, Jeanne C. Hadzi, Tiffany C. Bregu, Joli MacDonald, Marcy E. Gusella, James F. Chen, Jiang-Fan Akbarian, Schahram Weng, Zhiping Myers, Richard H. TI RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expression SO PLOS ONE LA English DT Article ID NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; NEURONAL DEGENERATION; TRANSCRIPTION FACTOR; ACTIVATION; CALCIUM; PROTEIN; ONSET; PROGRESSION; MUTATION AB Huntington's Disease (HD) is a devastating neurodegenerative disorder that is caused by an expanded CAG trinucleotide repeat in the Huntingtin (HTT) gene. Transcriptional dysregulation in the human HD brain has been documented but is incompletely understood. Here we present a genome-wide analysis of mRNA expression in human prefrontal cortex from 20 HD and 49 neuropathologically normal controls using next generation high-throughput sequencing. Surprisingly, 19% (5,480) of the 28,087 confidently detected genes are differentially expressed (FDR<0.05) and are predominantly up-regulated. A novel hypothesis-free geneset enrichment method that dissects large gene lists into functionally and transcriptionally related groups discovers that the differentially expressed genes are enriched for immune response, neuroinflammation, and developmental genes. Markers for all major brain cell types are observed, suggesting that HD invokes a systemic response in the brain area studied. Unexpectedly, the most strongly differentially expressed genes are a homeotic gene set (represented by Hox and other homeobox genes), that are almost exclusively expressed in HD, a profile not widely implicated in HD pathogenesis. The significance of transcriptional changes of developmental processes in the HD brain is poorly understood and warrants further investigation. The role of inflammation and the significance of non-neuronal involvement in HD pathogenesis suggest anti-inflammatory therapeutics may offer important opportunities in treating HD. C1 [Labadorf, Adam; Hoss, Andrew G.; Lagomarsino, Valentina; Latourelle, Jeanne C.; Hadzi, Tiffany C.; Bregu, Joli; Chen, Jiang-Fan; Myers, Richard H.] Boston Univ, Dept Neurol, Sch Med, Boston, MA 02215 USA. [Labadorf, Adam; Myers, Richard H.] Boston Univ, Bioinformat Program, Boston, MA 02215 USA. [MacDonald, Marcy E.; Gusella, James F.] Harvard Univ, Ctr Human Genet Res, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Akbarian, Schahram] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Psychiat, New York, NY 10029 USA. [Weng, Zhiping] Univ Massachusetts, Program Bioinformat & Integrat Biol, Sch Med, Worcester, MA 01605 USA. [Weng, Zhiping] Univ Massachusetts, Dept Biochem & Mol Pharmacol, Sch Med, Worcester, MA 01605 USA. [Myers, Richard H.] Boston Univ, Genome Sci Inst, Sch Med, Boston, MA 02215 USA. RP Myers, RH (reprint author), Boston Univ, Dept Neurol, Sch Med, Boston, MA 02215 USA. EM rmyers@bu.edu OI Labadorf, Adam/0000-0002-0753-8992 FU Jerry McDonald HD Research Fund; Public Health Service, National Institutes of Health grants; National Institute of Neurological disorders and stroke [R01-NS073947, R01-NS32765, PHY-1444389]; NSF-EArly-concept Grants for Exploratory Research (EAGER) [PHY-1444389] FX This work was supported by the Jerry McDonald HD Research Fund (RHM) and Public Health Service, National Institutes of Health grants, National Institute of Neurological disorders and stroke, R01-NS073947 (RHM) and R01-NS32765 (MEM) and PHY-1444389 NSF-EArly-concept Grants for Exploratory Research (EAGER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to acknowledge Ms. Jayalakshmi Mysore for her help with the HD postmortem brains and the HTT CAG genotyping. This work was supported by the Jerry McDonald HD Research Fund (RHM) and Public Health Service, National Institutes of Health grants, National Institute of Neurological disorders and stroke, R01-NS073947 (RHM) and R01NS32765 (MEM) and PHY-1444389 NSF-EArly-concept Grants for Exploratory Research (EAGER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 67 TC 12 Z9 12 U1 3 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 4 PY 2015 VL 10 IS 12 AR e0143563 DI 10.1371/journal.pone.0143563 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY1CH UT WOS:000366143800018 PM 26636579 ER PT J AU Homsy, J Zaidi, S Shen, YF Ware, JS Samocha, KE Karczewski, KJ DePalma, SR McKean, D Wakimoto, H Gorham, J Jin, SC Deanfield, J Giardini, A Porter, GA Kim, R Bilguvar, K Lopez-Giraldez, F Tikhonova, I Mane, S Romano-Adesman, A Qi, HJ Vardarajan, B Ma, LJ Daly, M Roberts, AE Russell, MW Mital, S Newburger, JW Gaynor, JW Breitbart, RE Iossifov, I Ronemus, M Sanders, SJ Kaltman, JR Seidman, JG Brueckner, M Gelb, BD Goldmuntz, E Lifton, RP Seidman, CE Chung, WK AF Homsy, Jason Zaidi, Samir Shen, Yufeng Ware, James S. Samocha, Kaitlin E. Karczewski, Konrad J. DePalma, Steven R. McKean, David Wakimoto, Hiroko Gorham, Josh Jin, Sheng Chih Deanfield, John Giardini, Alessandro Porter, George A., Jr. Kim, Richard Bilguvar, Kaya Lopez-Giraldez, Francesc Tikhonova, Irina Mane, Shrikant Romano-Adesman, Angela Qi, Hongjian Vardarajan, Badri Ma, Lijiang Daly, Mark Roberts, Amy E. Russell, Mark W. Mital, Seema Newburger, Jane W. Gaynor, J. William Breitbart, Roger E. Iossifov, Ivan Ronemus, Michael Sanders, Stephan J. Kaltman, Jonathan R. Seidman, Jonathan G. Brueckner, Martina Gelb, Bruce D. Goldmuntz, Elizabeth Lifton, Richard P. Seidman, Christine E. Chung, Wendy K. TI De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies SO SCIENCE LA English DT Article ID INTELLECTUAL DISABILITY; AUTISM; SPECTRUM; GENES; OUTCOMES AB Congenital heart disease (CHD) patients have an increased prevalence of extracardiac congenital anomalies (CAs) and risk of neurodevelopmental disabilities (NDDs). Exome sequencing of 1213 CHD parent-offspring trios identified an excess of protein-damaging de novo mutations, especially in genes highly expressed in the developing heart and brain. These mutations accounted for 20% of patients with CHD, NDD, and CA but only 2% of patients with isolated CHD. Mutations altered genes involved in morphogenesis, chromatin modification, and transcriptional regulation, including multiple mutations in RBFOX2, a regulator of mRNA splicing. Genes mutated in other cohorts examined for NDD were enriched in CHD cases, particularly those with coexisting NDD. These findings reveal shared genetic contributions to CHD, NDD, and CA and provide opportunities for improved prognostic assessment and early therapeutic intervention in CHD patients. C1 [Homsy, Jason; Ware, James S.; Samocha, Kaitlin E.; Karczewski, Konrad J.; DePalma, Steven R.; McKean, David; Wakimoto, Hiroko; Gorham, Josh; Daly, Mark; Seidman, Jonathan G.; Seidman, Christine E.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Homsy, Jason] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Zaidi, Samir; Jin, Sheng Chih; Bilguvar, Kaya; Brueckner, Martina; Lifton, Richard P.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Shen, Yufeng; Qi, Hongjian] Columbia Univ, Med Ctr, Dept Syst Biol, New York, NY USA. [Shen, Yufeng; Qi, Hongjian] Columbia Univ, Med Ctr, Dept Biomed Informat, New York, NY USA. [Ware, James S.] Royal Brampton & Harefield NHS Fdn & Trust, NIHR Cardiovasc Biomed Res Unit, London, England. [Ware, James S.] Univ London Imperial Coll Sci Technol & Med, London, England. [Ware, James S.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England. [Samocha, Kaitlin E.; Karczewski, Konrad J.; Daly, Mark] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Samocha, Kaitlin E.; Karczewski, Konrad J.; Daly, Mark] Harvard Univ, Sch Med, Boston, MA USA. [DePalma, Steven R.; Seidman, Christine E.] Harvard Univ, Howard Hughes Med Inst, Boston, MA 02115 USA. [Deanfield, John; Giardini, Alessandro] UCL, Dept Cardiol, London, England. [Deanfield, John; Giardini, Alessandro] Great Ormond St Hosp Sick Children, London, England. [Porter, George A., Jr.] Univ Rochester, Med Ctr, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Kim, Richard] Univ So Calif, Keck Sch Med, Sect Cardiothorac Surg, Los Angeles, CA 90033 USA. [Bilguvar, Kaya; Lopez-Giraldez, Francesc; Tikhonova, Irina; Mane, Shrikant] Yale Univ, Yale Ctr Genome Anal, New Haven, CT USA. [Romano-Adesman, Angela] Steven & Alexandra Cohen Childrens Med Ctr New Yo, New Hyde Pk, NY USA. [Qi, Hongjian] Columbia Univ, Dept Appl Phys & Appl Math, New York, NY USA. [Vardarajan, Badri] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA. [Ma, Lijiang; Chung, Wendy K.] Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10027 USA. [Roberts, Amy E.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA. [Russell, Mark W.] Univ Michigan, Div Pediat Cardiol, Ann Arbor, MI 48109 USA. [Mital, Seema] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada. [Newburger, Jane W.; Breitbart, Roger E.] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA. [Gaynor, J. William] Childrens Hosp Philadelphia, Dept Pediat Cardiac Surg, Philadelphia, PA 19104 USA. [Iossifov, Ivan; Ronemus, Michael] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA. [Sanders, Stephan J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kaltman, Jonathan R.] NHLBI, Heart Dev & Struct Dis Branch, Div Cardiovasc Sci, NIH, Bethesda, MD 20892 USA. [Gelb, Bruce D.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA. [Gelb, Bruce D.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Goldmuntz, Elizabeth] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Goldmuntz, Elizabeth] Childrens Hosp Philadelphia, Div Cardiol, Philadelphia, PA 19104 USA. [Lifton, Richard P.] Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA. [Seidman, Christine E.] Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Chung, Wendy K.] Columbia Univ, Dept Med, Med Ctr, New York, NY USA. RP Gelb, BD (reprint author), Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA. EM martina.brueckner@yale.edu; bruce.gelb@mssm.edu; goldmuntz@email.chop.edu; richard.lifton@yale.edu; cseidman@genetics.med.harvard.edu; wkc15@cumc.columbia.edu RI Lopez-Giraldez, Francesc/A-5251-2011; Porter, George/E-7315-2013; OI Lopez-Giraldez, Francesc/0000-0001-7476-9822; Porter, George/0000-0003-0726-9988; Karczewski, Konrad/0000-0003-2878-4671 FU National Heart, Lung, and Blood Institute (PCGC); National Heart, Lung, and Blood Institute (Pediatric Heart Network); National Heart, Lung, and Blood Institute (Cardiovascular Development Consortium); National Human Genome Research Institute of the National Institutes of Health (NIH); Howard Hughes Medical Institute; Simons Foundation for Autism Research; John S. LaDue Fellowship at Harvard Medical School; Medical Scientist Training Program; National Research Science Award; Academy of Medical Sciences; British Heart Foundation; Wellcome Trust; Arthritis Research UK; NIHR Cardiovascular Biomedical Research Unit at Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; Leducq Foundation; Heart and Stroke Foundation of Ontario; Ted Roger Centre for Heart Research; Kostin Family Innovation Fund; Aaron Stern Professorship at the University of Michigan; Braylon's Gift of Hope Fund FX The authors are grateful to the patients and families who participated in this research and team members who supported subject recruitment and sequencing: D. Awad, C. Breton, K. Celia, C. Duarte, D. Etwaru, N. Fishman, M. Kaspakova, J. Kline, R. Korsin, A. Lanz, E. Marquez, D. Queen, A. Rodriguez, J. Rose, J. K. Sond, D. Warburton, A. Wilpers, and R. Yee (Columbia Medical School); B. McDonough, A. Monafo, J. Stryker (Harvard Medical School); N. Cross (Yale School of Medicine); S. M. Edman, J. L. Garbarini, J. E. Tusi, S. H. Woyciechowski (Children's Hospital of Philadelphia); J. Ellashek and N. Tran (Children's Hospital of Los Angeles); K. Flack L. Panesar, N. Taylor (University College London); D. Gruber and N. Stellato (Steve and Alexandra Cohen Children's Medical Center of New York); D. Guevara, A. Julian, M. Mac Neal, C. Mintz (Icahn School of Medicine at Mount Sinai); and E. Taillie (University of Rochester School of Medicine and Dentistry). We thank P. Candrea, E. Mazaika, K. Pavlik, V. Spotlow, and M. Sotiropoulos for production exome sequences and variant confirmation. This work was supported by grants from the National Heart, Lung, and Blood Institute (PCGC, Pediatric Heart Network, and Cardiovascular Development Consortium) and the National Human Genome Research Institute of the National Institutes of Health (NIH), Howard Hughes Medical Institute, Simons Foundation for Autism Research, John S. LaDue Fellowship at Harvard Medical School, Medical Scientist Training Program and National Research Science Award, Academy of Medical Sciences, British Heart Foundation, Wellcome Trust, Arthritis Research UK and the NIHR Cardiovascular Biomedical Research Unit at Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, Leducq Foundation, Heart and Stroke Foundation of Ontario, Ted Roger Centre for Heart Research, Kostin Family Innovation Fund, Aaron Stern Professorship at the University of Michigan, and Braylon's Gift of Hope Fund. The views expressed are those of the authors and do not necessarily reflect those of the National Heart, Lung, and Blood Institute or NIH. R. P. L. is on the Board of Directors of Roche. J.G.S. and C. E. S. are founders of and own shares in Myocardia, a biotechnology company developing small molecules for the treatment of inherited cardiomyopathy. NR 22 TC 49 Z9 49 U1 1 U2 17 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 EI 1095-9203 J9 SCIENCE JI Science PD DEC 4 PY 2015 VL 350 IS 6265 BP 1262 EP 1266 DI 10.1126/science.aac9396 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CX4WG UT WOS:000365700500080 PM 26785492 ER PT J AU Scheid, JF AF Scheid, Johannes F. TI HIV-specific B cell response in patients with broadly neutralizing serum activity SO SCIENCE LA English DT Editorial Material ID ANTIBODIES; VIREMIA; MICE C1 [Scheid, Johannes F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Scheid, Johannes F.] Rockefeller Univ, New York, NY 10021 USA. RP Scheid, JF (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM fscheid@partners.org NR 18 TC 1 Z9 1 U1 1 U2 4 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 EI 1095-9203 J9 SCIENCE JI Science PD DEC 4 PY 2015 VL 350 IS 6265 DI 10.1126/science.aad7133 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CX4WG UT WOS:000365700500052 PM 26785466 ER PT J AU Roy, A Skibo, J Kalume, F Ni, J Rankin, S Lu, YL Dobyns, WB Mills, GB Zhao, JJ Baker, SJ Millen, KJ AF Roy, Achira Skibo, Jonathan Kalume, Franck Ni, Jing Rankin, Sherri Lu, Yiling Dobyns, William B. Mills, Gordon B. Zhao, Jean J. Baker, Suzanne J. Millen, Kathleen J. TI Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy SO ELIFE LA English DT Article ID FOCAL CORTICAL DYSPLASIA; TUBEROUS SCLEROSIS COMPLEX; LHERMITTE-DUCLOS-DISEASE; PATHWAY MUTATIONS CAUSE; I PI3K INHIBITOR; SOMATIC MUTATIONS; CAPILLARY MALFORMATION; CATALYTIC SUBUNIT; DRAVET SYNDROME; PTEN LOSS AB Mutations in the catalytic subunit of phosphoinositide 3-kinase (PIK3CA) and other PI3K-AKT pathway components have been associated with cancer and a wide spectrum of brain and body overgrowth. In the brain, the phenotypic spectrum of PIK3CA-related segmental overgrowth includes bilateral dysplastic megalencephaly, hemimegalencephaly and focal cortical dysplasia, the most common cause of intractable pediatric epilepsy. We generated mouse models expressing the most common activating Pik3ca mutations (H1047R and E545K) in developing neural progenitors. These accurately recapitulate all the key human pathological features including brain enlargement, cortical malformation, hydrocephalus and epilepsy, with phenotypic severity dependent on the mutant allele and its time of activation. Underlying mechanisms include increased proliferation, cell size and altered white matter. Notably, we demonstrate that acute 1 hr suppression of PI3K signaling despite the ongoing presence of dysplasia has dramatic anti-epileptic benefit. Thus PI3K inhibitors offer a promising new avenue for effective anti-epileptic therapy for intractable pediatric epilepsy patients. C1 [Roy, Achira; Skibo, Jonathan; Kalume, Franck; Dobyns, William B.; Millen, Kathleen J.] Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA USA. [Ni, Jing; Zhao, Jean J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Rankin, Sherri; Baker, Suzanne J.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA. [Lu, Yiling; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Millen, KJ (reprint author), Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA USA. EM kathleen.millen@seattlechildrens.org OI Dobyns, William/0000-0002-7681-2844 FU Seattle Children's Hydrocephalus Research Guild; National Institutes of Health [R01:NS072441, R01:NS058721, R01:CA188516, P50:CA015962-02, P01:CA142536]; National Cancer Institute [CCSG:CA16672]; Citizens United for Research in Epilepsy FX Seattle Children's Hydrocephalus Research Guild Seattle Children's Hydrocephalus Guild Seed Funds Kathleen J Millen; National Institutes of Health R01:NS072441 Kathleen J Millen; National Cancer Institute CCSG:CA16672 Gordon B Mills; Citizens United for Research in Epilepsy SUDEP grant 2014, Christopher Donalty and Kyle Coggins Award Franck Kalume; National Institutes of Health R01:NS058721 William B Dobyns; National Institutes of Health R01:CA188516 Suzanne J Baker; National Institutes of Health P50:CA015962-02 Jean J Zhao; National Institutes of Health P01:CA142536 Jean J Zhao NR 73 TC 1 Z9 1 U1 2 U2 3 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD DEC 3 PY 2015 VL 4 AR e12703 DI 10.7554/eLife.12703 PG 25 WC Biology SC Life Sciences & Biomedicine - Other Topics GA DJ2AU UT WOS:000374006900001 ER PT J AU Abramson, JS Blum, KA Flinn, IW Gutierrez, M Goy, A Maris, M Cooper, M O'Meara, M Borger, D Mertz, J Sims, RJ Jeffrey, S Younes, A AF Abramson, Jeremy S. Blum, Kristie A. Flinn, Ian W. Gutierrez, Martin Goy, Andre Maris, Michael Cooper, Michael O'Meara, Michael Borger, Darrell Mertz, Jennifer Sims, Robert J. Jeffrey, Supko Younes, Anas TI BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [Blum, Kristie A.] Ohio State Univ, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA. [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA. [Gutierrez, Martin; Goy, Andre] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Maris, Michael] Colorado Blood Canc Inst, Denver, CO USA. [Cooper, Michael; O'Meara, Michael; Mertz, Jennifer; Sims, Robert J.] Constellat Pharmaceut, Cambridge, MA USA. [Borger, Darrell] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jeffrey, Supko] Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA. [Younes, Anas] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004291 ER PT J AU Amodio, N Romeo, E Stamato, MA Morelli, E Fulciniti, M Raimondi, L Leotta, M Di Martino, MT Tagliaferri, P Munshi, NC Tassone, P AF Amodio, Nicola Romeo, Enrica Stamato, Maria Angelica Morelli, Eugenio Fulciniti, Mariateresa Raimondi, Lavinia Leotta, Marzia Di Martino, Maria Teresa Tagliaferri, Pierosandro Munshi, Nikhil C. Tassone, Pierfrancesco TI Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Amodio, Nicola; Romeo, Enrica; Stamato, Maria Angelica; Morelli, Eugenio; Leotta, Marzia; Di Martino, Maria Teresa] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy. [Fulciniti, Mariateresa] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Raimondi, Lavinia] Rizzoli Orthoped Inst, Lab Tissue Engn Innovat Technol Platforms Tissue, Palermo, Italy. [Tagliaferri, Pierosandro; Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Catanzaro, Italy. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003040 ER PT J AU Anderson, H Patch, T Reddy, P Hagedorn, E Tamplin, OJ Bauer, DE Paw, BH Vestweber, D Zon, LI Orkin, SH Daley, GQ Shah, DI AF Anderson, Heidi Patch, Taylor Reddy, Pavan Hagedorn, Elliott Tamplin, Owen J. Bauer, Daniel E. Paw, Barry H. Vestweber, Dietmar Zon, Leonard I. Orkin, Stuart H. Daley, George Q. Shah, Dhvanit I. TI Hematopoietic Stem Cells Develop in the Absence of Endothelial Cadherin 5 Expression SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Anderson, Heidi] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Patch, Taylor] Brigham & Womens Hosp, Boston, MA 02115 USA. [Reddy, Pavan; Hagedorn, Elliott] Boston Childrens Hosp, Boston, MA USA. [Tamplin, Owen J.] Childrens Hosp Boston, Stem Cell Program, Boston, MA USA. [Tamplin, Owen J.] Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA. [Bauer, Daniel E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Pediat Hematol Oncol,Boston Childrens Hosp, Boston, MA 02115 USA. [Paw, Barry H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA 02115 USA. [Vestweber, Dietmar] Max Planck Inst Mol Biomed, D-48149 Munster, Germany. [Zon, Leonard I.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Stem Cell Program,Boston Childrens Hosp, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Div Hematol Oncol,Boston Childrens Hosp, Boston, MA 02115 USA. [Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol,Boston Childrens Hosp,HHMI, Boston, MA 02115 USA. [Daley, George Q.] Childrens Hosp Boston, Harvard Stem Cell Inst, Boston, MA USA. [Shah, Dhvanit I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA. [Shah, Dhvanit I.] Harvard Stem Cell Inst, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003289 ER PT J AU Ansell, S Armand, P Timmerman, JM Shipp, MA Garelik, MBB Zhu, LL Lesokhin, AM AF Ansell, Stephen Armand, Philippe Timmerman, John M. Shipp, Margaret A. Garelik, M. Brigid Bradley Zhu, Lili Lesokhin, Alexander M. TI Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Ansell, Stephen] Mayo Clin, Rochester, MN USA. [Armand, Philippe; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Timmerman, John M.] UCLA Med Ctr, Los Angeles, CA USA. [Garelik, M. Brigid Bradley] Bristol Myers Squibb Co, Wallingford, CT USA. [Zhu, Lili] Bristol Myers Squibb Co, Princeton, NJ USA. [Lesokhin, Alexander M.] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 4 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002020 ER PT J AU Armand, P Shipp, MA Ribrag, V Michot, JM Zinzani, PL Gutierrez, M Snyder, E Ricart, AD Balakumaran, A Moskowitz, CH AF Armand, Philippe Shipp, Margaret A. Ribrag, Vincent Michot, Jean-Marie Zinzani, Pier Luigi Gutierrez, Martin Snyder, Ellen Ricart, Alejandro D. Balakumaran, Arun Moskowitz, Craig H. TI PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Armand, Philippe; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ribrag, Vincent] Gustave Roussy Canc Campus, DITEP Med, Villejuif, France. [Michot, Jean-Marie] Gustave Roussy Comprehens Canc Ctr, Villejuif, France. [Zinzani, Pier Luigi] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy. [Gutierrez, Martin] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Snyder, Ellen; Ricart, Alejandro D.; Balakumaran, Arun] Merck & Co Inc, Kenilworth, NJ USA. [Moskowitz, Craig H.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RI Zinzani, Pier Luigi/J-9182-2016 OI Zinzani, Pier Luigi/0000-0002-2112-2651 NR 0 TC 0 Z9 0 U1 2 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002021 ER PT J AU Asano, T Kishi, Y Meguri, Y Yoshioka, T Iwamoto, M Maeda, Y Yagita, H Tanimoto, M Koreth, J Ritz, J Matsuoka, KI AF Asano, Takeru Kishi, Yuriko Meguri, Yusuke Yoshioka, Takanori Iwamoto, Miki Maeda, Yoshinobu Yagita, Hideo Tanimoto, Mitsune Koreth, John Ritz, Jerome Matsuoka, Ken-Ichi TI PD-1 Signaling Has a Critical Role in Maintaining Regulatory T Cell Homeostasis; Implication for Treg Depletion Therapy By PD-1 Blockade SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Asano, Takeru; Kishi, Yuriko; Meguri, Yusuke; Yoshioka, Takanori; Iwamoto, Miki; Maeda, Yoshinobu; Tanimoto, Mitsune; Matsuoka, Ken-Ichi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol & Oncol, Okayama 7008530, Japan. [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan. [Koreth, John; Ritz, Jerome; Matsuoka, Ken-Ichi] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002285 ER PT J AU Atallah, E Horowitz, MM Logan, B Chen, M Boo, MJ Cutler, CS Deeg, J Gajewski, JL Confer, DL Farnia, S Greenberg, P Warlick, E Weisdorf, D Rizzo, JD AF Atallah, Ehab Horowitz, Mary M. Logan, Brent Chen, Min Boo, Michael J. Cutler, Corey S. Deeg, Joachim Gajewski, James L. Confer, Dennis L. Farnia, Stephanie Greenberg, Peter Warlick, Erica Weisdorf, Daniel Rizzo, J. Douglas TI Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Atallah, Ehab] Med Coll Wisconsin, Dept Hematol Oncol, Milwaukee, WI 53226 USA. [Horowitz, Mary M.; Chen, Min; Rizzo, J. Douglas] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Logan, Brent] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA. [Boo, Michael J.; Confer, Dennis L.; Farnia, Stephanie] Natl Marrow Donor Program, Minneapolis, MN USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Div Hematol Malignancies, Boston, MA USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Deeg, Joachim] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Gajewski, James L.] Fox Chase Temple BMT Program, Philadelphia, PA USA. [Greenberg, Peter] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA. [Warlick, Erica] Univ Minnesota, Minneapolis, MN USA. [Weisdorf, Daniel] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000257 ER PT J AU Attal, M Lauwers-Cances, V Hulin, C Facon, T Caillot, D Escoffre, M Arnulf, B Macro, M Belhadj, K Garderet, L Roussel, M Mathiot, C Avet-Loiseau, H Munshi, NC Richardson, PG Anderson, KC Harousseau, JL Moreau, P AF Attal, Michel Lauwers-Cances, Valerie Hulin, Cyrille Facon, Thierry Caillot, Denis Escoffre, Martine Arnulf, Bertrand Macro, Margaret Belhadj, Karim Garderet, Laurent Roussel, Murielle Mathiot, Claire Avet-Loiseau, Herve Munshi, Nikhil C. Richardson, Paul G. Anderson, Kenneth C. Harousseau, Jean Luc Moreau, Philippe TI Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Attal, Michel; Avet-Loiseau, Herve] Inst Univ Canc Toulouse Oncopole, Toulouse, France. [Lauwers-Cances, Valerie] CHU Toulouse, Toulouse, France. [Hulin, Cyrille] CHRU Hop Brabois, Nancy, France. [Facon, Thierry] CHRU Lille, Hop Claude Huriez, Malad Sang, F-59037 Lille, France. [Caillot, Denis] Hop Bocage, Dijon, France. [Escoffre, Martine] CHU Rennes, Rennes, France. [Arnulf, Bertrand] Hop St Louis, Paris, France. [Macro, Margaret] CHU Caen, F-14000 Caen, France. [Belhadj, Karim] CHU Henri Mondor, F-94010 Creteil, France. [Garderet, Laurent] Hop St Antoine, F-75571 Paris, France. [Roussel, Murielle] Inst Univ Canc, Toulouse, France. [Roussel, Murielle] Univ Hosp, Dept Hematol, Toulouse, France. [Mathiot, Claire] IFM, Paris, France. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Div Hematol Malignancy, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Anderson, Kenneth C.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Harousseau, Jean Luc] HAS, Paris, France. [Moreau, Philippe] Nantes Univ Hosp, Dept Hematol, Nantes, France. RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015 OI FACON, THIERRY/0000-0001-7705-8460; NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001143 ER PT J AU Avet-Loiseau, H Corre, J Lauwers-Cances, V Chretien, ML Robillard, N Leleu, X Hulin, C Gentil, C Arnulf, B Belhadj, K Brechignac, S Garderet, L Karlin, L Marit, G Benboubker, L Orsini-Piocelle, F Royer, B Drenou, B Tiab, M Lamy, T Macro, M Richardson, PG Anderson, KC Faham, M Facon, T Moreau, P Attal, M Munshi, NC AF Avet-Loiseau, Herve Corre, Jill Lauwers-Cances, Valerie Chretien, Marie-Lorraine Robillard, Nelly Leleu, Xavier Hulin, Cyrille Gentil, Catherine Arnulf, Bertrand Belhadj, Karim Brechignac, Sabine Garderet, Laurent Karlin, Lionel Marit, Gerald Benboubker, Lotfi Orsini-Piocelle, Frederique Royer, Bruno Drenou, Bernard Tiab, Mourad Lamy, Thierry Macro, Margaret Richardson, Paul G. Anderson, Kenneth C. Faham, Malek Facon, Thierry Moreau, Philippe Attal, Michel Munshi, Nikhil C. TI Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Avet-Loiseau, Herve] Inst Univ Canc, Unit Genom Myeloma, Toulouse, France. [Corre, Jill] Inst Univ Canc, Toulouse, France. [Lauwers-Cances, Valerie] CHU Toulouse, Toulouse, France. [Chretien, Marie-Lorraine] CHU Dijon, Serv Hematol, Dijon, France. [Robillard, Nelly; Moreau, Philippe] CHU Nantes, F-44035 Nantes 01, France. [Leleu, Xavier] CHRU, Hop Huriez, Serv Malad Sang, Lille, France. [Hulin, Cyrille] CHRU, Hop Brabois, Nancy, France. [Gentil, Catherine] CHU, Toulouse, France. [Arnulf, Bertrand] Hop St Louis, Paris, France. [Belhadj, Karim] CHU Henri Mondor, F-94010 Creteil, France. [Brechignac, Sabine] Hop Avicenne, F-93009 Bobigny, France. [Garderet, Laurent] Hop St Antoine, F-75571 Paris, France. [Karlin, Lionel] Ctr Hosp Lyon Sud, Serv Hematol, F-69310 Pierre Benite, France. [Marit, Gerald] CHU, Bordeaux, France. [Benboubker, Lotfi] CHU Tours, Tours, France. [Orsini-Piocelle, Frederique] CHD, Annecy, France. [Royer, Bruno] CHU, Amiens, France. [Royer, Bruno] Ctr Hosp Univ, Hematol, Amiens, France. [Drenou, Bernard] CH MULHOUSE, Mulhouse, France. [Tiab, Mourad] Hop La Roche Sur Yon, La Roche Sur Yon 9, France. [Lamy, Thierry] CHU Pontchaillou, Haematol, Rennes, France. [Macro, Margaret] Hop Cote Nacre, Caen 9, France. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Div Hematol Malignancy, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Faham, Malek] Adapt Biotechnol, San Francisco, CA USA. [Facon, Thierry] CHRU Lille, Hop Claude Huriez, Malad Sang, F-59037 Lille, France. [Moreau, Philippe] Hop Hotel Dieu & Hme, Nantes 1, France. [Moreau, Philippe] Nantes Univ Hosp, Hotel Dieu, Nantes, France. [Attal, Michel] Inst Univ Canc Toulouse Oncopole, Toulouse, France. [Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015 OI FACON, THIERRY/0000-0001-7705-8460; NR 0 TC 0 Z9 0 U1 1 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000255 ER PT J AU Bararia, D Heide, M Welner, RS Romashova, T Pastore, A Mathur, R Gascoyne, RD Kridel, R Willson, BG Roberts, CWM Hiddemann, W Weinstock, DM Weigert, O AF Bararia, Deepak Heide, Michael Welner, Robert S. Romashova, Tatiana Pastore, Alessandro Mathur, Radhika Gascoyne, Randy D. Kridel, Robert Willson, Boris G. Roberts, Charles W. M. Hiddemann, Wolfgang Weinstock, David M. Weigert, Oliver TI Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Bararia, Deepak; Heide, Michael; Romashova, Tatiana; Hiddemann, Wolfgang; Weigert, Oliver] Univ Munich, Dept Internal Med 3, Munich, Germany. [Welner, Robert S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol,Dept Med, Boston, MA 02215 USA. [Pastore, Alessandro] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Mathur, Radhika; Roberts, Charles W. M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Gascoyne, Randy D.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. [Kridel, Robert] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada. [Willson, Boris G.] GlaxoSmithKline, Oncol R&D, Mol Med Unit, Collegeville, PA USA. [Weinstock, David M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002008 ER PT J AU Bardhan, K Patsoukis, N Sari, D Anagnostou, T Chatterjee, P Freeman, GJ Li, LQ Boussiotis, VA AF Bardhan, Kankana Patsoukis, Nikolaos Sari, Duygu Anagnostou, Theodore Chatterjee, Pranam Freeman, Gordon J. Li, Lequn Boussiotis, Vassiliki A. TI PD-1 Inhibits TCR Proximal Signaling By Sequestering SHP-2 Phosphatase and Facilitating Csk-Mediated Inhibitory Phosphorylation of Lck SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Bardhan, Kankana; Patsoukis, Nikolaos; Sari, Duygu; Chatterjee, Pranam; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Hematol Oncol, Boston, MA 02215 USA. [Anagnostou, Theodore] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Freeman, Gordon J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001035 ER PT J AU Bauer, DE Canver, MC Smith, EC Sher, F Pinello, L Sanjana, NE Shalem, O Chen, DD Schupp, PG Vinjamur, DS Garcia, SP Luc, S Kurita, R Nakamura, Y Fujiwara, Y Maeda, T Yuan, GC Lettre, G Zhang, F Orkin, SH AF Bauer, Daniel E. Canver, Matthew C. Smith, Elenoe C. Sher, Falak Pinello, Luca Sanjana, Neville E. Shalem, Ophir Chen, Diane D. Schupp, Patrick G. Vinjamur, Divya S. Garcia, Sara P. Luc, Sidinh Kurita, Ryo Nakamura, Yukio Fujiwara, Yuko Maeda, Takahiro Yuan, Guo-Cheng Lettre, Guillaume Zhang, Feng Orkin, Stuart H. TI Crispr-Cas9 Saturating Mutagenesis Reveals an Achilles Heel in the BCL11A Erythroid Enhancer for Fetal Hemoglobin Induction (by Genome Editing) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Bauer, Daniel E.; Canver, Matthew C.; Smith, Elenoe C.; Sher, Falak; Luc, Sidinh] Harvard Univ, Sch Med, Dana Farber Canc Inst, Pediat Hematol Oncol,Boston Childrens Hosp, Boston, MA 02115 USA. [Pinello, Luca; Garcia, Sara P.; Yuan, Guo-Cheng] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Sanjana, Neville E.; Shalem, Ophir] Broad Inst MIT & Harvard, Cambridge, MA USA. [Chen, Diane D.; Schupp, Patrick G.] Boston Childrens Hosp, Boston, MA USA. [Vinjamur, Divya S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA. [Kurita, Ryo; Nakamura, Yukio] RIKEN BioResource Ctr, Cell Engn Div, Tsukuba, Ibaraki, Japan. [Fujiwara, Yuko] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp,HHMI, Boston, MA 02115 USA. [Maeda, Takahiro] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA 02115 USA. [Lettre, Guillaume] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada. [Zhang, Feng] MIT, Broad Inst MIT & Harvard, Cambridge, MA 02139 USA. [Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol,Boston Childrens Hosp,HHMI, Boston, MA 02115 USA. RI Nakamura, Yukio/A-5263-2016 NR 0 TC 0 Z9 0 U1 1 U2 6 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002075 ER PT J AU Bejar, R Papaemmanuil, E Haferlach, T Garcia-Manero, G Maciejewski, JP Sekeres, MA Walter, MJ Graubert, TA Cazzola, M Malcovati, L Ogawa, S Fenaux, P Hellstrom-Lindberg, E Kern, W Boultwood, J Pellagatti, A Bowen, D Tauro, S Groves, MJ Vyas, P Quek, L Nazha, A Thol, F Heuser, M Shih, LY Padron, E Sallman, D Komrokji, RS List, AF Santini, V Fontenay, M Campbell, PJ Tuechler, H Stevenson, K Neuberg, DS Greenberg, P Ebert, BL AF Bejar, Rafael Papaemmanuil, Elli Haferlach, Torsten Garcia-Manero, Guillermo Maciejewski, Jaroslaw P. Sekeres, Mikkael A. Walter, Matthew J. Graubert, Timothy A. Cazzola, Mario Malcovati, Luca Ogawa, Seishi Fenaux, Pierre Hellstrom-Lindberg, Eva Kern, Wolfgang Boultwood, Jacqueline Pellagatti, Andrea Bowen, David Tauro, Sudhir Groves, Michael J. Vyas, Paresh Quek, Lynn Nazha, Aziz Thol, Felicitas Heuser, Michael Shih, Lee-Yung Padron, Eric Sallman, David Komrokji, Rami S. List, Alan F. Santini, Valeria Fontenay, Michaela Campbell, Peter J. Tuechler, Heinz Stevenson, Kristen Neuberg, Donna S. Greenberg, Peter Ebert, Benjamin L. TI Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Bejar, Rafael] UCSD Moores Canc Ctr, La Jolla, CA USA. [Papaemmanuil, Elli] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Haferlach, Torsten; Kern, Wolfgang] MLL, Munich, Germany. [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Maciejewski, Jaroslaw P.] Cleveland Clin, Taussing Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA. [Sekeres, Mikkael A.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Walter, Matthew J.] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA. [Graubert, Timothy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Cazzola, Mario; Malcovati, Luca] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy. [Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan. [Fenaux, Pierre] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France. [Hellstrom-Lindberg, Eva] Karolinska Inst, Dept Med, Div Hem, Stockholm, Sweden. [Boultwood, Jacqueline] John Radcliffe Hosp, NDCLS, LRF Mol Haematol Unit, Oxford OX3 9DU, England. [Pellagatti, Andrea] Univ Oxford, Oxford, England. [Bowen, David] Leeds Teaching Hosp, St Jamess Inst Oncol, Leeds, W Yorkshire, England. [Tauro, Sudhir] Dundee Sch Med, Div Canc Res, Dundee, Scotland. [Groves, Michael J.] Ninewells Hosp, Dept Haematol, Dundee DD1 9SY, Scotland. [Vyas, Paresh] Univ Oxford, MRC, Mol Haematol Unit, Weatherall Inst Mol Med, Oxford, England. [Vyas, Paresh] Univ Oxford, Dept Haematol, Oxford, England. [Vyas, Paresh] Oxford Univ Hosp NHS Trust UK, Oxford, England. [Nazha, Aziz] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Oncol, Leukemia Program, Cleveland, OH 44106 USA. [Thol, Felicitas] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany. [Heuser, Michael] Hannover Med Sch, Hematol Hemostasis Oncol & SCT, Hannover, Germany. [Shih, Lee-Yung] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Dept Hematol Oncol, Taipei, Taiwan. [Padron, Eric] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL 33612 USA. [Sallman, David] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA. [Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA. [List, Alan F.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, Tampa, FL 33612 USA. [Santini, Valeria] Univ Florence, AOU Careggi, Florence, Italy. [Fontenay, Michaela] Univ Paris 05, Cochin Hosp, Paris, France. [Campbell, Peter J.] Wellcome Trust Sanger Inst, Canc Genome Project, Cambridge, England. [Tuechler, Heinz] Ludwig Boltzmann Inst Leukemia Resaerch, Vienna, Austria. [Stevenson, Kristen; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Greenberg, Peter] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA. [Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 5 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003031 ER PT J AU Benajiba, L Wagner, F Ross, L Galinsky, I DeAngelo, DJ Gale, J Pan, J Zhang, YL Sacher, J Weiwer, M Stone, RM Holson, E Stegmaier, K AF Benajiba, Lina Wagner, Florence Ross, Linda Galinsky, Ilene DeAngelo, Daniel J. Gale, Jennifer Pan, Jen Zhang, Yan-Lin Sacher, Joshua Weiwer, Michel Stone, Richard M. Holson, Edward Stegmaier, Kimberly TI Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Benajiba, Lina; Ross, Linda; Stegmaier, Kimberly] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Wagner, Florence; Holson, Edward] Broad Inst, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Galinsky, Ilene; DeAngelo, Daniel J.; Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Gale, Jennifer; Pan, Jen; Zhang, Yan-Lin; Sacher, Joshua; Weiwer, Michel] Broad Inst, Cambridge, MA USA. [Stegmaier, Kimberly] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002307 ER PT J AU Bianchi, P Fermo, E Eng, JC Ulirsch, JC Vercellati, C Braidotti, P Hildick-Smith, G Satchwell, TJ Pellegrin, S Zanella, A Barcellini, W Paw, BH Toye, AM Sankaran, VG AF Bianchi, Paola Fermo, Elisa Eng, Jennifer C. Ulirsch, Jacob C. Vercellati, Cristina Braidotti, Paola Hildick-Smith, Gordon Satchwell, Timothy J. Pellegrin, Stephanie Zanella, Alberto Barcellini, Wilma Paw, Barry H. Toye, Ashley Mark Sankaran, Vijay G. TI Biallelic Mutations in PARP4 Are Linked to a Variant Form of Congenital Dyserythropoietic Anemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Bianchi, Paola; Fermo, Elisa; Vercellati, Cristina; Zanella, Alberto] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Oncohematol Unit, Physiopathol Anemias Unit, Milan, Italy. [Eng, Jennifer C.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Div Hematol Oncol, Boston, MA USA. [Eng, Jennifer C.; Ulirsch, Jacob C.; Sankaran, Vijay G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Ulirsch, Jacob C.; Sankaran, Vijay G.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Braidotti, Paola] S Paolo Hosp, Dept Pathol, Milan, Italy. [Hildick-Smith, Gordon; Paw, Barry H.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Hildick-Smith, Gordon; Paw, Barry H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA. [Satchwell, Timothy J.; Pellegrin, Stephanie; Toye, Ashley Mark] Univ Bristol, Sch Med Sci, Sch Biochem, Bristol BS8 1TD, Avon, England. [Barcellini, Wilma] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Milan, Italy. [Toye, Ashley Mark] NHSBT, Bristol Inst Transfus Sci, Filton, England. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001024 ER PT J AU Blaser, BW Moore, J Li, B Tamplin, OJ Binder, V Zon, LI AF Blaser, Bradley Wayne Moore, Jessica Li, Brian Tamplin, Owen J. Binder, Vera Zon, Leonard I. TI IL-8 and CXCR1 Remodel the Vascular Niche to Promote Hematopoietic Stem and Progenitor Cell Engraftment SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Blaser, Bradley Wayne] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Blaser, Bradley Wayne; Moore, Jessica; Li, Brian] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Tamplin, Owen J.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston Childrens Hosp,Hematol Oncol, Boston, MA 02115 USA. [Binder, Vera; Zon, Leonard I.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Stem Cell Program,Boston Childrens Hosp, Boston, MA 02115 USA. [Binder, Vera; Zon, Leonard I.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Div Hematol Oncol,Boston Childrens Hosp, Boston, MA 02115 USA. [Binder, Vera] Univ Munich, Dept Hematol & Oncol, Dr von Hauner Childrens Hosp, Munich, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002220 ER PT J AU Blazar, BR O'Connor, RS Milone, MC Dustin, ML Riley, JL Vincent, BC Serody, JS Flynn, RP Paz, K Du, J Panoskaltsis-Mortari, A Jeffrey, M Ahmed, R Turka, LAA Freeman, GJ Sharpe, AH Saha, A AF Blazar, Bruce R. O'Connor, Roddy S. Milone, Michael C. Dustin, Michael L. Riley, James L. Vincent, Benjamin C. Serody, Jonathan S. Flynn, Ryan P. Paz, Katelyn Du, Jing Panoskaltsis-Mortari, Angela Jeffrey, Miller Ahmed, Rafi Turka, Laurence A. A. Freeman, Gordon J. Sharpe, Arlene H. Saha, Asim TI Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Blazar, Bruce R.] Univ Minnesota, Dept Med, Div Pediat, Ctr Canc, Minneapolis, MN 55455 USA. [O'Connor, Roddy S.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA. [Milone, Michael C.] Univ Penn, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA. [Dustin, Michael L.] Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England. [Riley, James L.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Vincent, Benjamin C.] Univ N Carolina, Chapel Hill, NC USA. [Serody, Jonathan S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Flynn, Ryan P.] Univ Minnesota, Dept Pediat, Div Hematol Oncol & Blood & Marrow Transplantat, Minneapolis, MN 55455 USA. [Paz, Katelyn; Panoskaltsis-Mortari, Angela] Univ Minnesota, Pediat Blood & Marrow Transplant, Minneapolis, MN USA. [Du, Jing; Jeffrey, Miller] Univ Minnesota, Minneapolis, MN USA. [Ahmed, Rafi] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Turka, Laurence A. A.] Univ Penn, Philadelphia, PA 19104 USA. [Freeman, Gordon J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sharpe, Arlene H.] Harvard Univ, Sch Med, Pathol, Boston, MA USA. [Saha, Asim] Univ Minnesota, Dept Pediat, Blood & Marrow Transplantat, Minneapolis, MN 55455 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000063 ER PT J AU Bolli, N Avet-Loiseau, H Gimondi, S Li, YL Sathiaseelan, V Sperling, AS Anderson, KC Minvielle, S Campbell, PJ Munshi, NC AF Bolli, Niccolo Avet-Loiseau, Herve Gimondi, Silvia Li, Yilong Sathiaseelan, Vijitha Sperling, Adam Samuel Anderson, Kenneth C. Minvielle, Stephane Campbell, Peter J. Munshi, Nikhil C. TI Genomic Landscape and Its Prognostic Implications in Multiple Myeloma Using a Targeted Sequencing Approach SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Bolli, Niccolo; Li, Yilong; Sathiaseelan, Vijitha] Wellcome Trust Sanger Inst, Cambridge, England. [Bolli, Niccolo; Gimondi, Silvia] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Div Hematol, Milan, Italy. [Avet-Loiseau, Herve] Toulouse Inst Natl Sante, Ctr Rech Cancerol, Toulouse, France. [Sperling, Adam Samuel] Dana Farber Canc Inst, Boston, MA 02115 USA. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Minvielle, Stephane] CHU Nantes, Unite Mixte Genom Canc, F-44035 Nantes 01, France. [Campbell, Peter J.] Wellcome Trust Sanger Inst, Canc Genome Project, Cambridge, England. [Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001122 ER PT J AU Brown, F Still, E Cifani, P Ficarro, S Pouliot, G Drill, E Gonen, M He, J Balasubramanian, S Zhong, S Pavlick, D Yilmazel, B Krivtsov, AV Alonzo, TA Meshinchi, S Kornblau, SM Stone, RM Marcucci, G Byrd, JC Levine, RL Armstrong, SA Gray, N Marto, J Kentsis, A AF Brown, Fiona Still, Eric Cifani, Paolo Ficarro, Scott Pouliot, Gayle Drill, Esther Gonen, Mithat He, Jie Balasubramanian, Sohail Zhong, Shan Pavlick, Dean Yilmazel, Bahar Krivtsov, Andrei V. Alonzo, Todd A. Meshinchi, Soheil Kornblau, Steven M. Stone, Richard M. Marcucci, Guido Byrd, John C. Levine, Ross L. Armstrong, Scott A. Gray, Nathanael Marto, Jarrod Kentsis, Alex TI Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Brown, Fiona; Still, Eric; Cifani, Paolo; Drill, Esther; Levine, Ross L.; Armstrong, Scott A.; Kentsis, Alex] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Ficarro, Scott; Marto, Jarrod] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pouliot, Gayle] Childrens Hosp Boston, Boston, MA USA. [Gonen, Mithat] Mem Sloan Kettering Canc Ctr, Stat, New York, NY 10021 USA. [He, Jie; Balasubramanian, Sohail; Zhong, Shan; Pavlick, Dean; Yilmazel, Bahar] Fdn Med Inc, Cambridge, MA USA. [Krivtsov, Andrei V.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA. [Alonzo, Todd A.] Childrens Oncol Grp, Monrovia, CA USA. [Meshinchi, Soheil] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Kornblau, Steven M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Marcucci, Guido] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Byrd, John C.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA. [Gray, Nathanael] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000152 ER PT J AU Brunner, AM Li, SL Fathi, AT Ho, VT Stone, RM Soiffer, RJ Chen, YB AF Brunner, Andrew M. Li, Shuli Fathi, Amir T. Ho, Vincent T. Stone, Richard M. Soiffer, Robert J. Chen, Yi-Bin TI Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Brunner, Andrew M.; Fathi, Amir T.; Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Brunner, Andrew M.; Li, Shuli; Ho, Vincent T.; Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 5 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002301 ER PT J AU Byrd, JC Wierda, W Jones, J O'Brien, S Brown, JR Schuh, A Hillmen, P Stephens, DM Ghia, P Devereux, S Chaves, JM Barrientos, JC Wang, MH Huang, J Covey, T Navarro, T Rothbaum, W Izumi, R Hamdy, A Furman, RR AF Byrd, John C. Wierda, William Jones, Jeffrey O'Brien, Susan Brown, Jennifer R. Schuh, Anna Hillmen, Peter Stephens, Deborah M. Ghia, Paolo Devereux, Steve Chaves, Jorge M. Barrientos, Jacqueline C. Wang, Min Hui Huang, Jane Covey, Todd Navarro, Tasheda Rothbaum, Wayne Izumi, Raquel Hamdy, Ahmed Furman, Richard R. TI The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Byrd, John C.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA. [Wierda, William] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Jones, Jeffrey] Ohio State Univ, Sch Med, Div Hematol, Columbus, OH 43210 USA. [O'Brien, Susan] Univ Calif Irvine, Orange, CA 92668 USA. [Brown, Jennifer R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Schuh, Anna] Univ Oxford, Oxford, England. [Hillmen, Peter] St James Univ Hosp, Haematol, Leeds, W Yorkshire, England. [Stephens, Deborah M.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Ghia, Paolo] Univ Vita Salute San Raffaele, Milan, Italy. [Ghia, Paolo] IRCCS Ist Sci San Raffaele, Milan, Italy. [Devereux, Steve] NHS Fdn Trust, Kings Coll Hosp, London, England. [Chaves, Jorge M.] Northwest Med Specialties PLLC, Tacoma, WA USA. [Barrientos, Jacqueline C.] North Shore LIJ, Lake Success, NY USA. [Wang, Min Hui; Huang, Jane; Navarro, Tasheda; Rothbaum, Wayne] Acerta Pharma BV, Redwood City, CA USA. [Covey, Todd; Izumi, Raquel; Hamdy, Ahmed] Acerta Pharma, Redwood City, CA USA. [Furman, Richard R.] New York Presbyterian Weill Cornell Med Ctr, New York, NY USA. RI Jones, Jeffrey/E-3321-2011 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002268 ER PT J AU Carey, A Cleary, MM Edwards, DK Eide, CA Traer, E McWeeney, SK Tyner, JW Bagby, GC Druker, BJ Agarwal, A AF Carey, Alyssa Cleary, Megan M. Edwards, David K. Eide, Christopher A. Traer, Elie McWeeney, Shannon K. Tyner, Jeffrey W. Bagby, Grover C. Druker, Brian J. Agarwal, Anupriya TI The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Carey, Alyssa; Cleary, Megan M.; Eide, Christopher A.; Traer, Elie; Bagby, Grover C.; Druker, Brian J.; Agarwal, Anupriya] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA. [Edwards, David K.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA. [Eide, Christopher A.; Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA. [McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Dept Bioinformat & Computat Biol, Portland, OR 97201 USA. [Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002303 ER PT J AU Carey, CD Connelly, C Gjini, E Roemer, MGM Stack, E Hodi, S Shipp, MA Rodig, SJ AF Carey, Christopher Daniel Connelly, Courtney Gjini, Evisa Roemer, Margaretha G. M. Stack, Edward Hodi, Stephen Shipp, Margaret A. Rodig, Scott J. TI Quantitative Assessment of PD-L1 Expression in Classical Hodgkin Lymphoma Suggests a Critical Role for Tumor Associated Macrophages in Suppressing Anti-Tumor Immunity SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Carey, Christopher Daniel; Gjini, Evisa] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Connelly, Courtney; Roemer, Margaretha G. M.; Hodi, Stephen; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stack, Edward] PerkinElmer, Hopkinton, MA USA. [Rodig, Scott J.] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004240 ER PT J AU Cea, M Cagnetta, A Lovera, D Grasso, R Colombo, N Bergamaschi, M Aquino, S Guolo, F Minetto, P Ballerini, F Canepa, L Adamia, S Nencioni, A Pierri, I Clavio, M Miglino, M Gobbi, M Lemoli, RM AF Cea, Michele Cagnetta, Antonia Lovera, Davide Grasso, Raffaella Colombo, Nicoletta Bergamaschi, Micaela Aquino, Sara Guolo, Fabio Minetto, Paola Ballerini, Filippo Canepa, Letizia Adamia, Sophia Nencioni, Alessio Pierri, Ivana Clavio, Marino Miglino, Maurizio Gobbi, Marco Lemoli, Roberto Massimo TI A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Cea, Michele; Cagnetta, Antonia; Lovera, Davide; Bergamaschi, Micaela; Canepa, Letizia; Nencioni, Alessio] Univ Genoa, Genoa, Italy. [Grasso, Raffaella; Colombo, Nicoletta; Guolo, Fabio; Minetto, Paola; Ballerini, Filippo; Miglino, Maurizio; Gobbi, Marco; Lemoli, Roberto Massimo] Univ Genoa, IRCCS AOU San Martino IST, Dept Internal Med DiMI, Chair Hematol, Genoa, Italy. [Aquino, Sara] Univ Genoa, Genoa, Italy. [Adamia, Sophia] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pierri, Ivana] Univ Genoa, IRCSS AOU S Martino IST, Hematol Clin, Genoa, Italy. [Clavio, Marino] S Martino Univ Hosp, Hematol, Genoa, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004175 ER PT J AU Chapuy, B Cheng, HW Watahiki, A Ducar, MD Gusenleitner, D Chen, LF Roemer, MGM Quyang, J Christie, AL Zhang, LY Tan, YX Abo, RP Bonin, F Thorner, AR Sun, HH Pinkus, GS van Hummelen, P Wulf, GG Aster, JC Weinstock, DM Monti, S Rodig, SJ Wang, YZ Shipp, MA AF Chapuy, Bjoern Cheng, Honwei Watahiki, Akira Ducar, Matthew D. Gusenleitner, Daniel Chen, Linfeng Roemer, Margaretha G. M. Quyang, Jing Christie, Amanda L. Zhang, Liye Tan, Yuxiang Abo, Ryan P. Bonin, Frederike Thorner, Aaron R. Sun, Heather H. Pinkus, Geraldine S. van Hummelen, Paul Wulf, Gerald G. Aster, Jon C. Weinstock, David M. Monti, Stefano Rodig, Scott J. Wang, Yuzhuo Shipp, Margaret A. TI Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chapuy, Bjoern; Chen, Linfeng; Roemer, Margaretha G. M.; Quyang, Jing; Weinstock, David M.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Cheng, Honwei; Watahiki, Akira; Wang, Yuzhuo] BC Canc Agcy, Expt Therapeut, Vancouver, BC, Canada. [Ducar, Matthew D.; Abo, Ryan P.; Thorner, Aaron R.; van Hummelen, Paul] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Gusenleitner, Daniel; Zhang, Liye; Tan, Yuxiang; Monti, Stefano] Boston Univ, Sch Med, Sect Computat Biomed, Boston, MA 02118 USA. [Bonin, Frederike; Wulf, Gerald G.] Univ Gottingen, Hematol & Oncol, D-37073 Gottingen, Germany. [Sun, Heather H.; Pinkus, Geraldine S.; Aster, Jon C.; Rodig, Scott J.] Brigham & Womens Hosp, Pathol, Boston, MA 02115 USA. [Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002254 ER PT J AU Chen, C Garzon, R Gutierrez, M Jacoby, MA Brown, P Flinn, I Stone, RM Savoie, ML Baz, R Gabrail, NY Wang, M Martin, P Siegel, D Mau-Sorensen, M Andreef, M Marshall, T Saint-Martin, JR Carlson, R Shacham, S Kauffman, M Kuruvilla, J AF Chen, Christine Garzon, Ramiro Gutierrez, Martin Jacoby, Meagan A. Brown, Peter Flinn, Ian Stone, Richard M. Savoie, Mary Lynn Baz, Rachid Gabrail, Nashat Y. Wang, Michael Martin, Peter Siegel, David Mau-Sorensen, Morten Andreef, Michael Marshall, Tracey Saint-Martin, Jean-Richard Carlson, Robert Shacham, Sharon Kauffman, Michael Kuruvilla, John TI Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chen, Christine] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Garzon, Ramiro] Ohio State Univ, Columbus, OH 43210 USA. [Gutierrez, Martin] John Theurer Canc Ctr, Hackensack, NJ USA. [Jacoby, Meagan A.] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA. [Brown, Peter; Mau-Sorensen, Morten] Univ Copenhagen Hosp, Rigshosp, DK-2100 Copenhagen, Denmark. [Flinn, Ian] Sarah Cannon Res Inst, Nashville, TN USA. [Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Savoie, Mary Lynn] Univ Calgary, Calgary, AB, Canada. [Baz, Rachid] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA. [Gabrail, Nashat Y.] Gabrail Canc Ctr, Canton, OH USA. [Wang, Michael] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA. [Martin, Peter] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA. [Siegel, David] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Andreef, Michael] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Marshall, Tracey; Saint-Martin, Jean-Richard; Carlson, Robert; Kauffman, Michael] Karyopharm Therapeut, Newton, MA USA. [Shacham, Sharon] Karyopharm Therapeut Inc, Newton, MA USA. [Kuruvilla, John] Univ Toronto, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada. RI Garzon, Ramiro/E-3104-2011 NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001010 ER PT J AU Chen, YB Le-Rademacher, J Kiefer, DM Hamadani, M DiPersio, JF Litzow, MR Craig, M Horwitz, ME Artz, A McClune, B Waller, EK Fernandez, HF Duong, HK Kobusingye, H Proue, M Drexler, RJ Horowitz, MM Miller, JP Devine, SM AF Chen, Yi-Bin Le-Rademacher, Jennifer Kiefer, Deidre Marie Hamadani, Mehdi DiPersio, John F. Litzow, Mark R. Craig, Michael Horwitz, Mitchell E. Artz, Andrew McClune, Brian Waller, Edmund K. Fernandez, Hugo F. Duong, Hien Kim Kobusingye, Hati Proue, Mandi Drexler, Rebecca J. Horowitz, Mary M. Miller, John P. Devine, Steven M. TI A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Le-Rademacher, Jennifer; Hamadani, Mehdi; Horowitz, Mary M.] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Kiefer, Deidre Marie; Kobusingye, Hati; Proue, Mandi; Drexler, Rebecca J.] Be Match, Natl Marrow Donor Program, CIBMTR, Minneapolis, MN USA. [Hamadani, Mehdi] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Milwaukee, WI 53226 USA. [DiPersio, John F.] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, MN USA. [Craig, Michael] West Virginia Univ Hosp Inc, Morgantown, WV USA. [Horwitz, Mitchell E.] Duke Univ, Med Ctr, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA. [Artz, Andrew] Univ Chicago, Med Ctr, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA. [McClune, Brian] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Waller, Edmund K.] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA. [Fernandez, Hugo F.] Univ S Florida, H Lee Moffitt Canc Ctr, Blood & Marrow Transplantat, Tampa, FL 33682 USA. [Duong, Hien Kim] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Miller, John P.] Natl Marrow Donor Program, Minneapolis, MN USA. [Devine, Steven M.] Ohio State Univ, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001141 ER PT J AU Chin, D Kutny, MA Grim, J Gerbing, RB Miller, K Farrar, JE Auvil, JMG Smith, MA Gerhard, DS Davidsen, TM Gesuwan, P Hermida, LC Marra, MA Mungall, AJ Moore, R Long, W Ma, Y Zong, S Kolb, EA Gamis, AS Alonzo, TA Meshinchi, S AF Chin, Diana Kutny, Matthew A. Grim, Jonathan Gerbing, Robert B. Miller, Kristen Farrar, Jason E. Auvil, Jaime M. Guidry Smith, Malcolm A. Gerhard, Daniela S. Davidsen, Tanja M. Gesuwan, Patee Hermida, Leandro C. Marra, Marco A. Mungall, Andrew J. Moore, Richard Long, William Ma, Yussanne Zong, Stuart Kolb, E. Anders Gamis, Alan S. Alonzo, Todd A. Meshinchi, Soheil TI Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chin, Diana; Miller, Kristen; Meshinchi, Soheil] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Kutny, Matthew A.] Univ Alabama Birmingham, Dept Pediat, Div Hematol Oncol, Birmingham, AL USA. [Grim, Jonathan] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Gerbing, Robert B.] Childrens Oncol Grp, Monrovia, CA USA. [Farrar, Jason E.] Univ Arkansas Med Sci, Dept Pediat, Hematol Oncol Sect, Little Rock, AR 72205 USA. [Auvil, Jaime M. Guidry; Gerhard, Daniela S.; Davidsen, Tanja M.; Gesuwan, Patee; Hermida, Leandro C.] NCI, Off Canc Genom, Bethesda, MD 20892 USA. [Smith, Malcolm A.] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Marra, Marco A.; Moore, Richard] British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada. [Mungall, Andrew J.; Long, William; Ma, Yussanne; Zong, Stuart] British Columbia Canc Agcy, Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada. [Kolb, E. Anders] Alfred I duPont Hosp Children, Nemours Ctr Canc & Blood Disorders, Wilmington, DE USA. [Gamis, Alan S.] Childrens Mercy Hosp & Clin, Div Hematol Oncol Bone Marrow Transplantat, Kansas City, MO USA. [Alonzo, Todd A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000234 ER PT J AU Chu, JI Henderson, LA Armant, M Male, F Dansereau, CH MacKinnon, B Burke, CJ Cavanaugh, ME London, WB Barlan, IB Ozen, A Baris, S Karakoc-Aydiner, E Kiykirn, A Hanson, IC Despotovic, JM Saitoh, A Takachi, T Imai, K King, A Arredondo, S Ritz, J Bushman, FD Galy, A Notarangelo, LD Williams, DA Pai, SY AF Chu, Julia I. Henderson, Lauren A. Armant, Myriam Male, Frances Dansereau, Colleen H. MacKinnon, Brenda Burke, Christopher J. Cavanaugh, Matthew E. London, Wendy B. Barlan, Isil B. Ozen, Ahmet Baris, Safa Karakoc-Aydiner, Elif Kiykirn, Ayca Hanson, Imelda Celine Despotovic, Jenny M. Saitoh, Akihiko Takachi, Takayuki Imai, Kohsuke King, Alejandra Arredondo, Silvia Ritz, Jerome Bushman, Frederic D. Galy, Anne Notarangelo, Luigi Daniele Williams, David A. Pai, Sung-Yun TI Gene Therapy Using a Self-Inactivating Lentiviral Vector Improves Clinical and Laboratory Manifestations of Wiskott-Aldrich Syndrome SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chu, Julia I.; Burke, Christopher J.; Cavanaugh, Matthew E.; London, Wendy B.; Williams, David A.; Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Chu, Julia I.; Armant, Myriam; London, Wendy B.; Williams, David A.; Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Henderson, Lauren A.; Notarangelo, Luigi Daniele] Boston Childrens Hosp, Div Immunol, Boston, MA USA. [Male, Frances; Bushman, Frederic D.] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA. [Dansereau, Colleen H.; MacKinnon, Brenda] Boston Childrens Hosp, Div Pediat Hematol, Boston, MA USA. [Barlan, Isil B.; Ozen, Ahmet; Baris, Safa; Karakoc-Aydiner, Elif; Kiykirn, Ayca] Marmara Univ, Divis Pediat Allergy Immunol, Istanbul, Turkey. [Hanson, Imelda Celine] Texas Childrens Hosp, Div Pediat Immunol Allergy & Rheumatol, Houston, TX 77030 USA. [Despotovic, Jenny M.] Baylor Coll Med, Texas Childrens Hematol Ctr, Houston, TX 77030 USA. [Saitoh, Akihiko; Takachi, Takayuki] Niigata Univ, Grad Sch Med & Dent Sci, Dept Pediat, Niigata, Japan. [Imai, Kohsuke] Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Tokyo, Japan. [King, Alejandra] Hosp Ninos Luis Calvo Mackenna, Santiago, Chile. [Arredondo, Silvia] Hosp Reg Talca, Serv Pediat, Talca, Chile. [Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Galy, Anne] Genethon, Evry, France. RI Notarangelo, Luigi/F-9718-2016 OI Notarangelo, Luigi/0000-0002-8335-0262 NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001012 ER PT J AU Chung, J Wittig, JG Bauer, DE Coon, JJ Pagliarini, DJ Dailey, HA Lodish, HF Paw, BH AF Chung, Jacky Wittig, Johannes G. Bauer, Daniel E. Coon, Joshua J. Pagliarini, Dave J. Dailey, Harry A. Lodish, Harvey F. Paw, Barry H. TI Mitochondrial Protein Kinase A Regulates Heme Biosynthesis SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chung, Jacky; Wittig, Johannes G.; Paw, Barry H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA. [Bauer, Daniel E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol,Boston Childrens Hosp, Boston, MA 02115 USA. [Coon, Joshua J.] Univ Wisconsin, Dept Chem, Madison, WI 53706 USA. [Pagliarini, Dave J.] Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA. [Dailey, Harry A.] Univ Georgia, Dept Microbiol, Athens, GA 30602 USA. [Dailey, Harry A.] Univ Georgia, Dept Biochem, Athens, GA 30602 USA. [Dailey, Harry A.] Univ Georgia, Dept Mol Biol, Athens, GA 30602 USA. [Lodish, Harvey F.] MIT, Whitehead Inst Biomed Res, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001023 ER PT J AU Cleynen, A Szalat, R Samur, MK Parmigiani, G Munshi, NC Avet-Loiseau, H AF Cleynen, Alice Szalat, Raphal Samur, Mehmet Kemal Parmigiani, Giovanni Munshi, Nikhil C. Avet-Loiseau, Herve TI The Fusion Gene Landscape in Multiple Myeloma, with Clinical Impact SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Cleynen, Alice; Samur, Mehmet Kemal; Parmigiani, Giovanni] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Szalat, Raphal] Hop St Louis, APHP, Serv Immunohematol, Paris, France. [Szalat, Raphal] Harvard Univ, Sch Med, Med Oncol, Boston, MA USA. [Szalat, Raphal; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA. [Avet-Loiseau, Herve] Inst Natl Sante, Ctr Rech Cancerol Toulouse, Toulouse, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002272 ER PT J AU Cole, PD Blonquist, TM Vijayanathan, V Neuberg, DS Vrooman, LM Sallan, SE Silverman, LB Finkelstein, Y AF Cole, Peter D. Blonquist, Traci M. Vijayanathan, Veena Neuberg, Donna S. Vrooman, Lynda M. Sallan, Stephen E. Silverman, Lewis B. Finkelstein, Yaron TI Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Cole, Peter D.] Montefiore Med Ctr, Albert Einstein Coll Med, Pediat, Bronx, NY 10467 USA. [Blonquist, Traci M.; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Vijayanathan, Veena] Albert Einstein Coll Med, Pediat, Bronx, NY 10467 USA. [Vrooman, Lynda M.] Dana Farber Canc Inst, Pediat Oncol, Boston, MA 02115 USA. [Sallan, Stephen E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Silverman, Lewis B.] Boston Childrens Hosp, Dana Farber Canc Inst, Pediat Oncol, Boston, MA USA. [Finkelstein, Yaron] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001003 ER PT J AU Connell, NT Abel, GA Connors, JM AF Connell, Nathan T. Abel, Gregory A. Connors, Jean M. TI Cost-Effectiveness Analysis of Warfarin Versus Low-Molecular Weight Heparin for the Treatment of Malignancy-Associated Venous Thromboembolism SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Connell, Nathan T.; Connors, Jean M.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Connell, Nathan T.; Abel, Gregory A.; Connors, Jean M.] Harvard Univ, Sch Med, Boston, MA USA. [Abel, Gregory A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002183 ER PT J AU Cui, B Chen, L Rassenti, LZ Ghia, EM Yu, J Zhang, L Neuberg, DS Wierda, W Keating, M Rai, KR Kay, NE Brown, JR Byrd, JC Gribben, J Kipps, TJ AF Cui, Bing Chen, Liguang Rassenti, Laura Z. Ghia, Emanuela M. Yu, Jian Zhang, Ling Neuberg, Donna S. Wierda, William Keating, Michael Rai, Kanti R. Kay, Neil E. Brown, Jennifer R. Byrd, John C. Gribben, John Kipps, Thomas J. TI High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Cui, Bing; Chen, Liguang; Rassenti, Laura Z.; Yu, Jian; Zhang, Ling; Kipps, Thomas J.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Ghia, Emanuela M.] CLL Res Consortium, Moores UCSD Canc Ctr, San Diego, CA USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Wierda, William] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Keating, Michael] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Rai, Kanti R.] North Shore LIJ Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA. [Kay, Neil E.] Mayo Clin, Div Hematol, Rochester, MN USA. [Brown, Jennifer R.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Byrd, John C.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA. [Gribben, John] London Sch Med, Barts Canc Ctr, London, England. [Gribben, John] Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, London, England. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005191 ER PT J AU Das, DS Ray, A Song, Y Richardson, P Trikha, M Chauhan, D Anderson, KC AF Das, Deepika Sharma Ray, Arghya Song, Yan Richardson, Paul Trikha, Mohit Chauhan, Dharminder Anderson, Kenneth C. TI Oral Proteasome Inhibitor Marizomib and IMiD (R) Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition in Vitro and In Vivo SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Das, Deepika Sharma; Ray, Arghya; Song, Yan; Richardson, Paul; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA. [Das, Deepika Sharma; Ray, Arghya; Song, Yan; Richardson, Paul; Chauhan, Dharminder] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Trikha, Mohit] Triphase Accelerator, San Diego, CA USA. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005299 ER PT J AU Das, DS Song, Y Ray, A Richardson, P Chauhan, D Anderson, KC AF Das, Deepika Sharma Song, Yan Ray, Arghya Richardson, Paul Chauhan, Dharminder Anderson, Kenneth C. TI Targeting Deubiquitylating Enzyme USP1 in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Das, Deepika Sharma; Song, Yan; Ray, Arghya; Richardson, Paul; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA. [Das, Deepika Sharma; Song, Yan; Ray, Arghya; Richardson, Paul; Chauhan, Dharminder] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005291 ER PT J AU Das, DS Ray, A Song, Y Richardson, P Oronsky, B Scicinski, J Chauhan, D Anderson, KC AF Das, Deepika Sharma Ray, Arghya Song, Yan Richardson, Paul Oronsky, Bryan Scicinski, Jan Chauhan, Dharminder Anderson, Kenneth C. TI The Hypoxia-Selective Epigenetic Agent, Rrx-001, Triggers Apoptosis and Overcomes Drug-Resistance in Multiple Myeloma Cells SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Das, Deepika Sharma; Ray, Arghya; Song, Yan; Richardson, Paul; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Das, Deepika Sharma; Ray, Arghya; Song, Yan; Richardson, Paul; Chauhan, Dharminder] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Oronsky, Bryan; Scicinski, Jan] EpicentRx, Ca, CA USA. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003042 ER PT J AU Davids, MS Kim, HT Costello, CL McSweeney, PA Liguori, R Lukez, A Avigan, D Chen, YB LeBoeuf, N Ho, VT Cutler, CS Koreth, J Alyea, EP Antin, JH Ritz, J Armand, P Ball, ED Bashey, A Soiffer, RJ AF Davids, Matthew S. Kim, Haesook T. Costello, Caitlin L. McSweeney, Peter A. Liguori, Rebecca Lukez, Alexander Avigan, David Chen, Yi-Bin LeBoeuf, Nicole Ho, Vincent T. Cutler, Corey S. Koreth, John Alyea, Edwin P. Antin, Joseph H. Ritz, Jerome Armand, Philippe Ball, Edward D. Bashey, Asad Soiffer, Robert J. TI A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Davids, Matthew S.; Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Costello, Caitlin L.] Moores UCSD Canc Ctr, La Jolla, CA USA. [McSweeney, Peter A.] Rocky Mt Canc Ctr, Denver, CO USA. [Liguori, Rebecca; Lukez, Alexander; Ho, Vincent T.; Koreth, John; Alyea, Edwin P.; Antin, Joseph H.; Soiffer, Robert J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [LeBoeuf, Nicole] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Ball, Edward D.] UCSD, Div Blood & Marrow Transplantat, La Jolla, CA USA. [Bashey, Asad] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002297 ER PT J AU DeAngelo, DJ Stevenson, K Neuberg, DS Silverman, LB Ballen, KK Asch, JD Abou Mourad, Y Paulson, K Seftel, MD Avigan, D Bergeron, J Couban, S Blum, W Storring, J Wadleigh, M Steensma, DP Supko, J Sallan, SE Stone, RM AF DeAngelo, Daniel J. Stevenson, Kristen Neuberg, Donna S. Silverman, Lewis B. Ballen, Karen K. Asch, Julie D. Abou Mourad, Yasser Paulson, Kristjan Seftel, Matthew D. Avigan, David Bergeron, Julie Couban, Stephen Blum, William Storring, John Wadleigh, Martha Steensma, David P. Supko, Jeffrey Sallan, Stephen E. Stone, Richard M. TI A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [DeAngelo, Daniel J.; Wadleigh, Martha; Steensma, David P.; Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Stevenson, Kristen; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Silverman, Lewis B.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Ballen, Karen K.; Supko, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Asch, Julie D.] Intermt Blood & Marrow Transplant Acute Leukemia, Salt Lake City, UT USA. [Abou Mourad, Yasser] Vancouver Gen Hosp, BC Canc Ctr, Vancouver, BC, Canada. [Paulson, Kristjan] CancerCare Manitoba, Winnipeg, MB, Canada. [Seftel, Matthew D.] CancerCare Manitoba, Dept Med Oncol Hematol, Winnipeg, MB, Canada. [Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Bergeron, Julie] Univ Montreal, Hop Maisonneuve Rosemont, Blood & Marrow Transplant Program, Montreal, PQ, Canada. [Bergeron, Julie] Univ Montreal, Hop Maisonneuve Rosemont, Div Hematol, Montreal, PQ, Canada. [Couban, Stephen] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. [Blum, William] Ohio State Univ, James Canc Ctr, Columbus, OH 43210 USA. [Storring, John] McGill Montreal Gen Hosp, Montreal, PQ, Canada. [Sallan, Stephen E.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Sallan, Stephen E.] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000144 ER PT J AU Deng, J Isik, E Fernandes, SM Brown, JR Letai, A Davids, MS AF Deng, Jing Isik, Elif Fernandes, Stacey M. Brown, Jennifer R. Letai, Anthony Davids, Matthew S. TI Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Deng, Jing; Isik, Elif; Fernandes, Stacey M.; Brown, Jennifer R.; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Davids, Matthew S.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001236 ER PT J AU Dhabangi, A Ainomugisha, B Cserti-Gazdewich, CM Ddungu, H Kyeyune, D Musisi, E Opoka, R Stowell, CP Dzik, WH AF Dhabangi, Aggrey Ainomugisha, Brenda Cserti-Gazdewich, Christine M. Ddungu, Henry Kyeyune, Dorothy Musisi, Ezra Opoka, Robert Stowell, Christopher P. Dzik, Walter H. TI Tissue Oxygenation By Transfusion in Severe Anemia with Lactic Acidosis (TOTAL): A Prospective, Randomized, Non-Inferiority Trial of Blood Storage Duration SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Dhabangi, Aggrey] Makerere Univ, Child Hlth & Dev Ctr, Kampala, Uganda. [Ainomugisha, Brenda] Mulago Hosp, Kampala, Uganda. [Cserti-Gazdewich, Christine M.] Univ Hlth Network, Div Hematol Med Oncol, Dept Med, Toronto, ON, Canada. [Ddungu, Henry] Mulago Hosp Complex, Kampala, Uganda. [Kyeyune, Dorothy; Musisi, Ezra] Uganda Natl Blood Transfus Serv, Kampala, Uganda. [Opoka, Robert] Makerere Univ, Dept Pediat, Kampala, Uganda. [Stowell, Christopher P.] Massachusetts Gen Hosp, Blood Transfus Serv, Boston, MA 02114 USA. [Dzik, Walter H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002206 ER PT J AU Diefenbach, CS Hong, FX Cohen, JB Robertson, MJ Ambinder, RF Fenske, TS Advani, RH Kahl, BS Ansell, S AF Diefenbach, Catherine S. Hong, Fangxin Cohen, Jonathon B. Robertson, Michael J. Ambinder, Richard F. Fenske, Timothy S. Advani, Ranjana H. Kahl, Brad S. Ansell, Stephen TI Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Diefenbach, Catherine S.] NYU Sch Med, NYU Perlmutter Canc Ctr, New York, NY USA. [Hong, Fangxin] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cohen, Jonathon B.] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA. [Robertson, Michael J.] Indiana Univ Sch Med, Lymphoma Program, Div Hematol Oncol, Indianapolis, IN 46202 USA. [Ambinder, Richard F.] Johns Hopkins Med Inst, SKCCC, Div Hematol Malignancies, Baltimore, MD 21205 USA. [Fenske, Timothy S.] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA. [Advani, Ranjana H.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Kahl, Brad S.] Washington Univ, St Louis, MO USA. [Ansell, Stephen] Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002022 ER PT J AU Dimopoulos, MA Lonial, S White, D Moreau, P Palumbo, A San Miguel, J Shpilberg, O Anderson, KC Grosicki, S Spicka, I Walter-Croneck, A Magen-Nativ, H Mateos, MV Belch, A Reece, D Beksac, M Bleickhardt, E Poulart, V Katz, J Singhal, AK Richardson, PG AF Dimopoulos, Meletios A. Lonial, Sagar White, Darrell Moreau, Philippe Palumbo, Antonio San Miguel, Jesus Shpilberg, Ofer Anderson, Kenneth C. Grosicki, Sebastian Spicka, Ivan Walter-Croneck, Adam Magen-Nativ, Hila Mateos, Maria-Victoria Belch, Andrew Reece, Donna Beksac, Meral Bleickhardt, Eric Poulart, Valerie Katz, Jessica Singhal, Anil K. Richardson, Paul G. TI Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-3-Year Safety and Efficacy Follow-up SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting and Exposition of the American-Society-of-Hematology CY DEC 04-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Athens 11528, Greece. [Lonial, Sagar] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. [White, Darrell] QEII Hlth Sci Ctr, Halifax, NS, Canada. [White, Darrell] Dalhousie Univ, Halifax, NS, Canada. [Moreau, Philippe] Univ Hosp, Nantes, France. [Palumbo, Antonio] Osped Molinette, AOU San Giovanni Bathsta Torino, Turin, Italy. [San Miguel, Jesus] Univ Navarra Clin, Pamplona, Spain. [Shpilberg, Ofer] Assuta Med Ctr, Tel Aviv, Israel. [Anderson, Kenneth C.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Grosicki, Sebastian] Silesian Med Univ, Katovvice, Poland. [Spicka, Ivan] Charles Univ Hosp, Prague, Czech Republic. [Walter-Croneck, Adam] Med Univ Lublin, Lublin, Poland. [Magen-Nativ, Hila] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel. [Magen-Nativ, Hila] Tel Aviv Univ, Ramat Aviv, Israel. [Mateos, Maria-Victoria] Univ Hosp Salamanca IBSAL, Salamanca, Spain. [Belch, Andrew] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. [Belch, Andrew] Univ Alberta, Edmonton, AB, Canada. [Reece, Donna] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Beksac, Meral] Ankara Univ, TR-06100 Ankara, Turkey. [Bleickhardt, Eric] Bristol Myers Squibb Co, 5 Res Pkwy, Wallingford, CT 06492 USA. [Poulart, Valerie] Bristol Myers Squibb Co, Braine Lalleud, Belgium. [Katz, Jessica] Bristol Myers Squibb Co, Princeton, NJ USA. [Singhal, Anil K.] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. RI richard, chrystelle/K-8595-2015 NR 1 TC 0 Z9 0 U1 2 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000092 ER PT J AU DiNardo, C de Botton, S Pollyea, DA Stein, EM Fathi, AT Roboz, GJ Collins, R Swords, RT Flinn, IW Altman, JK Tallman, MS Kantarjian, HM Derti, A Goldwasser, M Prahl, M Wu, B Yen, K Agresta, S Stone, RM AF DiNardo, Courtney de Botton, Stephane Pollyea, Daniel A. Stein, Eytan M. Fathi, Amir T. Roboz, Gail J. Collins, Robert Swords, Ronan T. Flinn, Ian W. Altman, Jessica K. Tallman, Martin S. Kantarjian, Hagop M. Derti, Adnan Goldwasser, Meredith Prahl, Malia Wu, Bin Yen, Katherine Agresta, Sam Stone, Richard M. TI Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [DiNardo, Courtney] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [de Botton, Stephane] Inst Gustave Roussy, Villejuif, France. [Pollyea, Daniel A.] Univ Colorado, Ctr Canc, Aurora, CO USA. [Stein, Eytan M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. [Roboz, Gail J.] Weill Cornell Med Coll, Joan & Sanford I Weill Dept Med, New York, NY USA. [Collins, Robert] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Swords, Ronan T.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA. [Flinn, Ian W.] Sarah Cannon Res Inst, Hematol Malignancies Res Program, Nashville, TN USA. [Altman, Jessica K.] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. [Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Derti, Adnan; Goldwasser, Meredith; Prahl, Malia; Wu, Bin; Yen, Katherine; Agresta, Sam] Agios Pharmaceut, Cambridge, MA USA. [Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 15 Z9 15 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004106 ER PT J AU DiNardo, C Pollyea, D Pratz, K Thirman, MJ Letai, A Frattini, M Jonas, B Leverson, J Zhu, M Dunbar, M Falotico, N Kirby, R Agarwal, S Mabry, M Potluri, J Humerickhouse, RA Kantarjian, HM Konopleva, M AF DiNardo, Courtney Pollyea, Daniel Pratz, Keith Thirman, Michael J. Letai, Anthony Frattini, Mark Jonas, Brian Leverson, Joel Zhu, Ming Dunbar, Martin Falotico, Nancy Kirby, Rachel Agarwal, Suresh Mabry, Mack Potluri, Jalaja Humerickhouse, Rod A. Kantarjian, Hagop M. Konopleva, Marina TI A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are >= to 65 Years and Not Eligible for Standard Induction Therapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [DiNardo, Courtney; Kantarjian, Hagop M.; Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Pollyea, Daniel] Univ Colorado, Sch Med, Div Hematol, Aurora, CO USA. [Pratz, Keith] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Thirman, Michael J.] Univ Chicago, Chicago, IL 60637 USA. [Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Frattini, Mark] Columbia Univ, Med Ctr, New York, NY USA. [Jonas, Brian] UC Davis Comprehens Canc Ctr, Sacramento, CA USA. [Leverson, Joel; Zhu, Ming; Dunbar, Martin; Falotico, Nancy; Kirby, Rachel; Agarwal, Suresh; Mabry, Mack; Potluri, Jalaja; Humerickhouse, Rod A.] AbbVie Inc, N Chicago, IL USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001079 ER PT J AU Dunleavy, K Noy, A Abramson, JS LaCasce, AS Link, BK Parekh, S Jagadeesh, D Bierman, PJ Mitsuyasu, RT Battini, R Watson, PR Peace, D Averbrook, BJ Naina, HV Leach, JW Hanna, WT Powell, BL Nagpal, S Roschewski, M Lucas, AN Steinberg, SM Kahl, BS Friedberg, JW Little, RF Bartlett, NL Fanale, MA Wilson, WH AF Dunleavy, Kieron Noy, Ariela Abramson, Jeremy S. LaCasce, Ann S. Link, Brian K. Parekh, Samir Jagadeesh, Deepa Bierman, Philip J. Mitsuyasu, Ronald T. Battini, Ramakrishna Watson, Peter R. Peace, David Averbrook, Bruce J. Naina, Harris V. Leach, Joseph W. Hanna, Wahid T. Powell, Bayard L. Nagpal, Sunil Roschewski, Mark Lucas, Andrea N. Steinberg, Seth M. Kahl, Brad S. Friedberg, Jonathan W. Little, Richard F. Bartlett, Nancy L. Fanale, Michelle A. Wilson, Wyndham H. TI Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Dunleavy, Kieron; Roschewski, Mark; Wilson, Wyndham H.] NCI, Lymphoid Malignancies Branch, Bethesda, MD 20892 USA. [Noy, Ariela] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY 10021 USA. [Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [LaCasce, Ann S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Link, Brian K.] Univ Iowa Hosp & Clin, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa City, IA 52242 USA. [Parekh, Samir] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA. [Jagadeesh, Deepa] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Bierman, Philip J.] Univ Nebraska Med Ctr, Omaha, NE USA. [Mitsuyasu, Ronald T.] UCLA Med Ctr, Los Angeles, CA USA. [Battini, Ramakrishna] Montefiore Med Ctr, Dept Oncol, New York, NY USA. [Watson, Peter R.] Kinston Med Specialists, Kinston, NC USA. [Peace, David] Univ Illinois, Div Hematol Oncol, Chicago, IL USA. [Averbrook, Bruce J.] Metrohlth Med Ctr, Cleveland, OH USA. [Naina, Harris V.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Hematol & Oncol, Dallas, TX 75390 USA. [Leach, Joseph W.] Unity Hosp, Monneapolis, MN USA. [Hanna, Wahid T.] Univ Tennessee, Inst Canc, Knoxville, TN USA. [Powell, Bayard L.] Wake Forest Sch Med, Ctr Comprehens Canc, Winston Salem, NC USA. [Nagpal, Sunil] West Michigan Canc Ctr, Kalamazoo, MI USA. [Lucas, Andrea N.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. [Steinberg, Seth M.] NCI, Biostat & Data Management Sect, Bethesda, MD 20892 USA. [Kahl, Brad S.] Washington Univ, St Louis, MO USA. [Friedberg, Jonathan W.] Univ Rochester, Rochester, NY USA. [Little, Richard F.] NCI, Canc Therapy Evaluat Program, Rockville, MD USA. [Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA. [Fanale, Michelle A.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001094 ER PT J AU El-Jawahri, A Chen, YB Brazauskas, R He, N Lee, SJ Knight, JM Hahn, T Khera, N Dalal, JD Bonfim, C Atsuta, Y Saber, W AF El-Jawahri, Areej Chen, Yi-Bin Brazauskas, Ruta He, Naya Lee, Stephanie J. Knight, Jennifer M. Hahn, Theresa Khera, Nandita Dalal, Jignesh D. Bonfim, Carmem Atsuta, Yoshiko Saber, Wael TI The Impact of Pre-Transplant Depression on Outcomes of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [El-Jawahri, Areej] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Brazauskas, Ruta; He, Naya] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Knight, Jennifer M.] Med Coll Wisconsin, Milwakee, WI USA. [Hahn, Theresa] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA. [Khera, Nandita] Mayo Clin Arizona, Dept Hematol Oncol, Phoenix, AZ USA. [Khera, Nandita] Phoenix Childrens Hosp, Phoenix, AZ USA. [Dalal, Jignesh D.] Childrens Mercy Hosp & Clincs, Bone Marrow Transplantat Pediat Hematol Oncol, Kansas City, MO USA. [Bonfim, Carmem] Univ Fed Parana, Hosp Clin, Bone Marrow Transplantat Ctr, BR-80060000 Curitiba, Parana, Brazil. [Atsuta, Yoshiko] Japanese Data Ctr Haematopoiet Cell Transplantat, Nagoya, Aichi, Japan. [Atsuta, Yoshiko] Nagoya Univ, Grad Sch Med, Dept Healthcare Adm, Nagoya, Aichi 4648601, Japan. [Saber, Wael] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001017 ER PT J AU Elf, S Abdelfattah, N Chen, E Perales-Paton, J Rosen, E Ko, A Peisker, F Florescu, N Giannini, S Wolach, O Morgan, EA Losman, JA Schneider, RK Al-Shahrour, F Mullaly, A AF Elf, Shannon Abdelfattah, Nouran Chen, Edwin Perales-Paton, Javier Rosen, Emily Ko, Amy Peisker, Fabian Florescu, Natalie Giannini, Silvia Wolach, Ofir Morgan, Elizabeth A. Losman, Julie-Aurore Schneider, Rebekka K. Al-Shahrour, Fatima Mullaly, Ann TI Physical Interaction Between Mutant Calreticulin and the Thrombopoietin Receptor Is Required for Hematopoietic Transformation SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Elf, Shannon; Abdelfattah, Nouran; Chen, Edwin; Rosen, Emily; Ko, Amy; Peisker, Fabian; Florescu, Natalie; Giannini, Silvia; Losman, Julie-Aurore; Schneider, Rebekka K.; Mullaly, Ann] Brigham & Womens Hosp, Boston, MA 02115 USA. [Perales-Paton, Javier; Al-Shahrour, Fatima] Spanish Natl Canc Res Ctr, Madrid, Spain. [Wolach, Ofir; Losman, Julie-Aurore] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Morgan, Elizabeth A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000005 ER PT J AU Etchin, J Berezovskaya, A Conway, AS Chen, WC Baloglu, E Landesman, Y Senapedis, W Ellis, J McCauley, D Stone, RM Galinsky, I DeAngelo, DJ Kauffman, M Shacham, S Wang, JCY Look, AT AF Etchin, Julia Berezovskaya, Alla Conway, Amy Saur Chen, Weihsu Claire Baloglu, Erkan Landesman, Yosef Senapedis, William Ellis, Joel McCauley, Dilara Stone, Richard M. Galinsky, Ilene DeAngelo, Daniel J. Kauffman, Michael Shacham, Sharon Wang, Jean C. Y. Look, A. Thomas TI Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Etchin, Julia] Harvard Univ, Sch Med, Boston, MA USA. [Etchin, Julia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol,Childrens Hosp Boston, Boston, MA 02115 USA. [Berezovskaya, Alla; Conway, Amy Saur; Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, Weihsu Claire] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. [Baloglu, Erkan; Landesman, Yosef; Senapedis, William; Ellis, Joel; McCauley, Dilara; Shacham, Sharon] Karyopharm Therapeut Inc, Newton, MA USA. [Stone, Richard M.; Galinsky, Ilene; DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Kauffman, Michael] Karyopharm Therapeut, Newton, MA USA. [Wang, Jean C. Y.] Univ Hlth Network, Div Med Oncol & Hematol, Toronto, ON, Canada. [Wang, Jean C. Y.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. [Wang, Jean C. Y.] Univ Toronto, Dept Med, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001078 ER PT J AU Fathi, AT Borate, U DeAngelo, DJ O'Brien, MM Trippett, T Shah, BD Hale, GA Foran, JM Silverman, LB Tibes, R Cramer, S Pauly, M Kim, S Kostic, A Huang, XH Pan, Y Chen, R AF Fathi, Amir T. Borate, Uma DeAngelo, Daniel J. O'Brien, Maureen M. Trippett, Tanya Shah, Bijal D. Hale, Gregory A. Foran, James M. Silverman, Lewis B. Tibes, Raoul Cramer, Stuart Pauly, Melinda Kim, Stella Kostic, Ana Huang, Xiaohui Pan, Yang Chen, Robert TI A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Borate, Uma] Univ Alabama Birmingham, Birmingham, AL USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [O'Brien, Maureen M.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Trippett, Tanya] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Shah, Bijal D.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Hale, Gregory A.] Johns Hopkins Univ, All Childrens Hosp, St Petersburg, FL USA. [Foran, James M.] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA. [Silverman, Lewis B.] Boston Childrens Hosp, Pediat Oncol, Dana Farber Canc Inst, Boston, MA USA. [Tibes, Raoul] Mayo Clin Arizona, Scottsdale, AZ USA. [Cramer, Stuart] Univ Alabama Birmingham, Childrens Alabama, Birmingham, AL USA. [Pauly, Melinda] Childrens Healthcare Atlanta Egleston, Atlanta, GA USA. [Kim, Stella] Cizik Eye Clin, Houston, TX USA. [Kostic, Ana; Huang, Xiaohui; Pan, Yang] Seattle Genet Inc, Bothell, WA USA. [Chen, Robert] City Hope Natl Med Ctr, Duarte, CA 91010 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004128 ER PT J AU Fathi, AT Erba, HP Lancet, JE Stein, EM Walter, RB DeAngelo, DJ Faderl, S Jillella, AP Ravandi, F Advani, AS Bixby, D Kovacsovics, TJ O'Meara, MM Kennedy, DA Stein, AS AF Fathi, Amir T. Erba, Harry P. Lancet, Jeffrey E. Stein, Eytan M. Walter, Roland B. DeAngelo, Daniel J. Faderl, Stefan Jillella, Anand P. Ravandi, Farhad Advani, Anjali S. Bixby, Dale Kovacsovics, Tibor J. O'Meara, Megan M. Kennedy, Dana A. Stein, Anthony S. TI SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Erba, Harry P.] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA. [Lancet, Jeffrey E.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA. [Stein, Eytan M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Walter, Roland B.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Faderl, Stefan] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Jillella, Anand P.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Ravandi, Farhad] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Advani, Anjali S.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Bixby, Dale] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Kovacsovics, Tibor J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [O'Meara, Megan M.] Seattle Genet Inc, Clin Dev, Bothell, WA USA. [Kennedy, Dana A.] Seattle Genet Inc, Clin, Bothell, WA USA. [Stein, Anthony S.] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, Duarte, CA 91010 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001206 ER PT J AU Foran, JM Sun, ZX Claxton, DF Lazarus, HM Thomas, ML Melnick, A Levine, RL Paietta, E Arber, D Zhang, YM Rowe, JM Godwin, JE Altman, JK Luger, S Al-Kali, A Zheng, H Pratz, K Broun, ER Powell, BL O'Dwyer, K Litzow, MR Tallman, MS AF Foran, James M. Sun, Zhuoxin Claxton, David F. Lazarus, Hillard M. Thomas, Mary L. Melnick, Ari Levine, Ross L. Paietta, Elisabeth Arber, Daniel Zhang, Yangming Rowe, Jacob M. Godwin, John E. Altman, Jessica K. Luger, Selina Al-Kali, Aref Zheng, Hong Pratz, Keith Broun, E. Randolph Powell, Bayard L. O'Dwyer, Kristen Litzow, Mark R. Tallman, Martin S. TI North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >= 60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Foran, James M.] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA. [Sun, Zhuoxin] Dana Farber Canc Inst, Boston, MA 02115 USA. [Claxton, David F.] Penn State Hershey Canc Inst, Hershey, PA USA. [Lazarus, Hillard M.] Univ Hosp Cleveland, Ireland Canc Ctr, Case Med Ctr, Cleveland, OH 44106 USA. [Thomas, Mary L.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Melnick, Ari] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Levine, Ross L.; Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. [Paietta, Elisabeth] Montefiore Med Ctr, North Div, Ctr Canc, Bronx, NY 10467 USA. [Arber, Daniel] Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA. [Zhang, Yangming] Northwestern Univ, Cytogenet, Chicago, IL 60611 USA. [Rowe, Jacob M.] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel. [Godwin, John E.] Providence Onc Hem Care Clin, Portland, OR USA. [Altman, Jessica K.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Luger, Selina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Al-Kali, Aref] Mayo Clin, Rochester, MN USA. [Zheng, Hong] Penn State Hershey Med Ctr, Dept Med, Hershey, PA USA. [Pratz, Keith] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Broun, E. Randolph] Jewish Hosp, Cincinnati, OH USA. [Powell, Bayard L.] Wake Forest Sch Med, Ctr Comprehens Canc, Winston Salem, NC USA. [O'Dwyer, Kristen] Univ Rochester, Med Ctr, James P Wilmot Canc Inst, Rochester, NY 14642 USA. [Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000281 ER PT J AU Forcade, E Kim, HT Cutler, CS Wang, KS Ho, VT Koreth, J Armand, P Alyea, EP Blazar, BR Soiffer, RJ Antin, JH Ritz, J AF Forcade, Edouard Kim, Haesook T. Cutler, Corey S. Wang, Kathy S. Ho, Vincent T. Koreth, John Armand, Philippe Alyea, Edwin P. Blazar, Bruce R. Soiffer, Robert J. Antin, Joseph H. Ritz, Jerome TI Activated Circulating T Follicular Helper Cells with Increased Function during Chronic Graft Versus Host Disease after Allogeneic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Forcade, Edouard; Cutler, Corey S.; Wang, Kathy S.; Koreth, John; Armand, Philippe; Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Forcade, Edouard; Cutler, Corey S.; Wang, Kathy S.; Koreth, John; Armand, Philippe; Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Forcade, Edouard; Cutler, Corey S.; Wang, Kathy S.; Ho, Vincent T.; Koreth, John; Armand, Philippe; Alyea, Edwin P.; Soiffer, Robert J.; Antin, Joseph H.; Ritz, Jerome] Harvard Univ, Sch Med, Boston, MA USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Kim, Haesook T.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Ho, Vincent T.; Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Alyea, Edwin P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Blazar, Bruce R.] Univ Minnesota, Dept Med, Ctr Canc, Div Pediat, Minneapolis, MN 55455 USA. [Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003048 ER PT J AU Fulciniti, M Lin, CY Samur, MK Lawlor, M Anderson, KC Bradner, JE Munshi, NC AF Fulciniti, Mariateresa Lin, Charles Y. Samur, Mehmet K. Lawlor, Matthew Anderson, Kenneth C. Bradner, James E. Munshi, Nikhil C. TI Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Fulciniti, Mariateresa; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Lin, Charles Y.; Lawlor, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA. [Samur, Mehmet K.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Bradner, James E.] Harvard Univ, Sch Med, Boston, MA USA. [Munshi, Nikhil C.] VA Med Hosp, Boston, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002275 ER PT J AU Fulciniti, M Samur, MK Rashid, NU Bandi, RL Bhasin, M Parmigiani, G Anderson, KC Munshi, NC AF Fulciniti, Mariateresa Samur, Mehmet Kemal Rashid, Naim Ur Bandi, Rajya Lakshmi Bhasin, Manoj Parmigiani, Giovanni Anderson, Kenneth C. Munshi, Nikhil C. TI Functional and Clinical Impact of Splicing Factor Dysregulation in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Fulciniti, Mariateresa; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Samur, Mehmet Kemal; Parmigiani, Giovanni] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Rashid, Naim Ur] Dana Farber, Boston, MA USA. [Bandi, Rajya Lakshmi] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bhasin, Manoj] BIDMC Genom Prote Bioinformat & Syst Biol Ctr, Boston, MA USA. [Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Munshi, Nikhil C.] VA Med Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002163 ER PT J AU Ganzel, C Victoria, WX Fielding, AK Rowe, JM Richards, SM Buck, G Chopra, R Durrant, IJ Marks, D Franklin, IM McMilan, AK Litzow, MR Paietta, E Luger, S Wiernik, PH Douer, D Lazarus, HM Tallman, MS Goldstone, AH AF Ganzel, Chezi Victoria, Wang Xin Fielding, Adele K. Rowe, Jacob M. Richards, Susan M. Buck, Georgina Chopra, Rajesh Durrant, I. Jill Marks, David Franklin, Ian M. McMilan, Andrew K. Litzow, Mark R. Paietta, Elisabeth Luger, Selina Wiernik, Peter H. Douer, Dan Lazarus, Hillard M. Tallman, Martin S. Goldstone, Anthony H. TI in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Ganzel, Chezi; Rowe, Jacob M.] Shaare Zedek Med Ctr, Hematol, Jerusalem, Israel. [Victoria, Wang Xin] Dana Farber Canc Inst, Boston, MA 02115 USA. [Fielding, Adele K.] Royal Free & Univ Coll Med Sch, Inst Canc, London WC1E 6BT, England. [Rowe, Jacob M.] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel. [Richards, Susan M.; Buck, Georgina; Durrant, I. Jill] Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England. [Chopra, Rajesh] Christie Hosptital Natl Hlth Serv NHS Trust, Manchester, Lancs, England. [Marks, David] Bristol Childrens Hosp, Bristol, Avon, England. [Franklin, Ian M.] Univ Glasgow, Snbts, Glasgow, Lanark, Scotland. [McMilan, Andrew K.] Univ Nottingham Hosp, Nottingham NG7 2UH, England. [Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, MN USA. [Paietta, Elisabeth] Montefiore Med Ctr, Ctr Canc, North Div, Bronx, NY 10467 USA. [Luger, Selina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Wiernik, Peter H.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Wiernik, Peter H.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Douer, Dan] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. Univ Hosp Case Med Ctr, Cleveland, OH USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. [Goldstone, Anthony H.] Univ Coll London Hosp, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002232 ER PT J AU Garrett-Bakelman, FE Li, S Chung, SS Hricik, T Franck, R Patel, J Dillon, R Vijay, P Brown, AL Perl, AE Cannon, BJ Sanders, MA Valk, PJM Bullinger, L Luger, S Becker, MW Lewis, ID To, LB D'Andrea, RJ Grimwade, D Delwel, R Lowenberg, B Dohner, H Dohner, K Hassane, DC Guzman, ML Roboz, GJ Carroll, M Park, CY Neuberg, DS Levine, RL Mason, C Melnick, A AF Garrett-Bakelman, Francine E. Li, Sheng Chung, Stephen S. Hricik, Todd Franck, Rapaport Patel, Jay Dillon, Richard Vijay, Priyanka Brown, Anna L. Perl, Alexander E. Cannon, B. Joy Sanders, Mathijs A. Valk, Peter J. M. Bullinger, Lars Luger, Selina Becker, Michael W. Lewis, Ian D. To, L. Bik D'Andrea, Richard J. Grimwade, David Delwel, Ruud Lowenberg, Bob Dohner, Hartmut Dohner, Konstanze Hassane, Duane C. Guzman, Monica L. Roboz, Gail J. Carroll, Martin Park, Christopher Y. Neuberg, Donna S. Levine, Ross L. Mason, Christopher Melnick, Ari TI Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Garrett-Bakelman, Francine E.] Weill Cornell Med Coll, Dept Med Hematol Oncol, New York, NY USA. [Li, Sheng] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA. [Chung, Stephen S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. [Hricik, Todd; Franck, Rapaport; Patel, Jay; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Dillon, Richard] Kings Coll London, Med & Mol Genet, London WC2R 2LS, England. [Vijay, Priyanka] Weill Cornell Med Coll, Inst Computat Biomed, New York, NY USA. [Brown, Anna L.] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia. [Perl, Alexander E.] Univ Penn, Abramson Comprehens Canc Ctr, Philadelphia, PA 19104 USA. [Cannon, B. Joy] Univ Penn, Philadelphia, PA 19104 USA. [Sanders, Mathijs A.] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands. [Valk, Peter J. M.] Erasmus Univ, Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands. [Bullinger, Lars] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany. [Luger, Selina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Becker, Michael W.] Univ Rochester, Med Ctr, James P Wilmot Canc Inst, Rochester, NY 14642 USA. [Lewis, Ian D.] Royal Adelaide Hosp, Dept Haematol, Adelaide, SA 5000, Australia. [To, L. Bik] SA Pathol, Div Haematol, Adelaide, SA, Australia. [To, L. Bik; D'Andrea, Richard J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia. [Grimwade, David] Kings Coll London, London WC2R 2LS, England. [Delwel, Ruud] Erasmus Univ, Med Ctr, Hematol, Rotterdam, Netherlands. [Lowenberg, Bob] Erasmus Univ, Med Ctr, Rotterdam, Netherlands. [Dohner, Hartmut] Univ Hosp Ulm, Ulm, Germany. [Dohner, Konstanze] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany. [Hassane, Duane C.] Weill Cornell Med Coll, Inst Computat Biomed, Div Hematol Oncol, New York, NY USA. [Guzman, Monica L.] Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA. [Roboz, Gail J.] Weill Cornell Med Coll, Joan & Sanford I Weill Dept Med, New York, NY USA. [Carroll, Martin] Univ Penn, Perelman Sch Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA. [Park, Christopher Y.] Mem Sloan Kettering Canc Ctr, Pathol & Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Mason, Christopher] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY USA. [Melnick, Ari] Weill Cornell Med Coll, Dept Med, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001058 ER PT J AU Gerecitano, JF Roberts, AW Seymour, JF Wierda, WG Kahl, BS Pagel, JM Puvvada, S Kipps, TJ Anderson, MA Dunbar, M Zhu, M Gressick, L Wagner, L Kim, SY Enschende, SH Humerickhouse, RA Davids, MS AF Gerecitano, John F. Roberts, Andrew W. Seymour, John F. Wierda, William G. Kahl, Brad S. Pagel, John M. Puvvada, Soham Kipps, Thomas J. Anderson, Mary Ann Dunbar, Martin Zhu, Ming Gressick, Lori Wagner, Lindsay Kim, Su Young Enschende, Sari Heitner Humerickhouse, Rod A. Davids, Matthew S. TI A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Gerecitano, John F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Roberts, Andrew W.; Anderson, Mary Ann] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia. [Roberts, Andrew W.; Anderson, Mary Ann] Royal Melbourne Hosp, Melbourne, Vic, Australia. [Seymour, John F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Wierda, William G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kahl, Brad S.] Univ Wisconsin, Madison, WI 53706 USA. [Pagel, John M.] Swedish Med Ctr, Seattle, WA USA. [Puvvada, Soham] Univ Arizona, Tucson, AZ 85721 USA. [Kipps, Thomas J.] Univ Calif San Diego, San Diego, CA 92103 USA. [Dunbar, Martin; Zhu, Ming; Gressick, Lori; Wagner, Lindsay; Kim, Su Young; Enschende, Sari Heitner; Humerickhouse, Rod A.] AbbVie Inc, N Chicago, IL USA. [Davids, Matthew S.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 27 Z9 27 U1 5 U2 10 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001006 ER PT J AU Gilbert, GE Kretz, C Ginsburg, D Novakovic, VA AF Gilbert, Gary E. Kretz, Colin Ginsburg, David Novakovic, Valerie Anne TI Platelet Phosphatidylserine Exposure, Survival and Blood Coagulation in Mice Lacking TMEM16F SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Gilbert, Gary E.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Med & Res, Boston, MA USA. [Kretz, Colin] Univ Michigan, Ann Arbor, MI 48109 USA. [Ginsburg, David] Univ Michigan, Howard Hughes Med Inst, Dept Human Genet, Ann Arbor, MI 48109 USA. [Ginsburg, David] Univ Michigan, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA. [Novakovic, Valerie Anne] Boston VA Med Ctr, West Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000035 ER PT J AU Gulla, A Samur, MK Fulciniti, M Shammas, MA Hideshima, T Tagliaferri, P Parmigiani, G Tassone, P Anderson, KC Munshi, NC AF Gulla, Annamaria Samur, Mehmet Kemal Fulciniti, Mariateresa Shammas, Masood A. Hideshima, Teru Tagliaferri, Pierosandro Parmigiani, Giovanni Tassone, Pierfrancesco Anderson, Kenneth C. Munshi, Nikhil C. TI Identification of a Novel Long Intergenic Noncoding RNA-Linc00936, with Significant Impact on Multiple Myeloma Cell Growth Via mTOR Pathway Inhibition SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Gulla, Annamaria; Fulciniti, Mariateresa; Hideshima, Teru] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. [Gulla, Annamaria; Tagliaferri, Pierosandro; Tassone, Pierfrancesco] Magna Craecia Univ, Catanzaro, Italy. [Samur, Mehmet Kemal; Parmigiani, Giovanni] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Shammas, Masood A.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Shammas, Masood A.; Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA. [Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001250 ER PT J AU Herrera, AF Mei, MG Low, L Merryman, RW Song, JY Paris, T Stiller, T Bedell, V Sun, H Brown, JR Budde, LE Chen, R Davids, MS Freedman, AS Fisher, DC Jacobsen, ED Jacobson, CA Kim, HT LaCasce, AS Murata-Collins, J Nademanee, AP Palmer, J Pihan, GA Siddiqi, T Sohani, AR Popplewell, LL Zain, J Kwak, LW Weinstock, DM Forman, SJ Weisenburger, DD Kim, Y Rodig, SJ Krishnan, A Armand, P AF Herrera, Alex F. Mei, Matthew G. Low, Lawrence Merryman, Reid W. Song, Joo Y. Paris, Tanya Stiller, Tracey Bedell, Victoria Sun, Heather Brown, Jennifer R. Budde, Lihua Elizabeth Chen, Robert Davids, Matthew S. Freedman, Arnold S. Fisher, David C. Jacobsen, Eric D. Jacobson, Caron A. Kim, Haesook T. LaCasce, Ann S. Murata-Collins, Joyce Nademanee, Auayporn P. Palmer, Joycelynne Pihan, German A. Siddiqi, Tanya Sohani, Aliyah R. Popplewell, Leslie L. Zain, Jasmine Kwak, Larry W. Weinstock, David M. Forman, Stephen J. Weisenburger, Dennis D. Kim, Young Rodig, Scott J. Krishnan, Amrita Armand, Philippe TI Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Herrera, Alex F.; Mei, Matthew G.] City Hope Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA. [Low, Lawrence; Chen, Robert] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Merryman, Reid W.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Song, Joo Y.; Weisenburger, Dennis D.; Kim, Young] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA. [Paris, Tanya; Stiller, Tracey; Bedell, Victoria; Krishnan, Amrita] City Hope Natl Med Ctr, Duarte, CA USA. [Sun, Heather; Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Brown, Jennifer R.; Freedman, Arnold S.; Fisher, David C.; Jacobsen, Eric D.; Weinstock, David M.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Budde, Lihua Elizabeth; Siddiqi, Tanya] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. [Davids, Matthew S.; Jacobson, Caron A.; LaCasce, Ann S.; Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Murata-Collins, Joyce] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA USA. [Nademanee, Auayporn P.] City Hope Natl Med Ctr, Dept Hematol & HCT, Duarte, CA USA. [Palmer, Joycelynne] City Hope Natl Med Ctr, Judy & Bernard Briskin Myeloma Ctr, Duarte, CA USA. [Pihan, German A.] BIDMC, Pathol, Boston, MA USA. [Sohani, Aliyah R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Zain, Jasmine] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA. [Kwak, Larry W.] City Hope Natl Med Ctr, Dept Hematol & Hematapiet Cell Transplantat, Duarte, CA USA. [Forman, Stephen J.] City Hope Natl Med Ctr, Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001268 ER PT J AU Hirakawa, M Matos, TR Koreth, J Forcade, E Whangbo, J Murase, K Liu, HY Nikiforow, S Ho, VT Cutler, CS Armand, P Alyea, EP Antin, JH Soiffer, RJ Ritz, J AF Hirakawa, Masahiro Matos, Tiago R. Koreth, John Forcade, Edouard Whangbo, Jennifer Murase, Kazuyuki Liu, Hongye Nikiforow, Sarah Ho, Vincent T. Cutler, Corey S. Armand, Philippe Alyea, Edwin P. Antin, Joseph H. Soiffer, Robert J. Ritz, Jerome TI IL-2 Induces Selective Activation of Helios-Positive Regulatory T Cells and CD56(bright) NK Cells in Vitro and in Patients with Chronic Gvhd Receiving Low-Dose IL-2 Therapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Hirakawa, Masahiro; Matos, Tiago R.; Koreth, John; Forcade, Edouard; Murase, Kazuyuki; Liu, Hongye; Nikiforow, Sarah; Cutler, Corey S.; Armand, Philippe; Alyea, Edwin P.; Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Hirakawa, Masahiro; Matos, Tiago R.; Koreth, John; Forcade, Edouard; Murase, Kazuyuki; Liu, Hongye; Nikiforow, Sarah; Cutler, Corey S.; Armand, Philippe; Alyea, Edwin P.; Antin, Joseph H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Whangbo, Jennifer; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Murase, Kazuyuki] Sapporo Med Univ, Sch Med, Dept Med Oncol & Hematol, Sapporo, Hokkaido, Japan. [Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Soiffer, Robert J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003043 ER PT J AU Hu, ZL Liu, Y Huarng, M Reyon, D Richter, C Stapleton, A Joung, JK Shavit, JA AF Hu, Zhilian Liu, Yang Huarng, Michael Reyon, Deepak Richter, Catherine Stapleton, Alexandra Joung, J. Keith Shavit, Jordan A. TI Factor X Mutant Zebrafish Tolerate a Severe Hemostatic Defect in Early Development Yet Develop Lethal Hemorrhage in Adulthood SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Hu, Zhilian; Liu, Yang; Huarng, Michael; Richter, Catherine; Stapleton, Alexandra; Shavit, Jordan A.] Univ Michigan, Pediat, Ann Arbor, MI 48109 USA. [Reyon, Deepak; Joung, J. Keith] Massachusetts Gen Hosp, Pathol, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001178 ER PT J AU Hunter, Z Xu, L Yang, G Tsakmaklis, N Liu, X Chen, J Manning, RR Chen, JJ Patterson, CJ Castillo, JJ Anderson, KC Munshi, NC Treon, SP AF Hunter, Zachary Xu, Lian Yang, Guang Tsakmaklis, Nicholas Liu, Xia Chen, Jie Manning, Robert R. Chen, Jiaji Patterson, Christopher J. Castillo, Jorge J. Anderson, Kenneth C. Munshi, Nikhil C. Treon, Steven P. TI Next Generation Sequencing Identifies a Distinct Transcriptional Profile, Including Isoform Dysregulation That Segue with Genomic Alterations in Waldenstrom's Macoglobulinemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Hunter, Zachary; Xu, Lian; Yang, Guang; Tsakmaklis, Nicholas; Liu, Xia; Chen, Jie; Manning, Robert R.; Chen, Jiaji; Patterson, Christopher J.; Treon, Steven P.] Dana Farber Canc Inst, Bing Ctr WM, Boston, MA 02115 USA. [Castillo, Jorge J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA. [Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000192 ER PT J AU Itkin, T Cohen, SG Spencer, JA Schajnovitz, A Ramasamy, SK Kusumbe, AP Jung, Y Ledergor, G Milo, I Poulos, MG Fernandez, MG Kalinkovich, A Ludin, A Kollet, O Shakhar, G Mendez-Ferrer, S Butler, JM Rafii, S Adams, RH Scadden, DT Lin, CP Lapidot, T AF Itkin, Tomer Cohen, Shiri Gur Spencer, Joel A. Schajnovitz, Amir Ramasamy, Saravana K. Kusumbe, Anjali P. Jung, Yookyung Ledergor, Guy Milo, Idan Poulos, Michael Gustave Garcia Fernandez, Maria Kalinkovich, Alexander Ludin, Aya Kollet, Orit Shakhar, Guy Mendez-Ferrer, Simon Butler, Jason M. Rafii, Shahin Adams, Ralf H. Scadden, David T. Lin, Charles P. Lapidot, Tsvee TI Distinct Bone Marrow Blood Vessels Differentially Regulate Normal and Malignant Hematopoietic Stem and Progenitor Cells SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Itkin, Tomer; Cohen, Shiri Gur; Ledergor, Guy; Milo, Idan; Kalinkovich, Alexander; Ludin, Aya; Kollet, Orit; Lapidot, Tsvee] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel. [Spencer, Joel A.; Jung, Yookyung; Lin, Charles P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Schajnovitz, Amir; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Ramasamy, Saravana K.; Kusumbe, Anjali P.; Adams, Ralf H.] Max Planck Inst Mol Biomed, D-48149 Munster, Germany. [Poulos, Michael Gustave] Weill Cornell Med Coll, Ansary Stem Cell Inst, Genet Med, New York, NY USA. [Garcia Fernandez, Maria] Ctr Nacl Invest Cardiovasc Carlos III, Madrid, Spain. [Shakhar, Guy] Weizmann Inst Sci, IL-76100 Rehovot, Israel. [Mendez-Ferrer, Simon] Univ Cambridge, Stem Cell Inst, Cambridge, England. [Mendez-Ferrer, Simon] Univ Cambridge, Dept Haematol, Cambridge, England. [Mendez-Ferrer, Simon] Natl Hlth Serv Blood & Transplant, Cambridge, England. [Mendez-Ferrer, Simon] CNIC, Madrid, Spain. [Butler, Jason M.] Weill Cornell Med Coll, Ansary Stem Cell Inst, New York, NY USA. [Rafii, Shahin] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Scadden, David T.] Harvard Stem Cell Inst, Cambridge, MA USA. [Scadden, David T.] Harvard Univ, Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 2 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002101 ER PT J AU Ivy, ZK Kassim, AA Payne, AB Macklin, EA Rodeghier, MJ Strunk, RC DeBaun, MR AF Ivy, Zalaya K. Kassim, Adetola A. Payne, Amanda B. Macklin, Eric A. Rodeghier, Mark J. Strunk, Robert C. DeBaun, Michael R. TI Lower Airway Obstruction Is Associated with Increased Vaso-Occlusive Pain Episodes in Adults with Sickle Cell Anemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Ivy, Zalaya K.] Meharry Med Coll, Nashville, TN 37208 USA. [Kassim, Adetola A.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Payne, Amanda B.] Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Macklin, Eric A.] Massachusetts Gen Hosp, MGH Biostat, Boston, MA 02114 USA. [Rodeghier, Mark J.] Rodeghier Consultants, Chicago, IL USA. [Strunk, Robert C.] Washington Univ, Sch Med, St Louis, MO USA. [DeBaun, Michael R.] Vanderbilt Univ, Sch Med, Vanderbilt Meharry Matthew Walker Ctr Excellence, Nashville, TN 37212 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003102 ER PT J AU Jones, J Mato, AR Coutre, S Wierda, W Choi, MY Davids, MS Lamanna, N Barr, P Burns, K Montalvo, N Zhu, M Busman, T Potluri, J Humerickhouse, RA Byrd, JC AF Jones, Jeffrey Mato, Anthony R. Coutre, Steven Wierda, William Choi, Michael Y. Davids, Matthew S. Lamanna, Nicole Barr, Paul Burns, Kim Montalvo, Nicholas Zhu, Ming Busman, Todd Potluri, Jalaja Humerickhouse, Rod A. Byrd, John C. TI Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Jones, Jeffrey; Byrd, John C.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Mato, Anthony R.] Univ Penn, Ctr Chron Lymphocyt Leukemia, Philadelphia, PA 19104 USA. [Coutre, Steven] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA. [Wierda, William] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Choi, Michael Y.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Davids, Matthew S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lamanna, Nicole] Columbia Univ, Med Ctr, New York, NY USA. [Barr, Paul] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA. [Burns, Kim; Montalvo, Nicholas; Zhu, Ming; Busman, Todd; Potluri, Jalaja; Humerickhouse, Rod A.] AbbVie Inc, N Chicago, IL USA. RI Jones, Jeffrey/E-3321-2011 NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002152 ER PT J AU Joyce, CE McGuinness, M Schneider, RK Fleming, MD Campagna, DR Schmidt, PJ Ebert, BL Novina, CD Sieff, CA AF Joyce, Cailin E. McGuinness, Meaghan Schneider, Rebekka K. Fleming, Mark D. Campagna, Dean R. Schmidt, Paul J. Ebert, Benjamin L. Novina, Carl D. Sieff, Colin A. TI A Novel Conditional Knockout of the Diamond Blackfan Anemia Gene Rpl11 Shows Failure of Erythropoiesis, a Marked Increase in BFU-E Progenitors By Phenotype That Proliferate Poorly in Culture, and Activation of p53 Target Genes SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Joyce, Cailin E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [McGuinness, Meaghan; Sieff, Colin A.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Schneider, Rebekka K.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Fleming, Mark D.; Campagna, Dean R.; Schmidt, Paul J.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Novina, Carl D.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004005 ER PT J AU Kahn, J Barrera, S Davila, R Roberts, E Jin, ZZ Stevenson, K Blonquist, TM Neuberg, DS Athale, UH Clavell, LA Cole, P Laverdiere, C Michon, B Schorin, MA Welch, JJG Sallan, SE Silverman, LB Kelly, KM AF Kahn, Justine Barrera, Sergio Davila, Randy Roberts, Emily Jin, ZheZhen Stevenson, Kristen Blonquist, Traci M. Neuberg, Donna S. Athale, Uma H. Clavell, Luis A. Cole, Peter Laverdiere, Caroline Michon, Bruno Schorin, Marshall A. Welch, Jennifer J. G. Sallan, Stephen E. Silverman, Lewis B. Kelly, Kara M. TI Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kahn, Justine; Kelly, Kara M.] Columbia Univ, Med Ctr, Pediat Hematol Oncol Stem Cell Transplantat, New York, NY USA. [Barrera, Sergio] Univ Arizona, Tucson, AZ USA. [Davila, Randy] Univ Calif Davis, Davis, CA 95616 USA. [Roberts, Emily] Coe Coll, Cedar Rapids, IA 52402 USA. [Jin, ZheZhen] Columbia Univ, Med Ctr, New York, NY USA. [Stevenson, Kristen; Blonquist, Traci M.; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Athale, Uma H.] Hamilton Hlth Sci, McMaster Childrens Hosp, Div Hematol Oncol, Hamilton, ON, Canada. [Clavell, Luis A.] San Jorge Childrens Hosp, San Juan, PR USA. [Cole, Peter] Montefiore Med Ctr, Bronx, NY 10467 USA. [Laverdiere, Caroline] Univ Montreal, St Justine Univ Hosp, Charles Bruneau Canc Ctr, Div Hematol Oncol, Montreal, PQ, Canada. [Michon, Bruno] Ctr Hosp Univ Quebec, Ste Foy, PQ, Canada. [Schorin, Marshall A.] Inova Fairfax Hosp Children, Falls Church, VA USA. [Welch, Jennifer J. G.] Brown Univ, Hasbro Childrens Hosp, Pediat Hematol Oncol, Providence, RI 02912 USA. [Sallan, Stephen E.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Sallan, Stephen E.] Boston Childrens Hosp, Boston, MA USA. [Silverman, Lewis B.] Boston Childrens Hosp, Div Pediat Hematol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000312 ER PT J AU Kaplan, LD Jung, SH Stock, W Bartlett, NL Pitcher, B Byrd, JC Blum, KA LaCasce, AS Fulton, N Hsi, ED Hurd, DD Czuczman, M Leonard, JP Cheson, BD AF Kaplan, Lawrence D. Jung, Sin-Ho Stock, Wendy Bartlett, Nancy L. Pitcher, Brandelyn Byrd, John C. Blum, Kristie A. LaCasce, Ann S. Fulton, Noreen Hsi, Eric D. Hurd, David D. Czuczman, Myron Leonard, John P. Cheson, Bruce D. TI Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kaplan, Lawrence D.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Jung, Sin-Ho; Pitcher, Brandelyn] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA. [Stock, Wendy] Univ Chicago, Med Ctr, Sect Hematol Oncol, Chicago, IL 60637 USA. [Bartlett, Nancy L.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA. [Byrd, John C.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA. [Blum, Kristie A.] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA. [LaCasce, Ann S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Fulton, Noreen] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Hsi, Eric D.] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Lab Med, Cleveland, OH 44106 USA. [Hurd, David D.] Wake Forest Univ, Ctr Comprehens Canc, Sect Hematol & Oncol, Winston Salem, NC 27109 USA. [Czuczman, Myron] Roswell Pk Canc Inst, Med Oncol, Buffalo, NY 14263 USA. [Leonard, John P.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Cheson, Bruce D.] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001089 ER PT J AU Kawano, Y Moschetta, M Kokubun, K Lukyanchykov, P Karreci, ES Manier, S Tsukamoto, S Takagi, S Shi, JT Reagan, MR Huynh, D Sacco, A Dorfman, DM Chesi, M Bergsagel, PL Roccaro, AM Azzi, J Ghobrial, IM AF Kawano, Yawara Moschetta, Michele Kokubun, Katsutoshi Lukyanchykov, Pavlo Karreci, Esilida Sula Manier, Salomon Tsukamoto, Shokichi Takagi, Satoshi Shi, Jiantao Reagan, Michaela R. Huynh, Daisy Sacco, Antonio Dorfman, David M. Chesi, Marta Bergsagel, Peter Leif Roccaro, Aldo M. Azzi, Jamil Ghobrial, Irene M. TI Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kawano, Yawara; Moschetta, Michele; Kokubun, Katsutoshi; Manier, Salomon; Tsukamoto, Shokichi; Takagi, Satoshi; Huynh, Daisy; Sacco, Antonio; Roccaro, Aldo M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Lukyanchykov, Pavlo; Karreci, Esilida Sula; Azzi, Jamil] Harvard Univ, Brigham & Womens Hosp, Sch Med, Transplantat Res Ctr,Renal Div, Boston, MA 02115 USA. [Shi, Jiantao] Harvard Univ, Sch Med, Dana Farber Canc Inst, Biostat, Boston, MA 02115 USA. [Reagan, Michaela R.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Dorfman, David M.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Chesi, Marta] Mayo Clin, Scottsdale, AZ USA. [Bergsagel, Peter Leif] Mayo Clin, Ctr Comprehens Canc, Scottsdale, AZ USA. [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RI Reagan, Michaela/E-3549-2017 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001248 ER PT J AU Kekre, N Kim, HT Ho, VT Cutler, CS Armand, P Nikiforow, S Alyea, EP Soiffer, RJ Antin, JH Connors, JM Koreth, J AF Kekre, Natasha Kim, Haesook T. Ho, Vincent T. Cutler, Corey S. Armand, Philippe Nikiforow, Sarah Alyea, Edwin P. Soiffer, Robert J. Antin, Joseph H. Connors, Jean M. Koreth, John TI Venous Thromboembolism Is Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kekre, Natasha; Antin, Joseph H.; Koreth, John] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Ho, Vincent T.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Cutler, Corey S.; Armand, Philippe; Nikiforow, Sarah; Alyea, Edwin P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Cutler, Corey S.; Armand, Philippe; Nikiforow, Sarah; Alyea, Edwin P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Connors, Jean M.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002179 ER PT J AU Komrokji, RS DeZern, AE Zell, K Al Ali, NH Padron, E Estling, C Zimmerman, C Hand, W Brown, F Rizzo, N Barnard, J Roboz, GJ Carraway, HE Maciejewski, JP List, AF Garcia-Manero, G Steensma, DP Sekeres, MA AF Komrokji, Rami S. DeZern, Amy E. Zell, Katrina Al Ali, Najla H. Padron, Eric Estling, Christopher Zimmerman, Cassie Hand, Wesley Brown, Francis Rizzo, Nicole Barnard, John Roboz, Gail J. Carraway, Hetty E. Maciejewski, Jaroslaw P. List, Alan F. Garcia-Manero, Guillermo Steensma, David P. Sekeres, Mikkael A. TI Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Komrokji, Rami S.; Al Ali, Najla H.; Padron, Eric; List, Alan F.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA. [DeZern, Amy E.; Hand, Wesley] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Zell, Katrina; Estling, Christopher; Zimmerman, Cassie; Barnard, John; Carraway, Hetty E.; Maciejewski, Jaroslaw P.; Sekeres, Mikkael A.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Brown, Francis; Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rizzo, Nicole] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. [Roboz, Gail J.] Weill Cornell Med Coll, Joan & Sanford I Weill Dept Med, New York, NY USA. [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005175 ER PT J AU Komrokji, RS DeZern, AE Zell, K Al Ali, NH Estling, C Zimmerman, C Hand, W Brown, F Rizzo, N Barnard, J Roboz, GJ Garcia-Manero, G Steensma, DP Sekeres, MA AF Komrokji, Rami S. DeZern, Amy E. Zell, Katrina Al Ali, Najla H. Estling, Christopher Zimmerman, Cassie Hand, Wesley Brown, Francis Rizzo, Nicole Barnard, John Roboz, Gail J. Garcia-Manero, Guillermo Steensma, David P. Sekeres, Mikkael A. TI Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Komrokji, Rami S.; Al Ali, Najla H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA. [DeZern, Amy E.; Hand, Wesley] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Zell, Katrina; Estling, Christopher; Zimmerman, Cassie; Barnard, John; Sekeres, Mikkael A.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Brown, Francis; Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rizzo, Nicole] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. [Roboz, Gail J.] Weill Cornell Med Coll, Joan & Sanford I Weill Dept Med, New York, NY USA. [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003033 ER PT J AU Krishnamurti, L Sullivan, KM Kamani, NR Waller, EK Abraham, A Campigotto, F Zhang, WD Smith, S Hassell, KL Decastro, L Wu, CJ Neuberg, DS Walters, MC AF Krishnamurti, Lakshmanan Sullivan, Keith M. Kamani, Naynesh R. Waller, Edmund K. Abraham, Allistair Campigotto, Federico Zhang, Wandi Smith, Shannon Hassell, Kathryn L. Decastro, Laura Wu, Catherine J. Neuberg, Donna S. Walters, Mark C. TI Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Krishnamurti, Lakshmanan; Smith, Shannon] Emory Univ, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA. [Sullivan, Keith M.] Duke Univ, Div Hematol Oncol Blood & Marrow Transplantat, Durham, NC USA. [Kamani, Naynesh R.] AABB Ctr Cellular Therapies, Washington, DC USA. [Waller, Edmund K.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA. [Abraham, Allistair] Childress Natl Med Ctr, Washington, DC USA. [Campigotto, Federico] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Zhang, Wandi; Wu, Catherine J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Hassell, Kathryn L.] Univ Colorado Denver, Hlth Sci Ctr, Aurora, CO USA. [Decastro, Laura] Univ Pittsburgh, Med Ctr, Div Hematol Oncol BMT, Pittsburgh, PA USA. [Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Walters, Mark C.] UCSF Benioff Childrens Hosp Oakland, Oakland, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001289 ER PT J AU Kuendgen, A Tuechler, H Nomdedeu, M Garcia-Manero, G Komrokji, RS Sekeres, MA Della Porta, MG List, AF Cazzola, M DeZern, AE Roboz, GJ Steensma, DP van de Loosdrecht, AA van de Loosdrecht, AA Schlenk, RF Calvo, X Blum, S Pereira, A Valent, P Costa, D Giagounidis, A Benlloch, L Platzbecker, U Pedro, C Lubbert, M Cedena, MT Machherndl-Spandl, S Lopez-Pavia, M Haase, D Martin, AA Baldus, CD de Sola, MM Stauder, R Merchan, B Mende, C Ardanaz, MT Ganster, C Cobo, F Schroeder, T Esteve, J Haas, R Benet, N Greenberg, PL Germing, U Sanz, G AF Kuendgen, Andrea Tuechler, Heinz Nomdedeu, Meritxell Garcia-Manero, Guillermo Komrokji, Rami S. Sekeres, Mikkael A. Della Porta, Matteo Giovanni List, Alan F. Cazzola, Mario DeZern, Amy E. Roboz, Gail J. Steensma, David P. van de Loosdrecht, Arjan A. van de Loosdrecht, Arjan A. Schlenk, Richard F. Calvo, Xavier Blum, Sabine Pereira, Arturo Valent, Peter Costa, Dolors Giagounidis, Aristoteles Benlloch, Luis Platzbecker, Uwe Pedro, Carmen Luebbert, Michael Teresa Cedena, Maria Machherndl-Spandl, Sigrid Lopez-Pavia, Maria Haase, Detlef Africa Martin, Ana Baldus, Claudia D. Martinez de Sola, Montserrat Stauder, Reinhard Merchan, Brayan Mende, Claudia Teresa Ardanaz, Maria Ganster, Christina Cobo, Francesc Schroeder, Thomas Esteve, Jordi Haas, Rainer Benet, Nomdedeu Greenberg, Peter L. Germing, Ulrich Sanz, Guillermo TI An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kuendgen, Andrea; Mende, Claudia; Schroeder, Thomas; Haas, Rainer; Germing, Ulrich] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany. [Tuechler, Heinz] Hanusch Hosp, Boltzmann Inst Leukemia Res, Vienna, Austria. [Nomdedeu, Meritxell; Pereira, Arturo; Costa, Dolors; Esteve, Jordi; Benet, Nomdedeu] Hosp Clin Barcelona, Spanish MDS Cooperat Grp, Barcelona, Spain. [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Komrokji, Rami S.; List, Alan F.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA. [Sekeres, Mikkael A.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Della Porta, Matteo Giovanni; Cazzola, Mario] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, I-27100 Pavia, Italy. [DeZern, Amy E.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Roboz, Gail J.] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA. [Steensma, David P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [van de Loosdrecht, Arjan A.; van de Loosdrecht, Arjan A.] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands. [Schlenk, Richard F.] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany. [Calvo, Xavier] Hosp del Mar, Spanish MDS Cooperat Grp, Barcelona, Spain. [Blum, Sabine] CHU Vaudois, Haematol Serv, Lausanne, Switzerland. [Valent, Peter] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, Vienna, Austria. [Giagounidis, Aristoteles] Marien Hosp, Dusseldorf, Germany. [Benlloch, Luis; Lopez-Pavia, Maria] Hosp Univ La Fe, GESMD, Valencia, Spain. [Platzbecker, Uwe] Tech Univ Dresden, Univ Klinikum, D-01062 Dresden, Germany. [Pedro, Carmen] Hosp del Mar, Dept Hematol, Barcelona, Spain. [Luebbert, Michael] Univ Freiburg, Div Hematol Oncol & Stem Cell Transplantat, D-79106 Freiburg, Germany. [Teresa Cedena, Maria] Hosp 12 Octubre, E-28041 Madrid, Spain. [Machherndl-Spandl, Sigrid] Elisabethinen Hosp, Dept Hematol & Oncol, Linz, Austria. [Haase, Detlef] Univ Med Gottingen, Dept Hematol & Med Oncol, Gottingen, Germany. [Africa Martin, Ana] Hosp Univ Salamanca, Salamanca, Spain. [Baldus, Claudia D.] Charite, Dept Hematol & Oncol, Berlin, Germany. [Martinez de Sola, Montserrat] Hosp Parc Tauli, Sabadell, Spain. [Stauder, Reinhard] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, A-6020 Innsbruck, Austria. [Merchan, Brayan] Hosp Valle De Hebron, Serv Hematol, Barcelona, Spain. [Teresa Ardanaz, Maria] Hosp Txagorritxu, Vitoria, Spain. [Ganster, Christina] Univ Gottingen, Dept Hematol & Med Oncol, D-37073 Gottingen, Germany. [Cobo, Francesc] Hosp Teknon, Barcelona, Spain. [Greenberg, Peter L.] Stanford Univ, Med Ctr, Div Hematol, Stanford, CA 94305 USA. [Sanz, Guillermo] Hosp Univ La Fe, Spanish MDS Cooperat Grp, Valencia, Spain. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002046 ER PT J AU Kuo, PY Jiang, ZW Perumal, D Leshchenko, VV Lagana, A Katz, SG Walensky, LD Shaknovich, R Ye, BH Parekh, S AF Kuo, Pei-Yu Jiang, Zewei Perumal, Deepak Leshchenko, Violetta V. Lagana, Alessandro Katz, Samuel G. Walensky, Loren D. Shaknovich, Rita Ye, B. Hilda Parekh, Samir TI SOX11 Cooperates with CCND1 in Mantle Cell Lymphoma Pathogenesis SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kuo, Pei-Yu; Jiang, Zewei; Perumal, Deepak; Leshchenko, Violetta V.; Lagana, Alessandro; Parekh, Samir] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA. [Katz, Samuel G.] Yale Univ, New Haven, CT USA. [Walensky, Loren D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Walensky, Loren D.] Dana Farber Canc Inst, Linde Program Canc Chem Biol, Boston, MA 02115 USA. [Shaknovich, Rita] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA. [Ye, B. Hilda] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004053 ER PT J AU Kwan, W Cortes, M Liu, S Frost, I Goessling, W North, T AF Kwan, Wanda Cortes, Mauricio Liu, Sarah Frost, Isaura Goessling, Wolfram North, Trista TI Hypoxic Stress-Induced Serotonergic Stimulation Controls Hematopoietic Stem Cell Production Via the Hypothalamic-Pituitary-Interrenal Axis and Glucocorticoid Signaling SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kwan, Wanda; Cortes, Mauricio; Liu, Sarah; Frost, Isaura] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Goessling, Wolfram] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. [Goessling, Wolfram] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA. [Goessling, Wolfram] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [North, Trista] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003019 ER PT J AU Laane, E Nanjappa, P Kumar, S Magrangeas, F Minvielle, S Everaus, H Anderson, KC Avet-Loiseau, H Shammas, MA Munshi, NC AF Laane, Edward Nanjappa, Purushothama Kumar, Subodh Magrangeas, Florence Minvielle, Stephane Everaus, Hele Anderson, Kenneth C. Avet-Loiseau, Herve Shammas, Masood A. Munshi, Nikhil C. TI XRCC5 Plays an Important Role in Homologous Recombination, Genome Stability and Survival of Myeloma Cells SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Laane, Edward] North Estonia Med Ctr Fdn, Tallinn, Estonia. [Laane, Edward; Nanjappa, Purushothama; Kumar, Subodh; Anderson, Kenneth C.; Shammas, Masood A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Laane, Edward; Kumar, Subodh; Shammas, Masood A.; Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA. [Magrangeas, Florence; Minvielle, Stephane] Univ Nantes, Ctr Rech Cancerol Nantes, Angers UMR Inserm 892, CNRS 6299, Nantes, France. [Magrangeas, Florence; Minvielle, Stephane] Univ Nantes, Inst Rech Therapeut, Nantes, France. [Everaus, Hele] Tartu Univ Hosp, Hematol Oncol, Tartu, Estonia. [Avet-Loiseau, Herve] IUCT Oncopole, Toulouse, France. [Avet-Loiseau, Herve] CHU Rangueil, Unite Genom Myelome, F-31054 Toulouse, France. [Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004018 ER PT J AU Lampson, BL Matos, T Kim, HT Kasar, S Morgan, EA Hirakawa, M Fein, J Fernandes, SM Ritz, J Brown, JR AF Lampson, Benjamin L. Matos, Tiago Kim, Haesook T. Kasar, Siddha Morgan, Elizabeth A. Hirakawa, Masahiro Fein, Joshua Fernandes, Stacey M. Ritz, Jerome Brown, Jennifer R. TI Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Lampson, Benjamin L.; Kasar, Siddha; Fein, Joshua; Fernandes, Stacey M.; Ritz, Jerome; Brown, Jennifer R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Matos, Tiago; Hirakawa, Masahiro] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Morgan, Elizabeth A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001243 ER PT J AU Landau, DA Tausch, E Bottcher, S Stewart, C Bozic, I Leischner, I Rosebrock, D Taylor-Weiner, A Mertens, D Sougnez, C Kless, S Kneba, M Ritgen, M Kluth, S Bahlo, J Fink, AM Fischer, K Gabriel, S Lander, E Dohner, H Hallek, M Neuberg, DS Nowak, M Getz, G Stilgenbauer, S Wu, CJ AF Landau, Dan A. Tausch, Eugen Boettcher, Sebastian Stewart, Chip Bozic, Ivana Leischner, Iganty Rosebrock, Daniel Taylor-Weiner, Amaro Mertens, Daniel Sougnez, Carrie Kless, Sabrina Kneba, Michael Ritgen, Matthias Kluth, Sandra Bahlo, Jasmin Fink, Anna-Maria Fischer, Kirsten Gabriel, Stacey Lander, Eric Dohner, Hartmut Hallek, Michael Neuberg, Donna S. Nowak, Martin Getz, Gad Stilgenbauer, Stephan Wu, Catherine J. TI Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Landau, Dan A.; Stewart, Chip; Leischner, Iganty; Rosebrock, Daniel; Taylor-Weiner, Amaro; Sougnez, Carrie; Gabriel, Stacey; Getz, Gad] Broad Inst, Cambridge, MA USA. [Landau, Dan A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Tausch, Eugen] Univ Ulm, Med Ctr, Dept Internal Med 3, D-89069 Ulm, Germany. [Boettcher, Sebastian] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany. [Bozic, Ivana; Nowak, Martin] Harvard Univ, Program Evolutionary Dynam, Cambridge, MA 02138 USA. [Rosebrock, Daniel] German Canc Res Ctr, Mech Leukemogenesis, Heidelberg, Germany. [Mertens, Daniel; Kless, Sabrina] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany. [Kneba, Michael] Univ Hosp Schleswig Holstein, Dept Hematol, Kiel, Germany. [Ritgen, Matthias] Univ Hosp Schleswig Holstein, Internal Med 2, Kiel, Germany. [Kluth, Sandra; Fink, Anna-Maria] Univ Cologne, German CLL Study Croup, Dept Internal Med 1, D-50931 Cologne, Germany. [Kluth, Sandra; Fink, Anna-Maria] Univ Cologne, German CLL Study Croup, Ctr Integrated Oncol Cologne Bonn, D-50931 Cologne, Germany. [Bahlo, Jasmin] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Dept Internal Med 1, Cologne, Germany. [Fischer, Kirsten] Univ Hosp Cologne, Cologne, Germany. [Lander, Eric] Broad Inst Harvard & MIT, Cambridge, MA USA. [Dohner, Hartmut] Univ Hosp Ulm, Ulm, Germany. [Hallek, Michael] Univ Hosp, Dept Internal Med, Cologne, Germany. [Hallek, Michael] Univ Hosp, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Stilgenbauer, Stephan] Univ Ulm, D-89069 Ulm, Germany. [Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001114 ER PT J AU Lee, SJ Logan, B Westervelt, P Cutler, CS Woolfrey, AE Khan, S Waller, EK Maziarz, RT Wu, J Shaw, BE Confer, DL Horowitz, MM Anasetti, C AF Lee, Stephanie J. Logan, Brent Westervelt, Peter Cutler, Corey S. Woolfrey, Ann E. Khan, Shakila Waller, Edmund K. Maziarz, Richard T. Wu, Juan Shaw, Bronwen E. Confer, Dennis L. Horowitz, Mary M. Anasetti, Claudio TI 5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Logan, Brent] Med Coll Wisconsin, Div Biostat, Milwuakee, WI USA. [Westervelt, Peter] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Woolfrey, Ann E.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Transplantat Biol Dept, Seattle, WA 98104 USA. [Khan, Shakila] Mayo Clin, Div Pediat Hematol Oncol, Rochester, MN USA. [Waller, Edmund K.] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Knight Canc Inst, Adult Blood & Marrow Stem Cell Transplant Program, Portland, OR 97201 USA. [Wu, Juan] Emmes Corp, Rockville, MD USA. [Shaw, Bronwen E.; Horowitz, Mary M.] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Confer, Dennis L.] Natl Marrow Donor Program, Minneapolis, MN USA. [Anasetti, Claudio] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Blood & Marrow Transplantat, Tampa, FL 33682 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001022 ER PT J AU Lin, JH Yang, C Kwart, A Zhao, JJ Samur, MK Zhang, WH Nanjappa, P Calimeri, T Ren, XB Ma, DD Jiang, XF Zhou, Y Shammas, M Anderson, KC Aster, JC Zon, LI Handin, RI Munshi, NC AF Lin, Jianhong Yang, Chun Kwart, Ariel Zhao, Jianjun Samur, Mehmet K. Zhang, Weihong Nanjappa, Purushothama Calimeri, Teresa Ren, Xiubao Ma, Dongdong Jiang, Xiaofeng Zhou, Yi Shammas, Masood Anderson, Kenneth C. Aster, Jon C. Zon, Leonard I. Handin, Robert I. Munshi, Nikhil C. TI Apurinic/Apyrimidinic Endonuclease 1 Induced Genomic Instability Causes T-Cell Acute Lymphoblastic Leukemia in Zebrafish SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Lin, Jianhong; Yang, Chun; Kwart, Ariel; Zhao, Jianjun; Zhang, Weihong; Nanjappa, Purushothama; Shammas, Masood; Anderson, Kenneth C.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Yang, Chun; Jiang, Xiaofeng] Harbin Med Univ, Hosp 4, Dept Clin Lab, Harbin, Peoples R China. [Samur, Mehmet K.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Zhang, Weihong; Ren, Xiubao] Tianjin Med Univ, Canc Inst & Hosp, Biotherapy Dept, Tianjin, Peoples R China. [Shammas, Masood; Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA. [Calimeri, Teresa] Ist Sci San Raffaele, Dept OncoHematol, Unit Lymphoid Malignancies, Div OncoHematol Med, I-20132 Milan, Italy. [Ma, Dongdong; Handin, Robert I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Hematol, Boston, MA 02115 USA. [Zhou, Yi; Zon, Leonard I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Stem Cell Program, Boston, MA 02115 USA. [Zhou, Yi; Zon, Leonard I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol Oncol,Howard Hughes Med Inst, Boston, MA 02115 USA. [Aster, Jon C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004231 ER PT J AU Liu, X Hunter, Z Xu, L Chen, J Chen, JJ Tsakmaklis, N Patterson, CJ Castillo, JJ Buhrlage, S Gray, N Treon, SP Yang, G AF Liu, Xia Hunter, Zachary Xu, Lian Chen, Jie Chen, Jiaji Tsakmaklis, Nicholas Patterson, Christopher J. Castillo, Jorge J. Buhrlage, Sara Gray, Nathanael Treon, Steven P. Yang, Guang TI Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Liu, Xia; Hunter, Zachary; Xu, Lian; Chen, Jie; Chen, Jiaji; Tsakmaklis, Nicholas; Patterson, Christopher J.; Castillo, Jorge J.; Treon, Steven P.; Yang, Guang] Dana Farber Canc Inst, Bing Ctr WM, Boston, MA 02115 USA. [Buhrlage, Sara; Gray, Nathanael] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005041 ER PT J AU Luger, S Wang, VX Paietta, E Ketterling, RP Rybka, W Lazarus, HM Litzow, MR Rowe, JM Larson, RA Appelbaum, FR Tallman, MS AF Luger, Selina Wang, Victoria X. Paietta, Elisabeth Ketterling, Rhett P. Rybka, Witold Lazarus, Hillard M. Litzow, Mark R. Rowe, Jacob M. Larson, Richard A. Appelbaum, Frederick R. Tallman, Martin S. TI Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Luger, Selina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Wang, Victoria X.] Dana Farber Canc Inst, ECOG ACRIN Biostat Ctr, Boston, MA 02115 USA. [Paietta, Elisabeth] Montefiore Med Ctr, Ctr Canc, North Div, Bronx, NY 10467 USA. [Ketterling, Rhett P.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA. [Rybka, Witold] Penn State Coll Med, Penn State Hershey Canc Inst, Hershey, PA USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Seidman Canc Ctr, Cleveland, OH USA. [Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, MN USA. [Rowe, Jacob M.] Shaare Zedek Med Ctr, Hematol, Jerusalem, Israel. [Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA. [Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Appelbaum, Frederick R.] Univ Washington, Seattle, WA 98195 USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Tallman, Martin S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004108 ER PT J AU Ma, S Brander, DM Seymour, JF Kipps, TJ Barrientos, JC Davids, MS Anderson, MA Choi, MY Tam, CS Mason-Bright, T Prine, B Munasinghe, W Zhu, M Kim, SY Humerickhouse, RA Roberts, AW AF Ma, Shuo Brander, Danielle M. Seymour, John F. Kipps, Thomas J. Barrientos, Jacqueline C. Davids, Matthew S. Anderson, Mary Ann Choi, Michael Y. Tam, Constantine S. Mason-Bright, Tanita Prine, Betty Munasinghe, Wijith Zhu, Ming Kim, Su Young Humerickhouse, Rod A. Roberts, Andrew W. TI Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Ma, Shuo] Northwestern Univ, Chicago, IL 60611 USA. [Brander, Danielle M.] Duke Univ, Med Ctr, Durham, NC USA. [Seymour, John F.; Tam, Constantine S.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Kipps, Thomas J.; Choi, Michael Y.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Barrientos, Jacqueline C.] Hofstra North Shore LIJ Sch Med, Hempstead, NY USA. [Davids, Matthew S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Anderson, Mary Ann; Roberts, Andrew W.] Royal Melbourne Hosp, Melbourne, Vic, Australia. [Anderson, Mary Ann; Roberts, Andrew W.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia. [Mason-Bright, Tanita; Prine, Betty; Munasinghe, Wijith; Zhu, Ming; Kim, Su Young; Humerickhouse, Rod A.] AbbVie Inc, N Chicago, IL USA. NR 0 TC 15 Z9 15 U1 3 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002267 ER PT J AU Manier, S Avet-Loiseau, H Campigotto, F Salem, K Huynh, D Glavey, S Sacco, A Roccaro, AM Minvielle, S Moreau, P Facon, T Leleu, X Weller, EA Ghobrial, IM AF Manier, Salomon Avet-Loiseau, Herve Campigotto, Federico Salem, Karma Huynh, Daisy Glavey, Siobhan Sacco, Antonio Roccaro, Aldo M. Minvielle, Stephane Moreau, Philippe Facon, Thierry Leleu, Xavier Weller, Edie A. Ghobrial, Irene M. TI Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Manier, Salomon; Salem, Karma; Huynh, Daisy; Sacco, Antonio; Roccaro, Aldo M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Avet-Loiseau, Herve] IUCT Oncopole, Toulouse, France. [Campigotto, Federico; Weller, Edie A.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Glavey, Siobhan] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Minvielle, Stephane] CHU Nantes, Unite Mixte Genom Canc, F-44035 Nantes 01, France. [Moreau, Philippe] Hop Hotel Dieu, Nantes Univ Hosp, Nantes, France. [Facon, Thierry; Leleu, Xavier] CHRU Lille, Hop Claude Huriez, Malad Sang, F-59037 Lille, France. [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015 OI FACON, THIERRY/0000-0001-7705-8460; NR 0 TC 5 Z9 5 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005248 ER PT J AU Manier, S Powers, J Sacco, A Glavey, S Huynh, D Reagan, MR Salem, K Moschetta, M Mishima, Y Leleu, X Roccaro, AM Daley, GQ Ghobrial, IM AF Manier, Salomon Powers, John Sacco, Antonio Glavey, Siobhan Huynh, Daisy Reagan, Michaela R. Salem, Karma Moschetta, Michele Mishima, Yuji Leleu, Xavier Roccaro, Aldo M. Daley, George Q. Ghobrial, Irene M. TI MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Manier, Salomon; Sacco, Antonio; Huynh, Daisy; Salem, Karma; Mishima, Yuji; Roccaro, Aldo M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Powers, John; Daley, George Q.] Childrens Hosp, Harvard Stem Cell Inst, Boston, MA 02115 USA. [Glavey, Siobhan; Reagan, Michaela R.; Moschetta, Michele] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Leleu, Xavier] CHRU Lille, Hop Claude Huriez, Malad Sang, F-59037 Lille, France. [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RI Reagan, Michaela/E-3549-2017 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005233 ER PT J AU Masuda, T Wang, X Maeda, M Canver, MC Sher, F Funnell, APW Fisher, C Suciu, M Martyn, GE Norton, LJ Zhu, RJ Kurita, R Nakamura, Y Xu, J Higgs, DR Crossley, M Bauer, DE Orkin, SH Kharchenko, PV Maeda, T AF Masuda, Takeshi Wang, Xin Maeda, Manami Canver, Matthew C. Sher, Falak Funnell, Alister P. W. Fisher, Chris Suciu, Maria Martyn, Gabriella E. Norton, Laura J. Zhu, Ruijia Kurita, Ryo Nakamura, Yukio Xu, Jian Higgs, Douglas R. Crossley, Merlin Bauer, Daniel E. Orkin, Stuart H. Kharchenko, Peter V. Maeda, Takahiro TI The LRF/ZBTB7A Transcription Factor Is a BCL11A-Independent Repressor of Fetal Hemoglobin SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Masuda, Takeshi; Maeda, Manami; Zhu, Ruijia; Maeda, Takahiro] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA 02115 USA. [Wang, Xin; Kharchenko, Peter V.] Harvard Univ, Sch Med, Dept Biomed Informat, Boston, MA USA. [Canver, Matthew C.; Sher, Falak; Bauer, Daniel E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Pediat Hematol Oncol,Boston Childrens Hosp, 44 Binney St, Boston, MA 02115 USA. [Funnell, Alister P. W.; Martyn, Gabriella E.; Norton, Laura J.; Crossley, Merlin] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia. [Fisher, Chris; Suciu, Maria; Higgs, Douglas R.] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England. [Kurita, Ryo; Nakamura, Yukio] RIKEN, BioResource Ctr, Cell Engn Div, Tsukuba, Ibaraki, Japan. [Xu, Jian] Univ Texas SW Med Ctr Dallas, Childrens Med Ctr Res Inst, Dallas, TX 75390 USA. [Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Hematol Oncol,Boston Childrens Hosp, 44 Binney St, Boston, MA 02115 USA. RI Nakamura, Yukio/A-5263-2016 NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000066 ER PT J AU Matos, TR Lampson, BL Hirakawa, M Kasar, S Fernandes, SM Brown, JR Ritz, J AF Matos, Tiago R. Lampson, Benjamin L. Hirakawa, Masahiro Kasar, Siddha Fernandes, Stacey M. Brown, Jennifer R. Ritz, Jerome TI Altered Expression of Functional Proteins in CD4 Regulatory T Cells during Therapy with Idelalisib SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Matos, Tiago R.; Hirakawa, Masahiro] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Matos, Tiago R.; Hirakawa, Masahiro] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Matos, Tiago R.] Univ Lisbon, Fac Med, Inst Mol Med, P-1699 Lisbon, Portugal. [Lampson, Benjamin L.; Kasar, Siddha; Fernandes, Stacey M.; Brown, Jennifer R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005213 ER PT J AU Michor, F AF Michor, Franziska TI Mathematical Models of Cancer Evolution and Cure SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Michor, Franziska] Harvard Univ, Sch Med, Dana Farber Canc Inst, Biostat, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 1 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000059 ER PT J AU Mishima, Y Paiva, B Shi, J Massoud, M Manier, S Flores, L Perilla-Glen, A Aljawai, Y Huynh, D Takagi, S Roccaro, AM Sacco, A Alignani, D Mateos, MV Blade, J Lahuerta, JJ Richardson, PG Laubach, JP Schlossman, RL Anderson, KC Munshi, NC Prosper, F Michor, F San Miguel, JF Ghobrial, IM AF Mishima, Yuji Paiva, Bruno Shi, Jiantao Massoud, Mira Manier, Salomon Flores, Ludmila Perilla-Glen, Adriana Aljawai, Yosra Huynh, Daisy Takagi, Satoshi Roccaro, Aldo M. Sacco, Antonio Alignani, Diego Victoria Mateos, Maria Blade, Joan Jose Lahuerta, Juan Richardson, Paul G. Laubach, Jacob P. Schlossman, Robert L. Anderson, Kenneth C. Munshi, Nikhil C. Prosper, Felipe Michor, Franziska San Miguel, J. F. Ghobrial, Irene M. TI Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Mishima, Yuji; Manier, Salomon; Perilla-Glen, Adriana; Aljawai, Yosra; Huynh, Daisy; Takagi, Satoshi; Roccaro, Aldo M.; Richardson, Paul G.; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, 44 Binney St, Boston, MA 02115 USA. [Paiva, Bruno; Alignani, Diego] Univ Navarra Clin, Pamplona, Spain. [Shi, Jiantao; Michor, Franziska] Harvard Univ, Sch Med, Dana Farber Canc Inst, Biostat, Boston, MA 02115 USA. [Flores, Ludmila] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Victoria Mateos, Maria] Hosp Univ Salamanca, Hematolgy, Salamanca, Spain. [Blade, Joan] Univ Barcelona, Dept Hematol, Amyloidosis & Myeloma Unit, Serv Hematol,Hosp Clin Barcelona,IDIBAPS, Barcelona, Spain. [Jose Lahuerta, Juan] Hosp 12 Octubre, E-28041 Madrid, Spain. [Laubach, Jacob P.; Schlossman, Robert L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Prosper, Felipe; San Miguel, J. F.] Univ Navarra Clin, Pamplona, Spain. [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000087 ER PT J AU Mishra, A Hartlage, A Sullivan, L Grinshpun, L Kwiatkowski, S Qi, J Bradner, JE Porcu, P Caligiuri, MA AF Mishra, Anjali Hartlage, Alex Sullivan, Laura Grinshpun, Leah Kwiatkowski, Sonya Qi, Jun Bradner, James E. Porcu, Pierluigi Caligiuri, Michael A. TI Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Mishra, Anjali; Hartlage, Alex; Sullivan, Laura; Grinshpun, Leah; Kwiatkowski, Sonya; Caligiuri, Michael A.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Qi, Jun] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Bradner, James E.] Harvard Univ, Sch Med, Boston, MA USA. [Porcu, Pierluigi] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA. [Porcu, Pierluigi] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002026 ER PT J AU Moon, DH Segal, M Boyraz, B Guinan, E Hofmann, I Cahan, P Tai, AK Agarwal, S AF Moon, Diane H. Segal, Matthew Boyraz, Baris Guinan, Eva Hofmann, Inga Cahan, Patrick Tai, Albert K. Agarwal, Suneet TI Mutations in the Poly(A)-Specific Ribonuclease (PARN) Impair Telomerase RNA 3 ' End Maturation in Dyskeratosis Congenita Patients SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Moon, Diane H.; Segal, Matthew; Boyraz, Baris; Hofmann, Inga; Cahan, Patrick; Agarwal, Suneet] Boston Childrens Hosp, Hematol Oncol, Boston, MA USA. [Moon, Diane H.; Segal, Matthew; Boyraz, Baris; Hofmann, Inga; Agarwal, Suneet] Dana Farber Canc Inst, Pediat Oncol, Boston, MA 02115 USA. [Moon, Diane H.; Segal, Matthew; Boyraz, Baris; Agarwal, Suneet] Harvard Stem Cell Inst, Boston, MA USA. [Boyraz, Baris] Hacettepe Univ, Inst Canc, Basic Oncol, Ankara, Turkey. [Guinan, Eva] Dana Farber Canc Inst, Radiat Oncol, Boston, MA 02115 USA. [Tai, Albert K.] Tufts Univ, Sch Med, Integrat Physiol & Pathobiol, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002106 ER PT J AU Moreau, P Masszi, T Grzasko, N Bahlis, NJ Hansson, M Pour, L Sandhu, I Ganly, P Baker, BW Jackson, S Stoppa, AM Simpson, DR Gimsing, P Palumbo, A Garderet, L Cavo, M Kumar, SK Touzeau, C Buadi, F Laubach, JP Lin, JC Berg, D DiBacco, A Hui, AM Richardson, PG AF Moreau, Philippe Masszi, Tunas Grzasko, Norbert Bahlis, Nizar J. Hansson, Markus Pour, Ludek Sandhu, Irwindeep Ganly, Peter Baker, Bartrum W. Jackson, Sharon Stoppa, Anne -Marie Simpson, David R. Gimsing, Peter Palumbo, Antonio Garderet, Laurent Cavo, Michele Kumar, Shaji K. Touzeau, Cyrille Buadi, Francis Laubach, Jacob P. Lin, Jianchang Berg, Deborah DiBacco, Alessandra Hui, Ai -Min Richardson, Paul G. TI Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Moreau, Philippe] Univ Nantes, Nantes, France. [Masszi, Tunas] St Istvan & St Laszlo Hosp Budapest, Dept Haematol & Stem Cell Transplantat, Budapest, Hungary. [Grzasko, Norbert] Med Univ Lublin, Dept Haematooncol & Bone Marrow Transplantat, Lublin, Poland. [Bahlis, Nizar J.] Univ Calgary, Southern Alberta Canc Res Inst, Calgary, AB, Canada. [Hansson, Markus] Lund Univ, Skane Univ Hosp, Dept Hematol, Lund, Sweden. [Pour, Ludek] Univ Hosp Brno, Brno, Czech Republic. [Sandhu, Irwindeep] Univ Alberta, Dept Med, Div Hematol, Edmonton, AB, Canada. [Ganly, Peter] Christchurch Hosp, Dept Haematol, Christchurch, New Zealand. [Baker, Bartrum W.] Palmerston North Hosp, Dept Haematol, Palmerston North, New Zealand. [Jackson, Sharon] Middlemore Hosp, Dept Haematol, Auckland 6, New Zealand. [Stoppa, Anne -Marie] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France. [Simpson, David R.] North Shore Hosp, Dept Haematol, Auckland, New Zealand. [Gimsing, Peter] Univ Hosp Rigshosp, Dept Hematol, Copenhagen, Denmark. [Palumbo, Antonio] Univ Turin, Turin, Italy. [Garderet, Laurent] Hop St Antoine, F-75571 Paris, France. [Cavo, Michele] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy. [Kumar, Shaji K.; Buadi, Francis] Mayo Clin, Div Hematol, Rochester, MN USA. [Touzeau, Cyrille] Nantes Univ Hosp, Hotel Dieu, Nantes, France. [Laubach, Jacob P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lin, Jianchang; Berg, Deborah; DiBacco, Alessandra; Hui, Ai -Min] Millennium Pharmaceut Inc, Cambridge, MA USA. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancy,Dept Med Oncol,Jerome Lipp, 44 Binney St, Boston, MA 02115 USA. RI richard, chrystelle/K-8595-2015 NR 0 TC 0 Z9 0 U1 1 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002164 ER PT J AU Moreau, P Attal, M Karlin, L Garderet, L Facon, T Macro, M Benboubker, L Caillot, D Escoffre, M Stoppa, AM Laribi, K Hulin, C Marit, G Eveillard, JR Caillon, F Bodet, C Pegourie, B Dorvaux, V Chaleteix, C Richardson, PG Anderson, KC Avet-Loiseau, H Caultier, A Nguyen, JM Dupas, B Bodere, F AF Moreau, Philippe Attal, Michel Karlin, Lionel Garderet, Laurent Facon, Thierry Macro, Margaret Benboubker, Lotfi Caillot, Denis Escoffre, Martine Stoppa, Anne-Marie Laribi, Kamel Hulin, Cyrille Marit, Gerald Eveillard, Jean Richard Caillon, Florence Bodet, Caroline Pegourie, Brigitte Dorvaux, Veronique Chaleteix, Carine Richardson, Paul G. Anderson, Kenneth C. Avet-Loiseau, Herve Caultier, Aurelie Nguyen, Jean Michel Dupas, Benoit Bodere, Francoise TI Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Moreau, Philippe] Nantes Univ Hosp, Hotel Dieu, Nantes, France. [Attal, Michel] Inst Univ Canc Toulouse Oncopole, Toulouse, France. [Karlin, Lionel] Ctr Hosp Lyon Sud, Serv Hematol, Pierre Benite, France. [Garderet, Laurent] CHU St Antoine, Hematol, Paris, France. [Facon, Thierry] CHRU Lille, Hop Claude Huriez, Malad Sang, F-59037 Lille, France. [Macro, Margaret] Hop Cote Nacre, Caen 9, France. [Benboubker, Lotfi] CHU Tours, Tours, France. [Caillot, Denis] Hop Bocage, Dijon, France. [Escoffre, Martine] CHU Rennes, Rennes, France. [Stoppa, Anne-Marie] Inst Paoli Calmettes, Marseille, France. [Laribi, Kamel] Ctr Hosp, Le Mans, France. [Hulin, Cyrille] CHRU Hop Brabois, Serv Hematol, Vandoeuvre Les Nancy, France. [Marit, Gerald] CHU, Bordeaux, France. [Eveillard, Jean Richard] Univ Hosp, Brest, France. [Caillon, Florence; Bodet, Caroline; Caultier, Aurelie; Nguyen, Jean Michel; Dupas, Benoit; Bodere, Francoise] Univ Hosp, Nantes, France. [Pegourie, Brigitte] Hop Albert Michallon, CHU Grenoble, Grenoble, France. [Dorvaux, Veronique] Hop Notre Dame Bon Secours, Med Interne, Metz, France. [Chaleteix, Carine] Univ Hosp, Clermont Ferrand, France. [Richardson, Paul G.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Avet-Loiseau, Herve] Toulouse Inst Natl Sante, Ctr Rech Cancerol, Toulouse, France. RI Kraeber-Bodere, Francoise/F-7143-2013; FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015 OI Kraeber-Bodere, Francoise/0000-0002-3417-0759; FACON, THIERRY/0000-0001-7705-8460; NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001147 ER PT J AU Mosen-Ansorena, D Bolli, N Samur, MK Magrangeas, F Minvielle, S Anderson, KC Campbell, PJ Avet-Loiseau, H Parmigiani, G Munshi, NC AF Mosen-Ansorena, David Bolli, Niccolo Samur, Mehmet K. Magrangeas, Florence Minvielle, Stephane Anderson, Kenneth C. Campbell, Peter J. Avet-Loiseau, Herve Parmigiani, Giovanni Munshi, Nikhil C. TI Redefining Mutational Profiling Using RNA-Seq: Insight into the Functional Mutational Landscape of Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Mosen-Ansorena, David; Samur, Mehmet K.; Parmigiani, Giovanni] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Mosen-Ansorena, David] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Bolli, Niccolo] Dana Farber Canc Inst, Pediat Oncol, Boston, MA 02115 USA. [Bolli, Niccolo; Campbell, Peter J.] Wellcome Trust Sanger Inst, Canc Genome Project, Cambridge, England. [Samur, Mehmet K.; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Samur, Mehmet K.; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Magrangeas, Florence; Minvielle, Stephane] CHU Nantes, Unite Mixte Genom Canc, F-44035 Nantes 01, France. [Avet-Loiseau, Herve] Toulouse Inst Natl Sante, Ctr Rech Cancerol, Toulouse, France. [Munshi, Nikhil C.] VA Med Hosp, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002274 ER PT J AU Munshi, NC Minvielle, S Tai, YT Fulciniti, M Samur, MK Richardson, PG Attal, M Moreau, P Magrangeas, F Anderson, KC Faham, M Avet-Loiseau, H AF Munshi, Nikhil C. Minvielle, Stephane Tai, Yu-Tzu Fulciniti, Mariateresa Samur, Mehmet K. Richardson, Paul G. Attal, Michel Moreau, Philippe Magrangeas, Florence Anderson, Kenneth C. Faham, Malek Avet-Loiseau, Herve TI Deep Igh Sequencing Identifies an Ongoing Somatic Hypermutation Process with Complex and Evolving Clonal Architecture in Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Munshi, Nikhil C.; Tai, Yu-Tzu] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Munshi, Nikhil C.] Boston Vet Adm Healthcare Syst, West Roxbury, MA USA. [Minvielle, Stephane; Moreau, Philippe; Magrangeas, Florence] CNRS 6299, UMR Inserm 892, Ctr Rech Cancerol Nantes, Nantes, France. [Minvielle, Stephane; Moreau, Philippe; Magrangeas, Florence] Univ Nantes, Inst Rech Therapeut, Nantes, France. [Fulciniti, Mariateresa; Samur, Mehmet K.; Richardson, Paul G.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA. [Attal, Michel; Avet-Loiseau, Herve] CHU Rangueil, Unite Genom Myelome, F-31054 Toulouse, France. [Faham, Malek] Adapt Biotechnol Corp, San Francisco, CA USA. RI richard, chrystelle/K-8595-2015 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000085 ER PT J AU Murnane, M Dhimolea, E Li, RJ Bariteau, MA Wheeler, DD Akhurst, RJ Logan, AC Munster, P Wiita, A Martin, TG Wolf, JL Liu, JO Mitsiades, CS Aftab, BT AF Murnane, Megan Dhimolea, Eugen Li, Ruojing Bariteau, Megan A. Wheeler, Diamond D. Akhurst, Rosemary J. Logan, Aaron C. Munster, Pamela Wiita, Arun Martin, Thomas G., III Wolf, Jeffrey L. Liu, Jun O. Mitsiades, Constantine S. Aftab, Blake T. TI Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Murnane, Megan; Munster, Pamela; Martin, Thomas G., III; Aftab, Blake T.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA 94143 USA. [Dhimolea, Eugen; Bariteau, Megan A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Li, Ruojing; Liu, Jun O.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA. [Wheeler, Diamond D.; Wiita, Arun] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Lab Med, San Francisco, CA 94143 USA. [Akhurst, Rosemary J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Anat, San Francisco, CA 94143 USA. [Logan, Aaron C.; Wolf, Jeffrey L.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Mitsiades, Constantine S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001249 ER PT J AU Mussetti, A Kanate, AS Kharfan-Dabaja, MA Ahn, KW DiGilio, A Ciurea, SO Armand, P Salit, RB Fenske, TS Smith, SM Sureda, A Bolanos-Meade, J Hamadani, M AF Mussetti, Alberto Kanate, Abraham Sebastian Kharfan-Dabaja, Mohamed A. Ahn, Kwang Woo DiGilio, Alyssa Ciurea, Stefan O. Armand, Philippe Salit, Rachel B. Fenske, Timothy S. Smith, Sonali M. Sureda, Anna Bolanos-Meade, Javier Hamadani, Mehdi TI Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor ( MUD) Transplant for Lymphoid Malignancies SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Mussetti, Alberto] Inst Nazl Tumori, SC Ematol & Trapianto Midollo Osseo, Milan, Italy. [Kanate, Abraham Sebastian] W Virginia Univ, Osborn Hematopoiet Malignancy & Transplantat Prog, Sect Hematol & Oncol, Morgantown, WV 26506 USA. [Kanate, Abraham Sebastian] W Virginia Univ, Dept Med, Morgantown, WV 26506 USA. [Kharfan-Dabaja, Mohamed A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA. [Ahn, Kwang Woo; DiGilio, Alyssa] Med Coll Wisconsin, CIBMTR, Dept Med, Milwaukee, WI 53226 USA. [Ciurea, Stefan O.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA. [Salit, Rachel B.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Fenske, Timothy S.] Med Coll Wisconsin, Div Hematolgy & Oncol, Milwaukee, WI 53226 USA. [Smith, Sonali M.] Univ Chicago, Chicago, IL 60637 USA. [Sureda, Anna] Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain. [Bolanos-Meade, Javier] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA. [Hamadani, Mehdi] Med Coll Wisconsin, CIBMTR, Div Med, Milwaukee, WI 53226 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000258 ER PT J AU Newell, LF Holtan, SG Rosenzweig, J Yates, J Garbati, M Rathbun, RK Keeble, W Tyner, JW Burd, I Bagby, GC AF Newell, Laura F. Holtan, Shernan G. Rosenzweig, Jason Yates, Jane Garbati, Michael Rathbun, R. K. Keeble, Winifred Tyner, Jeffrey W. Burd, Irina Bagby, Grover C. TI Placental Growth Factor Enhances Toll-like Receptor-Induced Inflammatory Cytokine Gene Expression Transcriptionally in Human Mononuclear Phagocytes SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Newell, Laura F.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA. [Holtan, Shernan G.] Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA. [Rosenzweig, Jason; Burd, Irina] Johns Hopkins Univ, Dept Obstet & Gynecol, Baltimore, MD USA. [Yates, Jane; Garbati, Michael; Rathbun, R. K.; Keeble, Winifred] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Yates, Jane] Portland VA Med Ctr, Portland, OR USA. [Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA. [Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA. [Bagby, Grover C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003130 ER PT J AU Nikiforow, S Hemmer, M Spellman, SR Alousi, AM Couriel, DR Pidala, JA Arora, M Cutler, CS Wang, T AF Nikiforow, Sarah Hemmer, Michael Spellman, Stephen R. Alousi, Amin M. Couriel, Daniel R. Pidala, Joseph A. Arora, Mukta Cutler, Corey S. Wang, Tao TI Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Nikiforow, Sarah; Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Nikiforow, Sarah; Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Nikiforow, Sarah] Harvard Univ, Sch Med, Boston, MA USA. [Hemmer, Michael] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Spellman, Stephen R.] Be Match, Natl Marrow Donor Program, CIBMTR, Minneapolis, MN USA. [Alousi, Amin M.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. [Couriel, Daniel R.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Pidala, Joseph A.] Univ S Florida, H Lee Moffitt Canc Ctr, Blood & Marrow Transplantat, Tampa, FL 33682 USA. [Arora, Mukta] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA. [Wang, Tao] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002294 ER PT J AU Nwankwo, JO Warburton, RR Gremmel, T Gerrits, AJ Richey, LJ Hill, NS Rivera, A Jakubowski, JA Frelinger, AL Chishti, AH AF Nwankwo, Jennifer O. Warburton, Rod R. Gremmel, Thomas Gerrits, Anja J. Richey, Lauren J. Hill, Nicholas S. Rivera, Alicia Jakubowski, Joseph A. Frelinger, Andrew L., III Chishti, Athar H. TI Hypoxia Reoxygenation Treatment Induces Platelet Hyperactivity and Relieves Calpain-1-Mediated Inhibition of Platelet Aggregation in a Mouse Model of Severe Sickle Cell Disease SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Nwankwo, Jennifer O.] Tufts Univ, Sackler Sch Grad Biomed Sci, Program Pharmacol & Expt Therapeut, Boston, MA 02111 USA. [Warburton, Rod R.; Hill, Nicholas S.] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA USA. [Gremmel, Thomas; Gerrits, Anja J.; Frelinger, Andrew L., III] Harvard Univ, Sch Med, Dana Farber Canc Inst,Childrens Hosp, Ctr Platelet Res Studies,Div Hematol Oncol,Boston, Boston, MA 02115 USA. [Richey, Lauren J.] Tufts Univ, Div Lab Anim Med, Boston, MA 02111 USA. [Rivera, Alicia] Harvard Univ, Sch Med, Boston Childens Hosp, Dept Lab Med, Boston, MA USA. [Rivera, Alicia] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Jakubowski, Joseph A.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Chishti, Athar H.] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Program Pharmacol & Expt Therapeut, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001165 ER PT J AU O'Connor, OA Ozcan, M Jacobsen, ED Vidal, JMR Trotman, J Demeter, J Masszi, T Pereira, J Ramchandren, R d'Amore, FA Foss, F Kim, WS Leonard, JP Chiattone, CS Zinzani, PL Liu, H Jung, J Zhou, XF Leonard, EJ Ullmann, CD Shustov, AR AF O'Connor, Owen A. Ozcan, Muhit Jacobsen, Eric D. Vidal, Josep Maria Roncero Trotman, Judith Demeter, Judit Masszi, Tamas Pereira, Juliana Ramchandren, Radhakrishnan d'Amore, Francesco A. Foss, Francine Kim, Won-Seog Leonard, John P. Chiattone, Carlos Sergio Zinzani, Pier Luigi Liu, Hua Jung, JungAh Zhou, Xiaofei Leonard, E. Jane Ullmann, Claudio Dansky Shustov, Andrei R. TI First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [O'Connor, Owen A.] Columbia Univ, Med Ctr, New York Presbyterian Hosp, Med,Ctr Lymphoid Malignancies, New York, NY USA. [Ozcan, Muhit] Ankara Univ, Sch Med, Cebeci Hosp, Dept Hematol & BMT, TR-06100 Ankara, Turkey. [Jacobsen, Eric D.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Vidal, Josep Maria Roncero] Catalan Inst Oncol, Clin Hematol, Girona, France. [Trotman, Judith] Concord Repatriat Gen Hosp, Dept Hematol, Concord, NSW, Australia. [Demeter, Judit] Semmelweis Univ, Div Haematol, Dept Internal Med 1, H-1085 Budapest, Hungary. [Masszi, Tamas] St Istvan & St Laszlo Hosp, Dept Haematol & Stem Cell Transplantat, Budapest, Hungary. [Pereira, Juliana] Univ Sao Paulo, Sch Med, Dept Hematol, Sao Paulo, Brazil. [Ramchandren, Radhakrishnan] Karmanos Canc Inst, Hematol Oncol, Detroit, MI USA. [d'Amore, Francesco A.] Aarhus Univ Hosp, Hematol, Bethesda, MD USA. [Foss, Francine] Yale Univ, Smilow Canc Hosp, Yale Hematol Cutaneous Lymphoma, New Haven, CT USA. [Kim, Won-Seog] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Hematol Oncol, Seoul, South Korea. [Leonard, John P.] Weill Cornell Med Coll, New York, NY USA. [Chiattone, Carlos Sergio] Santa Casa Med Sch, Dept Hematol & Oncol, Sao Paulo, Brazil. [Zinzani, Pier Luigi] Univ Bologna, Inst Hematol LeA Seragnoli, Bologna, Italy. [Liu, Hua; Jung, JungAh] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA. [Zhou, Xiaofei] Millennium Pharmaceut Inc, Clin Pharmacol, Cambridge, MA USA. [Leonard, E. Jane; Ullmann, Claudio Dansky] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA. [Shustov, Andrei R.] Univ Washington, Med Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA. [Shustov, Andrei R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RI Zinzani, Pier Luigi/J-9182-2016 OI Zinzani, Pier Luigi/0000-0002-2112-2651 NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001093 ER PT J AU Olszewski, AJ Fallah, J Eaton, CB Treon, SP Castillo, JJ AF Olszewski, Adam J. Fallah, Jaleh Eaton, Charles B. Treon, Steven P. Castillo, Jorge J. TI The Evolution of Management and Survival Outcomes of Waldenstrom Macroglobulinemia (WM) in the United States (US) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Olszewski, Adam J.] Brown Univ, Alpert Med Sch, Div Hematol Oncol, Providence, RI 02912 USA. [Olszewski, Adam J.; Fallah, Jaleh] Brown Univ, Mem Hosp Rhode Isl, Dept Med, Pawtucket, RI 02860 USA. [Eaton, Charles B.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA. [Treon, Steven P.; Castillo, Jorge J.] Dana Farber Canc Inst, Bing Ctr WM, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003006 ER PT J AU Ott, CJ Federation, AJ Kasar, S Klitgaard, JL Fernandes, SM Brown, JR Bradner, JE AF Ott, Christopher J. Federation, Alexander J. Kasar, Siddha Klitgaard, Josephine L. Fernandes, Stacey M. Brown, Jennifer R. Bradner, James E. TI Enhancer Landscapes Reveal Transcription Factor Network Dependencies in Chronic Lymphocytic Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Ott, Christopher J.; Federation, Alexander J.; Kasar, Siddha; Klitgaard, Josephine L.; Fernandes, Stacey M.; Brown, Jennifer R.; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001188 ER PT J AU Ottmann, OG Alimena, G DeAngelo, DJ Goh, YT Heinrich, MC Hochhaus, A Hughes, TP Mahon, FX Mauro, MJ Minami, H Nguyen, MH Rea, D Steegmann, JL Chatterjee, A Iyer, V Martinez, N Vanasse, GJ Dong-Wook, K AF Ottmann, Oliver G. Alimena, Giuliana DeAngelo, Daniel J. Goh, Yeow-Tee Heinrich, Michael C. Hochhaus, Andreas Hughes, Timothy P. Mahon, Francois-Xavier Mauro, Michael J. Minami, Hironobu Nguyen, Marie Huong Rea, Delphine Steegmann, Juan Luis Chatterjee, Arkendu Iyer, Varsha Martinez, Noelia Vanasse, Gary J. Dong-Wook, Kim TI ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Ottmann, Oliver G.] Cardiff Univ, Dept Haematol, Cardiff, S Glam, Wales. [Alimena, Giuliana] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00185 Rome, Italy. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Goh, Yeow-Tee] Singapore Gen Hosp, Dept Clin Res, Singapore, Singapore. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Hochhaus, Andreas] Univ Klinikum Jena, Abt Hamatol Onkol, Jena, Germany. [Hughes, Timothy P.] SA Pathol, Adelaide, SA, Australia. [Hughes, Timothy P.] South Australian Hlth, Adelaide, SA, Australia. [Hughes, Timothy P.] Univ Adelaide, Med Res Inst, Adelaide, SA, Australia. [Mahon, Francois-Xavier] Univ Victor Segalen, Lab Hematopoiese Leucem & Cible Therapeut, Inserm U1035, Bordeaux, France. [Mauro, Michael J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Minami, Hironobu] Kobe Univ, Sch Med, Kobe, Hyogo 650, Japan. [Nguyen, Marie Huong] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Div Hematol Oncol, Ann Arbor, MI 48109 USA. [Rea, Delphine] Hop St Louis, Serv Malad Sang, Paris, France. [Rea, Delphine] Hop St Louis, EA3518, Paris, France. [Steegmann, Juan Luis] Hosp Univ la Princesa, Hematol Dpt IIS IP, Madrid, Spain. [Chatterjee, Arkendu; Iyer, Varsha; Martinez, Noelia; Vanasse, Gary J.] Novartis Inst BioMed Res Inc, Cambridge, MA USA. [Dong-Wook, Kim] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea. NR 0 TC 4 Z9 4 U1 2 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000202 ER PT J AU Paiva, C Godbersen, C Spurgeon, SE Srinivasa, S Brown, JR Danilov, AV AF Paiva, Cody Godbersen, Claire Spurgeon, Stephen E. Srinivasa, Sreesha Brown, Jennifer R. Danilov, Alexey V. TI Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Paiva, Cody; Danilov, Alexey V.] OHSU Knight Canc Inst, Portland, OR USA. [Godbersen, Claire] Dartmouth Coll, Lebanon, NH 03756 USA. [Spurgeon, Stephen E.] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Portland, OR 97201 USA. [Srinivasa, Sreesha] Piramal Healthcare, Mumbai, Maharashtra, India. [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005230 ER PT J AU Palchaudhuri, R Saez, B Hoggatt, J Schajnovitz, A Sykes, DB Mansour, MK Scadden, DT AF Palchaudhuri, Rahul Saez, Borja Hoggatt, Jonathan Schajnovitz, Amir Sykes, David B. Mansour, Michael K. Scadden, David T. TI Immunotoxin Enables Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Palchaudhuri, Rahul; Saez, Borja; Schajnovitz, Amir] Harvard Univ, Stem Cell & Regenerat Biol, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Palchaudhuri, Rahul; Saez, Borja; Schajnovitz, Amir; Sykes, David B.; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Hoggatt, Jonathan] Harvard Univ, Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Hoggatt, Jonathan] Massachusetts Gen Hosp, Ctr Canc, Ctr Transplantat Sci, Boston, MA USA. [Mansour, Michael K.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA. [Scadden, David T.] Harvard Stem Cell Inst, Cambridge, MA USA. NR 0 TC 1 Z9 1 U1 2 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000096 ER PT J AU Palumbo, A Offidani, M Pegourie, B De La Rubia, J Garderet, L Laribi, K Bosi, A Marasca, R Laubach, JP Mohrbacher, A Carella, AM Singhal, AK Lynch, M Jou, YM Jakubowiak, A AF Palumbo, Antonio Offidani, Massimo Pegourie, Brigitte De La Rubia, Javier Garderet, Laurent Laribi, Kamel Bosi, Alberto Marasca, Roberto Laubach, Jacob P. Mohrbacher, Ann Carella, Angelo Michele Singhal, Anil K. Lynch, Mark Jou, Ying-Ming Jakubowiak, Andrzej TI Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Palumbo, Antonio] Azienda Osped Univ San Giovanni Battista Torino, Osped Molinette, Turin, Italy. [Offidani, Massimo] Azienda Osped Univ, Osped Riuniti Ancona, Ancona, Italy. [Pegourie, Brigitte] CHU Grenoble, Hop Albert Michallon, F-38043 Grenoble, France. [De La Rubia, Javier] HUP La Fe, Valencia, Spain. [Garderet, Laurent] Hop St Antoine, F-75571 Paris, France. [Laribi, Kamel] Ctr Hosp, Le Mans, France. [Bosi, Alberto] Azienda Osped Univ Careggi, Florence, Italy. [Marasca, Roberto] Azienda Osped Univ, Policlin Modena, Modena, Italy. [Laubach, Jacob P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mohrbacher, Ann] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. [Carella, Angelo Michele] IRCCS San Martino IST, Genoa, Italy. [Singhal, Anil K.] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA. [Lynch, Mark] Bristol Myers Squibb, Wallingford, CT USA. [Jou, Ying-Ming] Bristol Myers Squibb, Hopewell, NJ USA. [Jakubowiak, Andrzej] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. RI Marasca, Roberto/I-8072-2013 OI Marasca, Roberto/0000-0002-6431-6878 NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001256 ER PT J AU Park, JH Chung, SS Durham, B Chung, YR Scott, S Getta, B Kim, E Saven, A Stone, RM Rai, KR Grever, MR Altman, JK Rosen, N Levine, RL Berger, M Tallman, MS Abdel-Wahab, O AF Park, Jae H. Chung, Stephen S. Durham, Benjamin Chung, Young Rock Scott, Sasinya Getta, Bartlomiej Kim, Eunhee Saven, Alan Stone, Richard M. Rai, Kanti R. Grever, Michael R. Altman, Jessica K. Rosen, Neal Levine, Ross L. Berger, Michael Tallman, Martin S. Abdel-Wahab, Omar TI Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Park, Jae H.; Chung, Stephen S.; Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. [Durham, Benjamin; Scott, Sasinya; Getta, Bartlomiej; Kim, Eunhee; Levine, Ross L.; Abdel-Wahab, Omar] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Chung, Young Rock] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Saven, Alan] Scripps Hlth, La Jolla, CA USA. [Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Rai, Kanti R.] North Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY USA. [Grever, Michael R.] Ohio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA. [Altman, Jessica K.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Rosen, Neal] Mem Sloan Kettering Canc Ctr, Pharmacol, New York, NY 10021 USA. [Berger, Michael] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. NR 0 TC 9 Z9 9 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001201 ER PT J AU Perry, AM Zou, T Brunner, AM Neuberg, DS Fathi, AT AF Perry, Ashley M. Zou, Tao Brunner, Andrew M. Neuberg, Donna S. Fathi, Amir T. TI The Impact of Insurance Status at Diagnosis on Overall Survival in Chronic Myeloid Leukemia: A Population-Based Analysis SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Perry, Ashley M.; Zou, Tao; Brunner, Andrew M.; Fathi, Amir T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Brunner, Andrew M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002068 ER PT J AU Pikman, Y Puissant, A Alexe, G Furman, A Frumm, S Ross, L Chen, L Fenouille, N Bassil, CF Lewis, CA Stone, RM DeAngelo, DJ Galinsky, I Kung, AL Heiden, MV Hemann, MT Banerji, V Stegmaier, K AF Pikman, Yana Puissant, Alexandre Alexe, Gabriela Furman, Andrew Frumm, Stacey Ross, Linda Chen, Liying Fenouille, Nina Bassil, Christopher F. Lewis, Caroline A. Stone, Richard M. DeAngelo, Daniel J. Galinsky, Ilene Kung, Andrew L. Heiden, Matthew Vader Hemann, Michael T. Banerji, Versha Stegmaier, Kimberly TI Targeting MTHFD2 in Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Pikman, Yana; Puissant, Alexandre; Alexe, Gabriela; Furman, Andrew; Ross, Linda; Chen, Liying; Bassil, Christopher F.; Stegmaier, Kimberly] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Pikman, Yana; Stegmaier, Kimberly] Boston Childrens Hosp, Boston, MA USA. [Frumm, Stacey] UCSF, San Francisco, CA USA. [Fenouille, Nina; Lewis, Caroline A.; Heiden, Matthew Vader; Hemann, Michael T.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Stone, Richard M.] Dana Farber Canc Inst, Hematol Oncol, Boston, MA 02115 USA. [DeAngelo, Daniel J.; Galinsky, Ilene] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Kung, Andrew L.] Columbia Univ, Med Ctr, Div Pediat Hematol Oncol Stem Cell Transplantat, New York, NY USA. [Banerji, Versha] Canc Care Manitoba, Res Inst Oncol & Hematol, Winnipeg, MB, Canada. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001195 ER PT J AU Pine, AB Lee, EJ Sekeres, MA Steensma, DP Prebet, T DeZern, AE Komrokji, RS Litzow, MR Luger, S Stone, RM Erba, HP Garcia-Manero, G Lee, AI Podoltsev, NA Barbarotta, L Hendrickson, JE Gore, SD Zeidan, AM AF Pine, Alexander B. Lee, Eun-Ju Sekeres, Mikkael A. Steensma, David P. Prebet, Thomas DeZern, Amy E. Komrokji, Rami S. Litzow, Mark R. Luger, Selina Stone, Richard M. Erba, Harry P. Garcia-Manero, Guillermo Lee, Alfred I. Podoltsev, Nikolai A. Barbarotta, Lisa Hendrickson, Jeanne E. Gore, Steven D. Zeidan, Amer M. TI North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Pine, Alexander B.] Yale New Haven Med Ctr, New Haven, CT 06504 USA. [Lee, Eun-Ju] Yale Univ, Sch Med, Hematol, New Haven, CT USA. [Sekeres, Mikkael A.] Cleveland Clin, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH 44106 USA. [Sekeres, Mikkael A.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Prebet, Thomas; Lee, Alfred I.; Podoltsev, Nikolai A.; Barbarotta, Lisa] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA. [DeZern, Amy E.] Johns Hopkins Sch Med, Baltimore, MD USA. [Komrokji, Rami S.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, MN USA. [Luger, Selina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Erba, Harry P.] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA. [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Hendrickson, Jeanne E.] Yale Univ, Sch Med, Lab Med, New Haven, CT USA. [Gore, Steven D.; Zeidan, Amer M.] Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003262 ER PT J AU Plesner, T Arkenau, HT Gimsing, P Krejcik, J Lemech, C Minnema, MC Lassen, U Laubach, JP Palumbo, A Lisby, S Basse, L Wang, JP Sasser, AK Guckert, ME Yeh, H Ahmadi, T Lokhorst, HM Richardson, PG AF Plesner, Torben Arkenau, Hendrik-Tobias Gimsing, Peter Krejcik, Jakub Lemech, Charlotte Minnema, Monique C. Lassen, Ulrik Laubach, Jacob P. Palumbo, Antonio Lisby, Steen Basse, Linda Wang, Jianping Sasser, A. Kate Guckert, Mary E. Yeh, Howard Ahmadi, Tahamtan Lokhorst, Henk M. Richardson, Paul G. TI Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Plesner, Torben; Krejcik, Jakub] Vejle Hosp, Vejle, Denmark. [Arkenau, Hendrik-Tobias; Lemech, Charlotte] Sarah Cannon Res Inst, London, England. [Gimsing, Peter; Lassen, Ulrik] Univ Copenhagen, Rigshosp, Dept Haematol, DK-2100 Copenhagen, Denmark. [Minnema, Monique C.] UMC Utrecht Canc Ctr, Dept Hematol, Utrecht, Netherlands. [Laubach, Jacob P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Palumbo, Antonio] Univ Turin, Turin, Italy. [Lisby, Steen; Basse, Linda] Genmab AS, Copenhagen, Denmark. [Wang, Jianping; Sasser, A. Kate; Guckert, Mary E.; Ahmadi, Tahamtan] Janssen Res & Dev LLC, Spring House, PA USA. [Yeh, Howard] Janssen Res & Dev LLC, Raritan, NJ USA. [Lokhorst, Henk M.] UMC Utrecht, Hematol, Utrecht, Netherlands. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. NR 0 TC 15 Z9 15 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001253 ER PT J AU Pyzer, AR Stroopinsky, D Rajabi, H Rosenblatt, J Coll, MD Jain, S Palmer, KA Tagde, A Luptakova, K McMasters, M Levine, JD Joyce, R Arnason, JE Nahas, MR Leaf, RK Washington, A Bar-Natan, M Dutt, PS Kufe, D Avigan, D AF Pyzer, Athalia Rachel Stroopinsky, Dina Rajabi, Hasan Rosenblatt, Jacalyn Coll, Maxwell Douglas Jain, Salvia Palmer, Kristen Anna Tagde, Ashujit Luptakova, Katarina McMasters, Malgorzata Levine, James D. Joyce, Robin Arnason, Jon E. Nahas, Myrna Rita Leaf, Rebecca Karp Washington, Abigail Bar-Natan, Michal Dutt, Poorvi Somaiya Kuefe, Donald Avigan, David TI MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Pyzer, Athalia Rachel; Stroopinsky, Dina; Rosenblatt, Jacalyn; Coll, Maxwell Douglas; Palmer, Kristen Anna; Luptakova, Katarina; McMasters, Malgorzata; Levine, James D.; Arnason, Jon E.; Nahas, Myrna Rita; Leaf, Rebecca Karp; Washington, Abigail; Bar-Natan, Michal; Dutt, Poorvi Somaiya; Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Rajabi, Hasan; Tagde, Ashujit; Kuefe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Jain, Salvia] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Malignant Hematol & Bone Marrow Transplantat, Boston, MA 02215 USA. [Joyce, Robin] Harvard Univ, Sch Med, Div Hematol & Oncol, Boston, MA USA. [Joyce, Robin] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002080 ER PT J AU Raetz, E Loh, ML Devidas, M Maloney, K Larsen, EC Mattano, LA Borowitz, MJ Wood, BL Carroll, AJ Heerema, NA Chen, IM Friedmann, AM Schultz, KR Relling, MV Harvey, RC Gastier-Foster, J Willman, CL Winick, NJ Hunger, SP Carroll, WL AF Raetz, Elizabeth Loh, Mignon L. Devidas, Meenakshi Maloney, Kelly Larsen, Eric C. Mattano, Leonard A., Jr. Borowitz, Michael J. Wood, Brent L. Carroll, Andrew J. Heerema, Nyla A. Chen, I-Ming Friedmann, Alison M. Schultz, Kirk R. Relling, Mary V. Harvey, Richard C. Gastier-Foster, Julie Willman, Cheryl L. Winick, Naomi J. Hunger, Stephen P. Carroll, William L. TI Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Raetz, Elizabeth] Univ Utah, Dept Pediat, Huntsman Canc Inst, Salt Lake City, UT USA. [Raetz, Elizabeth] Univ Utah, Primary Childrens Hosp, Salt Lake City, UT USA. [Loh, Mignon L.] Univ Calif San Francisco, Dept Pediat, Benioff Childrens Hosp, San Francisco, CA USA. [Devidas, Meenakshi] Univ Florida, Coll Med, Dept Biostat, Gainesville, FL USA. [Devidas, Meenakshi] Univ Florida, Coll Publ Hlth, Dept Biostat, Gainesville, FL USA. [Devidas, Meenakshi] Univ Florida, Coll Hlth Profess, Dept Biostat, Gainesville, FL USA. [Maloney, Kelly] Childrens Hosp Colorado, Aurora, CO USA. [Larsen, Eric C.] Maine Childrens Canc Program, Scarborough, ME USA. [Mattano, Leonard A., Jr.] HARP Pharma Consulting, Mystic, CT USA. [Borowitz, Michael J.] Johns Hopkins Univ, Hematol Pathol, Baltimore, MD USA. [Wood, Brent L.] Seattle Canc Care Alliance, Seattle, WA USA. [Carroll, Andrew J.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA. [Heerema, Nyla A.] Ohio State Univ, Columbus, OH 43210 USA. [Chen, I-Ming] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA. [Friedmann, Alison M.] Massachusetts Gen Hosp, Pediat Hematol Oncol, Boston, MA 02114 USA. [Schultz, Kirk R.] Univ British Columbia, BC Childrens Hosp, Vancouver, BC V5Z 1M9, Canada. [Relling, Mary V.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA. [Harvey, Richard C.] Univ New Mexico, Ctr Canc, Pathol, Albuquerque, NM 87131 USA. [Gastier-Foster, Julie] Nationwide Childrens Hosp, Dept Pathol, Columbus, OH USA. [Willman, Cheryl L.] Univ New Mexico, Canc Res & Treatment Ctr, UNM Canc Res Facil, Albuquerque, NM 87131 USA. [Winick, Naomi J.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Hunger, Stephen P.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA. [Hunger, Stephen P.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Carroll, William L.] NYU, Dept Pediat, Perlmutter Canc Ctr, Med Ctr, New York, NY 10016 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002244 ER PT J AU Rasmussen, HK Wong, F Tate, T Scadden, DT Hoggatt, J AF Rasmussen, Hannah K. Wong, Frankie Tate, Tiffany Scadden, David T. Hoggatt, Jonathan TI Oncostatin M Enhances Hematopoietic Stem Cell Homing and Engraftment SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Rasmussen, Hannah K.; Wong, Frankie; Tate, Tiffany; Scadden, David T.; Hoggatt, Jonathan] Harvard Univ, Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Scadden, David T.; Hoggatt, Jonathan] Harvard Stem Cell Inst, Cambridge, MA USA. [Hoggatt, Jonathan] Massachusetts Gen Hosp, Ctr Canc, Ctr Transplantat Sci, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000095 ER PT J AU Reagan, MR McDonald, M Terry, R Pettitt, J Le, L Mohanty, S Kneissel, M Kramer, I Brooks, D Bouxsein, M Rosen, CJ Ghobrial, IM Croucher, P AF Reagan, Michaela R. McDonald, Michelle Terry, Rachael Pettitt, Jessica Le, Lawrence Mohanty, Sindhu Kneissel, Michaela Kramer, Ina Brooks, Daniel Bouxsein, Mary Rosen, Clifford J. Ghobrial, Irene M. Croucher, Peter TI Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Reagan, Michaela R.; Rosen, Clifford J.] Maine Med Ctr, Res Inst, Scarborough, ME USA. [Reagan, Michaela R.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [McDonald, Michelle; Terry, Rachael; Pettitt, Jessica; Le, Lawrence; Mohanty, Sindhu; Croucher, Peter] Garvan Inst Med Res, Sydney, NSW, Australia. [Kneissel, Michaela; Kramer, Ina] Novartis Inst BioMed Res, Basel, Switzerland. [Brooks, Daniel; Bouxsein, Mary] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RI Reagan, Michaela/E-3549-2017 NR 0 TC 2 Z9 2 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000183 ER PT J AU Rebekka, SK Schenone, M Ventura, MF Beier, F Bruemmendorf, TH Germing, U Platzbecker, U Busche, G McConkey, ME Waters, CS Lindsley, RC Ebert, BL AF Rebekka, Schneider K. Schenone, Monica Ventura, Monica Ferreira Beier, Fabian Bruemmendorf, Tim H. Germing, Ulrich Platzbecker, Uwe Buesche, Guntram McConkey, Marie E. Waters, Christopher S. Lindsley, R. Coleman Ebert, Benjamin L. TI Cooperating Effect of Rps14, Csnk1a1 and miRNA145/miRNA146a Haploinsufficiency in the Activation of the Innate Immune System in Del(5q) MDS SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Rebekka, Schneider K.] Univ Hosp RWTH Aachen, Dept Hematol, Aachen, Germany. [Schenone, Monica] Broad Inst, Boston, MA USA. [Ventura, Monica Ferreira] Rhein Westfal TH Aachen, Hematol, Aachen, Germany. [Beier, Fabian] Univ Hosp Aachen, Aachen, Germany. [Bruemmendorf, Tim H.] Rhein Westfal TH Aachen, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany. [Germing, Ulrich] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany. [Platzbecker, Uwe] Carl Gustav Carus Tech Univ, Univ Klinikum, Dresden, Germany. [Buesche, Guntram] Hannover Med Sch, Pathol, Hannover, Germany. [McConkey, Marie E.; Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Waters, Christopher S.] Brigham & Womens Hosp, Hematol, Boston, MA 02115 USA. [Lindsley, R. Coleman] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001108 ER PT J AU Richardson, PG Riches, M Kernan, NA Brochstein, JA Mineishi, S Termuhlen, AM Arai, S Grupp, SA Guinan, EC Martin, PL Steinbach, G Krishnan, A Nemecek, ER Giralt, SA Rodriguez, TE Duerst, R Doyle, JJ Antin, JH Smith, AR Lehmann, LE Champlin, RE Gillio, A Bajwa, R D'Agostino, RB Massaro, J Miloslavsky, M Hume, RL Iacobelli, M Nejadnik, B Hannah, AL Soiffer, RJ AF Richardson, Paul G. Riches, Marcie Kernan, Nancy A. Brochstein, Joel A. Mineishi, Shin Termuhlen, Amanda M. Arai, Sally Grupp, Stephan A. Guinan, Eva C. Martin, Paul L. Steinbach, Gideon Krishnan, Amrita Nemecek, Eneida R. Giralt, Sergio A. Rodriguez, Tulio E. Duerst, Reggie Doyle, John J. Antin, Joseph H. Smith, Angela R. Lehmann, Leslie E. Champlin, Richard E. Gillio, Alfred Bajwa, Rajinder D'Agostino, Ralph B. Massaro, Joseph Miloslavsky, Maja Hume, Robin L. Iacobelli, Massimo Nejadnik, Bijan Hannah, Alison L. Soiffer, Robert J. TI Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Richardson, Paul G.; Guinan, Eva C.; Antin, Joseph H.; Lehmann, Leslie E.; Soiffer, Robert J.] Childrens Hosp, Dana Farber Canc Inst, Massachusetts Gen, Boston, MA 02115 USA. [Riches, Marcie] North Carolina Canc Hosp, Univ N Carolina Hosp, Bone Marrow & Stem Cell Transplant Clin, Chapel Hill, NC USA. [Kernan, Nancy A.; Giralt, Sergio A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Brochstein, Joel A.; Gillio, Alfred] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Mineishi, Shin] Univ Alabama Birmingham, Birmingham, AL USA. [Termuhlen, Amanda M.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Arai, Sally] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Grupp, Stephan A.] Childrens Hosp Philadelphia, Pediat Oncol, Philadelphia, PA 19104 USA. [Martin, Paul L.] Duke Univ, Med Ctr, Durham, NC USA. [Steinbach, Gideon] Univ Washington, Sch Med, Seattle, WA USA. [Steinbach, Gideon] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Krishnan, Amrita] City Hope Natl Med Ctr, Duarte, CA USA. [Nemecek, Eneida R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Rodriguez, Tulio E.] Loyola Univ, Med Ctr, Chicago, IL 60611 USA. [Duerst, Reggie] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA. [Doyle, John J.] CancerCare Manitoba, Winnipeg, MB, Canada. [Doyle, John J.] Univ Manitoba, Winnipeg, MB, Canada. [Smith, Angela R.] Univ Minnesota, Minneapolis, MN USA. [Champlin, Richard E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Bajwa, Rajinder] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA. [D'Agostino, Ralph B.; Massaro, Joseph] Boston Univ, Boston, MA 02215 USA. [Miloslavsky, Maja; Hume, Robin L.; Nejadnik, Bijan; Hannah, Alison L.] Jazz Pharmaceut, Palo Alto, CA USA. [Iacobelli, Massimo] Gentium SpA, Villa Guardia, Italy. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002174 ER PT J AU Roccaro, AM Sacco, A Ma, DD Shi, JT Mishima, Y Moschetta, M Handin, RI Ghobrial, IM AF Roccaro, Aldo M. Sacco, Antonio Ma, Dongdong Shi, Jiantao Mishima, Yuji Moschetta, Michele Handin, Robert I. Ghobrial, Irene M. TI A New Model for Studying the Dissemination of Myeloma Cells throughout the Bone Marrow Using Embryonic Zebrafish SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Roccaro, Aldo M.; Sacco, Antonio; Mishima, Yuji] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Ma, Dongdong; Handin, Robert I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Hematol, Boston, MA 02115 USA. [Shi, Jiantao] Harvard Univ, Sch Med, Dana Farber Canc Inst, Biostat, Boston, MA 02115 USA. [Moschetta, Michele] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003039 ER PT J AU Roemer, MGM Advani, RH Ligon, AH Natkunam, Y Redd, RA Homer, H Connelly, C Sun, HH Daadi, SE Chapuy, B de Jong, D Hoppe, RT Neuberg, DS Rodig, SJ Shipp, MA AF Roemer, Margaretha G. M. Advani, Ranjana H. Ligon, Azra H. Natkunam, Yasodha Redd, Robert A. Homer, Heather Connelly, Courtney Sun, Heather H. Daadi, Sarah E. Chapuy, Bjoern de Jong, Daphne Hoppe, Richard T. Neuberg, Donna S. Rodig, Scott J. Shipp, Margaret A. TI PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Roemer, Margaretha G. M.; Homer, Heather; Chapuy, Bjoern] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Advani, Ranjana H.; Natkunam, Yasodha; Connelly, Courtney; Daadi, Sarah E.; Hoppe, Richard T.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Ligon, Azra H.; Sun, Heather H.; Rodig, Scott J.] Brigham & Womens Hosp, Pathol, Boston, MA 02115 USA. [Redd, Robert A.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Connelly, Courtney; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [de Jong, Daphne] Vrije Univ Amsterdam Med Ctr, Pathol, Amsterdam, Netherlands. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000240 ER PT J AU Saha, A O'Connor, RS Thangavelu, G Lovitch, SB Dandamudi, DB Wilson, CB Vincent, BG Aoyama, K Taylor, PA Panoskaltsis-Mortari, A Foncea, R Burrill, JS Guo, LL Sacristan, C Furlan, SN Snyder, NW Blair, IA Milone, MC Dustin, ML Riley, JL Bernlohr, DA Turka, LA Murphy, WJ Fife, BT Munn, DH Miller, JS Serody, JS Kean, L Freeman, GJ Sharpe, AH Blazar, BR AF Saha, Asim O'Connor, Roddy S. Thangavelu, Govindarajan Lovitch, Scott B. Dandamudi, Durga Bhavani Wilson, Caleph B. Vincent, Benjamin G. Aoyama, Kazutoshi Taylor, Patricia A. Panoskaltsis-Mortari, Angela Foncea, Rocio Burrill, Joel S. Guo, Lili Sacristan, Catarina Furlan, Scott N. Snyder, Nathaniel W. Blair, Ian A. Milone, Michael C. Dustin, Michael L. Riley, James L. Bernlohr, David A. Turka, Laurence A. Murphy, William J. Fife, Brian T. Munn, David H. Miller, Jeffrey S. Serody, Jonathan S. Kean, Leslie Freeman, Gordon J. Sharpe, Arlene H. Blazar, Bruce R. TI Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Saha, Asim; Thangavelu, Govindarajan] Univ Minnesota, Dept Pediat, Blood & Marrow Transplantat, Minneapolis, MN 55455 USA. [O'Connor, Roddy S.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA. [Lovitch, Scott B.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Dandamudi, Durga Bhavani; Sacristan, Catarina] NYU, Sch Med, Dept Pathol, New York, NY USA. [Wilson, Caleph B.] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA. [Vincent, Benjamin G.] Univ N Carolina, Chapel Hill, NC USA. [Aoyama, Kazutoshi] Chugoku Cent Hosp, Dept Hematol, Hiroshima, Japan. [Taylor, Patricia A.; Blazar, Bruce R.] Univ Minnesota, Dept Med, Ctr Canc, Div Pediat, Minneapolis, MN 55455 USA. [Panoskaltsis-Mortari, Angela] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA. [Foncea, Rocio; Burrill, Joel S.; Bernlohr, David A.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN USA. [Guo, Lili; Snyder, Nathaniel W.; Blair, Ian A.] Univ Penn, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA. [Furlan, Scott N.] Seattle Childrens Res Inst, Seattle, WA USA. [Snyder, Nathaniel W.] Drexel Univ, Philadelphia, PA 19104 USA. [Milone, Michael C.] Univ Penn, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA. [Dustin, Michael L.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Kennedy Inst Rheumatol, Oxford, England. [Riley, James L.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Turka, Laurence A.] Univ Penn, Philadelphia, PA 19104 USA. [Murphy, William J.] UC Davis Med Ctr, Dept Dermatol, Sacramento, CA USA. [Fife, Brian T.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA. [Fife, Brian T.] Univ Minnesota, Ctr Immunol, Minneapolis, MN USA. [Munn, David H.] Med Coll Georgia, Augusta, GA 30912 USA. [Miller, Jeffrey S.] Univ Minnesota, Hematol Oncol & Transplantat, Minneapolis, MN USA. [Serody, Jonathan S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Kean, Leslie] Fred Hutchinson Canc Res Ctr, Pediat BMT, Seattle, WA 98104 USA. [Freeman, Gordon J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sharpe, Arlene H.] Harvard Univ, Sch Med, Pathol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000211 ER PT J AU Sallman, D Garcia-Manero, G Jabbour, E Sekeres, MA DeZern, AE Steensma, DP Roboz, GJ Barnard, J Al Ali, NH Zimmerman, C Pierce, S Batista, D Lancet, JE Padron, E Maciejewski, JP List, AF Kantarjian, HM Komrokji, RS AF Sallman, David Garcia-Manero, Guillermo Jabbour, Elias Sekeres, Mikkael A. DeZern, Amy E. Steensma, David P. Roboz, Gail J. Barnard, John Al Ali, Najla H. Zimmerman, Cassie Pierce, Sherry Batista, Denise Lancet, Jeffrey E. Padron, Eric Maciejewski, Jaroslaw P. List, Alan F. Kantarjian, Hagop M. Komrokji, Rami S. TI Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Sallman, David] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA. [Garcia-Manero, Guillermo; Pierce, Sherry; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Jabbour, Elias] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Sekeres, Mikkael A.; Barnard, John; Zimmerman, Cassie] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [DeZern, Amy E.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Steensma, David P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Roboz, Gail J.] Weill Cornell Med Coll, Div Hematol & Oncol, Dept Med, New York, NY USA. [Al Ali, Najla H.; Lancet, Jeffrey E.; Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA. [Batista, Denise] Johns Hopkins Sch Med, Baltimore, MD USA. [Padron, Eric] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Div Hematol Malignancies, Tampa, FL 33612 USA. [Maciejewski, Jaroslaw P.] Cleveland Clin, Dept Translat Hematol & Oncol Res, Taussing Canc Inst, Cleveland, OH 44106 USA. [List, Alan F.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, Tampa, FL 33612 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005183 ER PT J AU San Miguel, J Mateos, MV Shah, JJ Ocio, EM Rodriguez-Otero, P Reece, D Munshi, NC Avigan, D Ge, Y Balakumaran, A Marinello, P Orlowski, RZ Siegel, D AF San Miguel, Jesus Mateos, Maria-Victoria Shah, Jatin J. Ocio, Enrique M. Rodriguez-Otero, Paula Reece, Donna Munshi, Nikhil C. Avigan, David Ge, Yang Balakumaran, Arun Marinello, Patricia Orlowski, Robert Z. Siegel, David TI Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [San Miguel, Jesus] Univ Navarra, Clin Univ Navarra, E-31080 Pamplona, Spain. [Mateos, Maria-Victoria] Hosp Univ Salamanca IBSAL, Salamanca, Spain. [Shah, Jatin J.; Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Ocio, Enrique M.] Univ Hosp Salamanca, Salamanca, Spain. [Rodriguez-Otero, Paula] Clin Univ Navarra, Pamplona, Spain. [Reece, Donna] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada. [Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Ge, Yang; Balakumaran, Arun; Marinello, Patricia] Merck & Co Inc, Kenilworth, NJ USA. [Siegel, David] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001251 ER PT J AU Savona, MR Odenike, O Amrein, PC Steensma, DP Harb, WA DeZern, AE Michaelis, LC Faderl, S Lowder, JN Taverna, P Oganesian, A Dua, R Nawabi, R Azab, M Garcia-Manero, G AF Savona, Michael R. Odenike, Olatoyosi Amrein, Philip C. Steensma, David P. Harb, Wael A. DeZern, Amy E. Michaelis, Laura C. Faderl, Stefan Lowder, James N. Taverna, Pietro Oganesian, Aram Dua, Richa Nawabi, Roya Azab, Mohammad Garcia-Manero, Guillermo TI Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Savona, Michael R.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Odenike, Olatoyosi] Univ Chicago, Chicago, IL 60637 USA. [Amrein, Philip C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Harb, Wael A.] Horizon Oncol Ctr, Lafayette, IN USA. [DeZern, Amy E.] Johns Hopkins Univ Hosp, Baltimore, MD USA. [Michaelis, Laura C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Faderl, Stefan] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Lowder, James N.; Taverna, Pietro; Oganesian, Aram; Dua, Richa; Nawabi, Roya; Azab, Mohammad] Astex Pharmaceut Inc, Pleasanton, CA USA. [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005161 ER PT J AU Scadden, DT AF Scadden, David T. TI Heterogeneity in the Making of Blood SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 1 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000029 ER PT J AU Scott, BL Pasquini, MC Logan, B Wu, J Devine, S Porter, DL Maziarz, RT Warlick, E Fernandez, HF Alyea, EP Hamadani, M Bashey, A Giralt, SA Leifer, E Geller, N Le-Rademacher, J Mendizabal, AM Horowitz, MM Deeg, HJ Horwitz, ME AF Scott, Bart L. Pasquini, Marcelo C. Logan, Brent Wu, Juan Devine, Steve Porter, David L. Maziarz, Richard T. Warlick, Erica Fernandez, Hugo F. Alyea, Edwin P. Hamadani, Mehdi Bashey, Asad Giralt, Sergio A. Leifer, Eric Geller, Nancy Le-Rademacher, Jennifer Mendizabal, Adam M. Horowitz, Mary M. Deeg, H. Joachim Horwitz, Mitchell E. TI Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Scott, Bart L.; Deeg, H. Joachim] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Scott, Bart L.; Deeg, H. Joachim] Univ Washington, Seattle, WA 98195 USA. [Pasquini, Marcelo C.] Med Coll Wisconsin, Med, Milwaukee, WI 53226 USA. [Logan, Brent] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA. [Wu, Juan] Emmes Corp, Rockville, MD USA. [Devine, Steve] Ohio State Univ, Columbus, OH 43210 USA. [Porter, David L.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Knight Canc Inst, Adult Blood & Marrow Stem Cell Transplant Program, Portland, OR 97201 USA. [Warlick, Erica] Univ Minnesota, Minneapolis, MN USA. [Fernandez, Hugo F.] Univ S Florida, H Lee Moffitt Canc Ctr, Blood & Marrow Transplantat, Tampa, FL 33682 USA. [Alyea, Edwin P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Alyea, Edwin P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Hamadani, Mehdi] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA. [Bashey, Asad] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA. [Giralt, Sergio A.] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY 10021 USA. [Leifer, Eric; Geller, Nancy] NHLBI, Bethesda, MD 20892 USA. [Le-Rademacher, Jennifer] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Mendizabal, Adam M.] EMMES Corp, Rockville, MD USA. [Horowitz, Mary M.] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Horwitz, Mitchell E.] Duke Univ, Med Ctr, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA. NR 0 TC 15 Z9 15 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000009 ER PT J AU Sekeres, MA Zell, K Barnard, J DeZern, AE Steensma, DP Zimmerman, C Estling, C Hand, W Roboz, GJ Rizzo, N Al Ali, NH List, AF Garcia-Manero, G Maciejewski, JP Komrokji, RS AF Sekeres, Mikkael A. Zell, Katrina Barnard, John DeZern, Amy E. Steensma, David P. Zimmerman, Cassie Estling, Christopher Hand, Wesley Roboz, Gail J. Rizzo, Nicole Al Ali, Najla H. List, Alan F. Garcia-Manero, Guillermo Maciejewski, Jaroslaw P. Komrokji, Rami S. TI Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Sekeres, Mikkael A.; Zell, Katrina; Barnard, John; Zimmerman, Cassie; Estling, Christopher; Maciejewski, Jaroslaw P.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [DeZern, Amy E.; Hand, Wesley] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Steensma, David P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Roboz, Gail J.; Rizzo, Nicole] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. [Al Ali, Najla H.; List, Alan F.; Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA. [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005174 ER PT J AU Sekeres, MA Othus, M List, AF Odenike, O Stone, RM Gore, SD Litzow, MR Buckstein, R Fang, M Roulston, D Bloomfield, CD Zhang, YM Velasco, MR Gaur, R Atallah, E Attar, EC Appelbaum, FR Erba, HP AF Sekeres, Mikkael A. Othus, Megan List, Alan F. Odenike, Olatoyosi Stone, Richard M. Gore, Steven D. Litzow, Mark R. Buckstein, Rena Fang, Min Roulston, Diane Bloomfield, Clara D. Zhang, Yanming Velasco, Mario R. Gaur, Rakesh Atallah, Ehab Attar, Eyal C. Appelbaum, Frederick R. Erba, Harry P. TI Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Sekeres, Mikkael A.] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA. [Othus, Megan] SWOG Stat Ctr, Seattle, WA USA. [List, Alan F.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, Tampa, FL 33612 USA. [Odenike, Olatoyosi] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Stone, Richard M.] Dana Farber Canc Inst, Hematol Oncol, Boston, MA 02115 USA. [Gore, Steven D.] Yale Canc Ctr, New Haven, CT USA. [Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, MN USA. [Buckstein, Rena] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Hematol Oncol, Toronto, ON M4N 3M5, Canada. [Fang, Min] Seattle Canc Care Alliance, Seattle, WA USA. [Roulston, Diane] Univ Michigan, Cytogenet Lab, Pathol, Ann Arbor, MI 48109 USA. [Bloomfield, Clara D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Zhang, Yanming] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA. [Velasco, Mario R.] Heartland NCORP, Canc Care Specialists Cent Illinois, Decatur, IL USA. [Gaur, Rakesh] Kansas City NCORP, Prairie Village, KS USA. [Atallah, Ehab] Med Coll Wisconsin, Dept Hematol Oncol, Milwaukee, WI 53226 USA. [Attar, Eyal C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Erba, Harry P.] Univ Alabama Birmingham, Birmingham, AL USA. [Erba, Harry P.] UAB Comprehens Canc Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003032 ER PT J AU Shaffer, BC Ahn, KW Hu, ZH Popat, UR Kalaycio, M Maziarz, RT Alyea, E Sobecks, RM Pavletic, SZ Tallman, MS Saber, W AF Shaffer, Brian C. Ahn, Kwang Woo Hu, Zhen-Huan Popat, Uday R. Kalaycio, Matt Maziarz, Richard T. Alyea, Edwin Sobecks, Ron M. Pavletic, Steven Z. Tallman, Martin S. Saber, Wael TI A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Shaffer, Brian C.] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplant Serv, Dept Med, 1275 York Ave, New York, NY 10021 USA. [Ahn, Kwang Woo; Saber, Wael] Med Coll Wisconsin, CIBMTR, Dept Med, Milwaukee, WI 53226 USA. [Hu, Zhen-Huan] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Popat, Uday R.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. [Kalaycio, Matt] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Knight Canc Inst, Adult Blood & Marrow Stem Cell Transplant Program, Portland, OR 97201 USA. [Alyea, Edwin] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA. [Sobecks, Ron M.] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA. [Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000128 ER PT J AU Shatzel, J Azar, S Gay, ND Luo, J Deloughery, TG Recht, M Taylor, JA AF Shatzel, Joseph Azar, Sharl Gay, Nathanael David Luo, Jai Deloughery, Thomas G. Recht, Michael Taylor, Jason A. TI The Clinical Associations and Outcomes of Patients Admitted with Acquired Hemophilia; A Review of the 2012 National Inpatient Sample SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Shatzel, Joseph] Oregon Hlth & Sci Univ, Dept Hematol Oncol, Portland, OR 97201 USA. [Azar, Sharl; Recht, Michael; Taylor, Jason A.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA. [Azar, Sharl] Portland VA Med Ctr, Portland, OR USA. [Gay, Nathanael David; Deloughery, Thomas G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Luo, Jai] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003215 ER PT J AU Shemer, OS Byrska-Bishop, M Ulirsch, JC Abdulmalik, O Yao, Y Kim, AR Gadue, P Kingsley, PD French, D Hardison, RC Palis, J Sankaran, VG Weiss, MJ AF Shemer, Orna Steinberg Byrska-Bishop, Marta Ulirsch, Jacob C. Abdulmalik, Osheiza Yao, Yu Kim, Ah Ram Gadue, Paul Kingsley, Paul D. French, Deborah Hardison, Ross C. Palis, James Sankaran, Vijay G. Weiss, Mitchell J. TI Temporally Distinct Developmental Waves of Erythropoiesis from Human Pluripotent Stem Cells SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Shemer, Orna Steinberg; Weiss, Mitchell J.] Childrens Hosp Philadelphia, Pediat, Philadelphia, PA 19104 USA. [Byrska-Bishop, Marta; Hardison, Ross C.] Penn State Univ, State Coll, PA USA. [Ulirsch, Jacob C.; Kim, Ah Ram; Sankaran, Vijay G.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Ulirsch, Jacob C.; Kim, Ah Ram; Sankaran, Vijay G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Abdulmalik, Osheiza; Gadue, Paul; French, Deborah] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA. [Yao, Yu; Weiss, Mitchell J.] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN 38105 USA. [Kingsley, Paul D.; Palis, James] Univ Rochester, Pediat, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003294 ER PT J AU Shin, TH Sweetser, DA AF Shin, Thomas H. Sweetser, David A. TI Loss of the TLE4 AML Tumor Suppressor Gene Contributes to Leukemic Cell Proliferation, Differentiation Arrest, and Chemotherapy Resistance through a COX-Dependent Inflammatory Pathway SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Shin, Thomas H.] Boston Univ, Sch Med, Dept Mol & Translat Med, Boston, MA 02118 USA. [Shin, Thomas H.; Sweetser, David A.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004041 ER PT J AU Shirai, CL Tripathi, M Ley, JN Ndonwi, M White, BS Tapia, R Saez, B Bertino, A Shao, J Kim, S Webb, TR Graubert, TA Walter, MJ AF Shirai, Cara Lunn Tripathi, Manorama Ley, James N. Ndonwi, Matthew White, Brian S. Tapia, Roberto Saez, Borja Bertino, Amy Shao, Jin Kim, Sanghyun Webb, Thomas R. Graubert, Timothy A. Walter, Matthew J. TI Preclinical Activity of Splicing Modulators in U2AF1 Mutant MDS/AML SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Shirai, Cara Lunn; Tripathi, Manorama; Ley, James N.; Tapia, Roberto; Kim, Sanghyun] Washington Univ, St Louis, MO USA. [Ndonwi, Matthew] Washington Univ, Sch Med, Oncol Stem Cell Biol, St Louis, MO USA. [White, Brian S.] Washington Univ, Sch Med, St Louis, MO USA. [Saez, Borja] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Saez, Borja] Massachusetts Gen Hosp, Ctr Regenerat Med, Cambridge, MA USA. [Saez, Borja] Harvard Stem Cell Inst, Cambridge, MA USA. [Bertino, Amy] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Shao, Jin; Walter, Matthew J.] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Webb, Thomas R.] SRI Int, Menlo Pk, CA 94025 USA. [Graubert, Timothy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005131 ER PT J AU Short, NJ Garcia-Manero, G Bravo, GM Sasaki, K Sekeres, MA Komrokji, RS Steensma, DP DeZern, AE Roboz, GJ Kadia, T Borthakur, G DiNardo, C Miller, D Estrov, Z Pemmaraju, N Daver, N Verstovsek, S Kantarjian, HM Jabbour, E AF Short, Nicholas J. Garcia-Manero, Guillermo Bravo, Guillermo Montalban Sasaki, Koji Sekeres, Mikkael A. Komrokji, Rami S. Steensma, David P. DeZern, Amy E. Roboz, Gail J. Kadia, Tapan Borthakur, Gautam DiNardo, Courtney Miller, Darla Estrov, Zeev Pemmaraju, Naveen Daver, Naval Verstovsek, Srdan Kantarjian, Hagop M. Jabbour, Elias TI Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low-or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Short, Nicholas J.; Garcia-Manero, Guillermo; Bravo, Guillermo Montalban; Sasaki, Koji; Kadia, Tapan; Borthakur, Gautam; DiNardo, Courtney; Miller, Darla; Estrov, Zeev; Pemmaraju, Naveen; Daver, Naval; Verstovsek, Srdan; Kantarjian, Hagop M.; Jabbour, Elias] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Sekeres, Mikkael A.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA. [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [DeZern, Amy E.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Roboz, Gail J.] Weill Cornell Med Coll, Joan & Sanford I Weill Dept Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000158 ER PT J AU Shulman, DS Mehrotra, P Surana, NK Blonquist, TM Silverman, LB Place, AE AF Shulman, David S. Mehrotra, Preeti Surana, Neeraj K. Blonquist, Traci M. Silverman, Lewis B. Place, Andrew E. TI Bacillus Infection Among Children with Hematologic Malignancy, a Single Institution Experience SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Shulman, David S.; Place, Andrew E.] Boston Childrens Hosp, Boston, MA USA. [Mehrotra, Preeti; Surana, Neeraj K.] Boston Childrens Hosp, Div Infect Dis, Boston, MA USA. [Blonquist, Traci M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Silverman, Lewis B.; Place, Andrew E.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004092 ER PT J AU Silberstein, L Kharchenko, PV Kfoury, YS Mercier, F Turcotte, R Lin, CP Baryawno, N Severe, N Tate, T Hoggatt, J Scadden, DT AF Silberstein, Lev Kharchenko, Peter V. Kfoury, Youmna Sami Mercier, Francois Turcotte, Raphael Lin, Charles P. Baryawno, Ninib Severe, Nicolas Tate, Tiffany Hoggatt, Jonathan Scadden, David T. TI Embigin Regulates HSPC Homing and Quiescence and Acts As a Cell Surface Marker for a Niche Factor-Enriched Subset of Osteolineage Cells SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Silberstein, Lev; Kfoury, Youmna Sami; Baryawno, Ninib; Severe, Nicolas; Hoggatt, Jonathan] Harvard Stem Cell Inst, Cambridge, England. [Silberstein, Lev; Turcotte, Raphael; Lin, Charles P.; Severe, Nicolas; Hoggatt, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kharchenko, Peter V.] Harvard Univ, Sch Med, Dept Biomed Informat, Boston, MA USA. [Mercier, Francois] Harvard Univ, Harvard Stem Cell Inst, Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Tate, Tiffany; Scadden, David T.] Harvard Univ, Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Scadden, David T.] Harvard Stem Cell Inst, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002100 ER PT J AU Sohani, AR Pitcher, B Chadburn, A Said, JW Martin, P Czuczman, MS Bartlett, NL Rosenbaum, CA Leonard, JP Cheson, BD Hsi, ED AF Sohani, Aliyah R. Pitcher, Brandy Chadburn, Amy Said, Jonathan W. Martin, Peter Czuczman, Myron S. Bartlett, Nancy L. Rosenbaum, Cara A. Leonard, John P. Cheson, Bruce D. Hsi, Eric D. TI Interfollicular CD10 Expression and Follicular PD1 Tumor -Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Sohani, Aliyah R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Pitcher, Brandy] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA. [Chadburn, Amy] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA. [Said, Jonathan W.] Univ Calif Los Angeles, Med Ctr, Dept Pathol, Los Angeles, CA 90024 USA. [Martin, Peter] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA. [Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA. [Rosenbaum, Cara A.] Univ Chicago, Chicago, IL 60637 USA. [Leonard, John P.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Cheson, Bruce D.] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Hsi, Eric D.] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Lab Med, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001086 ER PT J AU Song, Y Ray, A Sharma, D Chauhan, D Anderson, KC AF Song, Yan Ray, Arghya Sharma, Deepika Chauhan, Dharminder Anderson, Kenneth C. TI Targeting 19S-Proteasome Deubiquitinase Rpn11/POH1/PSMD14 in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Song, Yan; Ray, Arghya; Sharma, Deepika; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA. [Song, Yan; Ray, Arghya; Sharma, Deepika; Chauhan, Dharminder] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005289 ER PT J AU Sorror, ML Storer, BE Elsawy, M Fathi, AT Brunner, A Gerds, AT Sekeres, MA Mukherjee, S Medeiros, BC Shami, P Pena, E Wardyn, S Whitten, J Frenkel, H McCune, J Lee, SJ Estey, EH AF Sorror, Mohamed L. Storer, Barry E. Elsawy, Mahmoud Fathi, Amir T. Brunner, Andrew Gerds, Aaron T. Sekeres, Mikkael A. Mukherjee, Sudipto Medeiros, Bruno C. Shami, Paul Pena, Esteban Wardyn, Shylo Whitten, Jennifer Frenkel, Hannah McCune, Jeannine Lee, Stephanie J. Estey, Elihu H. TI Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Sorror, Mohamed L.; McCune, Jeannine; Estey, Elihu H.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Storer, Barry E.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Elsawy, Mahmoud; Wardyn, Shylo; Whitten, Jennifer; Frenkel, Hannah] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Fathi, Amir T.; Brunner, Andrew] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Gerds, Aaron T.; Sekeres, Mikkael A.; Mukherjee, Sudipto] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Medeiros, Bruno C.] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA. [Shami, Paul; Pena, Esteban] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001278 ER PT J AU Stein, AS Walter, RB Erba, HP Fathi, AT Advani, AS Lancet, JE Ravandi, F Kovacsovics, TJ DeAngelo, DJ Bixby, D Faderl, S Jillella, AP O'Meara, MM Zhao, BT Stein, EM AF Stein, Anthony S. Walter, Roland B. Erba, Harry P. Fathi, Amir T. Advani, Anjali S. Lancet, Jeffrey E. Ravandi, Farhad Kovacsovics, Tibor J. DeAngelo, Daniel J. Bixby, Dale Faderl, Stefan Jillella, Anand P. O'Meara, Megan M. Zhao, Baiteng Stein, Eytan M. TI A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Stein, Anthony S.] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, Duarte, CA 91010 USA. [Walter, Roland B.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Erba, Harry P.] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA. [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. [Advani, Anjali S.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Lancet, Jeffrey E.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA. [Ravandi, Farhad] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Kovacsovics, Tibor J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Bixby, Dale] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Faderl, Stefan] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Jillella, Anand P.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [O'Meara, Megan M.] Seattle Genet Inc, Clin Dev, Bothell, WA USA. [Zhao, Baiteng] Seattle Genet Inc, Bothell, WA USA. [Stein, Eytan M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001076 ER PT J AU Stein, EM DiNardo, C Altman, JK Collins, R DeAngelo, DJ Kantarjian, HM Sekeres, MA Fathi, AT Flinn, IW Frankel, AE Levine, RL Medeiros, BC Patel, MR Pollyea, D Roboz, GJ Stone, RM Swords, RT Tallman, MS Yen, K Attar, EC Xu, Q Tosolini, A Mei, JM Thakurta, A Knight, RD De Botton, S AF Stein, Eytan M. DiNardo, Courtney Altman, Jessica K. Collins, Robert DeAngelo, Daniel J. Kantarjian, Hagop M. Sekeres, Mikkael A. Fathi, Amir T. Flinn, Ian W. Frankel, Arthur E. Levine, Ross L. Medeiros, Bruno C. Patel, Manish R. Pollyea, Daniel Roboz, Gail J. Stone, Richard M. Swords, Ronan T. Tallman, Martin S. Yen, Katherine Attar, Eyal C. Xu, Qiang Tosolini, Alessandra Mei, Jay M. Thakurta, Anjan Knight, Robert D. De Botton, Stephane TI Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Stein, Eytan M.; Levine, Ross L.; Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [DiNardo, Courtney] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Altman, Jessica K.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Collins, Robert; Frankel, Arthur E.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [DeAngelo, Daniel J.; Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Sekeres, Mikkael A.] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH 44106 USA. [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA. [Medeiros, Bruno C.] Stanford Univ, Stanford Comprehens Canc Ctr, Div Hematol Oncol, Stanford, CA 94305 USA. [Patel, Manish R.] Sarah Cannon Res Inst, Florida Canc Specialists, Sarasota, FL USA. [Pollyea, Daniel] Univ Colorado, Sch Med, Div Hematol, Aurora, CO USA. [Roboz, Gail J.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. [Swords, Ronan T.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA. [Yen, Katherine; Attar, Eyal C.] Agios Pharmaceut, Cambridge, MA USA. [Xu, Qiang; Tosolini, Alessandra; Mei, Jay M.; Thakurta, Anjan; Knight, Robert D.] Celgene Corp, Summit, NJ USA. [De Botton, Stephane] Gustave Roussy, Clin Hematol, Villejuif, France. NR 0 TC 13 Z9 13 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 5 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001075 ER PT J AU Stilgenbauer, S Jones, JA Coutre, S Mato, AR Hillmen, P Tam, C Osterborg, A Siddiqi, T Thirman, MJ Furman, RR Ilhan, O Keating, M Call, TG Brown, JR Li, YF Eckert, K Chang, BY James, DF Chu, AD Hallek, M O'Brien, S AF Stilgenbauer, Stephan Jones, Jeffrey A. Coutre, Steven Mato, Anthony R. Hillmen, Peter Tam, Constantine Osterborg, Anders Siddiqi, Tanya Thirman, Michael J. Furman, Richard R. Ilhan, Osman Keating, Michael Call, Timothy G. Brown, Jennifer R. Li, Yunfeng Eckert, Karl Chang, Betty Y. James, Danelle F. Chu, Alvina D. Hallek, Michael O'Brien, Susan TI Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Stilgenbauer, Stephan] Univ Ulm Klinikum, Klin Innere Med 2, Ulm, Germany. [Jones, Jeffrey A.] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA. [Coutre, Steven] Stanford Univ, Sch Med, Stanford Canc Ctr, Div Hematol, Stanford, CA 94305 USA. [Mato, Anthony R.] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Mato, Anthony R.] Univ Penn, Dept Pathol & Lab Med, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA USA. [Hillmen, Peter] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England. [Tam, Constantine] Peter MacCallum Canc Ctr, East Melbourne, Australia. [Osterborg, Anders] Karolinska Univ Hosp Solna, Dept Hematol, Stockholm, Sweden. [Siddiqi, Tanya] City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. [Thirman, Michael J.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Furman, Richard R.] New York Presbyterian Weill Cornell Med Ctr, New York, NY USA. [Ilhan, Osman] Ankara Univ, Fac Med, TR-06100 Ankara, Turkey. [Keating, Michael; O'Brien, Susan] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Call, Timothy G.] Mayo Clin, Div Hematol, Rochester, MN USA. [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Li, Yunfeng; Eckert, Karl; Chang, Betty Y.; James, Danelle F.; Chu, Alvina D.] Pharmacycl LLC, Sunnyvale, CA USA. [Hallek, Michael] Univ Cologne, CECAD, CIO, Dept Internal Med 1, D-50931 Cologne, Germany. RI Jones, Jeffrey/E-3321-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002270 ER PT J AU Stone, RM Mandrekar, S Sanford, BL Geyer, S Bloomfield, CD Dohner, K Thiede, C Marcucci, G Lo-Coco, F Klisovic, RB Wei, A Sierra, J Sanz, MA Brandwein, JM de Witte, T Niederwieser, D Appelbaum, FR Medeiros, BC Tallman, MS Krauter, J Schlenk, RF Ganser, A Serve, H Ehninger, G Amadori, S Larson, RA Dohner, H AF Stone, Richard M. Mandrekar, Sumithra Sanford, Ben L. Geyer, Susan Bloomfield, Clara D. Dohner, Konstanze Thiede, Christian Marcucci, Guido Lo-Coco, Francesco Klisovic, Rebecca B. Wei, Andrew Sierra, Jorge Sanz, Miguel A. Brandwein, Joseph M. de Witte, Theo Niederwieser, Dietger Appelbaum, Frederick R. Medeiros, Bruno C. Tallman, Martin S. Krauter, Jurgen Schlenk, Richard F. Ganser, Arnold Serve, Hubert Ehninger, Gerhard Amadori, Sergio Larson, Richard A. Dohner, Hartmut TI The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Mandrekar, Sumithra] Mayo Clin, Rochester, MN USA. [Sanford, Ben L.] Duke Univ, Durham, NC USA. [Geyer, Susan] Ohio State Univ, Alliance Stat & Data Ctr, Columbus, OH 43210 USA. [Geyer, Susan] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA. [Bloomfield, Clara D.; Marcucci, Guido] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Dohner, Konstanze; Schlenk, Richard F.; Dohner, Hartmut] Univ Hosp Ulm, Ulm, Germany. [Thiede, Christian; Ehninger, Gerhard] Univ Hosp TU Dresden, Dept Med 1, Dresden, Germany. [Lo-Coco, Francesco] Tor Vergata Univ Hosp, Rome, Italy. [Klisovic, Rebecca B.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA. [Wei, Andrew] Alfred Hosp, Haematol, Melbourne, Vic, Australia. [Sierra, Jorge] Autonomous Univ Barcelona, Dept Hematol, Hosp Santa Creu & St Pau, Barcelona, Spain. [Sanz, Miguel A.] Hosp Univ Fe, Valencia, Spain. [Brandwein, Joseph M.] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada. [de Witte, Theo] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. [Niederwieser, Dietger] Univ Leipzig, Hematol & Oncol, D-04109 Leipzig, Germany. [Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Transplantat Biol Dept, Seattle, WA 98104 USA. [Medeiros, Bruno C.] Stanford Univ, Stanford Comprehens Canc Ctr, Div Hematol Oncol, Stanford, CA 94305 USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. [Krauter, Jurgen] Hannover Med Sch, Hannover, Germany. [Ganser, Arnold] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany. [Serve, Hubert] Goethe Univ Hosp Frankfurt, Hematol Oncol, Dept Med 2, Frankfurt, Germany. [Amadori, Sergio] Univ Roma Tor Vergata, Hematol, Rome, Italy. [Larson, Richard A.] Univ Chicago, Med, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 2 U2 6 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 5 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000070 ER PT J AU Sulis, ML Blonquist, TM Athale, UH Clavell, LA Cole, PD Kelly, KM Laverdiere, C Leclerc, JM Michon, B Schorin, MA Welch, JJG Neuberg, DS Sallan, SE Silverman, LB AF Sulis, Maria Luisa Blonquist, Traci M. Athale, Uma H. Clavell, Luis A. Cole, Peter D. Kelly, Kara M. Laverdiere, Caroline Leclerc, Jean-Marie Michon, Bruno Schorin, Marshall A. Welch, Jennifer J. G. Neuberg, Donna S. Sallan, Stephen E. Silverman, Lewis B. TI Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Sulis, Maria Luisa] Columbia Univ, Div Pediat Hematol Oncol & Stem Cell Transplant, New York, NY USA. [Blonquist, Traci M.; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Athale, Uma H.] McMaster Childrens Hosp, Hamilton Hlth Sci, Div Hematol Oncol, Hamilton, ON, Canada. [Clavell, Luis A.] San Jorge Childrens Hosp, San Juan, PR USA. [Cole, Peter D.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Kelly, Kara M.] Columbia Univ, Med Ctr, Pediat Hematol Oncol Stem Cell Transplantat, New York, NY USA. [Laverdiere, Caroline; Leclerc, Jean-Marie] Univ Montreal, St Justine Univ Hosp, Charles Bruneau Canc Ctr, Div Hematol Oncol, Montreal, PQ, Canada. [Michon, Bruno] Ctr Hosp Univ Quebec, Ste Foy, PQ, Canada. [Schorin, Marshall A.] Inova Fairfax Hosp Children, Falls Church, VA USA. [Welch, Jennifer J. G.] Brown Univ, Hasbro Childrens Hosp, Pediat Hematol Oncol, Providence, RI 02912 USA. [Sallan, Stephen E.; Silverman, Lewis B.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Sallan, Stephen E.; Silverman, Lewis B.] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001001 ER PT J AU Tai, YT Acharya, C An, G Moschetta, M Zhong, MK Feng, XY van Eenennaam, H van Elsas, A Qiu, LG Munshi, NC Anderson, KC AF Tai, Yu-Tzu Acharya, Chirag An, Gang Moschetta, Michele Zhong, Mike Feng, Xiaoyan van Eenennaam, Hans van Elsas, Andrea Qiu, Lugui Munshi, Nikhil C. Anderson, Kenneth C. TI APRIL/B Cell Maturation Antigen (BCMA) Signaling Cascades Promote Human Multiple Myeloma Growth and Mediate Immunosuppression in the Bone Marrow Microenvironment Via IL-10, TGF-b, and PD-L1 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Tai, Yu-Tzu; Acharya, Chirag; An, Gang; Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Moschetta, Michele] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Zhong, Mike] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Feng, Xiaoyan; Qiu, Lugui] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China. [Feng, Xiaoyan; Qiu, Lugui] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China. [Feng, Xiaoyan; Qiu, Lugui] Peking Union Med Coll, Tianjin, Peoples R China. [van Eenennaam, Hans; van Elsas, Andrea] BioNovion, NL-5342 Oss, Netherlands. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005288 ER PT J AU Takagi, S Tsukamoto, S Kawano, Y Moschetta, M Mishima, Y Kokubun, K Manier, S Salem, K Huynh, D Sacco, A Roccaro, AM Johnson, KE Battinelli, EM Ghobrial, IM AF Takagi, Satoshi Tsukamoto, Shokichi Kawano, Yawara Moschetta, Michele Mishima, Yuji Kokubun, Katsutoshi Manier, Salomon Salem, Karma Huynh, Daisy Sacco, Antonio Roccaro, Aldo M. Johnson, Kelly Elizabeth Battinelli, Elisabeth M. Ghobrial, Irene M. TI Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Takagi, Satoshi; Tsukamoto, Shokichi; Kawano, Yawara; Moschetta, Michele; Mishima, Yuji; Kokubun, Katsutoshi; Manier, Salomon; Salem, Karma; Huynh, Daisy; Sacco, Antonio; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Johnson, Kelly Elizabeth; Battinelli, Elisabeth M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Hematol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005271 ER PT J AU Tesar, B Improgo, R Klitgaard, JL Magori-Cohen, R Yu, LJ Chaudhary, D Miao, WY Fernandes, SM Hoang, K Westlin, WF Kim, HT Brown, JR AF Tesar, Bethany Improgo, Reina Klitgaard, Josephine L. Magori-Cohen, Reuma Yu, Lijian Chaudhary, Divya Miao, Wenyan Fernandes, Stacey M. Hoang, Kevin Westlin, William F. Kim, Haesook T. Brown, Jennifer R. TI MYD88 L265P Mutations Influence Clinical Outcome and Identify a Pathway for Targeted Inhibition in Chronic Lymphocytic Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Tesar, Bethany; Improgo, Reina; Yu, Lijian; Hoang, Kevin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Tesar, Bethany; Improgo, Reina; Klitgaard, Josephine L.; Yu, Lijian; Brown, Jennifer R.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Klitgaard, Josephine L.; Fernandes, Stacey M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Magori-Cohen, Reuma] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Magori-Cohen, Reuma] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Chaudhary, Divya; Miao, Wenyan; Westlin, William F.] Nimbus Therapeut Inc, Cambridge, MA USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Brown, Jennifer R.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001237 ER PT J AU Townsend, EC DeSouza, T Murakami, MA Montero, J Stevenson, K Christie, AL Christodolou, AN Vojinovic, U Kopp, N Barzagbi-Rinaudo, P Murakami, M Letai, A Jeay, S Wuerthner, J Halilovic, E Weinstock, DM AF Townsend, Elizabeth C. DeSouza, Tiffany Murakami, Mark A. Montero, Joan Stevenson, Kristen Christie, Amanda L. Christodolou, Alexandra N. Vojinovic, Una Kopp, Nadja Barzagbi-Rinaudo, Patrizia Murakami, Masato Letai, Anthony Jeay, Sebastien Wuerthner, Jens Halilovic, Ensar Weinstock, David M. TI The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Townsend, Elizabeth C.; Montero, Joan; Christodolou, Alexandra N.; Vojinovic, Una] Dana Farber Canc Inst, Boston, MA 02115 USA. [DeSouza, Tiffany; Murakami, Mark A.; Christie, Amanda L.; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Stevenson, Kristen] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Kopp, Nadja; Weinstock, David M.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Barzagbi-Rinaudo, Patrizia; Murakami, Masato] Novartis Inst Biomed Res, Basel, Switzerland. [Jeay, Sebastien; Wuerthner, Jens] Novartis Pharma AG, Basel, Switzerland. [Halilovic, Ensar] Novartis Inst BioMed Res, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002234 ER PT J AU Treon, SP Meid, K Gustine, J Patterson, CJ Matous, JV Ghobrial, IM Castillo, JJ AF Treon, Steven P. Meid, Kirsten Gustine, Joshua Patterson, Christopher J. Matous, Jeffrey V. Ghobrial, Irene M. Castillo, Jorge J. TI Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Treon, Steven P.; Meid, Kirsten; Gustine, Joshua; Patterson, Christopher J.] Dana Farber Canc Inst, Bing Ctr WM, Boston, MA 02115 USA. [Matous, Jeffrey V.] Colorado Blood Canc Inst, Denver, CO USA. [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Castillo, Jorge J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005311 ER PT J AU Ujjani, CS Jung, SH Pitcher, B Martin, P Park, SI Blum, KA Smith, SM Czuczman, MS Davids, MS Leonard, JP Cheson, BD AF Ujjani, Chaitra S. Jung, Sin-Ho Pitcher, Brandelyn Martin, Peter Park, Steven I. Blum, Kristie A. Smith, Sonali M. Czuczman, Myron S. Davids, Matthew S. Leonard, John P. Cheson, Bruce D. TI Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Ujjani, Chaitra S.; Cheson, Bruce D.] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Jung, Sin-Ho] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA. [Pitcher, Brandelyn] Duke Univ, Med Ctr, Durham, NC USA. [Martin, Peter] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA. [Park, Steven I.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Blum, Kristie A.] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA. [Smith, Sonali M.] Univ Chicago, Chicago, IL 60637 USA. [Czuczman, Myron S.] Celgene Corp, Summit, NJ USA. [Davids, Matthew S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Leonard, John P.] Weill Cornell Med Coll, Dept Med, New York, NY USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001217 ER PT J AU Usmani, S Weiss, B Bahlis, NJ Belch, A Lonial, S Lokhorst, H Voorhees, PM Richardson, PG Sasser, AK Axel, A Feng, HB Uhlar, C Wang, JP Khan, I Ahmadi, T Nahi, H AF Usmani, Saad Weiss, Brendan Bahlis, Nizar J. Belch, Andrew Lonial, Sagar Lokhorst, Henk Voorhees, Peter M. Richardson, Paul G. Sasser, A. Kate Axel, Amy Feng, Huaibao Uhlar, Clarissa Wang, Jianping Khan, Imran Ahmadi, Tahamtan Nahi, Hareth TI Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Usmani, Saad] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA. [Weiss, Brendan] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Weiss, Brendan] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Bahlis, Nizar J.] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada. [Belch, Andrew] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. [Lonial, Sagar] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. [Lokhorst, Henk] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands. [Voorhees, Peter M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol Oncol, Chapel Hill, NC 27599 USA. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Sasser, A. Kate; Axel, Amy; Uhlar, Clarissa; Wang, Jianping; Khan, Imran; Ahmadi, Tahamtan] Janssen Res & Dev LLC, Spring House, PA USA. [Feng, Huaibao] Janssen Res & Dev LLC, Raritan, NJ USA. [Nahi, Hareth] Karolinska Inst, Dept Med, Div Hematol, Karolinska Univ Hosp Huddinge, Stockholm, Sweden. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000093 ER PT J AU Uy, GL Duncavage, EJ Chang, GS Jacoby, MA Miller, CA Shao, J Heath, S Fulton, RS Fronick, CC O'Laughlin, M Abboud, CN Cashen, AF DiPersio, JF Wilson, RK Link, DC Welch, JS Westervelt, P Ley, TJ Graubert, TA Walter, MJ AF Uy, Geoffrey L. Duncavage, Eric J. Chang, Gue Su Jacoby, Meagan A. Miller, Christopher A. Shao, Jin Heath, Sharon Fulton, Robert S. Fronick, Catrina C. O'Laughlin, Michelle Abboud, Camille N. Cashen, Amanda F. DiPersio, John F. Wilson, Richard K. Link, Daniel C. Welch, John S. Westervelt, Peter Ley, Timothy J. Graubert, Timothy A. Walter, Matthew J. TI Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Uy, Geoffrey L.; Jacoby, Meagan A.; Shao, Jin; Heath, Sharon; Abboud, Camille N.; Cashen, Amanda F.; DiPersio, John F.; Welch, John S.; Westervelt, Peter; Ley, Timothy J.; Walter, Matthew J.] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Duncavage, Eric J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA. [Chang, Gue Su; Miller, Christopher A.; Fulton, Robert S.; Fronick, Catrina C.; O'Laughlin, Michelle; Wilson, Richard K.] Washington Univ, Sch Med, McDonnell Genome Inst, St Louis, MO USA. [Link, Daniel C.] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA. [Graubert, Timothy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002047 ER PT J AU Uy, GL Mandrekar, S Laumann, K Sanford, B Marcucci, G Zhao, WQ Levis, MJ Klepin, HD Baer, MR Powell, BL Westervelt, P DeAngelo, DJ Stock, W Bloomfield, CD Byrd, JC Stone, RM Larson, RA AF Uy, Geoffrey L. Mandrekar, Sumithra Laumann, Kristina Sanford, Ben Marcucci, Guido Zhao, Weiqiang Levis, Mark J. Klepin, Heidi D. Baer, Maria R. Powell, Bayard L. Westervelt, Peter DeAngelo, Daniel J. Stock, Wendy Bloomfield, Clara D. Byrd, John C. Stone, Richard M. Larson, Richard A. TI Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Uy, Geoffrey L.; Westervelt, Peter] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Mandrekar, Sumithra; Laumann, Kristina] Mayo Clin, Rochester, MN USA. [Sanford, Ben] Duke Univ, Durham, NC USA. [Marcucci, Guido] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Zhao, Weiqiang; Bloomfield, Clara D.; Byrd, John C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Levis, Mark J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Klepin, Heidi D.; Powell, Bayard L.] Wake Forest Sch Med, Ctr Comprehens Canc, Winston Salem, NC USA. [Baer, Maria R.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stock, Wendy; Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA. [Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001071 ER PT J AU Vardanyan, S Meid, K Udd, KA Wang, J Li, MJ Sanchez, E Wang, C Gillespie, A Spitzer, M Spektor, TM Shvartsur, A Harutyunyan, NM Garzio, G Tang, G Chen, HM Treon, SP Berenson, J AF Vardanyan, Suzie Meid, Kirsten Udd, Kyle A. Wang, James Li, Mingjie Sanchez, Eric Wang, Cathy Gillespie, Abigail Spitzer, Maya Spektor, Tanya M. Shvartsur, Anna Harutyunyan, Nika Manik Garzio, Gigi Tang, George Chen, Haiming Treon, Steven P. Berenson, James TI Serum Levels of B-Cell Maturation Antigen Are Elevated in Waldenstrom's Macroglobulinemia Patients and Correlate with Disease Status and Conventional M-Protein and IgM Levels SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Vardanyan, Suzie; Li, Mingjie; Sanchez, Eric; Wang, Cathy; Gillespie, Abigail; Shvartsur, Anna; Garzio, Gigi; Tang, George; Chen, Haiming; Berenson, James] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA. [Meid, Kirsten; Treon, Steven P.] Dana Farber Canc Inst, Bing Ctr WM, Boston, MA 02115 USA. [Udd, Kyle A.; Wang, James; Spitzer, Maya; Harutyunyan, Nika Manik; Berenson, James] James R Berenson MD Inc, West Hollywood, CA USA. [Spektor, Tanya M.; Berenson, James] Oncotherapeutics Inc, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005256 ER PT J AU Verstovsek, S Mesa, RA Foltz, LM Gupta, V Mascarenhas, JO Ritchie, EK Hoffman, R Silver, RT Kremyanskaya, M Pozdnyakova, O Hasserjian, RP Trehu, E Salama, ME Kantarjian, HM Gotlib, J AF Verstovsek, Srdan Mesa, Ruben A. Foltz, Lynda M. Gupta, Vikas Mascarenhas, John O. Ritchie, Ellen K. Hoffman, Ronald Silver, Richard T. Kremyanskaya, Marina Pozdnyakova, Olga Hasserjian, Robert P. Trehu, Elizabeth Salama, Mohamed E. Kantarjian, Hagop M. Gotlib, Jason TI PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Verstovsek, Srdan; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Mesa, Ruben A.] Mayo Clin Arizona, Hematol Oncol, Scottsdale, AZ USA. [Foltz, Lynda M.] St Pauls Hosp, Hematol, Vancouver, BC V6Z 1Y6, Canada. [Foltz, Lynda M.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Gupta, Vikas] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Mascarenhas, John O.; Hoffman, Ronald] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA. [Ritchie, Ellen K.] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA. [Silver, Richard T.] Weill Cornell Med Coll, New York, NY USA. [Kremyanskaya, Marina] Icahn Schoool Med Mt Sinai, Tisch Canc Inst, Myeloproliferat Res Consortium, Myeloproliferat Program, New York, NY USA. [Pozdnyakova, Olga] Brigham & Womens Hosp, Pathol, Boston, MA 02115 USA. [Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Trehu, Elizabeth] Promedior Inc, Lexington, MA USA. [Salama, Mohamed E.] Univ Utah, Dept Pathol, Salt Lake City, UT USA. [Gotlib, Jason] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000120 ER PT J AU Vindi, J Kridel, R Staiger, AM Szczepanowski, M Horn, H Dreyling, MH Rosenwald, A Ott, G Klapper, W Zelenetz, AD Friedberg, JW Ansell, S Sehn, LH Connors, JM Gascoyne, RD Weinstock, DM Hiddemann, W Unterhalt, M Hoster, E Weigert, O AF Vindi, Jurinovic Kridel, Robert Staiger, Annette M. Szczepanowski, Monika Horn, Heike Dreyling, Martin H. Rosenwald, Andreas Ott, German Klapper, Wolfram Zelenetz, Andrew D. Friedberg, Jonathan W. Ansell, Stephen Sehn, Laurie H. Connors, Joseph M. Gascoyne, Randy D. Weinstock, David M. Hiddemann, Wolfgang Unterhalt, Michael Hoster, Eva Weigert, Oliver TI A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Vindi, Jurinovic; Dreyling, Martin H.; Hoster, Eva] Univ Munich, Univ Hosp, Dept Med 3, Munich, Germany. [Vindi, Jurinovic; Hoster, Eva] Univ Munich, Univ Hosp, Inst Med Informat Biometry & Epidemiol, Munich, Germany. [Kridel, Robert; Sehn, Laurie H.; Connors, Joseph M.] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada. [Staiger, Annette M.; Horn, Heike; Ott, German] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany. [Szczepanowski, Monika; Klapper, Wolfram] Univ Kiel, Hematopathol Sect, Kiel, Germany. [Rosenwald, Andreas] Univ Wurzburg, Inst Pathol, Wurzburg, Germany. [Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Friedberg, Jonathan W.] Univ Rochester, Rochester, NY USA. [Ansell, Stephen] Mayo Clin, Rochester, MN USA. [Gascoyne, Randy D.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. [Weinstock, David M.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Hiddemann, Wolfgang; Weigert, Oliver] Univ Munich, Dept Internal Med 3, Munich, Germany. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001085 ER PT J AU Viny, AD Ott, CJ Spitzer, B Rivas, MA Meydan, C Papalexi, E Yelin, D Shank, K Reyes, J Chiu, A Thota, S Maciejewski, JP Melnick, A Bradner, JE Levine, RL AF Viny, Aaron D. Ott, Christopher J. Spitzer, Barbara Rivas, Martin A. Meydan, Cem Papalexi, Efthymia Yelin, Dana Shank, Kaitlyn Reyes, Jaime Chiu, April Thota, Swapna Maciejewski, Jaroslaw P. Melnick, Ari Bradner, James E. Levine, Ross L. TI Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Viny, Aaron D.; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. [Viny, Aaron D.; Spitzer, Barbara; Papalexi, Efthymia; Yelin, Dana; Shank, Kaitlyn] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Ott, Christopher J.; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Spitzer, Barbara] Mem Sloan Kettering Canc Ctr, Pediat, New York, NY 10021 USA. [Rivas, Martin A.; Meydan, Cem; Melnick, Ari] Weill Cornell Med Coll, Dept Med Hematol Oncol, New York, NY USA. [Rivas, Martin A.; Meydan, Cem; Melnick, Ari] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA. [Yelin, Dana] Rabin Med Ctr, Dept Med, Petah Tiqwa, Israel. [Reyes, Jaime] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chiu, April] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. [Thota, Swapna; Maciejewski, Jaroslaw P.] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Oncol, Cleveland, OH 44106 USA. [Thota, Swapna] Cleveland Clin, Taussing Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA. [Maciejewski, Jaroslaw P.] Cleveland Clin, Taussing Canc Inst, Translat Hematol & Oncol Res, Cleveland, OH 44106 USA. [Bradner, James E.] Harvard Univ, Sch Med, Boston, MA USA. [Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001187 ER PT J AU Vogl, DT Raje, NS Jagannath, S Richardson, PG Hari, P Orlowski, RZ Supko, J Tamang, D Jones, SS Wheeler, C Markelewicz, RJ Lonial, S AF Vogl, Dan T. Raje, Noopur S. Jagannath, Sundar Richardson, Paul G. Hari, Parameswaran Orlowski, Robert Z. Supko, Jeffrey Tamang, David Jones, Simon S. Wheeler, Catherine Markelewicz, Robert J., Jr. Lonial, Sagar TI Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Vogl, Dan T.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Raje, Noopur S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Jagannath, Sundar] Mt Sinai Hosp, Hematol & Med Oncol, New York, NY 10029 USA. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancy,Dept Med Oncol,Jerome Lipp, Boston, MA 02115 USA. [Hari, Parameswaran] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA. [Supko, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tamang, David; Jones, Simon S.; Wheeler, Catherine; Markelewicz, Robert J., Jr.] Acetylon Pharmaceut Inc, Boston, MA USA. [Lonial, Sagar] Emory Univ, Winship Canc Inst, Div BMT, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005305 ER PT J AU Voorhees, PM Mulkey, F Hassoun, H Paba-Prada, CE Efebera, YA Hoke, E Aquino, G Carlisle, D Suman, V Richardson, PG AF Voorhees, Peter M. Mulkey, Flora Hassoun, Hani Paba-Prada, Claudia E. Efebera, Yvonne A. Hoke, Eva Aquino, Guadalupe Carlisle, Destin Suman, Vera Richardson, Paul G. TI Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Voorhees, Peter M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Mulkey, Flora; Hoke, Eva] Alliance Stat & Data Ctr, Durham, NC USA. [Hassoun, Hani] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY 10021 USA. [Paba-Prada, Claudia E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Efebera, Yvonne A.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Aquino, Guadalupe] NINDS, Off Clin Res, NIH, Bethesda, MD 20892 USA. [Carlisle, Destin] Univ Chicago, Alliance Protocol Operat Off, Chicago, IL 60637 USA. [Suman, Vera] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Div Hematol Malignancy, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. RI Efebera, Yvonne/E-3012-2011 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001127 ER PT J AU Wang, LL Gambe, R Fan, J Wan, YZ Brooks, AN Sun, J Obeng, EA Neuberg, DS Meyerson, M Fleming, MD Ebert, BL Carrasco, RD Wu, CJ AF Wang, Lili Gambe, Rutendo Fan, Jean Wan, Youzhong Brooks, Angela N. Sun, Jing Obeng, Esther A. Neuberg, Donna S. Meyerson, Matthew Fleming, Mark D. Ebert, Benjamin L. Carrasco, Ruben D. Wu, Catherine J. TI Expressionof Sf3b1-K700Ein Murine B Cells Causes Pre-mRNA Splicing and Altered B Cell Differentiation and Function SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Wang, Lili; Gambe, Rutendo; Wan, Youzhong; Sun, Jing; Meyerson, Matthew; Carrasco, Ruben D.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Wang, Lili; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Wang, Lili; Obeng, Esther A.; Ebert, Benjamin L.; Wu, Catherine J.] Harvard Univ, Sch Med, Boston, MA USA. [Fan, Jean] Harvard Univ, Sch Med, Dept Biomed Informat, Boston, MA USA. [Wan, Youzhong] Jilin Univ, Sch Life Sci, Changchun 130023, Peoples R China. [Brooks, Angela N.; Meyerson, Matthew] Broad Inst, Cambridge, MA USA. [Brooks, Angela N.] Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA. [Obeng, Esther A.; Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Obeng, Esther A.] Boston Childrens Hosp, Pediat Hematol Oncol, Boston, MA USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Fleming, Mark D.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001118 ER PT J AU Wolach, O Stevenson, K Wadleigh, M DeAngelo, DJ Steensma, DP Soiffer, RJ Antin, JH Neuberg, DS Ho, VT Stone, RM AF Wolach, Ofir Stevenson, Kristen Wadleigh, Martha DeAngelo, Daniel J. Steensma, David P. Soiffer, Robert J. Antin, Joseph H. Neuberg, Donna S. Ho, Vincent T. Stone, Richard M. TI Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Wolach, Ofir; Wadleigh, Martha; DeAngelo, Daniel J.; Steensma, David P.; Soiffer, Robert J.; Antin, Joseph H.; Ho, Vincent T.; Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Stevenson, Kristen; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004104 ER PT J AU Wu, CJ AF Wu, Catherine J. TI Checkpoint Blockade with Neoantigen Cancer Vaccines for Personalized Immunotherapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000064 ER PT J AU Xu, L Hunter, Z Tsakmaklis, N Cao, Y Yang, G Chen, J Liu, X Kanan, S Castillo, JJ Tai, YT Zehnder, JL Brown, JR Carrasco, RD Advani, RH Argyropoulos, KV Palomba, ML Morra, E Trojani, A Greco, A Tedeschi, A Varettoni, M Arcaini, L Munshi, NC Anderson, KC Treon, SP AF Xu, Lian Hunter, Zachary Tsakmaklis, Nicholas Cao, Yang Yang, Guang Chen, Jie Liu, Xia Kanan, Sandra Castillo, Jorge J. Tai, Yu-Tzu Zehnder, James L. Brown, Jennifer R. Carrasco, Ruben D. Advani, Ranjana H. Argyropoulos, Kimon V. Palomba, M. Lia Morra, Enrica Trojani, Alessandra Greco, Antonino Tedeschi, Alessandra Varettoni, Marzia Arcaini, Luca Munshi, Nikhil C. Anderson, Kenneth C. Treon, Steven P. TI The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Xu, Lian; Hunter, Zachary; Tsakmaklis, Nicholas; Cao, Yang; Yang, Guang; Chen, Jie; Liu, Xia; Kanan, Sandra; Castillo, Jorge J.; Treon, Steven P.] Dana Farber Canc Inst, Bing Ctr WM, Boston, MA 02115 USA. [Cao, Yang] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA. [Tai, Yu-Tzu; Munshi, Nikhil C.; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Zehnder, James L.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA. [Brown, Jennifer R.; Carrasco, Ruben D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Advani, Ranjana H.] Stanford Univ, Med Ctr, Dept Med Oncol, Sch Med, Stanford, CA 94305 USA. [Argyropoulos, Kimon V.] Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10021 USA. [Palomba, M. Lia] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY 10021 USA. [Morra, Enrica; Trojani, Alessandra; Greco, Antonino; Tedeschi, Alessandra] Osped Niguarda Ca Granda, Div Hematol, Milan, Italy. [Varettoni, Marzia] Fdn IRCCS Policlin San Matteo, Dept Hematol & Oncol, Pavia, Italy. [Arcaini, Luca] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019004286 ER PT J AU Yang, C Lin, JH Liang, HY Kwart, A Jiang, M Zhao, JJ Jiang, XF Munshi, NC AF Yang, Chun Lin, Jianhong Liang, Hongyan Kwart, Ariel Jiang, Meng Zhao, Jianjun Jiang, Xiaofeng Munshi, Nikhil C. TI Blocking Specific CD44 Splicing Variant Isoform Inhibits the Differentiation of Th-2 Cells through Interfering with IL-4/IL-4R Signaling Pathway SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Yang, Chun; Lin, Jianhong; Kwart, Ariel; Jiang, Meng; Zhao, Jianjun] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Yang, Chun; Liang, Hongyan; Jiang, Xiaofeng] Harbin Med Univ, Hosp 4, Dept Clin Lab, Harbin, Peoples R China. [Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001037 ER PT J AU Yang, G Buhrlage, S Tan, L Liu, X Chen, J Hunter, Z Xu, L Tsakmaklis, N Chen, JJ Patterson, CJ Castillo, JJ Zhang, W Gray, N Treon, SP AF Yang, Guang Buhrlage, Sara Tan, Li Liu, Xia Chen, Jie Hunter, Zachary Xu, Lian Tsakmaklis, Nicholas Chen, Jiaji Patterson, Christopher J. Castillo, Jorge J. Zhang, Wei Gray, Nathanael Treon, Steven P. TI HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Yang, Guang; Liu, Xia; Chen, Jie; Hunter, Zachary; Xu, Lian; Tsakmaklis, Nicholas; Chen, Jiaji; Patterson, Christopher J.; Treon, Steven P.] Dana Farber Canc Inst, Bing Ctr WM, Boston, MA 02115 USA. [Buhrlage, Sara; Tan, Li; Gray, Nathanael] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Castillo, Jorge J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA. [Zhang, Wei] Univ Massachusetts, Coll Sci & Math, Boston, MA 02125 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002142 ER PT J AU Zeidan, AM Long, JB Wang, R Yu, JB Hall, J Abel, G Gore, SD Gross, CP Ma, XM Davidoff, AJ AF Zeidan, Amer M. Long, Jessica B. Wang, Rong Yu, James B. Hall, Jane Abel, Gregory Gore, Steven D. Gross, Cary P. Ma, Xiaomei Davidoff, Amy J. TI Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Zeidan, Amer M.; Yu, James B.; Gore, Steven D.; Gross, Cary P.] Yale Univ, Sch Med, New Haven, CT USA. [Long, Jessica B.; Wang, Rong; Hall, Jane; Ma, Xiaomei; Davidoff, Amy J.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Abel, Gregory] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019005154 ER PT J AU Zhang, H Kozono, D O'Connor, K Rousseau, A Moreau, L Gaudiano, E Greenberger, JS Bagby, GC Soulier, J Grompe, M Parmar, K D'Andrea, AD AF Zhang, Haojian Kozono, David O'Connor, Kevin Rousseau, Alix Moreau, Lisa Gaudiano, Emily Greenberger, Joel S. Bagby, Grover C., Jr. Soulier, Jean Grompe, Markus Parmar, Kalindi D'Andrea, Alan D. TI TGF-beta Pathway Inhibition Rescues the Function of Hematopoietic Stem and Progenitor Cells Derived from Patients with Fanconi Anemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Zhang, Haojian; Kozono, David; O'Connor, Kevin; Moreau, Lisa; Gaudiano, Emily; Parmar, Kalindi; D'Andrea, Alan D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Rousseau, Alix; Soulier, Jean] Univ Paris Diderot, Inst Hematol, Paris, France. [Greenberger, Joel S.] Univ Pittsburgh, Radiat Oncol, Pittsburgh, PA USA. [Bagby, Grover C., Jr.; Grompe, Markus] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019001049 ER PT J AU Zhu, JH Zhu, JQ Bougie, DW Aster, RH Springer, TA AF Zhu, Jianghai Zhu, Jieqing Bougie, Daniel W. Aster, Richard H. Springer, Timothy A. TI Structural Basis for Quinine-Dependent Antibody Binding to Platelet Integrin alphaIIbbeta3 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Zhu, Jianghai; Springer, Timothy A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Zhu, Jianghai; Springer, Timothy A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Zhu, Jianghai; Springer, Timothy A.] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Zhu, Jieqing; Bougie, Daniel W.; Aster, Richard H.] BloodCtr Wisconsin, Blood Res Inst, Milwaukee, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003187 ER PT J AU Zonder, JA Usiinani, S Scott, EC Harneister, CC Lendvai, N Berdeja, JC Anderson, LD Hari, P Singhal, S Orloff, G Craig, M Valent, J Lee, W Hart, L Hrom, J Tarantolo, S Faber, E Schiller, GJ Schreiber, J Oliver, C Rush, SA Tunquist, B Ptaszynski, M Raje, NS AF Zonder, Jeffrey A. Usiinani, Saad Scott, Emma C. Harneister, Craig C. Lendvai, Nikoletta Berdeja, Jesus C. Anderson, Larry D., Jr. Hari, Parameswaran Singhal, Seeina Orloff, Gregory Craig, Michael Valent, Jason Lee, Wes Hart, Lowell Hrom, J. Tarantolo, Stephano Faber, Edward Schiller, Gary J. Schreiber, Jennifer Oliver, Colleen Rush, Selena A. Tunquist, Brian Ptaszynski, Mieke Raje, Noopur S. TI Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Zonder, Jeffrey A.] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA. [Usiinani, Saad] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA. [Scott, Emma C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA. [Scott, Emma C.] Knight Canc Inst, Portland, OR USA. [Harneister, Craig C.] Ohio State Univ, Columbus, OH 43210 USA. [Lendvai, Nikoletta] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Berdeja, Jesus C.] Sarah Cannon Res Inst, Nashville, TN USA. [Anderson, Larry D., Jr.] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Dallas, TX USA. [Hari, Parameswaran] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA. [Singhal, Seeina] Northwestern Univ, Feinberg Sch Med, Div Hem Onc, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Orloff, Gregory] Fairfax Northern Virginia Hematol Oncol, Fairfax, VA USA. [Craig, Michael] West Virginia Univ Hosp Inc, Morgantown, WV USA. [Valent, Jason] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Lee, Wes] St Joseph Healthcare, Santa Rosa, CA USA. [Hart, Lowell] Florida Canc Specialists, Ft Myers, FL USA. [Hrom, J.] Forest Gen Canc Ctr, Hattiesburg, MS USA. [Tarantolo, Stephano] Nebraska Canc Specialists, Omaha, NE USA. [Faber, Edward] Oncol Hematol Care Blue Ash, Cincinnati, OH USA. [Schiller, Gary J.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. [Schreiber, Jennifer; Oliver, Colleen; Tunquist, Brian; Ptaszynski, Mieke] Array BioPharma, Boulder, CO USA. [Rush, Selena A.] Array BioPharma Inc, Boulder, CO USA. [Raje, Noopur S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002165 ER PT J AU Abel, GA Hshieh, TT Condron, NB Jacobson, CA Steensma, DP Laubach, JP Stone, RM Driver, JA AF Abel, Gregory A. Hshieh, Tammy T. Condron, Nolan B. Jacobson, Caron A. Steensma, David P. Laubach, Jacob P. Stone, Richard M. Driver, Jane A. TI Feasibility of Routine Frailty Screening Assessment for Patients in a Hematologic Oncology Clinic: Results from a Pilot Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Abel, Gregory A.; Condron, Nolan B.; Jacobson, Caron A.; Steensma, David P.; Laubach, Jacob P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hshieh, Tammy T.; Driver, Jane A.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA. [Laubach, Jacob P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104188 ER PT J AU Allen, J Tarapore, R Garnett, MJ Benes, C AF Allen, Joshua Tarapore, Rohinton Garnett, Mathew J. Benes, Cyril TI ONC201 Exhibits Mutation-Independent Efficacy with Superior Potency in Non-Hodgkin Lymphoma and Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Allen, Joshua; Tarapore, Rohinton] Oncoceutics Inc, Hummelstown, PA USA. [Garnett, Mathew J.] Wellcome Trust Sanger Inst, Cambridge, England. [Benes, Cyril] Harvard Univ, Sch Med, Ctr Canc, Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800130 ER PT J AU Beheshti, A Neuberg, DS McDonald, JT Evens, AM AF Beheshti, Afshin Neuberg, Donna S. McDonald, J. Tyson Evens, Andrew M. TI The Impact of Age and Sex in DLBCL: Determination of Biologic Dynamics and Delineation of Inter-Connected Signaling Networks Via a Systems Biology Analysis SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Beheshti, Afshin] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [McDonald, J. Tyson] Hampton Univ, Canc Res Ctr, Hampton, VA 23668 USA. [Evens, Andrew M.] Tufts Med Ctr, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102184 ER PT J AU Beltran, BE Morales, D Quinones, P Malaga, JM Castillo, JJ AF Beltran, Brady E. Morales, Domingo Quinones, Pilar Malaga, Jose M. Castillo, Jorge J. TI High Rates of HTLV-1 Seropositivity in Patients with EBV-Positive Diffuse Large B-Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Beltran, Brady E.; Morales, Domingo; Quinones, Pilar] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru. [Malaga, Jose M.] Hosp Carlos Seguin Escobedo, Arequipa, Peru. [Castillo, Jorge J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021804025 ER PT J AU Beltran, BE Malaga, JM Chavez, JC Sotomayor, EM Castillo, JJ AF Beltran, Brady E. Malaga, Jose M. Chavez, Julio C. Sotomayor, Eduardo M. Castillo, Jorge J. TI The Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with EBV-Positive Diffuse Large B-Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Beltran, Brady E.] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru. [Malaga, Jose M.] Hosp Carlos Seguin Escobedo, Arequipa, Peru. [Chavez, Julio C.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA. [Sotomayor, Eduardo M.] George Washington Univ, Ctr Canc, Div Hematol Oncol, Washington, DC USA. [Castillo, Jorge J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021804023 ER PT J AU Berdeja, JG Heinrich, M Dakhil, S Goldberg, SL Wadleigh, M Catchatourian, R Kuriakose, P Cortes, JE Radich, JP Rizzieri, DA Bonifacio, G Dautaj, I Warsi, G Mauro, MJ AF Berdeja, Jesus G. Heinrich, Michael Dakhil, Shaker Goldberg, Stuart L. Wadleigh, Martha Catchatourian, Rosalind Kuriakose, Philip Cortes, Jorge E. Radich, Jerald P. Rizzieri, David A. Bonifacio, Gaetano Dautaj, Ilva Warsi, Ghulam Mauro, Michael J. TI ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Berdeja, Jesus G.] Sarah Cannon Res Inst, Nashville, TN USA. [Heinrich, Michael] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Dakhil, Shaker] Canc Ctr Kansas, Wichita, KS USA. [Goldberg, Stuart L.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Div Leukemia, Hackensack, NJ USA. [Wadleigh, Martha] Dana Farber Canc Inst, Boston, MA 02115 USA. [Catchatourian, Rosalind] Cook Cty Hlth & Hosp Syst, Chicago, IL USA. [Kuriakose, Philip] Henry Ford Hlth Syst, Detroit, MI USA. [Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Radich, Jerald P.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Rizzieri, David A.] Duke Univ, Sch Med, Durham, NC USA. [Bonifacio, Gaetano; Dautaj, Ilva; Warsi, Ghulam] Novartis Pharmaceut, E Hanover, NJ USA. [Mauro, Michael J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800305 ER PT J AU Biran, N Jacobus, S Siegel, D Callander, NS Fonseca, R Vesole, DH Williams, ME Abonour, R Katz, MS Rajkumar, SV Greipp, PR AF Biran, Noa Jacobus, Susanna Siegel, David Callander, Natalie Scott Fonseca, Rafael Vesole, David H. Williams, Michael E. Abonour, Rafat Katz, Michael S. Rajkumar, S. Vincent Greipp, Philip R. TI Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Biran, Noa; Siegel, David] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Jacobus, Susanna] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Callander, Natalie Scott] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Fonseca, Rafael] Mayo Clin, Scottsdale, AZ USA. [Vesole, David H.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack UMC, Hackensack, NJ USA. [Williams, Michael E.] Univ Virginia, Charlottesville, VA USA. [Abonour, Rafat] Indiana Univ Sch Med, Hematol Oncol, Indianapolis, IN 46202 USA. [Katz, Michael S.] Int Myeloma Fdn, Los Angeles, CA USA. [Rajkumar, S. Vincent] Mayo Clin, Div Hematol, Rochester, MN USA. [Greipp, Philip R.] Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104056 ER PT J AU Boyle, E Fouquet, G Lejeune, J Manier, S Musset, L Bories, C Dulery, R Guidez, S Bonnet, S Onraed, B Faucompre, JL Tricot, S Poulain, S Leblond, V Snell, K Leleu, X AF Boyle, Eileen Fouquet, Guillemette Lejeune, Julie Manier, Salomon Musset, Lucile Bories, Claire Dulery, Remy Guidez, Stephanie Bonnet, Sarah Onraed, Brigitte Faucompre, Jean-Luc Tricot, Sabine Poulain, Stephanie Leblond, Veronique Snell, Kym Leleu, Xavier TI Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria? SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Boyle, Eileen; Fouquet, Guillemette; Bories, Claire; Guidez, Stephanie] CHRU Lille, Hop Claude Huriez, Malad Sang, F-59037 Lille, France. [Lejeune, Julie] Hop St Louis, AP HP, Paris, France. [Manier, Salomon] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Musset, Lucile] Hop La Pitie Salpetriere, Dept Immunol, Paris, France. [Dulery, Remy] CHRU Lille, Hop Claude Huriez, Serv Malad Sang, F-59037 Lille, France. [Bonnet, Sarah; Leleu, Xavier] CHRU Lille, Hop Claude Huriez, F-59037 Lille, France. [Onraed, Brigitte] CHRU Lille, Hosp Huriez, Serv Biochim Prot, F-59037 Lille, France. [Faucompre, Jean-Luc] CHRU Lille, Hosp Huriez, F-59037 Lille, France. [Tricot, Sabine] CHU, Valenciennes, France. [Poulain, Stephanie] Hosp Valenciennes, Valenciennes, France. [Leblond, Veronique] Univ Paris 06, Hop La Pitie Salpetriere, AP HP, Dept Hematol,Hematol, Paris, France. [Snell, Kym] Univ Birmingham, Birmingham, W Midlands, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020103237 ER PT J AU Brown, JR Cheson, BD Furman, RR Ghia, P Hallek, M Hillmen, P O'Brien, SM Sharman, JP Dubowy, RL Velasco, B Waldapfel, CC Zelenetz, AD AF Brown, Jennifer R. Cheson, Bruce D. Furman, Richard R. Ghia, Paolo Hallek, Michael Hillmen, Peter O'Brien, Susan M. Sharman, Jeff P. Dubowy, Ronald L. Velasco, Barbara Waldapfel, Christopher C. Zelenetz, Andrew D. TI Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cheson, Bruce D.] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Furman, Richard R.] Weill Cornell Med Ctr, New York Presbyterian, New York, NY USA. [Ghia, Paolo] Univ Vita Salute San Raffaele, Milan, Italy. [Ghia, Paolo] IRCCS Ist Sci San Raffaele, Milan, Italy. [Hallek, Michael] Univ Hosp, Dept Internal Med, Cologne, Germany. [Hallek, Michael] Univ Hosp, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany. [Hillmen, Peter] St James Univ Hosp, Haematol, Leeds, W Yorkshire, England. [O'Brien, Susan M.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA. [Sharman, Jeff P.] Willamette Valley Canc Inst, US Oncol Network, Springfield, OR USA. [Dubowy, Ronald L.; Velasco, Barbara; Waldapfel, Christopher C.] Gilead Sci Inc, Foster City, CA 94404 USA. [Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020103147 ER PT J AU Brunner, AM Neuberg, DS Wander, SA Sadrzadeh, H Ballen, KK Amrein, PC Hobbs, GS Chen, YB Perry, AM Joseph, C Burke, ME Ramos, AY Silver, R Galinsky, I Adamia, S Borger, D Iafrate, AJ Stone, RM Fathi, AT AF Brunner, Andrew M. Neuberg, Donna S. Wander, Seth A. Sadrzadeh, Hossein Ballen, Karen K. Amrein, Philip C. Hobbs, Gabriela S. Chen, Yi-Bin Perry, Ashley M. Joseph, Christelle Burke, Meghan E. Ramos, Aura Y. Silver, Regina Galinsky, Ilene Adamia, Sophia Borger, Darrell Iafrate, Anthony J. Stone, Richard M. Fathi, Arnir T. TI Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Brunner, Andrew M.; Wander, Seth A.; Ballen, Karen K.; Amrein, Philip C.; Hobbs, Gabriela S.; Chen, Yi-Bin; Perry, Ashley M.; Joseph, Christelle; Burke, Meghan E.; Ramos, Aura Y.; Silver, Regina; Borger, Darrell; Iafrate, Anthony J.; Fathi, Arnir T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Brunner, Andrew M.; Adamia, Sophia] Dana Farber Canc Inst, Boston, MA 02115 USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Sadrzadeh, Hossein] Capital Hlth Syst, Trenton, NJ USA. [Galinsky, Ilene; Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102109 ER PT J AU Brunstein, CG Cutler, CS DeFor, TE Spitzer, TR Bejanyan, N Garfall, AL Verneris, MR Chen, YB Warlick, E Kim, HT Miller, JS Antin, JH Weisdorf, DJ Soiffer, RJ Wagner, JE Ballen, KK AF Brunstein, Claudio G. Cutler, Corey S. DeFor, Todd E. Spitzer, Thomas R. Bejanyan, Nelli Garfall, Alfred L. Verneris, Michael R. Chen, Yi-Bin Warlick, Erica Kim, Haesook T. Miller, Jeffrey S. Antin, Joseph H. Weisdorf, Daniel J. Soiffer, Robert J. Wagner, John E. Ballen, Karen K. TI Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Brunstein, Claudio G.; Bejanyan, Nelli; Miller, Jeffrey S.] Univ Minnesota, Hematol Oncol & Transplantat, Minneapolis, MN USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. [DeFor, Todd E.; Verneris, Michael R.] Univ Minnesota, Adult & Pediat Blood & Marrow Transplant Program, Minneapolis, MN USA. [Spitzer, Thomas R.; Chen, Yi-Bin; Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Garfall, Alfred L.] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA. [Warlick, Erica] Univ Minnesota, Minneapolis, MN USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Antin, Joseph H.] Massachusetts Gen, Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA. [Weisdorf, Daniel J.] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA. [Soiffer, Robert J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Wagner, John E.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100187 ER PT J AU Callander, NS Freytes, CO Luo, SH Carson, KR AF Callander, Natalie Scott Freytes, Cesar O. Luo, Suhong Carson, Kenneth R. TI Previous Agent Orange Exposure Is Correlated with Worse Outcome in Patients with Multiple Myeloma (MM) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Callander, Natalie Scott] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Callander, Natalie Scott] Williams S Middleton Mem Vet Hosp, Madison, WI USA. [Freytes, Cesar O.] Audie L Murphy Mem Vet Adm Med Ctr, Med, San Antonio, TX 78284 USA. [Luo, Suhong; Carson, Kenneth R.] St Louis Vet Adm Med Ctr, Res Serv, St Louis, MO USA. [Carson, Kenneth R.] Washington Univ, Sch Med, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801136 ER PT J AU Cantafio, MEG Gulla, A Amodio, N Leone, E Morelli, E Biamonte, L Neri, A Tagliaferri, P Tassone, P Di Martino, MT AF Cantafio, Maria Eugenia Gallo Gulla, Annamaria Amodio, Nicola Leone, Emanuela Morelli, Eugenio Biamonte, Lavinia Neri, Antonino Tagliaferri, Pierosandro Tassone, Pierfrancesco Di Martino, Maria Teresa TI Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Cantafio, Maria Eugenia Gallo; Leone, Emanuela; Biamonte, Lavinia] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy. [Gulla, Annamaria; Tagliaferri, Pierosandro; Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Catanzaro, Italy. [Gulla, Annamaria] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. [Amodio, Nicola; Morelli, Eugenio; Di Martino, Maria Teresa] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy. [Neri, Antonino] Univ Milan, Dept Med Sci, Hematol CTMO 1, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy. NR 0 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020103220 ER PT J AU Carey, CD Gusenleitner, D Xuan, Z Sohani, AR Weinberg, O Yu, HB Chen, B Woda, B Fu, K Monti, S Rodig, SJ AF Carey, Christopher Daniel Gusenleitner, Daniel Xuan, Zhang Sohani, Aliyah R. Weinberg, Olga Yu, Hongbo Chen, Ben Woda, Bruce Fu, Kai Monti, Stefano Rodig, Scott J. TI Resolving the Biological Heterogeneity of B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between DLBCL and BL (BCL-U) Using Quantitative Profiles of Oncogenic Signaling Networks SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Carey, Christopher Daniel] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Gusenleitner, Daniel; Monti, Stefano] Boston Univ, Sch Med, Sect Computat Biomed, Boston, MA 02118 USA. [Xuan, Zhang] Univ Nebraska, Sch Med, Omaha, NE 68198 USA. [Sohani, Aliyah R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Weinberg, Olga] Boston Childrens Hosp, Boston, MA USA. [Yu, Hongbo; Chen, Ben; Woda, Bruce] Univ Massachusetts, Mem Med Ctr, Worcester, MA 01605 USA. [Fu, Kai] Univ Nebraska Med Ctr, Dept Pathol & Microbiol & Internal Med, Omaha, NE USA. [Rodig, Scott J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800160 ER PT J AU Chapuy, B Dunford, AJ Stewart, C Kamburov, A Kim, J Roemer, MGM Ziepert, M Li, AJ Lawrence, M Hess, J Rosenburg, M Taylor-Weiner, AN Redd, RA Horn, H Novak, A Cerhan, JR Haberman, TM Feldman, AL Link, BK Golub, TR Neuberg, DS Ott, G Siebert, R Rosenwald, A Wulf, GG Monti, S Rodig, SJ Loffler, M Pfreundschuh, M Trumper, L Getz, G Shipp, MA AF Chapuy, Bjoern Dunford, Andrew J. Stewart, Chip Kamburov, Atanas Kim, Jaegil Roemer, Margaretha G. M. Ziepert, Marita Li, Amy Jiayue Lawrence, Mike Hess, Julian Rosenburg, Mara Taylor-Weiner, Amaro N. Redd, Robert A. Horn, Heike Novak, Anne Cerhan, James R. Haberman, Thomas M. Feldman, Andrew L. Link, Brian K. Golub, Todd R. Neuberg, Donna S. Ott, German Siebert, Reiner Rosenwald, Andreas Wulf, Gerald G. Monti, Stefano Rodig, Scott J. Loeffler, Markus Pfreundschuh, Michael Truemper, Lorenz Getz, Gad Shipp, Margaret A. TI Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chapuy, Bjoern; Roemer, Margaretha G. M.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Dunford, Andrew J.; Stewart, Chip; Kamburov, Atanas; Kim, Jaegil; Lawrence, Mike; Hess, Julian; Rosenburg, Mara; Taylor-Weiner, Amaro N.; Golub, Todd R.; Getz, Gad] Broad Inst, Cambridge, MA USA. [Ziepert, Marita; Loeffler, Markus] Univ Leipzig, Inst Med Informat Stat & Epidemiol, D-04109 Leipzig, Germany. [Li, Amy Jiayue; Monti, Stefano] Boston Univ, Sch Med, Sect Computat Biomed, Boston, MA 02118 USA. [Redd, Robert A.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Horn, Heike; Shipp, Margaret A.] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany. [Horn, Heike; Shipp, Margaret A.] Univ Tubingen, Stuttgart, Germany. [Novak, Anne; Cerhan, James R.; Haberman, Thomas M.; Feldman, Andrew L.] Mayo Clin, Rochester, MN USA. [Link, Brian K.] Univ Iowa Hosp & Clin, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa City, IA 52242 USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Ott, German] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany. [Siebert, Reiner] Univ Kiel, Inst Human Genet, Kiel, Germany. [Rosenwald, Andreas] Univ Wurzburg, D-97070 Wurzburg, Germany. [Wulf, Gerald G.; Truemper, Lorenz] Univ Hosp Gottingen, Hematol & Oncol, Gottingen, Germany. [Rodig, Scott J.] Brigham & Womens Hosp, Pathol, Boston, MA 02115 USA. [Pfreundschuh, Michael] Univ Clin Saarland, Dept Hematol & Oncol, Homburg, Germany. [Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800179 ER PT J AU Chapuy, CI Aguad, MD Nicholson, RT AuBuchon, JP Cohn, CS Delaney, M Cid, J Dzik, W Fung, MK Greinacher, A Ang, AL Devine, DV Dunbar, NM Garritsen, H Goodnough, LT Herron, R Hervig, TA Knudson, CM Kutner, JM Nizzi, F Pandey, S Rioux-Masse, B Selleng, K Sweeney, J Takanashi, M Tobian, AAR Wall, L Wendel, S Westerman, DA Unger, M Doshi, P Murphy, MF Dumont, LJ Kaufman, RM AF Chapuy, Claudia I. Aguad, Maria D. Nicholson, Rachel T. AuBuchon, James P. Cohn, Claudia S. Delaney, Meghan Cid, Joan Dzik, Walter Fung, Mark K. Greinacher, Andreas Ang, Ai Leen Devine, Dana V. Dunbar, Nancy M. Garritsen, Henk Goodnough, Lawrence T. Herron, Ross Hervig, Tor A. Knudson, C. Michael Kutner, Jose M. Nizzi, Frank Pandey, Suchitra Rioux-Masse, Benjamin Selleng, Kathleen Sweeney, Joseph Takanashi, Minoko Tobian, Aaron A. R. Wall, Lorna Wendel, Silvano Westerman, David A. Unger, Meredith Doshi, Parul Murphy, Michael F. Dumont, Larry J. Kaufman, Richard M. CA BEST Collaborative TI International Validation of a Dithiothreitol (DTT)-Based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chapuy, Claudia I.] St Elizabeths Med Ctr, Boston, MA USA. [Aguad, Maria D.; Kaufman, Richard M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Nicholson, Rachel T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [AuBuchon, James P.] Bloodworks Northwest, Seattle, WA USA. [Cohn, Claudia S.] Univ Minnesota, Minneapolis, MN USA. [Delaney, Meghan] Univ Washington, Seattle Childrens Hosp, Bloodworks Northwest, Seattle, WA 98195 USA. [Cid, Joan] Hosp Clin Barcelona, Barcelona, Spain. [Dzik, Walter] Massachusetts Gen Hosp, Blood Transfuson Serv, Boston, MA 02114 USA. [Fung, Mark K.] Univ Vermont, Med Ctr, Burlington, VT USA. [Greinacher, Andreas; Selleng, Kathleen] Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, Greifswald, Germany. [Ang, Ai Leen] Hlth Sci Author, Blood Serv Grp, Singapore, Singapore. [Devine, Dana V.] Univ British Columbia, Canadian Blood Serv, Vancouver, BC V5Z 1M9, Canada. [Dunbar, Nancy M.; Dumont, Larry J.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Garritsen, Henk] Stadt Klinikum Braunschweig gGmbH, Braunschweig, Germany. [Goodnough, Lawrence T.] Stanford Univ, Pathol & Med, Stanford, CA 94305 USA. [Herron, Ross] Amer Red Cross Blood Serv, Pomona, CA USA. [Hervig, Tor A.] Haukeland Univ Sjukehus, Bergen, Norway. [Knudson, C. Michael] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. [Kutner, Jose M.] Hosp Israelita Albert Einstein, Hemotherapy & Cell Therapy Dept, Sao Paulo, Brazil. [Nizzi, Frank] Blood Syst, Scottsdale, AZ USA. [Pandey, Suchitra] Blood Ctr Pacific, San Francisco, CA USA. [Rioux-Masse, Benjamin] Ctr Hosp Univ Montreal, Dept Hematol & Transfus Med, Montreal, PQ, Canada. [Sweeney, Joseph] Miriam Hosp, Blood Bank, Barrington, RI USA. [Takanashi, Minoko] Japanese Red Cross, Blood Serv Headquarters, Tokyo, Japan. [Tobian, Aaron A. R.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Wall, Lorna] New Zealand Blood Serv, Auckland, New Zealand. [Wendel, Silvano] Hosp Sirio Libanes, Sao Paulo, Brazil. [Westerman, David A.] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia. [Unger, Meredith] Janssen Inc, Raritan, NJ USA. [Doshi, Parul] Janssen Res & Dev LLC, Spring House, PA USA. [Murphy, Michael F.] NHS Blood & Transplant, Oxford, England. [BEST Collaborative] Dartmouth Hitchcock Med Ctr, Hanover, NH USA. RI Dumont, Larry/B-3994-2011 OI Dumont, Larry/0000-0002-1715-0748 NR 0 TC 1 Z9 1 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020105133 ER PT J AU Chen, YB Li, SL Konkel, S Loiselle, C Efebera, YA Devine, SM El-Jawahri, A McAfee, SL Soiffer, RJ Ritz, J Cutler, CS Perales, M AF Chen, Yi-Bin Li, Shuli Konkel, Sarah Loiselle, Colleen Efebera, Yvonne A. Devine, Steven M. El-Jawahri, Areej McAfee, Steven L. Soiffer, Robert J. Ritz, Jerome Cutler, Corey S. Perales, Miguel TI Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Li, Shuli] Dana Farber Canc Inst, Boston, MA 02115 USA. [Konkel, Sarah; Loiselle, Colleen; McAfee, Steven L.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Efebera, Yvonne A.; Devine, Steven M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [El-Jawahri, Areej] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Soiffer, Robert J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. [Perales, Miguel] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA. RI Efebera, Yvonne/E-3012-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100095 ER PT J AU Christie, AL Christodoulou, AN DeSouza, T Murakami, MA Li, LS Kopp, N Koch, R Louissaint, A Ng, SY Jacobson, CA Shoji, B Davids, MS Odejide, OO LaCasce, AS Fisher, DC Freedman, AS Jacobsen, ED Bertagnolli, M Pinkus, GS Dorfman, DM Morgan, EA Aster, JC Shipp, MA Weinstock, DM AF Christie, Amanda L. Christodoulou, Alexandra N. DeSouza, Tiffany Murakami, Mark A. Li, Loretta S. Kopp, Nadja Koch, Raphael Louissaint, Abner, Jr. Ng, Samuel Y. Jacobson, Caron A. Shoji, Brent Davids, Matthew S. Odejide, Oreofe O. LaCasce, Ann S. Fisher, David C. Freedman, Arnold S. Jacobsen, Eric D. Bertagnolli, Monica Pinkus, Geraldine S. Dorfman, David M. Morgan, Elizabeth A. Aster, Jon C. Shipp, Margaret A. Weinstock, David M. TI B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Christie, Amanda L.; Christodoulou, Alexandra N.; DeSouza, Tiffany; Murakami, Mark A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Li, Loretta S.; Kopp, Nadja; Koch, Raphael; Ng, Samuel Y.; Fisher, David C.; Freedman, Arnold S.; Jacobsen, Eric D.; Weinstock, David M.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Louissaint, Abner, Jr.; Jacobson, Caron A.; Davids, Matthew S.; Odejide, Oreofe O.; LaCasce, Ann S.; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Shoji, Brent; Bertagnolli, Monica] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Pinkus, Geraldine S.; Aster, Jon C.] Brigham & Womens Hosp, Pathol, Boston, MA 02115 USA. [Dorfman, David M.; Morgan, Elizabeth A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800258 ER PT J AU Christie, AL Li, Y Togami, K Ghandi, M Christodoulou, AN Buczkowski, K Angelot-Delettre, F Biichle, S Chen, J Brooks, CL Weinstock, DM Garnache-Ottou, F Hammerman, PS Lane, AA AF Christie, Amanda L. Li, Yvonne Togami, Katsuhiro Ghandi, Mahmoud Christodoulou, Alexandra N. Buczkowski, Kevin Angelot-Delettre, Fanny Biichle, Sabeha Chen, Janice Brooks, Christopher L. Weinstock, David M. Garnache-Ottou, Francine Hammerman, Peter S. Lane, Andrew A. TI Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Christie, Amanda L.; Christodoulou, Alexandra N.; Lane, Andrew A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Li, Yvonne; Togami, Katsuhiro; Buczkowski, Kevin; Weinstock, David M.; Hammerman, Peter S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ghandi, Mahmoud] Broad Inst, Cambridge, MA USA. [Angelot-Delettre, Fanny; Biichle, Sabeha; Garnache-Ottou, Francine] Univ Bourgogne Franche Comte, INSERM, EFS RFC, UMR 1098, Besancon, France. [Chen, Janice; Brooks, Christopher L.] Stemline Therapeut Inc, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800054 ER PT J AU Cifani, P Shakiba, M Brown, F Dhabaria, A Bauer, DE Kentsis, A AF Cifani, Paolo Shakiba, Mojdeh Brown, Fiona Dhabaria, Avantika Bauer, Daniel E. Kentsis, Alex TI Functional Proteomics of Regulatory and Epigenetic Signaling in Normal and Malignant Hematopoiesis SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Cifani, Paolo; Shakiba, Mojdeh; Brown, Fiona; Dhabaria, Avantika; Kentsis, Alex] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Shakiba, Mojdeh] Weill Cornell Med Coll, New York, NY USA. [Bauer, Daniel E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Pediat Hematol Oncol,Boston Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021803275 ER PT J AU Cook, G Cella, D Durie, B Goldschmidt, H Kuter, D Moreau, P Vij, R Davis, C Oukessou, A Zyczynski, T Popov, S Palumbo, A AF Cook, Gordon Cella, David Durie, Brian Goldschmidt, Hartmut Kuter, David Moreau, Philippe Vij, Ravi Davis, Catherine Oukessou, Abderrahim Zyczynski, Teresa Popov, Sergey Palumbo, Antonio TI An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Cook, Gordon] Univ Leeds, Leeds, W Yorkshire, England. [Cella, David] Northwestern Univ, Evanston, IL USA. [Durie, Brian] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Goldschmidt, Hartmut] Univ Heidelberg Hosp, Heidelberg, Germany. [Kuter, David] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Moreau, Philippe] Univ Hosp, Nantes, France. [Vij, Ravi] Washington Univ, Sch Med, St Louis, MO USA. [Davis, Catherine; Oukessou, Abderrahim; Zyczynski, Teresa] Bristol Myers Squibb, Princeton, NJ USA. [Popov, Sergey] Parexel, St Petersburg, Russia. [Palumbo, Antonio] Osped Molinette, AOU San Giovanni Battista Torino, Turin, Italy. RI richard, chrystelle/K-8595-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100258 ER PT J AU Cortes, JE Kim, DW Pinilla-Ibarz, J le Coutre, PD Paquette, R Chuah, C Nicolini, FE Apperley, JF Khoury, HJ Talpaz, M DeAngelo, DJ Abruzzese, E Rea, D Baccarani, M Muller, MC Gambacorti-Passerini, C Lustgarten, S Conlan, M Guilhot, F Deininger, MW Hochhaus, A Hughes, TP Kantarjian, HM Shah, NP AF Cortes, Jorge E. Kim, Dong-Wook Pinilla-Ibarz, Javier le Coutre, Philipp D. Paquette, Ronald Chuah, Charles Nicolini, Franck E. Apperley, Jane F. Khoury, H. Jean Talpaz, Moshe DeAngelo, Daniel J. Abruzzese, Elisabetta Rea, Delphine Baccarani, Michele Mueller, Martin C. Gambacorti-Passerini, Carlo Lustgarten, Stephanie Conlan, Maureen Guilhot, Francois Deininger, Mochael W. Hochhaus, Andreas Hughes, Timothy P. Kantarjian, Hagop M. Shah, Neil P. TI Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Kim, Dong-Wook] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea. [Pinilla-Ibarz, Javier] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA. [le Coutre, Philipp D.] Charite, D-13353 Berlin, Germany. [Paquette, Ronald] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Chuah, Charles] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore. [Nicolini, Franck E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France. [Apperley, Jane F.] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England. [Khoury, H. Jean] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Talpaz, Moshe] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Abruzzese, Elisabetta] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy. [Rea, Delphine] Hop St Louis, Dept Hematol, Paris, France. [Baccarani, Michele] Univ Bologna, Inst Hematol, Bologna, Italy. [Mueller, Martin C.] Univ Med Mannheim, Mannheim, Germany. [Gambacorti-Passerini, Carlo] Univ Milano Bicocca, Azienda Osped San Gerardo, Monza, Italy. [Lustgarten, Stephanie; Conlan, Maureen] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA. [Guilhot, Francois] CHU Poitiers, Inserm CIC 1402, Poitiers, France. [Deininger, Mochael W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Hochhaus, Andreas] Jena Univ Hosp, Jena, Germany. [Hughes, Timothy P.] Univ Adelaide, SA Pathol, Adelaide, SA, Australia. [Hughes, Timothy P.] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia. [Kantarjian, Hagop M.; Shah, Neil P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7YP UT WOS:000368021804118 ER PT J AU Cottini, F Tonon, G Hideshima, T Richardson, PG Anderson, KC AF Cottini, Francesca Tonon, Giovanni Hideshima, Teru Richardson, Paul G. Anderson, Kenneth C. TI Targeting Replicative Stress to Treat Hematological Disorders SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Cottini, Francesca] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA. [Cottini, Francesca] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Tonon, Giovanni] Univ Milan, Osped San Raffaele, I-20127 Milan, Italy. [Hideshima, Teru] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Div Hematol Malignancy, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020101257 ER PT J AU Curran, KJ Riviere, I Silverman, LB Kobos, R Shukla, N Steinherz, PG Boulad, F Prockop, S Scaradavou, A Margossian, SP Wang, XY Wang, YZ Szenes, V Dansereau, CH MacKinnon, B Sauter, CS Park, JH Kernan, NA O'Reilly, RJ Sadelain, M Brentjens, RJ AF Curran, Kevin J. Riviere, Isabelle Silverman, Lewis B. Kobos, Rachel Shukla, Neerav Steinherz, Peter G. Boulad, Farid Prockop, Susan Scaradavou, Andromachi Margossian, Steven P. Wang, Xiuyan Wang, Yongzeng Szenes, Victoria Dansereau, Colleen H. MacKinnon, Brenda Sauter, Craig S. Park, Jae H. Kernan, Nancy A. O'Reilly, Richard J. Sadelain, Michel Brentjens, Renier J. TI Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Curran, Kevin J.; Kobos, Rachel; Shukla, Neerav; Steinherz, Peter G.; Boulad, Farid; Prockop, Susan; Scaradavou, Andromachi; Szenes, Victoria; Kernan, Nancy A.; O'Reilly, Richard J.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA. [Curran, Kevin J.; Riviere, Isabelle; Boulad, Farid; Wang, Xiuyan; Wang, Yongzeng; Kernan, Nancy A.; O'Reilly, Richard J.; Sadelain, Michel; Brentjens, Renier J.] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY 10021 USA. [Riviere, Isabelle; Sadelain, Michel] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [Silverman, Lewis B.; Margossian, Steven P.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Silverman, Lewis B.] Boston Childrens Hosp, Boston, MA USA. [Silverman, Lewis B.; Margossian, Steven P.; Dansereau, Colleen H.; MacKinnon, Brenda] Boston Childrens Hosp, Div Pediat Hematol, Boston, MA USA. [Sauter, Craig S.] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY 10021 USA. [Park, Jae H.; Brentjens, Renier J.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. NR 0 TC 4 Z9 4 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102045 ER PT J AU Davids, MS Kim, HT Fernandes, SM Hellman, J Francoeur, K Arnason, JE Jacobsen, E LaCasce, AS Fisher, DC Brown, JR AF Davids, Matthew S. Kim, Haesook T. Fernandes, Stacey M. Hellman, Jeffrey Francoeur, Karen Arnason, Jon E. Jacobsen, Eric LaCasce, Ann S. Fisher, David C. Brown, Jennifer R. TI A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Davids, Matthew S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Fernandes, Stacey M.; Hellman, Jeffrey; Francoeur, Karen; Jacobsen, Eric; LaCasce, Ann S.; Brown, Jennifer R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Arnason, Jon E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Fisher, David C.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801101 ER PT J AU Davids, MS Kim, HT Gilbert, E Cowen, L Francoeur, K Hellman, J Arnason, JE Fisher, DC Brown, JR AF Davids, Matthew S. Kim, Haesook T. Gilbert, Elizabeth Cowen, Leslie Francoeur, Karen Hellman, Jeffrey Arnason, Jon E. Fisher, David C. Brown, Jennifer R. TI Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Davids, Matthew S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Gilbert, Elizabeth; Cowen, Leslie; Fisher, David C.; Brown, Jennifer R.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Francoeur, Karen; Hellman, Jeffrey] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Arnason, Jon E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801100 ER PT J AU De La Puente, P Weisberg, E Nonami, A Luderer, MJ Stone, RM Melo, JV Griffin, JD Kareem, A AF De La Puente, Pilar Weisberg, Ellen Nonami, Atsushi Luderer, Micah John Stone, Richard M. Melo, Junia V. Griffin, James D. Kareem, Abdel TI Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [De La Puente, Pilar; Luderer, Micah John; Kareem, Abdel] Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO USA. [Weisberg, Ellen; Nonami, Atsushi; Griffin, James D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Melo, Junia V.] SA Pathol, Haematol, Adelaide, SA, Australia. [Melo, Junia V.] Ctr Canc Biol, Adelaide, SA, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XY UT WOS:000368020105260 ER PT J AU DeAngelo, DJ Walker, AR Schlenk, RF Sierra, J Medeiros, BC Ocio, EM Rollig, C Strickland, SA Thol, F Valera, SZ Wegener, A De, T Mu, S Binlich, F Stuart, RK AF DeAngelo, Daniel J. Walker, Alison R. Schlenk, Richard F. Sierra, Jorge Medeiros, Bruno C. Ocio, Enrique M. Roellig, Christoph Strickland, Stephen A. Thol, Felicitas Valera, Sue-Zette Wegener, Antje De, Tuli Mu, Song Binlich, Florence Stuart, Robert K. TI A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Walker, Alison R.] James Canc Hosp, Ohio State Comprehens Canc Ctr, Columbus, OH USA. [Schlenk, Richard F.] Univ Hosp Ulm, Ulm, Germany. [Sierra, Jorge] Univ Autonoma Barcelona, Dept Hematol, Hosp Santa Creu & St Pau, E-08193 Barcelona, Spain. [Medeiros, Bruno C.] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA. [Ocio, Enrique M.] Hosp Univ Salamanca, Salamanca, Spain. [Roellig, Christoph] Univ Klinikum Carl Gustav Carus, Dresden, Germany. [Strickland, Stephen A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Thol, Felicitas] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany. [Valera, Sue-Zette; Mu, Song] Novartis Pharmaceut, E Hanover, NJ USA. [Wegener, Antje; Binlich, Florence] Novartis Pharma SAS, Rueil Malmaison, France. [De, Tuli] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India. [Stuart, Robert K.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. RI Walker, Alison/E-4260-2011 NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102065 ER PT J AU DeAngelo, DJ Fathi, AT Werner, L Avigan, D Luptakova, K Wadleigh, M Steensma, DP Hobbs, GS Attar, EC Amrein, PC Stone, RM Ballen, KK AF DeAngelo, Daniel J. Fathi, Amir T. Werner, Lillian Avigan, David Luptakova, Katarina Wadleigh, Martha Steensma, David P. Hobbs, Gabriela Soriano Attar, Eyal C. Amrein, Philip C. Stone, Richard M. Ballen, Karen K. TI A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [DeAngelo, Daniel J.; Steensma, David P.; Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Fathi, Amir T.; Werner, Lillian; Hobbs, Gabriela Soriano; Attar, Eyal C.; Amrein, Philip C.; Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Luptakova, Katarina] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Wadleigh, Martha] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102062 ER PT J AU DeZern, AE Zeidan, AM Barnard, J Hand, W Al Ali, N Brown, F Zimmerman, C Roboz, GJ Komrokji, RS Garcia-Manero, G Steensma, DP Sekeres, MA AF DeZern, Amy E. Zeidan, Amer M. Barnard, John Hand, Wesley Al Ali, Najla Brown, Francis Zimmerman, Cassie Roboz, Gail J. Komrokji, Rami S. Garcia-Manero, Guillermo Steensma, David P. Sekeres, Mikkael A. TI Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Zeidan, Amer M.] Yale Univ, Sch Med, New Haven, CT USA. [Barnard, John; Zimmerman, Cassie] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Hand, Wesley] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Al Ali, Najla] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Brown, Francis; Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Roboz, Gail J.] Weill Cornell Med Coll, Joan & Sanford I Weill Dept Med, New York, NY USA. [Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA. [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Sekeres, Mikkael A.] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020103084 ER PT J AU Dhimolea, E King, E Sheffer, M Hu, YG Awate, PP Sarkar, S Matthews, GM Murnane, M Bariteau, MA Aftab, BT Mitsiades, CS AF Dhimolea, Eugen King, Emily Sheffer, Michal Hu, Yiguo Awate, Pallavi P. Sarkar, Subhashis Matthews, Geoffrey M. Murnane, Megan Bariteau, Megan A. Aftab, Blake T. Mitsiades, Constantine S. TI Constitutive Vs. Stroma-Induced Kinase Dependencies in Myeloma Cells: Functional Mapping Using Small Molecule Inhibitors As Chemical Probes SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Dhimolea, Eugen; King, Emily; Sheffer, Michal; Hu, Yiguo; Awate, Pallavi P.; Sarkar, Subhashis; Matthews, Geoffrey M.; Bariteau, Megan A.; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Murnane, Megan; Aftab, Blake T.] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XY UT WOS:000368020105275 ER PT J AU Dimopoulos, MA Trotman, J Tedeschi, A Matous, JV Macdonald, D Tam, C Tournilhac, O Ma, S Oriol, A Heffner, LT Shustik, C Garcia-Sanz, R Cornelli, RF de Larrea, CF Castillo, JJ Granell, M Kyrtsonis, MC Leblond, V Svmeonidis, A Singh, P Li, JL Graef, T Bilotti, E Treon, S Buske, C AF Dimopoulos, Meletios A. Trotman, Judith Tedeschi, Alessandra Matous, Jeffrey V. Macdonald, David Tam, Constantine Tournilhac, Oliver Ma, Shuo Oriol, Albert Heffner, Leonard T. Shustik, Chaim Garcia-Sanz, Ramon Cornelli, Robert F. Fernandez de Larrea, Carlos Castillo, Jorge J. Granell, Miquel Kyrtsonis, Marie-Christine Leblond, Veronique Svmeonidis, Argiris Singh, Priyanka Li, Jianling Graef, Thorsten Bilotti, Elizabeth Treon, Steven Buske, Christian TI Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenstrom's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE (TM)) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 11528, Greece. [Trotman, Judith] Univ Sydney, Concord Hosp, Dept Haematol, Concord, NSW, Australia. [Tedeschi, Alessandra] Osped Niguarda Ca Granda, Div Hematol, Milan, Italy. [Matous, Jeffrey V.] Colorado Blood Canc Inst, Denver, CO USA. [Macdonald, David] Dalhousie Univ, Div Hematol, Halifax, NS, Canada. [Tam, Constantine] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Tam, Constantine] St Vincents Hosp, Melbourne, Vic, Australia. [Tournilhac, Oliver] CHU Clermont Ferrand, Hematol Clin Adulte & Therapie Cellulaire, Clermont Ferrand, France. [Ma, Shuo] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Oriol, Albert] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain. [Heffner, Leonard T.] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA. [Shustik, Chaim] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada. [Garcia-Sanz, Ramon] Hosp Univ Salamanca, Dept Hematol, Salamanca, Spain. [Cornelli, Robert F.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Fernandez de Larrea, Carlos] Hosp Clin Barcelona, IDIBAPS, Amyloidosis & Myeloma Unit, Dept Hematol, Barcelona, Spain. [Castillo, Jorge J.; Treon, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA. [Granell, Miquel] St Pauls Hosp, Dept Hematol, Barcelona, Spain. [Kyrtsonis, Marie-Christine] Univ Athens, Laikon Univ Hosp, Sch Med, Hematol Sect,Dept Propaedeut Med 1, Athens 11528, Greece. [Leblond, Veronique] UPMC Univ Paris, Hematol Hop Pitie Salpetriere, APHP, Dept Hematol, Paris, France. [Svmeonidis, Argiris] Univ Patras, Sch Med, Dept Internal Med, GR-26110 Patras, Greece. [Singh, Priyanka; Li, Jianling; Graef, Thorsten; Bilotti, Elizabeth] Pharmacyclics LLC, Sunnyvale, CA USA. [Buske, Christian] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, Ulm, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102257 ER PT J AU Dunford, A Schumacher, SE Savova, V Gimelbrant, AA Beroukhim, R Lawrence, MS Getz, G Weinstock, DM Lane, AA AF Dunford, Andrew Schumacher, Stephen E. Savova, Virginia Gimelbrant, Alexander A. Beroukhim, Rameen Lawrence, Michael S. Getz, Gad Weinstock, David M. Lane, Andrew A. TI Escape from X-Inactivation Tumor Suppressor (EXITS) Genes Are Associated with Excess Incidence of Cancer in Men SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Dunford, Andrew; Schumacher, Stephen E.; Lawrence, Michael S.; Getz, Gad] Broad Inst, Cambridge, MA USA. [Savova, Virginia; Gimelbrant, Alexander A.; Beroukhim, Rameen; Weinstock, David M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lane, Andrew A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XY UT WOS:000368020105231 ER PT J AU Ebeid, E Abdallah, A Hammad, M Mansour, A Khairy, M Maher, OM Lehmann, LE AF Ebeid, Emad Abdallah, Amr Hammad, Mahmoud Mansour, Amira Khairy, Mai Maher, Ossama M. Lehmann, Leslie E. TI Outcome of Patients with Acute Lymphoblastic Leukemia in an Egyptian Institution with Limited Resources. January 2000-August 2011 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Ebeid, Emad; Abdallah, Amr; Hammad, Mahmoud; Maher, Ossama M.] Natl Canc Inst, Dept Pediat, Cairo, Egypt. [Ebeid, Emad] Menia Oncol Ctr, Dept Pediat, Menia, Egypt. [Mansour, Amira] Naser Canc Inst, Dept Pediat, Cairo, Egypt. [Khairy, Mai] Cairo Univ Hosp, Dept Pediat, Cairo, Egypt. [Maher, Ossama M.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA. [Lehmann, Leslie E.] Childrens Hosp, Dana Farber Canc Inst, Massachusetts Gen, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021803185 ER PT J AU El-Jawahri, A Keenan, T Abel, G Steensma, DP LeBlanc, TW Traeger, L Fathi, AT DeAngelo, DJ Wadleigh, M Hobbs, G Amrein, PC Stone, RM Ballen, KK Chen, YB Temel, JS AF El-Jawahri, Areej Keenan, Tanya Abel, Gregory Steensma, David P. LeBlanc, Thomas W. Traeger, Lara Fathi, Amir T. DeAngelo, Daniel J. Wadleigh, Martha Hobbs, Gabriela Amrein, Philip C. Stone, Richard M. Ballen, Karen K. Chen, Yi-Bin Temel, Jennifer S. TI Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [El-Jawahri, Areej; Amrein, Philip C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Keenan, Tanya; Traeger, Lara; Ballen, Karen K.; Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Abel, Gregory; Steensma, David P.; Wadleigh, Martha] Dana Farber Canc Inst, Boston, MA 02115 USA. [LeBlanc, Thomas W.] Duke Canc Inst, Durham, NC USA. [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [DeAngelo, Daniel J.; Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Hobbs, Gabriela] Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA. [Temel, Jennifer S.] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104192 ER PT J AU El-Jawahri, A Heavey, SF LeBlanc, TW Vandusen, H Abel, G Steensma, DP Traeger, L Fathi, AT DeAngelo, DJ Wadleigh, M Hobbs, G Amrein, PC Stone, RM Ballen, KK Chen, YB Temel, JS AF El-Jawahri, Areej Heavey, Sean F. LeBlanc, Thomas W. Vandusen, Harry Abel, Gregory Steensma, David P. Traeger, Lara Fathi, Amir T. DeAngelo, Daniel J. Wadleigh, Martha Hobbs, Gabriela Amrein, Philip C. Stone, Richard M. Ballen, Karen K. Chen, Yi-Bin Temel, Jennifer S. TI Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [El-Jawahri, Areej; Amrein, Philip C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Heavey, Sean F.; Temel, Jennifer S.] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA. [LeBlanc, Thomas W.] Duke Univ, Sch Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA. [Vandusen, Harry; Traeger, Lara; Ballen, Karen K.; Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Abel, Gregory; Steensma, David P.; Wadleigh, Martha] Dana Farber Canc Inst, Boston, MA 02115 USA. [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [DeAngelo, Daniel J.; Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Hobbs, Gabriela] Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100291 ER PT J AU Fan, J Wang, LL Brooks, AN Wan, YZ Neuberg, DS Rassenti, LZ Ghia, EM Kipps, TJ Brown, JR Li, SQ Livak, KJ Meyerson, MM Kharchenko, PV Wu, CJ AF Fan, Jean Wang, Lili Brooks, Angela N. Wan, Youzhong Neuberg, Donna S. Rassenti, Laura Z. Ghia, Emanuela M. Kipps, Thomas J. Brown, Jennifer R. Li, Shuqiang Livak, Kenneth J. Meyerson, Matthew M. Kharchenko, Peter V. Wu, Catherine J. TI Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Fan, Jean; Kharchenko, Peter V.] Harvard Univ, Sch Med, Dept Biomed Informat, Boston, MA USA. [Wang, Lili; Wan, Youzhong; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Wang, Lili; Wan, Youzhong; Brown, Jennifer R.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Brooks, Angela N.] Broad Inst, Cambridge, MA USA. [Brooks, Angela N.] Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA. [Wan, Youzhong] Jilin Univ, Sch Life Sci, Changchun 130023, Peoples R China. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Rassenti, Laura Z.] CLL Res Consortium, Moores UCSD Canc Ctr, La Jolla, CA USA. [Ghia, Emanuela M.] CLL Res Consortium, Moores UCSD Canc Ctr, San Diego, CA USA. [Kipps, Thomas J.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Brown, Jennifer R.; Wu, Catherine J.] Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA. [Li, Shuqiang; Livak, Kenneth J.] Fluidigm Corp, San Francisco, CA USA. [Meyerson, Matthew M.] Broad Inst MIT & Harvard, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020103101 ER PT J AU Field, JJ Majerus, EM Ataga, KI Vichinsky, EP Eaton, C Mazanet, R Nathan, DG AF Field, Joshua J. Majerus, Elaine M. Ataga, Ken I. Vichinsky, Elliott P. Eaton, Cheryl Mazanet, Rosemary Nathan, David G. TI NKTT120 Safely Depletes iNKT Cells in Stable Adult Sickle Cell Patients in a Phase 1 Trial SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Field, Joshua J.] Med Coll Wisconsin, BloodCtr Wisconsin, Milwaukee, WI 53226 USA. [Majerus, Elaine M.] Washington Univ, Sch Med, Div Hematol, St Louis, MO USA. [Ataga, Ken I.] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA. [Vichinsky, Elliott P.] Childrens Hosp & Res Ctr, Pediat Hematol Oncol, Oakland, CA USA. [Eaton, Cheryl; Mazanet, Rosemary] NKT Therapeut, Waltham, MA USA. [Nathan, David G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Nathan, David G.] Boston Childrens, Boston, MA USA. [Nathan, David G.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020101016 ER PT J AU Fletcher, SA Cronin, AM Zeidan, AM Odejide, OO Gore, SD Davidoff, AJ Steensma, DP Abel, GA AF Fletcher, Sean A. Cronin, Angel M. Zeidan, Amer M. Odejide, Oreofe O. Gore, Steven D. Davidoff, Amy J. Steensma, David P. Abel, Gregory A. TI Quality of End-of-Life Care for the Myelodysplastic Syndromes: Findings from a Large National Database SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Fletcher, Sean A.; Cronin, Angel M.; Odejide, Oreofe O.; Steensma, David P.; Abel, Gregory A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Zeidan, Amer M.; Gore, Steven D.; Davidoff, Amy J.] Yale Canc Ctr, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104169 ER PT J AU Foster, J Blonquist, TM EI-Jawahri, A Fathi, AT Amrein, PC Sadrzadeh, H Brunner, AM Hobbs, G Attar, EC Neuberg, DS Ballen, KK AF Foster, Judy Blonquist, Traci M. EI-Jawahri, Areej Fathi, Amir T. Amrein, Philip C. Sadrzadeh, Hossein Brunner, Andrew M. Hobbs, Gabriella Attar, Eyal C. Neuberg, Donna S. Ballen, Karen K. TI The End of Life for Patients with Acute Myeloid Leukemia (AML)- a Single Center Experience SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Foster, Judy; EI-Jawahri, Areej; Fathi, Amir T.; Amrein, Philip C.; Hobbs, Gabriella] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Blonquist, Traci M.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Sadrzadeh, Hossein] Capital Hlth Syst, Trenton, NJ USA. [Brunner, Andrew M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Attar, Eyal C.; Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104200 ER PT J AU Garcia-Manero, G Sekeres, MA Egyed, M Alimena, G Graux, C Cavenagh, JD Salman, H Illes, A Fenaux, P DeAngelo, DJ Stauder, R Yee, K Zhu, NY Lee, JH Valcarcel, D MacWhannell, A Borbenyi, Z Wegener, A Gazi, L Acharyya, S Binlich, F Ottmann, OG AF Garcia-Manero, Guillermo Sekeres, Mikkael A. Egyed, Miklos Alimena, Giuliana Graux, Carlos Cavenagh, Jamie D. Salman, Huda Illes, Arpad Fenaux, Pierre DeAngelo, Daniel J. Stauder, Reinhard Yee, Karen Zhu, Nancy Y. Lee, Je-Hwan Valcarcel, David MacWhannell, Alan Borbenyi, Zita Wegener, Antje Gazi, Lucien Acharyya, Suddhasatta Binlich, Florence Ottmann, Oliver G. TI Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Sekeres, Mikkael A.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Egyed, Miklos] Kaposi Mor Teaching Hosp, Kaposvar, Hungary. [Alimena, Giuliana] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00185 Rome, Italy. [Graux, Carlos] Mt Godinne Univ Hosp, Yvoir, Belgium. [Cavenagh, Jamie D.] Barts Hlth NHS Trust, London, England. [Salman, Huda] Georgia Regents Univ, Augusta, GA USA. [Illes, Arpad] Univ Debrecen, Med & Hlth Sci Ctr, Dept Hematol, Debrecen, Hungary. [Fenaux, Pierre] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Stauder, Reinhard] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, A-6020 Innsbruck, Austria. [Yee, Karen] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Zhu, Nancy Y.] Univ Alberta, Div Hematol, Edmonton, AB, Canada. [Lee, Je-Hwan] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Hematol, Seoul, South Korea. [Valcarcel, David] Univ Hosp Vall dHebron, Dept Hematol, Barcelona, Spain. [MacWhannell, Alan] Royal Wolverhampton Hosp NHS Trust, Wolverhampton, W Midlands, England. [Borbenyi, Zita] Univ Szeged, Fac Med, Dept Internal Med 2, Hematol Unit, Szeged, Hungary. [Wegener, Antje; Binlich, Florence] Novartis Pharma SAS, Rueil Malmaison, France. [Gazi, Lucien] Novartis Pharma AG, Basel, Switzerland. [Acharyya, Suddhasatta] Novartis Pharmaceut, E Hanover, NJ USA. [Ottmann, Oliver G.] Cardiff Univ, Dept Haematol, Cardiff CF10 3AX, S Glam, Wales. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020103056 ER PT J AU Gerds, AT Kalaycio, ME Ahn, KW Hu, ZH Alyea, EP Popat, UR Sobecks, RM Saber, W AF Gerds, Aaron T. Kalaycio, Matt E. Ahn, Kwang Woo Hu, Zhen-Huan Alyea, Edwin P. Popat, Uday R. Sobecks, Ronald M. Saber, Wael TI Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes: A Center for International Blood and Marrow Transplant Registry (CIBMTR (R)) Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Gerds, Aaron T.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Kalaycio, Matt E.] Cleveland Clin, Taussig Canc Inst, Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA. [Ahn, Kwang Woo; Hu, Zhen-Huan] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Ahn, Kwang Woo] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA. [Alyea, Edwin P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Alyea, Edwin P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Popat, Uday R.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. [Sobecks, Ronald M.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Saber, Wael] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100168 ER PT J AU Ghobrial, IM Shain, KH Laubach, J Henrick, P Vredenburg, J Crilley, P Constantine, M Block, C Basile, FG Cappuccio, J Azab, AK Lai, E Caola, A Banwait, R Savell, A Munshi, NC Paba-Prada, CE Schlossman, RL Chuma, S Noonan, K Anderson, KC Richardson, PG AF Ghobrial, Irene M. Shain, Kenneth H. Laubach, Jacob Henrick, Patrick Vredenburg, James Crilley, Pamela Constantine, Michael Block, Caroline Basile, Frank G. Cappuccio, Joseph Azab, Abdel Kareem Lai, Emily Caola, Aaron Banwait, Ranjit Savell, Alexandra Munshi, Nikhil C. Paba-Prada, Claudia E. Schlossman, Robert L. Chuma, Stacey Noonan, Kimberly Anderson, Kenneth C. Richardson, Paul G. TI Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Shain, Kenneth H.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Laubach, Jacob; Henrick, Patrick; Cappuccio, Joseph; Lai, Emily; Caola, Aaron; Banwait, Ranjit; Savell, Alexandra; Schlossman, Robert L.; Noonan, Kimberly] Dana Farber Canc Inst, Boston, MA 02115 USA. [Vredenburg, James] St Francis Care, Hartford, CT USA. [Crilley, Pamela] Eastern Reg Med Ctr, Philadelphia, PA USA. [Constantine, Michael] Dana Farber Canc Inst, Milford, MA USA. [Block, Caroline] Newton Wellesley Hosp, Newton, MA USA. [Basile, Frank G.] Cape Cod Hosp, Cape Cod, MA USA. [Azab, Abdel Kareem] Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO USA. [Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Paba-Prada, Claudia E.; Chuma, Stacey; Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Anderson, Kenneth C.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801198 ER PT J AU Gkotzamanidou, M Terpos, E Munshi, NC Souliotis, VL Dimopoulos, MA AF Gkotzamanidou, Maria Terpos, Evangelos Munshi, Nikhil C. Souliotis, Vassilis L. Dimopoulos, Meletios A. TI The Simultaneous Accumulation of the Extremely Cytotoxic Interstrand Cross-Links and Double-Strand Breaks Contributes to the Successful Anti-Myeloma Therapy; The Effect of DNA Repair Inhibitors SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Gkotzamanidou, Maria; Terpos, Evangelos] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 11528, Greece. [Gkotzamanidou, Maria] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Souliotis, Vassilis L.] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Athens, Greece. [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Athens 11528, Greece. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801119 ER PT J AU Gkotzamanidou, M Terpos, E Munshi, NC Souliotis, VL Dimopoulos, MA AF Gkotzamanidou, Maria Terpos, Evangelos Munshi, Nikhil C. Souliotis, Vassilis L. Dimopoulos, Meletios A. TI The State of Chromatin Condensation, the Expression of Genes Involved in DNA Damage Response and the DNA Repair Capacity Affect the Drug Sensitivity of PBMCs of Myeloma Patients Treated with Melphalan SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Gkotzamanidou, Maria; Terpos, Evangelos] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 11528, Greece. [Gkotzamanidou, Maria] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Souliotis, Vassilis L.] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Athens, Greece. [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Athens 11528, Greece. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020105194 ER PT J AU Grabowski, EF Liu, BH Gerace, M Grabowski, PE Gunnarsson, P Ezban, M AF Grabowski, Eric F. Liu, Bohan Gerace, Matthew Grabowski, Paul E. Gunnarsson, Peter Ezban, Mirella TI Recombinant FVIII and FVIIa Added to Flowing Hemophiliac Blood Co-Localize with Platelet Aggregates Adherent to a Collagen Surface, Promoting Local Fibrin Deposition in Wake-like Patterns Around the Aggregates SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Grabowski, Eric F.] Massachusetts Gen Hosp, Pediat Hematol Oncol, Boston, MA 02114 USA. [Grabowski, Eric F.] Harvard Univ, Sch Med, Boston, MA USA. [Liu, Bohan; Gerace, Matthew] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Grabowski, Paul E.] Univ Calif Irvine, Irvine, CA USA. [Gunnarsson, Peter; Ezban, Mirella] Novo Nordisk, Malov, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7XY UT WOS:000368020105065 ER PT J AU Hao, M Zang, MR Xu, Y Qin, Y Zhao, L Deng, SH Sui, WW An, G Li, ZJ Yi, SH Zhan, FH Qiu, LG AF Hao, Mu Zang, Meirong Xu, Yan Qin, Yu Zhao, Lei Deng, Shuhui Sui, Weiwei An, Gang Li, Zengjun Yi Shuhua Zhan, Fenghuang Qiu, Lugui TI Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Hao, Mu; Zang, Meirong; Qin, Yu; Deng, Shuhui; Sui, Weiwei; Li, Zengjun; Yi Shuhua; Qiu, Lugui] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China. [Hao, Mu; Zang, Meirong; Qin, Yu; Deng, Shuhui; Sui, Weiwei; Li, Zengjun; Yi Shuhua; Qiu, Lugui] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China. [Hao, Mu; Zang, Meirong; Xu, Yan; Qin, Yu; Deng, Shuhui; Sui, Weiwei; Li, Zengjun; Yi Shuhua; Qiu, Lugui] Peking Union Med Coll, Tianjin, Peoples R China. [Xu, Yan] Chinese Acad Med Sci, Inst Hematol, Lymphoma & Myeloma Dept, Tianjin, Peoples R China. [Xu, Yan] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China. [Zhao, Lei] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA USA. [An, Gang] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Zhan, Fenghuang] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801128 ER PT J AU Harris, AC Young, R Devine, SM Hogan, WJ Ayuk, F Bunworasate, U Chanswangphuwana, C Efebera, YA Holler, E Litzow, MR Ordemann, R Qayed, M Renteria, AS Reshef, R Woelfi, M Chen, YB Goldstein, S Jagasia, MH Locatelli, F Mielke, S Porter, DL Schechter, T Shekhovtsova, Z Ferrara, JLM Levine, JE AF Harris, Andrew C. Young, Rachel Devine, Steven M. Hogan, William J. Ayuk, Francis Bunworasate, Udomsak Chanswangphuwana, Chantiya Efebera, Yvonne A. Holler, Ernst Litzow, Mark R. Ordemann, Rainer Qayed, Muna Renteria, Anne S. Reshef, Ran Woelfi, Matthias Chen, Yi-Bin Goldstein, Steven Jagasia, Madan H. Locatelli, Franco Mielke, Stephan Porter, David L. Schechter, Tal Shekhovtsova, Zhanna Ferrara, James L. M. Levine, John E. TI Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Harris, Andrew C.] Univ Utah, Primary Childrens Med Ctr, Salt Lake City, UT USA. [Young, Rachel; Goldstein, Steven; Levine, John E.] Univ Michigan, Ann Arbor, MI 48109 USA. [Devine, Steven M.; Efebera, Yvonne A.] Ohio State Univ, Columbus, OH 43210 USA. [Hogan, William J.; Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, MN USA. [Ayuk, Francis] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany. [Bunworasate, Udomsak; Chanswangphuwana, Chantiya] Chulalongkorn Univ, Bangkok, Thailand. [Holler, Ernst] Univ Regensburg, D-93053 Regensburg, Germany. [Ordemann, Rainer] Univ Hosp TU Dresden, Dresden, Germany. [Qayed, Muna] Emory Univ, Atlanta, GA 30322 USA. [Renteria, Anne S.; Ferrara, James L. M.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Reshef, Ran] Columbia Univ, Med Ctr, New York, NY USA. [Woelfi, Matthias; Mielke, Stephan] Univ Wurzburg, D-97070 Wurzburg, Germany. [Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Locatelli, Franco] Univ Pavia, IRCCS Osped Pediat Bambino Gesu, Rome, Italy. [Porter, David L.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Schechter, Tal] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Shekhovtsova, Zhanna] Fed Ctr Pediat Hematol, Moscow, Russia. [Levine, John E.] Mt Sinai Sch Med, Blood & Marrow Transplant Program, New York, NY USA. [Levine, John E.] Univ Michigan, Med Ctr, Canc Ctr 5303, Ann Arbor, MI USA. RI Efebera, Yvonne/E-3012-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104036 ER PT J AU Harris, MH Blonquist, TM Athale, UH Clavell, LA Cole, PD Kelly, KM Laverdiere, C Leclerc, JM Michon, B Schorin, MA Welch, JJG Neuberg, DS Sallan, SE Silverman, LB AF Harris, Marian H. Blonquist, Traci M. Athale, Uma H. Clavell, Luis A. Cole, Peter D. Kelly, Kara M. Laverdiere, Caroline Leclerc, Jean-Marie Michon, Bruno Schorin, Marshall A. Welch, Jennifer J. G. Neuberg, Donna S. Sallan, Stephen E. Silverman, Lewis B. TI Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Harris, Marian H.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Blonquist, Traci M.; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Athale, Uma H.] McMaster Childrens Hosp, Hamilton Hlth Sci, Div Hematol Oncol, Hamilton, ON, Canada. [Clavell, Luis A.] San Jorge Childrens Hosp, San Juan, PR USA. [Cole, Peter D.] Montefiore Med Ctr, Albert Einstein Coll Med, Pediat, Bronx, NY 10467 USA. [Kelly, Kara M.] Columbia Univ, Med Ctr, Pediat Hematol Oncol Stem Cell Transplantat, New York, NY USA. [Laverdiere, Caroline; Leclerc, Jean-Marie] Univ Montreal, St Justine Univ Hosp, Charles Bruneau Canc Ctr, Div Hematol Oncol, Montreal, PQ, Canada. [Michon, Bruno] Ctr Hosp Univ Quebec, Ste Foy, PQ, Canada. [Schorin, Marshall A.] Inova Fairfax Hosp Children, Falls Church, VA USA. [Welch, Jennifer J. G.] Brown Univ, Hasbro Childrens Hosp, Pediat Hematol Oncol, Providence, RI 02912 USA. [Sallan, Stephen E.; Silverman, Lewis B.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Sallan, Stephen E.; Silverman, Lewis B.] Boston Childrens Hosp, Boston, MA USA. [Sallan, Stephen E.] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA USA. [Silverman, Lewis B.] Boston Childrens Hosp, Div Pediat Hematol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102125 ER PT J AU Henderson, TO Parsons, SK Wroblewski, K Chen, L Hong, FX Smith, SM McNeer, J Advani, R Cascoynee, RD Constine, L Horning, SJ Bartlett, NL Shah, BD Connors, JM Leonard, JP Kahl, BS Kelly, KM Schwartz, C Friedman, DL Gordon, LI Evens, AM AF Henderson, Tara O. Parsons, Susan K. Wroblewski, Kristen Chen, Lo Hong, Fangxin Smith, Sonali M. McNeer, Jennifer Advani, Ranjana Cascoynee, Randy D. Constine, Louis Horning, Sandra J. Bartlett, Nancy L. Shah, Bijal D. Connors, Joseph M. Leonard, John P. Kahl, Brad S. Kelly, Kara M. Schwartz, Cindy Friedman, Debra L. Gordon, Leo I. Evens, Andrew M. TI Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Henderson, Tara O.; McNeer, Jennifer] Univ Chicago, Corner Childrens Hosp, Chicago, IL 60637 USA. [Parsons, Susan K.] Tufts Med Ctr, Dept Med, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. [Parsons, Susan K.] Dept Pediat, Boston, MA USA. [Wroblewski, Kristen] Univ Chicago, Dept Hlth Sci, Chicago, IL 60637 USA. [Chen, Lo] Childrens Oncol Croup, Acadia, CA USA. [Hong, Fangxin] Dana Farber Canc Inst, Boston, MA 02115 USA. [Smith, Sonali M.] Univ Chicago, Chicago, IL 60637 USA. [Advani, Ranjana] Stanford Canc Ctr, Stanford, CA USA. [Cascoynee, Randy D.] British Columbia Canc Agcy, Ctr Lymphoid Canc, Dept Pathol & Lab Med, Vancouver, BC V5Z 4E6, Canada. [Constine, Louis] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Horning, Sandra J.] Genentech Inc, San Francisco, CA 94080 USA. [Bartlett, Nancy L.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA. [Shah, Bijal D.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA. [Connors, Joseph M.] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada. [Connors, Joseph M.] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada. [Leonard, John P.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Kahl, Brad S.] Univ Wisconsin, Dept Med Hematol Oncol, Madison, WI USA. [Kelly, Kara M.] Columbia Univ, Med Ctr, Pediat Hematol Oncol Stem Cell Transplantat, New York, NY USA. [Schwartz, Cindy] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Friedman, Debra L.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA. [Evens, Andrew M.] Tufts Med Ctr, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102148 ER PT J AU Hengeveld, PJ Matthews, GM Hu, YG Sheffer, M Bariteau, MA Poarch, HI Dhimolea, E Mitsiades, CS AF Hengeveld, Paul J. Matthews, Geoffrey M. Hu, Yiguo Sheffer, Michal Bariteau, Megan A. Poarch, Haley I. Dhimolea, Eugen Mitsiades, Constantine S. TI Systematic Evaluation of Preclinical Genetically Determined Vs. "Stochastic"/Transient Resistance to High-Dose Melphalan Treatment in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Hengeveld, Paul J.; Matthews, Geoffrey M.; Hu, Yiguo; Sheffer, Michal; Bariteau, Megan A.; Poarch, Haley I.; Dhimolea, Eugen; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. [Hengeveld, Paul J.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020101322 ER PT J AU Herrera, AF Merryman, RW Kong, KA Sun, H Brown, JR Fisher, DC Davids, MS Jacobsen, ED Jacobson, CA Kim, HT LaCasce, AS Pihan, GA Sohani, AR Rodig, SJ Freedman, AS Ritz, J Faham, M Armand, P AF Herrera, Alex F. Merryman, Reid W. Kong, Katherine A. Sun, Heather Brown, Jennifer R. Fisher, David C. Davids, Matthew S. Jacobsen, Eric D. Jacobson, Caron A. Kim, Haesook T. LaCasce, Ann S. Pihan, German A. Sohani, Aliyah R. Rodig, Scott J. Freedman, Arnold S. Ritz, Jerome Faham, Malek Armand, Philippe TI Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Herrera, Alex F.] City Hope Natl Med Ctr, Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA. [Merryman, Reid W.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Kong, Katherine A.; Faham, Malek] Adapt Biotechnol Corp, San Francisco, CA USA. [Sun, Heather] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Brown, Jennifer R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Fisher, David C.; Jacobsen, Eric D.; Freedman, Arnold S.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Davids, Matthew S.; Jacobson, Caron A.; LaCasce, Ann S.; Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Pihan, German A.] BIDMC, Pathol, Boston, MA USA. [Sohani, Aliyah R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Rodig, Scott J.] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA. [Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104038 ER PT J AU Hirakawa, M Matos, TR Forcade, E Wang, KS Espada, EL Whangbo, J Reynolds, CG Chammas, MJ Murase, K Ritz, J AF Hirakawa, Masahiro Matos, Tiago R. Forcade, Edouard Wang, Kathy S. Espada, Eduardo L. Whangbo, Jennifer Reynolds, Carol G. Chammas, Marie J. Murase, Kazuyuki Ritz, Jerome TI IL-2, IL-7, IL-15 and IL-6 Induce Differential Activation of Naive and Memory T Cell Subsets SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Hirakawa, Masahiro; Matos, Tiago R.; Forcade, Edouard; Wang, Kathy S.; Espada, Eduardo L.; Murase, Kazuyuki] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Hirakawa, Masahiro; Matos, Tiago R.; Forcade, Edouard; Wang, Kathy S.; Espada, Eduardo L.; Murase, Kazuyuki] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Whangbo, Jennifer; Reynolds, Carol G.; Chammas, Marie J.; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Murase, Kazuyuki] Sapporo Med Univ, Sch Med, Dept Med Oncol & Hematol, Sapporo, Hokkaido, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104307 ER PT J AU Hobbs, G Litvin, R Ahn, J Mckenney, AS Mauro, MJ Tallman, MS Berman, E Heaney, ML Levine, RL Rampal, RK AF Hobbs, Gabriella Litvin, Rivka Ahn, Jihae Mckenney, Anna Sophia Mauro, Michael J. Tallman, Martin S. Berman, Ellin Heaney, Mark Lawrence Levine, Ross L. Rampal, Raajit K. TI AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Hobbs, Gabriella] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Litvin, Rivka] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA. [Ahn, Jihae; Mckenney, Anna Sophia; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Mauro, Michael J.; Tallman, Martin S.; Berman, Ellin; Rampal, Raajit K.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. [Heaney, Mark Lawrence] Columbia Univ, Med Ctr, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801017 ER PT J AU Hochhaus, A Cortes, JE Kim, DW Pinilla-Ibarz, J le Coutre, PD Paquette, R Chuah, C Nicolini, FE Apperley, JF Khoury, HJ Talpaz, M DeAngelo, DJ Abruzzese, E Rea, D Baccarani, M Muller, MC Gambacorti-Passerini, C Lustgarten, S Conlan, M Rivera, VM Guilhot, F Deininger, MW Hughes, TP Shah, NP Kantarjian, HM AF Hochhaus, Andreas Cortes, Jorge E. Kim, Dong-Wook Pinilla-Ibarz, Javier le Coutre, Philipp D. Paquette, Ronald Chuah, Charles Nicolini, Franck. E. Apperley, Jane F. Khoury, H. Jean Talpaz, Moshe DeAngelo, Daniel J. Abruzzese, Elisabetta Rea, Delphine Baccarani, Michele Muller, Martin C. Gambacorti-Passerini, Carlo Lustgarten, Stephanie Conlan, Maureen Rivera, Victor M. Guilhot, Francois Deininger, Mochael W. Hughes, Timothy P. Shah, Neil P. Kantarjian, Hagop M. TI Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Hochhaus, Andreas] Jena Univ Hosp, Jena, Germany. [Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Kim, Dong-Wook] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea. [Pinilla-Ibarz, Javier] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA. [le Coutre, Philipp D.] Charite, D-13353 Berlin, Germany. [Paquette, Ronald] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Chuah, Charles] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore. [Nicolini, Franck. E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France. [Apperley, Jane F.] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England. [Khoury, H. Jean] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Talpaz, Moshe] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Abruzzese, Elisabetta] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy. [Rea, Delphine] Hop St Louis, Dept Hematol, Paris, France. [Baccarani, Michele] Univ Bologna, Inst Hematol, Bologna, Italy. [Muller, Martin C.] Univ Med Mannheim, Mannheim, Germany. [Gambacorti-Passerini, Carlo] Univ Milano Bicocca, Azienda Osped San Gerardo, Monza, Italy. [Lustgarten, Stephanie; Conlan, Maureen; Rivera, Victor M.] ARIAD Pharmaceut Inc, Cambridge, MA USA. [Guilhot, Francois] CHU Poitiers, INSERM, CIC 1402, Poitiers, France. [Deininger, Mochael W.] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA. [Hughes, Timothy P.] SA Pathol, Adelaide, SA, Australia. [Hughes, Timothy P.] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia. [Shah, Neil P.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 5 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800282 ER PT J AU Hunter, Z Lao, Y Yang, G Liu, X Chen, J Xu, L Tsakmaklis, N Chen, JJ Patterson, CJ Castillo, JJ Treon, SP AF Hunter, Zachary Lao, Yang Yang, Guang Liu, Xia Chen, Jie Xu, Lian Tsakmaklis, Nicholas Chen, Jiaji Patterson, Christopher J. Castillo, Jorge J. Treon, Steven P. TI Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88 SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Hunter, Zachary; Yang, Guang; Liu, Xia; Chen, Jie; Xu, Lian; Tsakmaklis, Nicholas; Chen, Jiaji; Patterson, Christopher J.; Treon, Steven P.] Dana Farber Canc Inst, Bing Ctr WM, Boston, MA 02115 USA. [Lao, Yang] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA. [Castillo, Jorge J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102177 ER PT J AU Jiang, H Acharya, C An, GAG Feng, XY Song, ZL Yang, G Adrian, F Qiu, LG Richardson, P Munshi, NC Tai, YT Anderson, KC AF Jiang, Hua Acharya, Chirag An, Gang An Gang Feng, Xiaoyan Song, Zhili Yang, Guang Adrian, Francisco Qiu, Lugui Richardson, Paul Munshi, Nikhil C. Tai, Yu-Tzu Anderson, Kenneth C. TI Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Jiang, Hua; Acharya, Chirag; An, Gang An Gang; Richardson, Paul] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Feng, Xiaoyan] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China. [Feng, Xiaoyan] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China. [Feng, Xiaoyan] Peking Union Med Coll, Tianjin, Peoples R China. [Song, Zhili; Yang, Guang; Adrian, Francisco] Sanofi Oncol, Cambridge, MA USA. [Qiu, Lugui] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China. [Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Tai, Yu-Tzu; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801195 ER PT J AU Jiang, X Bugno, J Hu, C Yang, Y Herold, T Qi, J Chen, P Gurbuxani, S Arnovitz, S Ulrich, B Weng, HY Wang, YG Huang, H Li, SL Strong, J Neilly, MB Larson, RA Le Beau, MM Bohlander, SK Jin, J Li, ZJ Bradner, JE Hong, S Chen, JJ AF Jiang, Xi Bugno, Jason Hu, Chao Yang, Yang Herold, Tobias Qi, Jun Chen, Ping Gurbuxani, Sandeep Arnovitz, Stephen Ulrich, Bryan Weng, Hengyou Wang, Yungui Huang, Hao Li, Shenglai Strong, Jennifer Neilly, Mary Beth Larson, Richard A. Le Beau, Michelle M. Bohlander, Stefan K. Jin, Jie Li, Zejuan Bradner, James E. Hong, Seungpyo Chen, Jianjun TI Targeted Treatment of FLT3-Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Jiang, Xi; Hu, Chao; Weng, Hengyou; Wang, Yungui; Strong, Jennifer; Chen, Jianjun] Univ Cincinnati, Dept Canc Biol, Cincinnati, OH USA. [Jiang, Xi; Hu, Chao; Chen, Ping; Arnovitz, Stephen; Ulrich, Bryan; Weng, Hengyou; Wang, Yungui; Huang, Hao; Li, Shenglai; Neilly, Mary Beth; Le Beau, Michelle M.; Li, Zejuan; Chen, Jianjun] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA. [Yang, Yang; Hong, Seungpyo] Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, Chicago, IL USA. [Hu, Chao; Wang, Yungui] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China. [Herold, Tobias] Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Munich, Germany. [Qi, Jun] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Gurbuxani, Sandeep] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA. [Larson, Richard A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Bohlander, Stefan K.] Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand. [Jin, Jie] Key Lab Hematopoiet Malignancies, Hangzhou, Zhejiang, Peoples R China. [Bradner, James E.] Harvard Univ, Sch Med, Boston, MA USA. [Hong, Seungpyo] Yonsei Univ, Underwood Int Coll, Div Integrated Sci & Engn, Inchon, South Korea. NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800041 ER PT J AU Karp, R Arnason, JE Rosenblatt, J Avigan, D Joyce, R Nahas, MR Uhlmann, E Hamdan, A AF Karp, Rebecca Arnason, Jon E. Rosenblatt, Jacalyn Avigan, David Joyce, Robin Nahas, Myrna Rita Uhlmann, Erik Hamdan, Ayad TI Pure Red Cell Aplasia after ABO-Mismatched Allogeneic Stem Cell Transplantation Treated with Therapeutic Plasma Exchange and Rituximab SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Karp, Rebecca; Arnason, Jon E.; Avigan, David; Nahas, Myrna Rita] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Rosenblatt, Jacalyn; Uhlmann, Erik] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Joyce, Robin] BIDMC, Hematol Oncol, Boston, MA USA. [Hamdan, Ayad] Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021805106 ER PT J AU Keenan, T LeBlanc, TW Traeger, L Vandusen, H Abel, GA Steensma, DP Fathi, AT DeAngelo, DJ Wadleigh, M Hobbs, G Amrein, PC Stone, RM Ballen, KK Chen, YB Temel, JS El-Jawahri, A AF Keenan, Tanya LeBlanc, Thomas W. Traeger, Lara Vandusen, Harry Abel, Gregory A. Steensma, David P. Fathi, Amir T. DeAngelo, Daniel J. Wadleigh, Martha Hobbs, Gabriela Amrein, Philip C. Stone, Richard M. Ballen, Karen K. Chen, Yi-Bin Temel, Jennifer S. El-Jawahri, Areej TI Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Keenan, Tanya; Traeger, Lara; Vandusen, Harry; Ballen, Karen K.; Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [LeBlanc, Thomas W.] Duke Canc Inst, Durham, NC USA. [Abel, Gregory A.; Steensma, David P.; DeAngelo, Daniel J.; Wadleigh, Martha] Dana Farber Canc Inst, Boston, MA 02115 USA. [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Hobbs, Gabriela] Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA. [Amrein, Philip C.; El-Jawahri, Areej] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Temel, Jennifer S.] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100269 ER PT J AU Kekre, N Marquez-Malaver, FJ Caballero, D Pinana, JI Esquirol, A Soiffer, RJ Cabrero, M Terol, MJ Martino, R Antin, JH Corral, LL Solano, C Armand, P Perez-Simon, JA AF Kekre, Natasha Marquez-Malaver, Francisco J. Caballero, Dolores Pinana, J. I. Esquirol, Albert Soiffer, Robert J. Cabrero, Monica Terol, M. J. Martino, Rodrigo Antin, Joseph H. Lopez Corral, L. Solano, Carlos Armand, Philippe Perez-Simon, Jose A. TI The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kekre, Natasha; Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA. [Marquez-Malaver, Francisco J.] Univ Seville, CSIC, Hosp Univ Virgen Rocio, Dept Hematol,Inst Biomed Sevilla IBIS, Seville, Spain. [Caballero, Dolores] Hosp Univ Salamanca, Salamanca, Spain. [Pinana, J. I.; Terol, M. J.] Hosp Clin Univ, Dept Hematol Oncol, Valencia, Spain. [Esquirol, Albert] Hosp Santa Creu & Sant Pau, Jose Carreras Leukemia Res Inst, Clin Hematol Serv, Barcelona, Spain. [Soiffer, Robert J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Cabrero, Monica; Lopez Corral, L.] Univ Salamanca, Inst Biosanitario Salamanca IBSAL, Univ Hosp, Hematol Serv, E-37008 Salamanca, Spain. [Martino, Rodrigo] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Antin, Joseph H.] Childrens Hosp, Dana Farber Canc Inst, Massachusetts Gen, Boston, MA 02115 USA. [Solano, Carlos] Hosp Clin Univ La Fe, Dept Hematol, Valencia, Spain. [Perez-Simon, Jose A.] Hosp Univ Virgen del Rocio, Dept Hematol, Seville, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100172 ER PT J AU Kelly, MJ Parsons, SK Hodgson, DC Cohen, JT Yeh, JM Abramson, JS Friedman, DL Henderson, TO Johnson, PW Pauker, SG Raemaekers, JM Winter, JN Kelly, KM Meyer, RM Castellino, SM Evens, AM AF Kelly, Michael J. Parsons, Susan K. Hodgson, David C. Cohen, Joshua T. Yeh, Jennifer M. Abramson, Jeremy S. Friedman, Debra L. Henderson, Tara O. Johnson, Peter W. Pauker, Stephen G. Raemaekers, John M. Winter, Jane N. Kelly, Kara M. Meyer, Ralph M. Castellino, Sharon M. Evens, Andrew M. TI An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kelly, Michael J.] Floating Hosp Children, Tufts Med Ctr, Dept Pediat, Div Pediat Hematol Oncol, Boston, MA USA. [Parsons, Susan K.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Dept Med, Boston, MA USA. [Parsons, Susan K.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Dept Pediat, Boston, MA USA. [Hodgson, David C.] Univ Toronto, Princess Margaret Canc Ctr, Radiat Med Programme, Toronto, ON, Canada. [Cohen, Joshua T.] Tufts Med Ctr, Ctr Evaluat Value & Risk Hlth, Boston, MA USA. [Yeh, Jennifer M.] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA 02115 USA. [Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [Friedman, Debra L.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Henderson, Tara O.] Univ Chicago, Comer Childrens Hosp, Chicago, IL 60637 USA. [Johnson, Peter W.] Univ Southampton, Canc Res UK Clin Ctr, Southampton, Hants, England. [Pauker, Stephen G.] Tufts Med Ctr, Div Clin Decis Making, Dept Med, Boston, MA USA. [Pauker, Stephen G.] Tufts Med Ctr, Div Clin Decis Making, Dept Psychiat, Boston, MA USA. [Raemaekers, John M.] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands. [Winter, Jane N.] Northwestern Univ, Feinberg Sch Med, Dept Med Hematol Oncol, Chicago, IL 60611 USA. [Kelly, Kara M.] Columbia Univ, Med Ctr, Pediat Hematol Oncol Stem Cell Transplantat, New York, NY USA. [Meyer, Ralph M.] Queens Univ, NCIC Clin Trials Grp, Dept Oncol, Kingston, ON, Canada. [Meyer, Ralph M.] Queens Univ, NCIC Clin Trials Grp, Dept Med, Kingston, ON, Canada. [Meyer, Ralph M.] Queens Univ, NCIC Clin Trials Grp, Dept Community Hlth, Kingston, ON, Canada. [Meyer, Ralph M.] Queens Univ, NCIC Clin Trials Grp, Dept Epidemiol, Kingston, ON, Canada. [Castellino, Sharon M.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Evens, Andrew M.] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102147 ER PT J AU Kernan, NA Grupp, SA Banerjee, K Hannah, AL Hume, RL Nejadnik, B Richardson, P AF Kernan, Nancy A. Grupp, Stephan A. Banerjee, Kamalika Hannah, Alison L. Hume, Robin L. Nejadnik, Bijan Richardson, Paul TI Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, Pediat BMT Serv, New York, NY 10021 USA. [Grupp, Stephan A.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA. [Grupp, Stephan A.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA. [Banerjee, Kamalika; Hannah, Alison L.; Hume, Robin L.; Nejadnik, Bijan] Jazz Pharmaceut, Palo Alto, CA USA. [Richardson, Paul] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801272 ER PT J AU Kernan, NA Richardson, PG Smith, AR Triplett, BM Grupp, SA Antin, JH Lehmann, LE Liang, W Hume, RL Hannah, AL Nejadnik, B Soiffer, RJ AF Kernan, Nancy A. Richardson, Paul G. Smith, Angela R. Triplett, Brandon M. Grupp, Stephan A. Antin, Joseph H. Lehmann, Leslie E. Liang, Wei Hume, Robin L. Hannah, Alison L. Nejadnik, Bijan Soiffer, Robert J. TI Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, Pediat BMT Serv, New York, NY 10021 USA. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancy,Dept Med Oncol,Jerome Lipp, Boston, MA 02115 USA. [Smith, Angela R.] Univ Minnesota, Div Pediat Blood & Marrow Transplantat, Minneapolis, MN USA. [Triplett, Brandon M.] St Jude Childrens Res Hosp, Bone Marrow Transplantat & Cellular Therapy, Memphis, TN 38105 USA. [Grupp, Stephan A.] Childrens Hosp Philadelphia, Pediat Oncol, Philadelphia, PA 19104 USA. [Antin, Joseph H.] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancy, Stem Cell Bone Marrow Transplantat Program, Boston, MA 02115 USA. [Lehmann, Leslie E.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Ctr Stem Cell Transplantat,Div Hematol Malignancy, Boston, MA 02115 USA. [Liang, Wei; Hume, Robin L.; Hannah, Alison L.; Nejadnik, Bijan] Jazz Pharmaceut, Palo Alto, CA USA. [Soiffer, Robert J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104003 ER PT J AU Khoury, HJ Wang, T Arora, M Hemmer, M Spellman, SR Cutler, CS Couriel, DR Alousi, AM Joseph, JA AF Khoury, Hanna Jean Wang, Tao Arora, Mukta Hemmer, Michael Spellman, Stephen R. Cutler, Corey S. Couriel, Daniel R. Alousi, Amin M. Joseph, Joseph A. TI Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved? SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Khoury, Hanna Jean] Emory Univ, Atlanta, GA 30322 USA. [Wang, Tao] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. [Arora, Mukta] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA. [Hemmer, Michael] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Spellman, Stephen R.] Natl Marrow Donor Program Be Match, CIBMTR, Minneapolis, MN USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Divis Hematol Malignancies, Boston, MA 02115 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Couriel, Daniel R.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Alousi, Amin M.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. [Joseph, Joseph A.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104014 ER PT J AU Kishi, Y Meguri, Y Iwamoto, M Asano, T Yoshioka, T Maeda, Y Tanimoto, M Koreth, J Ritz, J Matsuoka, KI AF Kishi, Yuriko Meguri, Yusuke Iwamoto, Miki Asano, Takeru Yoshioka, Takanori Maeda, Yoshinobu Tanimoto, Mitsune Koreth, John Ritz, Jerome Matsuoka, Ken-Ichi TI Interval of IL-2 Administration Has a Major Impact on Treatment Efficacy for Regulatory T Cell Expansion and Homeostasis SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kishi, Yuriko; Meguri, Yusuke; Iwamoto, Miki; Asano, Takeru; Yoshioka, Takanori; Maeda, Yoshinobu; Tanimoto, Mitsune; Matsuoka, Ken-Ichi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol & Oncol, Okayama 7008530, Japan. [Koreth, John; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100093 ER PT J AU Koch, R Chapuy, B AF Koch, Raphael Chapuy, Bjoern TI SFRP4-Mediated Inhibition of Canonical Wnt-Signaling in DLBCL SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Koch, Raphael] Univ Med Ctr Goettingen, Hematol & Oncol, Gottingen, Germany. [Chapuy, Bjoern] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800256 ER PT J AU Koulnis, M Eda, H Santo, L Siu, KT Ramachandran, J Panaroni, C Tanaka, T Raje, NS AF Koulnis, Miroslav Eda, Homare Santo, Loredana Siu, Ka Tat Ramachandran, Janani Panaroni, Cristina Tanaka, Takaaki Raje, Noopur S. TI Novel In Vivo Model of Multiple Myeloma Bone Disease Using beta-Tricalcium Phosphate Artificial Bone Grafts SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Koulnis, Miroslav; Eda, Homare; Santo, Loredana; Siu, Ka Tat; Ramachandran, Janani; Panaroni, Cristina; Raje, Noopur S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Tanaka, Takaaki] NHO Utsunoiya Natl Hosp, Dept Orthopaed Surg, Utsunoiya, Japan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801142 ER PT J AU Kumar, S Talluri, S Fulciniti, M Shammas, MA Munshi, NC AF Kumar, Subodh Talluri, Srikanth Fulciniti, Mariateresa Shammas, Masood A. Munshi, Nikhil C. TI Elevated APEX1 Disrupts G2/M Checkpoint, Contributing to Evolution and Survival of Myeloma Cells SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Kumar, Subodh; Talluri, Srikanth; Fulciniti, Mariateresa; Shammas, Masood A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Kumar, Subodh; Talluri, Srikanth; Shammas, Masood A.; Munshi, Nikhil C.] VA Boston Healthcare Syst, West Roxbury, MA USA. [Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020103192 ER PT J AU LaCasce, AS Bociek, G Sawas, A Caimi, PF Agura, E Matous, J Ansell, S Crosswell, H Islas-Ohlmayer, M Behler, C Cheung, E Forero-Torres, A Vose, J O'Connor, OA Josephson, N Advani, R AF LaCasce, Ann S. Bociek, Gregory Sawas, Ahmed Caimi, Paolo F. Agura, Edward Matous, Jeffrey Ansell, Stephen Crosswell, Howland Islas-Ohlmayer, Miguel Behler, Caroline Cheung, Eric Forero-Torres, Andres Vose, Julie O'Connor, Owen A. Josephson, Neil Advani, Ranjana TI Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [LaCasce, Ann S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bociek, Gregory; Vose, Julie] Univ Nebraska Med Ctr, Omaha, NE USA. [Sawas, Ahmed; O'Connor, Owen A.] Columbia Univ, Med Ctr, New York, NY USA. [Caimi, Paolo F.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Agura, Edward] Charles A Sammons Canc Ctr, Dallas, TX USA. [Matous, Jeffrey] Colorado Blood Canc Inst, Denver, CO USA. [Ansell, Stephen] Mayo Clin, Rochester, MN USA. [Crosswell, Howland] Bon Secours St Francis Hosp, Greenville, SC USA. [Islas-Ohlmayer, Miguel] Jewish Hosp Mercy Hlth, Cincinnati, OH USA. [Behler, Caroline] Pacific Hematol Oncol Associates, San Francisco, CA USA. [Cheung, Eric] Oncol Inst Hope & Innovat, Whittier, CA USA. [Forero-Torres, Andres] Univ Alabama Birmingham, Birmingham, AL USA. [Josephson, Neil] Seattle Genet Inc, Bothell, WA USA. [Advani, Ranjana] Stanford Canc Ctr, Stanford, CA USA. NR 0 TC 5 Z9 5 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800239 ER PT J AU LeBlanc, TW Wolf, SP El-Jawahri, A Davis, DM Locke, SC Abernethy, A AF LeBlanc, Thomas W. Wolf, Steven P. El-Jawahri, Areej Davis, Debra M. Locke, Susan C. Abernethy, Amy TI Symptom Burden, Quality of Life, and Distress in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy: Results of a Prospective Electronic Patient-Reported Outcomes Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [LeBlanc, Thomas W.] Duke Canc Inst, Durham, NC USA. [LeBlanc, Thomas W.] Duke Univ, Sch Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA. [Wolf, Steven P.; Davis, Debra M.; Locke, Susan C.] Duke Clin Res Inst, Ctr Learning Hlth Care, Durham, NC USA. [El-Jawahri, Areej] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Abernethy, Amy] Duke Univ, Sch Med, Durham, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7YP UT WOS:000368021802121 ER PT J AU LeBlanc, TW Fish, LJ Bloom, CT El-Jawahri, A Davis, DM Locke, SC Pollak, KI AF LeBlanc, Thomas W. Fish, Laura J. Bloom, Catherine T. El-Jawahri, Areej Davis, Debra M. Locke, Susan C. Pollak, Kathryn I. TI Patient Experiences of Acute Myeloid Leukemia (AML): A Qualitative Study about Diagnosis, Illness Understanding, and Treatment Decision-Making SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [LeBlanc, Thomas W.] Duke Canc Inst, Durham, NC USA. [LeBlanc, Thomas W.] Duke Univ, Sch Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA. [Fish, Laura J.; Pollak, Kathryn I.] Duke Canc Inst, Program Canc Control & Populat Sci, Durham, NC USA. [Bloom, Catherine T.] Duke Clin Res Inst, Durham, NC USA. [El-Jawahri, Areej] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Davis, Debra M.; Locke, Susan C.] Duke Clin Res Inst, Ctr Learning Hlth Care, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100284 ER PT J AU Li, A Makar, RS Hurwitz, S Uhl, L Kaufman, RM Stowell, CP Dzik, W Bendapudi, P AF Li, Ang Makar, Robert S. Hurwitz, Shelley Uhl, Lynne Kaufman, Richard M. Stowell, Christopher P. Dzik, Walter Bendapudi, Pavan TI Therapeutic Plasma Exchange for the Treatment of Thrombotic Microangiopathy without Severe ADAMTS13 Deficiency: A Propensity Score-Matched Study SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Li, Ang] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Makar, Robert S.] Massachusetts Gen Hosp, Dept Pathol, Blood Transfus Serv, Boston, MA 02114 USA. [Hurwitz, Shelley] Brigham & Womens Hosp, Ctr Clin Invest, Boston, MA 02115 USA. [Uhl, Lynne] Beth Israel Deaconess Med Ctr, Blood Transfus Serv, Boston, MA 02215 USA. [Kaufman, Richard M.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Stowell, Christopher P.; Dzik, Walter] Massachusetts Gen Hosp, Blood Transfus Serv, Boston, MA 02114 USA. [Bendapudi, Pavan] Massachusetts Gen Hosp, Div Hematol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020105037 ER PT J AU Lindblad, O Cordero, E Puissant, A Macaulay, L Kabir, NN Sun, JM Haraldsson, K Borg, A Levander, F Stegmaier, K Pietras, K Ronnstrand, L Kazi, JU AF Lindblad, Oscar Cordero, Eugenio Puissant, Alexandre Macaulay, Lucy Kabir, Nuzhat N. Sun, Jianmin Haraldsson, Karin Borg, Ake Levander, Fredrik Stegmaier, Kimberly Pietras, Kristian Ronnstrand, Lars Kazi, Julhash U. TI Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Lindblad, Oscar; Cordero, Eugenio; Macaulay, Lucy; Sun, Jianmin; Pietras, Kristian; Ronnstrand, Lars; Kazi, Julhash U.] Lund Univ, Dept Lab Med, Div Translat Canc Res, Lund, Sweden. [Lindblad, Oscar; Macaulay, Lucy; Sun, Jianmin; Ronnstrand, Lars; Kazi, Julhash U.] Lund Univ, Dept Lab Med, Lund Stem Cell Ctr, Lund, Sweden. [Lindblad, Oscar] Skane Univ Hosp, Dept Hematol & Vasc Disorders, Lund, Sweden. [Puissant, Alexandre] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Puissant, Alexandre] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA 02115 USA. [Kabir, Nuzhat N.; Kazi, Julhash U.] KN Biomed Res Inst, Lab Computat Biochem, Barisal, Bangladesh. [Haraldsson, Karin; Borg, Ake] Lund Univ, Dept Pathol & Oncol, Lund, Sweden. [Levander, Fredrik] Lund Univ, Dept Immunotechnol, BILS, Lund, Sweden. [Stegmaier, Kimberly] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Stegmaier, Kimberly] Boston Childrens Hosp, Boston, MA USA. RI PUISSANT, ALEXANDRE/O-9575-2016 OI PUISSANT, ALEXANDRE/0000-0002-3997-9282 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020101310 ER PT J AU Logan, AC Herrera, AF Ryan, CE Rezvani, AR Kong, KA Faham, M Alatrash, G Molldrem, JJ Sargent, RL Alyea, EP Ho, VT Brown, JR Ritz, J Miklos, DB AF Logan, Aaron C. Herrera, Alex F. Ryan, Christine E. Rezvani, Andrew R. Kong, Katherine A. Faham, Malek Alatrash, Gheath Molldrem, Jeffrey J. Sargent, Rachel L. Alyea, Edwin P. Ho, Vincent T. Brown, Jennifer R. Ritz, Jerome Miklos, David B. TI Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Logan, Aaron C.] Univ Calif San Francisco, Dept Med, Div Hematol & Blood & Marrow Transplantat, San Francisco, CA USA. [Herrera, Alex F.] City Hope Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA. [Ryan, Christine E.; Miklos, David B.] Stanford Univ, Med Ctr, Dept Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Rezvani, Andrew R.] Stanford Univ, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Kong, Katherine A.; Faham, Malek] Adapt Biotechnol Corp, San Francisco, CA USA. [Alatrash, Gheath; Molldrem, Jeffrey J.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. [Sargent, Rachel L.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Alyea, Edwin P.; Ho, Vincent T.; Brown, Jennifer R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801282 ER PT J AU Louissaint, A Schafernak, KT Geyer, JT Kovach, AE Gratzinger, D Roth, CG Paxton, CN Kim, S Namgyal, C Morgan, EA South, ST Harris, MH Hochberg, EP Hasserjian, RP Harris, NL Weinstock, DM AF Louissaint, Abner, Jr. Schafernak, Kristian T. Geyer, Julia T. Kovach, Alexandra E. Gratzinger, Dita Roth, Christine G. Paxton, Christian N. Kim, Sunhee Namgyal, Chungdak Morgan, Elizabeth A. South, Sarah T. Harris, Marian H. Hochberg, Ephraim P. Hasserjian, Robert P. Harris, Nancy L. Weinstock, David M. TI Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Louissaint, Abner, Jr.; Hasserjian, Robert P.; Harris, Nancy L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Louissaint, Abner, Jr.; Kim, Sunhee; Weinstock, David M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Schafernak, Kristian T.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol & Lab Med, Chicago, IL 60611 USA. [Geyer, Julia T.] NewYork Presbyterian Hosp, Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA. [Kovach, Alexandra E.; Harris, Marian H.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Gratzinger, Dita] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA. [Roth, Christine G.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA. [Paxton, Christian N.; South, Sarah T.] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA. [Namgyal, Chungdak; Morgan, Elizabeth A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [South, Sarah T.] Univ Utah, Dept Pathol, Salt Lake City, UT USA. [Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800182 ER PT J AU Luskin, MR Gimotty, P Smith, C Loren, A Figueroa, M Harrison, J Sun, ZX Tallman, MS Paietta, E Litzow, MR Levine, RL Fernandez, HF Luger, S Carroll, M Master, S Wertheim, G AF Luskin, Marlise R. Gimotty, Phyllis Smith, Catherine Loren, Alison Figueroa, Maria Harrison, Jenna Sun, Zhuoxin Tallman, Martin S. Paietta, Elisabeth Litzow, Mark R. Levine, Ross L. Fernandez, Hugo F. Luger, Selina Carroll, Martin Master, Stephen Wertheim, Gerald TI A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Luskin, Marlise R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Gimotty, Phyllis] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Smith, Catherine; Harrison, Jenna] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA. [Loren, Alison] Univ Penn, Abramson Canc Ctr, Ctr Chron Lymphocyt Leukemia, Philadelphia, PA 19104 USA. [Figueroa, Maria] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Sun, Zhuoxin] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. [Paietta, Elisabeth] Montefiore Med Ctr, Canc Ctr, North Div, Bronx, NY 10467 USA. [Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, MN USA. [Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Fernandez, Hugo F.] Univ S Florida, H Lee Moffitt Canc Ctr, Blood & Marrow Transplantat, Tampa, FL 33682 USA. [Luger, Selina; Carroll, Martin] Univ Penn, Div Hematol & Oncol, Philadelphia, PA 19104 USA. [Master, Stephen] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA. [Wertheim, Gerald] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102103 ER PT J AU Ma, XM Swern, AS Kiselev, P Fliss, A Lu, JJ Scott, BL Steensma, DP Sugrue, MM AF Ma, Xiaomei Swern, Arlene S. Kiselev, Pavel Fliss, Albert Lu, Jane J. Scott, Bart L. Steensma, David P. Sugrue, Mary M. TI Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Ma, Xiaomei] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Swern, Arlene S.; Kiselev, Pavel; Fliss, Albert; Lu, Jane J.; Sugrue, Mary M.] Celgene Corp, Summit, NJ USA. [Scott, Bart L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104201 ER PT J AU Majer, I Krishna, A van de Wetering, G San-Miguel, JF Richardson, PG AF Majer, Istvan Krishna, Arun van de Wetering, Gijs San-Miguel, Jesus F. Richardson, Paul G. TI Estimating Utilities for Panobinostat in Combination with Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma; Evidence from the Panorama-1 Trial SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Majer, Istvan; van de Wetering, Gijs] Pharmerit Int, Rotterdam, Netherlands. [Krishna, Arun] Novartis Pharmaceut, E Hanover, NJ USA. [San-Miguel, Jesus F.] Univ Navarra Clin, Pamplona, Spain. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7YP UT WOS:000368021802129 ER PT J AU Mantripragada, K Castillo, JJ Olszewski, AJ AF Mantripragada, Kalyan Castillo, Jorge J. Olszewski, Adam J. TI Risk Factors for Early Death after Immunochemotherapy in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Mantripragada, Kalyan] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912 USA. [Castillo, Jorge J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA. [Olszewski, Adam J.] Brown Univ, Alpert Med Sch, Div Hematol Oncol, Providence, RI 02912 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800171 ER PT J AU Mar, BG Kahn, J Zon, RL Grauman, PV Boettger, K Chu, SH Armstrong, SA Ebert, BL AF Mar, Brenton G. Kahn, Josephine Zon, Rebecca L. Grauman, Peter V. Boettger, Kevin Chu, Scott Haihua Armstrong, Scott A. Ebert, Benjamin L. TI SETD2 Heterozygous Loss in Leukemia Leads to Chemotherapy Resistance through Attenuation of the DNA Damage Response SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Mar, Brenton G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kahn, Josephine; Zon, Rebecca L.; Grauman, Peter V.; Boettger, Kevin] Brigham & Womens Hosp, Boston, MA 02115 USA. [Chu, Scott Haihua] Mem Sloan Kettering Canc Canc, New York, NY USA. [Armstrong, Scott A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102138 ER PT J AU Martin, P Chen, ZM Cheson, BD Ellis, T Robinson, KS Williams, ME Rajguru, SA Friedberg, JW van der Jagt, RH LaCasce, AS Joyce, R Ganjoo, KN Bartlett, NL Lemieux, B Vander Walde, AM Herst, JA Szer, J Bar, MH Cabanillas, F Dodds, AJ Montgomery, PG Pressnail, B Smith, MR Leonard, JP AF Martin, Peter Chen, Zhengming Cheson, Bruce D. Ellis, Tricia Robinson, Katherine Sue Williams, Michael E. Rajguru, Saurabh A. Friedberg, Jonathan W. van der Jagt, Richard H. LaCasce, Ann S. Joyce, Robin Ganjoo, Kristen N. Bartlett, Nancy L. Lemieux, Bernard Vander Walde, Ari M. Herst, Jordan A. Szer, Jeffrey Bar, Michael H. Cabanillas, Fernando Dodds, Anthony J. Montgomery, Paul G. Pressnail, Bryn Smith, Mitchell R. Leonard, John P. TI Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Martin, Peter] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA. [Chen, Zhengming] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA. [Cheson, Bruce D.] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Ellis, Tricia] Weill Cornell Med Coll, New York, NY USA. [Robinson, Katherine Sue] Dalhousie Univ, Victoria Gen Hosp Site, QEIIHSC, Halifax, NS, Canada. [Williams, Michael E.] Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA. [Rajguru, Saurabh A.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Friedberg, Jonathan W.] Univ Rochester, Rochester, NY USA. [van der Jagt, Richard H.] Ottawa Hosp, Ottawa, ON, Canada. [LaCasce, Ann S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Joyce, Robin] Harvard Univ, Sch Med, Div Hematol & Oncol, Boston, MA USA. [Joyce, Robin] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Ganjoo, Kristen N.] Stanford Univ, Palo Alto VAHCS, Palo Alto, CA 94304 USA. [Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA. [Lemieux, Bernard] CHUM, Hematooncol Dept, Montreal, PQ, Canada. [Vander Walde, Ari M.] City Hope Natl Med Ctr, Hematol & Stem Cell Transplantat, Duarte, CA USA. [Herst, Jordan A.] Sudbury Reg Hosp, Sudbury, ON, Canada. [Szer, Jeffrey] Royal Melbourne Hosp, Clin Haematol, Melbourne, Vic, Australia. [Bar, Michael H.] Bennett Canc Ctr, Stamford, CT USA. [Cabanillas, Fernando] Auxilio Mutuo Hosp, Auxilio Canc Ctr, San Juan, PR 00919 USA. [Dodds, Anthony J.] St Vincents Hosp, Sydney, NSW 2010, Australia. [Montgomery, Paul G.] Mt States Tumor Inst, Boise, ID USA. [Pressnail, Bryn] Royal Victoria Hosp, Barrie, ON, Canada. [Smith, Mitchell R.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Leonard, John P.] Weill Cornell Med Coll, Dept Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7YP UT WOS:000368021800218 ER PT J AU Matos, TR Liu, HY Hirakawa, M Alho, AC Ritz, J AF Matos, Tiago R. Liu, Hongye Hirakawa, Masahiro Alho, Ana Cristina Ritz, Jerome TI Maturation and Phenotypic Diversity of Human CD4(+) Regulatory T Cells in Umbilical Cord Blood and Peripheral Blood from Healthy Donors SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Matos, Tiago R.; Liu, Hongye] Harvard Univ, Sch Med, Div Hematol Malignancies, Boston, MA USA. [Matos, Tiago R.; Liu, Hongye] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Matos, Tiago R.] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal. [Hirakawa, Masahiro] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Alho, Ana Cristina; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Alho, Ana Cristina] Univ Lisbon, Inst Med Mol, Fac Med, Lisbon, Portugal. [Ritz, Jerome] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020101195 ER PT J AU Merryman, RW Kim, HT Zinzani, PL Carlo-Stella, C Ansell, SM Halwani, AS Perales, MA Ho, VT Antin, JH Ritz, J Soiffer, RJ Armand, P AF Merryman, Reid W. Kim, Haesook T. Zinzani, Pier Luigi Carlo-Stella, Carmelo Ansell, Stephen M. Halwani, Ahmad S. Perales, Miguel-Angel Ho, Vincent T. Antin, Joseph H. Ritz, Jerome Soiffer, Robert J. Armand, Philippe TI Safety and Efficacy of Allogeneic Hematopoetic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Merryman, Reid W.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Zinzani, Pier Luigi] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy. [Carlo-Stella, Carmelo] Humanitas Clin & Res Ctr, Milan, Italy. [Ansell, Stephen M.] Mayo Clin, Rochester, MN USA. [Halwani, Ahmad S.] Huntsman Canc Inst, Salt Lake City, UT USA. [Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY USA. [Ho, Vincent T.; Antin, Joseph H.; Soiffer, Robert J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA. RI Zinzani, Pier Luigi/J-9182-2016 OI Zinzani, Pier Luigi/0000-0002-2112-2651 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100183 ER PT J AU Montalban-Bravo, G Carcia-Manero, G Short, NJ Sasaki, K Sekeres, MA Komrokji, RS Steensma, DP DeZern, AE Roboz, GJ Kadia, T Borthakur, G DiNardo, C Miller, D Estrov, Z Pemmaraju, N Daver, N Konopleva, M Cortes, JE Kantarjian, HM Jabbour, E AF Montalban-Bravo, Guillermo Carcia-Manero, Guillermo Short, Nicholas J. Sasaki, Koji Sekeres, Mikkael A. Komrokji, Rami S. Steensma, David P. DeZern, Amy E. Roboz, Gail J. Kadia, Tapan Borthakur, Gautam DiNardo, Courtney Miller, Darla Estrov, Zeev Pemmaraju, Naveen Daver, Naval Konopleva, Marina Cortes, Jorge E. Kantarjian, Hagop M. Jabbour, Elias TI Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Montalban-Bravo, Guillermo; Carcia-Manero, Guillermo; Short, Nicholas J.; Kadia, Tapan; Borthakur, Gautam; DiNardo, Courtney; Miller, Darla; Estrov, Zeev; Pemmaraju, Naveen; Daver, Naval; Konopleva, Marina; Cortes, Jorge E.; Kantarjian, Hagop M.; Jabbour, Elias] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Sasaki, Koji] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. [Sekeres, Mikkael A.] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA. [Komrokji, Rami S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA. [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [DeZern, Amy E.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Roboz, Gail J.] Weill Cornell Med Coll, Dept Med, Div Hematol & Oncol, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 4 WC Hematology SC Hematology GA DA7XY UT WOS:000368020103072 ER PT J AU Morgan, EA Sweeney, MP Tomoka, T Kopp, N Redd, RA Carey, CD Masamba, L Kamiza, S Pinkus, GS Neuberg, DS Rodig, SJ Milner, DA Weinstock, DM AF Morgan, Elizabeth A. Sweeney, M. Patrick Tomoka, Tamiwe Kopp, Nadja Redd, Robert A. Carey, Christopher Daniel Masamba, Leo Kamiza, Steve Pinkus, Geraldine S. Neuberg, Donna S. Rodig, Scott J. Milner, Danny A., Jr. Weinstock, David M. TI Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Morgan, Elizabeth A.; Carey, Christopher Daniel] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Sweeney, M. Patrick] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Tomoka, Tamiwe; Kamiza, Steve] Univ Malawi, Coll Med, Dept Histopathol, Blantyre, Malawi. [Kopp, Nadja] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Redd, Robert A.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Masamba, Leo] Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi. [Pinkus, Geraldine S.; Rodig, Scott J.; Milner, Danny A., Jr.] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Weinstock, David M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020102167 ER PT J AU Murakami, MA Christodoulou, AN Christie, AL DeSouza, T Louissaint, A Vojinovic, U Koch, R Li, LS Kallgren, SP Rao, P Koster, J Vadhi, R Duberow, E Morgan, EA Wang, HJ Ahmed, SS Majewski, KL Konopleva, M Tamburini, J Gutierrez, A Kelliher, M Etchin, J Jeremias, I Weng, AP Kung, AL Lane, AA Carnache-Ottou, F Izraeli, S Jacobsen, E Galinsky, I Stone, RM Harris, MH Dorfman, DM Aster, JC Long, H Silverman, LB Weinstock, DM AF Murakami, Mark A. Christodoulou, Alexandra N. Christie, Amanda L. DeSouza, Tiffany Louissaint, Abner, Jr. Vojinovic, Una Koch, Raphael Li, Loretta S. Kallgren, Scott P. Rao, Prakash Koester, Johannes Vadhi, Raga Duberow, Eilene Morgan, Elizabeth A. Wang, Hongjun Ahmed, Samia S. Majewski, Katharine L. Konopleva, Marina Tamburini, Jerome Gutierrez, Alejandro Kelliher, Michelle Etchin, Julia Jeremias, Irmela Weng, Andrew P. Kung, Andrew L. Lane, Andrew A. Carnache-Ottou, Francine Izraeli, Shai Jacobsen, Eric Galinsky, Ilene Stone, Richard M. Harris, Marian H. Dorfman, David M. Aster, Jon C. Long, Henry Silverman, Lewis B. Weinstock, David M. TI Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Murakami, Mark A.; Christodoulou, Alexandra N.; Christie, Amanda L.; DeSouza, Tiffany; Rao, Prakash; Koester, Johannes; Vadhi, Raga; Duberow, Eilene; Lane, Andrew A.; Jacobsen, Eric; Galinsky, Ilene; Stone, Richard M.; Long, Henry; Weinstock, David M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Murakami, Mark A.; Kallgren, Scott P.] Harvard Univ, Sch Med, Dept Biomed Informat, Boston, MA USA. [Louissaint, Abner, Jr.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Vojinovic, Una] Dana Farber Canc Inst, Boston, MA 02115 USA. [Koch, Raphael; Li, Loretta S.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Rao, Prakash; Koester, Johannes; Vadhi, Raga; Duberow, Eilene; Long, Henry] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA. [Morgan, Elizabeth A.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Wang, Hongjun] Boston Childrens Hosp, Pathol, Boston, MA USA. [Ahmed, Samia S.; Majewski, Katharine L.] Dana Farber Canc Inst, Pediat Oncol, Boston, MA 02115 USA. [Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA. [Tamburini, Jerome] Inst Cochin, Hematol, Paris, France. [Gutierrez, Alejandro] Dana Farber Canc Inst, Pediat Hematol Oncol, Boston, MA 02115 USA. [Gutierrez, Alejandro] Childrens Hosp Boston, Boston, MA USA. [Kelliher, Michelle] Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA USA. [Etchin, Julia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol,Childrens Hosp Boston, 44 Binney St, Boston, MA 02115 USA. [Jeremias, Irmela] German Res Ctr Environm Hlth, Res Unit Gene Vectors, Helmholtz Ctr Munich, Munich, Germany. [Jeremias, Irmela] German Canc Res Ctr, Heidelberg, Germany. [Jeremias, Irmela] Univ Munich, Dept Oncol Dr von Haunersches Kinderspital, Munich, Germany. [Weng, Andrew P.] BC Canc Agcy, Dept Pathol, Terry Fox Lab, Vancouver, BC, Canada. [Kung, Andrew L.] Columbia Univ, Med Ctr, Div Pediat Hematol Oncol Stem Cell Transplant, New York, NY USA. Univ Bourgogne Franche Comte, Besancon, France. [Carnache-Ottou, Francine] INSERM, Besancon, France. [Carnache-Ottou, Francine] LabEX LipSTIC, Besancon, France. [Carnache-Ottou, Francine] EFS Bourgogne Franche Comte, Besancon, France. [Izraeli, Shai] Edmond & Lily Safra Children Hosp, Sheba Med Ctr, Pediat Hematol Oncol, Ramat Gan, Israel. [Izraeli, Shai] Tel Aviv Univ, Ramat Gan, Israel. [Harris, Marian H.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Aster, Jon C.] Brigham & Womens Hosp, Pathol, Boston, MA 02115 USA. [Silverman, Lewis B.] Boston Childrens Hosp, Div Pediat Hematol, Boston, MA USA. [Silverman, Lewis B.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Silverman, Lewis B.] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020104134 ER EF